<SEC-DOCUMENT>0000939767-22-000110.txt : 20221101
<SEC-HEADER>0000939767-22-000110.hdr.sgml : 20221101
<ACCEPTANCE-DATETIME>20221101161631
ACCESSION NUMBER:		0000939767-22-000110
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221101
DATE AS OF CHANGE:		20221101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		221350443

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:f874578b-aba8-4b11-9ee3-0aa3371a4a4f,g:18180dba-6dc6-4cf5-97a9-3c99224fbbee,d:549da58617674d2089ca2811b93aa142--><html xmlns:exel="http://www.exelixis.com/20220930" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80L2ZyYWc6YzkzYmNjNjg2Y2E0NGFlOGI4ZTJmNjMzYWFmODUwYjgvdGFibGU6MjJlMDkwYjNiNTMyNDM4ZmFlMTI1MjRkYWM0YmIyNWUvdGFibGVyYW5nZToyMmUwOTBiM2I1MzI0MzhmYWUxMjUyNGRhYzRiYjI1ZV8yLTEtMS0xLTgyMTMy_9da8cdfb-285f-4b9c-8aba-728c3ac8c905">false</ix:nonNumeric><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80L2ZyYWc6YzkzYmNjNjg2Y2E0NGFlOGI4ZTJmNjMzYWFmODUwYjgvdGFibGU6MjJlMDkwYjNiNTMyNDM4ZmFlMTI1MjRkYWM0YmIyNWUvdGFibGVyYW5nZToyMmUwOTBiM2I1MzI0MzhmYWUxMjUyNGRhYzRiYjI1ZV80LTEtMS0xLTgyMTMy_5b9c9ede-34d7-470a-8ef3-0a416c29825d">2022</ix:nonNumeric><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80L2ZyYWc6YzkzYmNjNjg2Y2E0NGFlOGI4ZTJmNjMzYWFmODUwYjgvdGFibGU6MjJlMDkwYjNiNTMyNDM4ZmFlMTI1MjRkYWM0YmIyNWUvdGFibGVyYW5nZToyMmUwOTBiM2I1MzI0MzhmYWUxMjUyNGRhYzRiYjI1ZV81LTEtMS0xLTgyMTMy_9c2caa4e-51d0-4cbc-a9d2-1cfd072a22e4">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80L2ZyYWc6YzkzYmNjNjg2Y2E0NGFlOGI4ZTJmNjMzYWFmODUwYjgvdGFibGU6MjJlMDkwYjNiNTMyNDM4ZmFlMTI1MjRkYWM0YmIyNWUvdGFibGVyYW5nZToyMmUwOTBiM2I1MzI0MzhmYWUxMjUyNGRhYzRiYjI1ZV82LTEtMS0xLTgyMTMy_f5bb4f1a-c098-424f-b28c-14ddf6a14613">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80L2ZyYWc6YzkzYmNjNjg2Y2E0NGFlOGI4ZTJmNjMzYWFmODUwYjgvdGFibGU6MjJlMDkwYjNiNTMyNDM4ZmFlMTI1MjRkYWM0YmIyNWUvdGFibGVyYW5nZToyMmUwOTBiM2I1MzI0MzhmYWUxMjUyNGRhYzRiYjI1ZV83LTEtMS0xLTgyMTMy_b8c61408-8f0a-4fc1-8865-5b413526ad5c">December 31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c2e3793b63a4e5fb7d9a4731fc85bfa_I20221024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i37a45756c9954dffb1597b6666f619f3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9c08664821924215a9a380432cc549fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i278c1109560d43989bb93fcb650c9afa_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e0a6faac267459387d713c98a6da04c_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac13ba8b31b461a9ee349f6df7ec401_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d1060e036714dc8b00e67d518425d7e_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3969d7ffe515467786d9f03efe7dd44a_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ffeb5a9e14d43f5bf61509594c23244_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e199975584423f9f9b5fc5676b433e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86031b3c8cd74803ab4a6280a4faaea9_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd67de25ab5242d6acec13d5bb1dcd8c_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3212d047299943f1aefbd2a60b170c8c_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f0edff0af2d424980d236133e9e6a27_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if06c48663d594ceeabfd8945d8b2d8be_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i825124e3b6104871b081a44c670a7a86_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b23ba8f2c94ddcb48f6a85901903b5_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdff014306a24f67bd885f70ff909a7d_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6604d7fea14d4e8fb16b161c841a6999_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64041df1701a4a07b8ef7d5c0f37f576_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i149d987491b846698276e3ab735170f7_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54dcb905f0384fd8bce6b7e44c2faa57_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44690402ba504bd1987f6bea7e60ccfc_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68253ae6a74648f0b87bb4a6390ffc5f_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d8665815014c9aae47cbac0416c062_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i283a9472e4fa421799257a1a2bd9fa1c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4697a4d7dcd4136b84bf95f0e95aac8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8188cffbcf746278fdee32a78f4a8cb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0570e9a9f97c4dfc9839b7ab1860e680_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f67f4b8f82417db30834591fb44d60_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd4b7ab3407c44cb8b1ed0210197c8e9_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic87ae071c1834ea6abd407e1ee1c295a_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6899e05fb3f5440cb7983ea4ae13b93b_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f3dc37f9c84491ba474d260d6688295_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2afa3de03a1043199b82592539c4213f_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81def5dda1a6445d84955509b0fe837a_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i029f475a4cb743c883c1e02d0bd1e0ca_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d2bb7e98f0347679cc8ee55fd39e05e_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if09ffd775b454fd28bc4ccc68d578a46_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6024509ae78487f8fce552a0976856d_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b72e0f00af411b8652e825b767f230_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacaf43cbe24a472ba26b4376244aeceb_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22983ccf5d88438696ca9ed782f2b97a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fa68b5c6fea4b5eb3e3e88045cc2288_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77a026db7c644033a1c8a0268a3cc765_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7950e15bb4194a85a2dfe92d26c1c011_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a29957ee8b14a00a22d941a4f3bb1cf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb6a382becc140a4b1da483762a0959f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ac406b2dc941da8bb9bf4a2a0c6bc4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i058269d798474c4f81f2c52f1a695d17_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f25495c49942328fe52185ebb36868_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbe63aa422cd4993aa00fe1bec11e108_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34b4239fc7694a5f9a055a4f8d0ea9d0_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i897ee6ad5f0f4e8a932659340f671c9b_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48eab2e753614354a3732f75587e636f_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0c9d8627fe44d7983aa3b965e06e09b_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbb5c647740f4d2d99a83b98b0fc1e73_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b44b1b4753f4fc19f53534dfb54799f_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f53e591b0874be8be6c8805109d1335_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i956b96970860433cac967eaa240e5cb1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>exel:product</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>exel:country</xbrli:measure></xbrli:unit><xbrli:context id="i0adfaf62ed654496b8aef139a0b4a6a0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exel:segment</xbrli:measure></xbrli:unit><xbrli:context id="i29e8fc05be13408780345631766d0815_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b04ee7fa7f744f3bd93b05af54ac638_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic228c7eb5cf24643909be765ba674a07_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i245c45138f3a4c37bf6f61ddc6a3d179_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c6da63ce1144dfe9238e2548fc27b35_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ac64684837b4a6da52ae5943bd15379_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11f269764820403288f53e33a88cf89f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i066aeee8d576453da3c5e154f00d7eac_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27a38704423047618c2b8b7c1b51be0e_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42beb11067e7404f9bc3d9896994366b_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c5cd1f508804375996b6d9886dc1ea9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21a57c281a93454aaf7038dc3b541516_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie65c3b49253c4aa7b9ec4c0202bebd90_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i5bf8a00473bf46afaa5c09de8f46aba6_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ddea34c561403e81f6dd80be859a85_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2eeedb844d94073adfe7b633274b258_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50245b1220fd4277b1ff3bbe18a1c24a_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb3f74547a9b413bac6630c8bb4155c6_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7149117a9e054f7f8e808e1fd2ff2e9e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib51bcc2f1cfb4c36aa8d080a8efad244_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c2a7f145b054c929254fd11464ef3b3_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e2dbdf48c448b29b598f9f2a0e5e19_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97213e89d9b746b5bf8fbd85fd21333c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa364ec98f294e0daf245b10590174ba_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ec8cf0e5c849b2922e3b9477ee666d_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia362249dbd9f44f1b5332ae17e959ded_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6dc5a498cf9414a802f893ec5b46c0f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dddd16fbc8540e2a41581289baa917d_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa0b05764a414ac78f6fd87d606b97fd_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c8fcad9f81446bcb60cc26cbc5f329f_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93f8e2a75c804d01bd28137196447c82_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da6b9fe3c7a45dfb9419e4c773ac239_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i218f04d9b7f145c4a3ab264f17ca1972_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971168baf86d4f9c9aee82b5e9765ccd_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fb1caa40c0048d0a80ef36f16745e1e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idde9ae17b3d542958541cede2a2481c6_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35a9f0667ea2442eb885a468202845d4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic52fe2f2070840529d3087ede78597e4_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04cd2aba94c64626b2bf9bb35be0b8ce_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0247826a7d194832a81af45a2cfe61dd_D20210102-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i445b3583a8f7464f94fbda78d87c16ea_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4011737647c446caa0d25b062561b85_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb8931e56e6c45ec95b31d5e8b47dc6e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10a8e5b6128d47dcbe8f521a6afdd884_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20d1b5c68b7248bd894117cbe81a2b72_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2aec28765054e47a8b50efa632378be_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab572d16389b4a3d99847cab2ea41fcc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic93479bb75b140d3802fac8c321d4809_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7080625bcf434804949496009873718c_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2efe1c927824b6abc801dccb6e57899_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b606e33b09d4e47ac8222e71af4b57d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic30704e87cef4c1f82e032e0b9646586_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92fb0f6b07fd46b6ba4261c7461fff4b_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0c29019e5ac47c4817bdab99ce15b5a_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d39089578604b9b9931f9e265946ecf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3056fc81cda24a63be80c8307b00b2da_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c3de4e4a9084bf98f767229d2d7f1f9_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b17a7fa5ce04b0bb62269c78f9e34bc_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia90bd12e1079420ab8c09c67bb824c80_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47e65bdb96ff4594b3069a428583550b_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9de5a5db4474de1862cf88701e361a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a7784b834fd4f77b0d696e7db0b1345_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifedb850ea024432c901960f936fab351_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieda8f95f074144778888a0e634d3e42b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i001a107c11d44b3f8675588a5f182420_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i291663fb25df40058a0517d4e9d7425e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc4ec47df1b34e468e64eed9bb89500e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f0371d74e96407b87bcc99e5690f80d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e205712f95140a09c2d11e6c6f425b7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e9f925ab5174bc3b4fed38f74de06a4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exel:TakedaAndIspenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i545cd28e851247caac6d1d375512f1c7_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90ee6fa4bd8843d2b764a321fa9de3f3_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c2d7715df546c183c0e89d6bd9ed3b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38484c00f8ed449e838f354569fb8a60_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fcd1390271d4d2abc556f67a01c14b4_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5138e445f8ee4ac79c11a13ebfd1db6a_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e7d911a57c6474c92d558bab6c033a4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a570d5f6c8420c9d45e3db1337a2a8_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i932765cb697a4b078cea923c81edd920_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80091c0e7cfb45668e3eb0d45b2c94f3_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1364c1c302444d838efffd43064715f9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41523be6e587448d8ab2f6b2f0c6f04b_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>exel:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i4913e232a2ad4455a008eed936155e00_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a62749d1d48443f886e9796c6337793_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id030fbf9dc0b477e938decac98663411_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a001be0ff84fe794c78832456ead43_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ee1ed1bb84547448046eae5336921cb_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26a61b54755e49e39e3e69a7ee48adb1_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ac924d3ae554ad193f222a56997ca8d_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8201aa36633a4adc95d3929b8b7b08c7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7699082fc113461698ab25c1cdd41c5f_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic70ffc1d027b441296ba4347fbd23534_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43e9d3f2b70a49bf940167c1f27ee63c_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c59059ae1a643cf9613f787f7e2b135_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie402c1037bde46c5af87b543056ba92d_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaa37e09ed2a4cc1877653a23011c082_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia63686e881124ae08b1ebf7e9f49fd77_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5970864bfa44baca1140501cee1fbfb_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ided9d969f2e1442982aa0a851fba5f6e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib50a0249433a4d278481e65be8ffe69f_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia12b136a6e174c9bbad11748d01a0e9c_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9da7e9b183de4698ac4c703b2c8f846c_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9527062f675b4046a1cebadb13e14991_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe693b49d3c949bd864806bd146b6a29_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8849b4c4c01946888c77e7fb6ccccb84_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c9d5031bdf542ceab4b6f6d4789fa7f_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithBioInventInternationalABBioInventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0491f03c0124ea5a708fd9ea63f6bc3_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithRyvuTherapeuticsSARyvuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f04ac5f92f4dfdb4acf9ff8f6d9471_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58839179e60147438d111534793e3584_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cfa17414554476d91dacbdd5d9a0abd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied291acb3b8349dcaa4d28395592f7e8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic96174b513db4b08a8d8022ebefad89f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eb3542aa68a458ba55ced4e19e05fd3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica491f30edaa49d7ad148efd0cbfa735_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe0063762fe744f0a9698d6a8a86e957_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc686d12fa4e4260b80a6d50f6424dc3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i701da0dfff384128b67d66f7cfc99222_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idef82cf2fbcf4ade8270cbe16f10de34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i172e305050d443b3a741d87593f63789_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i715f766ed6a447508a29b9beaf5cb949_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48ec553d89834f00b45ec9c811bb351c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>exel:investment</xbrli:measure></xbrli:unit><xbrli:unit id="bond"><xbrli:measure>exel:bond</xbrli:measure></xbrli:unit><xbrli:context id="if496ec13812c4ae893488d94baef090c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a8f66e27ef54639adf8c0c31673352c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i843bbd1a33f649a78d35d947eff4b9a7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51cbf38a72b74e8d987a9138cc078b1a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47c2e10640954a49859ec7c33dbb8e33_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81558c9856554de7833c4a2806a8b626_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id57f0a67c6b243ed9e67d6b085657e54_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1efce754a3e042719aca4d5d14d2cdc9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd3d6d7024114c76b5161677a09f1ff1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ee240d204304b82b2e177132d0e6bf1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb3f78b5c5b94afd80179a24fb7390ab_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec9a9b3bc1ed41a9bb7528566061b93f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88202d8592004d2c8c4852504e52b931_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibea0c087b202475e99958164943828bf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71fc629d67b1439596f3c19023047959_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b2ebe36f5674bb58674bb6f4330233f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebf3c208a48c4e599b699f4ab792b2db_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8475c0170e0e415f97fbec0694e96b99_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04b2a87a345c443dae1c0c9599142457_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b3c03a185f44b7cba57ea4cd0921028_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674f190343a44c93a3f972959dd570b6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5c375c63bd346fe978fb2534b5e3800_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a6d14de067741dca25498e9f73fd442_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i341945d209bf44d296c37ef93e0345ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3c5b394503146d3a0d022b6c8b89b92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a20eb1a92443bda7fa6b72c5a0d273_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie591104d91534932927cac2401b55411_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i830bd31e008547e886cd8a5ec319f87e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia04e0b0194d7409f8c9d6770aade56c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58211da7dc6f4d538de9873270446232_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i334c5f91f7f14f9fad4d7234cc49ea1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78e946b1e834488a8312b0d935e9f2a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f657f4786c94e5cabeabf0a738d4385_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i562efe5dbad445f48582bd754933cf24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3300c71f3304f4fabbe2333fa0e6f6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idede8e3136eb484884a82aa3c0a1d084_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie70ea002268c4a5caf09a2bd32761c1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fa1a26a550e4cdebc79e98ec28d3692_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica244ac307be4148a52ded97af82e32d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f2c7e017a444199ea80ad69ff9dc0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9e3be485f1040e99231bf20c8737b87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f55ae80ed464185acbc13298bd9b539_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d00e7f272ad46b9a14aaa1be9bc4934_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="forward_contract"><xbrli:measure>exel:forward_contract</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ica8f66740885481388f5091f3a93fae0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i047d415cbf9345cca4b2a12bea7fee45_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e8f6cf25ef845f4a4e6a6141299a680_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib058f0cc5ab4445c89f49affa1efcd07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide600b04f8ca45209f922b07e1285c93_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6daa97f735eb4c3cad12840eb32ed958_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie101975b1642454ca5efd600cefeebb7_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b4cfbc3bd5b41628d78e47135e8b32d_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86f9773b234244db921193fc80b4b36e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ac7f01c92b4900a09d849019f8bbde_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9969aa4426549599b32a31f08e5252b_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00a5e6ea88544cb1abee1be0125a342f_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i017ac814620d4a70b0883a3c64a8d2a4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i718d736b87a94552b1617644f5ddccec_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2435c09f4c4f918cabd7085d3ea04d_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f85bf38d0841c2b116c6c5df335710_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01b89020b108466aac157e717fc794ba_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc062842cb3848dd809f2e5dabf4b106_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia10e996f6a0045d68c311365d48c8ee0_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica6583f307a24123ab02aebe68d83ad5_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7f8b24349b54b9286007abc00e73aca_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id60e4edfc8694abe95bc6c4ad0cf0e80_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa1c4a397e174d8ba0fa3e03acd37402_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a96d01dde304dfb8bbc5a56f6a329e5_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7532b18472654211b7e84b715466a350_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c8d8dce3a7e43c8b39da1d6b4cad521_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81205acd3f214b2ebe487d5e61a93b20_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic592c97df7804add951c95d5fb5bae90_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9361d6f5134f4f68b7477fcf36e854a1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5282ce470894117a8f902fb69fc8b98_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if19df687aaf9496496468698046b7ca9_D20220525-20220525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-25</xbrli:startDate><xbrli:endDate>2022-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fc516136b174c0d801418fc499e2574_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia453aac57d974fd59f265a307e4added_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd464ef4ba6e4d6092da7bde626f4870_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia156218652c64c5d967262937d5d66a6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i538b59a91622490788eb54a07ebcd4bb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4cd574ea19b44f6a937ed92eb65fbdd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7e73b13cdc64519849d7dc7c3a4bab1_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">exel:Granted2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa050e767b3f498a8437c364816242c7_D20220702-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-02</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bebe181ca4a4b9cb14ab2651a68a39b_D20210703-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-03</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5af708b788b494aaa583b5ab133bc7f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a9356922a004cbe84b4a80ddb5be44e_D20210102-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6b335f201824eb588620f7043a28af2_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i937aea8377a0438cbd48a2aebc5ce5f0_D20220402-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-02</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7222e9059aa47e8a777492f23afd218_I20220415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if12649f24e1842e8bf8c979b733e75c6_D20220415-20220415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-15</xbrli:startDate><xbrli:endDate>2022-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0dc3aa0d4b14df392ed5c64240f0335_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:LeaseExpansionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f6fd2e746f24312a8f2a7091b4e91e5_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f643a473a8490da5ebb398751eb409_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09a2105efdab4080a91d211b2377ed70_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>exel:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i02f61410057849a2be1a95901d4749f3_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2fe2d2458b143ac93cfc5d3dd846556_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CybrexaTherapeuticsLLCCybrexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2acd12af1dc4ed6b0cbbf446ab05dc7_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CybrexaTherapeuticsLLCCybrexaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2df8f1634dda4f61b08a6be87c82e98b_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:SairopaBVSairopaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia221d1d4870d45218498c32c441b4569_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:SairopaBVSairopaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i549da58617674d2089ca2811b93aa142_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:199.50pt"><tr><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6ODkyZjQ2YjdiYzAyNGNjZjhjYjg5NjViZjQ4MjljM2YvdGFibGVyYW5nZTo4OTJmNDZiN2JjMDI0Y2NmOGNiODk2NWJmNDgyOWMzZl8wLTEtMS0xLTgyMTMy_657c51ce-8fde-4166-8298-f57130da1433">10-Q</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6ZGRjMzI1YmRhZTA2NGU0MGFlOTRkMGYzNTI5ZDY3MmIvdGFibGVyYW5nZTpkZGMzMjViZGFlMDY0ZTQwYWU5NGQwZjM1MjlkNjcyYl8wLTAtMS0xLTgyMTMy_99707f3c-0310-49f7-8e8c-93b700ea1b03">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the quarterly period ended <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl81NDk3NTU4MTU4MTU_43df44b1-e73d-47ae-9e5c-af6fd4c02814">September 30, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6YTk0N2UxNzkyZDM1NGMxNWJhYWVhNDAwMjE3NjkzMWUvdGFibGVyYW5nZTphOTQ3ZTE3OTJkMzU0YzE1YmFhZWE0MDAyMTc2OTMxZV8wLTAtMS0xLTgyMTMy_18420af4-fdbf-41a0-9965-e243b878cd73">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODkx_2d1a84e0-27a7-45f0-b5cf-02fc5cea3df3">000-30235</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-top:9pt;text-align:center"><img src="exel-20220930_g1.jpg" alt="exel-20220930_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:188px"/></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6YzU3ZWZkZDcyZmU2NGRhNThkM2Q2MjgyZThlNjM2OTMvdGFibGVyYW5nZTpjNTdlZmRkNzJmZTY0ZGE1OGQzZDYyODJlOGU2MzY5M18xLTAtMS0xLTgyMTMy_84c40751-cb26-4c97-85a8-cf1731ce84b7">EXELIXIS, INC.</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.359%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NzRjMzNkZTQ3ZGNlNDJmZWFmNjExNzg0ZTJjM2M1ZTcvdGFibGVyYW5nZTo3NGMzM2RlNDdkY2U0MmZlYWY2MTE3ODRlMmMzYzVlN18wLTAtMS0xLTgyMTMy_bb0ec148-5c36-4269-af4d-f5b097a724e3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NzRjMzNkZTQ3ZGNlNDJmZWFmNjExNzg0ZTJjM2M1ZTcvdGFibGVyYW5nZTo3NGMzM2RlNDdkY2U0MmZlYWY2MTE3ODRlMmMzYzVlN18wLTItMS0xLTgyMTMy_af196c3f-66b2-4f6f-905a-e8b0e80ce09f">04-3257395</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODg0_5fddd510-bf32-436b-b59e-dd42c377c024">1851 Harbor Bay Parkway</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODg1_6798fb05-7838-44b6-8ea8-e1e0125dd859">Alameda,</ix:nonNumeric> <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODky_4168bfe2-d121-46fe-8794-bb01ff8cab54">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODg2_c9d60c3d-8a95-48a4-81f4-782b2e641d57">94502</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODkz_f022c3c0-d168-446f-8aae-d58186c3a0f5">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODk0_400d8a3d-f3d3-4ae6-bb34-ea40f638df7e">837-7000</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NWYxYzk1ODgxZTA0NDQzZGE1MDczYzBiMDJkYjMxNzEvdGFibGVyYW5nZTo1ZjFjOTU4ODFlMDQ0NDNkYTUwNzNjMGIwMmRiMzE3MV8xLTAtMS0xLTgyMTMy_9de4a32c-5848-4875-a36a-26ee5144d6ad">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NWYxYzk1ODgxZTA0NDQzZGE1MDczYzBiMDJkYjMxNzEvdGFibGVyYW5nZTo1ZjFjOTU4ODFlMDQ0NDNkYTUwNzNjMGIwMmRiMzE3MV8xLTEtMS0xLTgyMTMy_7fdeb4b6-430a-4247-833b-248fcacf9e21">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NWYxYzk1ODgxZTA0NDQzZGE1MDczYzBiMDJkYjMxNzEvdGFibGVyYW5nZTo1ZjFjOTU4ODFlMDQ0NDNkYTUwNzNjMGIwMmRiMzE3MV8xLTItMS0xLTgyMTMy_7ccf9f7c-74a1-4551-aef9-dde358d12edb">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160; &#160;<ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODg3_b0d7cac2-ec94-4656-b6e2-1349a98d5fbb">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODg4_6667a983-e7ec-4cc9-a173-08ecc49e45a7">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.208%"><tr><td style="width:1.0%"></td><td style="width:31.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.169%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NmFkOGM3OTA3MmUzNGYyZjllNmNjYzY3ZjQ5MDhjNTIvdGFibGVyYW5nZTo2YWQ4Yzc5MDcyZTM0ZjJmOWU2Y2NjNjdmNDkwOGM1Ml8wLTAtMS0xLTgyMTMy_db45ac30-016b-4f57-979e-c98cc1f034f3">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NmFkOGM3OTA3MmUzNGYyZjllNmNjYzY3ZjQ5MDhjNTIvdGFibGVyYW5nZTo2YWQ4Yzc5MDcyZTM0ZjJmOWU2Y2NjNjdmNDkwOGM1Ml8xLTQtMS0xLTgyMTMy_2f33800e-7ff6-4cf0-b597-9416ead3d9cb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NmFkOGM3OTA3MmUzNGYyZjllNmNjYzY3ZjQ5MDhjNTIvdGFibGVyYW5nZTo2YWQ4Yzc5MDcyZTM0ZjJmOWU2Y2NjNjdmNDkwOGM1Ml8yLTQtMS0xLTgyMTMy_2bba6a2b-f7bf-4e15-8e64-06691229ecda">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act.    </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODkw_01a28733-4fcf-4f0a-88fe-d7e62e779fc7">&#253;</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of October 24, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i0c2e3793b63a4e5fb7d9a4731fc85bfa_I20221024" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODI5_dd1653d3-8439-4b93-b098-f7734642b4cc">322,561,418</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div></div></div><div id="i549da58617674d2089ca2811b93aa142_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_10">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_16">Condensed Consolidated Balance Sheets (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_19">Condensed Consolidated Statements of Income (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_22">Condensed Consolidated Statements of Comprehensive Income (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_25">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_28">Condensed Consolidated Statements of Cash Flows (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_31">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_67">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_82">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_82">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_85">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_85">37</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_88">PART II - OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_91">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_91">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_94">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_94">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_97">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_97">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_100">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_100">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_103">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_103">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_106">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_106">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_109">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_109">59</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_112">SIGNATURES</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i549da58617674d2089ca2811b93aa142_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i549da58617674d2089ca2811b93aa142_13"></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item 1. Financial Statements</span></div><div id="i549da58617674d2089ca2811b93aa142_16"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNy0xLTEtMS04MjEzMg_d758c5c2-f089-48fc-b071-cd6fb148fe80">675,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNy0zLTEtMS04MjEzMg_651fbf20-e254-43b5-a785-80449ad53db4">647,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfOC0xLTEtMS04MjEzMg_2b607926-6ef2-4f52-92e9-4e8cc6553066">871,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfOC0zLTEtMS04MjEzMg_57ca6e5b-324e-407f-b728-de8577258570">819,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfOS0xLTEtMS04MjEzMg_ff67e678-a799-45aa-871b-30887f4d54c6">215,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfOS0zLTEtMS04MjEzMg_10ca5535-3a56-4d3c-8bd9-35b55cfe23ad">282,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTAtMS0xLTEtODIxMzI_e02cbac1-197d-4803-ab38-6e9563b4c110">26,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTAtMy0xLTEtODIxMzI_fe94a74c-2037-4cfd-b4ba-ce46f55f3192">27,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTItMS0xLTEtODIxMzI_6bf6a16e-fec5-48ae-be41-58044d06d3bd">52,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTItMy0xLTEtODIxMzI_66c477db-5c49-4483-9929-bb81f624d1a5">57,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTMtMS0xLTEtODIxMzI_e555a663-7c6b-449d-90c3-78964ec569de">1,841,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTMtMy0xLTEtODIxMzI_2cf20b04-b743-4897-ae3b-dbfe0eb8394e">1,834,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTQtMS0xLTEtODIxMzI_0731fa04-7634-423d-9062-0be1f54712be">551,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTQtMy0xLTEtODIxMzI_fd80d528-1d8f-4248-9936-1b954ba37532">371,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTUtMS0xLTEtODIxMzI_57b57cb6-3023-4089-ab22-7f5ce60695b4">107,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTUtMy0xLTEtODIxMzI_779533a7-ad5a-4f2a-ba62-24a57a09ace2">104,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTYtMS0xLTEtODIxMzI_f9a1bca7-e00c-47c9-b237-874b5b4add91">116,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTYtMy0xLTEtODIxMzI_c9913c21-5089-4f2a-bef1-24d26b013555">111,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTctMS0xLTEtODIxMzI_29a85e54-6e88-490d-945f-cbfcef6cf21f">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTctMy0xLTEtODIxMzI_1cd40ba4-6d47-4746-8ca8-f471c6819200">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTgtMS0xLTEtODIxMzI_ae88755e-c8c2-47b6-90af-0490d1b2c0e2">280,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTgtMy0xLTEtODIxMzI_5d795ac2-1835-4336-8969-77b06d61de19">131,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTktMS0xLTEtODIxMzI_cbed35f0-4864-4976-9bc2-40f05ebd78c8">2,961,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTktMy0xLTEtODIxMzI_cba7b08f-9126-4f82-89b6-d0fd7cd16d39">2,616,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjItMS0xLTEtODIxMzI_92003ddf-f5f3-4b46-9a09-bfb90124c9b2">30,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjItMy0xLTEtODIxMzI_a1b57458-0879-4ce6-8acd-f2dccdd0d756">24,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjMtMS0xLTEtODIxMzI_c7400a53-10c2-4153-a5e2-0da2934cc083">66,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjMtMy0xLTEtODIxMzI_d1f0a0dc-45ab-49a9-a1d9-69b7392b89a6">61,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="exel:AccruedClinicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjQtMS0xLTEtODIxMzI_cbc38270-302b-4d71-98ec-4ce77468c44f">62,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="exel:AccruedClinicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjQtMy0xLTEtODIxMzI_2dee84b8-871b-4f2c-8a6a-0a188807fe27">77,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates and fees due to customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjUtMS0xLTEtODIxMzI_ff925608-1a8a-4dc0-925b-38a5463a5de6">43,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjUtMy0xLTEtODIxMzI_55310cf5-83a6-4b84-8c22-401c18f99e4a">33,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="exel:AccruedCollaborationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjYtMS0xLTEtODIxMzI_773a84a7-75e2-4f8e-b6f5-3bc8b94dd48c">18,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="exel:AccruedCollaborationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjYtMy0xLTEtODIxMzI_fb73b32f-bca1-41c2-a471-88ca60804d3b">86,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjgtMS0xLTEtODIxMzI_451ed19d-a14e-47d8-ba02-230cfc3aaab5">80,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjgtMy0xLTEtODIxMzI_3103d7a6-3ebf-4b14-a3af-9dfece1f75d9">53,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjktMS0xLTEtODIxMzI_1b7cab71-6a98-4240-8a7a-9f9b065b18a9">301,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjktMy0xLTEtODIxMzI_ef6937e9-c545-40f3-9db8-14ed7bbdac00">337,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzAtMS0xLTEtODIxMzI_8f2e4ad0-eae6-45b9-8e92-37ce02bfa5da">6,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzAtMy0xLTEtODIxMzI_95de69ca-6186-419d-bb40-b25950dca04d">8,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzEtMS0xLTEtODIxMzI_694575f9-e1fd-402e-81ad-f13b85c62b92">159,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzEtMy0xLTEtODIxMzI_c442118d-79bb-48b7-97ff-b511ed85a64a">51,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzItMS0xLTEtODIxMzI_dbb7c5b0-807a-4a21-b391-2db9fd73aa7e">1,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzItMy0xLTEtODIxMzI_9fa9e140-35e5-4cf6-b568-b729ec32173b">8,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzMtMS0xLTEtODIxMzI_48313467-6f19-454c-8762-b029df378282">469,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzMtMy0xLTEtODIxMzI_946550cc-f89d-4b2a-b958-e1c99d18b501">405,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzQtMS0xLTEtODIxMzI_d54b1b0e-b84c-43c4-b7d3-a90858b292d8"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzQtMy0xLTEtODIxMzI_11bcd1a9-32cb-4083-a514-74508680d20a"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjpkMTFiZTM5MWY0ZDA0ZmFlODQyYjJlODA0MzRmMTNjZl8yMQ_7a466327-04e5-4d16-bf24-76e3bff7dc02"><ix:nonFraction unitRef="usdPerShare" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjpkMTFiZTM5MWY0ZDA0ZmFlODQyYjJlODA0MzRmMTNjZl8yMQ_a37c71e0-6f53-4264-a9f4-9071aae192a3">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjpkMTFiZTM5MWY0ZDA0ZmFlODQyYjJlODA0MzRmMTNjZl8zNQ_4936bc2b-4d7e-4126-8ca0-858508dbcc29"><ix:nonFraction unitRef="shares" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjpkMTFiZTM5MWY0ZDA0ZmFlODQyYjJlODA0MzRmMTNjZl8zNQ_5a43d80d-2a4f-4d67-becc-d277187dfb81">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjpkMTFiZTM5MWY0ZDA0ZmFlODQyYjJlODA0MzRmMTNjZl82MA_04b4daeb-6bfb-4c5f-adfe-22d23fbb3f29"><ix:nonFraction unitRef="shares" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjpkMTFiZTM5MWY0ZDA0ZmFlODQyYjJlODA0MzRmMTNjZl82MA_6292b3d0-baad-4bd7-a2f8-8eb6b587db4c">no</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMS0xLTEtODIxMzI_2ae9ffbd-c9aa-45be-871f-23037ce31289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMy0xLTEtODIxMzI_d5ab79ab-cfe8-4803-bc0e-4a248501d07c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl8xOA_0c5770c2-c570-4cbf-96b7-523ad0e4e175"><ix:nonFraction unitRef="usdPerShare" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl8xOA_27a75278-0f9d-4d50-9c94-e62654ea7a7d">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl8zMg_3cc78733-c5f9-4905-b884-f0a07a382e38"><ix:nonFraction unitRef="shares" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl8zMg_6d79e4df-06ff-445f-be61-9a554c74daea">400,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl83OA_c911be28-8eae-4f9c-949c-e34620454448"><ix:nonFraction unitRef="shares" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl83OA_ecc47c08-2c6d-45d1-94d0-c0d795818779">322,541</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl84NQ_7e60924d-8d68-438e-924f-18701baf885e"><ix:nonFraction unitRef="shares" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl84NQ_c885091b-09fe-4b05-af7e-bf1631150476">318,842</ix:nonFraction></ix:nonFraction> at September&#160;30, 2022, and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMS0xLTEtODIxMzI_01972061-5bf7-4e6a-8a07-2c1cb6210e7b">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMy0xLTEtODIxMzI_08f3809c-0152-4be4-9310-90ae4e9c58c3">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzgtMS0xLTEtODIxMzI_8dd8b364-e07f-40bc-8955-6bdefa2e2cf5">2,512,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzgtMy0xLTEtODIxMzI_d104e345-31aa-41bc-9885-40d370dfc06e">2,427,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzktMS0xLTEtODIxMzI_f184518d-d983-4531-9747-744ed1e611a9">17,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzktMy0xLTEtODIxMzI_dc959ab4-9d44-4900-9f26-43042109b548">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNDAtMS0xLTEtODIxMzI_e406675e-7e00-4f52-bd0f-c3ba6728708f">4,052</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNDAtMy0xLTEtODIxMzI_fbc50c7c-0d82-4d16-91cc-647a132df4cd">216,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNDEtMS0xLTEtODIxMzI_62ed4920-391f-4842-b3a5-d0927398f127">2,491,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNDEtMy0xLTEtODIxMzI_b493f46f-80e4-48b1-84ec-d15f4f6d006b">2,210,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNDItMS0xLTEtODIxMzI_35c78909-818e-4421-83ea-610252b0c56b">2,961,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNDItMy0xLTEtODIxMzI_651c464c-088f-4a7a-b8a8-de6d4ef1484d">2,616,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i549da58617674d2089ca2811b93aa142_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.230%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i278c1109560d43989bb93fcb650c9afa_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMy0xLTEtMS04MjEzMg_38e3b007-f059-4afa-bd38-8dcff3636b6c">366,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0a6faac267459387d713c98a6da04c_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMy0zLTEtMS04MjEzMg_50af4c92-e8fb-4586-93e1-04914920724e">263,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac13ba8b31b461a9ee349f6df7ec401_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMy01LTEtMS04MjEzMg_7a776844-fbb8-45e3-89ca-61593d5d7896">1,023,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d1060e036714dc8b00e67d518425d7e_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMy03LTEtMS04MjEzMg_a27be67f-7809-4369-b6d3-8953f5c9462e">774,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3969d7ffe515467786d9f03efe7dd44a_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNC0xLTEtMS04MjEzMg_9a901ccd-9a8e-48c4-9246-d87873432d13">34,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ffeb5a9e14d43f5bf61509594c23244_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNC0zLTEtMS04MjEzMg_731c357c-bcc9-4384-87f6-135cb3c45fad">49,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e199975584423f9f9b5fc5676b433e_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNC01LTEtMS04MjEzMg_bc934172-bcf8-447d-af74-e61800e545c2">123,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86031b3c8cd74803ab4a6280a4faaea9_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNC03LTEtMS04MjEzMg_c6f22005-e83d-4c92-b079-63e262ecf15c">116,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd67de25ab5242d6acec13d5bb1dcd8c_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNS0xLTEtMS04MjEzMg_b18adcd8-ba5d-4ba8-a368-cf76e5bcb845">10,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3212d047299943f1aefbd2a60b170c8c_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNS0zLTEtMS04MjEzMg_5a5f80e6-9bd3-4dca-b3d4-3e6e65ce8426">15,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0edff0af2d424980d236133e9e6a27_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNS01LTEtMS04MjEzMg_51d9488b-1be2-46c2-92fc-80fac391ef98">39,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06c48663d594ceeabfd8945d8b2d8be_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNS03LTEtMS04MjEzMg_9aeb5cf4-8ad1-4d0a-b1e1-d1531ebba305">92,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNi0xLTEtMS04MjEzMg_c3c24c35-78a2-4ad4-9118-3f3ab6603e59">411,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNi0zLTEtMS04MjEzMg_74bdfb0e-7a9d-4b74-a136-1246b0efcb04">328,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNi01LTEtMS04MjEzMg_c54b7894-a480-4bc0-81c2-97b2de9eb46c">1,187,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNi03LTEtMS04MjEzMg_1b357370-1af1-40cc-852f-4eb3d98fe925">983,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOC0xLTEtMS04MjEzMg_2fb26b87-5c51-4f7d-870c-f3130ea520ca">15,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOC0zLTEtMS04MjEzMg_9cd572b0-1961-473e-b8c2-84b9eeb586f8">11,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOC01LTEtMS04MjEzMg_1aa61d98-1d1c-4c5b-b9db-672270139c1d">41,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOC03LTEtMS04MjEzMg_281ba82c-7770-4acc-a670-c107343e643d">39,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOS0xLTEtMS04MjEzMg_23aab516-3899-41d9-b7e4-1d006e6953bd">198,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOS0zLTEtMS04MjEzMg_ed23d226-6c91-4e9e-85ec-a2c78e5db921">163,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOS01LTEtMS04MjEzMg_d00c4325-b5d5-4951-ad13-0d494386c89b">554,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOS03LTEtMS04MjEzMg_81f79629-ac63-417c-8c5c-745159493d17">471,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTAtMS0xLTEtODIxMzI_c6b4c26d-732d-4522-8b10-2b4558630c7c">114,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTAtMy0xLTEtODIxMzI_ab1f1688-df4e-4d83-af73-72811fc63132">101,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTAtNS0xLTEtODIxMzI_79818db4-e796-435a-ae16-b150686f802d">340,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTAtNy0xLTEtODIxMzI_b6f09a15-e177-45fc-9944-b98ee9f7dfbe">302,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTEtMS0xLTEtODIxMzI_0969ccf7-9046-468d-916e-c056cd90a747">329,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTEtMy0xLTEtODIxMzI_9189c89b-3d54-4d06-bf7d-ba2b341ed5cc">276,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTEtNS0xLTEtODIxMzI_242c7805-9914-4719-9732-2e58c08bb1ab">937,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTEtNy0xLTEtODIxMzI_79724783-fcb5-4561-85f0-5ef7719b2288">813,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTItMS0xLTEtODIxMzI_c9f2e860-1728-44a0-a25b-646f85c3b888">82,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTItMy0xLTEtODIxMzI_8ce1c068-638f-478f-aee2-4865caab1af9">51,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTItNS0xLTEtODIxMzI_cd983915-d570-4115-ad06-c96afe8c5a5a">249,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTItNy0xLTEtODIxMzI_765457f4-b89b-4432-a8a3-7873ac30467b">170,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTMtMS0xLTEtODIxMzI_9c45ef61-6845-450c-8898-58cbaea7903e">9,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTMtMy0xLTEtODIxMzI_ea57eb8e-5526-4aa6-bce7-0915f3337222">1,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTMtNS0xLTEtODIxMzI_ecb43fe6-b728-4edf-bd88-6ebc6891bba4">16,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTMtNy0xLTEtODIxMzI_322d118f-deed-49a1-8ceb-1ff794b547d8">6,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTQtMS0xLTEtODIxMzI_ded368ae-02c8-424e-a001-3028dae32abe">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTQtMy0xLTEtODIxMzI_c0f39b8a-41c0-476b-a7e9-84d5db6ac4dc">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTQtNS0xLTEtODIxMzI_c63cf43a-7452-47b0-9572-5aa7d28c022d">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTQtNy0xLTEtODIxMzI_cd83b80d-2c76-4186-bdd5-1c1eea22dff6">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTUtMS0xLTEtODIxMzI_5d1c198a-499f-4fed-9dfd-85aa59a26ec9">92,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTUtMy0xLTEtODIxMzI_47057d1d-d5e3-4b2d-acfa-81a8ba1bd45f">53,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTUtNS0xLTEtODIxMzI_99db1bbf-685d-4982-8fc2-f9f819fc204b">265,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTUtNy0xLTEtODIxMzI_e053ec0f-98fd-4e02-ac63-01ac08bab1f1">176,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTYtMS0xLTEtODIxMzI_53e94e76-e1e8-4524-892e-1d98c382d5a5">18,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTYtMy0xLTEtODIxMzI_df4ef6ee-6abc-4f01-9995-7eee0c5e2b04">15,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTYtNS0xLTEtODIxMzI_ba834219-556e-477f-be04-7d70234abe4b">53,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTYtNy0xLTEtODIxMzI_cd57bfaa-bb91-462f-90b9-20244ccc81f8">40,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTctMS0xLTEtODIxMzI_889dbc69-cf05-4582-8067-599f9c261a92">73,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTctMy0xLTEtODIxMzI_1f6f8b86-278b-4f63-a418-c6e38dc6dd9f">38,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTctNS0xLTEtODIxMzI_b96f8e34-4f97-4c48-b413-5fc22d7afe47">212,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTctNy0xLTEtODIxMzI_fc8fca3f-c8bd-40e1-a0db-2d0e882cb922">135,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTktMS0xLTEtODIxMzI_af8c9812-f86c-4cd8-8cc2-c3876efed11b">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTktMy0xLTEtODIxMzI_e2b08333-422f-4063-8bc4-ecf08b9a8345">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTktNS0xLTEtODIxMzI_19cfb9ee-d3ab-4dfd-b643-e4dcd544c67a">0.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTktNy0xLTEtODIxMzI_1b7e678b-22cb-4a35-8c88-83c4a84bbffe">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjAtMS0xLTEtODIxMzI_c166bc86-c867-4741-a570-6e678ee0095b">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjAtMy0xLTEtODIxMzI_28dacb57-e729-44f5-96a7-df7dd34c5b64">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjAtNS0xLTEtODIxMzI_2b68a748-bb3d-4890-9f8e-0ddecb184328">0.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjAtNy0xLTEtODIxMzI_2592c4fd-12f1-41cc-b6bf-8bec35b6d458">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjItMS0xLTEtODIxMzI_febdea61-4101-4a5b-ab9d-a7a48040e83a">322,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjItMy0xLTEtODIxMzI_b47dcaaa-caad-4421-bf5a-82f44ca8542f">315,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjItNS0xLTEtODIxMzI_18116302-0c27-4db1-9bf6-4fff70cf994d">320,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjItNy0xLTEtODIxMzI_093674d5-4de6-4a90-a35f-1892dae4da1e">313,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjMtMS0xLTEtODIxMzI_b198bd09-986d-4f36-90c9-7c6e90be1772">325,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjMtMy0xLTEtODIxMzI_f73b231d-c4fc-4cb4-9b7d-6f69d0f935d7">322,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjMtNS0xLTEtODIxMzI_c39fd5eb-d0f1-4c1d-ba8e-5a294fe5b0a8">324,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjMtNy0xLTEtODIxMzI_d07b041c-8e17-4835-9875-296ab2c754b0">322,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div id="i549da58617674d2089ca2811b93aa142_22"></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.660%"><tr><td style="width:1.0%"></td><td style="width:40.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.929%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfMi0xLTEtMS04MjEzMg_889dbc69-cf05-4582-8067-599f9c261a92">73,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfMi0zLTEtMS04MjEzMg_1f6f8b86-278b-4f63-a418-c6e38dc6dd9f">38,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfMi01LTEtMS04MjEzMg_88dff030-d061-47ee-ba11-84c8c8ecae5f">212,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfMi03LTEtMS04MjEzMg_6a1e99be-fb1a-4cff-b998-444a07560966">135,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses on available-for-sale debt securities, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC0wLTEtMS04MjEzMi90ZXh0cmVnaW9uOmIxOTUzMjgxZGRhYTRlZmM4MjNlNzQ5ZWQzYzZlOTJhXzg2_1e4c54ba-a30e-4d4d-87a0-9cd8d3495dbd">2,457</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC0wLTEtMS04MjEzMi90ZXh0cmVnaW9uOmIxOTUzMjgxZGRhYTRlZmM4MjNlNzQ5ZWQzYzZlOTJhXzkw_163d3cf8-c634-41c0-bc2c-0eefb8cea42a">193</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC0wLTEtMS04MjEzMi90ZXh0cmVnaW9uOmIxOTUzMjgxZGRhYTRlZmM4MjNlNzQ5ZWQzYzZlOTJhXzk0_2ad40c17-57f9-4f68-b46f-e4a1afba0cd8">4,752</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC0wLTEtMS04MjEzMi90ZXh0cmVnaW9uOmIxOTUzMjgxZGRhYTRlZmM4MjNlNzQ5ZWQzYzZlOTJhXzEwMQ_adfe2fbd-8ac3-46b9-9fd6-0f7e7d2505e5">949</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC0xLTEtMS04MjEzMg_64e4256b-6a84-44ac-afa3-7b1e90a5f36e">8,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC0zLTEtMS04MjEzMg_395a0654-0940-4d7c-bb26-a9520f03175f">504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC01LTEtMS04MjEzMg_df3c120c-578f-4741-878b-303cdd2565b6">16,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC03LTEtMS04MjEzMg_627b5036-0117-400d-96ca-7380e4bf3e4b">2,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNi0xLTEtMS04MjEzMg_b68677e4-c4a5-4975-b84a-14ad6371157f">64,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNi0zLTEtMS04MjEzMg_fc1d60a8-6475-4184-baa6-820292d126c5">37,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNi01LTEtMS04MjEzMg_2fc63b8c-234a-4b77-ab4f-37fb1233ad25">195,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNi03LTEtMS04MjEzMg_bda69211-9a81-436d-9c56-566c861cc89f">132,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i549da58617674d2089ca2811b93aa142_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2022</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i825124e3b6104871b081a44c670a7a86_I20220701" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMy0xLTEtMS04MjEzMg_88f9a0fa-3479-4ec7-b11d-1ede53d55c61">321,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i825124e3b6104871b081a44c670a7a86_I20220701" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMy0zLTEtMS04MjEzMg_c5dea7d2-fc07-4517-96e2-ed9af9716315">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b23ba8f2c94ddcb48f6a85901903b5_I20220701" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMy01LTEtMS04MjEzMg_0991e768-a5dc-4d16-8ae8-66989b700767">2,477,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdff014306a24f67bd885f70ff909a7d_I20220701" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMy03LTEtMS04MjEzMg_703def8c-fbf3-441d-a802-acaf1009cd74">8,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6604d7fea14d4e8fb16b161c841a6999_I20220701" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMy05LTEtMS04MjEzMg_4453e24f-4b70-4d89-ace0-0aa40893b7de">77,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64041df1701a4a07b8ef7d5c0f37f576_I20220701" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMy0xMS0xLTEtODIxMzI_157eac20-425f-45ab-9b0a-e93ab3dfd6ca">2,391,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149d987491b846698276e3ab735170f7_D20220702-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNC05LTEtMS04MjEzMg_7f9433ea-eab2-41db-bbe4-f1485aa71c7d">73,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNC0xMS0xLTEtODIxMzI_6c043b1f-57d8-4ac8-8816-a1b18ef7f077">73,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54dcb905f0384fd8bce6b7e44c2faa57_D20220702-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNS03LTEtMS04MjEzMg_e532fa6e-90c8-49fb-b8b4-f5672fec9817">8,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNS0xMS0xLTEtODIxMzI_2700dfcd-3e26-410e-a03f-b0eadbb6cdc6">8,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44690402ba504bd1987f6bea7e60ccfc_D20220702-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNi0xLTEtMS04MjEzMg_419ed4dc-3082-4766-9460-e7829a682d0a">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44690402ba504bd1987f6bea7e60ccfc_D20220702-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNi0zLTEtMS04MjEzMg_07f7c624-b6aa-4851-9a9c-d9d38ed4c644">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68253ae6a74648f0b87bb4a6390ffc5f_D20220702-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNi01LTEtMS04MjEzMg_2f996cd1-797c-4186-8b38-1b680a392bf0">2,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNi0xMS0xLTEtODIxMzI_ecfef656-12da-4cc1-9e4b-5726ca80beec">2,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68253ae6a74648f0b87bb4a6390ffc5f_D20220702-20220930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNy01LTEtMS04MjEzMg_278a7f65-ae69-45d7-a036-be0d22d63d61">4,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNy0xMS0xLTEtODIxMzI_32931e5d-9265-4640-a6d0-db9903e22b7f">4,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68253ae6a74648f0b87bb4a6390ffc5f_D20220702-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOC01LTEtMS04MjEzMg_c61fefde-9196-4807-9c6b-2940fbfe979f">37,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOC0xMS0xLTEtODIxMzI_5f8059ee-aa4e-480a-b392-a7d916540f91">37,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00d8665815014c9aae47cbac0416c062_I20220930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOS0xLTEtMS04MjEzMg_72b95f3d-e8ce-4adf-8715-f90d571b8106">322,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d8665815014c9aae47cbac0416c062_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOS0zLTEtMS04MjEzMg_448eb1da-a79e-4386-b820-b671bb54d1fb">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283a9472e4fa421799257a1a2bd9fa1c_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOS01LTEtMS04MjEzMg_f68e1dec-610e-4fc4-b21d-468c6652c160">2,512,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4697a4d7dcd4136b84bf95f0e95aac8_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOS03LTEtMS04MjEzMg_8acfa912-4205-4100-9fa3-3725d095ebd4">17,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8188cffbcf746278fdee32a78f4a8cb_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOS05LTEtMS04MjEzMg_44115f66-1f75-4311-9d90-c4b8227a123f">4,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOS0xMS0xLTEtODIxMzI_2903f0c0-02e7-4204-bfa9-7ce62f39c7f2">2,491,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2021</span></div></td></tr><tr style="height:31pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0570e9a9f97c4dfc9839b7ab1860e680_I20210702" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTQtMS0xLTEtODIxMzI_2586ec11-7852-44fa-87d9-50a77a9f01e4">314,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0570e9a9f97c4dfc9839b7ab1860e680_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTQtMy0xLTEtODIxMzI_bf9d30d8-7b3f-4fba-bce0-9cda51de4ecc">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f67f4b8f82417db30834591fb44d60_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTQtNS0xLTEtODIxMzI_8e774cbe-bf40-4c42-b723-d2d7fd895cfa">2,390,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4b7ab3407c44cb8b1ed0210197c8e9_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTQtNy0xLTEtODIxMzI_f5526f80-1518-4c20-98f1-624b06c52b7a">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic87ae071c1834ea6abd407e1ee1c295a_I20210702" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTQtOS0xLTEtODIxMzI_e95beb8d-5de5-4f33-b843-47aa23920287">349,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6899e05fb3f5440cb7983ea4ae13b93b_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTQtMTEtMS0xLTgyMTMy_ec510cb7-36c5-41d4-82dd-c7d2a6e2dd82">2,043,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f3dc37f9c84491ba474d260d6688295_D20210703-20211001" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTUtOS0xLTEtODIxMzI_6e495d0a-6de3-4e44-92dc-f8cf4b986463">38,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTUtMTEtMS0xLTgyMTMy_ddfb530c-499b-4fbf-b55d-ab16ec274acc">38,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2afa3de03a1043199b82592539c4213f_D20210703-20211001" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTYtNy0xLTEtODIxMzI_ae4feb4a-bf01-4290-b0a8-c5832643b5e9">504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTYtMTEtMS0xLTgyMTMy_43966c99-8339-4bd2-9f65-17246063e3c3">504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81def5dda1a6445d84955509b0fe837a_D20210703-20211001" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTctMS0xLTEtODIxMzI_c46ca3bb-6c05-499f-adec-5bfb997fb364">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81def5dda1a6445d84955509b0fe837a_D20210703-20211001" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTctMy0xLTEtODIxMzI_bae53e67-11ab-434a-8474-9df7fa6742bc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029f475a4cb743c883c1e02d0bd1e0ca_D20210703-20211001" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTctNS0xLTEtODIxMzI_889e2c47-19a7-4bb4-a1bb-c6a967786512">3,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTctMTEtMS0xLTgyMTMy_a4da3d7b-89b6-4b87-9fd1-0bada84d04ce">3,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i029f475a4cb743c883c1e02d0bd1e0ca_D20210703-20211001" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTgtNS0xLTEtODIxMzI_f6916f24-4fed-40a4-8812-495da7414b64">5,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTgtMTEtMS0xLTgyMTMy_871daf8c-e7d5-4a18-a5d6-957831e4ba9b">5,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i029f475a4cb743c883c1e02d0bd1e0ca_D20210703-20211001" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTktNS0xLTEtODIxMzI_2305893c-d63a-47c7-8a4b-5f3717c9cb7c">34,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTktMTEtMS0xLTgyMTMy_e0519cd1-3efe-461e-b561-b1e7e017c247">34,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d2bb7e98f0347679cc8ee55fd39e05e_I20211001" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMjAtMS0xLTEtODIxMzI_791dd566-c808-411f-a249-64459ee5becb">316,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2bb7e98f0347679cc8ee55fd39e05e_I20211001" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMjAtMy0xLTEtODIxMzI_b0630a73-b085-4ffa-8a98-cee45249e6c5">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09ffd775b454fd28bc4ccc68d578a46_I20211001" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMjAtNS0xLTEtODIxMzI_477c6c4d-0c4e-4218-8315-69bacf4df36c">2,422,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6024509ae78487f8fce552a0976856d_I20211001" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMjAtNy0xLTEtODIxMzI_db23d639-d043-4640-840c-22a5e4b5fd91">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25b72e0f00af411b8652e825b767f230_I20211001" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMjAtOS0xLTEtODIxMzI_19a19aa5-d65f-4ceb-a16f-ba825c278378">311,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacaf43cbe24a472ba26b4376244aeceb_I20211001" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMjAtMTEtMS0xLTgyMTMy_a942ab13-398e-4802-b5d3-bb558d295545">2,112,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continued on next page</span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22983ccf5d88438696ca9ed782f2b97a_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMy0xLTEtMS04MjEzMg_4f8dc0af-be1a-4081-bf3b-9d3c7d04d4a7">318,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22983ccf5d88438696ca9ed782f2b97a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMy0zLTEtMS04MjEzMg_dabd5b60-0073-4e2f-a64b-92b27bb93c73">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa68b5c6fea4b5eb3e3e88045cc2288_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMy01LTEtMS04MjEzMg_15319750-b18b-47a6-8db3-4cb0d20b309e">2,427,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77a026db7c644033a1c8a0268a3cc765_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMy03LTEtMS04MjEzMg_c842194a-c6be-4fee-b2d8-8e1342751fdc">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7950e15bb4194a85a2dfe92d26c1c011_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMy05LTEtMS04MjEzMg_d1cc422b-3b6d-4c8e-a639-25ac52279ff5">216,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMy0xMS0xLTEtODIxMzI_5c968e48-718f-4045-b5b5-a78f51fe055e">2,210,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a29957ee8b14a00a22d941a4f3bb1cf_D20220101-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNC05LTEtMS04MjEzMg_5e35253e-61d3-4e23-9492-ade69cde7399">212,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNC0xMS0xLTEtODIxMzI_8437a22b-1414-43c2-9618-a9e2ae542ba3">212,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb6a382becc140a4b1da483762a0959f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNS03LTEtMS04MjEzMg_917a1f03-1aa2-47ab-8c25-535f5e0ab35b">16,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNS0xMS0xLTEtODIxMzI_e751bbe1-6d8b-43c9-a08f-23dac1a1a350">16,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock under equity incentive plans and stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6ac406b2dc941da8bb9bf4a2a0c6bc4_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNi0xLTEtMS04MjEzMg_99fb2a5c-e591-43ce-bfc3-bd689746683c">3,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ac406b2dc941da8bb9bf4a2a0c6bc4_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNi0zLTEtMS04MjEzMg_9867d2a9-b90a-41eb-bfc0-6ab345a56bcf">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058269d798474c4f81f2c52f1a695d17_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNi01LTEtMS04MjEzMg_96a979ca-0567-47b1-9cbf-fd1ad07e00bd">18,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNi0xMS0xLTEtODIxMzI_3b540f36-ecf5-4b03-a5fd-a155c8bc1caf">18,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i058269d798474c4f81f2c52f1a695d17_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNy01LTEtMS04MjEzMg_b52744ac-fcb5-496a-bd59-3f96eee3b3a7">16,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNy0xMS0xLTEtODIxMzI_77c7cb90-d8a9-49a5-9e66-c296af4f8cc0">16,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058269d798474c4f81f2c52f1a695d17_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOC01LTEtMS04MjEzMg_92df1d2f-d31b-4066-9d88-ec5792bb83d9">82,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOC0xMS0xLTEtODIxMzI_b49b3f15-7361-42eb-90d9-8d054508e26e">82,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at September&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00d8665815014c9aae47cbac0416c062_I20220930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOS0xLTEtMS04MjEzMg_d6a9b6fa-26ac-4944-b74d-f452765eb105">322,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d8665815014c9aae47cbac0416c062_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOS0zLTEtMS04MjEzMg_cce28ac9-89a4-4ee3-aba8-ced7ff5f3352">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283a9472e4fa421799257a1a2bd9fa1c_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOS01LTEtMS04MjEzMg_318fff7e-a004-4642-ba66-8be0d004dd7e">2,512,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4697a4d7dcd4136b84bf95f0e95aac8_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOS03LTEtMS04MjEzMg_adaf7b31-977c-41b9-973c-46a737fa2b29">17,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8188cffbcf746278fdee32a78f4a8cb_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOS05LTEtMS04MjEzMg_2a737fac-5697-4f52-b592-10c780b1c058">4,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOS0xMS0xLTEtODIxMzI_5a1755ad-6ab5-435e-9dde-f322d80f570c">2,491,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98f25495c49942328fe52185ebb36868_I20210101" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTQtMS0xLTEtODIxMzI_904163da-42b7-48c2-b128-508d85e03533">311,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f25495c49942328fe52185ebb36868_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTQtMy0xLTEtODIxMzI_1298f688-ff9f-4c8d-bdc4-04219a53ef30">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe63aa422cd4993aa00fe1bec11e108_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTQtNS0xLTEtODIxMzI_4dbfdc34-11f0-4c4b-ac4f-0c312e913805">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b4239fc7694a5f9a055a4f8d0ea9d0_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTQtNy0xLTEtODIxMzI_c9e38edc-4f66-4a91-bc54-40df5491b6ae">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i897ee6ad5f0f4e8a932659340f671c9b_I20210101" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTQtOS0xLTEtODIxMzI_a31fdc05-f35a-4015-a1b4-dbf4b79ce76f">447,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48eab2e753614354a3732f75587e636f_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTQtMTEtMS0xLTgyMTMy_bc62cfa4-c274-4dec-a5a3-0ef3f7415b9b">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c9d8627fe44d7983aa3b965e06e09b_D20210102-20211001" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTUtOS0xLTEtODIxMzI_dbd67927-4ce0-400e-9e48-17e96a651fc2">135,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTUtMTEtMS0xLTgyMTMy_007b9b71-f921-4b72-9c6f-a5372a20a389">135,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb5c647740f4d2d99a83b98b0fc1e73_D20210102-20211001" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTYtNy0xLTEtODIxMzI_ea0f1cd6-ea96-4cbe-8b27-80bb4fcaba7c">2,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTYtMTEtMS0xLTgyMTMy_6ab68952-65c7-4d41-a02c-e4b5acf1aeac">2,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock under equity incentive plans and stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b44b1b4753f4fc19f53534dfb54799f_D20210102-20211001" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTctMS0xLTEtODIxMzI_b181d70c-613b-4702-9114-294d587e528f">4,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b44b1b4753f4fc19f53534dfb54799f_D20210102-20211001" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTctMy0xLTEtODIxMzI_156213b7-7009-460a-b287-f06ce2115c01">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f53e591b0874be8be6c8805109d1335_D20210102-20211001" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTctNS0xLTEtODIxMzI_e211570f-4035-41e3-97c3-1a389ed9fa1d">18,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTctMTEtMS0xLTgyMTMy_09e34f1f-bc69-41de-8f69-6ba889d4da2d">18,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f53e591b0874be8be6c8805109d1335_D20210102-20211001" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTgtNS0xLTEtODIxMzI_a7ee1081-9e2d-4807-8722-e737f6f1824d">15,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTgtMTEtMS0xLTgyMTMy_e93d7321-b5db-4865-a986-4e19fc2ce505">15,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f53e591b0874be8be6c8805109d1335_D20210102-20211001" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTktNS0xLTEtODIxMzI_d5c63650-82e4-4cb9-9def-4898f2717970">97,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTktMTEtMS0xLTgyMTMy_2b2f53ba-e13f-4310-9d38-b1b101818bc7">97,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d2bb7e98f0347679cc8ee55fd39e05e_I20211001" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMjAtMS0xLTEtODIxMzI_52f2d6fa-c285-4466-b2e4-55e09153eaa4">316,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2bb7e98f0347679cc8ee55fd39e05e_I20211001" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMjAtMy0xLTEtODIxMzI_4023119f-7485-4c34-862a-e2463bc34d1c">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09ffd775b454fd28bc4ccc68d578a46_I20211001" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMjAtNS0xLTEtODIxMzI_47705539-727b-49c7-be8a-5781adab143d">2,422,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6024509ae78487f8fce552a0976856d_I20211001" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMjAtNy0xLTEtODIxMzI_482a7061-5990-435a-b4a4-03201eacc38d">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25b72e0f00af411b8652e825b767f230_I20211001" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMjAtOS0xLTEtODIxMzI_41cf401b-7286-4f82-86f7-bc176da25cb0">311,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacaf43cbe24a472ba26b4376244aeceb_I20211001" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMjAtMTEtMS0xLTgyMTMy_67775bd0-bb08-4452-8124-5daacca80839">2,112,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i549da58617674d2089ca2811b93aa142_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMi0xLTEtMS04MjEzMg_4e6a99a4-49bc-44a1-b242-935ce057113c">212,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMi0zLTEtMS04MjEzMg_fc8fca3f-c8bd-40e1-a0db-2d0e882cb922">135,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNC0xLTEtMS04MjEzMg_30db53ac-abd9-4e9e-977c-a74e40a1531d">14,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNC0zLTEtMS04MjEzMg_e9f7c583-e6c1-4cfa-9fe6-3f904c735ac6">11,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNS0xLTEtMS04MjEzMg_3a5dcdfd-0300-4093-977d-0aab17c200c8">81,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNS0zLTEtMS04MjEzMg_cda5d5d0-c224-4b17-a463-f49fe8a259a0">96,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNi0xLTEtMS04MjEzMg_f32077fe-6865-4432-9755-a41cfa903b5a">11,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNi0zLTEtMS04MjEzMg_7a08d9ad-1079-4363-b13b-0f7889b3644a">3,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNy0xLTEtMS04MjEzMg_f0fe44ea-6131-423b-9324-43f3d62d7f2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNy0zLTEtMS04MjEzMg_a47b29f7-1e43-43d4-a6cb-ed003ef9e885">32,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfOC0xLTEtMS04MjEzMg_e9b5c4a4-88df-4569-aa4a-7b057c7f0521">7,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfOC0zLTEtMS04MjEzMg_94975213-b5df-4f4d-b2b7-3f26f1d17f07">35,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTAtMS0xLTEtODIxMzI_da6cbf9e-f7ad-4314-8c42-a59736c354bd">66,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTAtMy0xLTEtODIxMzI_795d132a-2f28-42c4-a560-bdeb615386a3">20,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTEtMS0xLTEtODIxMzI_995acbd0-d211-4adf-af0e-9020fbde1d33">9,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTEtMy0xLTEtODIxMzI_25b59340-271e-4651-94b0-fb3a20c502df">26,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTMtMS0xLTEtODIxMzI_31c769f7-5f37-4d80-b23f-75f875beb528">35,166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTMtMy0xLTEtODIxMzI_70fbf17e-6aec-4564-806d-fdbe3a5aead0">24,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTUtMS0xLTEtODIxMzI_b3d3dc20-f238-4295-b650-0931720085fb">3,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTUtMy0xLTEtODIxMzI_e1e3ddb9-aa2a-4d6b-b7a9-6104cf9b9461">11,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" sign="-" name="exel:IncreaseDecreaseInAccruedCollaborationLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTYtMS0xLTEtODIxMzI_82a8bfb2-cdd8-450e-8501-00d7bc06075b">64,976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="exel:IncreaseDecreaseInAccruedCollaborationLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTYtMy0xLTEtODIxMzI_f85ed745-ad43-47d9-8f20-04a259f2dc71">13,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTctMS0xLTEtODIxMzI_ff3cab39-a6f2-4e8d-9d6a-6db90e15aa1e">6,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTctMy0xLTEtODIxMzI_350501ac-c6ac-46d5-8b9a-11ebde6c8622">33,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTktMS0xLTEtODIxMzI_ea0ee515-5e02-4bb5-986c-93bde19aa9d7">288,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTktMy0xLTEtODIxMzI_515e7f52-1cb1-46d5-b278-e97c87e2699c">304,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjEtMS0xLTEtODIxMzI_53ee6850-1abf-435d-a73e-cb0bbaa1aa9a">25,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjEtMy0xLTEtODIxMzI_0b2c2470-bbcc-4b28-8723-355000e7304e">48,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjMtMS0xLTEtODIxMzI_eb7d2578-4e61-4541-816f-e0bf95aa18d7">1,079,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjMtMy0xLTEtODIxMzI_21604cfb-5475-46b8-826f-353bbcd04589">1,077,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjQtMS0xLTEtODIxMzI_440a2e0c-c65c-422e-8ca8-fb5e2fae44f9">826,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjQtMy0xLTEtODIxMzI_60a9d008-38b6-482e-bdd2-964efcf41a59">1,095,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjUtMS0xLTEtODIxMzI_91c8de0e-b6ec-40a5-a940-9834d45cfa33">278,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjUtMy0xLTEtODIxMzI_6ee5a83b-accf-45e6-b86f-5ba3858e47ee">29,829</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjctMS0xLTEtODIxMzI_fa415496-78a7-4483-b135-16f6a1fb7c8f">18,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjctMy0xLTEtODIxMzI_a217dfd3-1a60-4a9b-baf9-e290feec5798">18,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjgtMS0xLTEtODIxMzI_4db85822-7124-4e40-8fb5-8bfd36640885">16,091</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjgtMy0xLTEtODIxMzI_b78ae3fa-33c5-413b-967e-ca2ee25aff41">15,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzEtMS0xLTEtODIxMzI_0172da2a-95af-4530-9f40-8931afb65d24">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzEtMy0xLTEtODIxMzI_8385c921-ab7f-4f16-af4b-b87416478b2f">3,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzItMS0xLTEtODIxMzI_6beff7b2-6b52-40cf-8255-86325366a552">12,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzItMy0xLTEtODIxMzI_15e39bfc-dde9-4c84-94fd-2cdf71e1d71d">277,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzMtMS0xLTEtODIxMzI_69fa3cf8-3ed9-460f-a835-39d8d3968d25">663,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48eab2e753614354a3732f75587e636f_I20210101" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzMtMy0xLTEtODIxMzI_2b559ec0-4ab5-4e57-9b57-b4f59bc2a96b">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzQtMS0xLTEtODIxMzI_1267ea22-82b8-441f-b759-03faf11d47e8">676,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacaf43cbe24a472ba26b4376244aeceb_I20211001" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzQtMy0xLTEtODIxMzI_93c6dda8-31d9-4e0f-84d4-d0bf878edb3b">598,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzktMS0xLTEtODIxMzI_8901720b-fa85-4cf7-bdae-a42d5f391ce9">121,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzktMy0xLTEtODIxMzI_d33a0c6d-4db2-4d82-a010-cb0248ee864d">4,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred for purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNDEtMS0xLTEtODIxMzI_b1868bf7-9733-49fa-bdcc-b829550706ee">1,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNDEtMy0xLTEtODIxMzI_303d7ae0-0717-4367-91b4-33653cd9a6e4">5,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred in asset acquisition</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:LiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNDItMS0xLTEtODIxMzI_edf92cf0-4ca4-4659-95ce-dbe2240cef70">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:LiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNDItMy0xLTEtODIxMzI_c110055d-24d6-431a-aa6a-3b98755375ae">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i549da58617674d2089ca2811b93aa142_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i549da58617674d2089ca2811b93aa142_34"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk3Mg_a7d3e284-f4f1-4712-8f34-407358fd6fc2" continuedAt="i9037d16233a340d6a88e6fc6385a6b02" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i9037d16233a340d6a88e6fc6385a6b02" continuedAt="i39c577d85bc44caaa53978f93371eea0"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for patients with difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, <ix:nonFraction unitRef="product" contextRef="i956b96970860433cac967eaa240e5cb1_D20220101-20220930" decimals="INF" name="exel:NumberofProductsinCommercialMarket" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjkx_58c68580-6b81-47ce-87ca-32149a68f2b7">four</ix:nonFraction> products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in <ix:nonFraction unitRef="country" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="INF" name="exel:NumberOfCountriesWithDrugApprovalExcludingTheUS" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfMTA2Nw_ccaf5794-c9d5-47fb-88a0-40cfee914b6c">62</ix:nonFraction> other countries as: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other <ix:nonFraction unitRef="product" contextRef="i0adfaf62ed654496b8aef139a0b4a6a0_D20220101-20220930" decimals="INF" name="exel:NumberofProductsinCommercialMarket" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfMTc0Mg_39572ac5-bdba-4723-b6ac-9bc92a596b63">two</ix:nonFraction> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. a member of the Roche Group (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk2NA_98a5cf46-e9eb-4e03-8e8e-9e47ed67b3a6" escape="true">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk2Nw_ea8707f9-521e-4ea5-bf6e-e2bd295d4d12" escape="true">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;18, 2022 (Fiscal 2021 Form 10-K).</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:FiscalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk1OA_d57bb99c-a6c3-412c-8339-9ffaff325920" continuedAt="ibc13f0d1d8f0416088bd1315206dfbfb" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibc13f0d1d8f0416088bd1315206dfbfb">. Fiscal year 2022, which is a 52-week fiscal year, will end on December&#160;30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the fiscal period ended October 1, 2021, and as of and for the fiscal year ending December&#160;30, 2022 are indicated as being as of and for the period ended September&#160;30, 2021, and the year ending December&#160;31, 2022, respectively.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk0OA_7fd39603-1ce7-4ee3-bafd-278f7ce8997a" continuedAt="i47c5b6795e5546909a74fd704aa561ce" escape="true">We operate in <ix:nonFraction unitRef="segment" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNDIwOA_e5d2dd2b-e751-4689-8582-5fd8994441b9">one</ix:nonFraction> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and </ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><ix:continuation id="i39c577d85bc44caaa53978f93371eea0"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i47c5b6795e5546909a74fd704aa561ce">allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</ix:continuation></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk0OQ_17bca455-3d2b-4000-84f1-22ad8f0a913b" escape="true">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk1OQ_00c61344-58dc-4a87-a89b-d3c28ce50fa4" escape="true">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies during the nine months ended September 30, 2022, compared to the significant accounting policies disclosed in &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk4Mg_747476c8-ea85-4268-b711-86a6bcddb6db" escape="true"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div id="i549da58617674d2089ca2811b93aa142_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDg0OA_0c799b84-1d9c-459d-8900-a92ca1989b43" continuedAt="if6d1a881bd93407a88e41e1763b8c837" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="if6d1a881bd93407a88e41e1763b8c837" continuedAt="i86166fbae77140809f164bb340b3691d"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDg0NA_9c147fad-d26b-4b94-ba00-1a3957292ae9" continuedAt="if49736ce96974a2caf182a25c8ddd2a6" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e8fc05be13408780345631766d0815_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMy0xLTEtMS04MjEzMg_f132589e-fb1a-4d51-bfb5-99e690fa259c">496,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b04ee7fa7f744f3bd93b05af54ac638_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMy0zLTEtMS04MjEzMg_8ea4023f-1885-43f8-b7c3-b32c5b440461">357,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic228c7eb5cf24643909be765ba674a07_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMy01LTEtMS04MjEzMg_362d68e9-96f9-4452-b759-ce23eb92cce3">1,427,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245c45138f3a4c37bf6f61ddc6a3d179_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMy03LTEtMS04MjEzMg_bc46c6e2-16da-44b2-a5e2-a02439456a53">1,051,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c6da63ce1144dfe9238e2548fc27b35_D20220702-20220930" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNC0xLTEtMS04MjEzMg_8ffbaece-da2c-4a24-8e5d-74f358e8720f">129,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ac64684837b4a6da52ae5943bd15379_D20210703-20211001" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNC0zLTEtMS04MjEzMg_73361daa-e959-4a57-a07c-36438623dcf7">94,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f269764820403288f53e33a88cf89f_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNC01LTEtMS04MjEzMg_ca859939-79e4-4ead-82da-f0f4ff4ba3a0">403,627</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i066aeee8d576453da3c5e154f00d7eac_D20210102-20211001" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNC03LTEtMS04MjEzMg_1823220b-0602-456c-8a33-e5ad17fc05ae">277,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i278c1109560d43989bb93fcb650c9afa_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNS0xLTEtMS04MjEzMg_38e3b007-f059-4afa-bd38-8dcff3636b6c">366,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0a6faac267459387d713c98a6da04c_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNS0zLTEtMS04MjEzMg_50af4c92-e8fb-4586-93e1-04914920724e">263,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac13ba8b31b461a9ee349f6df7ec401_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNS01LTEtMS04MjEzMg_727ed75b-f74c-4db8-94f5-84372fd1c217">1,023,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d1060e036714dc8b00e67d518425d7e_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNS03LTEtMS04MjEzMg_a27be67f-7809-4369-b6d3-8953f5c9462e">774,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3969d7ffe515467786d9f03efe7dd44a_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNy0xLTEtMS04MjEzMg_9a901ccd-9a8e-48c4-9246-d87873432d13">34,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ffeb5a9e14d43f5bf61509594c23244_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNy0zLTEtMS04MjEzMg_731c357c-bcc9-4384-87f6-135cb3c45fad">49,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e199975584423f9f9b5fc5676b433e_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNy01LTEtMS04MjEzMg_bc934172-bcf8-447d-af74-e61800e545c2">123,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86031b3c8cd74803ab4a6280a4faaea9_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNy03LTEtMS04MjEzMg_c6f22005-e83d-4c92-b079-63e262ecf15c">116,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd67de25ab5242d6acec13d5bb1dcd8c_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOC0xLTEtMS04MjEzMg_b18adcd8-ba5d-4ba8-a368-cf76e5bcb845">10,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3212d047299943f1aefbd2a60b170c8c_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOC0zLTEtMS04MjEzMg_5a5f80e6-9bd3-4dca-b3d4-3e6e65ce8426">15,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0edff0af2d424980d236133e9e6a27_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOC01LTEtMS04MjEzMg_51d9488b-1be2-46c2-92fc-80fac391ef98">39,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06c48663d594ceeabfd8945d8b2d8be_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOC03LTEtMS04MjEzMg_9aeb5cf4-8ad1-4d0a-b1e1-d1531ebba305">92,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27a38704423047618c2b8b7c1b51be0e_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOS0xLTEtMS04MjEzMg_6976af98-1ce0-4520-82cb-82f4ad6d7f15">45,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42beb11067e7404f9bc3d9896994366b_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOS0zLTEtMS04MjEzMg_c0c6de27-9d43-4574-85f5-1f8bded0c356">65,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5cd1f508804375996b6d9886dc1ea9_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOS01LTEtMS04MjEzMg_a861bd63-d776-4328-a378-5501a75975f9">163,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a57c281a93454aaf7038dc3b541516_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOS03LTEtMS04MjEzMg_54ed94e0-13e9-4e85-bde9-2fa5628a5639">209,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMTAtMS0xLTEtODIxMzI_31429fd4-f62d-47ee-b212-7da6274d5216">411,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMTAtMy0xLTEtODIxMzI_43ae1f82-2e35-4f5f-a46c-de353e1305e6">328,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMTAtNS0xLTEtODIxMzI_6f3101de-abc4-443b-b325-9185553ebd4d">1,187,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMTAtNy0xLTEtODIxMzI_0eb2fbf6-1913-4f47-ab7d-883fdc27d037">983,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><ix:continuation id="i86166fbae77140809f164bb340b3691d" continuedAt="i65757576314945e2b8ed015caa2446ca"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDg3MA_68455a9d-82a4-4cb8-9368-d2a32a3acfea" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:37.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.655%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie65c3b49253c4aa7b9ec4c0202bebd90_D20220702-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMi0xLTEtMS04MjEzMg_d8d92ba0-575d-4f9b-a711-75ae16edbda6">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5bf8a00473bf46afaa5c09de8f46aba6_D20210703-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMi0zLTEtMS04MjEzMg_b8f87609-f4fa-4ad7-bc4e-08ecd11a72a6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i77ddea34c561403e81f6dd80be859a85_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMi01LTEtMS04MjEzMg_7577109a-f077-4e20-af61-9262f9ad08e0">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2eeedb844d94073adfe7b633274b258_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMi03LTEtMS04MjEzMg_960b225c-6ac5-4265-8e79-642fab5aafae">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50245b1220fd4277b1ff3bbe18a1c24a_D20220702-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMy0xLTEtMS04MjEzMg_49566a87-4534-4157-bd2f-fdecbfaa705a">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb3f74547a9b413bac6630c8bb4155c6_D20210703-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMy0zLTEtMS04MjEzMg_4a58bea2-b81d-4047-909d-9a4435d1c963">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7149117a9e054f7f8e808e1fd2ff2e9e_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMy01LTEtMS04MjEzMg_170b0cc9-5078-4b4b-98a2-e5a5bc39eb4c">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib51bcc2f1cfb4c36aa8d080a8efad244_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMy03LTEtMS04MjEzMg_c37d93bd-b263-4a4d-92de-187ce7abd0b7">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c2a7f145b054c929254fd11464ef3b3_D20220702-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNC0xLTEtMS04MjEzMg_814b178b-8002-49a5-8e2a-33d5c0d0cb7a">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4e2dbdf48c448b29b598f9f2a0e5e19_D20210703-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNC0zLTEtMS04MjEzMg_0e45b70b-8c11-44f6-95c7-8723b5cb8e31">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97213e89d9b746b5bf8fbd85fd21333c_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNC01LTEtMS04MjEzMg_23766742-81b4-479f-b040-df941d35eca8">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa364ec98f294e0daf245b10590174ba_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNC03LTEtMS04MjEzMg_4d87a664-3c69-4518-9108-926610005018">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05ec8cf0e5c849b2922e3b9477ee666d_D20220702-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNS0xLTEtMS04MjEzMg_81c0fc4a-0415-4942-8f83-236c9f8e2f6a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia362249dbd9f44f1b5332ae17e959ded_D20210703-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNS0zLTEtMS04MjEzMg_58a58c7d-f579-46d4-b39d-8ec8151b96eb">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6dc5a498cf9414a802f893ec5b46c0f_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNS01LTEtMS04MjEzMg_aea37bb7-7d18-4d47-bf0c-90194b94ea7b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5dddd16fbc8540e2a41581289baa917d_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNS03LTEtMS04MjEzMg_c7b9cfa4-57da-49c7-94de-81f53d076419">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa0b05764a414ac78f6fd87d606b97fd_D20220702-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNy0xLTEtMS04MjEzMg_aaffd8bd-0b27-4d08-963a-6e7d9902a36d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c8fcad9f81446bcb60cc26cbc5f329f_D20210703-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNy0zLTEtMS04MjEzMg_dcb279a3-a8c0-4365-9d69-800a0adadcbb">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93f8e2a75c804d01bd28137196447c82_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNy01LTEtMS04MjEzMg_67572b8a-c37f-4caf-9bc8-f41c1093839f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8da6b9fe3c7a45dfb9419e4c773ac239_D20210102-20211001" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNy03LTEtMS04MjEzMg_a30ae449-8f24-4ce4-8155-2794d88245c3">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i218f04d9b7f145c4a3ab264f17ca1972_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfMS0xLTEtMS04ODgyOQ_3bccc27e-3113-4a66-9126-fb53828fc14d">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i971168baf86d4f9c9aee82b5e9765ccd_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfMS0zLTEtMS04ODgyOQ_77753b40-c7c5-4ec3-9035-5f070331aeb7">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1fb1caa40c0048d0a80ef36f16745e1e_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfMS0xLTEtMS04MjEzMg_fafc39eb-7d97-49e9-9b24-cc92a633a941">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idde9ae17b3d542958541cede2a2481c6_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfMS0zLTEtMS04MjEzMg_b5c28117-03ea-49b0-8239-f38745894f2c">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35a9f0667ea2442eb885a468202845d4_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfMy0xLTEtMS04MjEzMg_174be163-c322-4102-bd61-a0351c92bb3c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic52fe2f2070840529d3087ede78597e4_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfMy0zLTEtMS04MjEzMg_d2f82033-4d6f-4705-abc5-c25bbee2f3fc">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04cd2aba94c64626b2bf9bb35be0b8ce_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfNC0xLTEtMS04MjEzMg_cdae35cc-2ffa-4ea5-9b60-af1e0fa43ec6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0247826a7d194832a81af45a2cfe61dd_D20210102-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfNC0zLTEtMS04MjEzMg_807eeb3b-5982-4432-8e6e-87e79e024f76">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDgzOQ_29a2b733-1080-4f07-b394-4a2d29725b6e" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445b3583a8f7464f94fbda78d87c16ea_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMi0xLTEtMS04MjEzMg_4804c691-4961-40d7-8292-246210783628">369,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4011737647c446caa0d25b062561b85_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMi0zLTEtMS04MjEzMg_6823d723-60b0-4e56-933b-1e2e3c620a4d">266,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb8931e56e6c45ec95b31d5e8b47dc6e_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMi01LTEtMS04MjEzMg_cd18d884-5d0d-4d29-a1d4-6975960be66d">1,033,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10a8e5b6128d47dcbe8f521a6afdd884_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMi03LTEtMS04MjEzMg_7a02aa93-1774-4306-88da-0e3d06cb6991">783,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d1b5c68b7248bd894117cbe81a2b72_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMy0xLTEtMS04MjEzMg_7b53e2dd-02b3-4cdf-a4ff-17e597e72297">34,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2aec28765054e47a8b50efa632378be_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMy0zLTEtMS04MjEzMg_5ecc78f0-fd3e-490b-8fdc-d0edebaf804b">38,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab572d16389b4a3d99847cab2ea41fcc_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMy01LTEtMS04MjEzMg_5edfd92e-acbb-4b75-a4ac-498ac257a4ea">131,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93479bb75b140d3802fac8c321d4809_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMy03LTEtMS04MjEzMg_ae07ab6f-af9c-4bf7-9e55-5b47081910ae">162,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7080625bcf434804949496009873718c_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNC0xLTEtMS04MjEzMg_ac25f32f-b0ac-466b-b560-c23f48054ba0">7,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2efe1c927824b6abc801dccb6e57899_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNC0zLTEtMS04MjEzMg_a538e1bc-8992-4b08-9c99-6c1ccc194086">23,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b606e33b09d4e47ac8222e71af4b57d_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNC01LTEtMS04MjEzMg_3f2f9382-0403-4ec5-ac68-29755b872b45">22,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30704e87cef4c1f82e032e0b9646586_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNC03LTEtMS04MjEzMg_c3cdcabd-4edc-475c-9644-c30b35f88c91">37,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNS0xLTEtMS04MjEzMg_867e537a-ea6d-420e-9a89-6cf821e9f6d2">411,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNS0zLTEtMS04MjEzMg_559d3a38-d40e-4517-a3a2-09ec3dd9dc21">328,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNS01LTEtMS04MjEzMg_1ecd80c9-3e44-43a0-af52-36fbaf11e80c">1,187,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNS03LTEtMS04MjEzMg_b5fe5a75-e62a-4946-b419-80463f17d004">983,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDg0Nw_560c66ff-1efd-4df7-a62e-0ffad0a71cfd" continuedAt="i3b9a091a31864b9eb478891f500b8ea8" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.</span></div></ix:nonNumeric><ix:continuation id="if49736ce96974a2caf182a25c8ddd2a6"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:37.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.655%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92fb0f6b07fd46b6ba4261c7461fff4b_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMi0xLTEtMS04MjEzMg_cfd87573-80dc-495e-ace6-b7e648a8a428">361,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0c29019e5ac47c4817bdab99ce15b5a_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMi0zLTEtMS04MjEzMg_876eb391-3551-4a16-9593-26aa08ca162d">259,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d39089578604b9b9931f9e265946ecf_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMi01LTEtMS04MjEzMg_3e747fbc-2242-404a-a85c-84f349ed235d">1,003,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3056fc81cda24a63be80c8307b00b2da_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMi03LTEtMS04MjEzMg_5109c5b8-6516-4b78-a78f-36b7721942b7">759,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c3de4e4a9084bf98f767229d2d7f1f9_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMy0xLTEtMS04MjEzMg_64fa667e-1df6-4da4-bd4c-83e7056a5422">5,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b17a7fa5ce04b0bb62269c78f9e34bc_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMy0zLTEtMS04MjEzMg_82c82d00-79bb-4271-a3cc-1cbe11215345">3,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90bd12e1079420ab8c09c67bb824c80_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMy01LTEtMS04MjEzMg_3ea61437-80ac-48e9-8347-ab5d7b9622ac">20,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e65bdb96ff4594b3069a428583550b_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMy03LTEtMS04MjEzMg_9b862b6f-0afa-4772-9850-f44b38461605">15,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i278c1109560d43989bb93fcb650c9afa_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfNC0xLTEtMS04MjEzMg_2f05c431-2334-4c30-8391-c03a01d16d07">366,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0a6faac267459387d713c98a6da04c_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfNC0zLTEtMS04MjEzMg_9f2a5a70-d555-4ebc-bddc-40214bd663e9">263,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac13ba8b31b461a9ee349f6df7ec401_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfNC01LTEtMS04MjEzMg_0f5572e0-6829-41d2-80c1-6d9cecd43dc1">1,023,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d1060e036714dc8b00e67d518425d7e_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfNC03LTEtMS04MjEzMg_dcd12b9f-de2e-4a27-b2ab-88b527075421">774,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><ix:continuation id="i65757576314945e2b8ed015caa2446ca" continuedAt="i4226e88ed508446885b7ee4e3cf1aac9"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDg1Mg_b6fcbca3-8971-44f2-be93-3caaef6daa89" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:41.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9de5a5db4474de1862cf88701e361a7_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMS0xLTEtMS04MjEzMg_7995cd7e-f744-4c37-ab7a-653f46fa143e">14,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7784b834fd4f77b0d696e7db0b1345_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMS0zLTEtMS04MjEzMg_fab8088d-5cee-431f-b5b4-b1e573b2da14">8,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedb850ea024432c901960f936fab351_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMS01LTEtMS04MjEzMg_1187c586-b147-4dfc-b26d-e8560c09bace">24,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMS05LTEtMS04MjEzMg_01d1557c-ca95-43a2-901b-bddfcdcf03b8">48,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda8f95f074144778888a0e634d3e42b_D20220101-20220930" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMy0xLTEtMS04MjEzMg_af756419-55e9-42bd-8dad-399205a14d58">261,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001a107c11d44b3f8675588a5f182420_D20220101-20220930" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMy0zLTEtMS04MjEzMg_4a345502-dc22-468a-bc43-5c7177513ceb">36,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291663fb25df40058a0517d4e9d7425e_D20220101-20220930" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMy01LTEtMS04MjEzMg_fa034fdc-305a-46cb-b078-9c1386f475e9">105,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMy05LTEtMS04MjEzMg_28fab06c-1f84-4043-8efe-d5682c6ff0a2">403,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda8f95f074144778888a0e634d3e42b_D20220101-20220930" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNC0xLTEtMS04MjEzMg_5558d036-bd43-4538-b5c0-5134db634164">632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i001a107c11d44b3f8675588a5f182420_D20220101-20220930" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNC0zLTEtMS04MjEzMg_6c70c60c-634b-467e-84b2-cb363250c47e">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i291663fb25df40058a0517d4e9d7425e_D20220101-20220930" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNC01LTEtMS04MjEzMg_8b3927f6-281d-4ea5-9ba1-fdca795e89a1">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNC05LTEtMS04MjEzMg_d5f70118-e41c-4c01-abbe-20dc7bcf188f">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieda8f95f074144778888a0e634d3e42b_D20220101-20220930" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNS0xLTEtMS04MjEzMg_614f7ef4-e492-47fe-8c66-e0bbbab936d4">255,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i001a107c11d44b3f8675588a5f182420_D20220101-20220930" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNS0zLTEtMS04MjEzMg_be855f49-95ef-4416-bffc-897002c05b98">32,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i291663fb25df40058a0517d4e9d7425e_D20220101-20220930" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNS01LTEtMS04MjEzMg_9310e1eb-9aad-495a-b967-457b5a9e75e9">98,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNS05LTEtMS04MjEzMg_d53a29c8-72c0-4c66-9ed6-fc263ae6bc06">386,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4ec47df1b34e468e64eed9bb89500e_I20220930" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNi0xLTEtMS04MjEzMg_789a255e-ea23-4a39-bebe-3940ae3e7772">21,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0371d74e96407b87bcc99e5690f80d_I20220930" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNi0zLTEtMS04MjEzMg_49b336d0-1b26-46b6-b3e9-382b8f6569f6">12,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e205712f95140a09c2d11e6c6f425b7_I20220930" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNi01LTEtMS04MjEzMg_9332c76a-2d8e-49b8-b4d5-a8347c57101c">31,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNi05LTEtMS04MjEzMg_d92abb2f-031b-498d-9238-cad236348ce1">65,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="i3b9a091a31864b9eb478891f500b8ea8"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule, and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDg1NQ_2733307d-8aea-4025-9670-63134a552119" continuedAt="ia8fb6982fa9e4180a4c68f2754308e3b" escape="true">Contract assets and liabilities were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="ia8fb6982fa9e4180a4c68f2754308e3b" continuedAt="ief9c649a76b645be9bf464c7ad5ee8c9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfNC0xLTEtMS04MjEzMg_742d572b-04e1-4ebb-9824-e2be3a1d901f">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfNC0zLTEtMS04MjEzMg_747567b1-ed63-4f34-bb23-ad39e63f6125">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfNy0xLTEtMS04MjEzMg_6c3104ea-f7a3-4c58-85d1-c817bd135cea">6,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfNy0zLTEtMS04MjEzMg_ba21ab27-94ce-409e-b853-bee953f4477f">7,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfOC0xLTEtMS04MjEzMg_1e46b377-6fa2-4cda-81bb-eba00097b1a6">6,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfOC0zLTEtMS04MjEzMg_b3df5665-9daf-486e-bd41-2374ca43b08c">8,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfOS0xLTEtMS04MjEzMg_31597365-9713-4530-9a1d-becd6d9f95c6">13,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfOS0zLTEtMS04MjEzMg_7ea3b021-e65c-4aba-b25b-b0123b0648c5">16,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:continuation id="ief9c649a76b645be9bf464c7ad5ee8c9"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE5Mjgy_247340c0-e724-4ee3-91be-67c9b11d3be0">6.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE4Nzg2_9902e657-aaab-4a1e-98cd-0ea42a78fbb5">6.8</ix:nonFraction>&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE5MzEy_7d9ce258-7669-4851-8b3b-122bbfc51312">33.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE5MzQ2_ce68406f-4460-493a-a480-a2b63e157eb7">125.0</ix:nonFraction>&#160;million, respectively, in revenues for performance obligations satisfied in previous periods, as compared to $<ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE5MDU1_1e11791d-cae6-4a35-b7f3-c5402cc7db60">48.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE5MDcw_57435d2d-a90a-4a72-9bee-2d921e86db85">116.2</ix:nonFraction>&#160;million for the corresponding prior year periods. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech and the recognition of license revenue for the achievement of milestones during the second quarter of 2022, allocated to the license performance obligations for our collaboration with Ipsen.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><ix:continuation id="i4226e88ed508446885b7ee4e3cf1aac9"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i4e9f925ab5174bc3b4fed38f74de06a4_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE5NDU1_a38cf8a1-4322-4a1e-9ae1-4fbec36127a9">83.1</ix:nonFraction>&#160;million of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he co</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mbined transaction prices for our Ipsen a</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Takeda collaborations were allocated to our research and development services performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K for additional information about the expected timing to satisfy these performance obligations.</span></ix:continuation></div><div id="i549da58617674d2089ca2811b93aa142_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNzE4OQ_57c4d1a6-86ed-4e98-9e2c-38e3c40adbfd" continuedAt="i8f07defeb36e4be9adcf13e8edd9ba69" escape="true">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="i8f07defeb36e4be9adcf13e8edd9ba69" continuedAt="ib24f36076f974f719c626a4e1f9890ad"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaborations, in-licensing arrangements and other strategic transactions to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading pharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K, as further described below, for additional information on certain of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNzIxNg_1f6ca181-bb5f-447f-be42-b368cdec5fa9" continuedAt="ie912bd74f16448f3ada248f7c341d443" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i545cd28e851247caac6d1d375512f1c7_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMi0xLTEtMS04MjEzMg_b34da901-d1d4-4047-8e12-64f52045bfb8">27,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90ee6fa4bd8843d2b764a321fa9de3f3_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMi0zLTEtMS04MjEzMg_d25af809-31a3-4f53-9430-7535adc205be">25,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c2d7715df546c183c0e89d6bd9ed3b_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMi01LTEtMS04MjEzMg_c04ce9e1-1dcf-487a-9d16-2847b5f768d9">103,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38484c00f8ed449e838f354569fb8a60_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMi03LTEtMS04MjEzMg_3f3582df-b8ef-470d-8623-1e88d8102808">81,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fcd1390271d4d2abc556f67a01c14b4_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMy0xLTEtMS04MjEzMg_456a8085-bc98-4575-8489-d3d93ed15854">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5138e445f8ee4ac79c11a13ebfd1db6a_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMy0zLTEtMS04MjEzMg_28ebfc3f-0261-430f-aaf5-d7b88098f1c6">12,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7d911a57c6474c92d558bab6c033a4_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMy01LTEtMS04MjEzMg_4d5f2b78-1ffe-45b0-998b-3e446e6853ca">28,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a570d5f6c8420c9d45e3db1337a2a8_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMy03LTEtMS04MjEzMg_95aa36c8-7c38-43dc-a4c4-ca21fbfe8922">81,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i932765cb697a4b078cea923c81edd920_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfNC0xLTEtMS04MjEzMg_6977b243-6513-4380-8f56-de1f49425ef7">34,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80091c0e7cfb45668e3eb0d45b2c94f3_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfNC0zLTEtMS04MjEzMg_b74751b7-52dd-465c-a30d-a0fb2b201d50">38,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1364c1c302444d838efffd43064715f9_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfNC01LTEtMS04MjEzMg_7e0a156b-fc03-4644-a854-d8a52a6e8516">131,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41523be6e587448d8ab2f6b2f0c6f04b_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfNC03LTEtMS04MjEzMg_1d330055-5dc7-470c-ba4d-3e70eb3e7a6e">162,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="i1364c1c302444d838efffd43064715f9_D20220101-20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxOTQ0_ceb5fede-c52c-4196-954a-80637bc290ed">25.8</ix:nonFraction>&#160;million in revenues in connection with <ix:nonFraction unitRef="milestone" contextRef="i1364c1c302444d838efffd43064715f9_D20220101-20220930" decimals="INF" name="exel:NumberOfRegulatoryMilestone" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfMjc0ODc3OTA3NzI5Ng_61ae0318-1d91-438a-bdbf-bc58a585aa94">two</ix:nonFraction> regulatory milestones totaling $<ix:nonFraction unitRef="usd" contextRef="i1364c1c302444d838efffd43064715f9_D20220101-20220930" decimals="-5" name="exel:ContractWithCustomerMilestoneRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxNjM3_3aba26e6-ec1a-45f8-8586-ce3d39a0bc39">27.0</ix:nonFraction>&#160;million upon approval by the European Commission and Health Canada, of cabozantinib as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to RAI who have progressed during or after prior systemic therapy.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i4913e232a2ad4455a008eed936155e00_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxOTc4_17b8a163-77b4-4519-97e7-806e8179a120">49.3</ix:nonFraction>&#160;million of the transaction price for this collaboration was allocated to our research and development services performance obligations that have not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><ix:continuation id="ib24f36076f974f719c626a4e1f9890ad" continuedAt="i9acca80f7d5047ccb84911f2d8c5b7da"><ix:continuation id="ie912bd74f16448f3ada248f7c341d443" continuedAt="i6222ef2580f24b5cbfa78be863281e4e"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a62749d1d48443f886e9796c6337793_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMi0xLTEtMS04MjEzMg_df03fa53-ce11-4761-b4b5-8bbd15f36001">2,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id030fbf9dc0b477e938decac98663411_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMi0zLTEtMS04MjEzMg_a31491a0-4d13-4a9f-b4c0-24fd6982abee">20,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a001be0ff84fe794c78832456ead43_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMi01LTEtMS04MjEzMg_1f46eabf-80c6-4ad8-897a-32ac97e6ace3">7,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee1ed1bb84547448046eae5336921cb_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMi03LTEtMS04MjEzMg_7eaa4757-c788-478a-afd4-8a5f7647acb4">23,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a61b54755e49e39e3e69a7ee48adb1_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMy0xLTEtMS04MjEzMg_dc0b00f8-b6fa-4b29-a836-e74b7db8e5e5">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ac924d3ae554ad193f222a56997ca8d_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMy0zLTEtMS04MjEzMg_b6fe7ebe-c908-4138-a261-eec072deea8c">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8201aa36633a4adc95d3929b8b7b08c7_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMy01LTEtMS04MjEzMg_8ab7e913-bcf6-4341-95e9-e3aa262d3bb1">11,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7699082fc113461698ab25c1cdd41c5f_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMy03LTEtMS04MjEzMg_ef39f962-762e-41ad-87e4-8726c4508576">10,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic70ffc1d027b441296ba4347fbd23534_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfNC0xLTEtMS04MjEzMg_327c83e8-d7ca-45ea-863d-00ee75fe2d54">6,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43e9d3f2b70a49bf940167c1f27ee63c_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfNC0zLTEtMS04MjEzMg_f4a3a93f-4f63-4830-a7cb-7d822dd81c8e">22,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c59059ae1a643cf9613f787f7e2b135_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfNC01LTEtMS04MjEzMg_de884c33-dd47-450d-beb2-86d51b854b1b">18,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie402c1037bde46c5af87b543056ba92d_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfNC03LTEtMS04MjEzMg_5e90f046-e486-4156-97a3-34142d56e5bc">34,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="ibaa37e09ed2a4cc1877653a23011c082_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxODQz_a0f6ec63-8363-464d-9424-825d6109d966">33.8</ix:nonFraction>&#160;million of the transaction price for this collaboration was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a <ix:nonFraction unitRef="number" contextRef="ia63686e881124ae08b1ebf7e9f49fd77_D20220101-20220930" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfMzYwNA_2d03e6fd-6177-45c7-a8af-4e525c206903">3</ix:nonFraction>% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib sold by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and in connection with sales by our collaboration partners are included as a reduction of collaboration services revenues. Such royalties were $<ix:nonFraction unitRef="usd" contextRef="ia5970864bfa44baca1140501cee1fbfb_D20220702-20220930" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxODc0_95b00254-206f-4d4e-87b7-29eb9cda2e72">14.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ided9d969f2e1442982aa0a851fba5f6e_D20220101-20220930" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxOTA0_ccb35097-1e0a-4440-a689-cfb70dd10335">42.6</ix:nonFraction>&#160;million during the three and nine months ended September&#160;30, 2022, respectively, as compared to $<ix:nonFraction unitRef="usd" contextRef="ib50a0249433a4d278481e65be8ffe69f_D20210703-20211001" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxMjY4_6266890f-bbe9-4abb-aa01-5e69d511a6bf">11.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia12b136a6e174c9bbad11748d01a0e9c_D20210102-20211001" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxMjgz_a75c12ba-5e0a-4108-af71-b76229bb31ae">33.7</ix:nonFraction>&#160;million for the corresponding prior year periods.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients.</span></div><ix:continuation id="i6222ef2580f24b5cbfa78be863281e4e"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da7e9b183de4698ac4c703b2c8f846c_D20220702-20220930" decimals="-3" name="exel:CollaborativeArrangementIncomeLossFromAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMi0xLTEtMS04MjEzMg_c111f67c-9824-499b-9cee-ca2e619ff89c">1,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9527062f675b4046a1cebadb13e14991_D20210703-20211001" decimals="-3" name="exel:CollaborativeArrangementIncomeLossFromAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMi0zLTEtMS04MjEzMg_c12941c4-179a-4b1e-8a35-f3321ec0d900">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe693b49d3c949bd864806bd146b6a29_D20220101-20220930" decimals="-3" name="exel:CollaborativeArrangementIncomeLossFromAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMi01LTEtMS04MjEzMg_156956be-229c-469e-b98a-0894f60cdae9">5,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8849b4c4c01946888c77e7fb6ccccb84_D20210102-20211001" decimals="-3" name="exel:CollaborativeArrangementIncomeLossFromAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMi03LTEtMS04MjEzMg_593e97a9-6311-4ada-8b4d-8ec6d67dde6a">5,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da7e9b183de4698ac4c703b2c8f846c_D20220702-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMy0xLTEtMS04MjEzMg_d96b04df-c5d4-424f-b92a-a046a1a2ce45">1,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9527062f675b4046a1cebadb13e14991_D20210703-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMy0zLTEtMS04MjEzMg_21a60e30-eead-420c-876e-3b5bfbb502d8">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe693b49d3c949bd864806bd146b6a29_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMy01LTEtMS04MjEzMg_63fc545b-7926-4648-a2ed-56b870851dc8">4,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8849b4c4c01946888c77e7fb6ccccb84_D20210102-20211001" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMy03LTEtMS04MjEzMg_f7adc9e7-5748-489f-a462-31d4c421edc6">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, which are generally paid upon the closing of the transaction, and also milestone payments (in connection with development, regulatory or commercial achievements) and royalty payments, which are contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations and in-licensing arrangements provide us exclusive options that give us the right to license programs developed under the research collaborations for further discovery and development. When we decide to exercise an option, we are required to pay an exercise fee and then, in most instances, we will assume the responsibilities for all subsequent clinical development, manufacturing and commercialization of the licensed asset.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><ix:continuation id="i9acca80f7d5047ccb84911f2d8c5b7da"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we entered into an exclusive option and license agreement with BioInvent International AB (BioInvent), upon which we paid an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i9c9d5031bdf542ceab4b6f6d4789fa7f_D20220601-20220630" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODI2MTU2_a22841b8-5fc0-4737-b031-06147ad405b9">25.0</ix:nonFraction>&#160;million. Upon option exercise, we will pay BioInvent an option exercise fee, and BioInvent will be eligible for additional payments from us for future development and commercial milestones, as well as royalties on our future net product sales. In July 2022, we entered into an exclusive license agreement with Ryvu Therapeutics S.A. (Ryvu) and paid an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="if0491f03c0124ea5a708fd9ea63f6bc3_D20220701-20220731" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIzMDE0_1d3cbc36-6906-436a-b656-7a3b24688f4e">3.0</ix:nonFraction>&#160;million. Ryvu is eligible for potential future development and commercial milestones as well as royalties on future net product sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of September&#160;30, 2022, in conjunction with each of our research collaborations and in-licensing arrangements, and an asset purchase agreement entered into in 2021, we are subject to contingent payments for potential future development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="ie2f04ac5f92f4dfdb4acf9ff8f6d9471_I20220930" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIyMDIx_105873e1-aa93-4dfe-87c3-5c61334a02e3">364.7</ix:nonFraction>&#160;million, regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="ie2f04ac5f92f4dfdb4acf9ff8f6d9471_I20220930" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIzMDQ2_618cdf10-15bc-4705-8fe4-a815234e13a2">453.4</ix:nonFraction>&#160;million and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="ie2f04ac5f92f4dfdb4acf9ff8f6d9471_I20220930" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIzMDc5_b03cf2f6-2cf4-4d5b-864f-a9668b3c621e">2,443.4</ix:nonFraction>&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales.</span></div></ix:continuation><div id="i549da58617674d2089ca2811b93aa142_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMzAxNA_912ba8c5-c2f8-4104-82bd-79e5e75cdf30" continuedAt="icaf9b674690944048079e3a45d1f227d" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="icaf9b674690944048079e3a45d1f227d" continuedAt="idb74f7fc24af42e7be3254bcf998920e"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjk3MQ_a10b2a2e-9772-49fb-a0d5-be205a7127e3" continuedAt="i027e493c87784870952bef149eb25c29" escape="true"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjk5NQ_4367e9b5-7337-4298-9ac3-dee0a7b8ad5e" continuedAt="if8ab80adab4e482ba5f0b85a5bc490b5" escape="true">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i027e493c87784870952bef149eb25c29"><ix:continuation id="if8ab80adab4e482ba5f0b85a5bc490b5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjZiYTc4ZmQ1MDAwZTRmZTc4ZDE0ZmNlY2NhYzJkN2FmL3RhYmxlcmFuZ2U6NmJhNzhmZDUwMDBlNGZlNzhkMTRmY2VjY2FjMmQ3YWZfMS0xLTEtMS04MjEzMg_d758c5c2-f089-48fc-b071-cd6fb148fe80">675,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjZiYTc4ZmQ1MDAwZTRmZTc4ZDE0ZmNlY2NhYzJkN2FmL3RhYmxlcmFuZ2U6NmJhNzhmZDUwMDBlNGZlNzhkMTRmY2VjY2FjMmQ3YWZfMS0zLTEtMS04MjEzMg_651fbf20-e254-43b5-a785-80449ad53db4">647,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjZiYTc4ZmQ1MDAwZTRmZTc4ZDE0ZmNlY2NhYzJkN2FmL3RhYmxlcmFuZ2U6NmJhNzhmZDUwMDBlNGZlNzhkMTRmY2VjY2FjMmQ3YWZfMy0xLTEtMS04MjEzMg_159ba7a8-1cd1-4150-8d5b-d2b1699c3057">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjZiYTc4ZmQ1MDAwZTRmZTc4ZDE0ZmNlY2NhYzJkN2FmL3RhYmxlcmFuZ2U6NmJhNzhmZDUwMDBlNGZlNzhkMTRmY2VjY2FjMmQ3YWZfMy0zLTEtMS04MjEzMg_97d9eb47-10f6-4a14-9918-20333f6c6bca">16,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjZiYTc4ZmQ1MDAwZTRmZTc4ZDE0ZmNlY2NhYzJkN2FmL3RhYmxlcmFuZ2U6NmJhNzhmZDUwMDBlNGZlNzhkMTRmY2VjY2FjMmQ3YWZfNC0xLTEtMS04MjEzMg_e3433ad6-c302-47a3-9111-40ff42222fda">676,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjZiYTc4ZmQ1MDAwZTRmZTc4ZDE0ZmNlY2NhYzJkN2FmL3RhYmxlcmFuZ2U6NmJhNzhmZDUwMDBlNGZlNzhkMTRmY2VjY2FjMmQ3YWZfNC0zLTEtMS04MjEzMg_69fa3cf8-3ed9-460f-a835-39d8d3968d25">663,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. The standby letter of credit entered in January 2021, as a guarantee of our obligation to fund our portion of the tenant improvements related to our Alameda build-to-suit lease was terminated and the related collateral was returned in the third quarter of 2022, following the substantial completion of the building and the commencement of the lease.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjk5Mg_be828481-e247-42f2-b0e2-8627fc570cb3" continuedAt="i525a24eaf8a543d7b9b8bec6f9264de4" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58839179e60147438d111534793e3584_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMy0xLTEtMS04MjEzMg_664f00aa-a747-4954-8db1-8ee19f810862">874,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58839179e60147438d111534793e3584_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMy0zLTEtMS04MjEzMg_37277cb7-591f-4550-8179-b06a55299fb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58839179e60147438d111534793e3584_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMy01LTEtMS04MjEzMg_52415716-338b-43a2-8903-0ff74bf26b27">364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58839179e60147438d111534793e3584_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMy03LTEtMS04MjEzMg_793f306f-a571-4972-a1d4-238e0fe9795a">873,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNC0xLTEtMS04MjEzMg_4f5b157f-4b69-4ffa-87c5-12fa14b2edbb">633,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNC0zLTEtMS04MjEzMg_167ea2f2-5fd0-4cdd-be80-d88fd76d83bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNC01LTEtMS04MjEzMg_4e2d1e74-32fa-48b2-8847-1ce7fb1a2b43">15,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNC03LTEtMS04MjEzMg_19e38a0a-4690-4f0b-8197-b2365c1700a5">618,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied291acb3b8349dcaa4d28395592f7e8_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNS0xLTEtMS04MjEzMg_4feb25bd-8f65-4d62-8558-a5cd29516502">307,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied291acb3b8349dcaa4d28395592f7e8_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNS0zLTEtMS04MjEzMg_826f6da0-ef1a-4290-afb4-7e3b74e74aea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied291acb3b8349dcaa4d28395592f7e8_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNS01LTEtMS04MjEzMg_5d46eace-ae76-4cd3-b3e1-82940295e28b">6,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied291acb3b8349dcaa4d28395592f7e8_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNS03LTEtMS04MjEzMg_11406855-5cc8-45fe-b515-2870fb4f9c7c">301,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNi0xLTEtMS04MjEzMg_712cab7d-a9dc-4033-b2bd-f05b4a8fd705">16,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNi0zLTEtMS04MjEzMg_c617e6a4-8f04-4203-89b1-30889d47fd4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNi01LTEtMS04MjEzMg_bdfb596b-8641-4978-97e6-fc03cbeff21b">312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNi03LTEtMS04MjEzMg_bb562aad-7fa1-4daf-9acb-069cfa9296af">16,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNy0xLTEtMS04MjEzMg_019dd0c2-323b-4022-87de-5eb92eec1bed">1,831,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNy0zLTEtMS04MjEzMg_b50c7c50-a673-4374-89ce-4144a0831edd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNy01LTEtMS04MjEzMg_f79be4a9-0a5f-4e38-bc51-b2ff34a04e23">22,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNy03LTEtMS04MjEzMg_52f7d2ea-d524-4124-9cd8-6b91bb2754fb">1,809,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb3542aa68a458ba55ced4e19e05fd3_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOC0xLTEtMS04MjEzMg_16b0c2bb-8851-4789-b0c3-a104b2876fa7">113,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb3542aa68a458ba55ced4e19e05fd3_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOC0zLTEtMS04MjEzMg_b6a102e6-912e-4deb-8b52-d9b987742092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb3542aa68a458ba55ced4e19e05fd3_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOC01LTEtMS04MjEzMg_5b698df6-6ad7-4b61-beff-1368ea956a33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb3542aa68a458ba55ced4e19e05fd3_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOC03LTEtMS04MjEzMg_3e2ae531-c797-473d-a274-d7bebd65f0b5">113,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica491f30edaa49d7ad148efd0cbfa735_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOS0xLTEtMS04MjEzMg_660e5c11-5a89-4f03-8d75-c4fa1fdbce90">62,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica491f30edaa49d7ad148efd0cbfa735_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOS0zLTEtMS04MjEzMg_4f3fe7d8-c408-4ae9-a3a3-94c2f7dfaf86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica491f30edaa49d7ad148efd0cbfa735_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOS01LTEtMS04MjEzMg_39b35d4c-788b-4060-b2e7-d8de9216a02c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica491f30edaa49d7ad148efd0cbfa735_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOS03LTEtMS04MjEzMg_ede79158-7e67-4517-b643-f091e99f5dc5">62,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0063762fe744f0a9698d6a8a86e957_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTAtMS0xLTEtODIxMzI_9be13a92-0180-4344-b677-ba44f7494ba6">114,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0063762fe744f0a9698d6a8a86e957_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTAtMy0xLTEtODIxMzI_4a0f0ec4-4c40-4650-a6d2-407889955ffe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0063762fe744f0a9698d6a8a86e957_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTAtNS0xLTEtODIxMzI_6732e5ec-4731-47ae-8e96-431a0073ec25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0063762fe744f0a9698d6a8a86e957_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTAtNy0xLTEtODIxMzI_9f089710-367c-4ec3-a4a8-57b8a4aed11b">114,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTEtMS0xLTEtODIxMzI_0786e5c2-3ee3-4b9a-9de8-49b4d2036360">2,122,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTEtMy0xLTEtODIxMzI_7263f7f0-a584-4788-bfe1-300cdd292b35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTEtNS0xLTEtODIxMzI_86478670-6843-4e10-a539-1347687763ca">22,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTEtNy0xLTEtODIxMzI_9d5e7d3f-5992-4a7d-a3c8-28b08d3f92d1">2,100,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><ix:continuation id="idb74f7fc24af42e7be3254bcf998920e" continuedAt="ifa7b74e8eb34464abce79df3430023d2"><div style="margin-top:9pt;text-align:center"><ix:continuation id="i525a24eaf8a543d7b9b8bec6f9264de4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc686d12fa4e4260b80a6d50f6424dc3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMy0xLTEtMS04MjEzMg_2d2199f7-eed8-4fa2-9ba6-d91245288c16">945,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc686d12fa4e4260b80a6d50f6424dc3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMy0zLTEtMS04MjEzMg_c264142c-f413-4e7d-b16e-2d7a230c590d">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc686d12fa4e4260b80a6d50f6424dc3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMy01LTEtMS04MjEzMg_edb1e95c-7f51-4c6f-859b-52f6a797c6e3">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc686d12fa4e4260b80a6d50f6424dc3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMy03LTEtMS04MjEzMg_f23ec107-35dc-4f47-816c-03d66edbbff2">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNC0xLTEtMS04MjEzMg_ffa7a991-c631-4210-8350-55f9c1398852">541,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNC0zLTEtMS04MjEzMg_44e7290d-046a-48a0-aa44-72bfde58d07d">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNC01LTEtMS04MjEzMg_75e6994d-6f99-4640-a218-41abaac29147">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNC03LTEtMS04MjEzMg_6d7e0a52-f321-46f9-abb1-895ecc063d01">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701da0dfff384128b67d66f7cfc99222_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNS0xLTEtMS04MjEzMg_f2d30699-4938-4624-8a14-b57097cac77e">33,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701da0dfff384128b67d66f7cfc99222_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNS0zLTEtMS04MjEzMg_48cde852-a508-42db-a1be-9e9e7fb63180">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i701da0dfff384128b67d66f7cfc99222_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNS01LTEtMS04MjEzMg_de1f04d2-ba47-407d-a09d-8d92969e7185">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701da0dfff384128b67d66f7cfc99222_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNS03LTEtMS04MjEzMg_e0eebd7f-119b-4f0e-b98c-2b254481f1df">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef82cf2fbcf4ade8270cbe16f10de34_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNi0xLTEtMS04MjEzMg_657ce787-b38b-41c0-bea2-2344c1231c31">12,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef82cf2fbcf4ade8270cbe16f10de34_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNi0zLTEtMS04MjEzMg_1665ff73-065e-4e37-b942-f5196cbea599">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idef82cf2fbcf4ade8270cbe16f10de34_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNi01LTEtMS04MjEzMg_ac4d8d1d-3d99-409c-a1ea-35933f0831b7">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef82cf2fbcf4ade8270cbe16f10de34_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNi03LTEtMS04MjEzMg_370dfa5a-f603-403f-bdc8-37fc55f2f858">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNy0xLTEtMS04MjEzMg_1ff01e5d-a95a-4578-8467-8bfbdf036611">1,534,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNy0zLTEtMS04MjEzMg_7b8d3564-78bc-48d8-9570-c0c732fc7c9b">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNy01LTEtMS04MjEzMg_5de6c428-42ba-4b57-aa3f-551b0b43f3f9">1,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNy03LTEtMS04MjEzMg_889e2559-fc14-4e79-b2e1-12492824454b">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172e305050d443b3a741d87593f63789_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOC0xLTEtMS04MjEzMg_103d3075-d5d0-4f80-bc90-8d2cf1a9c771">135,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172e305050d443b3a741d87593f63789_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOC0zLTEtMS04MjEzMg_039a10bf-b0e5-4640-8f24-8e61acc298a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172e305050d443b3a741d87593f63789_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOC01LTEtMS04MjEzMg_b9a94146-9f7a-4022-a4f6-9b96e8de69fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172e305050d443b3a741d87593f63789_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOC03LTEtMS04MjEzMg_49372d60-de96-42f1-9710-579f414cf16c">135,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i715f766ed6a447508a29b9beaf5cb949_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOS0xLTEtMS04MjEzMg_15f32e69-9d01-4ee9-9b00-8bd9e87ece3f">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i715f766ed6a447508a29b9beaf5cb949_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOS0zLTEtMS04MjEzMg_bac8b01a-8236-42a9-bc11-76a2ae498a2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i715f766ed6a447508a29b9beaf5cb949_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOS01LTEtMS04MjEzMg_429db479-465a-436e-9177-daf70671e8ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i715f766ed6a447508a29b9beaf5cb949_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOS03LTEtMS04MjEzMg_2dac35f8-55f5-404a-ab9c-733d6f3d59e3">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48ec553d89834f00b45ec9c811bb351c_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTAtMS0xLTEtODIxMzI_a443df73-3ed8-43a8-978b-8e06cf9915f3">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48ec553d89834f00b45ec9c811bb351c_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTAtMy0xLTEtODIxMzI_0ce18fbb-ac79-4258-a5df-e6a792afd58c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48ec553d89834f00b45ec9c811bb351c_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTAtNS0xLTEtODIxMzI_1d481180-a618-4da7-88b0-3530e55cbbe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48ec553d89834f00b45ec9c811bb351c_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTAtNy0xLTEtODIxMzI_ad65bcb6-676c-4894-bd52-b48f759da0c5">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTEtMS0xLTEtODIxMzI_34d80c81-7aaf-4307-a6f9-d2a2531d39ae">1,855,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTEtMy0xLTEtODIxMzI_f01caddb-df3e-4f1a-8158-678ccbda4d37">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTEtNS0xLTEtODIxMzI_7011d323-572a-42e1-a40c-a5b28ee72b92">1,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTEtNy0xLTEtODIxMzI_954c25ec-d076-4652-b88c-9008c7ce9b49">1,854,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $<ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMTM0OA_bc7cf352-8cd2-4c4a-aaff-cece99db81d5">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMTM1NQ_5d7f025c-7eed-46f8-8f2f-6ec1d2a1489f">2.9</ix:nonFraction> million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2021, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three and nine months ended September&#160;30, 2022 and 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjk2NA_1b4c500e-a873-4769-ae0c-c8cc5699f171" continuedAt="i3072bc476b84443dbc78a93587f233b1" escape="true">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i3072bc476b84443dbc78a93587f233b1"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:64.520%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfMy05LTEtMS04MjEzMg_14290957-c96a-4a7f-b8b8-78fa30ffa24f">613,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfMy0xMS0xLTEtODIxMzI_0d1bd52e-d8f6-452c-b478-a821c1b19162">15,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied291acb3b8349dcaa4d28395592f7e8_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfNC05LTEtMS04MjEzMg_a1a48e8a-ebd4-4afd-a03e-c3464df83184">301,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied291acb3b8349dcaa4d28395592f7e8_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfNC0xMS0xLTEtODIxMzI_48fff48b-cfe2-4068-ac35-57878c437aac">6,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58839179e60147438d111534793e3584_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfNS05LTEtMS04MjEzMg_7f72281f-2e4e-4a8e-b5a2-1618225f50e7">36,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58839179e60147438d111534793e3584_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfNS0xMS0xLTEtODIxMzI_66916dfb-3359-4b1b-b835-cde49b178322">364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfNi05LTEtMS04MjEzMg_37065f48-7b78-4572-a27a-ad762c740e9f">16,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfNi0xMS0xLTEtODIxMzI_34a9a842-4afd-4b00-ae79-5d28231e845b">312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfOC05LTEtMS04MjEzMg_6ec9b638-83d2-4cc4-acda-ff082a011abc">967,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfOC0xMS0xLTEtODIxMzI_1e35497b-85f5-4cc8-99bf-b383ad7e83a8">22,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:64.520%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfMi05LTEtMS04MjEzMg_954d2e79-af48-4ae9-9845-8cb28631c019">385,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfMi0xMS0xLTEtODIxMzI_5d506384-3208-4ad8-be12-3820773738f8">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc686d12fa4e4260b80a6d50f6424dc3_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfMy05LTEtMS04MjEzMg_5dbaaac8-4169-47c0-bbb1-e2abb67d317a">43,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc686d12fa4e4260b80a6d50f6424dc3_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfMy0xMS0xLTEtODIxMzI_95bac544-e1e5-450b-adb8-521149e07db0">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701da0dfff384128b67d66f7cfc99222_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfNC05LTEtMS04MjEzMg_b4af110e-462f-416b-bc30-a242df6eba20">18,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i701da0dfff384128b67d66f7cfc99222_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfNC0xMS0xLTEtODIxMzI_e9ad3fac-3ffd-419d-bbee-a0d903b973b1">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef82cf2fbcf4ade8270cbe16f10de34_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfNS05LTEtMS04MjEzMg_7fb607b6-9496-493b-a4bd-5b8469f91b5e">7,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idef82cf2fbcf4ade8270cbe16f10de34_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfNS0xMS0xLTEtODIxMzI_83de70ac-dbab-4a8f-b135-3382b01e201e">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfNi05LTEtMS04MjEzMg_db577575-542d-432d-8f23-b690120b979f">454,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfNi0xMS0xLTEtODIxMzI_22cbc9ca-5f82-4f2d-a728-765f85e55965">1,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="investment" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjAwMg_72b30679-96d3-45aa-839f-937bb60fc229">276</ix:nonFraction> and <ix:nonFraction unitRef="investment" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjAwOQ_755fd77d-9197-4816-be5a-c337cf693c74">133</ix:nonFraction> investments in an unrealized loss position as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2021, respectively. All securities presented above have been in an unrealized loss position for less than twelve months except for <ix:nonFraction unitRef="bond" contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930" decimals="INF" name="exel:NumberOfBondSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfNTQ5NzU1ODE3NzE3_1b9563d5-6808-40bc-b5ec-92fbd225b488">25</ix:nonFraction> corporate bond securities and <ix:nonFraction unitRef="bond" contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930" decimals="INF" name="exel:NumberOfBondSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjc0ODc3OTA3MzMwNg_f48a8556-76b1-4587-9a5a-6c9e26b4335c">1</ix:nonFraction> municipal bond security with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfNTQ5NzU1ODE3NjU0_c83d6f92-e7fb-4dcd-ade6-a37dc395d5b4">64.0</ix:nonFraction>&#160;million and an aggregate $<ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfNTQ5NzU1ODE3Njk1_4101529e-1e79-47c7-b598-1c64c03a6598">2.4</ix:nonFraction>&#160;million unrealized loss as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the nine months ended September 30, 2022 and 2021, we did <ix:nonFraction unitRef="usd" contextRef="iacaf43cbe24a472ba26b4376244aeceb_I20211001" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjM0Ng_0cba800f-1af4-43d0-8f9f-43cb3c280a87"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjM0Ng_86fba902-04da-492b-89ff-7b0c56bc0967">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses or other impairment charges on our investment securities. Based </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><ix:continuation id="ifa7b74e8eb34464abce79df3430023d2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjk3MA_20887b01-c11d-45fe-add5-f19bd1310065" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOmVmNjRhNWY4MmM0MDQ1ZmRhZWI3ZGQ5MDk2NmVlOGFmL3RhYmxlcmFuZ2U6ZWY2NGE1ZjgyYzQwNDVmZGFlYjdkZDkwOTY2ZWU4YWZfMS0xLTEtMS04MjEzMg_8670bfe1-0bf9-4176-84d6-505f8809ea0f">1,260,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOmVmNjRhNWY4MmM0MDQ1ZmRhZWI3ZGQ5MDk2NmVlOGFmL3RhYmxlcmFuZ2U6ZWY2NGE1ZjgyYzQwNDVmZGFlYjdkZDkwOTY2ZWU4YWZfMS0zLTEtMS04MjEzMg_fe6cc996-1452-4bcc-8ee1-56b6df73fba5">1,168,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOmVmNjRhNWY4MmM0MDQ1ZmRhZWI3ZGQ5MDk2NmVlOGFmL3RhYmxlcmFuZ2U6ZWY2NGE1ZjgyYzQwNDVmZGFlYjdkZDkwOTY2ZWU4YWZfMi0xLTEtMS04MjEzMg_8d6120f2-2099-43f5-8c2e-63d6911945fa">548,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOmVmNjRhNWY4MmM0MDQ1ZmRhZWI3ZGQ5MDk2NmVlOGFmL3RhYmxlcmFuZ2U6ZWY2NGE1ZjgyYzQwNDVmZGFlYjdkZDkwOTY2ZWU4YWZfMi0zLTEtMS04MjEzMg_e41590c7-d40c-4bd9-9c16-a157a57061b7">365,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOmVmNjRhNWY4MmM0MDQ1ZmRhZWI3ZGQ5MDk2NmVlOGFmL3RhYmxlcmFuZ2U6ZWY2NGE1ZjgyYzQwNDVmZGFlYjdkZDkwOTY2ZWU4YWZfMy0xLTEtMS04MjEzMg_1bd56e1f-053d-44d6-b95e-4807d8baaa46">1,809,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOmVmNjRhNWY4MmM0MDQ1ZmRhZWI3ZGQ5MDk2NmVlOGFmL3RhYmxlcmFuZ2U6ZWY2NGE1ZjgyYzQwNDVmZGFlYjdkZDkwOTY2ZWU4YWZfMy0zLTEtMS04MjEzMg_1143ac89-34a5-413e-ad17-352f0d0e9084">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i549da58617674d2089ca2811b93aa142_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfMjM1Ng_7f49712e-0e1c-4878-85b6-1a925c470528" continuedAt="ic7124139c5454d168075724951be7c28" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ic7124139c5454d168075724951be7c28" continuedAt="i61b813e53de84c05875fdbb675889844"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfMjM2Mg_2b56b19e-af1c-44e6-894c-471dc69e5310" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if496ec13812c4ae893488d94baef090c_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfMi0xLTEtMS04MjEzMg_6cbb714c-387e-429b-b19f-159c428749b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8f66e27ef54639adf8c0c31673352c_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfMi0zLTEtMS04MjEzMg_234bf425-f088-4245-8fbc-73c972c97bfb">873,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i843bbd1a33f649a78d35d947eff4b9a7_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfMi01LTEtMS04MjEzMg_a252c4b0-4ee6-4285-925e-9774ad2a0d38">873,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51cbf38a72b74e8d987a9138cc078b1a_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfMy0xLTEtMS04MjEzMg_23d8f508-7c27-4c49-85e9-9c2df109fbc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c2e10640954a49859ec7c33dbb8e33_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfMy0zLTEtMS04MjEzMg_9930a240-bda5-4161-81f0-5461a8646463">618,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81558c9856554de7833c4a2806a8b626_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfMy01LTEtMS04MjEzMg_dbff3f95-95ea-4f1b-b1b0-55c65eb70598">618,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57f0a67c6b243ed9e67d6b085657e54_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNC0xLTEtMS04MjEzMg_d63e4dee-0375-4f98-a604-f6b1c279aecb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efce754a3e042719aca4d5d14d2cdc9_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNC0zLTEtMS04MjEzMg_76ae33bb-97d8-4e0c-9d96-54468285b164">301,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3d6d7024114c76b5161677a09f1ff1_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNC01LTEtMS04MjEzMg_eca85d65-9472-42ce-9965-88263f7d1b38">301,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee240d204304b82b2e177132d0e6bf1_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNS0xLTEtMS04MjEzMg_ead0979d-3be4-4ba1-b47a-0838720ef4d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3f78b5c5b94afd80179a24fb7390ab_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNS0zLTEtMS04MjEzMg_1c777fe8-b209-4ece-a3de-a7e8fbcde0f7">16,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9a9b3bc1ed41a9bb7528566061b93f_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNS01LTEtMS04MjEzMg_ecdc702e-afac-478f-bb69-aab200cc2729">16,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88202d8592004d2c8c4852504e52b931_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNi0xLTEtMS04MjEzMg_1f2faa02-f4ac-4492-9fe1-1f79f2fdee10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea0c087b202475e99958164943828bf_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNi0zLTEtMS04MjEzMg_a909dee1-ff1c-4269-bb04-f244f64032e2">1,809,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71fc629d67b1439596f3c19023047959_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNi01LTEtMS04MjEzMg_37072a4a-d55f-4109-94af-730a75e30d35">1,809,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2ebe36f5674bb58674bb6f4330233f_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNy0xLTEtMS04MjEzMg_56335ebb-903f-4e4c-89d6-f7730e177292">62,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebf3c208a48c4e599b699f4ab792b2db_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNy0zLTEtMS04MjEzMg_a8ca3796-49f6-4451-b879-f39285d09420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8475c0170e0e415f97fbec0694e96b99_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNy01LTEtMS04MjEzMg_6b9a2cce-a1ec-42b9-a11b-855983199ed0">62,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b2a87a345c443dae1c0c9599142457_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfOC0xLTEtMS04MjEzMg_4a7049b2-a9d6-4c1a-809f-081a025d7cc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b3c03a185f44b7cba57ea4cd0921028_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfOC0zLTEtMS04MjEzMg_fe81a064-6ff1-4c45-b3c7-1ad8546a9cc2">114,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674f190343a44c93a3f972959dd570b6_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfOC01LTEtMS04MjEzMg_0e2bdcf2-cf0f-453d-b2e7-f8e18edebdc3">114,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88202d8592004d2c8c4852504e52b931_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfOS0xLTEtMS04MjEzMg_95f57dd0-ba33-472f-9047-d98cbccb656f">62,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea0c087b202475e99958164943828bf_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfOS0zLTEtMS04MjEzMg_08d88bd5-ea39-4285-9de1-53ddfb881604">1,923,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71fc629d67b1439596f3c19023047959_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfOS01LTEtMS04MjEzMg_ea22ca1e-f1f5-467b-bef9-c4685cd940c8">1,986,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c375c63bd346fe978fb2534b5e3800_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfMi0xLTEtMS04MjEzMg_47a15ce4-b854-4d72-9cb9-3ecf4823015a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a6d14de067741dca25498e9f73fd442_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfMi0zLTEtMS04MjEzMg_e66a792c-71db-4cc4-ac3e-9fc122a26287">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i341945d209bf44d296c37ef93e0345ef_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfMi01LTEtMS04MjEzMg_1cda12da-c02a-429e-8814-2c3174e15c31">945,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c5b394503146d3a0d022b6c8b89b92_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfMy0xLTEtMS04MjEzMg_eb8ba3ee-511d-46a3-aa70-fda2ac355457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a20eb1a92443bda7fa6b72c5a0d273_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfMy0zLTEtMS04MjEzMg_412e7167-69b2-48fb-84ea-24b47deda186">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie591104d91534932927cac2401b55411_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfMy01LTEtMS04MjEzMg_c4eb7ac3-e210-47ef-83c3-f949a83393cc">540,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830bd31e008547e886cd8a5ec319f87e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNC0xLTEtMS04MjEzMg_312bf827-26b1-474b-bece-df8c74e97a4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04e0b0194d7409f8c9d6770aade56c6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNC0zLTEtMS04MjEzMg_30f80f9e-76b3-44e3-9704-ea19d8714634">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58211da7dc6f4d538de9873270446232_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNC01LTEtMS04MjEzMg_2c42afe8-1691-4b59-97ad-960a5c0cb9e3">33,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i334c5f91f7f14f9fad4d7234cc49ea1b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNS0xLTEtMS04MjEzMg_7c607202-8bfd-4b48-896a-9b97ba411858">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e946b1e834488a8312b0d935e9f2a0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNS0zLTEtMS04MjEzMg_308eeb62-6511-4bd3-8dbe-e0150bb17430">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f657f4786c94e5cabeabf0a738d4385_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNS01LTEtMS04MjEzMg_e666efbb-e05f-444c-9a31-cf503b0c66da">12,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562efe5dbad445f48582bd754933cf24_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNi0xLTEtMS04MjEzMg_821eaa55-d5f7-4759-ad10-524d7d8fde4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3300c71f3304f4fabbe2333fa0e6f6a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNi0zLTEtMS04MjEzMg_264a2ebb-ed1a-45c5-8c99-d401a3232e45">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idede8e3136eb484884a82aa3c0a1d084_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNi01LTEtMS04MjEzMg_7eb6c7f6-1385-4962-832a-4d6acffe6ae4">1,533,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ea002268c4a5caf09a2bd32761c1d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNy0xLTEtMS04MjEzMg_2ebea58e-f05c-4e63-b3d1-6806d7e295e9">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa1a26a550e4cdebc79e98ec28d3692_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNy0zLTEtMS04MjEzMg_8b54f2b2-4075-4c3d-bbd4-a05cda3961ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica244ac307be4148a52ded97af82e32d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNy01LTEtMS04MjEzMg_a1fdd889-d38f-4dca-9267-cfa67192a27f">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8f2c7e017a444199ea80ad69ff9dc0e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfOC0xLTEtMS04MjEzMg_3f94b807-0eac-4057-ad07-1a93add4db5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e3be485f1040e99231bf20c8737b87_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfOC0zLTEtMS04MjEzMg_86dd6249-0886-409d-856d-f55bde6c7872">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f55ae80ed464185acbc13298bd9b539_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfOC01LTEtMS04MjEzMg_20150137-d573-42f1-b682-9dd46a62222a">119,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562efe5dbad445f48582bd754933cf24_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfOS0xLTEtMS04MjEzMg_74770736-16d0-48c4-ba17-9e0c0f2d1b63">66,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3300c71f3304f4fabbe2333fa0e6f6a_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfOS0zLTEtMS04MjEzMg_9baafffc-9098-4a2a-a0d6-c8de81242ebf">1,652,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idede8e3136eb484884a82aa3c0a1d084_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfOS01LTEtMS04MjEzMg_609587c1-e86c-462e-b698-86b419e764da">1,719,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><ix:continuation id="i61b813e53de84c05875fdbb675889844"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had <ix:nonFraction unitRef="forward_contract" contextRef="i5d00e7f272ad46b9a14aaa1be9bc4934_I20220930" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfMTgxNw_a3ba4df0-0199-4a22-b0f8-e5b8537806f9">one</ix:nonFraction> forward contract outstanding to sell &#8364;<ix:nonFraction unitRef="eur" contextRef="i5d00e7f272ad46b9a14aaa1be9bc4934_I20220930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfNTQ5NzU1ODE2NDg4_b58108dd-cd26-49d2-bde4-eabdbf00fd39">10.0</ix:nonFraction>&#160;million. The forward contract with a maturity of <ix:nonNumeric contextRef="ica8f66740885481388f5091f3a93fae0_D20220101-20220930" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfMTkwMQ_7ff6a84a-f87e-4167-b57b-71ff7856c67c">three months</ix:nonNumeric> is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The unrealized loss on the forward contract is not material as of September&#160;30, 2022. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the nine months period ended September&#160;30, 2022, and 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="ica8f66740885481388f5091f3a93fae0_D20220101-20220930" decimals="-5" name="us-gaap:GainOnDerivativeInstrumentsPretax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfNTQ5NzU1ODE2NDYy_e1e93473-9d61-439d-bf70-796efc1f4ed9">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i047d415cbf9345cca4b2a12bea7fee45_D20210102-20211001" decimals="-5" name="us-gaap:GainOnDerivativeInstrumentsPretax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfNTQ5NzU1ODE2MzEw_c91c304b-ecab-482c-adec-8c2b40ddb0ef">0.5</ix:nonFraction>&#160;million, respectively, of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.</span></div></ix:continuation><div id="i549da58617674d2089ca2811b93aa142_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RleHRyZWdpb246ZTI4YjRjZTExOGY4NGVmNDlmNzcwMDU0MzQyMDdkMmVfODQ_7dcdec90-123e-4d85-a70f-7c4b3d3e4ccc" continuedAt="i4a6d4989b81241909b2fb2994483bea0" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="i4a6d4989b81241909b2fb2994483bea0"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RleHRyZWdpb246ZTI4YjRjZTExOGY4NGVmNDlmNzcwMDU0MzQyMDdkMmVfODA_c115b0db-e29f-42e5-bb9a-8ccd09f71fa2" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:64.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfMS0xLTEtMS04MjEzMg_4634fde5-a570-4d3d-b5e0-745e990ac4cf">9,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfMS0zLTEtMS04MjEzMg_164262f6-0c46-4734-9b9e-8a3876165ed9">8,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfMi0xLTEtMS04MjEzMg_aadfaf07-12ce-441e-b965-39a086e0e8d1">39,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfMi0zLTEtMS04MjEzMg_65bf5017-0148-4624-ac10-125574ca9ba9">27,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfMy0xLTEtMS04MjEzMg_51a611cd-b3d6-48ba-8e82-667556cda9a5">11,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfMy0zLTEtMS04MjEzMg_3166ced0-0130-4b24-b07c-275d3018cc4e">12,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfNC0xLTEtMS04MjEzMg_fc90998a-92e9-493f-a50f-ec133169e29c">60,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfNC0zLTEtMS04MjEzMg_825f0919-ceb7-4854-81b7-ee521264c857">49,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e8f6cf25ef845f4a4e6a6141299a680_I20220930" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfNy0xLTEtMS04MjEzMg_a2eb5cb5-fa1f-49c7-a3f3-a5c2ed15510f">26,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib058f0cc5ab4445c89f49affa1efcd07_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfNy0zLTEtMS04MjEzMg_8b52668c-56ac-4f0e-a264-32641e6a699c">27,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide600b04f8ca45209f922b07e1285c93_I20220930" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfOC0xLTEtMS04MjEzMg_136c46b0-5bd2-499b-bd50-536c97d16549">33,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6daa97f735eb4c3cad12840eb32ed958_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfOC0zLTEtMS04MjEzMg_4e87cb3a-1f30-4a47-8820-6356768ac429"><ix:nonFraction unitRef="usd" contextRef="i6daa97f735eb4c3cad12840eb32ed958_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfOC0zLTEtMS04MjEzMg_b695a512-7b30-4817-9f26-31d40573334a">22,018</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfOS0xLTEtMS04MjEzMg_d3bd2ffa-8149-475f-b2cd-facd970222bc">60,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c08664821924215a9a380432cc549fd_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfOS0zLTEtMS04MjEzMg_f2971c4f-db61-4238-accd-e9bf4798063c">49,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i549da58617674d2089ca2811b93aa142_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMzYxOQ_e0448d80-d806-462e-a793-1bf116b6ff15" continuedAt="ifd5c58cf714a46a29e1b0e3311a48576" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="ifd5c58cf714a46a29e1b0e3311a48576" continuedAt="i68fbe14be1234d5a8859698bcbcb1d6b"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMzYzOQ_0a78209b-16e0-4667-9c6e-21ce16b380f1" continuedAt="i0c3e59effdf645f18dff8500df37253c" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie101975b1642454ca5efd600cefeebb7_D20220702-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfMy0xLTEtMS04MjEzMg_6ae7038b-3bfd-469a-9a38-14ee70bef8e0">16,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4cfbc3bd5b41628d78e47135e8b32d_D20210703-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfMy0zLTEtMS04MjEzMg_aa1f3123-1255-4380-8ab7-8f8102aa9c3a">11,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86f9773b234244db921193fc80b4b36e_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfMy01LTEtMS04MjEzMg_c525c833-5401-4188-89ed-c845c91c6bc8">34,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ac7f01c92b4900a09d849019f8bbde_D20210102-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfMy03LTEtMS04MjEzMg_c6049196-81a5-4435-a499-b98393faea99">37,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9969aa4426549599b32a31f08e5252b_D20220702-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNC0xLTEtMS04MjEzMg_202fdc8e-9e1d-471d-97e9-7661a15a9cac">20,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a5e6ea88544cb1abee1be0125a342f_D20210703-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNC0zLTEtMS04MjEzMg_c3e8d60c-6467-4f99-bcaa-a52f8331b736">22,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017ac814620d4a70b0883a3c64a8d2a4_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNC01LTEtMS04MjEzMg_a2a0f5d7-ec53-4500-838f-4e89b0ae04ee">46,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i718d736b87a94552b1617644f5ddccec_D20210102-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNC03LTEtMS04MjEzMg_d4a50e1e-44fd-4987-a608-b8baa65299a9">59,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNS0xLTEtMS04MjEzMg_b8e02b64-1fee-49bb-996d-194d06b92939">37,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNS0zLTEtMS04MjEzMg_5cb21673-edc8-4c5b-987e-f75b41f2d17d">33,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNS01LTEtMS04MjEzMg_44eb7adb-3fe2-42d9-bccc-c0f46b3bf5c5">81,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNS03LTEtMS04MjEzMg_b0fddfdb-8953-4da6-a30c-d7af255251f9">96,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><ix:continuation id="i68fbe14be1234d5a8859698bcbcb1d6b" continuedAt="i4c3fb5dee91045e08c50d04526db67e8"><ix:continuation id="i0c3e59effdf645f18dff8500df37253c"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2435c09f4c4f918cabd7085d3ea04d_D20220702-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMi0xLTEtMS04MjEzMg_39afa3a0-9438-4957-b188-168d23d5aaa7">3,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f85bf38d0841c2b116c6c5df335710_D20210703-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMi0zLTEtMS04MjEzMg_2fe3fd99-8e94-4301-a292-e60a5d2c9cc2">4,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b89020b108466aac157e717fc794ba_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMi01LTEtMS04MjEzMg_be61d16e-08a8-4807-9849-a7d3afccd003">10,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc062842cb3848dd809f2e5dabf4b106_D20210102-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMi03LTEtMS04MjEzMg_a353723d-c581-45a3-b563-d6b8d16d0cf8">15,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10e996f6a0045d68c311365d48c8ee0_D20220702-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMy0xLTEtMS04MjEzMg_7a837628-2584-4c8e-bab7-05cc566a4004">22,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6583f307a24123ab02aebe68d83ad5_D20210703-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMy0zLTEtMS04MjEzMg_234f34a0-ca6b-49df-b658-12475845e0fc">13,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f8b24349b54b9286007abc00e73aca_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMy01LTEtMS04MjEzMg_ebf9be84-ccec-4e33-8613-d466d6303569">54,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60e4edfc8694abe95bc6c4ad0cf0e80_D20210102-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMy03LTEtMS04MjEzMg_a861cbf3-caea-4c4b-b7c7-70596ac5cc4b">40,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1c4a397e174d8ba0fa3e03acd37402_D20220702-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNC0xLTEtMS04MjEzMg_3f06b92d-762b-43b0-a7a7-06277e60a8cb">11,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a96d01dde304dfb8bbc5a56f6a329e5_D20210703-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNC0zLTEtMS04MjEzMg_061ed7e8-ec37-427c-a3bf-b13fa8d10752">14,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7532b18472654211b7e84b715466a350_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNC01LTEtMS04MjEzMg_90cceb85-3864-4290-bc4c-9199b8f0e3ea">14,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c8d8dce3a7e43c8b39da1d6b4cad521_D20210102-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNC03LTEtMS04MjEzMg_37096564-e813-44a2-ba4e-65f2ed8700ef">37,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81205acd3f214b2ebe487d5e61a93b20_D20220702-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNS0xLTEtMS04MjEzMg_c22a5e08-7942-4939-b8e8-36963e5d3869">474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic592c97df7804add951c95d5fb5bae90_D20210703-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNS0zLTEtMS04MjEzMg_c6a5c404-889b-4f17-b314-5b253fe953b4">667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9361d6f5134f4f68b7477fcf36e854a1_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNS01LTEtMS04MjEzMg_c0baabde-fe89-4b9a-b50c-a725eb5f3086">2,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5282ce470894117a8f902fb69fc8b98_D20210102-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNS03LTEtMS04MjEzMg_c928ab5c-595e-4818-a89d-f739a144f5ec">3,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNi0xLTEtMS04MjEzMg_14c0d988-dde5-456d-96e1-2ed35cf872cf">37,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNi0zLTEtMS04MjEzMg_5e9378b7-2475-4e0e-889a-bfaea64df3c9">33,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNi01LTEtMS04MjEzMg_e808b7b7-de95-45f7-90f1-ab3f07965c34">81,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNi03LTEtMS04MjEzMg_e039f76b-89fa-44de-8f60-90e0278f67af">96,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 25, 2022, at the 2022 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The amendment and restatement increased the share reserve under the 2017 Plan by <ix:nonFraction unitRef="shares" contextRef="if19df687aaf9496496468698046b7ca9_D20220525-20220525" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNjAy_e79a2346-2d6b-4ab1-aa0d-2416be79810e">28,500,000</ix:nonFraction> shares. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNDM5ODA0NjUxNTkzMA_58383855-4f43-43ae-873d-9a98811c1796">31,485,656</ix:nonFraction> sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the 2017 Plan. The share reserve is reduced by <ix:nonFraction unitRef="shares" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNzQz_d0b987ce-d542-4e9d-b5ce-a6eaafa64178">1</ix:nonFraction> share for each share issued pursuant to a stock option and <ix:nonFraction unitRef="shares" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfODA1_2eeb367c-15f3-4ea9-b0bc-8a9418baa700">2</ix:nonFraction> shares for full value awards, including restricted stock units (RSUs).&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, we granted <ix:nonFraction unitRef="shares" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4MzUx_7568ae58-e158-467d-974a-6bbdda268bf9">588,862</ix:nonFraction> stock options with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfOTY1_3cccc010-4b07-46db-9c5f-677191be7709">19.99</ix:nonFraction> per share and a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMTAyNg_3560f72c-3c9a-4d20-bd29-9b0f0a3f313a">8.36</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were <ix:nonFraction unitRef="shares" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4Mzgw_2fbf8883-96e7-4cc5-b946-ac1b71b14163">11,416,151</ix:nonFraction> stock options outstanding and $<ix:nonFraction unitRef="usd" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4NDA5_c6105cc6-85db-482b-8e2f-c33bcc37d63a">19.6</ix:nonFraction>&#160;million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we awarded to certain employees an aggregate of <ix:nonFraction unitRef="shares" contextRef="i3fc516136b174c0d801418fc499e2574_D20220301-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMTIwNg_7cad7fd2-febf-45c5-800c-d8d4611deebf">1,003,482</ix:nonFraction> (the target amount) RSUs that are subject to a total shareholder return (TSR) market condition (the TSR-based RSUs). The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 1, 2022 through January 3, 2025. Depending on the results relative to the TSR market condition, the holders of the TSR-based RSUs may earn up to <ix:nonFraction unitRef="number" contextRef="i3fc516136b174c0d801418fc499e2574_D20220301-20220331" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMTY0NQ_758052e3-9bb3-447e-9980-fc6cd4ab4c5e">175</ix:nonFraction>% of the target amount of shares. <ix:nonFraction unitRef="number" contextRef="ia453aac57d974fd59f265a307e4added_D20220301-20220331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMTY4MA_ad3d7d43-99a6-4a1b-8de2-261a15927185">50</ix:nonFraction>% of the shares earned pursuant to the TSR-based RSU awards will vest at the end of the performance period, and the remainder will vest approximately <ix:nonNumeric contextRef="ia453aac57d974fd59f265a307e4added_D20220301-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMTgzMQ_a5d78e44-0dc1-4773-ac77-877410a89e3b">one year</ix:nonNumeric> later, subject to employee&#8217;s continuous service. These TSR-based RSUs will be forfeited if the market condition at or above a threshold level is not achieved at the end of the performance period on January 3, 2025.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMzY2Mw_9e3e5e5e-3e7a-4963-a800-712bfaf20f85" continuedAt="i6aa63597e95a4564913204b9a7472f07" escape="true">We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibd464ef4ba6e4d6092da7bde626f4870_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMjE2MQ_8c97f439-a761-4be3-b0c6-ef9bea68a53f">33.17</ix:nonFraction> per share for the TSR-based RSUs:</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i6aa63597e95a4564913204b9a7472f07"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:90.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia156218652c64c5d967262937d5d66a6_I20220930" decimals="2" name="us-gaap:SharePrice" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmFjYzllMTUxODYyZjQzZGRiYTA5MTAwZTM1N2JmNTBlL3RhYmxlcmFuZ2U6YWNjOWUxNTE4NjJmNDNkZGJhMDkxMDBlMzU3YmY1MGVfMC0xLTEtMS04MjEzMg_beab1213-263e-4edf-9c61-55d1a1c63cb8">20.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd464ef4ba6e4d6092da7bde626f4870_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmFjYzllMTUxODYyZjQzZGRiYTA5MTAwZTM1N2JmNTBlL3RhYmxlcmFuZ2U6YWNjOWUxNTE4NjJmNDNkZGJhMDkxMDBlMzU3YmY1MGVfMS0xLTEtMS04MjEzMg_b3c06552-d76b-4b8f-81e5-514d5acf059c">46.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd464ef4ba6e4d6092da7bde626f4870_D20220101-20220930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmFjYzllMTUxODYyZjQzZGRiYTA5MTAwZTM1N2JmNTBlL3RhYmxlcmFuZ2U6YWNjOWUxNTE4NjJmNDNkZGJhMDkxMDBlMzU3YmY1MGVfMi0xLTEtMS04MjEzMg_c76df5a7-27a1-43d8-bae7-3209a4684275">1.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd464ef4ba6e4d6092da7bde626f4870_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmFjYzllMTUxODYyZjQzZGRiYTA5MTAwZTM1N2JmNTBlL3RhYmxlcmFuZ2U6YWNjOWUxNTE4NjJmNDNkZGJhMDkxMDBlMzU3YmY1MGVfMy0xLTEtMS04MjEzMg_25583fe7-9178-4092-aa8a-3d1d03bf2e0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#8217;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, we granted <ix:nonFraction unitRef="shares" contextRef="id7f8b24349b54b9286007abc00e73aca_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4NDM3_45988936-8c7e-4aba-bc55-3b157948938d">5,292,088</ix:nonFraction> service-based RSUs with a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="id7f8b24349b54b9286007abc00e73aca_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4NDU4_c61bde3f-b012-43f1-992d-500f97cc7509">20.56</ix:nonFraction> per share. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were <ix:nonFraction unitRef="shares" contextRef="i538b59a91622490788eb54a07ebcd4bb_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4NDgw_c7f7b70f-5812-4e6d-9785-7c9a8585fec4">11,864,173</ix:nonFraction> RSUs outstanding, including the TSR-based RSUs, and $<ix:nonFraction unitRef="usd" contextRef="i538b59a91622490788eb54a07ebcd4bb_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4OTk2_e049bc8f-b444-43b0-b8af-d290f863febe">193.8</ix:nonFraction>&#160;million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and service-based RSUs granted to employees during the nine months ended September 30, 2022 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were&#160;<ix:nonFraction unitRef="shares" contextRef="ie4cd574ea19b44f6a937ed92eb65fbdd_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4NTIz_fb62df27-bf73-4442-b4db-b1e168eeca1e">5,367,906</ix:nonFraction> performance-based restricted stock units (PSUs) outstanding and $<ix:nonFraction unitRef="usd" contextRef="ie4cd574ea19b44f6a937ed92eb65fbdd_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE5MDM1_adcd6e7e-9928-43ea-a01f-84d66d043c4a">101.0</ix:nonFraction>&#160;million of related unrecognized stock-based compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. During the three months ended September 30, 2022, we achieved a performance condition for threshold achievement for <ix:nonFraction unitRef="shares" contextRef="ie7e73b13cdc64519849d7dc7c3a4bab1_D20220702-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNDM5ODA0NjUxNTk3OA_63282d1b-e04c-42b9-8240-a754377071e7">495,886</ix:nonFraction> PSUs granted during 2020 (the 2020 PSUs) and have recognized $<ix:nonFraction unitRef="usd" contextRef="ie7e73b13cdc64519849d7dc7c3a4bab1_D20220702-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNDM5ODA0NjUxNTk1Ng_34de550d-9307-4a21-b68b-39ff76513361">9.7</ix:nonFraction>&#160;million of stock-based compensation expense related to the 2020 PSUs during the three </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4c3fb5dee91045e08c50d04526db67e8">months ended September&#160;30, 2022. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</ix:continuation></span></div><div id="i549da58617674d2089ca2811b93aa142_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81NS9mcmFnOjAzYjk0YzE4YWFmMjQ0OTE4N2ZmMTc5ZDc2MjllY2Y4L3RleHRyZWdpb246MDNiOTRjMThhYWYyNDQ5MTg3ZmYxNzlkNzYyOWVjZjhfNTIy_6e7565d3-a96b-4fbc-b156-3a82690fc872" continuedAt="i9e6c573251404a89b740f8103a4fa864" escape="true">PROVISION FOR INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i9e6c573251404a89b740f8103a4fa864"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and nine months ended September&#160;30, 2022, were <ix:nonFraction unitRef="number" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81NS9mcmFnOjAzYjk0YzE4YWFmMjQ0OTE4N2ZmMTc5ZDc2MjllY2Y4L3RleHRyZWdpb246MDNiOTRjMThhYWYyNDQ5MTg3ZmYxNzlkNzYyOWVjZjhfNDM5ODA0NjUxMzQzMQ_40af2db2-136f-4077-814c-a596e14baa94">20.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81NS9mcmFnOjAzYjk0YzE4YWFmMjQ0OTE4N2ZmMTc5ZDc2MjllY2Y4L3RleHRyZWdpb246MDNiOTRjMThhYWYyNDQ5MTg3ZmYxNzlkNzYyOWVjZjhfNDM5ODA0NjUxMzQ2OQ_43fedaae-e3ae-4048-8ed1-480f86555602">20.1</ix:nonFraction>% respectively, as compared to <ix:nonFraction unitRef="number" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81NS9mcmFnOjAzYjk0YzE4YWFmMjQ0OTE4N2ZmMTc5ZDc2MjllY2Y4L3RleHRyZWdpb246MDNiOTRjMThhYWYyNDQ5MTg3ZmYxNzlkNzYyOWVjZjhfNTQ5NzU1ODE0NDI4_16182108-9c2a-4da0-8003-96f45e1cce34">28.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81NS9mcmFnOjAzYjk0YzE4YWFmMjQ0OTE4N2ZmMTc5ZDc2MjllY2Y4L3RleHRyZWdpb246MDNiOTRjMThhYWYyNDQ5MTg3ZmYxNzlkNzYyOWVjZjhfNTQ5NzU1ODE0NDM1_1bd58953-28ee-4161-8cdf-572092e863c4">22.8</ix:nonFraction>% for the corresponding periods in 2021. The effective tax rates for the three and nine months ended September&#160;30, 2022 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, which were partially offset by state taxes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and nine months ended September&#160;30, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to non-deductible executive compensation, which was partially offset by excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits.</span></div></ix:continuation><div id="i549da58617674d2089ca2811b93aa142_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RleHRyZWdpb246MDI4YzBhZWIyZDczNDQ0ODg3ODdmODk5MGRhMTQ0ZGNfNzQ3_b97b3bfe-e550-4b85-8940-6007c7dec559" continuedAt="i7bee0a2fdfe04003afbbcf12f2bfdda5" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i7bee0a2fdfe04003afbbcf12f2bfdda5"><ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RleHRyZWdpb246MDI4YzBhZWIyZDczNDQ0ODg3ODdmODk5MGRhMTQ0ZGNfNzU3_384bf119-098b-4c4c-b87e-05312b094380" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:50.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy0xLTEtMS04MjEzMg_2a9c3c86-a970-48b3-b90d-27c72602770d"><ix:nonFraction unitRef="usd" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy0xLTEtMS04MjEzMg_44c62d4f-e19b-4517-b1c2-6544e824323f">73,210</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy0zLTEtMS04MjEzMg_20a6a81f-7686-48c8-88fb-a619a91414e4"><ix:nonFraction unitRef="usd" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy0zLTEtMS04MjEzMg_88e58389-3777-429d-af18-9ce3341b3d92">38,204</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy01LTEtMS04MjEzMg_338bdceb-78be-467c-9e1f-2deacafebca5"><ix:nonFraction unitRef="usd" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy01LTEtMS04MjEzMg_c0a5fa9f-2265-433d-a267-c0311a320ee9">212,455</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy03LTEtMS04MjEzMg_c96f2e37-50f5-46e9-9e5d-11a48b15f9fe"><ix:nonFraction unitRef="usd" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy03LTEtMS04MjEzMg_e5815647-8297-4b41-8575-479cbf04b57c">135,897</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNS0xLTEtMS04MjEzMg_febdea61-4101-4a5b-ab9d-a7a48040e83a">322,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNS0zLTEtMS04MjEzMg_b47dcaaa-caad-4421-bf5a-82f44ca8542f">315,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNS01LTEtMS04MjEzMg_18116302-0c27-4db1-9bf6-4fff70cf994d">320,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNS03LTEtMS04MjEzMg_093674d5-4de6-4a90-a35f-1892dae4da1e">313,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNi0xLTEtMS04MjEzMg_b0442bf3-137e-417b-8c56-7e01c49500a1">2,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNi0zLTEtMS04MjEzMg_6ffba483-110f-4d3f-bbf1-6ccd7df026e5">6,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNi01LTEtMS04MjEzMg_2de4d9c7-bfab-4b81-b72c-2378e36b5abc">3,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNi03LTEtMS04MjEzMg_9b532cf4-a0e9-4a86-9272-5f72f7a863b9">8,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNy0xLTEtMS04MjEzMg_11ab27e6-d02b-4b9a-97eb-20ef3217982b">325,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNy0zLTEtMS04MjEzMg_f73b231d-c4fc-4cb4-9b7d-6f69d0f935d7">322,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNy01LTEtMS04MjEzMg_04927659-821a-4f5c-8113-a745a6b566e0">324,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNy03LTEtMS04MjEzMg_d07b041c-8e17-4835-9875-296ab2c754b0">322,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfOS0xLTEtMS04MjEzMg_bd1ba8dd-5906-4063-a69f-091707145122">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfOS0zLTEtMS04MjEzMg_0ca9ca3c-bd33-4050-a864-e9c0a12ef429">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfOS01LTEtMS04MjEzMg_f92e325c-a284-434c-8965-ee971ceccec3">0.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfOS03LTEtMS04MjEzMg_058b2932-3a92-4f53-ae9f-01a1c15dcb6e">0.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMTAtMS0xLTEtODIxMzI_53bd56f6-f789-41ab-8142-012d7347b2d4">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMTAtMy0xLTEtODIxMzI_cee634d2-c31f-443f-9b3f-05b5a2688e2d">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMTAtNS0xLTEtODIxMzI_00b15a35-a947-4107-973b-652af1e1528f">0.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMTAtNy0xLTEtODIxMzI_c030024a-8cb9-48de-93c5-caef1d683151">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, unvested RSUs, including TSR-based RSUs, PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RleHRyZWdpb246MDI4YzBhZWIyZDczNDQ0ODg3ODdmODk5MGRhMTQ0ZGNfNzUy_efaf7690-1731-491b-941a-327caf97ef25" continuedAt="i2e7f8c58914d4379ba79dc0d6a91c710" escape="true">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i2e7f8c58914d4379ba79dc0d6a91c710"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:50.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa050e767b3f498a8437c364816242c7_D20220702-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjVhYTRiNjQwODU3MDQ0ODVhNjdjZmY3MmUxZDU1ODkxL3RhYmxlcmFuZ2U6NWFhNGI2NDA4NTcwNDQ4NWE2N2NmZjcyZTFkNTU4OTFfMi0xLTEtMS04MjEzMg_21dc9ec0-99ed-44e1-a63a-de78be29e145">15,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bebe181ca4a4b9cb14ab2651a68a39b_D20210703-20211001" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjVhYTRiNjQwODU3MDQ0ODVhNjdjZmY3MmUxZDU1ODkxL3RhYmxlcmFuZ2U6NWFhNGI2NDA4NTcwNDQ4NWE2N2NmZjcyZTFkNTU4OTFfMi0zLTEtMS04MjEzMg_646df0e6-df65-4d78-89a4-b6138a20ae65">20,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5af708b788b494aaa583b5ab133bc7f_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjVhYTRiNjQwODU3MDQ0ODVhNjdjZmY3MmUxZDU1ODkxL3RhYmxlcmFuZ2U6NWFhNGI2NDA4NTcwNDQ4NWE2N2NmZjcyZTFkNTU4OTFfMi01LTEtMS04MjEzMg_573f7012-11c3-4e95-9dbe-59eb9f25ed5d">15,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a9356922a004cbe84b4a80ddb5be44e_D20210102-20211001" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjVhYTRiNjQwODU3MDQ0ODVhNjdjZmY3MmUxZDU1ODkxL3RhYmxlcmFuZ2U6NWFhNGI2NDA4NTcwNDQ4NWE2N2NmZjcyZTFkNTU4OTFfMi03LTEtMS04MjEzMg_813e4077-26a3-4507-a00b-2b9bca2b421a">14,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div id="i549da58617674d2089ca2811b93aa142_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMjc0ODc3OTA5Mzc5OQ_d6d2eb8c-fa9b-47fc-a339-daa02653247a" continuedAt="ic6ee423fa7d54fedb81e66b8679fd09a" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ic6ee423fa7d54fedb81e66b8679fd09a" continuedAt="i5f84e162cf154557ae3768e4f970603f"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Build-to-Suit Lease and Headquarters Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the office building (New Premises) associated with our October 2019 build-to-suit lease agreement (Build-to-Suit Lease) was substantially completed. The New Premises is <ix:nonFraction unitRef="sqft" contextRef="ia6b335f201824eb588620f7043a28af2_I20220430" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMjY5_ec6f8455-5bef-4a88-ba6d-ae105c01a763">220,517</ix:nonFraction> square feet and is in Alameda, California, adjacent to our existing corporate headquarters. The Build-to-Suit Lease term is <ix:nonNumeric contextRef="ia6b335f201824eb588620f7043a28af2_I20220430" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMzk2_6c2aeae4-2756-4b56-aee0-a25794b39106">242</ix:nonNumeric> months, includes <ix:nonFraction unitRef="segment" contextRef="i937aea8377a0438cbd48a2aebc5ce5f0_D20220402-20220430" decimals="INF" name="exel:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfNDA5_0004e1e4-e0f0-4594-b2b0-65242d2245d5">two</ix:nonFraction> <ix:nonNumeric contextRef="ia6b335f201824eb588620f7043a28af2_I20220430" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMTM5OTU_9024a157-84f6-4460-9ed2-2744f5cdbfc6">five-year</ix:nonNumeric> options to extend the term of the lease and a one-time option to terminate the lease after <ix:nonNumeric contextRef="i937aea8377a0438cbd48a2aebc5ce5f0_D20220402-20220430" name="exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfNTEz_ab12c7ae-97eb-43aa-9e28-9e2e4324293c">180</ix:nonNumeric> months. In addition to the monthly lease payments, currently estimated at $<ix:nonFraction unitRef="usd" contextRef="i937aea8377a0438cbd48a2aebc5ce5f0_D20220402-20220430" decimals="-5" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfNTgz_3a743fc7-e74d-4bab-8589-09db03c55161">0.7</ix:nonFraction>&#160;million, subject to an annual increase of <ix:nonFraction unitRef="number" contextRef="i937aea8377a0438cbd48a2aebc5ce5f0_D20220402-20220430" decimals="2" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfNjIw_85745324-0e26-4efe-9029-accffbe32b29">3</ix:nonFraction>% during the Term, we are also </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><ix:continuation id="i5f84e162cf154557ae3768e4f970603f" continuedAt="ie98116f7a5ee4a3c96a5d661c8815370"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsible for paying operating expenses related to the New Premises. On April 15, 2022, the lease commenced for the New Premises. We determined the classification of the lease was an operating lease. Upon commencement of the lease, we recognized a right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="ie7222e9059aa47e8a777492f23afd218_I20220415" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfOTI0_21551c67-ba0a-4bcc-b7ac-62b38aaaefcd">160.9</ix:nonFraction>&#160;million inclusive of $<ix:nonFraction unitRef="usd" contextRef="ie7222e9059aa47e8a777492f23afd218_I20220415" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfOTQw_04e28aef-2d3e-480e-89f4-0cda9e2a9fbc">44.9</ix:nonFraction>&#160;million for the cost of the tenant improvements in excess of the allowance provided by the lessor and an operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="ie7222e9059aa47e8a777492f23afd218_I20220415" decimals="-5" name="exel:TenantLeaseImprovementsAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMTA2OQ_38ff7bdc-2654-428a-b7a0-2f5f3a9bd679">116.0</ix:nonFraction>&#160;million discounted over <ix:nonNumeric contextRef="if12649f24e1842e8bf8c979b733e75c6_D20220415-20220415" name="exel:OperatingLeaseLiabilityDiscountedPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMTA4OA_cdc22f89-c60d-4c44-81a0-263fa0157c8f">180</ix:nonNumeric> months using our estimated incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="ie7222e9059aa47e8a777492f23afd218_I20220415" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMTE0MQ_f6d73bd6-c4f7-40cc-81ed-b5a21d941de2">4.9</ix:nonFraction>%.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we entered into the seventh amendment to the lease for our corporate headquarters located on Harbor Bay Parkway, Alameda, California (the Alameda Lease). The May 2022 amendment to the Alameda Lease (the Seventh Lease Amendment) provides, among other things, for the expansion of the premises under the Alameda Lease by <ix:nonFraction unitRef="sqft" contextRef="ie0dc3aa0d4b14df392ed5c64240f0335_I20220531" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMTQ3Mw_56c7793b-52ed-4220-952a-7036876ffd72">34,745</ix:nonFraction> square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Expansion Space). The term for the 1751 Expansion Space will run coterminous with the term of the Alameda Lease for the existing space. In connection with the Seventh Lease Amendment, we remeasured our lease components under the Alameda Lease relating to the existing premises using an incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i0f6fd2e746f24312a8f2a7091b4e91e5_I20220531" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMTg5MQ_2f8d227a-5620-42b1-92e4-d87e0114f836">5.0</ix:nonFraction>%. As of June 1, 2022, we have taken possession of the 1751 Expansion Space, and accordingly we have adjusted our right-of-use asset and liability by $<ix:nonFraction unitRef="usd" contextRef="id8f643a473a8490da5ebb398751eb409_I20220601" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMjA0MA_22d873af-bf35-45f2-91d2-612b9ece51ba"><ix:nonFraction unitRef="usd" contextRef="id8f643a473a8490da5ebb398751eb409_I20220601" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMjA0MA_622510ba-d7a5-4703-bcc8-c424f71035a7">4.3</ix:nonFraction></ix:nonFraction>&#160;million.<br/><br/>For more information about our Leases, see &#8220;Note 11. Commitments and Contingencies&#8212;Leases&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSN I ANDA Litigation </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (individually and collectively with certain of its affiliates, including MSN Laboratories Private Limited, referred to as MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. The <ix:nonFraction unitRef="lawsuit" contextRef="i09a2105efdab4080a91d211b2377ed70_I20210430" decimals="INF" name="exel:LossContingencyNumberOfLawsuitsConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfNDk1OQ_cf94eaf7-edc3-4945-84ec-ee660c7e3108">two</ix:nonFraction> lawsuits comprising this litigation (collectively referred to as MSN I), numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our MSN I complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties have narrowed </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><ix:continuation id="ie98116f7a5ee4a3c96a5d661c8815370" continuedAt="i619a654c99574d0fa5ea3d9929aaafd3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN has, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claim 1 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial for MSN I occurred in May 2022, and a judgment is expected during the fourth quarter of 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSN II ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are invalid and not infringed. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#8217;s further amendment of its ANDA Filing with the FDA. On August 9, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 11,298,349 are invalid and not infringed. The <ix:nonFraction unitRef="lawsuit" contextRef="i02f61410057849a2be1a95901d4749f3_I20221031" decimals="INF" name="exel:LossContingencyNumberOfLawsuitsConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMjc0ODc3OTA5Mzc5Nw_7a1dca06-e20b-4cc4-b4e3-5fc7e6f2b043">two</ix:nonFraction> lawsuits comprising this litigation (collectively referred to as MSN II), numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated in October 2022 and involve Exelixis patents that are different from those asserted in the MSN I litigation described above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would also infringe certain claims of each patent, if those claims are not found to be invalid. In our MSN II complaints, we are seeking, among other remedies, equitable relief enjoining MSN from infringing this patent, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032. A bench trial for MSN II has been scheduled for October 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teva ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). On September 2, 2022, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#8217;s amended ANDA filing with the FDA. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873, 10,039,757 and 11,298,349, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On September 30, 2022, the parties filed a stipulation to consolidate the <ix:nonFraction unitRef="lawsuit" contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930" decimals="INF" name="exel:LossContingencyNumberOfLawsuitsConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMjc0ODc3OTA5Mzc5OA_2b36055c-8994-4e28-b53c-bf6a9cb47414">two</ix:nonFraction> lawsuits, numbered Civil Action Nos. 21-00871 and 22-01168, and to stay all proceedings, </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><ix:continuation id="i619a654c99574d0fa5ea3d9929aaafd3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was granted by the Delaware District Court on October 3, 2022. Following a similar order granted by the Delaware District Court on February 9, 2022 to stay all proceedings with respect to Civil Action No. 21-00871, this case remained administratively closed, and Civil Action No. 22-01168 was administratively closed on October 3, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div></ix:continuation><div id="i549da58617674d2089ca2811b93aa142_64"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfMjc0ODc3OTA4MjkxNQ_f101c713-e313-4eac-9bc0-6937632b3f32" continuedAt="id0b718fddf9f4252bd7b717ecf83938a" escape="true">SUBSEQUENT EVENTS<br/><br/>&#160;&#160;&#160;&#160;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="id0b718fddf9f4252bd7b717ecf83938a" continuedAt="id12e39e02d9441d9be091f2bcadc3b53">Cybrexa Therapeutics, LLC (Cybrexa)</ix:continuation></span></div><ix:continuation id="id12e39e02d9441d9be091f2bcadc3b53"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we entered into an agreement with Cybrexa Therapeutics, LLC (Cybrexa), which provides us the right to acquire CBX-12 (alphalex&#8482; exatecan), a clinical-stage peptide-drug conjugate (PDC) that utilizes Cybrexa&#8217;s proprietary alphalex technology to enhance delivery of exatecan to tumor cells. Under the terms of the agreement, we will pay an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="ic2fe2d2458b143ac93cfc5d3dd846556_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MTUw_ececcf4a-5e6d-477b-b11a-208aaa90cc0e">60.0</ix:nonFraction>&#160;million for a warrant entitling us to the right to acquire the Cybrexa affiliate that controls CBX-12 and related assets, and to fund certain development and manufacturing expenses incurred by Cybrexa to advance CBX-12 during the warrant period. Cybrexa will continue the development of CBX-12 according to an agreed development plan, including phase 1 studies, and may be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ib2acd12af1dc4ed6b0cbbf446ab05dc7_I20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MTY1_eb3c6a48-4448-44ee-ac93-225d467d22a3">65.0</ix:nonFraction>&#160;million in additional development milestone payments, during the warrant period. We may exercise the warrant for up to $<ix:nonFraction unitRef="usd" contextRef="ic2fe2d2458b143ac93cfc5d3dd846556_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementMaximumAmountOfWarrantExercise" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MTgw_e86b3436-6331-4176-8e63-7ad3bbe39462">300.0</ix:nonFraction>&#160;million based upon our evaluation of a pre-specified clinical data package to be delivered by Cybrexa. Following exercise of the warrant, Cybrexa would be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ic2fe2d2458b143ac93cfc5d3dd846556_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MTk2_4129d04a-9615-4b6c-a41f-0645ce4d1efc">277.5</ix:nonFraction>&#160;million in additional payments upon achievement of further development, regulatory and commercial milestones. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sairopa, B.V. (Sairopa)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we entered into an exclusive option and license agreement with Sairopa, B.V. (Sairopa). Under the terms of the agreement, we will make an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i2df8f1634dda4f61b08a6be87c82e98b_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MjQz_be38382c-f3a0-4ee7-a834-91320dcf6e1a">40.0</ix:nonFraction>&#160;million for an option to obtain an exclusive, worldwide license to develop and commercialize ADU-1805 and other anti-SIRP&#945; antibodies, and for certain expenses to be incurred by Sairopa in conducting phase 1 clinical studies of ADU-1805. Sairopa is eligible to receive additional development milestone payments during the option period totaling up to $<ix:nonFraction unitRef="usd" contextRef="ia221d1d4870d45218498c32c441b4569_I20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MjI4_abcb6eb5-b824-4c71-918f-d69dbeb05559">97.5</ix:nonFraction>&#160;million. Following the completion of the clinical studies, we may exercise the option for $<ix:nonFraction unitRef="usd" contextRef="i2df8f1634dda4f61b08a6be87c82e98b_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsExerciseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MjEy_c19b4821-41e1-4850-9789-f7de20c02363">225.0</ix:nonFraction>&#160;million based upon our evaluation of a pre-specified clinical data package to be delivered by Sairopa. Following the exercise of the option, Sairopa would be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i2df8f1634dda4f61b08a6be87c82e98b_D20221101-20221130" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MjU4_62bf1b7b-387e-4d49-9916-46c41852462c">465.0</ix:nonFraction>&#160;million in additional development, commercial, and net sales milestone payments, as well as tiered royalties on future net sales of products.</span></div></ix:continuation><div id="i549da58617674d2089ca2811b93aa142_67"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (Exelixis, we, our or us) current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Risk Factors&#8221; in Part II, Item&#160;1A of this Quarterly Report on Form 10-Q, as well as those discussed elsewhere in this report. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and the consolidated financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the Securities and Exchange Commission (SEC) on February&#160;18, 2022 (Fiscal 2021 Form 10-K).</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for patients with difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 62 other countries as: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc., a member of the Roche Group (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo, Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan is to utilize our operating cash flows and cash and investments to expand the cabozantinib franchise by potentially adding new indications in areas of unmet medical need. We will also leverage our operating cash flows to continue advancing our diverse small molecule and biotherapeutics programs, exploring multiple modalities and mechanisms of action to discover new oncology drugs. So far, these drug discovery and preclinical activities have resulted in four clinical-stage compounds: XL092, a next-generation oral tyrosine kinase inhibitor (TKI); XB002, an antibody drug conjugate (ADC) that targets tissue factor (TF); XL102, a potent, selective and orally bioavailable covalent inhibitor of cyclin-dependent kinase 7 (CDK7); and XL114, a n</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ovel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 (CBM) complex</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Franchise</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA first approved CABOMETYX as a monotherapy for previously treated patients with advanced RCC in April 2016, and then for previously untreated patients with advanced RCC in December 2017. In January 2021, the CABOMETYX label was expanded to include first-line advanced RCC in combination with OPDIVO, which was the first CABOMETYX regimen approved for treatment in combination with an immune checkpoint inhibitor (ICI). In addition to RCC, in January 2019, the FDA approved CABOMETYX for the treatment of patients with HCC previously treated with sorafenib, and then in September 2021, the FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen and Takeda. We granted to Ipsen the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda we granted the rights to develop and commercialize cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of the cabozantinib franchise in other potential indications, and we work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the European Union (EU), the United Kingdom (U.K.) and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. In addition, in March 2021, Ipsen and BMS received regulatory approval from the EC for CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC, followed by additional regulatory approvals for the combination in other territories beyond the EU. Most recently, in May 2022, we announced that Ipsen received regulatory approval from the EC for CABOMETYX as a monotherapy for the treatment of adult patients with locally advanced or metastatic, RAI-refractory or ineligible DTC and who have progressed during or after prior systemic therapy. With respect to the Japanese market, Takeda received </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing and Marketing Approvals in 2020 from the Japanese Ministry of Health, Labour and Welfare (MHLW) of CABOMETYX as a treatment of patients with curatively unresectable or metastatic RCC and as a treatment of patients with unresectable HCC who progressed after cancer chemotherapy. In August 2021, Takeda and Ono Pharmaceutical Co., Ltd. (Ono), BMS&#8217; development and commercialization partner in Japan, received Manufacturing and Marketing Approval from the MHLW of CABOMETYX in combination with OPDIVO as a treatment for unresectable or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest-of-world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could potentially benefit from this medicine. We continue to evaluate cabozantinib, both as a single agent and in combination with ICIs, in a broad development program comprising over 100 ongoing or planned clinical trials across multiple tumor types. We, along with our collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator sponsored trial (IST) program. The data from these third-party clinical trials have helped advance our development program for the cabozantinib franchise by informing subsequent label-enabling trials, including COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib in previously treated patients with RAI-refractory DTC, from which positive results served as the basis for the FDA&#8217;s and EC&#8217;s approvals of CABOMETYX for DTC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building on preclinical and clinical observations that cabozantinib in combination with ICIs may promote a more immune-permissive tumor environment, we initiated numerous pivotal studies to further explore these combination regimens. The first of these studies to deliver results was CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of CABOMETYX and OPDIVO compared to sunitinib in previously untreated, advanced or metastatic RCC, and positive results from CheckMate -9ER served as the basis for the FDA&#8217;s, EC&#8217;s and MHLW&#8217;s approvals of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC in January 2021, March 2021 and August 2021, respectively. We are also collaborating with BMS on COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. We announced top-line results from COSMIC-313 in July 2022, and in September 2022 we presented the data at the Presidential Symposium III at the 2022 European Society for Medical Oncology (ESMO) Congress. The trial met its primary endpoint, demonstrating significant improvement in blinded independent radiology committee (BIRC) assessed progression free survival (PFS) at the primary analysis for the triplet combination, reducing the risk of disease progression or death compared with the doublet combination of nivolumab and ipilimumab (hazard ratio: 0.73; 95% confidence interval [CI]: 0.57-0.94; P=0.01). Median PFS for the triplet combination was not reached (95% CI: 14.0-not estimable) versus 11.3 months for the doublet combination of nivolumab and ipilimumab (95% CI: 7.7-18.2). At a prespecified interim analysis for the secondary endpoint of overall survival (OS), the triplet combination did not demonstrate a significant benefit, and therefore, the trial will continue to the next analysis of OS. The safety profile observed in the trial was reflective of the known safety profiles for each single agent, as well as the combination regimens used in this study. Based on feedback from the FDA, we do not intend to submit a supplemental new drug application (sNDA) for the combination regimen based on the currently available data, and we plan to discuss a potential regulatory submission with the FDA when the results of the next OS analysis are available.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our exploration of combinations with ICIs, we also initiated multiple trials evaluating cabozantinib in combination with F. Hoffmann-La Roche Ltd.&#8217;s (Roche) ICI, atezolizumab, beginning in 2017 with COSMIC-021, a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with a wide variety of locally advanced or metastatic solid tumors. The data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the initiation of COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC, and three phase 3 pivotal trials in collaboration with Roche, CONTACT-01, CONTACT-02 and CONTACT-03, evaluating the combination of cabozantinib with atezolizumab in patients with metastatic non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (mCRPC) and advanced RCC, respectively. CONTACT-01 and CONTACT-03 are sponsored by Roche and co-funded by us, and we announced the completion of enrollment for the two trials in November 2021 and January 2022, respectively. We expect to receive results from CONTACT-01 in the fourth quarter of 2022 and from CONTACT-03 in the first half of 2023. CONTACT-02 is sponsored by us and co-funded by Roche, and we anticipate completing enrollment in the first half of 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our small molecule discovery programs are supported by a robust and expanding infrastructure, including a library of 4.6&#160;million compounds. We have extensive experience in the identification and optimization of drug candidates against </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">multiple target classes for oncology, inflammation and metabolic diseases. The first compound to enter the clinic following our re-initiation of drug discovery activities in 2017 was XL092, a next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer&#8217;s growth and spread. In designing XL092, we sought to build upon our experience with cabozantinib, retaining a similar target profile while improving key characteristics, including the pharmacokinetic half-life. To date, we have initiated two large phase 1b clinical trials studying XL092: STELLAR-001 and STELLAR-002. STELLAR-001 is a phase 1b clinical trial evaluating XL092, both as a monotherapy and in combination with either atezolizumab or avelumab, an ICI developed by Merck KGaA Damstadt, Germany and Pfizer Inc. We have established a recommended dose of 100 mg for both single-agent XL092 and XL092 in combination with atezolizumab, and we have begun enrolling expansion cohorts for patients with clear cell RCC, non-clear cell RCC, hormone-receptor positive breast cancer, mCRPC and colorectal cancer (CRC); the dose-escalation stage for XL092 in combination with avelumab is ongoing, with expansion cohorts planned initially in urothelial carcinoma (UC). We presented data from STELLAR-001 during poster sessions at the 2022 ESMO Congress in September 2022, which showed XL092 has demonstrated preliminary, clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors and dose levels, with a manageable safety profile. STELLAR-002 is a phase 1b clinical trial evaluating XL092 in combination with either nivolumab, nivolumab and ipilimumab, or a fixed dose of nivolumab and relatlimab, a lymphocyte activation gene-3 (LAG-3)-blocking antibody developed by BMS (replacing Nektar Therapeutics&#8217; bempegaldesleukin in the original trial protocol following the expansion of our clinical trial collaboration and supply agreement with BMS, which we announced in October 2022). We are enrolling patients with advanced solid tumors in dose-escalation cohorts, and depending on the dose-escalation results, STELLAR-002 may enroll expansion cohorts for patients with clear cell and non-clear cell RCC, mCRPC, UC, CRC, HCC, NSCLC and head and neck squamous cell carcinoma. To better understand the individual contribution of the therapies, treatment arms in the expansion cohorts may include XL092 as a single-agent in addition to the ICI combination regimens. We also initiated STELLAR-303, the first global phase 3 pivotal trial for XL092, in June 2022, and we expect to initiate a second pivotal trial in late 2022 with others to follow in 2023. STELLAR-303 is evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic non-microsatellite instability-high or non-mismatch repair-deficient CRC who have progressed after or are intolerant to the current standard of care, and the trial aims to enroll approximately 600 patients worldwide with documented RAS status. The primary objective of STELLAR-303 is to evaluate the efficacy of the combination in patients with RAS wild-type disease, and outcomes in patients with RAS-mutated disease will also be evaluated. The primary endpoint of STELLAR-303 is OS, and additional efficacy endpoints include PFS, objective response rate (ORR) and duration response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1. as assessed by the investigator. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies. The most advanced compounds to emerge from these arrangements are XL102, the lead program targeting CDK7 under our collaboration with Aurigene Discovery Technologies Limited (Aurigene), and XL114, Aurigene&#8217;s novel anti-cancer compound that inhibits the CBM complex. Based on encouraging preclinical data, we exercised our exclusive options to license XL102 and XL114 from Aurigene and initiated phase 1 clinical trials evaluating XL102 and XL114 in January 2021 and April 2022, respectively, and we expect to provide clinical updates from the phase 1 study of XL102 in the fourth quarter of 2022. Most recently, in November 2022, we entered into an agreement with Cybrexa Therapeutics, LLC (Cybrexa), which provides us the right to acquire CBX-12 (alphalex&#8482; exatecan), a clinical-stage peptide-drug conjugate (PDC) that utilizes Cybrexa&#8217;s proprietary alphalex technology to enhance delivery of exatecan to tumor cells. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond small molecules, we have also launched rigorous efforts to discover and advance various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, ADCs and other innovative treatments. ADCs in particular present a unique opportunity for new cancer treatments, given their capabilities to deliver anti-cancer payload drugs to targets with increased precision while minimizing impact on healthy tissues, and this biotherapeutic approach has been validated by multiple regulatory approvals for the commercial sale of ADCs in the past several years. To facilitate the growth of these programs, we have established multiple research collaborations and in-licensing arrangements and entered into other strategic transactions that provide us with access to antibodies, binders, payloads and conjugation technologies, which are the components employed to generate next-generation ADCs or multispecific antibodies. We have already made significant progress under these arrangements and expect we will continue to advance our biotherapeutics programs throughout the remainder of 2022 and in future years: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Sairopa. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a collaboration with Sairopa, B.V. (Sairopa) in November 2022, focused on the development of ADU-1805, a monoclonal antibody (mAb) that targets SIRP&#945;. The collaboration is intended to expand our clinical pipeline with an IND filing for ADU-1805 anticipated in early 2023 to explore its applicability across multiple tumor types, as well as the potential to combine ADU-1805 with XL092 and approved ICIs.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Ryvu</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into a collaboration with Ryvu Therapeutics S.A. (Ryvu) in July 2022, focused on the development of novel targeted therapies utilizing Ryvu&#8217;s STING (STimulator of INterferon Genes) technology. The collaboration is intended to expand our portfolio of biotherapeutics by combining our tumor-specific targeting approaches with Ryvu&#8217;s proprietary small molecule STING agonists and STING biology know-how. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">BioInvent</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into a collaboration with BioInvent International AB (BioInvent) in June 2022, focused on the identification and development of novel antibodies for use as oncology therapeutics. The collaboration is intended to expand our portfolio of antibody-based therapies and will utilize BioInvent&#8217;s proprietary n-CoDeR&#174; antibody library and patient-centric F.I.R.S.T</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> screening platform, which together are designed to allow for parallel target and antibody discovery. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">GamaMabs. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed an asset purchase from GamaMabs Pharma SA (GamaMabs) in May 2022. In the transaction, we acquired all rights, title and interest in GamaMabs&#8217; antibody program directed at anti-M&#252;llerian hormone receptor 2 (AMHR2), a novel oncology target with relevance in multiple forms of cancer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Iconic.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We in-licensed XB002, our lead TF-targeting ADC program, from Iconic, Inc. (Iconic) in December 2020 and initiated the JEWEL-101 phase 1 clinical trial in June 2021, and we presented promising initial dose-escalation results from the trial at the 34th EORTC-NCI-AACR (ENA) Symposium in October 2022. In December 2021, we amended our exclusive option and license agreement with Iconic to acquire broad rights to use the anti-TF antibody used in XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Invenra</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have expanded our collaboration with Invenra, Inc. (Invenra) several times since our first engagement in 2018, most recently in August 2021 to include an additional 20 oncology targets.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">WuXi Bio.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We expanded our access to antibodies through arrangements with WuXi Biologics Ireland Limited, a wholly owned subsidiary of WuXi Biologics (Cayman) Inc. (individually and collectively referred to as WuXi Bio) in March 2021. We are focused on leveraging WuXi Bio&#8217;s panel of mAbs against an undisclosed target for the development of ADC, bispecific and certain other novel tumor-targeting biotherapeutics. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Adagene</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into a collaboration with Adagene Inc. (Adagene) in February 2021, focused on using Adagene&#8217;s SAFEbody&#174; technology to develop novel masked ADCs or other innovative biotherapeutics, with the potential to develop ADCs or other biotherapeutics with improved therapeutic index.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">NBE and Catalent</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We entered into collaborations with NBE-Therapeutics AG (NBE) and Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc. (individually and collectively referred to as Catalent) in September 2020. These platform collaborations allow us to utilize their site-specific conjugation technologies and payloads to construct ADCs using the antibodies we have sourced from our arrangements with WuXi Bio, GamaMabs and Invenra. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements have led directly to the advancement of two biotherapeutics development candidates, XB010 and XB014. XB010, our first ADC advanced internally, targets the tumor antigen 5T4 and incorporates antibodies sourced from Invenra. It was constructed using Catalent&#8217;s SMARTag&#174; site-specific bioconjugation platform. XB014 is our first bispecific antibody, which combines a PD-L1 targeting arm with a CD47 targeting arm to block a macrophage checkpoint, and was developed through our collaboration with Invenra. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report, we expect to advance multiple programs into preclinical development over the next six months. We will continue to engage in business development initiatives with the goal of acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report on Form 10-Q, the COVID-19 pandemic continues to have a modest impact on our business operations. While the pandemic has created operational difficulties and complexities, we have thus far been successful at devising solutions designed to mitigate its impact. We will continue to monitor new developments that could pose additional risks for us, including the spread of the Omicron variant and its subvariants in the U.S. and other countries, and the potential emergence of new SARS-CoV-2 variants that may prove especially contagious or virulent. Despite our COVID-19 pandemic mitigation efforts, we may experience delays or an inability to execute on our clinical and preclinical development plans, reduced revenues or other adverse impacts to our business as described in more detail in </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. We recognize that this pandemic will continue to present unique challenges for us throughout the remainder of 2022, and potentially into 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Quarter 2022 Business Updates and Financial Highlights</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we continued to execute on our business objectives, generating significant revenues from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for the quarter and subsequent to quarter-end include:</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In July 2022, we announced an exclusive license agreement with Ryvu to develop novel targeted therapies utilizing Ryvu&#8217;s STING technology. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In July 2022, we announced results from the phase 3 COSMIC-313 trial, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n which the triplet combination of cabozantinib, nivolumab and ipilimumab met its primary endpoint, demonstrating significant improvement in PFS versus the doublet combination of nivolumab and ipilimumab at the primary analysis. At a prespecified interim analysis for the secondary endpoint of OS, the triplet combination did not demonstrate a significant benefit, and therefore the trial will continue to the next analysis of OS.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In July 2022, we filed a patent lawsuit in the United States District Court for the District of Delaware (the Delaware District Court) against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (individually and collectively referred to as MSN) asserting infringement of U.S. Patent No. 11,298,349 (pharmaceutical composition) arising from MSN&#8217;s further amendment of its Abbreviated New Drug Application (ANDA), originally filed with the FDA in September 2019.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This lawsuit, our fourth case against MSN, has been consolidated with the patent lawsuit we filed in February 2022 (collectively, MSN II) and involves an Exelixis patent that is different from those asserted previously in February 2022 and in the consolidated patent lawsuits that we filed in 2019 and 2020 (collectively, MSN I), for which a trial took place in May 2022. In our MSN II complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of the patents at issue in MSN II, the latest of which expires on February 10, 2032. For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In September 2022, we filed a patent lawsuit in the Delaware District Court against Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva), asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#8217;s amendment of its ANDA, originally filed with the FDA in May 2021. This lawsuit, our second case against Teva, has been consolidated with the prior patent lawsuit we filed in June 2021 and involves an Exelixis patent that is different from those asserted previously in June 2021. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA would be a date no earlier than the expiration of the patents at issue in our consolidated patent lawsuits against Teva, the latest of which expires on July 9, 2033. All proceedings were stayed pursuant to an order of the Delaware District Court in October 2022. For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In September 2022, clinical data from COSMIC-313 were presented as part of Presidential Symposium III at the 2022 ESMO Congress. In addition, cabozantinib was the subject of multiple data presentations in RCC, DTC and advanced adrenocortical carcinoma, and we also presented phase 1b data from STELLAR-001, in which XL092 demonstrated preliminary clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In October 2022, we announced an expansion of our clinical trial collaboration and supply agreement with BMS to include the use of the fixed-dose combination of nivolumab and relatlimab in STELLAR-002, our ongoing </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">phase 1b clinical trial evaluating XL092 in combination with multiple ICIs in advanced solid tumors. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In October 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we announced promising initial dose-escalation results from JEWEL-101, the ongoing phase 1 trial evaluating XB002 in patients with advanced solid tumors, during the Antibody-drug Conjugates Poster Session at the 34th ENA Symposium. The data demonstrated that XB002 was well-tolerated at multiple dose levels, and a pharmacokinetic analysis confirmed that XB002 was stable with low levels of free payload.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.02pt">In November 2022, we announced an agreement with Cybrexa that provides us the right to acquire CBX-12, a clinical-stage PDC that utilizes Cybrexa&#8217;s proprietary alphalex technology to enhance delivery of exatecan to tumor cells.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.02pt">In November 2022, we announced an exclusive option and license agreement and clinical development collaboration with Sairopa to develop ADU-1805, a mAb that targets SIRP&#945;.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net product revenues for the third quarter of 2022 were $366.5 million, as compared to $263.1 million for the third quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Total revenues for the third quarter of 2022 were $411.7 million, as compared to $328.4 million for the third quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Research and development expenses for the third quarter of 2022 were $198.8 million, as compared to $163.4&#160;million for the third quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Selling, general and administrative expenses for the third quarter of 2022 were $115.0 million, as compared to $101.6 million for the third quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Provision for income taxes for the third quarter of 2022 was $18.8 million, as compared to $15.1 million for the third quarter of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net income for the third quarter of 2022 was $73.2 million, or $0.23 per share, basic and diluted, as compared to net income of $38.2 million, or $0.12 per share, basic and diluted, for the third quarter of 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Results of Operations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outlook, Challenges and Risks</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to face numerous challenges and risks that may impact our ability to execute on our business objectives. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. However, we cannot be certain that the clinical trials we and our collaboration partners are conducting will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if the required regulatory approvals to market cabozantinib for additional indications are achieved, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. As is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets. In addition, healthcare policymakers in the U.S. are increasingly expressing concern over healthcare costs, and corresponding legislative and policy initiatives and activities have been launched, aimed at increasing the healthcare cost burdens borne by pharmaceutical manufacturers, as well as expanding access to, and restricting the prices and growth in prices of, pharmaceuticals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achievement of our business objectives will also depend on our ability to maintain a competitive position in the shifting landscape of therapeutic strategies for the treatment of cancer, which we may not be able to do. On an ongoing basis, we assess the constantly evolving landscape of other approved and investigational cancer therapies that could be competitive, or complementary in combination, with our products, and then we adapt our development strategies for the cabozantinib franchise and our pipeline product candidates accordingly, such as by modifying our clinical trials to include evaluation of our therapies with ICIs and other targeted agents. Even if our current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in NSCLC and mCRPC or evaluating XL092 in combination with an ICI in CRC, produce positive results sufficient to obtain marketing approval by the FDA and other global regulatory authorities, it is uncertain whether physicians will choose to prescribe regimens containing our products instead of competing products and product combinations in approved indications. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic versions of CABOMETYX tablets that are the subject of ANDAs submitted to the FDA by MSN and by Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva). The approval of either MSN&#8217;s or Teva&#8217;s ANDA and subsequent launch of any generic version of CABOMETYX could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with drug discovery operations, especially on the global level. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these challenges and risks are specific to our business, others are common to companies in the biopharmaceutical industry with development and commercial operations, and an additional category are macroeconomic, affecting all companies. For a more detailed discussion of challenges and risks we face, see &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Convention</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2022, which is a 52-week fiscal year, will end on December&#160;30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the fiscal period ended October&#160;1, 2021, and as of and for the fiscal year ending December&#160;30, 2022 are indicated as being as of and for the period ended September&#160;30, 2021, and the year ending December&#160;31, 2022, respectively.</span></div><div id="i549da58617674d2089ca2811b93aa142_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:27.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.972%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,738&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues, discounts and allowances, and net product revenues were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:27.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.972%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,659)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,627)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,482&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:27.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.972%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,482&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in net product revenues for the three and nine months ended September 30, 2022, as compared to the corresponding prior year periods, were primarily related to increases of 30% and 27%, respectively, in the number of units sold, and to a lesser extent 7% and 4% increases in the average net selling price of CABOMETYX for the three and nine months ended September&#160;30, 2022, respectively, as compared to the corresponding prior year periods.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project that our net product revenues may increase for the remainder of 2022, as compared to the corresponding prior year period, for similar reasons noted above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;included in Part II, Item 8 of our Fiscal 2021 Form 10-K. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in discounts and allowances for the three months ended September 30, 2022, as compared to the corresponding prior year period, was primarily the result of an increase in the dollar amount of chargebacks related to the government&#8217;s 340B Drug Pricing Program (the 340B Program), which mandates drug manufacturers offer discount drug pricing for certain eligible covered entities that meet 340B Program requirements. The increase in discounts and allowances for the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared to the corresponding prior year period, was primarily from higher utilization in the 340B Program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and allowances as a percentage of gross revenues have increased over time as the number of patients participating in government programs, including the government-mandated 340B Program, as well as the discounts given and rebates paid to government payers, has also increased. We project this trend will continue and that our discounts and allowances as a percentage of gross revenues may increase during the remainder of 2022, as compared to the corresponding prior year period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues generally include: (a) the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the related period that the milestone would be achieved and a significant reversal of revenues would not occur; (b) royalty revenues; and (c) the profit on the U.S. commercialization of COTELLIC from Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues, which are allocated between license revenues and collaboration services revenues, were $1.7&#160;million and $28.5&#160;million for the three and nine months ended September 30, 2022, respectively, as compared to $19.7&#160;million and $33.1&#160;million for the corresponding prior year periods. Milestone revenues by period included the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">For the nine months ended September 30, 2022, $25.8&#160;million in revenues was recognized in connection with two regulatory milestones totaling $27.0&#160;million upon the approval by the European Commission and Health Canada, of cabozantinib as a monotherapy for the treatment of adult patients with locally advanced or metastatic DTC, refractory or not eligible to RAI who have progressed during or after prior systemic therapy.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">For the three and nine months ended September&#160;30, 2021, $18.8&#160;million in revenues was recognized in connection with a $20.0&#160;million milestone we achieved following Takeda&#8217;s first commercial sale in Japan of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable or metastatic RCC.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">For the nine months ended September 30, 2021, $11.9&#160;million in revenues was recognized in connection with a $12.5&#160;million regulatory milestone we determined was probable of achievement. The milestone was achieved in the third quarter of 2021 upon Ipsen&#8217;s submission of a variation application to the EMA for CABOMETYX as a treatment for patients with previously treated, RAI-refractory DTC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenues increased primarily as a result of increases in Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan. Ipsen royalties were $27.6 million and $79.7 million for the three and nine months ended September 30, 2022, respectively, as compared to $25.1&#160;million and $70.4&#160;million for the corresponding prior year periods. Ipsen&#8217;s net sales of cabozantinib have continued to grow since Ipsen&#8217;s commercial sale of CABOMETYX in the fourth quarter of 2016, primarily due to regulatory approvals in new territories, including regulatory approval in the EU for the combination therapy of CABOMETYX and OPDIVO received in March 2021. Royalty revenues for the three and nine months ended September 30, 2022 also included $2.7 million and $7.8 million, respectively, related to Takeda&#8217;s net sales of CABOMETYX, as compared to $2.0&#160;million and $5.4&#160;million for the corresponding prior year periods. Takeda royalty revenues have continued to grow since Takeda&#8217;s first commercial sale of CABOMETYX in Japan in 2020. As of September&#160;30, 2022, CABOMETYX is approved and is commercially available in 62 countries outside the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech was $1.5&#160;million and $5.3&#160;million for the three and nine months ended September 30, 2022, respectively, as compared to $1.7&#160;million and $5.7 million for the corresponding prior year periods. We also earned royalties on ex-U.S. net sales of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COTELLIC by Genentech of $1.5&#160;million and $4.0&#160;million for the three and nine months ended September 30, 2022, respectively, as compared to $1.6 million and $3.3&#160;million for the corresponding prior year periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and milestones can vary significantly from period to period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Services Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, and product supply revenues, which are net of product supply costs and the royalties we pay on sales by Ipsen and Takeda of products containing cabozantinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development cost reimbursements were $13.1&#160;million and $47.7&#160;million for the three and nine months ended September 30, 2022, respectively, as compared to $17.5&#160;million and $98.4&#160;million for the corresponding prior year periods. The decrease in development cost reimbursements for the three months ended September 30, 2022, as compared to the corresponding prior year period, was primarily attributable to decreases in spending on the COSMIC-021 and COSMIC-312 studies, which was partially offset by an increase in spending on the CONTACT-02 study. The decrease in development cost reimbursements for the nine months ended September 30, 2022, as compared to the corresponding prior year period was primarily due to Ipsen&#8217;s decision to opt in and co-fund COSMIC-311 development costs in the second quarter of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inclu</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ded a cumulative catch up for Ipsen&#8217;s share of global development costs incurred since the beginning of the study. To a lesser extent, the decrease was attributable to decreases in spending on the COSMIC-021 and COSMIC-312 studies, which was partially offset by an increase in spending on the CONTACT-02 study. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues were reduced by $3.9&#160;million and $11.9&#160;million for the three and nine months ended September 30, 2022, respectively, as compared to $3.7&#160;million and $10.5&#160;million for the corresponding prior year periods, for the 3% royalty we are required to pay on the net sales by Ipsen and Takeda of any product incorporating cabozantinib. As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments have also increased.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our collaboration services revenues may decrease for the remainder of 2022, as compared to the corresponding prior year period, primarily as a result of decreased development cost reimbursements related to Ipsen&#8217;s opt-in and co-funding of COSMIC-311 and the related cumulative catch-up in development cost reimbursements recognized in 2021, for which no similar event is projected to occur in 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of goods sold and our gross margin were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:27.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.972%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,305</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,874</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,989</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,956</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty payable on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring, excess and obsolete inventory, and other third-party logistics costs. The increases in cost of goods sold for the three and nine months ended September 30, 2022, as compared to the corresponding prior year periods, were primarily due to an increase in </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oyalties as a result of increased U.S. CABOMETYX sales, which were partially offset by lower period costs. We project our gross margin will not change significantly during the remainder of 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully burdened research and development expenses on a project-by-project basis. We group our research and development expenses into three categories: (1) development; (2) drug discovery; and (3) other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies, including in-licensed technologies, to enable the rapid discovery, optimization and extensive </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">characterization of lead compounds and biotherapeutics in order to select development candidates with the best potential for further evaluation and advancement into clinical development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses by category were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:27.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.972%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other development costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other drug discovery costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total drug discovery</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,369&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,886&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,837&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,370&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primarily includes development milestone expenses related to our in-licensing collaboration agreements as well as other miscellaneous development costs. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primarily includes upfront license fees, research funding commitments and other payments associated with our in-licensing collaboration programs in preclinical development stage.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primarily includes personnel expenses, consulting and outside services and laboratory supplies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the allocation of general corporate costs to research and development services, and development cost reimbursements in connection with our collaboration arrangement with Roche executed in December 2019.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he increases in research </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development expenses for the three and nine months ended September 30, 2022, as compared to the corresponding prior year periods, were primarily related to increases in personnel expenses, clinical trial costs, and consulting and outside services, which were partially offset by a decrease in other development costs. Clinical trial costs, which include services performed by third-party contract research organizations and other vendors who support our clinical trials, increased primarily due to higher costs associated with the various XL092 and XB002 studies, as well as the CONTACT-02 cabozantinib study, which were partially offset by decreases in costs associated with the COSMIC-313, COSMIC-021, and COSMIC-312 cabozantinib studies. Personnel expenses increased primarily due to an increase in headcount to support our expanding discovery and development organization. Consulting and outside services expenses increased primarily as a result of the continued growth in our discovery and research activities. The reduction in other development costs is primarily due to the reversal of a development milestone in the third quarter of 2022, which was recorded in the third quarter of 2021. The compound has not progressed as expected and therefore we are no longer able to predict when the milestone will occur. License and other collaboration costs increased for the three months ended September 30, 2022, as compared to the corresponding prior year period, primarily due to an increase in development milestone payments, which was partially offset by a decrease in upfront license fees from business activities. License and other collaboration costs decreased during the nine months ended September 30, 2022, as compared to the corresponding prior period, primarily due to lower upfront license fees from business development activities. Stock-based compensation expense increased for the three months ended September 30, 2022, as compared to the corresponding prior year period, primarily due to the impact of modifying certain stock-based compensation awards during the three months ended September 30, 2022, which was partially offset by lower stock-based compensation expense associated with the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of PSUs. Stock-based compensation expense decreased for the nine months ended September 30, 2022, as compared to the corresponding prior year period, primarily due to lower stock-based compensation expense associated with the achievement of PSUs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. These factors include enrollment in clinical trials for our drug candidates, preliminary data and final results from clinical trials, the potential indications, and clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focusing a significant amount of our development efforts on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we project that a substantial portion of our research and development expenses will relate to the continuing clinical development program of cabozantinib, which includes over 100 ongoing or planned clinical trials across multiple indications. Notable ongoing company-sponsored studies resulting from this program include: COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge; and CONTACT-02, for which Roche is sharing the development costs and providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biotherapeutics programs with multiple modalities and mechanisms of action, with the goal of identifying new product candidates to advance into clinical trials. We also continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets, with the goal of utilizing our established preclinical and clinical development infrastructure to further characterize and develop such platforms and assets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our research and development expenses may increase for the remainder of 2022, as compared to the corresponding prior year period, primarily driven by our ongoing clinical evaluation of cabozantinib, the initiation of new clinical trials and expansion of ongoing clinical trials evaluating other product candidates in our pipeline, including STELLAR-303 and planned initiation of a second phase 3 pivotal trial for XL092, and also our current early-stage trials evaluating XL092, XB002, XL102 and XL114, as well as anticipated business development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of the risks and uncertainties with respect to our research and development activities and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:27.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.972%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,899&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,832&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,983&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,558&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,404&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel expenses, stock-based compensation, marketing costs and certain other administrative costs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in selling, general and administrative expenses for the three and </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022, as compared </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the corresponding prior year periods, were primarily related to increases in personnel expenses, marketing costs, business technology initiatives, and rent and utilities expenses, partially offset by a decrease in stock-based compensation expense.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel expenses increased primarily due to an increase in administrative headcount to support our commercial and research and development organizations. Marketing costs increased primarily due to increased spending in support of the commercialization of</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the combination therapy of CABOMETYX and OPDIVO for the treatment of advanced RCC. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business technology initiatives increased primarily to support productivity and efficiency in our organization. Rent and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilities expenses increased primarily related to the commencement of our Alameda built-to-suit lease in the second quarter of 2022. Stock-based compensation expense decreased primarily due to lower compensation expense associated with the achievement of PSUs and fewer stock options granted, which was partially offset by an increase in the number of RSUs granted.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our selling, general and administrative expenses may increase for the remainder of 2022, as compared to the corresponding prior year period primarily driven by our continuing commercial investment in CABOMETYX and the growth of the broader organization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-operating Income</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income was as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:27.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.972%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in non-operating income for the three and nine months ended September 30, 2022, as compared to the corresponding prior year periods, were primarily the result of increases in interest income due to higher interest rates and higher investment balances.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:27.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.972%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and nine months ended September 30, 2022, differed from the U.S. federal statutory rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, which were partially offset by state taxes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and nine months ended September&#160;30, 2021 differed from the U.S. federal statutory rate of 21% primarily due to non-deductible executive compensation, partially offset by excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits. </span></div><div id="i549da58617674d2089ca2811b93aa142_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had $2.1 billion in cash, cash equivalents, restricted cash equivalents and investments, as compared to $1.9 billion as of December&#160;31, 2021. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, net product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary cash requirements for operating activities, which we project will increase for the remainder of 2022, as compared to the corresponding period in 2021, are for: employee related expenditures; costs related to our development and discovery programs; income tax payments; cash payments for inventory; royalty payments on our net product sales; and our leased facilities. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act, signed into law on December 22, 2017, modified the tax treatment of research and development expenditures beginning in 2022. In general, research and development expenditures are no longer deductible in the current period but instead must be amortized ratably over five years for domestic expenditures or 15 years for foreign expenditures. As a result, we anticipate a higher federal income tax liability in 2022 and have paid higher estimated federal taxes. We will realize a reduction of our federal income tax liability in future years as the capitalized research and development expenditures are amortized for tax purposes.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of operating cash are: cash collections from customers related to net product sales, which we project will increase for the remainder of 2022, as compared to the corresponding period in 2021; cash collections related to royalties earned from our commercial collaboration arrangements with Ipsen, Takeda and others and cash collections upon achievement of certain development, regulatory and commercial milestones; and cash collections for cost reimbursements under certain of our development programs. The timing of cash generated from commercial collaborations and cash payments required for in-licensing collaborations relative to upfront license fee payments, research funding commitments, cost reimbursements and other contingent payments such as development milestone payments may vary from period to period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have cash requirements related to capital expenditures to support the planned growth of our business including investments in laboratory facilities and equipment. We project that we may continue to spend significant amounts of cash to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including additional research collaborations, in-licensing arrangements and other strategic transactions that align with our oncology drug development, regulatory and commercial expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity based on market conditions or strategic considerations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of $1.5&#160;million and $16.7&#160;million as of September&#160;30, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standby letter of credit entered in January 2021, as a guarantee of our obligation to fund our portion of the tenant improvements related to our Alameda build-to-suit lease was terminated and the related collateral was returned in the third quarter of 2022, following the substantial completion of the building and the commencement of the lease.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash equivalents, and investments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working capital</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The increase in working capital as of September&#160;30, 2022, as compared to December&#160;31, 2021, was primarily due to the favorable impacts to our net current assets resulting from our net income during the nine months ended September 30, 2022, which was partially offset by purchases of long-term investments and estimated tax payments made that are classified as long-term. In the future, our working capital may be impacted by one of these factors or other factors, the amounts and timing of which are variable.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash and cash equivalents primarily consist of cash deposits held at major banks, commercial paper and other securities with original maturities 90 days or less. Restricted cash equivalents and investments relate to our standby letter of credit agreements and are invested in short-term marketable securities. For additional information regarding our cash, cash equivalents, restricted cash equivalents and investments, see &#8220;Note 4. Cash and Investments,&#8221; in our &#8220;Notes to Condensed Consolidated Financial Statements&#8221; included in Part I, Item 1 of this Quarterly Report on Form 10-Q. The increase in cash, cash equivalents, restricted cash equivalents and investments at September&#160;30, 2022, as compared to December&#160;31, 2021, was primarily due to cash inflows generated by our operations, including collections of amounts due from customers, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collection of a $100.0&#160;million milestone payment from Ipsen, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by operating cash payments for employee-related expenditures, cash payments to support our development and discovery programs, cash payments for capital expenditures and lease payments.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow activities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities is derived by adjusting our net income for non-cash operating items such as deferred taxes, stock-based compensation, depreciation, non-cash lease expense and changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities for the nine months ended September 30, 2022 decreased, as compared to the corresponding prior year period, primarily due to an increase in cash paid for certain operating expenses resulting in net unfavorable changes in operating assets and liabilities, which was partially offset by an increase in cash received on sales of our products and from our commercial collaboration arrangements, including collection of a $100.0&#160;million milestone payment from Ipsen. </span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in cash flows from investing activities primarily relates to the timing of marketable securities investment activity and capital expenditures. Our capital expenditures primarily consist of investments to expand our operations and acquire assets that further support our research and development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased, as compared to the corresponding prior year period, primarily due to a decrease in cash proceeds from maturities and sales of investments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and an increase in purchases of investments, which were partially offset by a decrease in </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital expenditures.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in cash flows from financing activities primarily relate to proceeds from employee stock programs and taxes paid related to net share settlement of equity awards.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased, as compared to the corresponding prior year period, primarily due to an increase in withholding taxes remitted to the government related to net share settlements of equity awards, which was partially offset by an increase in proceeds received from the issuance of common stock under our equity incentive plans.</span></div><div id="i549da58617674d2089ca2811b93aa142_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we entered into the seventh amendment to the lease for our corporate headquarters l</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ocated on Harbor Bay Parkway, Alameda, California (the Alameda Lease) for the expansion of the premises by 34,745 square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Expansion Space). The term of the 1751 Expansion Space is coterminous with the term of the Alameda Lease for the existing space.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the office building (New Premises) associated with our October 2019 build-to-suit lease agreement (Build-to-Suit Lease) was substantially completed. The New Premises is 220,517 square feet and is in Alameda, California, adjacent to our existing corporate headquarters. The Build-to-Suit Lease term is 242 months, includes two five-year options to extend the term of the lease and a one-time option to terminate the lease after 180 months. In addition to the lease payments, we are also responsible for paying operating expenses related to the New Premises.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes outside of the ordinary course of business in our contractual obligations as of September&#160;30, 2022 from those disclosed in our Fiscal 2021 Form 10-K. For more information about our Build-to-Suit Lease, and our other contractual obligations see &#8220;Note 10. Commitments and contingencies&#8221; in &#8220;Notes to Condensed Consolidated Financial Statements&#8221; included in Part I, Item I of this Quarterly Report on Form 10-Q and see &#8220;Note 11. Commitments and contingencies&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i549da58617674d2089ca2811b93aa142_79"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liabilities; valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market and/or performance conditions; and the amounts of deferred tax assets and liabilities including the related valuation allowance. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the nine months ended September 30, 2022, compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Part II, Item 7 of our Fiscal 2021 Form 10-K.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div id="i549da58617674d2089ca2811b93aa142_82"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks as of September&#160;30, 2022 have not changed significantly from those described in Item&#160;7A of our Fiscal 2021 Form 10-K.</span></div><div id="i549da58617674d2089ca2811b93aa142_85"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the effectiveness of controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i549da58617674d2089ca2811b93aa142_88"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i549da58617674d2089ca2811b93aa142_91"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSN I ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. The two lawsuits comprising the MSN I litigation, numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our MSN I complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties have narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN has, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claim 1 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial for MSN I occurred in May 2022, and a judgment is expected during the fourth quarter of 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSN II ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are invalid and not infringed. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certification. As currently amended, MSN&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#8217;s further amendment of its ANDA Filing with the FDA. On August 9, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent No. 11,298,349 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are invalid and not infringed. The two lawsuits comprising the MSN II litigation, numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated in October 2022 and involve Exelixis patents that are different from those asserted in the MSN I litigation described above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would also infringe certain claims of each patent, if those claims are not found to be invalid. In our MSN II complaints, we are seeking, among other remedies, equitable relief enjoining MSN from infringing this patent, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032. A bench trial for MSN II has been scheduled for October 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teva ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). On September 2, 2022, we filed</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#8217;s amended ANDA filing with the FDA.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873, 10,039,757 and 11,298,349, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On September 30, 2022, the parties filed a stipulation to consolidate the two lawsuits, numbered Civil Action Nos. 21-00871 and 22-01168, and to stay all proceedings, which was granted by the Delaware District Court on October 3, 2022. Following a similar order granted by the Delaware District Court on February 9, 2022 to stay all proceedings with respect to Civil Action No. 21-00871, this case remained administratively closed, and Civil Action No. 22-01168 was administratively closed on October 3, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div id="i549da58617674d2089ca2811b93aa142_94"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to the risks discussed elsewhere in this report, the following are important factors that make an investment in our securities speculative or risky, and that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business and the value of your investment in our company could be harmed.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications and the continued clinical development, regulatory approval, clinical acceptance and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Pricing for pharmaceutical products, both in the U.S. and in foreign countries, has come under increasing attention and scrutiny by federal, state and foreign national governments, legislative bodies and enforcement agencies. Initiatives arising from this scrutiny may result in changes that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The timing of the entrance of generic competitors to CABOMETYX and legislative and regulatory action designed to reduce the barriers to the development, approval and adoption of generic drugs in the U.S. could limit the revenue we derive from our products, most notably CABOMETYX, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">We are subject to healthcare laws, regulations and enforcement, as well as laws and regulations relating to privacy, data collection and processing of personal data; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy, uncertain and subject to change, and may not result in regulatory approvals for additional cabozantinib indications or for our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">We may be unable to expand our discovery and development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our other product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks. For example, we rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and we are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S. In addition, our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Data breaches, cyber-attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications and the continued clinical development, regulatory approval, clinical acceptance and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. In this regard, part of our strategy is to pursue additional indications for CABOMETYX and increase the number of cancer patients who could potentially benefit from this medicine. However, we cannot be certain that the clinical trials we and our collaboration partners are conducting will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if the required regulatory approvals to market cabozantinib for additional indications are achieved, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. If revenue from CABOMETYX decreases or remains flat, or if we are unable to expand the number of labeled indications for which CABOMETYX is approved, or if we or our collaboration partners fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow revenues from sales of CABOMETYX depends upon the degree of market acceptance among physicians, patients, healthcare payers, and the medical community.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase or maintain revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, foreign and U.S. government healthcare payers such as Medicare and Medicaid, commercial healthcare plans and the medical community. Market acceptance for CABOMETYX could be impacted by numerous factors, including the effectiveness and safety profile, or the perceived effectiveness and safety profile, of CABOMETYX compared to competing products, the strength of CABOMETYX sales and marketing efforts and changes in pricing and reimbursement for CABOMETYX. If CABOMETYX does not continue to be prescribed broadly for the treatment of patients in its approved indications, our product revenues could flatten or decrease, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our competitors may develop products and technologies that impair the relative value of our marketed products and any current and future product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is competitive and characterized by constant technological change and diverse offerings of products, particularly in the area of oncology therapies. Many of our competitors have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage. Further, our competitors may be more effective at in-licensing and developing new commercial products that could render our products, and those of our collaboration partners, obsolete and noncompetitive. We face, and will continue to face, intense competition from biopharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing scientific and clinical research activities similar to ours.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. Even if our current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in NSCLC and mCRPC or evaluating XL092 in combination with an ICI in CRC, produce positive results sufficient to obtain marketing approval by the FDA and other global regulatory authorities, it is uncertain whether physicians will choose to prescribe regimens containing our products instead of competing products and product combinations in approved indications.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain or increase our sales, marketing, market access and product distribution capabilities for our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with maintaining and continuously improving our commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and precommercial-stage, oncology-focused biopharmaceutical companies seeking to build out and maintain their commercial organizations, as well as larger biopharmaceutical organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly scale the size and experience of our commercialization teams to market and sell CABOMETYX successfully in an expanded number of indications. If we are unable to maintain or scale our commercial function appropriately, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including foreign and U.S. governmental payers, such as Medicare and Medicaid, and private health insurers. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and may limit reimbursement for newly approved products and indications. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. Accordingly, market acceptance of CABOMETYX and COMETRIQ is dependent on the extent to which coverage and reimbursement is available from third-party payers. These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting, or alternatively for patients who rely on our co-pay assistance program, implement co-pay accumulators or maximizers that exempt such co-pay assistance from patient deductibles, which has increased and could further increase the costs of our co-pay assistance program or cause patients to abandon CABOMETYX or COMETRIQ therapy due to higher out-of-pocket costs. If third-party payers do not provide or increase limitations on coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations may suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governments in the U.S. are considering legislative and regulatory proposals to change the U.S. healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Similarly, among policy makers and payers, there is significant interest in promoting such changes with the stated goals of containing healthcare costs and expanding patient access. The life sciences industry and specifically the market for the sale, insurance coverage and distribution of pharmaceuticals has been a particular focus of these efforts and would likely be significantly affected by any major legislative or regulatory initiatives. For instance, efforts to repeal, substantially modify or invalidate some or all of the provisions of the Patient Protection and Affordable Care Act of 2010, as amended (PPACA), some of which have been successful, create considerable uncertainties for all businesses involved in healthcare, including our own.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there have been, and may in the future be, initiatives at both the federal and state level that could significantly modify the terms and scope of government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. Although such attempts to reform the U.S. healthcare system have not significantly impacted our business to date, it is possible that additional legislative, executive and judicial activities in the future could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because we participate in the 340B Program to sell a portion of our marketed products, changes in the administration of the program could have a material adverse impact on our revenues. Some manufacturers are currently involved in ongoing litigation regarding the legality of contract pharmacy arrangements under the 340B Program, which may affect the way in which manufacturers are required to extend discounts to covered entities through contract pharmacies. Effective July 2022, we implemented a 340B Program &#8220;integrity initiative,&#8221; pursuant to which we request all hospital covered entities (i.e., hospitals that participate in the 340B Program) to provide claims-level data for CABOMETYX and COMETRIQ dispensed by contract pharmacies. A covered entity that elects not to provide this limited claims data and that does not have an in-house pharmacy may designate a single contract pharmacy location within our authorized specialty pharmacy network. We believe this initiative will provide much-needed transparency and promote compliance with program requirements, and at the same time, should not restrict patient access to our medicines. The U.S. Department of Health and Human Services (HHS) has notified us that it is reviewing our policy, and we have responded to HHS&#8217; request for information. Since 2021, numerous manufacturers that previously implemented similar contract pharmacy integrity programs have received enforcement letters from HHS stating that those manufacturers&#8217; actions restricted contract pharmacy transactions in violation of the 340B Program statute, which may subject them to repayment of overcharges and civil monetary penalties. As mentioned above, certain of these manufacturers are now in litigation with the government over the legality of these programs, and depending on the outcome of such litigation, we may be required to modify or suspend our 340B Program integrity initiative program. Further, it is possible that HHS could seek to implement administrative proceedings to recover overcharges and/or impose civil monetary penalties against us regarding our 340B Program integrity initiative. If such proceedings were implemented against us, a negative ruling could have a material adverse effect on our business, financial condition and results of operations. Due to general uncertainty with respect to this litigation and in the current regulatory and healthcare policy environment, and specifically regarding positions that the Biden Administration may take with respect to these issues, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. If enacted, we and any third parties we may engage may be unable to adapt to any changes implemented as a result of such measures, and we may have difficulties in maintaining or increasing profitability or otherwise experience a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. Initiatives arising from this scrutiny may result in changes that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continue to be U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying drug prices to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits; implement additional data collection and transparency reporting regarding drug pricing, rebates, fees and other remuneration provided by drug manufacturers; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid; eliminate the Anti-Kickback Statute (AKS) discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers; and revise the rebate methodology under the Medicaid Drug Rebate Program. For instance in August 2022, President Biden signed the Inflation Reduction Act, which among other things: allows for the Centers for Medicare and Medicaid Services (CMS) to impose price controls for certain single-source drugs and biotherapeutics reimbursed under Medicare Part B and Part D; subjects drug manufacturers to civil monetary penalties and a potential excise tax for offering a price that is not equal to or less than the government-imposed &#8220;maximum fair price&#8221; under the law and imposes additional rebates for price increases that exceed inflation; and redesigns the funding and benefit structure of the Medicare Part D program, potentially increasing manufacturer liability while capping annual out-of-pocket drug expenses for Medicare beneficiaries. These provisions will take effect incrementally starting in 2023 and may be subject to various legal challenges. Although public rulemaking and related agency guidance for the Inflation Reduction Act has yet to be issued and it is uncertain what impact the Inflation Reduction Act will ultimately have upon our business, over time the Inflation Reduction Act could reduce the revenues we are able to collect from sales of our products and increase our government discount and rebate liabilities. In addition, we cannot know the final form or timing of any other legislative, regulatory and/or administrative measures, and some of these pending and enacted legislative proposals or executive rulemaking, if implemented without successful legal challenges, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biotherapeutic product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. In particular, the obligation to provide notices of price increases to purchasers under laws such as California&#8217;s SB-17 may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of these drug pricing transparency regulations, and our associated compliance obligations, may increase our general and administrative costs and/or diminish our revenues. Implementation of these federal and/or state cost-containment measures or other healthcare reforms may limit our ability to generate product revenue or commercialize our products, and in the case of drug pricing transparency regulations, may result in fluctuations in our results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., including major markets in the EU and Japan, the pricing and reimbursement of prescription pharmaceuticals is generally subject to governmental control. In these countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partners Ipsen and Takeda may also be required to conduct a study or otherwise provide data that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, cost-control initiatives, increasingly based on affordability and accessibility, as well as post-marketing assessments of the added value of CABOMETYX and COMETRIQ as compared to existing treatments, could influence the prices paid for and net revenues we realize from CABOMETYX and COMETRIQ, or the indications for which we are able to obtain reimbursement, which would result in lower license revenues to us. Upcoming legislative and policy changes in the EU are aimed at increasing cooperation between the EU Member States. Such initiatives, particularly the Regulation on Health Technology Assessment adopted in December 2021, may further impact the price and reimbursement status of CABOMETYX and COMETRIQ in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The timing of the entrance of generic competitors to CABOMETYX and legislative and regulatory action designed to reduce barriers to the development, approval and adoption of generic drugs in the U.S. could limit the revenue we derive from our products, most notably CABOMETYX, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Federal Food, Drug and Cosmetic Act (FDCA), the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve a New Drug Application (NDA) under section 505(b)(2) of the FDCA that relies in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug, where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. Both the ANDA and 505(b)(2) NDA processes are discussed in more detail in &#8220;Item 1. Business&#8212;Government Regulation&#8212;FDA Review and Approval&#8212;Abbreviated FDA Approval Pathways and Generic Products&#8221; in our Fiscal 2021 Form 10-K. In either case, if an ANDA or 505(b)(2) NDA applicant submits an application referencing one of our marketed products prior to the expiry of one or more our Orange Book-listed patents for the applicable product, we may litigate with the potential generic competitor to protect our patent rights, which would result in substantial costs, divert the attention of management, and could have an adverse impact on our stock price. For example, MSN and Teva have separately submitted ANDAs to the FDA requesting approval to market their respective generic versions of CABOMETYX tablets, and we have subsequently filed patent lawsuits against both companies. For a more detailed discussion of these litigation matters, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q. It is possible that MSN, Teva or other companies, following FDA approval of an ANDA or 505(b)(2) NDA, could introduce generic or otherwise competitor versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Therefore, regardless of the regulatory approach, the introduction of a generic version of cabozantinib would likely decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results of operations. There are also equivalent procedures in the EU permitting authorization of generic versions and biosimilars of medicinal products authorized in the EU once related data and market exclusivity periods have expired.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government has also taken numerous legislative and regulatory actions to expedite the development and approval of generic drugs and biosimilars. Both Congress and the FDA are considering, and have enacted, various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Ensuring Innovation Act, enacted in April 2021, amended the FDA&#8217;s statutory authority for granting new chemical entity (NCE) exclusivity to reflect the agency&#8217;s existing regulations and longstanding interpretation that award NCE exclusivity based on a drug&#8217;s active moiety, as opposed to its active ingredient, which is intended to limit the applicability of NCE exclusivity, thereby potentially facilitating generic competition. The FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; healthcare costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs. In addition, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the Creating and Restoring Equal Access To Equivalent Samples (CREATES) legislation, purports to promote competition in the market for drugs and biotherapeutic products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biotherapeutic products, including by allowing ANDA, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biotherapeutic product samples. While the full impact of these provisions is unclear at this time, its provisions do have the potential to facilitate the development and future approval of generic versions of our products, introducing generic competition that could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare Regulatory and Other Legal Compliance Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal and state healthcare laws and regulations, which laws and regulations are enforced by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper business conduct or inaccurate reporting, we could be subject to enforcement of the following, including, without limitation:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the federal AKS;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the FDCA and its implementing regulations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal civil and criminal false claims laws, including the civil False Claims Act, and the Civil Monetary Penalties Law;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations, as amended; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state law equivalents of each of the above federal laws;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Open Payments program of the PPACA;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and local laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and federal pharmaceutical price and price reporting laws and regulations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, medical professionals employed by national healthcare programs) and its foreign equivalents, as well as federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These federal and state healthcare laws and regulations govern drug marketing practices, including off-label promotion, and also impact our current and future business arrangements with third parties, including various healthcare entities. If our operations are found, or even alleged, to be in violation of the laws described above or other governmental regulations that apply to us, we, or our officers or employees, may be subject to significant penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, imprisonment, reputational harm, additional reporting requirements and oversight through a Corporate Integrity </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement or other monitoring agreement, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Furthermore, responding to any such allegation or investigation and/or defending against any such enforcement actions can be time-consuming and would require significant financial and personnel resources. Therefore, if any state or the federal government initiates an enforcement action against us, our business may be impaired, and even if we are ultimately successful in our defense, litigating these actions could result in substantial costs and divert the attention of management.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer patient assistance programs and donations to patient assistance foundations created by charitable organizations could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of Congressional interest and enhanced government scrutiny. The HHS Office of Inspector General established guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations that provide co-pay assistance to Medicare patients, provided that manufacturers meet certain specified compliance requirements. In the event we make such donations but are found not to have complied with these guidelines and other laws or regulations respecting the operation of these programs, we could be subject to significant damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. Moreover, in December 2020, the CMS finalized changes to Medicaid Drug Rebate Program pricing calculations regarding the provision of co-payment assistance to patients that may be impacted by private insurer accumulator programs. The portion of this rule dealing with manufacturer co-payment assistance (and related support programs) was struck down by the U.S. District Court for the District of Columbia in May 2022 (and the deadline for an appeal has lapsed). Consequently, while this rule has been vacated, it is also possible that CMS could issue new rulemaking or guidance on this topic that would affect the amount of rebates owed under the Medicaid program or otherwise limit our ability to support our patient co-pay assistance program. We also rely on a third-party hub provider and exercise oversight to monitor patient assistance program activities. Hub providers are generally hired by manufacturers to assist patients with insurance coverage, financial assistance and treatment support after the patients receive a prescription from their healthcare professional. For manufacturers of specialty pharmaceuticals (including our marketed products), the ability to have a single point of contact for their therapies helps ensure efficient medication distribution to patients. Accordingly, our hub activities are also subject to scrutiny and may create risk for us if not conducted appropriately. A variety of entities, including independent charitable foundations and pharmaceutical manufacturers, but not including our company, have received subpoenas from the U.S. Department of Justice (DOJ) and other enforcement authorities seeking information related to their patient assistance programs and support, and certain of these entities have entered into costly civil settlement agreements with DOJ and other enforcement authorities that include requirements to maintain complex corporate integrity agreements that impose significant reporting and other requirements. Should we or our hub providers receive a subpoena or other process, regardless of whether we are ultimately found to have complied with the regulations governing patient assistance programs, this type of government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory landscape for privacy and data protection continues to evolve in the U.S. and other jurisdictions around the world. For example, the California Consumer Privacy Act of 2018 (CCPA) went into operation in 2020 and affords California residents expanded privacy rights and protections, including civil penalties for violations and statutory damages under a private right of action for data security breaches. These protections will be expanded by the California Privacy Rights Act (CPRA), which will be operational in most key respects on January 1, 2023. Similar legislative proposals have passed or are being advanced in other states, and Congress is also considering additional federal privacy legislation. In addition, most healthcare professionals and facilities are subject to privacy and security requirements under HIPAA with respect to our clinical and commercial activities. Although we are not considered to be a covered entity or business associate under HIPAA, we could be subject to penalties if we use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, in the EU, the EU General Data Protection Regulation 2016/679 (GDPR) regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also places restrictions on transfers of such data to countries outside of the EU, including the U.S. Should we fail to provide adequate privacy or data security protections or </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintain compliance with these laws and regulations, including the CCPA, CPRA and GDPR, we could be subject to sanctions or other penalties, litigation, an increase in our cost of doing business and questions concerning the validity of our data processing activities, including clinical trials.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Growth of Our Product Portfolio and Research and Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval of a product candidate or of an approved product for a new indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and late-stage or other potentially label-enabling clinical trials may fail to confirm the results observed in early-stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events, during or as a result of clinical investigations, that could delay or prevent commercialization of cabozantinib in new indications or of XL092 or other new product candidates. These events may include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lack of acceptable efficacy or a tolerable safety profile;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to identify and maintain a sufficient number of clinical trial sites; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lower-than-anticipated patient registration or enrollment in our clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additional complexities posed by clinical trials evaluating cabozantinib, XL092 or our other product candidates in combination with other therapies, including extended timelines to provide for collaboration on clinical development planning, the failure by our collaboration partners to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">reduced staffing or shortages in laboratory supplies and other resources necessary to complete the trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials or delays, variations, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing Russo-Ukrainian War has had a modest impact on our clinical development operations, particularly with respect to patient recruitment, potentially delaying our ability to complete enrollment in a timely manner. In addition, this conflict has had and may continue to have an adverse impact on the ability of clinical sites and their patients to adhere to trial protocols for in-office clinical visits and other procedures, our ability to supply clinical sites with cabozantinib or other study drugs and to pay clinical sites and investigators for work performed, as well as our ability to collect data and conduct site monitoring visits, all of which could undermine the data quality for patients enrolled at these clinical sites. The need to shift enrollment of patients away from these clinical sites or close certain sites entirely, or to replace patients in affected territories should investigators be unable to continue treating and monitoring them, could further impact our anticipated timelines for completing the trials and achieving clinical endpoints, as well as increase our clinical development expenses. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are further delays in or termination of the clinical testing of cabozantinib, XL092 or our other product candidates due to any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our collaboration partners to fund a significant portion of our clinical development programs. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for financing the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further development of the cabozantinib franchise, XL092 or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to pursue the further development of the cabozantinib franchise, XL092 or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions in accordance with our stated timelines or at all. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or otherwise may not result in an approvable product. The duration and the cost of clinical trials vary significantly as a result of factors relating to a particular clinical trial, including, among others: the characteristics of the product candidate under investigation; the number of patients who ultimately participate in the clinical trial; the duration of patient follow-up; the number of clinical sites included in the trial; and the length of time required to enroll eligible patients. Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, uncertain and subject to change, and may not result in regulatory approvals for additional cabozantinib indications or for our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities associated with the research, development and commercialization of the cabozantinib franchise, XL092 and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as well as by comparable regulatory authorities in other territories. The processes of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a marketing authorization application to the EMA or any application or submission to comparable regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for XL092 or our other product candidates. For example, the FDA launched Project Optimus in 2021 as an initiative to reform the dose optimization and dose selection paradigm in oncology drug development, which was driven by the FDA&#8217;s concerns that the current paradigm for dose selection may result in doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating pivotal trials. Through collaboration with the biopharmaceutical industry, academia and other stakeholders, the FDA&#8217;s goal for this initiative is to advance an oncology dose-finding and dose optimization paradigm that emphasizes dose selections that maximize efficacy as well as safety and tolerability. In support of this initiative, the FDA may request sponsors of oncology product candidates to conduct dose optimization studies pre- or post-approval, and the FDA also continues to develop and finalize guidance documents and implement initiatives regarding the development and clinical research of oncology product candidates. Recently, in part due to questions raised by the process underlying the approval of the Alzheimer&#8217;s disease drug Aduhelm</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government authorities and other stakeholders have been scrutinizing the accelerated approval pathway, with some stakeholders advocating for reforms. Even prior to the Aduhelm approval, FDA has held Oncologic Drugs Advisory Committee meetings to discuss accelerated approvals for which confirmatory trials have not verified clinical benefit. Such scrutiny, among other factors, has resulted in voluntary withdrawals of certain products and indications approved on an accelerated basis. Moreover, also spurred by the Aduhelm controversy, the HHS Office of Inspector General has initiated an assessment of how the FDA implements the accelerated approval pathway. In addition, members of Congress have introduced proposed legislation to revise the statutory accelerated approval pathway, including with respect to the FDA&#8217;s ability to rapidly withdraw products and indications for which effectiveness is not confirmed in post-marketing studies. At this time, it is not clear what impact, if any, these developments may have on the statutory accelerated approval pathway or our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications or approves one of our other product candidates, including XL092, for use, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the product and could impose requirements for post-marketing studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XL092 or our other product candidates in any new indications. Failure to complete post-marketing requirements of the FDA in connection with a specific approval in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib, XL092 or another product candidate in the approved indication. Regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Further, current or any future laws or executive orders governing FDA or foreign regulatory approval processes that may be enacted or executed could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to expand our discovery and development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we have invested in substantial technical, financial and human resources toward drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. Notwithstanding this investment, many programs that initially show promise will ultimately fail to yield product candidates for multiple reasons. For example, product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apart from our drug discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates and technologies. However, the in-licensing and acquisition of product candidates and technologies is a highly competitive area, and many other companies are pursuing the same or similar product candidates and technologies to those that we may consider attractive. In particular, larger companies with more capital resources and more extensive clinical development and commercialization capabilities may have a competitive advantage over us. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to in-license or acquire additional product candidates and technologies on acceptable terms that would allow us to realize an appropriate return on our investment. Even if we succeed in our efforts to obtain rights to suitable product candidates and technologies, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products and technologies will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target company, or retain key personnel of the acquired business. Furthermore, we could assume unknown or contingent liabilities or otherwise incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our financial condition and results of operations. If our drug discovery efforts, including research collaborations, in-licensing arrangements and other business development activities, do not result in suitable product candidates, our business and prospects for growth could suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Financial Matters and Capital Requirements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our other product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we reported net income of $73.2&#160;million and $212.5&#160;million for the three and nine months ended September 30, 2022, respectively, and $231.1 million for the fiscal year ended December&#160;31, 2021, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; our achievement of development, regulatory and commercial milestones, if any, under our collaboration agreements; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements; other collaboration revenues; and the level of our expenses, including those associated with our extensive drug discovery, clinical development and business development activities, both for the cabozantinib franchise and our other product candidates, as well as our general business expansion plans. Our expected future expenses in particular may also be </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased by inflationary pressures, whether resulting from the effects of the ongoing Russo-Ukrainian War or the COVID-19 pandemic or otherwise, which could increase the costs of outside services, labor, raw materials and finished drug product. We expect to continue to spend substantial amounts to fund the continued development of the cabozantinib franchise for additional indications and of our other product candidates, as well as the commercialization of our approved products. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including research collaborations, in-licensing arrangements and other strategic transactions that align with our oncology drug development, regulatory and commercial expertise, which efforts could involve substantial costs. To offset these costs in the future, we will need to generate substantial revenues. If these costs exceed our current expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of the cabozantinib franchise and our other product candidates, and increasing drug discovery activities, as well as through the execution of business development transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing macroeconomic conditions and financial, business and other factors beyond our control. We do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and we are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon the regulatory, commercial, medical affairs, market access and other expertise and resources of our collaboration partners, Ipsen and Takeda, for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaboration partners dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaboration partners depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. If our collaboration partners are unable or unwilling to invest the resources necessary to commercialize CABOMETYX successfully in the EU, Japan and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established clinical and commercial collaborations with leading biopharmaceutical companies for the development and commercialization of our products, and our dependence on these collaboration partners subjects us to a number of risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; decision to terminate our collaboration, or their failure to comply with the terms of our collaboration agreements and related ancillary agreements, either intentionally or as a result of negligence or other insufficient performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to control the amount and timing of resources that our collaboration partners devote to the development or commercialization of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may stop or delay clinical trials, fail to supply us on a timely basis with product required for a combination trial, or deliver product that fails to meet appropriate quality and regulatory standards;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our collaboration partners that result in the delay or termination of the development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may experience financial difficulties that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; inability to obtain regulatory approvals in a timely manner, or at all; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to comply with legal and regulatory requirements relevant to the authorization, marketing, distribution and supply of our marketed products in the territories outside the U.S. where they are approved; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, and our product development efforts and prospects for growth could be delayed or disrupted, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our early-stage product pipeline, we have augmented our drug discovery activities with multiple research collaborations and in-licensing arrangements with other companies. Our dependence on our relationships with these research and in-licensing partners subjects us to numerous risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; decision to terminate our relationship, or their failure to comply with the terms of our agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our research and in-licensing partners that result in the delay or termination of research activities with respect to any in-licensed assets or supporting technology platforms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our research and in-licensing partners may experience financial difficulties that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; failure to properly maintain or defend their intellectual property rights or their use of third-party intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our license to develop these assets or utilize technology platforms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">laws, regulations or practices imposed by countries outside the U.S. that could impact or inhibit scientific research or the development of healthcare products by foreign competitors or otherwise disadvantage healthcare products made by foreign competitors, as well as general political or economic instability in those countries, any of which could complicate, interfere with or impede our relationships with our ex-U.S. research, development and in-licensing partners; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations related to Good Manufacturing Practice and Good Laboratory Practice.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not be able to expand our product pipeline or otherwise realize a return on the resources we will have invested to develop these early-stage assets, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government, third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical trial or data security protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cabozantinib beyond currently approved indications or obtain regulatory approval for XL092 or our other product candidates. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to help advance our drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We lack our own manufacturing and distribution capabilities necessary for us to produce materials required for certain preclinical activities and to produce and distribute our products for clinical development or for commercial sale, and our reliance on third parties for these services subjects us to various risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing or distribution facilities for chemistry, manufacturing and control development activities, preclinical, clinical or commercial production and distribution for our current products and new product candidates. Instead, we rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we continue to expand our supply chain through secondary third-party contract manufacturers, distributors and suppliers. To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party contract manufacturers may not be able to produce or deliver material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical development and commercial needs and applicable regulatory requirements. Although we have not yet experienced significant production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic or the ongoing Russo-Ukrainian War, our third-party contract manufacturers, distributors and suppliers could experience operational delays due to lack of capacity or resources, facility closures and other hardships as a result of these types of global events, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our preclinical, clinical or commercial products. If our third-party contract manufacturers, distributors and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing, distribution and supply arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude meeting commercial or clinical product supply requirements for us or our partners, which could delay product development and future commercialization efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA). If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party scientific advisors and contractors we rely on to assist with our drug discovery efforts do not perform as expected, the expansion of our product pipeline may be delayed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with scientific advisors at academic and other institutions, as well as third-party contractors in various locations throughout the world, that assist us in our research and development efforts, including in drug discovery and preclinical development strategy. These third parties are not our employees and may have other commitments or contractual obligations that limit their availability to us. Although these third-party scientific advisors and contractors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as scientific advisors and contractors or otherwise limit our access to these experts, or that the scientific advisors themselves may now be more reluctant to work with industry partners. Even if these scientific advisors and contractors with whom we have engaged intend to meet their contractual obligations, their ability to perform services may be impacted by increased demand for such services from other companies or by other external factors, such as reduced capacity to perform services, as we experienced in the early stages of the COVID-19 pandemic. If we experience additional delays in the receipt of services, lose work performed by these scientific advisors and contractors or are unable to engage them in the first place, our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Information Technology and Intellectual Property</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data breaches, cyber-attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and our third-party service providers, such as contract research organizations, collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our collaboration partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cybersecurity efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber-attack. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber-attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt critical business operations, expend key information technology resources and divert the attention of management. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the aggregate impact of cyber-attacks on our operations and financial condition has not been material to date, we and our third-party service providers have frequently been the target of threats of this nature and expect them to continue. Any future data breach and/or unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information or sensitive business information of our collaboration partners, which may lead to significant liability for us. A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others and result in harm to our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents including the GDPR, subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cybersecurity systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our third-party service providers may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, we received Paragraph IV certification notice letters from MSN and Teva concerning the respective ANDAs that each had filed with the FDA seeking approval to market their respective generic versions of CABOMETYX tablets. Should MSN, Teva or any other third parties receive FDA approval of an ANDA or a 505(b)(2) NDA with respect to cabozantinib, it is possible that such company or </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and the resulting generic competition could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. They may also be negatively impacted by the decisions of foreign courts, which could limit the protection contemplated by the original regulatory approval and our ability to thwart the development of competing products that might otherwise have been determined to infringe our intellectual property rights. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in the EU, have compulsory licensing laws based on related EU rules, under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the Russian Federation has and may further limit protections on patents originating from &#8220;unfriendly countries&#8221; (including the U.S.) in response to sanctions relating to the ongoing Russo-Ukrainian War, and in general, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We also rely on trade secret protection for some of our confidential and proprietary information, and we are taking security measures to protect our proprietary information and trade secrets, particularly in light of recent instances of data loss and misappropriation of intellectual property in the biopharmaceutical industry. However, these measures may not provide adequate protection, and while we seek to protect our proprietary information by entering into confidentiality agreements with employees, partners and consultants, as well as maintain cybersecurity protocols within our information technology infrastructure, we cannot provide assurance that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense. In addition, we may be subject to claims that our employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that they used or sought to use patent inventions belonging to their former employers. Furthermore, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs and divert the attention of management and key technical personnel in defending ourselves against any such claims or enforcing our own patents. In the event of any third party&#8217;s successful claim of patent infringement or misappropriation of trade secrets, we may lose valuable intellectual property rights or personnel, which could impede or prevent the achievement of our product development goals, or we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations, Managing Our Growth and Employee Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the COVID-19 pandemic has had a modest impact on our business operations, in particular with respect to our clinical trial, drug discovery and commercial activities. For example, to varying degrees and at different rates across our clinical trials, we experienced declines in screening and enrollment activity during the early days of the COVID-19 pandemic, as well as delays in new site activations and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. As the COVID-19 pandemic continues to have a significant presence in various parts of the world, particularly with the potential emergence of new variants that may prove especially contagious or virulent, the impact on our clinical development operations could continue or grow more severe. We anticipate that a further prolonged, or more severe, global public health crisis could limit our ability to identify and work with clinical investigators at clinical trial sites globally to enroll, initiate and maintain treatment per protocol of patients for our ongoing clinical trials. Disruptions to medical and administrative operations at clinical trial sites, including staffing and materials shortages and the implementation of crisis management initiatives, have and may continue to reduce personnel and other resources necessary to conduct our clinical trials, which could further delay some of our clinical trial plans or may require certain trials to be temporarily suspended. In addition, increased costs connected with our efforts to mitigate the adverse impacts resulting from the COVID-19 pandemic on our clinical trials could cause the expenses we incur in conducting those clinical trials to increase considerably. Depending upon the duration and severity of the COVID-19 pandemic, we could also experience delays in planning and conducting new clinical trials of the investigative product candidates entering and advancing through our development pipeline, which could increase the operating expenses associated with these trials and adversely affect their timelines for completion and ultimately our ability to obtain regulatory approvals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both drug discovery work in our laboratories and outsourced drug discovery activities have fully resumed following temporary suspensions during the early days of the COVID-19 pandemic; however, we may be unable to maximize the potential of these programs due to the imposition of increased safety protocols, and should the effects of the COVID-19 pandemic become more severe, we may have to again scale back or suspend activities in the future. We are also reliant on laboratory materials manufactured and distributed from areas impacted by both the COVID-19 pandemic and other natural disasters, for which supply has become limited. If we are unable to obtain the requisite materials to conduct our planned drug discovery activities, we may be required to redirect the focus of, or even suspend, such activities. Should the COVID-19 pandemic be further prolonged or grow in severity, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines, which could have a material adverse impact on our prospects for growth. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, it remains possible that the evolving dynamics of the COVID-19 pandemic may require further modifications to our standard sales and marketing practices, including shifts from in-person back to primarily telephonic and virtual interactions with healthcare professionals. Such changes in our commercial operations could negatively impact the flow of important information regarding our medicines, which along with obstacles to patient access to healthcare professionals, could diminish sales of our marketed products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These continuing or future effects of the COVID-19 pandemic could materially and adversely affect our business, financial condition, results of operations and growth prospects, and exacerbate the other risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations, in particular as we continue to expand the cabozantinib franchise into new indications and grow our pipeline of product candidates. This growth places significant demands on our management and resources, and our current and planned personnel and operating practices may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We continue to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, or we are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial, scientific and pharmaceutical operations personnel will be critical to support activities related to advancing the development programs for the cabozantinib franchise and our other product candidates, successfully executing upon our commercialization plan for the cabozantinib franchise and our proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials, and our operations can produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge, or any resultant injury from these materials, and we may face liability under applicable laws for any injury or contamination that results from our use or the use by our collaboration partners or other third parties of these materials. Such liability may exceed our insurance coverage and our total assets, and in addition, we may be required to indemnify our collaboration partners against all damages and other liabilities arising out of our development activities or products produced in connection with our collaborations with them. Moreover, our continued compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be held liable if any product we or our collaboration partners develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. We maintain limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib. However, our insurance may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and may in the future be highly volatile.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been highly volatile, and it may remain highly volatile or fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of FDA or other regulatory approval or non-approval, or delays in the FDA or other regulatory review process with respect to cabozantinib, XL092 or our other product candidates, our collaboration partners&#8217; product candidates being developed in combination with either cabozantinib, XL092 or our other product candidates, or our competitors&#8217; product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the commercial performance of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products, including royalties paid under our collaboration and license agreements;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">adverse or inconclusive results or announcements related to our or our collaboration partners&#8217; clinical trials or delays in those clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing of achievement of our clinical, regulatory, partnering, commercial and other milestones for the cabozantinib franchise, XL092 or any of our other product candidates or programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to make future investments in the expansion of our pipeline through drug discovery, including future research collaborations, in-licensing arrangements and other strategic transactions;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to obtain the materials and services, including an adequate product supply for any approved drug product, from our third-party vendors or do so at acceptable prices;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib, XL092 and our other product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib, XL092 or our other product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of new products or clinical trial data by our competitors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of regulatory applications, such as MSN&#8217;s and Teva&#8217;s respective ANDAs, seeking approval of generic versions of our marketed products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in our relationships with our collaboration partners, including the termination or modification of our agreements, or other events or conflicts that may affect our collaboration partners&#8217; timing and willingness to develop, or if approved, commercialize our products and product candidates out-licensed to them;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of an in-licensed product candidate or strategic acquisition;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in earnings estimates or recommendations by securities analysts, or financial guidance from our management team, and any failure to achieve the operating results projected by securities analysts or by our management team;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the entry into new financing arrangements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">developments in the biopharmaceutical industry;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additions and departures of key personnel or board members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the disposition of any of our technologies or compounds; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">general market, macroeconomic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors could have material adverse impact on the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Likewise, as a result of significant changes in U.S. or global political and macroeconomic conditions, including historically high inflation, as well as policies governing foreign trade and healthcare spending and delivery, or the ongoing Russo-Ukrainian War, the financial markets could continue to experience significant volatility that could also continue to negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been initiated. A securities class action suit against us could result in substantial costs and divert the attention of management, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">a prohibition on actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">advance notice requirements for director nominations and stockholder proposals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div id="i549da58617674d2089ca2811b93aa142_97"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i549da58617674d2089ca2811b93aa142_100"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i549da58617674d2089ca2811b93aa142_103"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i549da58617674d2089ca2811b93aa142_106"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i549da58617674d2089ca2811b93aa142_109"></div><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:8.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.833%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000076/exel20210526ex31restatedce.htm">Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000028/exhibit31amendedandrestate.htm">Amended and Restated Bylaws of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/3/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel2022930exhibit10110q.htm">Cash Compensation Information for Non-Employee Directors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20220930exhibit31110q.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20220930exhibit31210q.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:8.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.833%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20220930exhibit32110q.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i549da58617674d2089ca2811b93aa142_112"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i549da58617674d2089ca2811b93aa142_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-top:5pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher J. Senner</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief&#160;Financial&#160;Officer </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Duly Authorized Officer and Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exel2022930exhibit10110q.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5418d4fbca99448e9a5232cd875be176_35"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-18pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CASH COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-right:-9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cash Compensation for Non-Employee Directors </font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Board of Directors</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$55,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional Chair Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$31,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">12</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2,500</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Audit Committee</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$12,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional Chair Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$13,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">13</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compensation Committee</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$10,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional Chair Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$10,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">13</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nominating&#160;and Corporate Governance Committee</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$5,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional Chair Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$10,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">14</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research&#160;&#38; Development Committee</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$5,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional Chair Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$10,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">14</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Risk Committee</font></div></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$5,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional Chair Retainer Fee</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$10,000</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">14</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$1,000</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meetings for which minutes are generated count toward the meeting threshold to determine when Meeting Fees are to be paid.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee paid for all meetings in excess of eight meetings.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee paid for all meetings in excess of seven meetings.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Meeting Fee paid for all meetings in excess of four meetings.</font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exel20220930exhibit31110q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia51b06db57a6477884f53692fce37d54_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael M. Morrissey, Ph.D., certify that&#58;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.22pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;1, 2022 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exel20220930exhibit31210q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i247ff19b1d1142a8b3ee7d6a2d0a2071_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher J. Senner, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.22pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;1, 2022 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exel20220930exhibit32110q.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia403292e043b4ba48f191023e31bb37e_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.92pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended September&#160;30, 2022, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.92pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Witness Whereof, the undersigned have set their hands hereto as of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1st</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of November 2022.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>exel-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f874578b-aba8-4b11-9ee3-0aa3371a4a4f,g:18180dba-6dc6-4cf5-97a9-3c99224fbbee-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>0000010 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivities" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities">
        <link:definition>0000011 - Disclosure - Collaboration Agreements And Business Development Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestments" roleURI="http://www.exelixis.com/role/CashandInvestments">
        <link:definition>0000012 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>0000014 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>0000015 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxes" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxes">
        <link:definition>0000016 - Disclosure - Provision For Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>0000017 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.exelixis.com/role/CommitmentsandContingencies">
        <link:definition>0000018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.exelixis.com/role/SubsequentEvents">
        <link:definition>0000019 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>0000021 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables">
        <link:definition>0000022 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsTables" roleURI="http://www.exelixis.com/role/CashandInvestmentsTables">
        <link:definition>0000023 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>0000024 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>0000025 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>0000026 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>0000027 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails">
        <link:definition>0000029 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails">
        <link:definition>0000030 - Disclosure - Revenues - Revenues Disaggregated by Concentration Risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
        <link:definition>0000031 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedbyProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
        <link:definition>0000032 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
        <link:definition>0000033 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails">
        <link:definition>0000034 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
        <link:definition>0000035 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
        <link:definition>0000036 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
        <link:definition>0000037 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
        <link:definition>0000038 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails">
        <link:definition>0000039 - Disclosure - Collaboration Agreements And Business Development Activities - GSK Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
        <link:definition>0000040 - Disclosure - Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails">
        <link:definition>0000041 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000042 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails">
        <link:definition>0000043 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails">
        <link:definition>0000044 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails_1" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1">
        <link:definition>0000044 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
        <link:definition>0000045 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails">
        <link:definition>0000046 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>0000047 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativesDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails">
        <link:definition>0000048 - Disclosure - Fair Value Measurements - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>0000049 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>0000050 - Disclosure - Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
        <link:definition>0000051 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000052 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEstimateGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails">
        <link:definition>0000053 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails">
        <link:definition>0000054 - Disclosure - Provision For Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>0000055 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails">
        <link:definition>0000056 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000057 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.exelixis.com/role/SubsequentEventsDetails">
        <link:definition>0000058 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exel_CollaborationAgreementWithBioInventInternationalABBioInventMember" abstract="true" name="CollaborationAgreementWithBioInventInternationalABBioInventMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" abstract="true" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" abstract="false" name="LesseeOperatingLeaseOptionToTerminateAfterPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" abstract="false" name="CollaborativeArrangementRightsAndObligationsExerciseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NumberOfBondSecurities" abstract="false" name="NumberOfBondSecurities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_SairopaBVSairopaMember" abstract="true" name="SairopaBVSairopaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" abstract="false" name="CollaborativeArrangementMaximumAmountOfWarrantExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LeaseArrangementsDomain" abstract="true" name="LeaseArrangementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ResultingFromDiscoveryEffortsMember" abstract="true" name="ResultingFromDiscoveryEffortsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" abstract="false" name="NumberOfCountriesWithDrugApprovalExcludingTheUS" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LeaseArrangementsAxis" abstract="true" name="LeaseArrangementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_TSRBasedRestrictedStockUnitsMember" abstract="true" name="TSRBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ProductSalesDiscountsAndAllowancesMember" abstract="true" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AccruedClinicalLiabilitiesCurrent" abstract="false" name="AccruedClinicalLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementIncomeLossFromAgreement" abstract="false" name="CollaborativeArrangementIncomeLossFromAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_IpsenMember" abstract="true" name="IpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AccruedCollaborationLiabilityCurrent" abstract="false" name="AccruedCollaborationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithIpsenMember" abstract="true" name="CollaborativeArrangementwithIpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ChargebacksAndDiscountsForPromptPaymentMember" abstract="true" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_Granted2020Member" abstract="true" name="Granted2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LossContingencyNumberOfLawsuitsConsolidated" abstract="false" name="LossContingencyNumberOfLawsuitsConsolidated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_ProductOrServiceAxisDomain" abstract="true" name="ProductOrServiceAxisDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" abstract="true" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CybrexaTherapeuticsLLCCybrexaMember" abstract="true" name="CybrexaTherapeuticsLLCCybrexaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LeaseExpansionMember" abstract="true" name="LeaseExpansionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ProductOrServiceAxisAxis" abstract="true" name="ProductOrServiceAxisAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_RoyalPharmaMember" abstract="true" name="RoyalPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OtherLongtermAssetsMember" abstract="true" name="OtherLongtermAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CotellicMember" abstract="true" name="CotellicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember" abstract="true" name="CollaborationAgreementWithRyvuTherapeuticsSARyvuMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CabometyxMember" abstract="true" name="CabometyxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AccredoHealthIncorporatedMember" abstract="true" name="AccredoHealthIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_IncreaseDecreaseInAccruedCollaborationLiabilities" abstract="false" name="IncreaseDecreaseInAccruedCollaborationLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithTakedaMember" abstract="true" name="CollaborativeArrangementwithTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AffiliatesOfAmerisourceBergenCorporationMember" abstract="true" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ProductsDerivedFromOtherCompoundsMember" abstract="true" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_AffiliatesofMcKessonCorporationMember" abstract="true" name="AffiliatesofMcKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CometriqMember" abstract="true" name="CometriqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" abstract="true" name="BuiltToSuitLeaseAndHeadquartersLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" abstract="false" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithGenentechMember" abstract="true" name="CollaborativeArrangementwithGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AllowanceForProductRebatesMember" abstract="true" name="AllowanceForProductRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_NumberOfRegulatoryMilestone" abstract="false" name="NumberOfRegulatoryMilestone" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" abstract="true" name="ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ProductGrossMember" abstract="true" name="ProductGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesofCVSHealthCorporationMember" abstract="true" name="AffiliatesofCVSHealthCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_TakedaAndIspenMember" abstract="true" name="TakedaAndIspenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" abstract="false" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_ContractWithCustomerMilestoneRevenueRecognized" abstract="false" name="ContractWithCustomerMilestoneRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_TenantLeaseImprovementsAllowance" abstract="false" name="TenantLeaseImprovementsAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NumberofProductsinCommercialMarket" abstract="false" name="NumberofProductsinCommercialMarket" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" abstract="false" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" abstract="true" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_OperatingLeaseLiabilityDiscountedPeriod" abstract="false" name="OperatingLeaseLiabilityDiscountedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" abstract="false" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>exel-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f874578b-aba8-4b11-9ee3-0aa3371a4a4f,g:18180dba-6dc6-4cf5-97a9-3c99224fbbee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0fce3750-8203-42c8-932a-28ef731e8a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_df637caa-45b0-46aa-82f8-766f0fbf94d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0fce3750-8203-42c8-932a-28ef731e8a62" xlink:to="loc_us-gaap_PreferredStockValue_df637caa-45b0-46aa-82f8-766f0fbf94d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9fe92b3c-186d-475f-a192-fe3aef5c1afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0fce3750-8203-42c8-932a-28ef731e8a62" xlink:to="loc_us-gaap_CommonStockValue_9fe92b3c-186d-475f-a192-fe3aef5c1afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bc76133e-e279-4b7b-a437-bbb0c27ecb20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0fce3750-8203-42c8-932a-28ef731e8a62" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bc76133e-e279-4b7b-a437-bbb0c27ecb20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a9130594-ce8d-48d3-b578-699c2e694a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0fce3750-8203-42c8-932a-28ef731e8a62" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a9130594-ce8d-48d3-b578-699c2e694a33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f7fbc50d-3d5b-4609-8e71-e73788beed79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0fce3750-8203-42c8-932a-28ef731e8a62" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f7fbc50d-3d5b-4609-8e71-e73788beed79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_23ca1534-9840-4fe6-84a1-84d5b97d8650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e734b5dd-8047-44f9-8699-f83285683b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23ca1534-9840-4fe6-84a1-84d5b97d8650" xlink:to="loc_us-gaap_AccountsPayableCurrent_e734b5dd-8047-44f9-8699-f83285683b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6dc77b2f-ba77-4643-8d9a-960327a4e10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23ca1534-9840-4fe6-84a1-84d5b97d8650" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6dc77b2f-ba77-4643-8d9a-960327a4e10c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_3a9b1e31-62cb-4b2c-9a23-252465669ac6" xlink:href="exel-20220930.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23ca1534-9840-4fe6-84a1-84d5b97d8650" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_3a9b1e31-62cb-4b2c-9a23-252465669ac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_367ab992-d0d7-4de6-9266-3c788cbee4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23ca1534-9840-4fe6-84a1-84d5b97d8650" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_367ab992-d0d7-4de6-9266-3c788cbee4d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_5a9d6e0b-2e08-4e5a-ad69-7732335ca93f" xlink:href="exel-20220930.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23ca1534-9840-4fe6-84a1-84d5b97d8650" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_5a9d6e0b-2e08-4e5a-ad69-7732335ca93f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2c5f8c96-d514-47b1-83e2-ae2fc6e4d6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_23ca1534-9840-4fe6-84a1-84d5b97d8650" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2c5f8c96-d514-47b1-83e2-ae2fc6e4d6f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bbeffa29-ba0d-4f76-a142-ceddb3bae229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f567c297-1d80-4013-a3de-6eda725f38a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bbeffa29-ba0d-4f76-a142-ceddb3bae229" xlink:to="loc_us-gaap_Liabilities_f567c297-1d80-4013-a3de-6eda725f38a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1b8e5e2d-d74c-4b03-b784-b4a2273b8118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bbeffa29-ba0d-4f76-a142-ceddb3bae229" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1b8e5e2d-d74c-4b03-b784-b4a2273b8118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eff365a9-b96f-497e-b548-6559e4db9f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bbeffa29-ba0d-4f76-a142-ceddb3bae229" xlink:to="loc_us-gaap_StockholdersEquity_eff365a9-b96f-497e-b548-6559e4db9f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1bf75c54-8f4d-4972-8ebb-a4f19c2c7e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e4de8373-73c6-496e-aed3-549f9d2fd578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1bf75c54-8f4d-4972-8ebb-a4f19c2c7e9f" xlink:to="loc_us-gaap_LiabilitiesCurrent_e4de8373-73c6-496e-aed3-549f9d2fd578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e81b5e64-db0b-4fd0-b643-452151e41d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1bf75c54-8f4d-4972-8ebb-a4f19c2c7e9f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e81b5e64-db0b-4fd0-b643-452151e41d66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0ec7a219-253c-44dc-8112-5362fce69913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1bf75c54-8f4d-4972-8ebb-a4f19c2c7e9f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0ec7a219-253c-44dc-8112-5362fce69913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_81613f4c-cbb5-4726-be83-15f435c1db37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1bf75c54-8f4d-4972-8ebb-a4f19c2c7e9f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_81613f4c-cbb5-4726-be83-15f435c1db37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_60f80df9-65aa-4875-b968-85628005ffe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_374589cd-5fce-4752-b3db-57503366811e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_60f80df9-65aa-4875-b968-85628005ffe3" xlink:to="loc_us-gaap_ShortTermInvestments_374589cd-5fce-4752-b3db-57503366811e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_a7d426f2-7b36-40fa-bed3-b55e2e4aa732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_60f80df9-65aa-4875-b968-85628005ffe3" xlink:to="loc_us-gaap_ReceivablesNetCurrent_a7d426f2-7b36-40fa-bed3-b55e2e4aa732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0a1f75ed-1324-489f-8cb1-80f5d3c1d23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_60f80df9-65aa-4875-b968-85628005ffe3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0a1f75ed-1324-489f-8cb1-80f5d3c1d23d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5215194b-5bc3-43db-8026-4007db059219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_60f80df9-65aa-4875-b968-85628005ffe3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5215194b-5bc3-43db-8026-4007db059219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_79e9c3c0-f8df-4808-9318-9e26953259d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_60f80df9-65aa-4875-b968-85628005ffe3" xlink:to="loc_us-gaap_InventoryNet_79e9c3c0-f8df-4808-9318-9e26953259d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_704bccc5-db61-49c4-9651-04ff80fa9e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7d9cd904-7006-4eb8-afc9-a6b790e83bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_704bccc5-db61-49c4-9651-04ff80fa9e21" xlink:to="loc_us-gaap_AssetsCurrent_7d9cd904-7006-4eb8-afc9-a6b790e83bc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_88556905-cf68-4d26-9cf2-8b20ea96af3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_704bccc5-db61-49c4-9651-04ff80fa9e21" xlink:to="loc_us-gaap_LongTermInvestments_88556905-cf68-4d26-9cf2-8b20ea96af3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1a70c924-017e-4fec-87f7-8c16d0d58e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_704bccc5-db61-49c4-9651-04ff80fa9e21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1a70c924-017e-4fec-87f7-8c16d0d58e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_38150307-986e-4140-a64f-288033a57e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_704bccc5-db61-49c4-9651-04ff80fa9e21" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_38150307-986e-4140-a64f-288033a57e90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_53d39de1-ba75-4c2a-841c-d522ee67ccb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_704bccc5-db61-49c4-9651-04ff80fa9e21" xlink:to="loc_us-gaap_Goodwill_53d39de1-ba75-4c2a-841c-d522ee67ccb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5e53bb17-a30a-4501-8a59-7e52870eabec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_704bccc5-db61-49c4-9651-04ff80fa9e21" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5e53bb17-a30a-4501-8a59-7e52870eabec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_bce3f248-a7ed-4089-8f18-0d8d98d88ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_dbfc30d7-8551-4665-b165-714fb24492a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bce3f248-a7ed-4089-8f18-0d8d98d88ad7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_dbfc30d7-8551-4665-b165-714fb24492a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ea2118c7-dfdb-4e5a-b727-514a44967c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bce3f248-a7ed-4089-8f18-0d8d98d88ad7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ea2118c7-dfdb-4e5a-b727-514a44967c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dda01948-0078-410c-aea4-25f49dec4bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bce3f248-a7ed-4089-8f18-0d8d98d88ad7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dda01948-0078-410c-aea4-25f49dec4bfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_618d12a6-ec40-4790-8402-04e3444c7d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_48824add-5510-4243-b519-6025b5d4779b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_618d12a6-ec40-4790-8402-04e3444c7d5b" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_48824add-5510-4243-b519-6025b5d4779b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f39409a8-f072-4982-b326-3d8a1b010a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_618d12a6-ec40-4790-8402-04e3444c7d5b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f39409a8-f072-4982-b326-3d8a1b010a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9cba0bb2-e746-4a9b-a8a4-89aea18d461b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_02b542ae-5ae8-4755-ab24-39f97076cf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9cba0bb2-e746-4a9b-a8a4-89aea18d461b" xlink:to="loc_us-gaap_CostsAndExpenses_02b542ae-5ae8-4755-ab24-39f97076cf8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7557e3c-7a95-4c35-b044-f2b1f945ad74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9cba0bb2-e746-4a9b-a8a4-89aea18d461b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7557e3c-7a95-4c35-b044-f2b1f945ad74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_280a690b-6e2c-4e63-8223-31dac0a79109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_54a21e7b-359f-45ef-a255-20ecdaa634b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_280a690b-6e2c-4e63-8223-31dac0a79109" xlink:to="loc_us-gaap_OperatingIncomeLoss_54a21e7b-359f-45ef-a255-20ecdaa634b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_445c658b-d2c8-49d9-b214-43e2d6a840eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_280a690b-6e2c-4e63-8223-31dac0a79109" xlink:to="loc_us-gaap_InterestIncomeOther_445c658b-d2c8-49d9-b214-43e2d6a840eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_84fd5ca3-14ee-45f3-b209-9d138a8076ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_280a690b-6e2c-4e63-8223-31dac0a79109" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_84fd5ca3-14ee-45f3-b209-9d138a8076ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4360f5cc-7982-480d-8f27-e91cb6720796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e21ca7fc-f770-448e-8385-309d6bb654fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4360f5cc-7982-480d-8f27-e91cb6720796" xlink:to="loc_us-gaap_NetIncomeLoss_e21ca7fc-f770-448e-8385-309d6bb654fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_be812d6a-9845-4c60-91e0-90cfe6ef27bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4360f5cc-7982-480d-8f27-e91cb6720796" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_be812d6a-9845-4c60-91e0-90cfe6ef27bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_af2dd655-2964-491e-a287-560d6101659e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31346a0e-44e0-4599-b84a-22bcc1b7e03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_af2dd655-2964-491e-a287-560d6101659e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_31346a0e-44e0-4599-b84a-22bcc1b7e03f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1757b880-1644-4497-b1a0-9c1fa6698151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_af2dd655-2964-491e-a287-560d6101659e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1757b880-1644-4497-b1a0-9c1fa6698151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8b0ebdd-0b20-42ec-9105-e062ed88be60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_af2dd655-2964-491e-a287-560d6101659e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8b0ebdd-0b20-42ec-9105-e062ed88be60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0872de04-985e-4ad6-a2de-6eb8cb117843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_377146b1-0eab-42d6-82d2-73439dcef008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0872de04-985e-4ad6-a2de-6eb8cb117843" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_377146b1-0eab-42d6-82d2-73439dcef008" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9cd0bafb-77b4-41b6-9f30-9d3a949316ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0872de04-985e-4ad6-a2de-6eb8cb117843" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9cd0bafb-77b4-41b6-9f30-9d3a949316ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_42ff3fc3-5cba-4b7c-bd17-0d7d4e124fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_584d08fc-dbfb-46c4-8176-781de26cab39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_42ff3fc3-5cba-4b7c-bd17-0d7d4e124fca" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_584d08fc-dbfb-46c4-8176-781de26cab39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_4c2aa673-95b8-44b6-bf2c-33e96bac09d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_42ff3fc3-5cba-4b7c-bd17-0d7d4e124fca" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_4c2aa673-95b8-44b6-bf2c-33e96bac09d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c3ea49e9-7303-4b6d-b919-1fe2cb031c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_42ff3fc3-5cba-4b7c-bd17-0d7d4e124fca" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c3ea49e9-7303-4b6d-b919-1fe2cb031c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8aca19e6-c593-4f80-9232-7e86f1330df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:to="loc_us-gaap_NetIncomeLoss_8aca19e6-c593-4f80-9232-7e86f1330df8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4a40a7bd-37a1-493f-b322-83871198986d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4a40a7bd-37a1-493f-b322-83871198986d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_345c54a6-97d0-4f22-965c-0cc6236498ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:to="loc_us-gaap_ShareBasedCompensation_345c54a6-97d0-4f22-965c-0cc6236498ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_f9f40ec3-1478-46f4-af4c-308604d0373c" xlink:href="exel-20220930.xsd#exel_NoncashLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:to="loc_exel_NoncashLeaseExpense_f9f40ec3-1478-46f4-af4c-308604d0373c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_453fa481-9af9-4246-a04f-052e49d37324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_453fa481-9af9-4246-a04f-052e49d37324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1f1290cb-9c20-432a-83e5-5eab7d3822eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1f1290cb-9c20-432a-83e5-5eab7d3822eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1d0943c9-87a2-4968-a1aa-e0a2350d5605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1d0943c9-87a2-4968-a1aa-e0a2350d5605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3227e0ef-6cfb-4711-8dd1-99422edbe63b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3227e0ef-6cfb-4711-8dd1-99422edbe63b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_39c8809e-034f-4108-beb3-c8c933db9093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_39c8809e-034f-4108-beb3-c8c933db9093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_38cefee6-d76b-4f1d-9ecb-1fc14d530716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_38cefee6-d76b-4f1d-9ecb-1fc14d530716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4305495f-7c8a-4189-8b7e-7b47e783dd58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_4305495f-7c8a-4189-8b7e-7b47e783dd58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_cea1f7b0-2cbb-4ad9-922f-1db1a51c420a" xlink:href="exel-20220930.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38286ce-8aeb-45e5-89f8-f6b029ac717e" xlink:to="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_cea1f7b0-2cbb-4ad9-922f-1db1a51c420a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_bc6b7d91-9295-4675-8b6f-61bfba0677b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7cef14e8-079c-4c45-a696-499d1c3968f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_bc6b7d91-9295-4675-8b6f-61bfba0677b2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7cef14e8-079c-4c45-a696-499d1c3968f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_aa2ba360-5653-42bc-a485-3dd536fefac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_bc6b7d91-9295-4675-8b6f-61bfba0677b2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_aa2ba360-5653-42bc-a485-3dd536fefac5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c677be66-4ddf-4e94-a2bb-1c98df3ed21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_0acf9e14-2b1b-4edc-8918-0594a97af69c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c677be66-4ddf-4e94-a2bb-1c98df3ed21c" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_0acf9e14-2b1b-4edc-8918-0594a97af69c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_188200a9-d396-4720-8c7e-897b6f93e2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c677be66-4ddf-4e94-a2bb-1c98df3ed21c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_188200a9-d396-4720-8c7e-897b6f93e2a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_54629e06-1231-44a3-87f5-17d2996fda93" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_47e4df98-10f7-400a-a4df-e43f979650b5" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_54629e06-1231-44a3-87f5-17d2996fda93" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_47e4df98-10f7-400a-a4df-e43f979650b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57767940-1f44-4b39-9fa7-8bd6756879f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_54629e06-1231-44a3-87f5-17d2996fda93" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_57767940-1f44-4b39-9fa7-8bd6756879f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_b478e6db-8acf-4c63-80a6-ba2f68e321ed" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf0f637a-e848-488d-ae9f-f86bff81ace5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_b478e6db-8acf-4c63-80a6-ba2f68e321ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf0f637a-e848-488d-ae9f-f86bff81ace5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_48969afa-0fb2-48b7-80e1-5860e7ce606b" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_b478e6db-8acf-4c63-80a6-ba2f68e321ed" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_48969afa-0fb2-48b7-80e1-5860e7ce606b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_0c38a870-a181-4752-98cc-75517e9880d6" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a40b28b0-55c8-4b61-ad16-f7527a42fa36" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_0c38a870-a181-4752-98cc-75517e9880d6" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a40b28b0-55c8-4b61-ad16-f7527a42fa36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_299b3a41-abcd-42e1-a21e-375140b867ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_0c38a870-a181-4752-98cc-75517e9880d6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_299b3a41-abcd-42e1-a21e-375140b867ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a221e803-9114-408e-8cbf-5284338060b1" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_521e0d12-94af-4009-8ec4-5cb19c7e169e" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a221e803-9114-408e-8cbf-5284338060b1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_521e0d12-94af-4009-8ec4-5cb19c7e169e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_73775c83-fe36-4f53-bdb7-cbf6c43494bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a221e803-9114-408e-8cbf-5284338060b1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_73775c83-fe36-4f53-bdb7-cbf6c43494bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a9b3b2da-7802-46c2-983a-e636c454b2a2" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_da7ebae2-993b-42de-b9c1-7debfd147fdf" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a9b3b2da-7802-46c2-983a-e636c454b2a2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_da7ebae2-993b-42de-b9c1-7debfd147fdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_a2280998-e521-44e5-b0af-0d38a73a7761" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a9b3b2da-7802-46c2-983a-e636c454b2a2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_a2280998-e521-44e5-b0af-0d38a73a7761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_159c4d0e-5610-4529-aecf-634c2ddc8753" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a9b3b2da-7802-46c2-983a-e636c454b2a2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_159c4d0e-5610-4529-aecf-634c2ddc8753" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_93e618ba-7d28-4d7b-8991-f11e67c38417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_61c0107e-da25-4f92-a7f2-bcfa4edb0518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_93e618ba-7d28-4d7b-8991-f11e67c38417" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_61c0107e-da25-4f92-a7f2-bcfa4edb0518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_593957d8-9395-4f7f-ae74-99ca820a06c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_93e618ba-7d28-4d7b-8991-f11e67c38417" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_593957d8-9395-4f7f-ae74-99ca820a06c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_47cab4b1-40f2-4d8a-8fd8-8c5a35655a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_93e618ba-7d28-4d7b-8991-f11e67c38417" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_47cab4b1-40f2-4d8a-8fd8-8c5a35655a04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_18497ba4-c127-4046-8574-80c2d0fcd60e" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_cd144891-234d-4703-89ec-f5b657ea25f4" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_18497ba4-c127-4046-8574-80c2d0fcd60e" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_cd144891-234d-4703-89ec-f5b657ea25f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0f51cfe4-4758-4457-8f52-1dd9e8ec7018" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_18497ba4-c127-4046-8574-80c2d0fcd60e" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0f51cfe4-4758-4457-8f52-1dd9e8ec7018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_99fd14f9-f0ac-488c-9700-e42d9ab49a9a" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_18497ba4-c127-4046-8574-80c2d0fcd60e" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_99fd14f9-f0ac-488c-9700-e42d9ab49a9a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_00b950f5-1f33-40ff-9f15-bbaed71cd21d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f5605eec-ef65-4ae4-922e-6573be4b6242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_00b950f5-1f33-40ff-9f15-bbaed71cd21d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f5605eec-ef65-4ae4-922e-6573be4b6242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b51f18ba-064f-4a49-a90f-458d8bf474f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_00b950f5-1f33-40ff-9f15-bbaed71cd21d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b51f18ba-064f-4a49-a90f-458d8bf474f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1b6c4446-0808-4bac-b4ff-209a38cf7b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fc82c77c-6234-429d-a708-de8a519c56fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1b6c4446-0808-4bac-b4ff-209a38cf7b10" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fc82c77c-6234-429d-a708-de8a519c56fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a175ec13-65c4-4212-90e5-71f9db89a1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1b6c4446-0808-4bac-b4ff-209a38cf7b10" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a175ec13-65c4-4212-90e5-71f9db89a1a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_699ea7fd-0a41-4f1a-b361-5ff6131c2ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_cfe52184-f85a-42ef-8c2d-636aa632380f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_699ea7fd-0a41-4f1a-b361-5ff6131c2ece" xlink:to="loc_us-gaap_InventoryRawMaterials_cfe52184-f85a-42ef-8c2d-636aa632380f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_56bbc0a6-6946-43ed-bd25-21b1370a9a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_699ea7fd-0a41-4f1a-b361-5ff6131c2ece" xlink:to="loc_us-gaap_InventoryWorkInProcess_56bbc0a6-6946-43ed-bd25-21b1370a9a14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_92ae5edd-aaff-4bd5-b587-2f055c4e88ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_699ea7fd-0a41-4f1a-b361-5ff6131c2ece" xlink:to="loc_us-gaap_InventoryFinishedGoods_92ae5edd-aaff-4bd5-b587-2f055c4e88ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fe830956-3c1d-4e74-8961-ae1446769884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_53d382de-3bbf-4130-9264-0a87231ee682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fe830956-3c1d-4e74-8961-ae1446769884" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_53d382de-3bbf-4130-9264-0a87231ee682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_838da324-95b9-4573-9ccd-f5b8f8da05ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fe830956-3c1d-4e74-8961-ae1446769884" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_838da324-95b9-4573-9ccd-f5b8f8da05ee" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>exel-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f874578b-aba8-4b11-9ee3-0aa3371a4a4f,g:18180dba-6dc6-4cf5-97a9-3c99224fbbee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended" id="i20887605a1134d62b4c9f8d07290392d_CondensedConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_319ae399-c2d3-43fa-9da6-b5187b078f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_RevenuesAbstract_319ae399-c2d3-43fa-9da6-b5187b078f8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce3c9771-daed-4fb9-837c-137781994f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_319ae399-c2d3-43fa-9da6-b5187b078f8f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce3c9771-daed-4fb9-837c-137781994f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9446fc37-8d13-445c-8359-6abfecdc8dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_OperatingExpensesAbstract_9446fc37-8d13-445c-8359-6abfecdc8dad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0c977b66-189a-4548-a149-db5465e69c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9446fc37-8d13-445c-8359-6abfecdc8dad" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0c977b66-189a-4548-a149-db5465e69c77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e6daae40-ae39-4d18-a305-f1cc1a4ceb27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9446fc37-8d13-445c-8359-6abfecdc8dad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e6daae40-ae39-4d18-a305-f1cc1a4ceb27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b39a1034-1887-41a6-b400-816ae64e577b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9446fc37-8d13-445c-8359-6abfecdc8dad" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b39a1034-1887-41a6-b400-816ae64e577b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2a5d3813-51e5-4303-a741-5f02d95d69cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9446fc37-8d13-445c-8359-6abfecdc8dad" xlink:to="loc_us-gaap_CostsAndExpenses_2a5d3813-51e5-4303-a741-5f02d95d69cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0d887d81-fe05-4bb2-b892-d1047b2c852c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_OperatingIncomeLoss_0d887d81-fe05-4bb2-b892-d1047b2c852c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_745dded1-c13c-4148-bc41-82747c74afb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_InterestIncomeOther_745dded1-c13c-4148-bc41-82747c74afb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_270bfa4c-0c20-47f3-baad-3208a6b882c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_270bfa4c-0c20-47f3-baad-3208a6b882c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_f2205f1e-95ce-4cfb-8406-a999241e87af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_f2205f1e-95ce-4cfb-8406-a999241e87af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cb1900df-fb79-401e-8cac-dd248438eaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cb1900df-fb79-401e-8cac-dd248438eaa9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6b799c84-87f8-4061-a5c6-0075597a2a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_NetIncomeLoss_6b799c84-87f8-4061-a5c6-0075597a2a77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_08d1c348-3b12-4207-a813-7e46799b97b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_EarningsPerShareAbstract_08d1c348-3b12-4207-a813-7e46799b97b1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bea4ab06-063d-423c-9d9c-a4a6cc9608e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08d1c348-3b12-4207-a813-7e46799b97b1" xlink:to="loc_us-gaap_EarningsPerShareBasic_bea4ab06-063d-423c-9d9c-a4a6cc9608e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e42cdfd6-0fe5-40b8-8a92-daadefa8d40d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08d1c348-3b12-4207-a813-7e46799b97b1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e42cdfd6-0fe5-40b8-8a92-daadefa8d40d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2bd22d04-e802-4dc1-ac28-05e5e6e53f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2bd22d04-e802-4dc1-ac28-05e5e6e53f1c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dff73bd5-ac10-48ac-8b9d-452df5f729e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2bd22d04-e802-4dc1-ac28-05e5e6e53f1c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dff73bd5-ac10-48ac-8b9d-452df5f729e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bba75807-9497-4a14-bb52-96740adb7f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2bd22d04-e802-4dc1-ac28-05e5e6e53f1c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bba75807-9497-4a14-bb52-96740adb7f54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7326b5cd-7b8b-4797-b517-904a130cd1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_StatementTable_7326b5cd-7b8b-4797-b517-904a130cd1b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f429fbf4-cf3e-490e-aa28-4255198c2f52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7326b5cd-7b8b-4797-b517-904a130cd1b4" xlink:to="loc_srt_ProductOrServiceAxis_f429fbf4-cf3e-490e-aa28-4255198c2f52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f429fbf4-cf3e-490e-aa28-4255198c2f52_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f429fbf4-cf3e-490e-aa28-4255198c2f52" xlink:to="loc_srt_ProductsAndServicesDomain_f429fbf4-cf3e-490e-aa28-4255198c2f52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_db578b35-b272-433d-9977-9970125d39f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f429fbf4-cf3e-490e-aa28-4255198c2f52" xlink:to="loc_srt_ProductsAndServicesDomain_db578b35-b272-433d-9977-9970125d39f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_823d5443-8597-44ed-97e1-723715b0050d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_db578b35-b272-433d-9977-9970125d39f4" xlink:to="loc_us-gaap_ProductMember_823d5443-8597-44ed-97e1-723715b0050d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_eae4096a-493f-42d1-ab8b-40904b2bd295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_db578b35-b272-433d-9977-9970125d39f4" xlink:to="loc_us-gaap_LicenseMember_eae4096a-493f-42d1-ab8b-40904b2bd295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_584a0962-1136-4f1c-bb6e-9bc8646bc377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_db578b35-b272-433d-9977-9970125d39f4" xlink:to="loc_us-gaap_ServiceMember_584a0962-1136-4f1c-bb6e-9bc8646bc377" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i331374b9cc5045f78fb31ef88610e707_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_31ac229c-b30f-4cf7-bd2c-b118f782ac57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_31ac229c-b30f-4cf7-bd2c-b118f782ac57" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_351b7186-7ad0-4c7e-b59b-d37a34fd6626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_351b7186-7ad0-4c7e-b59b-d37a34fd6626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b1523592-9805-4471-977c-bc0d47d45bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_StockholdersEquity_b1523592-9805-4471-977c-bc0d47d45bb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_89fabb7e-22a5-435f-a35c-3bc8e799dc32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_NetIncomeLoss_89fabb7e-22a5-435f-a35c-3bc8e799dc32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_09c4ee87-9a29-45dc-8436-e488db2dfed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_09c4ee87-9a29-45dc-8436-e488db2dfed5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_81dbba24-631a-452f-981a-0d1db9a17f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_81dbba24-631a-452f-981a-0d1db9a17f01" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c3f1ba9a-1dd7-4fc8-9c41-d8600a76cfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c3f1ba9a-1dd7-4fc8-9c41-d8600a76cfcd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_fd64d232-3963-4994-b81b-755b8cb200ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_fd64d232-3963-4994-b81b-755b8cb200ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5fe7a452-9e51-4708-86c4-b7631a03e831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5fe7a452-9e51-4708-86c4-b7631a03e831" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_88f0cf3e-488a-4ebb-b239-4c65f9f3e1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8e3f6179-3942-4321-848b-5d7729936677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7c30c3d6-290f-4737-8eda-b187e8bf82e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_31ac229c-b30f-4cf7-bd2c-b118f782ac57" xlink:to="loc_us-gaap_StatementTable_7c30c3d6-290f-4737-8eda-b187e8bf82e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aedd80d3-f445-4d05-86d2-49050b3d0d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7c30c3d6-290f-4737-8eda-b187e8bf82e6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aedd80d3-f445-4d05-86d2-49050b3d0d9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aedd80d3-f445-4d05-86d2-49050b3d0d9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aedd80d3-f445-4d05-86d2-49050b3d0d9f" xlink:to="loc_us-gaap_EquityComponentDomain_aedd80d3-f445-4d05-86d2-49050b3d0d9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_51ad7d4b-ef6d-4e15-a7b7-46c6b664554a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aedd80d3-f445-4d05-86d2-49050b3d0d9f" xlink:to="loc_us-gaap_EquityComponentDomain_51ad7d4b-ef6d-4e15-a7b7-46c6b664554a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf18435c-d0fe-4c58-9eca-95d26d25e334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_51ad7d4b-ef6d-4e15-a7b7-46c6b664554a" xlink:to="loc_us-gaap_CommonStockMember_cf18435c-d0fe-4c58-9eca-95d26d25e334" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5eb0ed3f-f0d8-49b1-9e09-7de2e2130f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_51ad7d4b-ef6d-4e15-a7b7-46c6b664554a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5eb0ed3f-f0d8-49b1-9e09-7de2e2130f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1eb7a5eb-76d2-48bd-a2a5-e62002c5e4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_51ad7d4b-ef6d-4e15-a7b7-46c6b664554a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1eb7a5eb-76d2-48bd-a2a5-e62002c5e4c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_71324ea8-7862-4570-88b0-e708e8ffd5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_51ad7d4b-ef6d-4e15-a7b7-46c6b664554a" xlink:to="loc_us-gaap_RetainedEarningsMember_71324ea8-7862-4570-88b0-e708e8ffd5f6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i95026bc45a83470b9931540075e81fd0_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_386ae60b-b21d-4c1b-b232-b5cbf9177067" xlink:href="exel-20220930.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_6501cbf6-01e9-40f7-acd0-a4f77c9d32cb" xlink:href="exel-20220930.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_386ae60b-b21d-4c1b-b232-b5cbf9177067" xlink:to="loc_exel_NumberofProductsinCommercialMarket_6501cbf6-01e9-40f7-acd0-a4f77c9d32cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_8cecf0a3-6172-49f8-8ae4-f8175765dd5d" xlink:href="exel-20220930.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_386ae60b-b21d-4c1b-b232-b5cbf9177067" xlink:to="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_8cecf0a3-6172-49f8-8ae4-f8175765dd5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_bc458c64-5f1d-443b-8330-27e2a959f613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_386ae60b-b21d-4c1b-b232-b5cbf9177067" xlink:to="loc_us-gaap_NumberOfOperatingSegments_bc458c64-5f1d-443b-8330-27e2a959f613" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5973924b-06f4-4020-b894-1d84caa1e128" xlink:href="exel-20220930.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_386ae60b-b21d-4c1b-b232-b5cbf9177067" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5973924b-06f4-4020-b894-1d84caa1e128" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3d5856ff-fa9d-42c0-932b-7db5bd0bb16f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5973924b-06f4-4020-b894-1d84caa1e128" xlink:to="loc_srt_ProductOrServiceAxis_3d5856ff-fa9d-42c0-932b-7db5bd0bb16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3d5856ff-fa9d-42c0-932b-7db5bd0bb16f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3d5856ff-fa9d-42c0-932b-7db5bd0bb16f" xlink:to="loc_srt_ProductsAndServicesDomain_3d5856ff-fa9d-42c0-932b-7db5bd0bb16f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a1203f0f-dafa-4458-bb58-6fa684836313" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3d5856ff-fa9d-42c0-932b-7db5bd0bb16f" xlink:to="loc_srt_ProductsAndServicesDomain_a1203f0f-dafa-4458-bb58-6fa684836313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_9b0b02b4-6010-4a62-a3f8-9ce17ed11f40" xlink:href="exel-20220930.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a1203f0f-dafa-4458-bb58-6fa684836313" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_9b0b02b4-6010-4a62-a3f8-9ce17ed11f40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_bb9750f1-a9df-4f1f-9b6e-fe58bf569eed" xlink:href="exel-20220930.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a1203f0f-dafa-4458-bb58-6fa684836313" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_bb9750f1-a9df-4f1f-9b6e-fe58bf569eed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended" id="i5ac9c60d9b7a4e60a26a022fdd208c48_RevenuesRevenuesbyDisaggregatedCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_130d5c79-b076-4c04-a9e5-91b1e3df51fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39793a93-5d81-4c61-b7cd-688c7386899b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_130d5c79-b076-4c04-a9e5-91b1e3df51fc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39793a93-5d81-4c61-b7cd-688c7386899b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2a829a5f-ee82-477e-b320-86c39defaaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_130d5c79-b076-4c04-a9e5-91b1e3df51fc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2a829a5f-ee82-477e-b320-86c39defaaa4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_476659f2-fb9a-4e7e-b193-c03c04839bba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2a829a5f-ee82-477e-b320-86c39defaaa4" xlink:to="loc_srt_ProductOrServiceAxis_476659f2-fb9a-4e7e-b193-c03c04839bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_476659f2-fb9a-4e7e-b193-c03c04839bba_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_476659f2-fb9a-4e7e-b193-c03c04839bba" xlink:to="loc_srt_ProductsAndServicesDomain_476659f2-fb9a-4e7e-b193-c03c04839bba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_476659f2-fb9a-4e7e-b193-c03c04839bba" xlink:to="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_5bcc7e04-0973-417a-87bb-e29944d3568d" xlink:href="exel-20220930.xsd#exel_ProductGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:to="loc_exel_ProductGrossMember_5bcc7e04-0973-417a-87bb-e29944d3568d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_38487ae1-ac25-4aa4-b3eb-bddb483f6f20" xlink:href="exel-20220930.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_38487ae1-ac25-4aa4-b3eb-bddb483f6f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_577df7c7-35f9-4a76-96d0-6b166dce4196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:to="loc_us-gaap_ProductMember_577df7c7-35f9-4a76-96d0-6b166dce4196" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_7da541b9-1d64-42f1-9218-ebacbd7d2a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:to="loc_us-gaap_LicenseMember_7da541b9-1d64-42f1-9218-ebacbd7d2a0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_597ccb92-73f3-4eb0-bae2-fbaa47be1eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:to="loc_us-gaap_ServiceMember_597ccb92-73f3-4eb0-bae2-fbaa47be1eca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_1b50316a-c436-4b91-be20-05ba8214de0a" xlink:href="exel-20220930.xsd#exel_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:to="loc_exel_CollaborationMember_1b50316a-c436-4b91-be20-05ba8214de0a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="extended" id="i901a4850a5d644b6b46979b4801eaf15_RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_b77b0c2a-686a-4564-a91a-29b5a1a065de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_df1c9f3d-cbd1-4783-8b57-56a01602b95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b77b0c2a-686a-4564-a91a-29b5a1a065de" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_df1c9f3d-cbd1-4783-8b57-56a01602b95e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_befbdc7f-5602-4dfb-8cf3-0318d1ceb39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b77b0c2a-686a-4564-a91a-29b5a1a065de" xlink:to="loc_us-gaap_ConcentrationRiskTable_befbdc7f-5602-4dfb-8cf3-0318d1ceb39e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2dc0e3b1-7b81-44f1-a020-e966315badfc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_befbdc7f-5602-4dfb-8cf3-0318d1ceb39e" xlink:to="loc_srt_MajorCustomersAxis_2dc0e3b1-7b81-44f1-a020-e966315badfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2dc0e3b1-7b81-44f1-a020-e966315badfc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_2dc0e3b1-7b81-44f1-a020-e966315badfc" xlink:to="loc_srt_NameOfMajorCustomerDomain_2dc0e3b1-7b81-44f1-a020-e966315badfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_2dc0e3b1-7b81-44f1-a020-e966315badfc" xlink:to="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_eaf8a335-68a8-4d3c-acd4-bc306cd3fc13" xlink:href="exel-20220930.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_eaf8a335-68a8-4d3c-acd4-bc306cd3fc13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_748fada2-7937-4d7b-b17e-0f539642bfa5" xlink:href="exel-20220930.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_748fada2-7937-4d7b-b17e-0f539642bfa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_3368b191-b2ec-4a62-b900-29f01227da2d" xlink:href="exel-20220930.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_3368b191-b2ec-4a62-b900-29f01227da2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_f79eee03-8d6e-4e64-a40d-692dfaf35202" xlink:href="exel-20220930.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:to="loc_exel_IpsenMember_f79eee03-8d6e-4e64-a40d-692dfaf35202" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember_2e17f178-3a22-46af-8aab-7db0571725be" xlink:href="exel-20220930.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:to="loc_exel_AccredoHealthIncorporatedMember_2e17f178-3a22-46af-8aab-7db0571725be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df931b01-a611-48af-936f-248fa15a3a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_befbdc7f-5602-4dfb-8cf3-0318d1ceb39e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df931b01-a611-48af-936f-248fa15a3a1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_df931b01-a611-48af-936f-248fa15a3a1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df931b01-a611-48af-936f-248fa15a3a1c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_df931b01-a611-48af-936f-248fa15a3a1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36e2afba-7677-442c-8ada-bab54a913ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df931b01-a611-48af-936f-248fa15a3a1c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36e2afba-7677-442c-8ada-bab54a913ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8cb900dc-04f1-4f47-b5da-3201ba1b6e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36e2afba-7677-442c-8ada-bab54a913ce0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8cb900dc-04f1-4f47-b5da-3201ba1b6e06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_ea70dc83-0928-4d74-8991-0787628664d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36e2afba-7677-442c-8ada-bab54a913ce0" xlink:to="loc_us-gaap_AccountsReceivableMember_ea70dc83-0928-4d74-8991-0787628664d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e5a7c06e-7b0c-44f2-bff3-ce0b76c9a446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_befbdc7f-5602-4dfb-8cf3-0318d1ceb39e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e5a7c06e-7b0c-44f2-bff3-ce0b76c9a446" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e5a7c06e-7b0c-44f2-bff3-ce0b76c9a446_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e5a7c06e-7b0c-44f2-bff3-ce0b76c9a446" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e5a7c06e-7b0c-44f2-bff3-ce0b76c9a446_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a6b87076-04cc-48da-aa6d-1a296fc67912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e5a7c06e-7b0c-44f2-bff3-ce0b76c9a446" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a6b87076-04cc-48da-aa6d-1a296fc67912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4a9596f8-3a2c-4ba0-8f2b-eb8cb25142ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a6b87076-04cc-48da-aa6d-1a296fc67912" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4a9596f8-3a2c-4ba0-8f2b-eb8cb25142ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended" id="ie0a2f759642d46daa3910f1255f30284_RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d20a51bb-be70-4dbb-b86e-c006841ba986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8757735-2ca9-4d3f-ac59-566fda520cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d20a51bb-be70-4dbb-b86e-c006841ba986" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8757735-2ca9-4d3f-ac59-566fda520cff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b43af564-581e-4845-92fd-446d723b86b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d20a51bb-be70-4dbb-b86e-c006841ba986" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b43af564-581e-4845-92fd-446d723b86b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ab9a3125-3313-43cf-97c2-b10090499e2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b43af564-581e-4845-92fd-446d723b86b6" xlink:to="loc_srt_StatementGeographicalAxis_ab9a3125-3313-43cf-97c2-b10090499e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ab9a3125-3313-43cf-97c2-b10090499e2b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ab9a3125-3313-43cf-97c2-b10090499e2b" xlink:to="loc_srt_SegmentGeographicalDomain_ab9a3125-3313-43cf-97c2-b10090499e2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a3867d52-bd0e-4d07-bd70-b3908717ade1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ab9a3125-3313-43cf-97c2-b10090499e2b" xlink:to="loc_srt_SegmentGeographicalDomain_a3867d52-bd0e-4d07-bd70-b3908717ade1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a7bf2f88-567f-4b8c-9a35-08e97f516ce6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a3867d52-bd0e-4d07-bd70-b3908717ade1" xlink:to="loc_country_US_a7bf2f88-567f-4b8c-9a35-08e97f516ce6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_dca023b6-2b43-4316-8e37-3f17b5da1ee0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a3867d52-bd0e-4d07-bd70-b3908717ade1" xlink:to="loc_srt_EuropeMember_dca023b6-2b43-4316-8e37-3f17b5da1ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_9dc13900-d734-4613-8646-e7ce84e25ebf" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a3867d52-bd0e-4d07-bd70-b3908717ade1" xlink:to="loc_country_JP_9dc13900-d734-4613-8646-e7ce84e25ebf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended" id="if03a79e3998045118db82d175536fd8c_RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c4a97007-13ad-4a96-ba78-5bb438506099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c68e1b9c-d3b4-4c99-98ca-81135045d366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c4a97007-13ad-4a96-ba78-5bb438506099" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c68e1b9c-d3b4-4c99-98ca-81135045d366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7ed294f2-cc4f-47f7-b091-e6263dadefcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c4a97007-13ad-4a96-ba78-5bb438506099" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7ed294f2-cc4f-47f7-b091-e6263dadefcc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c1cff367-2259-4332-aaea-6a66e8a2073f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7ed294f2-cc4f-47f7-b091-e6263dadefcc" xlink:to="loc_srt_ProductOrServiceAxis_c1cff367-2259-4332-aaea-6a66e8a2073f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c1cff367-2259-4332-aaea-6a66e8a2073f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c1cff367-2259-4332-aaea-6a66e8a2073f" xlink:to="loc_srt_ProductsAndServicesDomain_c1cff367-2259-4332-aaea-6a66e8a2073f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1204b745-e37b-4978-b6ec-038fcc87cccd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c1cff367-2259-4332-aaea-6a66e8a2073f" xlink:to="loc_srt_ProductsAndServicesDomain_1204b745-e37b-4978-b6ec-038fcc87cccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2ec05803-9fcc-4e09-a702-521887aaef98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1204b745-e37b-4978-b6ec-038fcc87cccd" xlink:to="loc_us-gaap_ProductMember_2ec05803-9fcc-4e09-a702-521887aaef98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_48e5cbe6-8599-49fc-8ad6-f98e4eb5c411" xlink:href="exel-20220930.xsd#exel_CabometyxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_2ec05803-9fcc-4e09-a702-521887aaef98" xlink:to="loc_exel_CabometyxMember_48e5cbe6-8599-49fc-8ad6-f98e4eb5c411" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_2052aa8d-a84a-4276-a4ac-c97359943a6b" xlink:href="exel-20220930.xsd#exel_CometriqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_2ec05803-9fcc-4e09-a702-521887aaef98" xlink:to="loc_exel_CometriqMember_2052aa8d-a84a-4276-a4ac-c97359943a6b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended" id="i7bdc34b4acd245da8fa0d9ca362c9641_RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b77bf2f7-d133-40a8-8ed6-82f12c33c266" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e0a588e2-ffdd-42fa-a31a-27dadc9e9ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b77bf2f7-d133-40a8-8ed6-82f12c33c266" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e0a588e2-ffdd-42fa-a31a-27dadc9e9ac8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_15103aa6-c511-4a9b-8eb7-b15e5f988f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e0a588e2-ffdd-42fa-a31a-27dadc9e9ac8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_15103aa6-c511-4a9b-8eb7-b15e5f988f9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_cbee311f-debc-4395-9bd2-054c6989a9d5" xlink:href="exel-20220930.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e0a588e2-ffdd-42fa-a31a-27dadc9e9ac8" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_cbee311f-debc-4395-9bd2-054c6989a9d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_59690969-7a55-4355-b7c2-6197add8c3f3" xlink:href="exel-20220930.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_cbee311f-debc-4395-9bd2-054c6989a9d5" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_59690969-7a55-4355-b7c2-6197add8c3f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_cffdd4d9-5a8f-4c36-964b-ea452d99adf2" xlink:href="exel-20220930.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_cbee311f-debc-4395-9bd2-054c6989a9d5" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_cffdd4d9-5a8f-4c36-964b-ea452d99adf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_fb3c5f4e-86bf-407a-b615-5be65d48d94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e0a588e2-ffdd-42fa-a31a-27dadc9e9ac8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_fb3c5f4e-86bf-407a-b615-5be65d48d94a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_16eb04e8-3bdc-4d48-a80c-e98b7ff10404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_4a8a5f81-21a2-4c5a-a287-8fdd40764c84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b77bf2f7-d133-40a8-8ed6-82f12c33c266" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_4a8a5f81-21a2-4c5a-a287-8fdd40764c84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a4b65e56-9fcb-4f7e-ba73-21ddb68ee16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_4a8a5f81-21a2-4c5a-a287-8fdd40764c84" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a4b65e56-9fcb-4f7e-ba73-21ddb68ee16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_a4b65e56-9fcb-4f7e-ba73-21ddb68ee16b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a4b65e56-9fcb-4f7e-ba73-21ddb68ee16b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_a4b65e56-9fcb-4f7e-ba73-21ddb68ee16b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_f6d72f63-1030-41a8-861d-141ac191ab31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a4b65e56-9fcb-4f7e-ba73-21ddb68ee16b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_f6d72f63-1030-41a8-861d-141ac191ab31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_719ed4db-ffc3-4664-b7d9-d9c15d71a9ee" xlink:href="exel-20220930.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f6d72f63-1030-41a8-861d-141ac191ab31" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_719ed4db-ffc3-4664-b7d9-d9c15d71a9ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_a63a1785-1092-4990-b367-5b071c57c726" xlink:href="exel-20220930.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f6d72f63-1030-41a8-861d-141ac191ab31" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_a63a1785-1092-4990-b367-5b071c57c726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_afd11c20-3513-4a17-b4bf-53a6295790c4" xlink:href="exel-20220930.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f6d72f63-1030-41a8-861d-141ac191ab31" xlink:to="loc_exel_AllowanceForProductRebatesMember_afd11c20-3513-4a17-b4bf-53a6295790c4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended" id="i23ccaeca881745e1b3d6f69e47c01503_RevenuesContractAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_ccee7eb5-be57-4354-bf08-a36db3ac18d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_ccee7eb5-be57-4354-bf08-a36db3ac18d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_59c60803-c984-4857-854d-fdd909388b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_ccee7eb5-be57-4354-bf08-a36db3ac18d2" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_59c60803-c984-4857-854d-fdd909388b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_5b7ee59f-ab0d-4201-9714-93dbd027c178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_5b7ee59f-ab0d-4201-9714-93dbd027c178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_83571b78-4276-40bf-b2c0-bccc31f6365a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_5b7ee59f-ab0d-4201-9714-93dbd027c178" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_83571b78-4276-40bf-b2c0-bccc31f6365a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_430bf2d4-c096-4fee-a49a-30c07c080ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_5b7ee59f-ab0d-4201-9714-93dbd027c178" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_430bf2d4-c096-4fee-a49a-30c07c080ef4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_08b133a4-45d9-4e23-9660-5fa8903acb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_5b7ee59f-ab0d-4201-9714-93dbd027c178" xlink:to="loc_us-gaap_ContractWithCustomerLiability_08b133a4-45d9-4e23-9660-5fa8903acb3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_4222b8fb-5369-42e9-9231-6b940b88e800" xlink:href="exel-20220930.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_4222b8fb-5369-42e9-9231-6b940b88e800" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_5d975c6a-1414-4d6c-9679-eedc97fcba9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_5d975c6a-1414-4d6c-9679-eedc97fcba9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_24833d7a-0e93-46dd-b1a8-7859c1d34fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_24833d7a-0e93-46dd-b1a8-7859c1d34fcb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b217425b-0bd4-4697-b2de-d79749101c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b217425b-0bd4-4697-b2de-d79749101c68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c9190082-dfb5-40ed-92c5-d259d54a428b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b217425b-0bd4-4697-b2de-d79749101c68" xlink:to="loc_srt_CounterpartyNameAxis_c9190082-dfb5-40ed-92c5-d259d54a428b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9190082-dfb5-40ed-92c5-d259d54a428b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c9190082-dfb5-40ed-92c5-d259d54a428b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c9190082-dfb5-40ed-92c5-d259d54a428b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98c7e412-0f1a-44f9-9b2b-230ac9fa6bac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c9190082-dfb5-40ed-92c5-d259d54a428b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98c7e412-0f1a-44f9-9b2b-230ac9fa6bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaAndIspenMember_2cb6fd6b-b22d-4768-9a15-0c8d10d9b535" xlink:href="exel-20220930.xsd#exel_TakedaAndIspenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98c7e412-0f1a-44f9-9b2b-230ac9fa6bac" xlink:to="loc_exel_TakedaAndIspenMember_2cb6fd6b-b22d-4768-9a15-0c8d10d9b535" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended" id="i8ddfca606b2b40fd9db038e80f418776_CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_208a032a-9a2e-46b2-a891-96b0311011b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdca3060-1d02-495c-834f-8cbbfd5b8828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_208a032a-9a2e-46b2-a891-96b0311011b1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdca3060-1d02-495c-834f-8cbbfd5b8828" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27370109-d08c-4522-99bf-aff5dc2200a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_208a032a-9a2e-46b2-a891-96b0311011b1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27370109-d08c-4522-99bf-aff5dc2200a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_614efae7-7264-41af-8337-2bfc1982f18c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27370109-d08c-4522-99bf-aff5dc2200a4" xlink:to="loc_srt_ProductOrServiceAxis_614efae7-7264-41af-8337-2bfc1982f18c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_614efae7-7264-41af-8337-2bfc1982f18c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_614efae7-7264-41af-8337-2bfc1982f18c" xlink:to="loc_srt_ProductsAndServicesDomain_614efae7-7264-41af-8337-2bfc1982f18c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e6f7ecc8-23df-4492-9b10-6a11ffaefa27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_614efae7-7264-41af-8337-2bfc1982f18c" xlink:to="loc_srt_ProductsAndServicesDomain_e6f7ecc8-23df-4492-9b10-6a11ffaefa27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_bfb6e6b4-b792-4807-b1d8-b2b90671e4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6f7ecc8-23df-4492-9b10-6a11ffaefa27" xlink:to="loc_us-gaap_LicenseMember_bfb6e6b4-b792-4807-b1d8-b2b90671e4e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_4b450160-a188-4ddd-b321-32a2cc52755f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6f7ecc8-23df-4492-9b10-6a11ffaefa27" xlink:to="loc_us-gaap_ServiceMember_4b450160-a188-4ddd-b321-32a2cc52755f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5f539641-9db8-4ec6-bab8-ebddaea03dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27370109-d08c-4522-99bf-aff5dc2200a4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5f539641-9db8-4ec6-bab8-ebddaea03dbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f539641-9db8-4ec6-bab8-ebddaea03dbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5f539641-9db8-4ec6-bab8-ebddaea03dbb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f539641-9db8-4ec6-bab8-ebddaea03dbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_06dec1a0-6aa0-4c0a-bfcf-e53de5557bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5f539641-9db8-4ec6-bab8-ebddaea03dbb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_06dec1a0-6aa0-4c0a-bfcf-e53de5557bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_3377db17-8cce-499f-a321-1edfc5bea903" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_06dec1a0-6aa0-4c0a-bfcf-e53de5557bd1" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_3377db17-8cce-499f-a321-1edfc5bea903" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended" id="id4bbf39251b74fe08789683608f28196_CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbb66b4a-2d63-414b-830e-056b7fb3a3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e34570e6-d198-4e10-992d-5de3f280cabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbb66b4a-2d63-414b-830e-056b7fb3a3ad" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e34570e6-d198-4e10-992d-5de3f280cabc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfRegulatoryMilestone_eea59611-c161-4dce-ae53-70b35f79919b" xlink:href="exel-20220930.xsd#exel_NumberOfRegulatoryMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbb66b4a-2d63-414b-830e-056b7fb3a3ad" xlink:to="loc_exel_NumberOfRegulatoryMilestone_eea59611-c161-4dce-ae53-70b35f79919b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerMilestoneRevenueRecognized_7b80e53f-b2ff-4d8c-b9d3-32a8de0e01c2" xlink:href="exel-20220930.xsd#exel_ContractWithCustomerMilestoneRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbb66b4a-2d63-414b-830e-056b7fb3a3ad" xlink:to="loc_exel_ContractWithCustomerMilestoneRevenueRecognized_7b80e53f-b2ff-4d8c-b9d3-32a8de0e01c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_b63ba933-8d63-46f2-90cf-7378c1e26884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbb66b4a-2d63-414b-830e-056b7fb3a3ad" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_b63ba933-8d63-46f2-90cf-7378c1e26884" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a848657b-18e8-4cc3-8914-0cab72b477cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbb66b4a-2d63-414b-830e-056b7fb3a3ad" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a848657b-18e8-4cc3-8914-0cab72b477cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bbd21929-6ae5-45fd-92fa-67d316f4a5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a848657b-18e8-4cc3-8914-0cab72b477cc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bbd21929-6ae5-45fd-92fa-67d316f4a5ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbd21929-6ae5-45fd-92fa-67d316f4a5ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bbd21929-6ae5-45fd-92fa-67d316f4a5ec" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bbd21929-6ae5-45fd-92fa-67d316f4a5ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18f9e22b-d3e5-4201-9cf9-1df996c7c083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bbd21929-6ae5-45fd-92fa-67d316f4a5ec" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18f9e22b-d3e5-4201-9cf9-1df996c7c083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_768c277a-405d-4970-aa71-c400d0cd75a4" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18f9e22b-d3e5-4201-9cf9-1df996c7c083" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_768c277a-405d-4970-aa71-c400d0cd75a4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended" id="i3a07f9f2dafb4c2fb748ea88dfa69feb_CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a9b9268-78aa-4de7-a7d1-efdfd1420dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c21fb5d0-191e-4e70-9cf1-de913d8b6ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a9b9268-78aa-4de7-a7d1-efdfd1420dd3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c21fb5d0-191e-4e70-9cf1-de913d8b6ee1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e050a0c0-e550-44c7-a905-eb669d1c1f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a9b9268-78aa-4de7-a7d1-efdfd1420dd3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e050a0c0-e550-44c7-a905-eb669d1c1f5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4faebfec-d6b8-46cb-a427-22af25f37d23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e050a0c0-e550-44c7-a905-eb669d1c1f5d" xlink:to="loc_srt_ProductOrServiceAxis_4faebfec-d6b8-46cb-a427-22af25f37d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4faebfec-d6b8-46cb-a427-22af25f37d23_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4faebfec-d6b8-46cb-a427-22af25f37d23" xlink:to="loc_srt_ProductsAndServicesDomain_4faebfec-d6b8-46cb-a427-22af25f37d23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_876004ff-0791-4754-af84-a05f39b43a37" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4faebfec-d6b8-46cb-a427-22af25f37d23" xlink:to="loc_srt_ProductsAndServicesDomain_876004ff-0791-4754-af84-a05f39b43a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_4c6c3040-3280-4d83-8a76-351429668d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_876004ff-0791-4754-af84-a05f39b43a37" xlink:to="loc_us-gaap_LicenseMember_4c6c3040-3280-4d83-8a76-351429668d87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_a93b6e32-b11b-40a2-944d-204986a1f1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_876004ff-0791-4754-af84-a05f39b43a37" xlink:to="loc_us-gaap_ServiceMember_a93b6e32-b11b-40a2-944d-204986a1f1d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7200e49a-ad90-4cb5-89a8-38a6f41011dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e050a0c0-e550-44c7-a905-eb669d1c1f5d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7200e49a-ad90-4cb5-89a8-38a6f41011dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7200e49a-ad90-4cb5-89a8-38a6f41011dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7200e49a-ad90-4cb5-89a8-38a6f41011dd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7200e49a-ad90-4cb5-89a8-38a6f41011dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbadeb75-417b-4ac5-a74e-83c641fdbc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7200e49a-ad90-4cb5-89a8-38a6f41011dd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbadeb75-417b-4ac5-a74e-83c641fdbc7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_894fdc2c-c228-4a20-a537-b078dee1ceba" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbadeb75-417b-4ac5-a74e-83c641fdbc7d" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_894fdc2c-c228-4a20-a537-b078dee1ceba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended" id="ie2293fdb348a4e86affabf781143cfe9_CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f1cffdef-3650-4e7b-9dbe-d03ba4f937d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_012cddc2-9bd4-4a66-a33c-e6b448f063e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f1cffdef-3650-4e7b-9dbe-d03ba4f937d6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_012cddc2-9bd4-4a66-a33c-e6b448f063e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01421d10-012d-4cd1-8980-8bc704b64577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f1cffdef-3650-4e7b-9dbe-d03ba4f937d6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01421d10-012d-4cd1-8980-8bc704b64577" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a619fbec-f85e-439a-b363-83cff9065e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01421d10-012d-4cd1-8980-8bc704b64577" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a619fbec-f85e-439a-b363-83cff9065e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a619fbec-f85e-439a-b363-83cff9065e72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a619fbec-f85e-439a-b363-83cff9065e72" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a619fbec-f85e-439a-b363-83cff9065e72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8cefcbc-934c-4dd1-afbd-9524a7edb540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a619fbec-f85e-439a-b363-83cff9065e72" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8cefcbc-934c-4dd1-afbd-9524a7edb540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_772da4b0-d153-4495-a06b-0f106d564851" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8cefcbc-934c-4dd1-afbd-9524a7edb540" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_772da4b0-d153-4495-a06b-0f106d564851" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" xlink:type="extended" id="i3d67fe77b9af4a398eac34314c8a1a9a_CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c025946e-8570-49df-9eb4-ae83d82cdc77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_5b03e3f7-1ed0-468d-b764-8a23dae2474f" xlink:href="exel-20220930.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c025946e-8570-49df-9eb4-ae83d82cdc77" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_5b03e3f7-1ed0-468d-b764-8a23dae2474f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_0635e082-91ce-4d5c-8491-d1be2bada2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c025946e-8570-49df-9eb4-ae83d82cdc77" xlink:to="loc_us-gaap_RoyaltyExpense_0635e082-91ce-4d5c-8491-d1be2bada2f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ad5fe60-545a-4948-a7e8-308981ff2049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c025946e-8570-49df-9eb4-ae83d82cdc77" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ad5fe60-545a-4948-a7e8-308981ff2049" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_912eb377-27dc-488a-a4dc-2109af632fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ad5fe60-545a-4948-a7e8-308981ff2049" xlink:to="loc_us-gaap_TypeOfArrangementAxis_912eb377-27dc-488a-a4dc-2109af632fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_912eb377-27dc-488a-a4dc-2109af632fd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_912eb377-27dc-488a-a4dc-2109af632fd3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_912eb377-27dc-488a-a4dc-2109af632fd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eea3280a-ad31-4f31-9244-3b5e1ad9c0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_912eb377-27dc-488a-a4dc-2109af632fd3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eea3280a-ad31-4f31-9244-3b5e1ad9c0ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_7f9bd8df-299d-4ac4-829f-90674df37a4b" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eea3280a-ad31-4f31-9244-3b5e1ad9c0ca" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_7f9bd8df-299d-4ac4-829f-90674df37a4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyalPharmaMember_3b36a2af-f1ac-4847-8777-5222817ceec8" xlink:href="exel-20220930.xsd#exel_RoyalPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eea3280a-ad31-4f31-9244-3b5e1ad9c0ca" xlink:to="loc_exel_RoyalPharmaMember_3b36a2af-f1ac-4847-8777-5222817ceec8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended" id="i44558c49adef42f6aa615e11003f64b7_CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d96c968-3167-4e5e-b1a6-0b8ec7385b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_dd56f889-beda-479a-92d2-faa030ae29d9" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d96c968-3167-4e5e-b1a6-0b8ec7385b8d" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_dd56f889-beda-479a-92d2-faa030ae29d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1555f9b0-66c8-4f6d-8212-6346380fe5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d96c968-3167-4e5e-b1a6-0b8ec7385b8d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1555f9b0-66c8-4f6d-8212-6346380fe5aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45e8d38c-e4db-4be3-ace5-d57af3791da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d96c968-3167-4e5e-b1a6-0b8ec7385b8d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45e8d38c-e4db-4be3-ace5-d57af3791da0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5c679491-d856-43e9-80e2-3c7f3e3edddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45e8d38c-e4db-4be3-ace5-d57af3791da0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5c679491-d856-43e9-80e2-3c7f3e3edddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5c679491-d856-43e9-80e2-3c7f3e3edddb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5c679491-d856-43e9-80e2-3c7f3e3edddb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5c679491-d856-43e9-80e2-3c7f3e3edddb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d46bdd3-e16a-4456-b66c-979d89eed20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5c679491-d856-43e9-80e2-3c7f3e3edddb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d46bdd3-e16a-4456-b66c-979d89eed20e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_84de864e-bdc5-4c35-bd15-ee03273850b4" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d46bdd3-e16a-4456-b66c-979d89eed20e" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_84de864e-bdc5-4c35-bd15-ee03273850b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisAxis_15bfdddd-ed5f-44cf-92ee-da5f6b7806db" xlink:href="exel-20220930.xsd#exel_ProductOrServiceAxisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45e8d38c-e4db-4be3-ace5-d57af3791da0" xlink:to="loc_exel_ProductOrServiceAxisAxis_15bfdddd-ed5f-44cf-92ee-da5f6b7806db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisDomain_15bfdddd-ed5f-44cf-92ee-da5f6b7806db_default" xlink:href="exel-20220930.xsd#exel_ProductOrServiceAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_ProductOrServiceAxisAxis_15bfdddd-ed5f-44cf-92ee-da5f6b7806db" xlink:to="loc_exel_ProductOrServiceAxisDomain_15bfdddd-ed5f-44cf-92ee-da5f6b7806db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisDomain_9d4e4270-86d0-416c-b189-3c6ac6a60805" xlink:href="exel-20220930.xsd#exel_ProductOrServiceAxisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_ProductOrServiceAxisAxis_15bfdddd-ed5f-44cf-92ee-da5f6b7806db" xlink:to="loc_exel_ProductOrServiceAxisDomain_9d4e4270-86d0-416c-b189-3c6ac6a60805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_f0efff7c-f732-4b03-b74d-1ba01e2e7987" xlink:href="exel-20220930.xsd#exel_CotellicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProductOrServiceAxisDomain_9d4e4270-86d0-416c-b189-3c6ac6a60805" xlink:to="loc_exel_CotellicMember_f0efff7c-f732-4b03-b74d-1ba01e2e7987" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="extended" id="ib9badf824dc842d28c42629c303f1063_CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_c0e111df-9f42-4bc7-9166-0ff94d275f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_ca27ceab-45b1-4c5c-8068-880e1ee7fa5d" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_c0e111df-9f42-4bc7-9166-0ff94d275f88" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_ca27ceab-45b1-4c5c-8068-880e1ee7fa5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_0c012fb6-e089-4d33-a850-f2b4f50aadf9" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_c0e111df-9f42-4bc7-9166-0ff94d275f88" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_0c012fb6-e089-4d33-a850-f2b4f50aadf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_bbeff56e-6a91-47e8-8f50-68fdff1d69a0" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_c0e111df-9f42-4bc7-9166-0ff94d275f88" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_bbeff56e-6a91-47e8-8f50-68fdff1d69a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_a912394a-d88d-4841-abba-95500406a985" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_c0e111df-9f42-4bc7-9166-0ff94d275f88" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_a912394a-d88d-4841-abba-95500406a985" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_2876b40f-c4e7-47c8-8c61-f35a1c3bb61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_c0e111df-9f42-4bc7-9166-0ff94d275f88" xlink:to="loc_us-gaap_AssetAcquisitionTable_2876b40f-c4e7-47c8-8c61-f35a1c3bb61f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_76625837-dbd9-435d-bcc3-4a0d13408f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2876b40f-c4e7-47c8-8c61-f35a1c3bb61f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_76625837-dbd9-435d-bcc3-4a0d13408f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625837-dbd9-435d-bcc3-4a0d13408f40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76625837-dbd9-435d-bcc3-4a0d13408f40" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76625837-dbd9-435d-bcc3-4a0d13408f40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d1d770a-527c-4bf7-94ca-a41cf69e58a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76625837-dbd9-435d-bcc3-4a0d13408f40" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d1d770a-527c-4bf7-94ca-a41cf69e58a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember_ab3b0948-5ed6-4dcd-9d10-b30755690f73" xlink:href="exel-20220930.xsd#exel_CollaborationAgreementWithBioInventInternationalABBioInventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d1d770a-527c-4bf7-94ca-a41cf69e58a1" xlink:to="loc_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember_ab3b0948-5ed6-4dcd-9d10-b30755690f73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember_373380b7-647c-4c25-9b77-98cfc9b8e178" xlink:href="exel-20220930.xsd#exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d1d770a-527c-4bf7-94ca-a41cf69e58a1" xlink:to="loc_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember_373380b7-647c-4c25-9b77-98cfc9b8e178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_b8102a33-0759-4c5e-9b81-f695a953ca08" xlink:href="exel-20220930.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d1d770a-527c-4bf7-94ca-a41cf69e58a1" xlink:to="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_b8102a33-0759-4c5e-9b81-f695a953ca08" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended" id="ib8a5b2af9869496ebb1f43456d6accad_CashandInvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_c72bd28d-ae06-4a6c-bd36-ffb391a5d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_us-gaap_InterestReceivable_c72bd28d-ae06-4a6c-bd36-ffb391a5d79c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_953efdf8-7375-492f-94b8-e26a3f285959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_953efdf8-7375-492f-94b8-e26a3f285959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfBondSecurities_f302608f-fba2-4d1c-ad2d-527fd3ccdf5f" xlink:href="exel-20220930.xsd#exel_NumberOfBondSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_exel_NumberOfBondSecurities_f302608f-fba2-4d1c-ad2d-527fd3ccdf5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_50aaf167-dfb3-44cc-82ab-d3bcae0130ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_50aaf167-dfb3-44cc-82ab-d3bcae0130ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3d51ec01-c0ba-4e8e-a154-e71bcf1dfc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3d51ec01-c0ba-4e8e-a154-e71bcf1dfc74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_93e72b01-dfae-4d5a-8d7d-1882f1bdc699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_93e72b01-dfae-4d5a-8d7d-1882f1bdc699" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f79e11dd-a5f9-48b0-839a-65f923fe6599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f79e11dd-a5f9-48b0-839a-65f923fe6599" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e3aa3306-9870-4389-8006-576dc2063f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f79e11dd-a5f9-48b0-839a-65f923fe6599" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e3aa3306-9870-4389-8006-576dc2063f62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3aa3306-9870-4389-8006-576dc2063f62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e3aa3306-9870-4389-8006-576dc2063f62" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3aa3306-9870-4389-8006-576dc2063f62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_88492f49-602f-49b4-960d-b41e526eacac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e3aa3306-9870-4389-8006-576dc2063f62" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_88492f49-602f-49b4-960d-b41e526eacac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_937bc3d7-cea1-4aa8-a881-ad21468ebed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_88492f49-602f-49b4-960d-b41e526eacac" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_937bc3d7-cea1-4aa8-a881-ad21468ebed7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_ae8ed183-9746-4dd2-a872-deb2d3e8ecd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_88492f49-602f-49b4-960d-b41e526eacac" xlink:to="loc_us-gaap_MunicipalBondsMember_ae8ed183-9746-4dd2-a872-deb2d3e8ecd7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended" id="ie5d183c1fe5a4f0ca5631b1fd9f2a0d8_CashandInvestmentsInvestmentsbySecurityTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_18c63046-fa96-4f29-a8fd-64920b7735e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_18c63046-fa96-4f29-a8fd-64920b7735e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_007971a4-a4ff-4866-98b0-68957d992327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_18c63046-fa96-4f29-a8fd-64920b7735e1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_007971a4-a4ff-4866-98b0-68957d992327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23b45144-6657-4cba-bede-f9093ea817bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_18c63046-fa96-4f29-a8fd-64920b7735e1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23b45144-6657-4cba-bede-f9093ea817bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_07fa4a9c-f458-43ab-a1e3-0faf5f598b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_18c63046-fa96-4f29-a8fd-64920b7735e1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_07fa4a9c-f458-43ab-a1e3-0faf5f598b53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d6ecada1-4775-4a5e-a721-f2d7a7567b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_18c63046-fa96-4f29-a8fd-64920b7735e1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d6ecada1-4775-4a5e-a721-f2d7a7567b56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3f1c5255-9e33-4924-9a2a-ca2b7fbdcdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3f1c5255-9e33-4924-9a2a-ca2b7fbdcdaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_1683f802-f13d-49b1-9eac-d6a482e8e508" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3f1c5255-9e33-4924-9a2a-ca2b7fbdcdaa" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_1683f802-f13d-49b1-9eac-d6a482e8e508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_e2154ee4-2ecc-47a4-a923-ba9deea239a5" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3f1c5255-9e33-4924-9a2a-ca2b7fbdcdaa" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_e2154ee4-2ecc-47a4-a923-ba9deea239a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_bca4428f-edaa-401b-bdb6-622f6612d6b0" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3f1c5255-9e33-4924-9a2a-ca2b7fbdcdaa" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_bca4428f-edaa-401b-bdb6-622f6612d6b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_0c485617-8735-418e-a87b-e4c8790696b8" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3f1c5255-9e33-4924-9a2a-ca2b7fbdcdaa" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_0c485617-8735-418e-a87b-e4c8790696b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_62091103-15f1-473b-b1c3-ed857cf2b369" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_62091103-15f1-473b-b1c3-ed857cf2b369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8844b072-ec8f-4008-9663-45a558dfb79a" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8844b072-ec8f-4008-9663-45a558dfb79a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_82637847-785c-480b-aa08-a2271e1b97bf" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_82637847-785c-480b-aa08-a2271e1b97bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_3eba8069-6dcc-4c65-8da1-83eeae6fea1b" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_3eba8069-6dcc-4c65-8da1-83eeae6fea1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e76e21e-2fc8-4537-b269-82c1f25143bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e76e21e-2fc8-4537-b269-82c1f25143bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_075543e8-99ea-407f-b14d-fd20ccd4bf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e76e21e-2fc8-4537-b269-82c1f25143bd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_075543e8-99ea-407f-b14d-fd20ccd4bf5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_075543e8-99ea-407f-b14d-fd20ccd4bf5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_075543e8-99ea-407f-b14d-fd20ccd4bf5b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_075543e8-99ea-407f-b14d-fd20ccd4bf5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_075543e8-99ea-407f-b14d-fd20ccd4bf5b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cbf58cfb-fdf7-49af-80a5-d5ba3517ccee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_CommercialPaperMember_cbf58cfb-fdf7-49af-80a5-d5ba3517ccee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ed5cb036-340a-41e6-a5f0-f5feff6115ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ed5cb036-340a-41e6-a5f0-f5feff6115ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_b4e8275b-ca42-4482-abac-1b123cd8b14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_b4e8275b-ca42-4482-abac-1b123cd8b14d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_f04ab85b-f6c5-4b8e-bf77-76ddd3c4f15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_MunicipalBondsMember_f04ab85b-f6c5-4b8e-bf77-76ddd3c4f15c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_82f13c7c-c70c-4b0f-b7cc-959cc045f9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_CashMember_82f13c7c-c70c-4b0f-b7cc-959cc045f9ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e9f10d0b-bc05-4f93-adb4-0ca48d143591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e9f10d0b-bc05-4f93-adb4-0ca48d143591" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0b5e6a89-9d95-4647-b71b-77f0b456e17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0b5e6a89-9d95-4647-b71b-77f0b456e17c" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended" id="i6aa58dcf223f4624a5874bd4198a3b83_CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2df9110c-620e-48dc-9e54-9a944cdc82d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_21f2e244-4d37-4895-9305-34912b7639ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2df9110c-620e-48dc-9e54-9a944cdc82d6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_21f2e244-4d37-4895-9305-34912b7639ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_002e7db4-18ce-4bfc-8d8d-46afef5072c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_21f2e244-4d37-4895-9305-34912b7639ed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_002e7db4-18ce-4bfc-8d8d-46afef5072c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_bc7ccb60-85eb-47fe-a360-db5e6be3674c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_21f2e244-4d37-4895-9305-34912b7639ed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_bc7ccb60-85eb-47fe-a360-db5e6be3674c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f6d7e858-d9a5-4936-945a-7751441578fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2df9110c-620e-48dc-9e54-9a944cdc82d6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f6d7e858-d9a5-4936-945a-7751441578fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3d8fb619-7d3c-47cc-b787-55fd0ce17c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f6d7e858-d9a5-4936-945a-7751441578fc" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3d8fb619-7d3c-47cc-b787-55fd0ce17c40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3d8fb619-7d3c-47cc-b787-55fd0ce17c40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3d8fb619-7d3c-47cc-b787-55fd0ce17c40" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3d8fb619-7d3c-47cc-b787-55fd0ce17c40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7505c944-5da6-4d9d-a56c-f24e1da392b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3d8fb619-7d3c-47cc-b787-55fd0ce17c40" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7505c944-5da6-4d9d-a56c-f24e1da392b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_b8fe72fb-eb2f-4995-ac06-f7c0fc6a22bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7505c944-5da6-4d9d-a56c-f24e1da392b8" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_b8fe72fb-eb2f-4995-ac06-f7c0fc6a22bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_13896989-bc8d-475a-a4bc-acd9033f3814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7505c944-5da6-4d9d-a56c-f24e1da392b8" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_13896989-bc8d-475a-a4bc-acd9033f3814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_85389a33-9f20-4ced-8dfc-f9e118588bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7505c944-5da6-4d9d-a56c-f24e1da392b8" xlink:to="loc_us-gaap_CommercialPaperMember_85389a33-9f20-4ced-8dfc-f9e118588bc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_5a484f2b-8a1b-4499-a6fb-c054f0104172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7505c944-5da6-4d9d-a56c-f24e1da392b8" xlink:to="loc_us-gaap_MunicipalBondsMember_5a484f2b-8a1b-4499-a6fb-c054f0104172" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="if66e3799ac084aa9ba896e4ba7f94a8a_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a8afc2e-957d-4d69-94c8-3ee73225f660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b1b1be1-1f9a-44f0-bde4-3c08f0582d85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a8afc2e-957d-4d69-94c8-3ee73225f660" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b1b1be1-1f9a-44f0-bde4-3c08f0582d85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_626029a3-9782-4f25-afee-6f8026244c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a8afc2e-957d-4d69-94c8-3ee73225f660" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_626029a3-9782-4f25-afee-6f8026244c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_06558a71-41a0-4bd6-982a-ce56cc0a6250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a8afc2e-957d-4d69-94c8-3ee73225f660" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_06558a71-41a0-4bd6-982a-ce56cc0a6250" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce632fd1-4e18-430c-bb16-40262aab3cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a8afc2e-957d-4d69-94c8-3ee73225f660" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce632fd1-4e18-430c-bb16-40262aab3cb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1a4f0161-883d-4f8d-8bf9-34efe5d56a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce632fd1-4e18-430c-bb16-40262aab3cb9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1a4f0161-883d-4f8d-8bf9-34efe5d56a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a4f0161-883d-4f8d-8bf9-34efe5d56a83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1a4f0161-883d-4f8d-8bf9-34efe5d56a83" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a4f0161-883d-4f8d-8bf9-34efe5d56a83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1a4f0161-883d-4f8d-8bf9-34efe5d56a83" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1a888dca-1de8-44ae-b0fc-d3d945cce4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:to="loc_us-gaap_CommercialPaperMember_1a888dca-1de8-44ae-b0fc-d3d945cce4e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_1706979f-5e75-4265-911e-727aa2bcbce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_1706979f-5e75-4265-911e-727aa2bcbce5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_a4a8d750-3da9-45fb-b221-839d032351b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_a4a8d750-3da9-45fb-b221-839d032351b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_6a643d47-7245-4867-aac8-939a9c7cf59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:to="loc_us-gaap_MunicipalBondsMember_6a643d47-7245-4867-aac8-939a9c7cf59a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e09af174-d349-437e-a34d-e59cc4a4061e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e09af174-d349-437e-a34d-e59cc4a4061e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7f8e36cd-9010-4e6c-8552-2951f199a161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7f8e36cd-9010-4e6c-8552-2951f199a161" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea60d900-980a-41c8-a388-128e544ba626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce632fd1-4e18-430c-bb16-40262aab3cb9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea60d900-980a-41c8-a388-128e544ba626" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea60d900-980a-41c8-a388-128e544ba626_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea60d900-980a-41c8-a388-128e544ba626" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea60d900-980a-41c8-a388-128e544ba626_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e8d1640a-56ae-4f9b-8280-d7c4c262585e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea60d900-980a-41c8-a388-128e544ba626" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e8d1640a-56ae-4f9b-8280-d7c4c262585e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d8ed6d3b-7f63-4762-820e-f227d1426c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e8d1640a-56ae-4f9b-8280-d7c4c262585e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d8ed6d3b-7f63-4762-820e-f227d1426c16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a807484a-ec86-4f00-b236-ef6cd617c347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e8d1640a-56ae-4f9b-8280-d7c4c262585e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a807484a-ec86-4f00-b236-ef6cd617c347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfab1d71-10c7-4217-9d8c-769d44af95fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce632fd1-4e18-430c-bb16-40262aab3cb9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfab1d71-10c7-4217-9d8c-769d44af95fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bfab1d71-10c7-4217-9d8c-769d44af95fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfab1d71-10c7-4217-9d8c-769d44af95fe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bfab1d71-10c7-4217-9d8c-769d44af95fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b8ed6c15-9061-41df-83e7-d6a30d9db043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfab1d71-10c7-4217-9d8c-769d44af95fe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b8ed6c15-9061-41df-83e7-d6a30d9db043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4ba296a5-7411-44ae-8023-6282b37303df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b8ed6c15-9061-41df-83e7-d6a30d9db043" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4ba296a5-7411-44ae-8023-6282b37303df" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended" id="i12ee50b8d75149ecbb62a9ed410ae6a5_FairValueMeasurementsNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6367702e-f0fa-4f7b-9c63-b2d4941e69d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_8c964974-ce61-42bc-aeda-3d3d8502c19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6367702e-f0fa-4f7b-9c63-b2d4941e69d8" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_8c964974-ce61-42bc-aeda-3d3d8502c19b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_b60b8c1b-95e8-4050-b1b8-c59c64036fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6367702e-f0fa-4f7b-9c63-b2d4941e69d8" xlink:to="loc_us-gaap_DerivativeNotionalAmount_b60b8c1b-95e8-4050-b1b8-c59c64036fcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_60465114-42f0-4287-ab46-135424307a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6367702e-f0fa-4f7b-9c63-b2d4941e69d8" xlink:to="loc_us-gaap_DerivativeTermOfContract_60465114-42f0-4287-ab46-135424307a6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_7b35f61b-0b57-41c3-b96d-805ec5921ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6367702e-f0fa-4f7b-9c63-b2d4941e69d8" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_7b35f61b-0b57-41c3-b96d-805ec5921ecf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_904fce0f-a277-450d-a871-4acbda32ad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6367702e-f0fa-4f7b-9c63-b2d4941e69d8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_904fce0f-a277-450d-a871-4acbda32ad1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_42f126de-c145-4528-a807-e987ec2db7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_904fce0f-a277-450d-a871-4acbda32ad1c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_42f126de-c145-4528-a807-e987ec2db7ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_42f126de-c145-4528-a807-e987ec2db7ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_42f126de-c145-4528-a807-e987ec2db7ee" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_42f126de-c145-4528-a807-e987ec2db7ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_86fb7a41-f3ac-4df4-8a02-41eae9b3ff52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_42f126de-c145-4528-a807-e987ec2db7ee" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_86fb7a41-f3ac-4df4-8a02-41eae9b3ff52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_2297a625-3f7d-4625-952a-f61904db1502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_86fb7a41-f3ac-4df4-8a02-41eae9b3ff52" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_2297a625-3f7d-4625-952a-f61904db1502" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended" id="i49a57cb14d414cf09e44c4681018472e_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_457fc7fe-c6f1-47b9-bbf3-95716a3e8cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_009a91ab-7326-4643-abc8-a1cca5546d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_457fc7fe-c6f1-47b9-bbf3-95716a3e8cea" xlink:to="loc_us-gaap_InventoryRawMaterials_009a91ab-7326-4643-abc8-a1cca5546d92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_37417b98-8c42-4832-80f7-44c7754f1874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_457fc7fe-c6f1-47b9-bbf3-95716a3e8cea" xlink:to="loc_us-gaap_InventoryWorkInProcess_37417b98-8c42-4832-80f7-44c7754f1874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_82a47d58-f6bf-48ec-af45-1cc7934efb71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_457fc7fe-c6f1-47b9-bbf3-95716a3e8cea" xlink:to="loc_us-gaap_InventoryFinishedGoods_82a47d58-f6bf-48ec-af45-1cc7934efb71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d8e3da51-e763-4c3b-a54b-19e5afbaea36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_457fc7fe-c6f1-47b9-bbf3-95716a3e8cea" xlink:to="loc_us-gaap_InventoryGross_d8e3da51-e763-4c3b-a54b-19e5afbaea36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_bae19922-bd2e-4272-9cc7-d2bec39200ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_457fc7fe-c6f1-47b9-bbf3-95716a3e8cea" xlink:to="loc_us-gaap_InventoryCurrentTable_bae19922-bd2e-4272-9cc7-d2bec39200ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3c17fcc5-9892-4b64-8c58-5a877346c8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_bae19922-bd2e-4272-9cc7-d2bec39200ab" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3c17fcc5-9892-4b64-8c58-5a877346c8dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3c17fcc5-9892-4b64-8c58-5a877346c8dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3c17fcc5-9892-4b64-8c58-5a877346c8dc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3c17fcc5-9892-4b64-8c58-5a877346c8dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a2adc545-903a-4dee-84e6-60f462c83e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3c17fcc5-9892-4b64-8c58-5a877346c8dc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a2adc545-903a-4dee-84e6-60f462c83e32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_5b677445-b966-41e6-981e-b5ed45e52139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a2adc545-903a-4dee-84e6-60f462c83e32" xlink:to="loc_us-gaap_InventoriesMember_5b677445-b966-41e6-981e-b5ed45e52139" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_cae67acd-82ab-4e0f-a374-fce2e7baeddc" xlink:href="exel-20220930.xsd#exel_OtherLongtermAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a2adc545-903a-4dee-84e6-60f462c83e32" xlink:to="loc_exel_OtherLongtermAssetsMember_cae67acd-82ab-4e0f-a374-fce2e7baeddc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" id="i089f03ccbce94fdbbaf1a8f9ceaf3bd1_StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28fe5af2-9888-4e72-8c7d-2c5772905fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_72303d91-42df-4700-a26a-fa20e6a62062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28fe5af2-9888-4e72-8c7d-2c5772905fd2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_72303d91-42df-4700-a26a-fa20e6a62062" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790e382e-e696-4eb7-9bf2-14072539338e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28fe5af2-9888-4e72-8c7d-2c5772905fd2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790e382e-e696-4eb7-9bf2-14072539338e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_01517ba5-34e3-49e8-a284-576288e361ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790e382e-e696-4eb7-9bf2-14072539338e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_01517ba5-34e3-49e8-a284-576288e361ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_01517ba5-34e3-49e8-a284-576288e361ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_01517ba5-34e3-49e8-a284-576288e361ae" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_01517ba5-34e3-49e8-a284-576288e361ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a1943964-d668-46e4-9b25-b3fd6ada74f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_01517ba5-34e3-49e8-a284-576288e361ae" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a1943964-d668-46e4-9b25-b3fd6ada74f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_52e95c83-4163-40f9-a69b-a98ecdbcf7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a1943964-d668-46e4-9b25-b3fd6ada74f9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_52e95c83-4163-40f9-a69b-a98ecdbcf7bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f4c4b64f-8f54-4f37-a9e3-5e798c84bdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a1943964-d668-46e4-9b25-b3fd6ada74f9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f4c4b64f-8f54-4f37-a9e3-5e798c84bdb0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended" id="i39ba044d59f7430a8aad80e70bae8fdd_StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ec8441e-1d4f-43c9-8c26-c0be98286d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_303319e5-83d9-4f5e-a262-146b3529f7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ec8441e-1d4f-43c9-8c26-c0be98286d5d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_303319e5-83d9-4f5e-a262-146b3529f7dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd9bc7d-a6f8-4b55-a430-31a5fe32de50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ec8441e-1d4f-43c9-8c26-c0be98286d5d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd9bc7d-a6f8-4b55-a430-31a5fe32de50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_796eca67-aafa-4904-88a5-ddc853285360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd9bc7d-a6f8-4b55-a430-31a5fe32de50" xlink:to="loc_us-gaap_AwardTypeAxis_796eca67-aafa-4904-88a5-ddc853285360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_796eca67-aafa-4904-88a5-ddc853285360_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_796eca67-aafa-4904-88a5-ddc853285360" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_796eca67-aafa-4904-88a5-ddc853285360_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fde12f16-abfc-4c1e-ac5a-ddef80bf8f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_796eca67-aafa-4904-88a5-ddc853285360" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fde12f16-abfc-4c1e-ac5a-ddef80bf8f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_010e62d0-1653-4ddc-b1bc-5697ef122d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fde12f16-abfc-4c1e-ac5a-ddef80bf8f51" xlink:to="loc_us-gaap_EmployeeStockOptionMember_010e62d0-1653-4ddc-b1bc-5697ef122d31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_da61ce98-51e7-4c7c-bda5-dd0a39bd8032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fde12f16-abfc-4c1e-ac5a-ddef80bf8f51" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_da61ce98-51e7-4c7c-bda5-dd0a39bd8032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a04298d0-3ea2-42bd-b6f0-43d3472c0b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fde12f16-abfc-4c1e-ac5a-ddef80bf8f51" xlink:to="loc_us-gaap_PerformanceSharesMember_a04298d0-3ea2-42bd-b6f0-43d3472c0b7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c6732f41-7edc-4818-bd37-c6034030ba6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fde12f16-abfc-4c1e-ac5a-ddef80bf8f51" xlink:to="loc_us-gaap_EmployeeStockMember_c6732f41-7edc-4818-bd37-c6034030ba6f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i909508a445db423c81724a4df65d823a_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_deffc386-50ce-4889-a103-e734038e8b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_deffc386-50ce-4889-a103-e734038e8b8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dc90b132-49b1-483b-85be-ad1e64060218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dc90b132-49b1-483b-85be-ad1e64060218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_164ec416-b71e-423d-9d25-ffd26b303f00" xlink:href="exel-20220930.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_164ec416-b71e-423d-9d25-ffd26b303f00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_c81193dc-65db-49c4-9d40-a9cd2900eafc" xlink:href="exel-20220930.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_c81193dc-65db-49c4-9d40-a9cd2900eafc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_62cbc0d8-8336-4aae-b8bb-26ec48476318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_62cbc0d8-8336-4aae-b8bb-26ec48476318" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_58e7a8b9-aea8-4421-b387-f4ed5b407977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_58e7a8b9-aea8-4421-b387-f4ed5b407977" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66eb8d01-194c-4680-843e-ec89838180fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66eb8d01-194c-4680-843e-ec89838180fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f096d9c6-5cc7-4bd9-b6f0-1e65b6ddbc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f096d9c6-5cc7-4bd9-b6f0-1e65b6ddbc30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2e948603-560c-4323-97ca-6d1026cc9252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2e948603-560c-4323-97ca-6d1026cc9252" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_34dec5d4-c007-4324-8357-a5b80b1fc3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_34dec5d4-c007-4324-8357-a5b80b1fc3f2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_4abbef97-4a4e-46b0-bca3-259af7528675" xlink:href="exel-20220930.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_4abbef97-4a4e-46b0-bca3-259af7528675" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_de416b26-dfe9-4f9e-9270-c430161e701d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_de416b26-dfe9-4f9e-9270-c430161e701d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3c2c4238-05fe-4190-aad1-132294fad31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3c2c4238-05fe-4190-aad1-132294fad31e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a7c7c6b0-3672-436f-894a-656cc9029a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a7c7c6b0-3672-436f-894a-656cc9029a38" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a45347d9-ecf0-499b-bea1-4c6c74e08771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a45347d9-ecf0-499b-bea1-4c6c74e08771" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e7f32616-1d1c-4c0a-b47d-b2bab4c71085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e7f32616-1d1c-4c0a-b47d-b2bab4c71085" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf9fcc1-e1cc-4d5e-a7ad-92b411da408c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf9fcc1-e1cc-4d5e-a7ad-92b411da408c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_95b47178-519e-4c91-be70-56c03397eb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf9fcc1-e1cc-4d5e-a7ad-92b411da408c" xlink:to="loc_us-gaap_AwardTypeAxis_95b47178-519e-4c91-be70-56c03397eb3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95b47178-519e-4c91-be70-56c03397eb3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_95b47178-519e-4c91-be70-56c03397eb3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95b47178-519e-4c91-be70-56c03397eb3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b341b4e-2dae-4556-8820-5cf1b713c940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_95b47178-519e-4c91-be70-56c03397eb3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b341b4e-2dae-4556-8820-5cf1b713c940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e9ece991-a30b-4740-b0e1-49aa4fff4d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b341b4e-2dae-4556-8820-5cf1b713c940" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e9ece991-a30b-4740-b0e1-49aa4fff4d6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_627fac5c-b20a-4b04-aa2c-6d53a5130e30" xlink:href="exel-20220930.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_e9ece991-a30b-4740-b0e1-49aa4fff4d6e" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_627fac5c-b20a-4b04-aa2c-6d53a5130e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1560fb6d-1b83-4cb6-b43c-d98e21e85700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b341b4e-2dae-4556-8820-5cf1b713c940" xlink:to="loc_us-gaap_PerformanceSharesMember_1560fb6d-1b83-4cb6-b43c-d98e21e85700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_438d5809-0ef9-4b66-91d6-4945854d2783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf9fcc1-e1cc-4d5e-a7ad-92b411da408c" xlink:to="loc_us-gaap_VestingAxis_438d5809-0ef9-4b66-91d6-4945854d2783" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_438d5809-0ef9-4b66-91d6-4945854d2783_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_438d5809-0ef9-4b66-91d6-4945854d2783" xlink:to="loc_us-gaap_VestingDomain_438d5809-0ef9-4b66-91d6-4945854d2783_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7016848c-3012-4971-9104-ec772314078e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_438d5809-0ef9-4b66-91d6-4945854d2783" xlink:to="loc_us-gaap_VestingDomain_7016848c-3012-4971-9104-ec772314078e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e5f02116-f6a3-4e86-af13-6e5142379aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7016848c-3012-4971-9104-ec772314078e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e5f02116-f6a3-4e86-af13-6e5142379aeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_cad6ac7e-e997-4df1-83e7-c680b505fc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf9fcc1-e1cc-4d5e-a7ad-92b411da408c" xlink:to="loc_us-gaap_AwardDateAxis_cad6ac7e-e997-4df1-83e7-c680b505fc6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_cad6ac7e-e997-4df1-83e7-c680b505fc6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_cad6ac7e-e997-4df1-83e7-c680b505fc6e" xlink:to="loc_us-gaap_AwardDateDomain_cad6ac7e-e997-4df1-83e7-c680b505fc6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_32e73187-85bd-40cc-87e9-29909a2c10ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_cad6ac7e-e997-4df1-83e7-c680b505fc6e" xlink:to="loc_us-gaap_AwardDateDomain_32e73187-85bd-40cc-87e9-29909a2c10ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_Granted2020Member_d1df339e-436a-4dba-ac57-670b66210dce" xlink:href="exel-20220930.xsd#exel_Granted2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_32e73187-85bd-40cc-87e9-29909a2c10ed" xlink:to="loc_exel_Granted2020Member_d1df339e-436a-4dba-ac57-670b66210dce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended" id="i2a07e8df6cd9481c91638039f862925d_StockBasedCompensationEstimateGrantDateFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aa6871-14ef-40d1-b6cc-2d6a35f1a592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_1be1f374-9e55-4219-b626-7455779ac218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aa6871-14ef-40d1-b6cc-2d6a35f1a592" xlink:to="loc_us-gaap_SharePrice_1be1f374-9e55-4219-b626-7455779ac218" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_59b2bf12-7e50-4378-af6f-4563d5ba8616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aa6871-14ef-40d1-b6cc-2d6a35f1a592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_59b2bf12-7e50-4378-af6f-4563d5ba8616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_056aca66-0ab7-47f3-abc6-46549bec2423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aa6871-14ef-40d1-b6cc-2d6a35f1a592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_056aca66-0ab7-47f3-abc6-46549bec2423" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0614d17a-f09f-4fd6-a694-aa23bad8f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aa6871-14ef-40d1-b6cc-2d6a35f1a592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0614d17a-f09f-4fd6-a694-aa23bad8f6a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fbef674-a8fe-4d83-bd31-25d4cb90c76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aa6871-14ef-40d1-b6cc-2d6a35f1a592" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fbef674-a8fe-4d83-bd31-25d4cb90c76c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_814d0d67-96ce-4266-ba7b-6d2af279dc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fbef674-a8fe-4d83-bd31-25d4cb90c76c" xlink:to="loc_us-gaap_AwardTypeAxis_814d0d67-96ce-4266-ba7b-6d2af279dc71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_814d0d67-96ce-4266-ba7b-6d2af279dc71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_814d0d67-96ce-4266-ba7b-6d2af279dc71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_814d0d67-96ce-4266-ba7b-6d2af279dc71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_197cd947-37c2-4796-8147-a61481b38f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_814d0d67-96ce-4266-ba7b-6d2af279dc71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_197cd947-37c2-4796-8147-a61481b38f8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_5d6eeac1-a5b5-49e5-a1d0-8b168592b7f7" xlink:href="exel-20220930.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_197cd947-37c2-4796-8147-a61481b38f8a" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_5d6eeac1-a5b5-49e5-a1d0-8b168592b7f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="extended" id="i6320a077b76a4e2283f3dcaabe021cf5_NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38b3dd46-aee5-4de3-8900-209d6cb002a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4ac49038-fbfc-40dc-8f04-a0a3409a18f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38b3dd46-aee5-4de3-8900-209d6cb002a7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4ac49038-fbfc-40dc-8f04-a0a3409a18f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb539ad5-3fd2-4994-9d79-db1e89c7606a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38b3dd46-aee5-4de3-8900-209d6cb002a7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb539ad5-3fd2-4994-9d79-db1e89c7606a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e69b2e83-99ed-404b-ae8e-1da97b2d0db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb539ad5-3fd2-4994-9d79-db1e89c7606a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e69b2e83-99ed-404b-ae8e-1da97b2d0db7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e69b2e83-99ed-404b-ae8e-1da97b2d0db7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e69b2e83-99ed-404b-ae8e-1da97b2d0db7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e69b2e83-99ed-404b-ae8e-1da97b2d0db7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e75bbf6c-6879-49df-90e7-29688b1150a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e69b2e83-99ed-404b-ae8e-1da97b2d0db7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e75bbf6c-6879-49df-90e7-29688b1150a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_2d31a9d9-1b10-4d38-9452-dc7782360c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e75bbf6c-6879-49df-90e7-29688b1150a0" xlink:to="loc_us-gaap_StockCompensationPlanMember_2d31a9d9-1b10-4d38-9452-dc7782360c9d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i6c7781e884934faeac8f9dd27d73e1e8_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_80ac20a1-ab89-42b3-9ff6-b0a0667c6d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_80ac20a1-ab89-42b3-9ff6-b0a0667c6d33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4b257d93-3071-4dfa-b770-511531ff290b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4b257d93-3071-4dfa-b770-511531ff290b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_9af59be7-b0d6-4439-91e0-887077ef403e" xlink:href="exel-20220930.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_9af59be7-b0d6-4439-91e0-887077ef403e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9df61264-9fc6-4d69-850c-436dd3826cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9df61264-9fc6-4d69-850c-436dd3826cfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_78072aed-674d-4ef4-bc4f-8b028d3bcc40" xlink:href="exel-20220930.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_78072aed-674d-4ef4-bc4f-8b028d3bcc40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_46f5422d-b93a-47da-9376-00869ce437d1" xlink:href="exel-20220930.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_46f5422d-b93a-47da-9376-00869ce437d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_17b02606-f5f3-4faf-a4a7-85082b54e5d8" xlink:href="exel-20220930.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_17b02606-f5f3-4faf-a4a7-85082b54e5d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5a276d8f-4bfa-4636-a276-052701dbe8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5a276d8f-4bfa-4636-a276-052701dbe8a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2c0b1519-8148-4ff6-876e-3552e1803f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_OperatingLeaseLiability_2c0b1519-8148-4ff6-876e-3552e1803f49" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_31b60c0f-ef5d-47dc-9bb2-e039948d8e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_TenantImprovements_31b60c0f-ef5d-47dc-9bb2-e039948d8e7f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_d3f1e3af-b19a-46dd-a3a3-65a42016acac" xlink:href="exel-20220930.xsd#exel_TenantLeaseImprovementsAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_d3f1e3af-b19a-46dd-a3a3-65a42016acac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseLiabilityDiscountedPeriod_57a33da5-f054-4f8e-ba33-ee3aef7552c3" xlink:href="exel-20220930.xsd#exel_OperatingLeaseLiabilityDiscountedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_OperatingLeaseLiabilityDiscountedPeriod_57a33da5-f054-4f8e-ba33-ee3aef7552c3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a1d6018a-65f1-4811-81ef-39e31f491db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a1d6018a-65f1-4811-81ef-39e31f491db9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_1313552e-06e0-401a-8b18-102c779767f8" xlink:href="exel-20220930.xsd#exel_LossContingencyNumberOfLawsuitsConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_1313552e-06e0-401a-8b18-102c779767f8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_fa24f61a-1279-4a57-b691-ddd9798795f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_OtherCommitmentsTable_fa24f61a-1279-4a57-b691-ddd9798795f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis_84e40146-1c63-4f70-9631-ee49f06301f2" xlink:href="exel-20220930.xsd#exel_LeaseArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_fa24f61a-1279-4a57-b691-ddd9798795f6" xlink:to="loc_exel_LeaseArrangementsAxis_84e40146-1c63-4f70-9631-ee49f06301f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_84e40146-1c63-4f70-9631-ee49f06301f2_default" xlink:href="exel-20220930.xsd#exel_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_LeaseArrangementsAxis_84e40146-1c63-4f70-9631-ee49f06301f2" xlink:to="loc_exel_LeaseArrangementsDomain_84e40146-1c63-4f70-9631-ee49f06301f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_1b8a14ca-f884-409d-bcf0-63e846b5faa2" xlink:href="exel-20220930.xsd#exel_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_LeaseArrangementsAxis_84e40146-1c63-4f70-9631-ee49f06301f2" xlink:to="loc_exel_LeaseArrangementsDomain_1b8a14ca-f884-409d-bcf0-63e846b5faa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_657dd450-9287-4741-91a1-1d4fd37c7324" xlink:href="exel-20220930.xsd#exel_BuiltToSuitLeaseAndHeadquartersLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_1b8a14ca-f884-409d-bcf0-63e846b5faa2" xlink:to="loc_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_657dd450-9287-4741-91a1-1d4fd37c7324" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseExpansionMember_c5106e87-6802-4c30-8895-cf9586dbb033" xlink:href="exel-20220930.xsd#exel_LeaseExpansionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_1b8a14ca-f884-409d-bcf0-63e846b5faa2" xlink:to="loc_exel_LeaseExpansionMember_c5106e87-6802-4c30-8895-cf9586dbb033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3590a693-d7f0-4f08-81ff-86fe6710486e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_fa24f61a-1279-4a57-b691-ddd9798795f6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3590a693-d7f0-4f08-81ff-86fe6710486e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3590a693-d7f0-4f08-81ff-86fe6710486e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3590a693-d7f0-4f08-81ff-86fe6710486e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3590a693-d7f0-4f08-81ff-86fe6710486e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_058b7e59-9b5f-4bc7-966d-6bcb07bf587b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3590a693-d7f0-4f08-81ff-86fe6710486e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_058b7e59-9b5f-4bc7-966d-6bcb07bf587b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9ba41cd5-5e9c-4cd4-89ed-2829f7f39285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_058b7e59-9b5f-4bc7-966d-6bcb07bf587b" xlink:to="loc_us-gaap_SubsequentEventMember_9ba41cd5-5e9c-4cd4-89ed-2829f7f39285" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:type="extended" id="i0b8e0391d1414e4ebdf95a160941c662_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_c6789f6e-6d9a-4826-bc0b-337073625e63" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_c6789f6e-6d9a-4826-bc0b-337073625e63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_c8fd8f8b-207c-4458-8665-a3c7abaa6c5b" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_c8fd8f8b-207c-4458-8665-a3c7abaa6c5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_9c31f832-c0a7-4564-8e96-1862004af9c0" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementMaximumAmountOfWarrantExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_9c31f832-c0a7-4564-8e96-1862004af9c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_0ba9d328-94b7-44f9-8ab2-f28ff71a96c8" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_0ba9d328-94b7-44f9-8ab2-f28ff71a96c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_e66e5a97-282f-49b6-a85a-33e4b8fcd02c" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsExerciseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_e66e5a97-282f-49b6-a85a-33e4b8fcd02c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d88889fe-5190-4939-b4d5-e0807cc7c5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:to="loc_us-gaap_SubsequentEventTable_d88889fe-5190-4939-b4d5-e0807cc7c5dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_093dc4a1-397b-4d92-b8e9-1d753f540321" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d88889fe-5190-4939-b4d5-e0807cc7c5dd" xlink:to="loc_srt_StatementScenarioAxis_093dc4a1-397b-4d92-b8e9-1d753f540321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_093dc4a1-397b-4d92-b8e9-1d753f540321_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_093dc4a1-397b-4d92-b8e9-1d753f540321" xlink:to="loc_srt_ScenarioUnspecifiedDomain_093dc4a1-397b-4d92-b8e9-1d753f540321_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_21b3494e-01cf-4d20-be27-fbf24c3802b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_093dc4a1-397b-4d92-b8e9-1d753f540321" xlink:to="loc_srt_ScenarioUnspecifiedDomain_21b3494e-01cf-4d20-be27-fbf24c3802b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f0c67131-89ab-4cc7-b3e8-4ef84c305d8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_21b3494e-01cf-4d20-be27-fbf24c3802b7" xlink:to="loc_srt_ScenarioForecastMember_f0c67131-89ab-4cc7-b3e8-4ef84c305d8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a788cc78-97a3-46f0-94a4-c301dc6f15b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d88889fe-5190-4939-b4d5-e0807cc7c5dd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a788cc78-97a3-46f0-94a4-c301dc6f15b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a788cc78-97a3-46f0-94a4-c301dc6f15b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a788cc78-97a3-46f0-94a4-c301dc6f15b7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a788cc78-97a3-46f0-94a4-c301dc6f15b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee0181b2-e46d-4009-b4d7-275989c1c06b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a788cc78-97a3-46f0-94a4-c301dc6f15b7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee0181b2-e46d-4009-b4d7-275989c1c06b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CybrexaTherapeuticsLLCCybrexaMember_7f7696bd-b7ee-4874-9e41-d47ee86e0165" xlink:href="exel-20220930.xsd#exel_CybrexaTherapeuticsLLCCybrexaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee0181b2-e46d-4009-b4d7-275989c1c06b" xlink:to="loc_exel_CybrexaTherapeuticsLLCCybrexaMember_7f7696bd-b7ee-4874-9e41-d47ee86e0165" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SairopaBVSairopaMember_24e3ee61-3604-4fd9-968e-5a3d3bc7a84d" xlink:href="exel-20220930.xsd#exel_SairopaBVSairopaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee0181b2-e46d-4009-b4d7-275989c1c06b" xlink:to="loc_exel_SairopaBVSairopaMember_24e3ee61-3604-4fd9-968e-5a3d3bc7a84d" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>exel-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f874578b-aba8-4b11-9ee3-0aa3371a4a4f,g:18180dba-6dc6-4cf5-97a9-3c99224fbbee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_33ffb8ba-717c-4553-b41a-2d4d67110fe7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f87a21bf-4834-4b27-9f97-75ac5799fe84_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_33aea95e-0911-4726-a1a0-08c363f19340_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_61961f25-97db-462c-b00f-22b14b927107_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits on U.S. commercialization</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:to="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_f3f5f6b5-1d0d-4b67-bdd0-0424c18e0e15_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_549ccce8-b33a-4186-a2a4-4d3b40f2d098_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_70f43ead-e1d8-4a05-9342-43922b009ded_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_126f6f43-b341-450b-bc13-1d0ebbad84f2_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of lease property (in square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_1e5d98e9-05ef-4995-8408-461900c774eb_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products derived from other compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:href="exel-20220930.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IpsenMember_7c64accc-d774-425e-a313-717758c201ef_terseLabel_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Pharma SAS</link:label>
    <link:label id="lab_exel_IpsenMember_label_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_documentation_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember" xlink:href="exel-20220930.xsd#exel_IpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember" xlink:to="lab_exel_IpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1b588dc5-aa56-4f90-833a-667f8e50ac83_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_4412c562-a9dc-4c8f-818b-1752aa8f1964_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductOrServiceAxisAxis_3ef589f1-e067-4665-9441-2af3245be295_terseLabel_en-US" xlink:label="lab_exel_ProductOrServiceAxisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Axis]</link:label>
    <link:label id="lab_exel_ProductOrServiceAxisAxis_label_en-US" xlink:label="lab_exel_ProductOrServiceAxisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Axis]</link:label>
    <link:label id="lab_exel_ProductOrServiceAxisAxis_documentation_en-US" xlink:label="lab_exel_ProductOrServiceAxisAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisAxis" xlink:href="exel-20220930.xsd#exel_ProductOrServiceAxisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductOrServiceAxisAxis" xlink:to="lab_exel_ProductOrServiceAxisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_9f60fbdb-b5e1-4e5c-b785-d735469659ff_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OperatingLeaseLiabilityDiscountedPeriod_ad229e93-e0d6-48c7-8786-6596d7d0383a_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseLiabilityDiscountedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability discounted period</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilityDiscountedPeriod_label_en-US" xlink:label="lab_exel_OperatingLeaseLiabilityDiscountedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Discounted Period</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilityDiscountedPeriod_documentation_en-US" xlink:label="lab_exel_OperatingLeaseLiabilityDiscountedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Discounted Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseLiabilityDiscountedPeriod" xlink:href="exel-20220930.xsd#exel_OperatingLeaseLiabilityDiscountedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseLiabilityDiscountedPeriod" xlink:to="lab_exel_OperatingLeaseLiabilityDiscountedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_e6ed401a-c635-49e0-8c91-7022ae4c8d6f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_54cd47a6-6edf-4283-9112-a9a5e14eb820_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_e63492f7-bc4f-46aa-8ca5-802a77187f0f_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate development milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2894d96-aaec-4604-8323-c39f7a2845ba_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ae47c860-395d-4981-b743-691bde9fb37e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate incremental borrowing rate (in percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5e8b4c6-03cd-4ad5-9ad2-716c9d6869fb_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_8a73a222-9e51-42e8-9fd6-995f9d10c25d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_Granted2020Member_5c1b15ad-1084-45a7-82fb-e8295548170e_terseLabel_en-US" xlink:label="lab_exel_Granted2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted 2020</link:label>
    <link:label id="lab_exel_Granted2020Member_label_en-US" xlink:label="lab_exel_Granted2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted 2020 [Member]</link:label>
    <link:label id="lab_exel_Granted2020Member_documentation_en-US" xlink:label="lab_exel_Granted2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_Granted2020Member" xlink:href="exel-20220930.xsd#exel_Granted2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_Granted2020Member" xlink:to="lab_exel_Granted2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_2729215f-3294-4c97-88e5-ed11ecdb9497_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OtherLongtermAssetsMember_c6168373-5e3f-4729-95bc-bdbb372aad22_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember" xlink:href="exel-20220930.xsd#exel_OtherLongtermAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember" xlink:to="lab_exel_OtherLongtermAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_64e7ffb6-8291-41c9-841c-88bd6d6fe410_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_75a96b5b-f259-4d5d-8c3a-14b096781842_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_580a8a2a-4fc5-4221-a9e0-462064b59ca2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_34847121-bd60-4133-98e3-21a5ba2dfd77_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:href="exel-20220930.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_362e8b77-4d4b-4852-afc9-01ebaee5435c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b51130f1-0069-4a42-86fa-7cc6e7bcdc42_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0fb5a530-d05f-4a4f-940b-b2a874e8b802_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_a523d060-bafc-46e9-a1e5-039125d8973a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8e5d67b3-8b3c-45b8-aa9f-9b08cbf9b84e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_f636d1b1-9ea3-4e19-8b48-29e16fe79f23_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember" xlink:href="exel-20220930.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember" xlink:to="lab_exel_AllowanceForProductRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_540a1cb7-6b6f-4343-b91c-6c2b1a06598e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0dbd6a2b-e75c-4b2d-a85d-7805793e0d2f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_fdc4d863-29d2-4622-b919-361dadd4c13a_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_17e87034-4a38-4895-b1f3-7b593d5a4f82_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_1a318b83-2d76-458c-b40e-fd963c3e4215_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4800741e-6249-402b-87a2-955607edf572_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting award percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_7563e42a-f736-45f8-9920-ac7dbd275abf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_90511465-b452-448a-91ba-e7c2b8c94479_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_562173ae-2235-4482-b797-5615904dedca_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivative instruments, pretax</link:label>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_label_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Derivative Instruments, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:to="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_153a5680-8a0a-440b-bcd4-2e17156e45bd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_11bf94c8-a671-49c0-8c99-abbf3a632af7_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2bfd3c3a-f9c7-47a3-af01-0e23dab3726e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_835661bc-d34b-4619-9cfe-2e6c43c046c8_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate regulatory milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3edf35ad-f557-4a4a-aef4-783c9f4da7f1_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_1e6ba9d9-4a6f-4c8c-9c2c-22376fee2276_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5a8cac87-6afd-4400-9494-48e4e166bf71_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_de178428-fbf2-41e1-bc64-707fb768c4db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6851a61e-0709-45b8-a37f-505d8818d802_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f4cb247c-e965-46cc-9a7f-d3e3e271f917_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_e4fee809-3230-430c-ba61-03dd87e514f8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_46fbd28c-1065-4c6a-9ac0-fb62a165625c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationMember_b4cf22b2-0f9b-4cf1-8b0d-6792a1a7bdf7_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_label_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_documentation_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember" xlink:href="exel-20220930.xsd#exel_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember" xlink:to="lab_exel_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_eb2a5238-906e-4cc2-8221-02aaf1d62ef6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5075502b-6924-4ce0-be24-897b516d5837_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0b8f5014-f273-4d5e-b46d-1e721259540b_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bf4aec72-ecdc-4387-88f9-a4ef9364fc61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_afcfca61-8a07-4f4c-b6f7-a730cac7c0f7_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional development regulatory and commercial milestones payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development, Regulatory And Commercial Milestones Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development, Regulatory And Commercial Milestones Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_7c0a0ef3-d42d-415b-867f-6508c52e356a_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_13d15ed8-c33c-41af-972c-79b87de785e8_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0c25d7f8-cdae-4f2d-986d-33b79e8af779_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d1aaac8-4f3c-475b-abb9-a2da1c2fbf1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e6ac0239-0952-4579-b39d-92690f98500c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4abfb4a2-981e-4421-aefb-4482c9d31b15_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0f68aedb-4231-44f3-b4d0-71e7d25508fe_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86b7bc2c-fa9c-4088-8b1a-0db78e44e9c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_f6151d07-ce77-48ba-be8d-44334caf623e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_61331e5c-d5ea-4666-afff-2bf14965865c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_34b3b9af-bb93-45b4-9cdc-315b9f9f96e2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_9c3ecac9-d658-4e37-8705-fc6559503e24_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7911a3fc-6bb3-43dd-98c2-6c5e96907879_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_778c0c31-0487-4047-8f2d-bb5a13be125c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_1867fcac-2b7e-4007-a684-ae83732226ea_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d2d8137d-c0bc-40d8-a6a5-b3273618f5b6_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_2d28e0c9-22e6-44d0-aff3-063636e99655_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after stock option or stock appreciation award (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:href="exel-20220930.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_aead458a-ef62-4b6d-bcad-2fcbf7134fb4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_53a7e840-2aab-4692-869e-fbddc4c270e2_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:href="exel-20220930.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d00f0558-4227-41e1-8c3d-2be465fa403c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_2ec64c4c-37fc-4fb2-b06b-92321f0015f9_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:href="exel-20220930.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_d5d2ea86-6897-48ee-8515-d4ab595c4895_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseArrangementsDomain_a365e58b-62c2-489b-b941-6754ec477664_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_label_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain" xlink:href="exel-20220930.xsd#exel_LeaseArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsDomain" xlink:to="lab_exel_LeaseArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyalPharmaMember_3ccb3bd7-3a66-4678-86e2-fe5e593069f1_terseLabel_en-US" xlink:label="lab_exel_RoyalPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharma</link:label>
    <link:label id="lab_exel_RoyalPharmaMember_label_en-US" xlink:label="lab_exel_RoyalPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharma [Member]</link:label>
    <link:label id="lab_exel_RoyalPharmaMember_documentation_en-US" xlink:label="lab_exel_RoyalPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyalPharmaMember" xlink:href="exel-20220930.xsd#exel_RoyalPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyalPharmaMember" xlink:to="lab_exel_RoyalPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_08240fdb-f130-4895-80ed-eab026a95de6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_05167e2e-6f16-4d92-adff-6233579cfdc3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_04afbe97-c72e-4094-aba0-81a88488d8cc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_50d073de-e030-4270-9f64-4e7c19f0c789_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_b7a2f017-98d7-4bed-ba5d-4f06e636e60f_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base rent, lease not yet commenced, annual percentage increase</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:href="exel-20220930.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_501badf3-29e0-4096-b6cf-15bf3e9e145c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_6ac10a60-c813-48cc-9955-e80a0e0a1657_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_4ed67648-bb6d-4e7e-8c33-f926ef5b4904_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_61325fa7-e87c-4ae7-82ef-b28ba44d1b64_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b7093f44-6277-4181-b22f-6833a8e5e87a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_30d09c5f-8bd5-4581-b9e5-7a5cc2068d77_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_4687416a-00cd-470c-8cbe-8f89c00af808_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_79f62f23-6f4e-4a84-b770-fd118bfcc400_terseLabel_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</link:label>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_label_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member]</link:label>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:href="exel-20220930.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:to="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_2bf2bbd5-ded9-43ce-a9e8-7dea6e4be7e7_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3697c6e5-a3ab-4be1-a4da-2123b382c9dc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_bc907a56-0a5d-4e15-afc6-35a4a4af714c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_26b33e6d-f382-4767-a51c-cd12d2489bce_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:href="exel-20220930.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_484bed6b-cb3c-4be3-a4d0-84d43b6bf6ca_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f21b1d9b-79cb-4a74-87e7-21e9d385b1a5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4a6e122b-d104-4a3a-b5ad-a9a9b4ee0698_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_d410c9d4-fece-4c34-8579-bab615457b43_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_fe8fdb67-ec0a-4d2c-bdbb-027b61e643b3_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_7e682553-4372-4b0b-ac8e-4abee331ee15_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_6ee25e10-6444-44d6-a028-7a82d67a6420_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberOfBondSecurities_d95e9674-8fa5-4679-a029-1a712c196b97_terseLabel_en-US" xlink:label="lab_exel_NumberOfBondSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of bond securities</link:label>
    <link:label id="lab_exel_NumberOfBondSecurities_label_en-US" xlink:label="lab_exel_NumberOfBondSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Bond Securities</link:label>
    <link:label id="lab_exel_NumberOfBondSecurities_documentation_en-US" xlink:label="lab_exel_NumberOfBondSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Bond Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfBondSecurities" xlink:href="exel-20220930.xsd#exel_NumberOfBondSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberOfBondSecurities" xlink:to="lab_exel_NumberOfBondSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0fdf2c10-1834-4b2c-8760-98beb61db571_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_02913495-5c2d-429d-8aba-2adf7e53eed8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_5d652ed5-1fd5-4ada-b05e-beddbbafedb8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_b6499a0a-1f48-4987-a86f-c4c4c1a62c80_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4a1cb644-dccc-45aa-aa4a-03a52b156ad6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_56f8f099-4882-4f07-9416-74477504cf10_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0b584a0e-b099-4eab-91f0-40a9cb98bbcf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NoncashLeaseExpense_a1dfd844-2850-48dc-939b-d248e91f7f01_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense" xlink:href="exel-20220930.xsd#exel_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense" xlink:to="lab_exel_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0e74423d-becd-4e2e-99c9-0b919bd643ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c090ebb7-bd1a-4177-a23a-f2bc82a5fa0b_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_796b794e-3f01-44c1-b393-21e76d39baf6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_48f2f46b-27b4-4d26-8948-fbcc4bc13f94_terseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inclusive of operating lease liability</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_28fe710d-a781-4d26-91fc-6183c731fb10_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e5c8e685-cbb9-49d4-a935-7ad32b05ab93_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6ccdc51f-76a8-4049-83d7-27d4cdf64be7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_512fc691-3042-413e-ba1d-23e19a3d0db4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5cf62249-c5ef-42c3-b507-b7d929aa3fa7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_8b181a16-58e9-4774-a352-eeeabaa394e4_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7224a5da-080d-496b-911e-e92a48555a94_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_16cc8c05-d962-418a-8c8b-cf1992bca519_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_4d1dbb5a-977a-4be1-9dc0-75c9c4032380_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Company's common stock on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_d5ebb10f-fd22-468c-af10-92ee292ef12b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_dc2a4a5b-1e89-49b9-9420-819e81423b42_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_07b434f6-13c7-4685-9766-b98c7dc2786e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_0a68eea8-1ec7-4d20-8de9-e69056e3a7d5_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_368cbe50-b495-49f2-aae9-3ca980596e0f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_a2fc593d-2dc4-43d9-8ee5-946cf25b0dd1_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_fe4d652a-c9c2-402b-8016-f2a90974c39c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4a1cb0ea-abbd-4b1e-9414-47a3c4c2f458_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b24660d7-ff60-400a-8551-6122f6447c19_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cfb87cbd-6931-4595-b2c8-946d6f8c7665_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_f429b8c4-f597-4f11-bce5-faefdffc9b5c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e9201236-9d25-4f26-ada5-34249784f846_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9803a189-633d-4e55-9817-d64edd704a21_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ec50d0a3-725a-45d8-b403-82f8d364c2df_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_64db6d1e-a841-43ae-bae7-2811e3022b34_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_1a592e8b-d1a1-4993-8f26-0b4039a04d59_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_e83c13ec-434e-44d4-a8b9-9f9469f8e2bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SairopaBVSairopaMember_2d902cb0-b366-4752-9a52-0a0437f13132_terseLabel_en-US" xlink:label="lab_exel_SairopaBVSairopaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sairopa, B.V. (Sairopa)</link:label>
    <link:label id="lab_exel_SairopaBVSairopaMember_label_en-US" xlink:label="lab_exel_SairopaBVSairopaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sairopa, B.V. (Sairopa) [Member]</link:label>
    <link:label id="lab_exel_SairopaBVSairopaMember_documentation_en-US" xlink:label="lab_exel_SairopaBVSairopaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sairopa, B.V. (Sairopa)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SairopaBVSairopaMember" xlink:href="exel-20220930.xsd#exel_SairopaBVSairopaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SairopaBVSairopaMember" xlink:to="lab_exel_SairopaBVSairopaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1a95c97b-1ac2-491a-8dfc-45992aecea6a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a86a3bd3-8100-48eb-ac6f-354657590c02_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_1a3931d6-3578-40b8-b1fe-7508c0ff324c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_aa22e828-8784-47c7-9b24-f4e4d56df714_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in share reserve under 2017 plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_36b56f57-0aaf-4f52-b910-ea9839f14c73_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROVISION FOR INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_4476c99d-f54a-4009-aa06-23dbf352ad2c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ed66ec79-bd83-4c8e-916a-427fc1c12334_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_690ba243-e305-4ebe-b193-1bcc22a4048d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f3907300-ce9d-43ed-8b51-92eb3adf3d6a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_b6cffd24-4919-4224-ad1b-d8b55796a939_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_694f5c72-1d75-4af9-8e2a-1ab287f3bf7c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_79d299d9-fcd6-468b-8017-c358f4675b79_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1f01933c-ebcc-4c30-a2b7-b626378e9ba1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_116f7e42-488c-47a6-8d0e-4590073d3070_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_5100b0fd-c0b1-471b-ab9c-d54bb080d09d_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_7097592b-f321-4270-ae45-53fe8be09687_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_110ebee4-1a84-4c11-bce5-6aa36d517b25_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_a82b241b-90ad-48e7-b486-a86ace17641d_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to exercise, amount</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Exercise Amount</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Exercise Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsExerciseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9025dca2-dd02-450c-aebb-2630d3f5c41b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_413ca92f-e12a-4b21-aca1-791644793b5e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b8ab107f-7e24-408b-b2aa-da7078982283_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_f1c21f63-392f-4943-b194-1476cb5df529_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_69d4db5f-5691-4b26-b984-494db33c0b69_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_bb37efdc-062f-4832-8822-21aec94fa604_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:href="exel-20220930.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_10984ca3-a0ee-4855-9131-acd7206a9888_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6393ee3b-9bf7-4495-ab9a-d0a0d0228b97_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1778cad7-46f6-4fe5-83f1-be17edd52a8c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_518eb7b4-1a79-4b27-adb1-1c6e7b7677c4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_65f818af-318d-44a1-a377-6ed43b75c81a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive plans and stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_25db2ba3-6a94-45de-84f1-2e6a1c1e3629_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend the lease</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="exel-20220930.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_18f6cc1c-9f46-406e-9e15-04deb8774961_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_09142386-7878-400b-aaa2-01295b621e02_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_e6f37251-ec6a-4680-a411-328b00fa0584_terseLabel_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_label_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_documentation_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TenantLeaseImprovementsAllowance" xlink:href="exel-20220930.xsd#exel_TenantLeaseImprovementsAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TenantLeaseImprovementsAllowance" xlink:to="lab_exel_TenantLeaseImprovementsAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_2e6caf2e-bf52-43f6-a31f-c87f3f7bc884_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_cd1dc46c-ecee-4fd1-83b9-5d8ea8079ead_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease option to extend period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_615298fb-2c9f-4c99-bef8-2d1b4768cf0e_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_4ff7657c-7156-40c8-9174-1c152612529b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_58affa5d-991e-4888-bf09-93261e1bfa15_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ae013c59-3262-4429-9276-0c5c05aa8f8e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_6abfd4a1-a4df-467c-8f5f-88d0f52f50f4_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CometriqMember_d0d5797c-0723-4432-bf31-1fa30f32d966_terseLabel_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_label_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_documentation_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember" xlink:href="exel-20220930.xsd#exel_CometriqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember" xlink:to="lab_exel_CometriqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_abcf8abe-f026-4188-8ab3-47a6220a5091_negatedTerseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_ea5b5e52-4947-46ab-96b6-25d3c23e069f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues Disaggregated by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5ff70b47-3574-4bc5-9bca-6db9acbac691_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_f5b89c02-750a-4b30-ba6e-4d4e516a929b_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_1b01156d-26c6-4318-80c9-a76bdf1a7a1c_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_72c2b0d3-3786-4bef-b95b-c4c47538ffb4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_53f6e4fd-b700-4d55-942c-27efa6abe9eb_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_3eb0f677-5f55-4dba-82a4-f43fd01ce33a_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting from discovery efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:href="exel-20220930.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d3291a1e-30f3-41d0-aee2-47e00bca1a98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_9e4c4ce4-d50c-4ae7-88c4-22f0d5c69798_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6c353260-9d37-4142-a29a-f2126821185b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_018e0aab-09a0-43d9-b3a7-1a3cd8cce027_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseExpansionMember_3f29fc93-d6bb-451e-8b11-84aa3ec6947e_terseLabel_en-US" xlink:label="lab_exel_LeaseExpansionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1751 Expansion Space</link:label>
    <link:label id="lab_exel_LeaseExpansionMember_label_en-US" xlink:label="lab_exel_LeaseExpansionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Expansion [Member]</link:label>
    <link:label id="lab_exel_LeaseExpansionMember_documentation_en-US" xlink:label="lab_exel_LeaseExpansionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Expansion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseExpansionMember" xlink:href="exel-20220930.xsd#exel_LeaseExpansionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseExpansionMember" xlink:to="lab_exel_LeaseExpansionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02c8132a-7287-4948-b72b-6e7113907c62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_833bbfa3-5ed4-4447-b1e7-9970254d6369_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3e220922-a672-4dfb-840e-bbdb3069b566_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_2ac0d9ac-b4cf-42da-bc5a-54bc578cdd5a_terseLabel_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries with drug approval, excluding the u.s.</link:label>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_label_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries With Drug Approval, Excluding The U.S.</link:label>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_documentation_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries With Drug Approval, Excluding The U.S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:href="exel-20220930.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:to="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductGrossMember_2ac5d11a-6723-4da6-b764-82c484f70d9a_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_label_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_documentation_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember" xlink:href="exel-20220930.xsd#exel_ProductGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember" xlink:to="lab_exel_ProductGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_fcfed604-c0b8-4053-8ec9-49399f4a4136_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e68e507b-7685-440c-ab18-642b93bfbccd_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_2fe34eb6-586a-48e6-a9a5-06e0daf632d8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_84e7a99b-73dc-461f-a1db-d21e9734391f_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_c0b78324-5431-4117-9889-8c2e9317ca77_netLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9c49b069-c11a-49af-b07a-f59d3a9c82a0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_e0188c51-2b6f-4a93-ad52-ce52c95e6857_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5779d429-8f8e-435e-8fc8-f9a6c5ef9dcd_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_21c6d918-e7c3-49ae-8139-d26373be3d4e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_374ea0a5-6968-4ae8-adb3-9e5cd218e24e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_7eeb6c36-7fac-435b-a67c-bf03bb3575f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_b09eaee5-160b-4a05-8bbb-354995fbec8e_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, upfront payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a491ec47-2c1b-4a92-b50f-0f1d02e68da8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_53edbee3-c2dc-42da-99a5-eb114fb3c3ca_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_89a0cc26-0e64-4430-99ad-aacb6a36b5e8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_28af8b42-0bb6-4c85-9b6e-96bc8a289f0f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d9044f23-a800-4f9f-aa94-fbb1ee617ce9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d020e820-384a-49e9-b390-7d2a6d4ba618_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_359d0771-6266-4745-a479-b701cb59f330_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_8b1a292d-cd11-44d6-b795-699504a4dc9e_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_bc559927-d09a-46df-a928-c88fa4ca80cc_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_e6f8e3ce-f9b6-4f89-9a0f-4c3702f8fc94_verboseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_e8d04bb2-be27-4c11-ac30-40cd318845bc_netLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_9a40b665-2f39-49fe-8671-7ea65ef1f3e6_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e62dd1cf-e576-4195-b832-6d083ffffda4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CotellicMember_c31501f5-2df2-431a-a7ec-0b4c61b30faa_terseLabel_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic</link:label>
    <link:label id="lab_exel_CotellicMember_label_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_documentation_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember" xlink:href="exel-20220930.xsd#exel_CotellicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember" xlink:to="lab_exel_CotellicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_00623993-ad25-4fe4-aa1e-0653c65b8268_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0a6ae6a0-3b3d-443f-bae7-30eeb32f6813_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b5a87641-7c53-4088-af48-a4e02135a74c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_4bc133d1-0d2f-4ca8-bdf9-ce9d9a041a0a_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_158194bb-b4c8-4c14-96b6-bdd56c0c0f66_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_71369f98-9359-42e2-a28e-d763f83f4ccc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_5b59b400-8e42-41c6-9e54-4cf0ae05b962_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_dfe5a153-1888-49cb-9704-4279d8b9d60f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3dcc30cb-3002-41d4-ae80-dacf22348af5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_98b46e40-fd5d-4f78-bfdf-9704e6814e7d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d63b385b-21e2-43bf-8213-196c8afa8d14_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_230c2c37-226a-437d-ba5f-4c07b4bfe143_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e1517419-537a-4df5-89bc-8259158b0b7e_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ffbbac80-aa03-4149-9549-89151889a647_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_32289aa7-f14a-425f-9b1d-663a8374e5fa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred in asset acquisition</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_1e6a1ba9-2e43-46d8-9ab4-1569fa754b49_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:href="exel-20220930.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_6f1bc992-495f-4925-87f6-280342a2b51d_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue recognized, including revenue from deferred revenue beginning balance</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="exel-20220930.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c919c714-7462-4acd-8403-ab2c74b7de60_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f759d36f-fb61-4b4b-9d64-659167060981_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_b0c3179c-d9d9-4e66-b7d7-1cb7f8481e83_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_fa759232-93c3-42d4-82e5-9e8bd44ebb88_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_81c04a22-aefd-487e-ba34-2936e0ee9bfc_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:href="exel-20220930.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_88b38d1e-aa1c-4548-9d70-246faace0776_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 322,541 and 318,842 at September&#160;30, 2022, and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_66d179e7-0657-4cd4-8406-8235c25840bd_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:href="exel-20220930.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_b4d200ff-1d1c-497f-a362-f03cf12578f8_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:href="exel-20220930.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_73ee36cb-b77a-43e1-9ba7-6a2bc363d7fb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0781821a-f004-49d3-a895-7ec6d1c00ede_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_b72a7be5-09a7-4da4-859f-a7d1a2eb43ab_verboseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated monthly base rent</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:href="exel-20220930.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_8735a740-8713-47d2-956d-7c1f650f5095_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_acd22abb-c9b0-410c-b878-4cc400d439c4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5dbc0e0-c49f-47d9-b152-19427b2286b2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4f355583-f36e-4d2e-a80c-fd734b20b86a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ca7dbfaa-264a-49d4-9fb0-00b19090d73c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_323fc815-5121-470e-ae00-3611916e7496_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c9e1ef63-37ad-4175-91ca-980b97b46c49_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income, Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_c4963af8-0e98-4cf3-b20d-529fed4f6d05_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0cd0ce05-f25d-400d-b33b-7cfbde2b7f8f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_8a1dd081-5a15-4a9b-8818-094c55237c76_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_147b8eee-854e-4f19-a28b-52ec19a228cf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_ac4e146b-116c-40f2-823f-a4eef558bf84_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_037f535b-9123-42d0-b620-47b74fd169e2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_cc5501d3-3702-4348-b69b-ec5abb42c6aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7eee7419-9ffd-4fc4-9ebc-d19ef4bb5c14_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b31be7b1-70ae-4ab4-abec-e2a242d688ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7b14846d-1160-4de0-8caa-bf30cf7e6d42_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d9d7ff19-9a71-43df-99b3-7521cf5abfbf_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_122d036c-283f-4108-abbb-d63db948707d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_632b7cbc-80a4-4e30-9e8e-b0b85d0a2988_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_526be95f-03a1-4951-80d6-0d33867a4ce6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7a3d9a7d-f2eb-4393-ae47-583a90261fa0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_75bed37b-b1cc-41fc-b7bc-5f97faf54a4a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_70890e57-f3b3-47d2-8762-d6cb9e66ffff_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_42c342c0-0e64-432d-b2c1-8f567f1652b2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_92ef1387-759b-4612-b0c5-b68df4ca8c4f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_0af9eb98-1d77-4ef7-8a4f-f87546360757_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Collaboration Liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Collaboration Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:href="exel-20220930.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:to="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_de04eb12-59e6-4279-ad85-384f77a71c14_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_291a6f89-18c6-40f7-a9e2-7f709fb888ac_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_8c844168-1ef6-4170-91c1-0b8576c4b048_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CybrexaTherapeuticsLLCCybrexaMember_7115bc90-5b5e-46fe-a9af-341cf55a5df1_terseLabel_en-US" xlink:label="lab_exel_CybrexaTherapeuticsLLCCybrexaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cybrexa Therapeutics, LLC (Cybrexa)</link:label>
    <link:label id="lab_exel_CybrexaTherapeuticsLLCCybrexaMember_label_en-US" xlink:label="lab_exel_CybrexaTherapeuticsLLCCybrexaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cybrexa Therapeutics, LLC (Cybrexa) [Member]</link:label>
    <link:label id="lab_exel_CybrexaTherapeuticsLLCCybrexaMember_documentation_en-US" xlink:label="lab_exel_CybrexaTherapeuticsLLCCybrexaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cybrexa Therapeutics, LLC (Cybrexa)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CybrexaTherapeuticsLLCCybrexaMember" xlink:href="exel-20220930.xsd#exel_CybrexaTherapeuticsLLCCybrexaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CybrexaTherapeuticsLLCCybrexaMember" xlink:to="lab_exel_CybrexaTherapeuticsLLCCybrexaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4a468a20-a33d-4c71-b278-42b98a1c6e95_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fe5e19e3-2979-4ea4-a885-9891adad6fb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ContractWithCustomerMilestoneRevenueRecognized_36111f96-a962-46db-a2ad-053f99b11f32_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerMilestoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue recognized</link:label>
    <link:label id="lab_exel_ContractWithCustomerMilestoneRevenueRecognized_label_en-US" xlink:label="lab_exel_ContractWithCustomerMilestoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Milestone Revenue Recognized</link:label>
    <link:label id="lab_exel_ContractWithCustomerMilestoneRevenueRecognized_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerMilestoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Milestone Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerMilestoneRevenueRecognized" xlink:href="exel-20220930.xsd#exel_ContractWithCustomerMilestoneRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerMilestoneRevenueRecognized" xlink:to="lab_exel_ContractWithCustomerMilestoneRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_e1a50f45-b54b-4eb9-a66f-90ffdbdf06dc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a5770d90-d228-42a7-b99a-fdda47a6d8d3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73df67f1-910d-46d6-994c-b462b334703b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_663a72ab-2288-497b-8ba8-f3239e0b912f_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket" xlink:href="exel-20220930.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket" xlink:to="lab_exel_NumberofProductsinCommercialMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b75754e9-945a-4b1a-940c-cdcf8b482f99_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0edcd338-8b24-4d61-b10c-2929f8a6783b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_195f1935-6bac-49ba-98a1-f21a2fafa81b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductOrServiceAxisDomain_6f50a16f-9955-4aad-80d4-625619f140d5_terseLabel_en-US" xlink:label="lab_exel_ProductOrServiceAxisDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Domain]</link:label>
    <link:label id="lab_exel_ProductOrServiceAxisDomain_label_en-US" xlink:label="lab_exel_ProductOrServiceAxisDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Domain]</link:label>
    <link:label id="lab_exel_ProductOrServiceAxisDomain_documentation_en-US" xlink:label="lab_exel_ProductOrServiceAxisDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Or Service Axis [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisDomain" xlink:href="exel-20220930.xsd#exel_ProductOrServiceAxisDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductOrServiceAxisDomain" xlink:to="lab_exel_ProductOrServiceAxisDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5a840763-e6d9-4a31-98df-eb6e38fee4a2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_cc9f6187-58ba-44ea-a217-b927ed00f0c7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_50edb046-e1aa-4d7a-8b0b-f140477ea667_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_860305c3-3b9c-418a-b989-26429327d22b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_73d49dd4-5227-46e9-97e0-d87f0abad622_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_347963f1-c286-42c7-ab30-95aaa46c1285_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c1e79e24-5000-4508-be55-04df9a40887e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CabometyxMember_74664687-ea2b-4d25-8c66-d908b8335514_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_label_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_documentation_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember" xlink:href="exel-20220930.xsd#exel_CabometyxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember" xlink:to="lab_exel_CabometyxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_efe517c3-6d45-4424-9491-5e0c44ccb394_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_ad3d9eb0-a1cc-4f6a-9abd-e9b18ac0bffb_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after all other awards (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:href="exel-20220930.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_976002d2-28b8-4cc6-acd1-d79c67c6318b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b60ddcd6-19e0-4703-9475-1d68fcf00044_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_74adfc1d-38a9-45e1-ba58-1aac375df080_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_dc3aa091-4847-4b99-8853-5df8d7891efd_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b19e5d57-a61d-43d2-94e3-653d6e562ba0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_44f8dedb-1672-4ed1-b2d8-7b17ada9f4be_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9f26e53b-5d15-4b9f-8a4c-f4ca6998b2fb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenues recognized included in the beginning contract liability balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fc72db73-b0a7-4685-8bc1-ef028187a5b1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_a57f73c1-fdc4-452d-94f9-5811e873e01a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_375c75de-8f38-4684-9a89-c8a76e727b5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_5e0e803e-7192-4a79-960f-1e95f08f523c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_c826a830-4410-4fc4-8250-eb63150398fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0e6d277b-ed2e-4a3a-92d2-20a1691a7c4e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_0f036c95-170a-4088-8d67-9f209ac07e2c_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:href="exel-20220930.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_da4a6a74-a6cb-4e5d-b35e-b6eea1f6691e_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_34ee3faa-6e41-4186-947e-bd5ffe234cb9_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration Risks</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_dec17989-9d2a-4437-8db6-151ff2ad25ba_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:href="exel-20220930.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a6d1335b-21c9-45d5-aa1a-1049412b29e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8b742004-38f5-4d5e-bc2a-33eeaa7f91a4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_da4c07cf-2b33-4773-ac1e-c04ed2bf5bbe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_6a319cad-7659-4e53-953b-e6f4810ad321_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_4bc6b781-6371-4a08-af3a-00fe2d0b16f2_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_f6c2f6a1-9b4f-4609-9022-c29e9a250361_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to terminate lease (after period)</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:href="exel-20220930.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:to="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_4a6b8a38-51dc-405f-8380-d8dbb960b7d7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_26154c59-6354-45fb-a9b5-df4e71838369_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts for Prompt Payment and Other</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:href="exel-20220930.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_c43b6f29-7390-4e2e-a3a7-31c4313f902f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_15ad4aaa-9e14-416b-a625-87a40be79fc4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_083f36d2-ae91-4493-af66-53fb8e8b855c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_0677b5fb-6dd9-4712-b80b-22e9ea3b2df4_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:href="exel-20220930.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_6373b51d-4fd6-4de1-9cc1-d5629be1f63a_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:href="exel-20220930.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_db623f3d-d4f1-472d-a455-fc3597b52ec2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_aec5fb84-7bfe-4767-bf53-131948c8e708_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at September&#160;30, 2022</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_26d50875-4c80-4114-8ff9-ed28c8d7c2c4_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e8098fca-40f8-4f7c-826c-91ed2c421273_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_5db5abb4-8039-4c0d-94a4-c65b76271689_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_950d295b-225e-47b5-b2e4-bcb2119aa4b6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_35a5ec12-e7b4-45c2-9f06-b3713b037234_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d8112ceb-f4dc-4f4f-98c5-9460cfa9aef2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_92a7b0cb-ee5e-4176-8ef0-46a6a499decb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_8dc5376c-7b6a-4e12-be0f-77e115042c9a_terseLabel_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="exel-20220930.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_bc0205b3-5aae-4015-a2c9-cce64c19d5ca_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_dcc4cc29-be45-4765-9fed-289ea7facc41_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c840a3fc-9dca-4d20-82ba-aef40f76c36c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_89ceff32-d940-49d2-8aed-5384186a7c5e_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_153ac579-bcd1-4191-b3e6-a55d9524ebef_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e675c9d7-9beb-4108-bc6c-cbb6a80556c0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_adf5e6fa-c99c-466b-af95-bf8ce46119cd_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_ccb61fca-f73d-4301-9878-c546d2d6fe09_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4f3ca456-e111-46d7-9c02-e21bfaa10d8f_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b66523b2-bc3c-44bc-9410-ae750b3b4773_netLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_adf343f3-f000-43c1-846e-a37da5f2e484_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_aa686ef2-1d9d-491c-867e-b8406ff6d265_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f605f12b-fea3-433f-8365-59a494b1bc19_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c488183a-5dd0-4e51-86cd-4378a98c3ce0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_8acba8e7-2b9c-4a0f-bad8-24f41ffd1134_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_3a1192ad-fcff-4509-b020-5489f936b2b4_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_018afc88-2e9d-485b-93ef-17b1ce4dc893_netLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_6926eac2-087c-4094-a84b-36b31b426360_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_87955084-1d81-4ea4-ac8e-f9480c9284f6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_34a2ffb9-46b9-4503-a499-8372f7496500_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7e778aea-7fd8-4c27-a741-d428e9e552f7_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0fcfde03-b888-48b0-beee-181a46f5ecd1_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues on ex-U.S. sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_f88cb99b-3cd9-4291-8b9e-e82674debd4d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_0d0f22cf-84c8-4271-9185-9edc53bfbffa_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ef3f27ee-4efd-429b-b009-a228509cd038_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0c2a0e46-09cf-43df-8c33-1e377c905d93_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_eb54ca32-8564-4f33-b968-c87421f16997_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_6460e8fd-7858-4be9-8e5a-e02cf56d0daa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_2b97da0c-367b-4a1a-99bb-08b4bd17b9fb_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_73c1e0a1-242a-426a-bbab-6fb6b81ca27d_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_b519f813-79dc-4691-ade2-c10a244f0b78_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential to vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:href="exel-20220930.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:to="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_06bf6fb6-b575-4fe9-ad40-8e025ac76373_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_e773b1ae-24d9-4a2b-834c-978d73050374_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_bd42ea1c-bd31-47d4-ba81-6c58c6de6597_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6d423093-063e-4980-8830-4e91455765ab_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c4859458-3f7a-4187-80e8-a6e155ebc982_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_7b38e75d-e8ce-4658-9806-042f14a37536_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_3756e4f1-0461-4ad6-b50c-816177f298a3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb52b457-b863-4429-a7fd-c922878e0916_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LossContingencyNumberOfLawsuitsConsolidated_926a9688-5fee-4767-974c-972e5c54df4f_terseLabel_en-US" xlink:label="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_exel_LossContingencyNumberOfLawsuitsConsolidated_label_en-US" xlink:label="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Lawsuits Consolidated</link:label>
    <link:label id="lab_exel_LossContingencyNumberOfLawsuitsConsolidated_documentation_en-US" xlink:label="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Lawsuits Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:href="exel-20220930.xsd#exel_LossContingencyNumberOfLawsuitsConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:to="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a1d0cdc3-204b-486b-ada0-0af8a1c9ed74_negatedTotalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5475e3e6-97cf-432d-922d-fdd24901e8c3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_db5b5331-4611-4f66-838f-534dd50d2828_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_a6e67f92-32a7-4491-9906-bd581f350351_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_231e26f1-376e-45a8-9f9a-e50359acc3d0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5c75621a-49fb-4c89-9d8f-e05b7df691f2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income, Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_c240894d-ebff-4379-946b-63734e0cd6f8_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_95154ee0-7a85-4361-9e20-396f1206ef13_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cab65e91-bde0-4561-a010-2ca7c6da1c59_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_19db854c-0b46-46f0-b02c-dd279f48f1fa_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b83e4a20-e90b-4963-befa-d83f62fe74c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberOfRegulatoryMilestone_41c5d107-8965-4699-a089-f050e4049938_terseLabel_en-US" xlink:label="lab_exel_NumberOfRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of regulatory milestone</link:label>
    <link:label id="lab_exel_NumberOfRegulatoryMilestone_label_en-US" xlink:label="lab_exel_NumberOfRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Regulatory Milestone</link:label>
    <link:label id="lab_exel_NumberOfRegulatoryMilestone_documentation_en-US" xlink:label="lab_exel_NumberOfRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Regulatory Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfRegulatoryMilestone" xlink:href="exel-20220930.xsd#exel_NumberOfRegulatoryMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberOfRegulatoryMilestone" xlink:to="lab_exel_NumberOfRegulatoryMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_829eb641-2912-4bed-b215-7e7e1ca658a4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_d6885ee8-3468-4d53-b0fc-778e115eccb9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_93994d92-42d2-466e-9e54-3627a7537311_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_e3c7e3b2-5abb-4b36-a8c6-fef44cc19f10_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_d6ba4128-5b65-462e-92b0-dc825e8fdebe_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TakedaAndIspenMember_bbdab29b-9c3b-4638-91d6-b1348dee281a_terseLabel_en-US" xlink:label="lab_exel_TakedaAndIspenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda and Ispen</link:label>
    <link:label id="lab_exel_TakedaAndIspenMember_label_en-US" xlink:label="lab_exel_TakedaAndIspenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda And Ispen [Member]</link:label>
    <link:label id="lab_exel_TakedaAndIspenMember_documentation_en-US" xlink:label="lab_exel_TakedaAndIspenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda And Ispen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaAndIspenMember" xlink:href="exel-20220930.xsd#exel_TakedaAndIspenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TakedaAndIspenMember" xlink:to="lab_exel_TakedaAndIspenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_7286c810-c3b0-4302-873a-71731b722673_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_41d32b12-fa49-4f2f-8ec3-ac99bb7b7dac_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_9a6787f0-bd67-453d-acf0-87f9b18e24fd_terseLabel_en-US" xlink:label="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease And Headquarters Lease</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_label_en-US" xlink:label="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease And Headquarters Lease [Member]</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_documentation_en-US" xlink:label="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" xlink:href="exel-20220930.xsd#exel_BuiltToSuitLeaseAndHeadquartersLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" xlink:to="lab_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_32ca482e-ad86-44ea-9c89-6ab4a3634afc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_bb2fdb28-3a8c-4feb-8535-b2d97ee25cfc_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_e0ef4b6b-a539-4193-abcc-7fd42d364d97_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_554417fe-9520-4c97-b042-4282886e5cf8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_858ee8b2-48e5-4967-9a1b-086a80a3df29_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_db13aefe-f94e-4b6f-92ea-bac025e0dc90_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseArrangementsAxis_d258c25a-8c9b-465e-809b-7037513c4b4d_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_label_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis" xlink:href="exel-20220930.xsd#exel_LeaseArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsAxis" xlink:to="lab_exel_LeaseArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_8ef30d48-d6dd-4f98-be2a-c077814cbfd0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6308ec39-3e2e-499c-9041-77cd07828106_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized losses on available-for-sale debt securities, net of tax impact of $2,457, $193, $4,752 and $949, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8a0a460e-7833-4167-a66f-4adf8c5c3223_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_c76ded0c-8967-43da-b22d-9bb5ebaca1f5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_7fa00a4a-41e1-4f18-89e6-49437ddf0571_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of warrant to be exercised</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Of Warrant Exercise</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Of Warrant Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementMaximumAmountOfWarrantExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_7d5de1b6-74e5-40f9-ab4d-4522848013ae_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_efb6ae02-79ae-43c9-b8ec-6eb91f502295_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2e7afa90-08f8-4cff-a84e-1fe04aaa2af6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_5399df7d-3c0e-4413-81b8-6c943c1d6607_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_80feff66-0fce-4011-8bd1-5770ad39aed1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_9cff6b1b-8d20-4b89-b10c-408b3eb5f11e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_b3bcf7f9-7e51-413a-8bdd-ec884e582588_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_c978c119-6c9a-4f68-9be6-8a9283af7aa9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_a48df312-0f96-46e2-b8fe-b8f829323a55_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_850ba7e6-2947-4804-8239-5de294fd8f03_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_630304b7-7574-487b-bf4e-764a717f32d9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets:</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_893f44b5-a974-41ea-87fd-e051f9f8785e_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember" xlink:href="exel-20220930.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember" xlink:to="lab_exel_AccredoHealthIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_23da23ed-3c87-4b88-8d13-403fc702e175_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:href="exel-20220930.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c9ba6503-8857-4b00-be6f-cf31faca1f6f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c0885343-9c45-49f9-8994-a9fac04b464c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_56efc307-81a2-447d-b021-77067fd1a5f1_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_e620723d-be56-4745-b45b-f1d48dc8c819_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d1bc8521-42ca-4982-abbf-115bc519f7cb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5a08b82d-f297-44b2-8f74-aca46f3edab4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a2542ef7-0fac-4c78-8337-e11741afaed0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_dea2ff92-e71c-4b62-923e-9ef600465b4b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5c3c4eb9-710a-454b-a1f0-49eef78b763e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_399ca95b-bf58-412e-b761-436c8992c675_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_0316fcb5-e42d-4206-b091-3fa271eeec78_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7adbc795-3b76-4cc6-964a-b59fd56eab67_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1f365961-3b62-4999-910b-3d00d5c9801c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_418180f7-fe9d-4ca7-8264-81e499c707fa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f05f1b81-736a-4911-ae3b-073e94235609_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20a0ab62-dbd8-4996-acdf-2edacb04b4d3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_647c98d3-c663-4888-adf0-1f87c1fcde2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_043181c6-3504-4912-ba24-1a149b756636_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_fdcf8399-3a5e-4670-aed4-eb3cfec40852_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember_b95e071f-33ac-4aa2-9dd2-ea510f2861b9_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Ryvu Therapeutics S.A. (Ryvu)</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember_label_en-US" xlink:label="lab_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Ryvu Therapeutics S.A. (Ryvu) [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Ryvu Therapeutics S.A. (Ryvu)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember" xlink:href="exel-20220930.xsd#exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember" xlink:to="lab_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember_378176ff-4463-4d98-bfd7-803cd5804a36_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With BioInvent International AB (BioInvent)</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember_label_en-US" xlink:label="lab_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With BioInvent International AB (BioInvent) [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With BioInvent International AB (BioInvent)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember" xlink:href="exel-20220930.xsd#exel_CollaborationAgreementWithBioInventInternationalABBioInventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember" xlink:to="lab_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TSRBasedRestrictedStockUnitsMember_d2cadc8b-31ff-413b-aaec-47422508bd50_terseLabel_en-US" xlink:label="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR-Based Restricted Stock Units</link:label>
    <link:label id="lab_exel_TSRBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_exel_TSRBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember" xlink:href="exel-20220930.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TSRBasedRestrictedStockUnitsMember" xlink:to="lab_exel_TSRBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_39318629-dc30-4b0c-9894-b27cb407043d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_fa4385e5-157e-4b72-a1f4-202c61f30ef2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_5d7603a0-1df4-452f-b7ba-0ac1334a27bf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_d9e3af66-d099-4161-ab8d-717dff91eec5_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_42c88e64-16d2-4ca1-a3a1-e855e7bba851_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fec53d40-69dc-47b7-a533-d4471b2e5f00_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_af0c3f6b-289e-472e-9749-141284c0decb_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>exel-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f874578b-aba8-4b11-9ee3-0aa3371a4a4f,g:18180dba-6dc6-4cf5-97a9-3c99224fbbee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2a44eaaa-c0c1-4880-a348-a2f287596d24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_DocumentType_2a44eaaa-c0c1-4880-a348-a2f287596d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_391eece9-555b-4ca3-8f0a-2f49f199968a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_DocumentQuarterlyReport_391eece9-555b-4ca3-8f0a-2f49f199968a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e00c05cd-a953-403b-a805-3ae86ecab0bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_DocumentPeriodEndDate_e00c05cd-a953-403b-a805-3ae86ecab0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a556f963-71b3-43d5-81fe-7f784e32e0e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_DocumentTransitionReport_a556f963-71b3-43d5-81fe-7f784e32e0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2a4afb9d-b03a-4087-903b-54323707f375" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityFileNumber_2a4afb9d-b03a-4087-903b-54323707f375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7ac09b61-3096-4f58-8998-c21c1312b869" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityRegistrantName_7ac09b61-3096-4f58-8998-c21c1312b869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d24fd5db-ed94-45aa-b7e2-4c3854410385" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d24fd5db-ed94-45aa-b7e2-4c3854410385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_76e9dbfb-12b1-47d5-83d2-aa9d35fdf748" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityTaxIdentificationNumber_76e9dbfb-12b1-47d5-83d2-aa9d35fdf748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c4509e72-461f-480d-aacc-adb2c965695d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityAddressAddressLine1_c4509e72-461f-480d-aacc-adb2c965695d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1243519e-f7a5-4f23-814e-f7b0812bcffc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityAddressCityOrTown_1243519e-f7a5-4f23-814e-f7b0812bcffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6f049a98-6ffa-424f-a24e-e98e3c7c7369" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityAddressStateOrProvince_6f049a98-6ffa-424f-a24e-e98e3c7c7369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8298800f-a629-44b4-b7fa-7bbc437e3726" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityAddressPostalZipCode_8298800f-a629-44b4-b7fa-7bbc437e3726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_350c6f79-cade-453c-957a-c663f7951e1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_CityAreaCode_350c6f79-cade-453c-957a-c663f7951e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bd876037-68c9-407e-814b-85f2e333c847" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_LocalPhoneNumber_bd876037-68c9-407e-814b-85f2e333c847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4ac3af86-480a-4ab0-95c1-491027ca51cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_Security12bTitle_4ac3af86-480a-4ab0-95c1-491027ca51cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4f31adc6-9c3b-48dd-9835-ceb13d104d87" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_TradingSymbol_4f31adc6-9c3b-48dd-9835-ceb13d104d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c26a30a4-73f5-4a57-b656-5e0e4bc54845" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_SecurityExchangeName_c26a30a4-73f5-4a57-b656-5e0e4bc54845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3df5573c-65dc-4590-831e-baa4fd8c6b47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityCurrentReportingStatus_3df5573c-65dc-4590-831e-baa4fd8c6b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2ff62526-aabe-4720-beb8-34b7225e972d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityInteractiveDataCurrent_2ff62526-aabe-4720-beb8-34b7225e972d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_91241cf9-7900-4a4c-90ed-483cfecfd00a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityFilerCategory_91241cf9-7900-4a4c-90ed-483cfecfd00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b713d3eb-d896-433c-9d26-093dcd2c1f66" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntitySmallBusiness_b713d3eb-d896-433c-9d26-093dcd2c1f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a1367380-d5e7-491c-b947-bf0ab0a35fa2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityEmergingGrowthCompany_a1367380-d5e7-491c-b947-bf0ab0a35fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b7148603-6f89-4da0-a1be-54ae052b8cba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityShellCompany_b7148603-6f89-4da0-a1be-54ae052b8cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5d6e82ad-3811-4991-b216-0a8a911c3d0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5d6e82ad-3811-4991-b216-0a8a911c3d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_403d8801-6dfc-4f51-974a-ecfc09249d59" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_AmendmentFlag_403d8801-6dfc-4f51-974a-ecfc09249d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f6366f27-9cb3-490f-85e8-9fb7c37bc555" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_DocumentFiscalYearFocus_f6366f27-9cb3-490f-85e8-9fb7c37bc555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e7b17e3f-2f36-4380-b446-3fcbb734ba54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e7b17e3f-2f36-4380-b446-3fcbb734ba54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_712c6322-f7b1-4009-a99a-5f7a8fdcda47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_EntityCentralIndexKey_712c6322-f7b1-4009-a99a-5f7a8fdcda47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9a8d2176-43b2-45ed-9d79-03e7eacc5fbb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_532ef33c-dcae-4b94-9953-32e224cbcd8a" xlink:to="loc_dei_CurrentFiscalYearEndDate_9a8d2176-43b2-45ed-9d79-03e7eacc5fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b8d9223b-34c5-4aeb-9c9a-809f0c91ffac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0e4186a8-b053-40d4-bb47-bf7dc71daeca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b8d9223b-34c5-4aeb-9c9a-809f0c91ffac" xlink:to="loc_us-gaap_AssetsAbstract_0e4186a8-b053-40d4-bb47-bf7dc71daeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_49a4cca0-e904-4325-9bce-5043d21e7136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e4186a8-b053-40d4-bb47-bf7dc71daeca" xlink:to="loc_us-gaap_AssetsCurrentAbstract_49a4cca0-e904-4325-9bce-5043d21e7136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_066cefc3-a04f-4d87-b1b1-a812e287ec70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_49a4cca0-e904-4325-9bce-5043d21e7136" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_066cefc3-a04f-4d87-b1b1-a812e287ec70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c72ed879-c799-4a25-b7dd-3c2f3d57f228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_49a4cca0-e904-4325-9bce-5043d21e7136" xlink:to="loc_us-gaap_ShortTermInvestments_c72ed879-c799-4a25-b7dd-3c2f3d57f228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_c5edfaae-455b-43ab-9fc8-55548122fe26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_49a4cca0-e904-4325-9bce-5043d21e7136" xlink:to="loc_us-gaap_ReceivablesNetCurrent_c5edfaae-455b-43ab-9fc8-55548122fe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b49805fb-53fc-4989-9216-2c7f3adce4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_49a4cca0-e904-4325-9bce-5043d21e7136" xlink:to="loc_us-gaap_InventoryNet_b49805fb-53fc-4989-9216-2c7f3adce4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_22f43944-0be0-40cc-98a6-c70996675827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_49a4cca0-e904-4325-9bce-5043d21e7136" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_22f43944-0be0-40cc-98a6-c70996675827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ad503842-1c3b-4fce-8823-75a197a90346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_49a4cca0-e904-4325-9bce-5043d21e7136" xlink:to="loc_us-gaap_AssetsCurrent_ad503842-1c3b-4fce-8823-75a197a90346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_3068e3e7-855d-4e3f-9616-a1a365f5e422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e4186a8-b053-40d4-bb47-bf7dc71daeca" xlink:to="loc_us-gaap_LongTermInvestments_3068e3e7-855d-4e3f-9616-a1a365f5e422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8a2dea3d-1d54-4d00-881d-dc7f8da33bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e4186a8-b053-40d4-bb47-bf7dc71daeca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8a2dea3d-1d54-4d00-881d-dc7f8da33bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_bdbceb95-5da4-45af-b001-74c64d624a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e4186a8-b053-40d4-bb47-bf7dc71daeca" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_bdbceb95-5da4-45af-b001-74c64d624a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fa6bf23d-2c04-45b7-87ea-171dd630a9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e4186a8-b053-40d4-bb47-bf7dc71daeca" xlink:to="loc_us-gaap_Goodwill_fa6bf23d-2c04-45b7-87ea-171dd630a9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_299a7d3a-26bc-4629-9994-12d5755d1937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e4186a8-b053-40d4-bb47-bf7dc71daeca" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_299a7d3a-26bc-4629-9994-12d5755d1937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c663e105-5fb1-4e0d-940d-600f3d0852d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e4186a8-b053-40d4-bb47-bf7dc71daeca" xlink:to="loc_us-gaap_Assets_c663e105-5fb1-4e0d-940d-600f3d0852d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc033c5-5a6f-40f9-8024-9e7059f2b81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b8d9223b-34c5-4aeb-9c9a-809f0c91ffac" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc033c5-5a6f-40f9-8024-9e7059f2b81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cea8041c-7a37-4551-b22c-fa2672804762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc033c5-5a6f-40f9-8024-9e7059f2b81e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cea8041c-7a37-4551-b22c-fa2672804762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f036456c-b020-43e3-ab4d-35068333bed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cea8041c-7a37-4551-b22c-fa2672804762" xlink:to="loc_us-gaap_AccountsPayableCurrent_f036456c-b020-43e3-ab4d-35068333bed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_3cbfea66-5b7a-41d3-94d4-a6624baba6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cea8041c-7a37-4551-b22c-fa2672804762" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_3cbfea66-5b7a-41d3-94d4-a6624baba6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_deed54e9-a2cb-40bf-ab12-567a53e8b3fa" xlink:href="exel-20220930.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cea8041c-7a37-4551-b22c-fa2672804762" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_deed54e9-a2cb-40bf-ab12-567a53e8b3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_5631334f-8d41-41c3-a491-838acfa7c229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cea8041c-7a37-4551-b22c-fa2672804762" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_5631334f-8d41-41c3-a491-838acfa7c229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_f181a53f-539f-4b0d-81c6-90e956b49ca8" xlink:href="exel-20220930.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cea8041c-7a37-4551-b22c-fa2672804762" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_f181a53f-539f-4b0d-81c6-90e956b49ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8f3d54a2-8f55-4e87-b0be-e8171634db28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cea8041c-7a37-4551-b22c-fa2672804762" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8f3d54a2-8f55-4e87-b0be-e8171634db28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2525898c-033c-42fe-9e82-888c879d7f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cea8041c-7a37-4551-b22c-fa2672804762" xlink:to="loc_us-gaap_LiabilitiesCurrent_2525898c-033c-42fe-9e82-888c879d7f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b34a94c4-3c48-40f6-89d3-afd350f43245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc033c5-5a6f-40f9-8024-9e7059f2b81e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b34a94c4-3c48-40f6-89d3-afd350f43245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_671526e3-bdf7-461a-976a-7ce1724f9fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc033c5-5a6f-40f9-8024-9e7059f2b81e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_671526e3-bdf7-461a-976a-7ce1724f9fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3990e4d1-78a9-4296-8ac7-6c3e86da3cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc033c5-5a6f-40f9-8024-9e7059f2b81e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3990e4d1-78a9-4296-8ac7-6c3e86da3cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_caf31204-168e-44ac-873c-333f27fb769a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc033c5-5a6f-40f9-8024-9e7059f2b81e" xlink:to="loc_us-gaap_Liabilities_caf31204-168e-44ac-873c-333f27fb769a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_dc289096-ecce-4fd2-9c47-d5c90c1cc525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc033c5-5a6f-40f9-8024-9e7059f2b81e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_dc289096-ecce-4fd2-9c47-d5c90c1cc525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1b374155-a076-4696-8af8-7c49b5ad24e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc033c5-5a6f-40f9-8024-9e7059f2b81e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1b374155-a076-4696-8af8-7c49b5ad24e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8f8719ea-354d-40c1-a4dd-58a51edb231a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1b374155-a076-4696-8af8-7c49b5ad24e5" xlink:to="loc_us-gaap_PreferredStockValue_8f8719ea-354d-40c1-a4dd-58a51edb231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e54225cd-418f-4983-a0d6-d5e62c0d75f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1b374155-a076-4696-8af8-7c49b5ad24e5" xlink:to="loc_us-gaap_CommonStockValue_e54225cd-418f-4983-a0d6-d5e62c0d75f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f68ff23d-cc68-4f8b-87f8-403d4f8af2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1b374155-a076-4696-8af8-7c49b5ad24e5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f68ff23d-cc68-4f8b-87f8-403d4f8af2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d3215827-e70f-4726-b36f-e06b6608732f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1b374155-a076-4696-8af8-7c49b5ad24e5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d3215827-e70f-4726-b36f-e06b6608732f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_796cf281-fda6-4460-8c82-50195c55e59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1b374155-a076-4696-8af8-7c49b5ad24e5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_796cf281-fda6-4460-8c82-50195c55e59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1c4bdfef-a057-4739-8a66-47c3ec12d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1b374155-a076-4696-8af8-7c49b5ad24e5" xlink:to="loc_us-gaap_StockholdersEquity_1c4bdfef-a057-4739-8a66-47c3ec12d7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_85e596f6-5067-47a4-bb4f-496076a16c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddc033c5-5a6f-40f9-8024-9e7059f2b81e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_85e596f6-5067-47a4-bb4f-496076a16c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_89041cdc-f01e-492c-875e-1acfeaa0870d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edfe6ed8-f6ef-4558-89df-b35cd6891d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89041cdc-f01e-492c-875e-1acfeaa0870d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edfe6ed8-f6ef-4558-89df-b35cd6891d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e2139add-9aa6-4d0d-a4b6-725b29de8b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_edfe6ed8-f6ef-4558-89df-b35cd6891d86" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e2139add-9aa6-4d0d-a4b6-725b29de8b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_395a6318-7141-42bc-ba2a-b349e5eb8f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e2139add-9aa6-4d0d-a4b6-725b29de8b32" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_395a6318-7141-42bc-ba2a-b349e5eb8f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7e62748e-affb-4b1b-aa7a-a2d4a245b540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_395a6318-7141-42bc-ba2a-b349e5eb8f5c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7e62748e-affb-4b1b-aa7a-a2d4a245b540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f7148731-8716-4aa1-88c0-e4ef1c72073a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_395a6318-7141-42bc-ba2a-b349e5eb8f5c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f7148731-8716-4aa1-88c0-e4ef1c72073a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8dbfe0a0-43c4-4551-b17a-7d407bd847d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_395a6318-7141-42bc-ba2a-b349e5eb8f5c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8dbfe0a0-43c4-4551-b17a-7d407bd847d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e725ed26-8d23-481f-95ae-a588b19c9bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e2139add-9aa6-4d0d-a4b6-725b29de8b32" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e725ed26-8d23-481f-95ae-a588b19c9bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd446bc3-e55a-4176-9726-7266494f7379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e725ed26-8d23-481f-95ae-a588b19c9bdf" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd446bc3-e55a-4176-9726-7266494f7379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d64f12db-243b-46ad-a6c7-64444157907c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e725ed26-8d23-481f-95ae-a588b19c9bdf" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d64f12db-243b-46ad-a6c7-64444157907c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e6dc3c75-b4ea-4f88-9f16-8486846208f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e725ed26-8d23-481f-95ae-a588b19c9bdf" xlink:to="loc_us-gaap_CommonStockSharesIssued_e6dc3c75-b4ea-4f88-9f16-8486846208f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2076c6bb-a6c9-4b08-a40a-7910394d71e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e725ed26-8d23-481f-95ae-a588b19c9bdf" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2076c6bb-a6c9-4b08-a40a-7910394d71e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_868b2692-12ae-4cc9-ba40-4c097cf20ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7326b5cd-7b8b-4797-b517-904a130cd1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_868b2692-12ae-4cc9-ba40-4c097cf20ff0" xlink:to="loc_us-gaap_StatementTable_7326b5cd-7b8b-4797-b517-904a130cd1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f429fbf4-cf3e-490e-aa28-4255198c2f52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7326b5cd-7b8b-4797-b517-904a130cd1b4" xlink:to="loc_srt_ProductOrServiceAxis_f429fbf4-cf3e-490e-aa28-4255198c2f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_db578b35-b272-433d-9977-9970125d39f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f429fbf4-cf3e-490e-aa28-4255198c2f52" xlink:to="loc_srt_ProductsAndServicesDomain_db578b35-b272-433d-9977-9970125d39f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_823d5443-8597-44ed-97e1-723715b0050d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_db578b35-b272-433d-9977-9970125d39f4" xlink:to="loc_us-gaap_ProductMember_823d5443-8597-44ed-97e1-723715b0050d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_eae4096a-493f-42d1-ab8b-40904b2bd295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_db578b35-b272-433d-9977-9970125d39f4" xlink:to="loc_us-gaap_LicenseMember_eae4096a-493f-42d1-ab8b-40904b2bd295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_584a0962-1136-4f1c-bb6e-9bc8646bc377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_db578b35-b272-433d-9977-9970125d39f4" xlink:to="loc_us-gaap_ServiceMember_584a0962-1136-4f1c-bb6e-9bc8646bc377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7326b5cd-7b8b-4797-b517-904a130cd1b4" xlink:to="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_319ae399-c2d3-43fa-9da6-b5187b078f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_RevenuesAbstract_319ae399-c2d3-43fa-9da6-b5187b078f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce3c9771-daed-4fb9-837c-137781994f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_319ae399-c2d3-43fa-9da6-b5187b078f8f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce3c9771-daed-4fb9-837c-137781994f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9446fc37-8d13-445c-8359-6abfecdc8dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_OperatingExpensesAbstract_9446fc37-8d13-445c-8359-6abfecdc8dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0c977b66-189a-4548-a149-db5465e69c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9446fc37-8d13-445c-8359-6abfecdc8dad" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0c977b66-189a-4548-a149-db5465e69c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e6daae40-ae39-4d18-a305-f1cc1a4ceb27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9446fc37-8d13-445c-8359-6abfecdc8dad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e6daae40-ae39-4d18-a305-f1cc1a4ceb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b39a1034-1887-41a6-b400-816ae64e577b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9446fc37-8d13-445c-8359-6abfecdc8dad" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b39a1034-1887-41a6-b400-816ae64e577b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2a5d3813-51e5-4303-a741-5f02d95d69cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9446fc37-8d13-445c-8359-6abfecdc8dad" xlink:to="loc_us-gaap_CostsAndExpenses_2a5d3813-51e5-4303-a741-5f02d95d69cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0d887d81-fe05-4bb2-b892-d1047b2c852c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_OperatingIncomeLoss_0d887d81-fe05-4bb2-b892-d1047b2c852c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_745dded1-c13c-4148-bc41-82747c74afb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_InterestIncomeOther_745dded1-c13c-4148-bc41-82747c74afb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_270bfa4c-0c20-47f3-baad-3208a6b882c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_270bfa4c-0c20-47f3-baad-3208a6b882c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_f2205f1e-95ce-4cfb-8406-a999241e87af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_f2205f1e-95ce-4cfb-8406-a999241e87af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cb1900df-fb79-401e-8cac-dd248438eaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cb1900df-fb79-401e-8cac-dd248438eaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6b799c84-87f8-4061-a5c6-0075597a2a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_NetIncomeLoss_6b799c84-87f8-4061-a5c6-0075597a2a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_08d1c348-3b12-4207-a813-7e46799b97b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_EarningsPerShareAbstract_08d1c348-3b12-4207-a813-7e46799b97b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bea4ab06-063d-423c-9d9c-a4a6cc9608e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08d1c348-3b12-4207-a813-7e46799b97b1" xlink:to="loc_us-gaap_EarningsPerShareBasic_bea4ab06-063d-423c-9d9c-a4a6cc9608e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e42cdfd6-0fe5-40b8-8a92-daadefa8d40d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08d1c348-3b12-4207-a813-7e46799b97b1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e42cdfd6-0fe5-40b8-8a92-daadefa8d40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2bd22d04-e802-4dc1-ac28-05e5e6e53f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_582ddb3b-1dc4-4b5f-8c14-bb77b1f5d714" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2bd22d04-e802-4dc1-ac28-05e5e6e53f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dff73bd5-ac10-48ac-8b9d-452df5f729e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2bd22d04-e802-4dc1-ac28-05e5e6e53f1c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dff73bd5-ac10-48ac-8b9d-452df5f729e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bba75807-9497-4a14-bb52-96740adb7f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2bd22d04-e802-4dc1-ac28-05e5e6e53f1c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bba75807-9497-4a14-bb52-96740adb7f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7dd03076-da0c-49ba-9a1a-9681f0e0debb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e39f2ef7-e169-417b-9698-e41981cd800e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7dd03076-da0c-49ba-9a1a-9681f0e0debb" xlink:to="loc_us-gaap_NetIncomeLoss_e39f2ef7-e169-417b-9698-e41981cd800e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_43a7696b-e0f9-4f8f-a13e-d42abcc4b14f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7dd03076-da0c-49ba-9a1a-9681f0e0debb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_43a7696b-e0f9-4f8f-a13e-d42abcc4b14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_11fb5967-6d27-4ce9-9f10-ea81e8f07e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_43a7696b-e0f9-4f8f-a13e-d42abcc4b14f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_11fb5967-6d27-4ce9-9f10-ea81e8f07e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5719001e-1795-419d-843f-46f45bd00369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7dd03076-da0c-49ba-9a1a-9681f0e0debb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5719001e-1795-419d-843f-46f45bd00369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5dcaa8f0-b967-4536-a6f8-f41ca9aa7c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ced614a2-2dfc-4740-ae7e-591ae3a124ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_5dcaa8f0-b967-4536-a6f8-f41ca9aa7c54" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ced614a2-2dfc-4740-ae7e-591ae3a124ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7ab126b9-4626-4209-b20d-228b1ab33875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7c30c3d6-290f-4737-8eda-b187e8bf82e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7ab126b9-4626-4209-b20d-228b1ab33875" xlink:to="loc_us-gaap_StatementTable_7c30c3d6-290f-4737-8eda-b187e8bf82e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aedd80d3-f445-4d05-86d2-49050b3d0d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7c30c3d6-290f-4737-8eda-b187e8bf82e6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aedd80d3-f445-4d05-86d2-49050b3d0d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_51ad7d4b-ef6d-4e15-a7b7-46c6b664554a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aedd80d3-f445-4d05-86d2-49050b3d0d9f" xlink:to="loc_us-gaap_EquityComponentDomain_51ad7d4b-ef6d-4e15-a7b7-46c6b664554a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf18435c-d0fe-4c58-9eca-95d26d25e334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_51ad7d4b-ef6d-4e15-a7b7-46c6b664554a" xlink:to="loc_us-gaap_CommonStockMember_cf18435c-d0fe-4c58-9eca-95d26d25e334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5eb0ed3f-f0d8-49b1-9e09-7de2e2130f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_51ad7d4b-ef6d-4e15-a7b7-46c6b664554a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5eb0ed3f-f0d8-49b1-9e09-7de2e2130f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1eb7a5eb-76d2-48bd-a2a5-e62002c5e4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_51ad7d4b-ef6d-4e15-a7b7-46c6b664554a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1eb7a5eb-76d2-48bd-a2a5-e62002c5e4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_71324ea8-7862-4570-88b0-e708e8ffd5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_51ad7d4b-ef6d-4e15-a7b7-46c6b664554a" xlink:to="loc_us-gaap_RetainedEarningsMember_71324ea8-7862-4570-88b0-e708e8ffd5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_31ac229c-b30f-4cf7-bd2c-b118f782ac57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7c30c3d6-290f-4737-8eda-b187e8bf82e6" xlink:to="loc_us-gaap_StatementLineItems_31ac229c-b30f-4cf7-bd2c-b118f782ac57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_31ac229c-b30f-4cf7-bd2c-b118f782ac57" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_351b7186-7ad0-4c7e-b59b-d37a34fd6626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_351b7186-7ad0-4c7e-b59b-d37a34fd6626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b1523592-9805-4471-977c-bc0d47d45bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_StockholdersEquity_b1523592-9805-4471-977c-bc0d47d45bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_89fabb7e-22a5-435f-a35c-3bc8e799dc32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_NetIncomeLoss_89fabb7e-22a5-435f-a35c-3bc8e799dc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_09c4ee87-9a29-45dc-8436-e488db2dfed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_09c4ee87-9a29-45dc-8436-e488db2dfed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_81dbba24-631a-452f-981a-0d1db9a17f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_81dbba24-631a-452f-981a-0d1db9a17f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c3f1ba9a-1dd7-4fc8-9c41-d8600a76cfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c3f1ba9a-1dd7-4fc8-9c41-d8600a76cfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_fd64d232-3963-4994-b81b-755b8cb200ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_fd64d232-3963-4994-b81b-755b8cb200ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5fe7a452-9e51-4708-86c4-b7631a03e831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5fe7a452-9e51-4708-86c4-b7631a03e831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_88f0cf3e-488a-4ebb-b239-4c65f9f3e1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_88f0cf3e-488a-4ebb-b239-4c65f9f3e1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8e3f6179-3942-4321-848b-5d7729936677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ed966b92-30d2-45f0-a2d7-2d518fefdaff" xlink:to="loc_us-gaap_StockholdersEquity_8e3f6179-3942-4321-848b-5d7729936677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f0d572f8-0fde-4ff5-8ead-af60791fee06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_193995ff-de61-4945-bac8-3e92bcfa5d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f0d572f8-0fde-4ff5-8ead-af60791fee06" xlink:to="loc_us-gaap_NetIncomeLoss_193995ff-de61-4945-bac8-3e92bcfa5d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d2d6f18a-1f33-4ac1-8712-df671f84cb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f0d572f8-0fde-4ff5-8ead-af60791fee06" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d2d6f18a-1f33-4ac1-8712-df671f84cb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f1cda61d-fd4b-435a-b5f8-e84cf85507d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d2d6f18a-1f33-4ac1-8712-df671f84cb12" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f1cda61d-fd4b-435a-b5f8-e84cf85507d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e275486e-269a-4265-8657-4804b424c90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d2d6f18a-1f33-4ac1-8712-df671f84cb12" xlink:to="loc_us-gaap_ShareBasedCompensation_e275486e-269a-4265-8657-4804b424c90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_2a1fdebb-396d-4573-8875-5c544519fcbe" xlink:href="exel-20220930.xsd#exel_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d2d6f18a-1f33-4ac1-8712-df671f84cb12" xlink:to="loc_exel_NoncashLeaseExpense_2a1fdebb-396d-4573-8875-5c544519fcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0cdd8cbd-2a32-45f2-b93a-dcc9492f1a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d2d6f18a-1f33-4ac1-8712-df671f84cb12" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0cdd8cbd-2a32-45f2-b93a-dcc9492f1a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_863c0c63-958c-4f5d-9a6f-b36a4b3f5e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d2d6f18a-1f33-4ac1-8712-df671f84cb12" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_863c0c63-958c-4f5d-9a6f-b36a4b3f5e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d03ac46d-ac1d-45cd-94db-cd04fbdfe564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d2d6f18a-1f33-4ac1-8712-df671f84cb12" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d03ac46d-ac1d-45cd-94db-cd04fbdfe564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b5ab2415-0c4c-4816-8271-372d9cad18aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d03ac46d-ac1d-45cd-94db-cd04fbdfe564" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b5ab2415-0c4c-4816-8271-372d9cad18aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_642a327e-831d-4eb4-8d39-ef6eb0e10ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d03ac46d-ac1d-45cd-94db-cd04fbdfe564" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_642a327e-831d-4eb4-8d39-ef6eb0e10ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f8362342-adaa-48f3-bd3c-0756a8f771e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d03ac46d-ac1d-45cd-94db-cd04fbdfe564" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f8362342-adaa-48f3-bd3c-0756a8f771e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1a346386-74cc-4d1e-9c43-a454b7c37ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d03ac46d-ac1d-45cd-94db-cd04fbdfe564" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1a346386-74cc-4d1e-9c43-a454b7c37ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_1eddfb3e-f00d-472c-a34b-888065cd27a3" xlink:href="exel-20220930.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d03ac46d-ac1d-45cd-94db-cd04fbdfe564" xlink:to="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_1eddfb3e-f00d-472c-a34b-888065cd27a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a6527b3a-017c-41f8-9800-96744a1cd299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d03ac46d-ac1d-45cd-94db-cd04fbdfe564" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a6527b3a-017c-41f8-9800-96744a1cd299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1df1130a-a24f-48f7-9492-b4ee3b432a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f0d572f8-0fde-4ff5-8ead-af60791fee06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1df1130a-a24f-48f7-9492-b4ee3b432a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62854ede-c93f-43d6-8e92-f0341ef89810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f0d572f8-0fde-4ff5-8ead-af60791fee06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62854ede-c93f-43d6-8e92-f0341ef89810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e067bb97-c428-48e3-af6b-04973c074a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62854ede-c93f-43d6-8e92-f0341ef89810" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e067bb97-c428-48e3-af6b-04973c074a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_bdb0d97a-9681-4e2c-89c7-b47d8982dc81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62854ede-c93f-43d6-8e92-f0341ef89810" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_bdb0d97a-9681-4e2c-89c7-b47d8982dc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_8ff480d0-fba3-4c67-a3fe-29ca8975aea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62854ede-c93f-43d6-8e92-f0341ef89810" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_8ff480d0-fba3-4c67-a3fe-29ca8975aea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45ff586f-2956-45ce-98b3-54cca18e34a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_62854ede-c93f-43d6-8e92-f0341ef89810" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45ff586f-2956-45ce-98b3-54cca18e34a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_781dacab-b36e-4681-bf5f-5b82cac531d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f0d572f8-0fde-4ff5-8ead-af60791fee06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_781dacab-b36e-4681-bf5f-5b82cac531d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f2769287-7cdc-4c51-9080-cf17357bc51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_781dacab-b36e-4681-bf5f-5b82cac531d2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f2769287-7cdc-4c51-9080-cf17357bc51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3b23d706-815b-4481-9a0c-2f3519a4c19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_781dacab-b36e-4681-bf5f-5b82cac531d2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3b23d706-815b-4481-9a0c-2f3519a4c19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b35b262-6bd6-4d17-a3a7-c600e1228cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_781dacab-b36e-4681-bf5f-5b82cac531d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b35b262-6bd6-4d17-a3a7-c600e1228cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_37bb92db-c61c-4e31-a6cf-4ba118fcff30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f0d572f8-0fde-4ff5-8ead-af60791fee06" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_37bb92db-c61c-4e31-a6cf-4ba118fcff30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_74295096-4cb3-4a4a-97a0-bc1685668550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f0d572f8-0fde-4ff5-8ead-af60791fee06" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_74295096-4cb3-4a4a-97a0-bc1685668550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02bf133d-64da-429a-962e-70e5c72f0dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f0d572f8-0fde-4ff5-8ead-af60791fee06" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_02bf133d-64da-429a-962e-70e5c72f0dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3a111f34-0afa-410a-b32a-c1d46595c283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f0d572f8-0fde-4ff5-8ead-af60791fee06" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3a111f34-0afa-410a-b32a-c1d46595c283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_f9da9948-146f-434e-931b-dc404812951f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3a111f34-0afa-410a-b32a-c1d46595c283" xlink:to="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_f9da9948-146f-434e-931b-dc404812951f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f59bb949-9d34-4e7f-b228-4afd7f266ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_f9da9948-146f-434e-931b-dc404812951f" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f59bb949-9d34-4e7f-b228-4afd7f266ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4287e089-dfcc-42a9-8c8c-eed7698add3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3a111f34-0afa-410a-b32a-c1d46595c283" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4287e089-dfcc-42a9-8c8c-eed7698add3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_72f9f592-d411-4b37-ace3-83012ea7307d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4287e089-dfcc-42a9-8c8c-eed7698add3d" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_72f9f592-d411-4b37-ace3-83012ea7307d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_b3e3587d-1ae3-4207-926b-1b712cff8072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_4287e089-dfcc-42a9-8c8c-eed7698add3d" xlink:to="loc_us-gaap_LiabilitiesAssumed1_b3e3587d-1ae3-4207-926b-1b712cff8072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20220930.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6a11e2f-e54f-4dfd-baf3-3c6a4cc154f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f2fa7748-be84-4519-b3bf-833d014f1a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6a11e2f-e54f-4dfd-baf3-3c6a4cc154f7" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f2fa7748-be84-4519-b3bf-833d014f1a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20220930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1bb9fd4f-c233-4186-9cd4-34dd2c3cc440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_62776900-a4f3-431e-b6cc-e66f6b0fe908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1bb9fd4f-c233-4186-9cd4-34dd2c3cc440" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_62776900-a4f3-431e-b6cc-e66f6b0fe908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivities"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8df2de2d-f1a6-4272-a2f1-232ae739700a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2ab925ac-4e47-47f6-8fb7-58830348f40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8df2de2d-f1a6-4272-a2f1-232ae739700a" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2ab925ac-4e47-47f6-8fb7-58830348f40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestments"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fadf935b-22c2-40aa-9914-83eeffa8c02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_229215ad-e5e1-4918-889a-ece35fba1581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fadf935b-22c2-40aa-9914-83eeffa8c02f" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_229215ad-e5e1-4918-889a-ece35fba1581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20220930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6c48757b-524b-41ec-8c46-0ccf397ac74f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4aac0b31-69e0-49fc-a310-6912bdb93862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6c48757b-524b-41ec-8c46-0ccf397ac74f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4aac0b31-69e0-49fc-a310-6912bdb93862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20220930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_544fb057-a59f-48d5-8157-fe70c3d918e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_ecac776d-41a1-436f-b25c-f9a2985fa021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_544fb057-a59f-48d5-8157-fe70c3d918e3" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_ecac776d-41a1-436f-b25c-f9a2985fa021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="exel-20220930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dfc610fc-9c4f-4efc-9860-49f498893665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f61d6e60-1072-4c0d-968a-ec2c1f538a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dfc610fc-9c4f-4efc-9860-49f498893665" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f61d6e60-1072-4c0d-968a-ec2c1f538a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxes" xlink:type="simple" xlink:href="exel-20220930.xsd#ProvisionForIncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b8b09cde-cb26-4af7-9b8c-8b58de26a10e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a6d487b1-9ced-4f87-a2e4-e5865e51d085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b8b09cde-cb26-4af7-9b8c-8b58de26a10e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a6d487b1-9ced-4f87-a2e4-e5865e51d085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20220930.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5e14cab1-342c-458c-b8bf-6616b9e5a06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_852c485e-3894-4e66-b0c0-2d3e43a90341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5e14cab1-342c-458c-b8bf-6616b9e5a06e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_852c485e-3894-4e66-b0c0-2d3e43a90341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2cccc990-cceb-459a-ad7e-9665065854a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1f053fde-fe02-4dd5-b0ce-0efee6698100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2cccc990-cceb-459a-ad7e-9665065854a4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1f053fde-fe02-4dd5-b0ce-0efee6698100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEvents" xlink:type="simple" xlink:href="exel-20220930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9c2ef55e-a698-4897-a8c6-e6c173b12bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_af1867c3-46bb-4f17-94f6-a7836fd4dff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9c2ef55e-a698-4897-a8c6-e6c173b12bdc" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_af1867c3-46bb-4f17-94f6-a7836fd4dff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20220930.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e66c4b65-056b-4fa8-85ef-283b5d0bd07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_078f695a-8519-46b3-a35b-688b845b9207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e66c4b65-056b-4fa8-85ef-283b5d0bd07a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_078f695a-8519-46b3-a35b-688b845b9207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4adb7369-308a-4c70-b572-e5ea54fb0ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e66c4b65-056b-4fa8-85ef-283b5d0bd07a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4adb7369-308a-4c70-b572-e5ea54fb0ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_0230cd78-9dc5-469b-82bf-0890b1b4e5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e66c4b65-056b-4fa8-85ef-283b5d0bd07a" xlink:to="loc_us-gaap_FiscalPeriod_0230cd78-9dc5-469b-82bf-0890b1b4e5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_302cce3e-2b27-4058-9f52-87dab40d9090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e66c4b65-056b-4fa8-85ef-283b5d0bd07a" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_302cce3e-2b27-4058-9f52-87dab40d9090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_812478ef-6c44-4106-bfcb-8906d20dca3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e66c4b65-056b-4fa8-85ef-283b5d0bd07a" xlink:to="loc_us-gaap_UseOfEstimates_812478ef-6c44-4106-bfcb-8906d20dca3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_ef525a52-448d-4631-ba7c-1805c077250b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e66c4b65-056b-4fa8-85ef-283b5d0bd07a" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_ef525a52-448d-4631-ba7c-1805c077250b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_65d0ec22-0ff9-42a1-b282-62262d543c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e66c4b65-056b-4fa8-85ef-283b5d0bd07a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_65d0ec22-0ff9-42a1-b282-62262d543c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_49cb45da-7899-40b3-87d2-deef76587d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e66c4b65-056b-4fa8-85ef-283b5d0bd07a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_49cb45da-7899-40b3-87d2-deef76587d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ff9336a-7752-42f0-9afb-793f25076d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_02cd1bf7-93ec-4dfa-bd7e-45fef288a64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ff9336a-7752-42f0-9afb-793f25076d80" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_02cd1bf7-93ec-4dfa-bd7e-45fef288a64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_5e5a9146-e40a-4a4d-b4e6-5763899a7194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ff9336a-7752-42f0-9afb-793f25076d80" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_5e5a9146-e40a-4a4d-b4e6-5763899a7194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_1e8a313f-36bc-4992-b5b0-03765bc5c809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ff9336a-7752-42f0-9afb-793f25076d80" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_1e8a313f-36bc-4992-b5b0-03765bc5c809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_d1676b39-99a6-47c4-886a-03d444eb9cda" xlink:href="exel-20220930.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ff9336a-7752-42f0-9afb-793f25076d80" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_d1676b39-99a6-47c4-886a-03d444eb9cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_25eec0e9-d91f-4efa-9607-1c1b9f19bc14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ff9336a-7752-42f0-9afb-793f25076d80" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_25eec0e9-d91f-4efa-9607-1c1b9f19bc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45dfe435-41f8-4dc2-9b6f-0063be571aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_14e3c2c0-6ead-4273-9452-74a1609be823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45dfe435-41f8-4dc2-9b6f-0063be571aba" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_14e3c2c0-6ead-4273-9452-74a1609be823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a828e5db-d65a-4a13-be3d-060a9c8a7c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_e972ae61-3dd9-40f8-a4dc-af5f9530d471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a828e5db-d65a-4a13-be3d-060a9c8a7c59" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_e972ae61-3dd9-40f8-a4dc-af5f9530d471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1b81a4a7-7ca8-4bd5-a3dd-5baf88f4410a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a828e5db-d65a-4a13-be3d-060a9c8a7c59" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1b81a4a7-7ca8-4bd5-a3dd-5baf88f4410a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_ecda8bfb-10a2-4f33-904b-33f2645a4bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a828e5db-d65a-4a13-be3d-060a9c8a7c59" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_ecda8bfb-10a2-4f33-904b-33f2645a4bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_9ef1df71-6022-4423-86e6-622b61e672d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a828e5db-d65a-4a13-be3d-060a9c8a7c59" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_9ef1df71-6022-4423-86e6-622b61e672d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_ef69e833-5673-4d60-8824-92780b0887f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a828e5db-d65a-4a13-be3d-060a9c8a7c59" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_ef69e833-5673-4d60-8824-92780b0887f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20220930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_04a8d96e-72c1-412e-9c9b-2e68f7455deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_6d0e630f-b4c0-4969-bd4b-e9eee6cd70d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_04a8d96e-72c1-412e-9c9b-2e68f7455deb" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_6d0e630f-b4c0-4969-bd4b-e9eee6cd70d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20220930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_fa1fad4a-42b5-4380-96b6-21d846837e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_19816a32-0e41-4b7f-91c0-e7554929d286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fa1fad4a-42b5-4380-96b6-21d846837e29" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_19816a32-0e41-4b7f-91c0-e7554929d286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="exel-20220930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_043438fb-79e4-423c-917d-c4f564190aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c483ec48-a0cc-48fb-841b-d2ebab5021b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_043438fb-79e4-423c-917d-c4f564190aa7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c483ec48-a0cc-48fb-841b-d2ebab5021b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_c5b79496-b40e-4d54-ad27-99eefb4137e1" xlink:href="exel-20220930.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_043438fb-79e4-423c-917d-c4f564190aa7" xlink:to="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_c5b79496-b40e-4d54-ad27-99eefb4137e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20220930.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_718e5435-5e1b-410b-9f6f-0c0b0a295faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cf3a1ca7-d135-4b81-a30f-5d084e27fdea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_718e5435-5e1b-410b-9f6f-0c0b0a295faa" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cf3a1ca7-d135-4b81-a30f-5d084e27fdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_769878f0-a6a3-40c8-b05a-f5d1d7fb79b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_718e5435-5e1b-410b-9f6f-0c0b0a295faa" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_769878f0-a6a3-40c8-b05a-f5d1d7fb79b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74c9ea71-dac8-4d4b-ad72-d3c8ee1dbc41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5973924b-06f4-4020-b894-1d84caa1e128" xlink:href="exel-20220930.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74c9ea71-dac8-4d4b-ad72-d3c8ee1dbc41" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5973924b-06f4-4020-b894-1d84caa1e128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3d5856ff-fa9d-42c0-932b-7db5bd0bb16f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5973924b-06f4-4020-b894-1d84caa1e128" xlink:to="loc_srt_ProductOrServiceAxis_3d5856ff-fa9d-42c0-932b-7db5bd0bb16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a1203f0f-dafa-4458-bb58-6fa684836313" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3d5856ff-fa9d-42c0-932b-7db5bd0bb16f" xlink:to="loc_srt_ProductsAndServicesDomain_a1203f0f-dafa-4458-bb58-6fa684836313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_9b0b02b4-6010-4a62-a3f8-9ce17ed11f40" xlink:href="exel-20220930.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a1203f0f-dafa-4458-bb58-6fa684836313" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_9b0b02b4-6010-4a62-a3f8-9ce17ed11f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_bb9750f1-a9df-4f1f-9b6e-fe58bf569eed" xlink:href="exel-20220930.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a1203f0f-dafa-4458-bb58-6fa684836313" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_bb9750f1-a9df-4f1f-9b6e-fe58bf569eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_386ae60b-b21d-4c1b-b232-b5cbf9177067" xlink:href="exel-20220930.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5973924b-06f4-4020-b894-1d84caa1e128" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_386ae60b-b21d-4c1b-b232-b5cbf9177067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_6501cbf6-01e9-40f7-acd0-a4f77c9d32cb" xlink:href="exel-20220930.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_386ae60b-b21d-4c1b-b232-b5cbf9177067" xlink:to="loc_exel_NumberofProductsinCommercialMarket_6501cbf6-01e9-40f7-acd0-a4f77c9d32cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_8cecf0a3-6172-49f8-8ae4-f8175765dd5d" xlink:href="exel-20220930.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_386ae60b-b21d-4c1b-b232-b5cbf9177067" xlink:to="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_8cecf0a3-6172-49f8-8ae4-f8175765dd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_bc458c64-5f1d-443b-8330-27e2a959f613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_386ae60b-b21d-4c1b-b232-b5cbf9177067" xlink:to="loc_us-gaap_NumberOfOperatingSegments_bc458c64-5f1d-443b-8330-27e2a959f613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e789ae9f-b3da-4bad-972c-2069403f5c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2a829a5f-ee82-477e-b320-86c39defaaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e789ae9f-b3da-4bad-972c-2069403f5c7e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2a829a5f-ee82-477e-b320-86c39defaaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_476659f2-fb9a-4e7e-b193-c03c04839bba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2a829a5f-ee82-477e-b320-86c39defaaa4" xlink:to="loc_srt_ProductOrServiceAxis_476659f2-fb9a-4e7e-b193-c03c04839bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_476659f2-fb9a-4e7e-b193-c03c04839bba" xlink:to="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_5bcc7e04-0973-417a-87bb-e29944d3568d" xlink:href="exel-20220930.xsd#exel_ProductGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:to="loc_exel_ProductGrossMember_5bcc7e04-0973-417a-87bb-e29944d3568d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_38487ae1-ac25-4aa4-b3eb-bddb483f6f20" xlink:href="exel-20220930.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_38487ae1-ac25-4aa4-b3eb-bddb483f6f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_577df7c7-35f9-4a76-96d0-6b166dce4196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:to="loc_us-gaap_ProductMember_577df7c7-35f9-4a76-96d0-6b166dce4196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_7da541b9-1d64-42f1-9218-ebacbd7d2a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:to="loc_us-gaap_LicenseMember_7da541b9-1d64-42f1-9218-ebacbd7d2a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_597ccb92-73f3-4eb0-bae2-fbaa47be1eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:to="loc_us-gaap_ServiceMember_597ccb92-73f3-4eb0-bae2-fbaa47be1eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_1b50316a-c436-4b91-be20-05ba8214de0a" xlink:href="exel-20220930.xsd#exel_CollaborationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22ed2e35-082e-46a8-a10b-8eb7deb9cb97" xlink:to="loc_exel_CollaborationMember_1b50316a-c436-4b91-be20-05ba8214de0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_130d5c79-b076-4c04-a9e5-91b1e3df51fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2a829a5f-ee82-477e-b320-86c39defaaa4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_130d5c79-b076-4c04-a9e5-91b1e3df51fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39793a93-5d81-4c61-b7cd-688c7386899b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_130d5c79-b076-4c04-a9e5-91b1e3df51fc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39793a93-5d81-4c61-b7cd-688c7386899b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f03698a9-ff9e-4c07-9bf6-140605e8f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_befbdc7f-5602-4dfb-8cf3-0318d1ceb39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f03698a9-ff9e-4c07-9bf6-140605e8f8c3" xlink:to="loc_us-gaap_ConcentrationRiskTable_befbdc7f-5602-4dfb-8cf3-0318d1ceb39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2dc0e3b1-7b81-44f1-a020-e966315badfc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_befbdc7f-5602-4dfb-8cf3-0318d1ceb39e" xlink:to="loc_srt_MajorCustomersAxis_2dc0e3b1-7b81-44f1-a020-e966315badfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_2dc0e3b1-7b81-44f1-a020-e966315badfc" xlink:to="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_eaf8a335-68a8-4d3c-acd4-bc306cd3fc13" xlink:href="exel-20220930.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_eaf8a335-68a8-4d3c-acd4-bc306cd3fc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_748fada2-7937-4d7b-b17e-0f539642bfa5" xlink:href="exel-20220930.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_748fada2-7937-4d7b-b17e-0f539642bfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_3368b191-b2ec-4a62-b900-29f01227da2d" xlink:href="exel-20220930.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_3368b191-b2ec-4a62-b900-29f01227da2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_f79eee03-8d6e-4e64-a40d-692dfaf35202" xlink:href="exel-20220930.xsd#exel_IpsenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:to="loc_exel_IpsenMember_f79eee03-8d6e-4e64-a40d-692dfaf35202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember_2e17f178-3a22-46af-8aab-7db0571725be" xlink:href="exel-20220930.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_90a3c760-a90d-4924-8b7b-94bbc8069a89" xlink:to="loc_exel_AccredoHealthIncorporatedMember_2e17f178-3a22-46af-8aab-7db0571725be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df931b01-a611-48af-936f-248fa15a3a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_befbdc7f-5602-4dfb-8cf3-0318d1ceb39e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df931b01-a611-48af-936f-248fa15a3a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36e2afba-7677-442c-8ada-bab54a913ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_df931b01-a611-48af-936f-248fa15a3a1c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36e2afba-7677-442c-8ada-bab54a913ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8cb900dc-04f1-4f47-b5da-3201ba1b6e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36e2afba-7677-442c-8ada-bab54a913ce0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8cb900dc-04f1-4f47-b5da-3201ba1b6e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_ea70dc83-0928-4d74-8991-0787628664d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_36e2afba-7677-442c-8ada-bab54a913ce0" xlink:to="loc_us-gaap_AccountsReceivableMember_ea70dc83-0928-4d74-8991-0787628664d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e5a7c06e-7b0c-44f2-bff3-ce0b76c9a446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_befbdc7f-5602-4dfb-8cf3-0318d1ceb39e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e5a7c06e-7b0c-44f2-bff3-ce0b76c9a446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a6b87076-04cc-48da-aa6d-1a296fc67912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e5a7c06e-7b0c-44f2-bff3-ce0b76c9a446" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a6b87076-04cc-48da-aa6d-1a296fc67912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4a9596f8-3a2c-4ba0-8f2b-eb8cb25142ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a6b87076-04cc-48da-aa6d-1a296fc67912" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4a9596f8-3a2c-4ba0-8f2b-eb8cb25142ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_b77b0c2a-686a-4564-a91a-29b5a1a065de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_befbdc7f-5602-4dfb-8cf3-0318d1ceb39e" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_b77b0c2a-686a-4564-a91a-29b5a1a065de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_df1c9f3d-cbd1-4783-8b57-56a01602b95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b77b0c2a-686a-4564-a91a-29b5a1a065de" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_df1c9f3d-cbd1-4783-8b57-56a01602b95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_925b7d09-ceb6-4b6b-b7ce-61c338371208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b43af564-581e-4845-92fd-446d723b86b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_925b7d09-ceb6-4b6b-b7ce-61c338371208" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b43af564-581e-4845-92fd-446d723b86b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ab9a3125-3313-43cf-97c2-b10090499e2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b43af564-581e-4845-92fd-446d723b86b6" xlink:to="loc_srt_StatementGeographicalAxis_ab9a3125-3313-43cf-97c2-b10090499e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a3867d52-bd0e-4d07-bd70-b3908717ade1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ab9a3125-3313-43cf-97c2-b10090499e2b" xlink:to="loc_srt_SegmentGeographicalDomain_a3867d52-bd0e-4d07-bd70-b3908717ade1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a7bf2f88-567f-4b8c-9a35-08e97f516ce6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a3867d52-bd0e-4d07-bd70-b3908717ade1" xlink:to="loc_country_US_a7bf2f88-567f-4b8c-9a35-08e97f516ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_dca023b6-2b43-4316-8e37-3f17b5da1ee0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a3867d52-bd0e-4d07-bd70-b3908717ade1" xlink:to="loc_srt_EuropeMember_dca023b6-2b43-4316-8e37-3f17b5da1ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_9dc13900-d734-4613-8646-e7ce84e25ebf" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a3867d52-bd0e-4d07-bd70-b3908717ade1" xlink:to="loc_country_JP_9dc13900-d734-4613-8646-e7ce84e25ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d20a51bb-be70-4dbb-b86e-c006841ba986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b43af564-581e-4845-92fd-446d723b86b6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d20a51bb-be70-4dbb-b86e-c006841ba986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8757735-2ca9-4d3f-ac59-566fda520cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d20a51bb-be70-4dbb-b86e-c006841ba986" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a8757735-2ca9-4d3f-ac59-566fda520cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61b4015a-1700-4343-bbcb-7b18ab1bdb30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7ed294f2-cc4f-47f7-b091-e6263dadefcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61b4015a-1700-4343-bbcb-7b18ab1bdb30" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7ed294f2-cc4f-47f7-b091-e6263dadefcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c1cff367-2259-4332-aaea-6a66e8a2073f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7ed294f2-cc4f-47f7-b091-e6263dadefcc" xlink:to="loc_srt_ProductOrServiceAxis_c1cff367-2259-4332-aaea-6a66e8a2073f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1204b745-e37b-4978-b6ec-038fcc87cccd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c1cff367-2259-4332-aaea-6a66e8a2073f" xlink:to="loc_srt_ProductsAndServicesDomain_1204b745-e37b-4978-b6ec-038fcc87cccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2ec05803-9fcc-4e09-a702-521887aaef98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1204b745-e37b-4978-b6ec-038fcc87cccd" xlink:to="loc_us-gaap_ProductMember_2ec05803-9fcc-4e09-a702-521887aaef98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_48e5cbe6-8599-49fc-8ad6-f98e4eb5c411" xlink:href="exel-20220930.xsd#exel_CabometyxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_2ec05803-9fcc-4e09-a702-521887aaef98" xlink:to="loc_exel_CabometyxMember_48e5cbe6-8599-49fc-8ad6-f98e4eb5c411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_2052aa8d-a84a-4276-a4ac-c97359943a6b" xlink:href="exel-20220930.xsd#exel_CometriqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_2ec05803-9fcc-4e09-a702-521887aaef98" xlink:to="loc_exel_CometriqMember_2052aa8d-a84a-4276-a4ac-c97359943a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c4a97007-13ad-4a96-ba78-5bb438506099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7ed294f2-cc4f-47f7-b091-e6263dadefcc" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c4a97007-13ad-4a96-ba78-5bb438506099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c68e1b9c-d3b4-4c99-98ca-81135045d366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c4a97007-13ad-4a96-ba78-5bb438506099" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c68e1b9c-d3b4-4c99-98ca-81135045d366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9e20d581-e839-4dc6-8ace-a16783e67ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_4a8a5f81-21a2-4c5a-a287-8fdd40764c84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9e20d581-e839-4dc6-8ace-a16783e67ffb" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_4a8a5f81-21a2-4c5a-a287-8fdd40764c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a4b65e56-9fcb-4f7e-ba73-21ddb68ee16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_4a8a5f81-21a2-4c5a-a287-8fdd40764c84" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a4b65e56-9fcb-4f7e-ba73-21ddb68ee16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_f6d72f63-1030-41a8-861d-141ac191ab31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a4b65e56-9fcb-4f7e-ba73-21ddb68ee16b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_f6d72f63-1030-41a8-861d-141ac191ab31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_719ed4db-ffc3-4664-b7d9-d9c15d71a9ee" xlink:href="exel-20220930.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f6d72f63-1030-41a8-861d-141ac191ab31" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_719ed4db-ffc3-4664-b7d9-d9c15d71a9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_a63a1785-1092-4990-b367-5b071c57c726" xlink:href="exel-20220930.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f6d72f63-1030-41a8-861d-141ac191ab31" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_a63a1785-1092-4990-b367-5b071c57c726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_afd11c20-3513-4a17-b4bf-53a6295790c4" xlink:href="exel-20220930.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f6d72f63-1030-41a8-861d-141ac191ab31" xlink:to="loc_exel_AllowanceForProductRebatesMember_afd11c20-3513-4a17-b4bf-53a6295790c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b77bf2f7-d133-40a8-8ed6-82f12c33c266" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_4a8a5f81-21a2-4c5a-a287-8fdd40764c84" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b77bf2f7-d133-40a8-8ed6-82f12c33c266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e0a588e2-ffdd-42fa-a31a-27dadc9e9ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b77bf2f7-d133-40a8-8ed6-82f12c33c266" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e0a588e2-ffdd-42fa-a31a-27dadc9e9ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_15103aa6-c511-4a9b-8eb7-b15e5f988f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e0a588e2-ffdd-42fa-a31a-27dadc9e9ac8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_15103aa6-c511-4a9b-8eb7-b15e5f988f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_cbee311f-debc-4395-9bd2-054c6989a9d5" xlink:href="exel-20220930.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e0a588e2-ffdd-42fa-a31a-27dadc9e9ac8" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_cbee311f-debc-4395-9bd2-054c6989a9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_59690969-7a55-4355-b7c2-6197add8c3f3" xlink:href="exel-20220930.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_cbee311f-debc-4395-9bd2-054c6989a9d5" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_59690969-7a55-4355-b7c2-6197add8c3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_cffdd4d9-5a8f-4c36-964b-ea452d99adf2" xlink:href="exel-20220930.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_cbee311f-debc-4395-9bd2-054c6989a9d5" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_cffdd4d9-5a8f-4c36-964b-ea452d99adf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_fb3c5f4e-86bf-407a-b615-5be65d48d94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e0a588e2-ffdd-42fa-a31a-27dadc9e9ac8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_fb3c5f4e-86bf-407a-b615-5be65d48d94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_16eb04e8-3bdc-4d48-a80c-e98b7ff10404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e0a588e2-ffdd-42fa-a31a-27dadc9e9ac8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_16eb04e8-3bdc-4d48-a80c-e98b7ff10404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61779b8c-9ba6-468f-953a-9372b50ee658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b217425b-0bd4-4697-b2de-d79749101c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61779b8c-9ba6-468f-953a-9372b50ee658" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b217425b-0bd4-4697-b2de-d79749101c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c9190082-dfb5-40ed-92c5-d259d54a428b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b217425b-0bd4-4697-b2de-d79749101c68" xlink:to="loc_srt_CounterpartyNameAxis_c9190082-dfb5-40ed-92c5-d259d54a428b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98c7e412-0f1a-44f9-9b2b-230ac9fa6bac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c9190082-dfb5-40ed-92c5-d259d54a428b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98c7e412-0f1a-44f9-9b2b-230ac9fa6bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaAndIspenMember_2cb6fd6b-b22d-4768-9a15-0c8d10d9b535" xlink:href="exel-20220930.xsd#exel_TakedaAndIspenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98c7e412-0f1a-44f9-9b2b-230ac9fa6bac" xlink:to="loc_exel_TakedaAndIspenMember_2cb6fd6b-b22d-4768-9a15-0c8d10d9b535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b217425b-0bd4-4697-b2de-d79749101c68" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_ccee7eb5-be57-4354-bf08-a36db3ac18d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_ccee7eb5-be57-4354-bf08-a36db3ac18d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_59c60803-c984-4857-854d-fdd909388b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrentAbstract_ccee7eb5-be57-4354-bf08-a36db3ac18d2" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_59c60803-c984-4857-854d-fdd909388b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_5b7ee59f-ab0d-4201-9714-93dbd027c178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_5b7ee59f-ab0d-4201-9714-93dbd027c178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_83571b78-4276-40bf-b2c0-bccc31f6365a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_5b7ee59f-ab0d-4201-9714-93dbd027c178" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_83571b78-4276-40bf-b2c0-bccc31f6365a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_430bf2d4-c096-4fee-a49a-30c07c080ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_5b7ee59f-ab0d-4201-9714-93dbd027c178" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_430bf2d4-c096-4fee-a49a-30c07c080ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_08b133a4-45d9-4e23-9660-5fa8903acb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_5b7ee59f-ab0d-4201-9714-93dbd027c178" xlink:to="loc_us-gaap_ContractWithCustomerLiability_08b133a4-45d9-4e23-9660-5fa8903acb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_4222b8fb-5369-42e9-9231-6b940b88e800" xlink:href="exel-20220930.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_4222b8fb-5369-42e9-9231-6b940b88e800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_5d975c6a-1414-4d6c-9679-eedc97fcba9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_5d975c6a-1414-4d6c-9679-eedc97fcba9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_24833d7a-0e93-46dd-b1a8-7859c1d34fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3367b278-fbcf-429b-8672-b313f6638906" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_24833d7a-0e93-46dd-b1a8-7859c1d34fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d1b7fbb-2419-42a9-ad64-68b32586690a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27370109-d08c-4522-99bf-aff5dc2200a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d1b7fbb-2419-42a9-ad64-68b32586690a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27370109-d08c-4522-99bf-aff5dc2200a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_614efae7-7264-41af-8337-2bfc1982f18c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27370109-d08c-4522-99bf-aff5dc2200a4" xlink:to="loc_srt_ProductOrServiceAxis_614efae7-7264-41af-8337-2bfc1982f18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e6f7ecc8-23df-4492-9b10-6a11ffaefa27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_614efae7-7264-41af-8337-2bfc1982f18c" xlink:to="loc_srt_ProductsAndServicesDomain_e6f7ecc8-23df-4492-9b10-6a11ffaefa27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_bfb6e6b4-b792-4807-b1d8-b2b90671e4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6f7ecc8-23df-4492-9b10-6a11ffaefa27" xlink:to="loc_us-gaap_LicenseMember_bfb6e6b4-b792-4807-b1d8-b2b90671e4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_4b450160-a188-4ddd-b321-32a2cc52755f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6f7ecc8-23df-4492-9b10-6a11ffaefa27" xlink:to="loc_us-gaap_ServiceMember_4b450160-a188-4ddd-b321-32a2cc52755f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5f539641-9db8-4ec6-bab8-ebddaea03dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27370109-d08c-4522-99bf-aff5dc2200a4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5f539641-9db8-4ec6-bab8-ebddaea03dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_06dec1a0-6aa0-4c0a-bfcf-e53de5557bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5f539641-9db8-4ec6-bab8-ebddaea03dbb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_06dec1a0-6aa0-4c0a-bfcf-e53de5557bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_3377db17-8cce-499f-a321-1edfc5bea903" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_06dec1a0-6aa0-4c0a-bfcf-e53de5557bd1" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_3377db17-8cce-499f-a321-1edfc5bea903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_208a032a-9a2e-46b2-a891-96b0311011b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27370109-d08c-4522-99bf-aff5dc2200a4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_208a032a-9a2e-46b2-a891-96b0311011b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdca3060-1d02-495c-834f-8cbbfd5b8828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_208a032a-9a2e-46b2-a891-96b0311011b1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdca3060-1d02-495c-834f-8cbbfd5b8828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee072502-96cb-49ce-afaf-53de18e2c445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a848657b-18e8-4cc3-8914-0cab72b477cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee072502-96cb-49ce-afaf-53de18e2c445" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a848657b-18e8-4cc3-8914-0cab72b477cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bbd21929-6ae5-45fd-92fa-67d316f4a5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a848657b-18e8-4cc3-8914-0cab72b477cc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bbd21929-6ae5-45fd-92fa-67d316f4a5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18f9e22b-d3e5-4201-9cf9-1df996c7c083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bbd21929-6ae5-45fd-92fa-67d316f4a5ec" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18f9e22b-d3e5-4201-9cf9-1df996c7c083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_768c277a-405d-4970-aa71-c400d0cd75a4" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18f9e22b-d3e5-4201-9cf9-1df996c7c083" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_768c277a-405d-4970-aa71-c400d0cd75a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbb66b4a-2d63-414b-830e-056b7fb3a3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a848657b-18e8-4cc3-8914-0cab72b477cc" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbb66b4a-2d63-414b-830e-056b7fb3a3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e34570e6-d198-4e10-992d-5de3f280cabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbb66b4a-2d63-414b-830e-056b7fb3a3ad" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e34570e6-d198-4e10-992d-5de3f280cabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfRegulatoryMilestone_eea59611-c161-4dce-ae53-70b35f79919b" xlink:href="exel-20220930.xsd#exel_NumberOfRegulatoryMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbb66b4a-2d63-414b-830e-056b7fb3a3ad" xlink:to="loc_exel_NumberOfRegulatoryMilestone_eea59611-c161-4dce-ae53-70b35f79919b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerMilestoneRevenueRecognized_7b80e53f-b2ff-4d8c-b9d3-32a8de0e01c2" xlink:href="exel-20220930.xsd#exel_ContractWithCustomerMilestoneRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbb66b4a-2d63-414b-830e-056b7fb3a3ad" xlink:to="loc_exel_ContractWithCustomerMilestoneRevenueRecognized_7b80e53f-b2ff-4d8c-b9d3-32a8de0e01c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_b63ba933-8d63-46f2-90cf-7378c1e26884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbb66b4a-2d63-414b-830e-056b7fb3a3ad" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_b63ba933-8d63-46f2-90cf-7378c1e26884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d1a219e9-d241-41d9-84c2-35f5fcab0ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e050a0c0-e550-44c7-a905-eb669d1c1f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d1a219e9-d241-41d9-84c2-35f5fcab0ca5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e050a0c0-e550-44c7-a905-eb669d1c1f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4faebfec-d6b8-46cb-a427-22af25f37d23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e050a0c0-e550-44c7-a905-eb669d1c1f5d" xlink:to="loc_srt_ProductOrServiceAxis_4faebfec-d6b8-46cb-a427-22af25f37d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_876004ff-0791-4754-af84-a05f39b43a37" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4faebfec-d6b8-46cb-a427-22af25f37d23" xlink:to="loc_srt_ProductsAndServicesDomain_876004ff-0791-4754-af84-a05f39b43a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_4c6c3040-3280-4d83-8a76-351429668d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_876004ff-0791-4754-af84-a05f39b43a37" xlink:to="loc_us-gaap_LicenseMember_4c6c3040-3280-4d83-8a76-351429668d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_a93b6e32-b11b-40a2-944d-204986a1f1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_876004ff-0791-4754-af84-a05f39b43a37" xlink:to="loc_us-gaap_ServiceMember_a93b6e32-b11b-40a2-944d-204986a1f1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7200e49a-ad90-4cb5-89a8-38a6f41011dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e050a0c0-e550-44c7-a905-eb669d1c1f5d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7200e49a-ad90-4cb5-89a8-38a6f41011dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbadeb75-417b-4ac5-a74e-83c641fdbc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7200e49a-ad90-4cb5-89a8-38a6f41011dd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbadeb75-417b-4ac5-a74e-83c641fdbc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_894fdc2c-c228-4a20-a537-b078dee1ceba" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fbadeb75-417b-4ac5-a74e-83c641fdbc7d" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_894fdc2c-c228-4a20-a537-b078dee1ceba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a9b9268-78aa-4de7-a7d1-efdfd1420dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e050a0c0-e550-44c7-a905-eb669d1c1f5d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a9b9268-78aa-4de7-a7d1-efdfd1420dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c21fb5d0-191e-4e70-9cf1-de913d8b6ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a9b9268-78aa-4de7-a7d1-efdfd1420dd3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c21fb5d0-191e-4e70-9cf1-de913d8b6ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12ab89ab-1cfe-4f77-9a8c-400d7d6900c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01421d10-012d-4cd1-8980-8bc704b64577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12ab89ab-1cfe-4f77-9a8c-400d7d6900c4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01421d10-012d-4cd1-8980-8bc704b64577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a619fbec-f85e-439a-b363-83cff9065e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01421d10-012d-4cd1-8980-8bc704b64577" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a619fbec-f85e-439a-b363-83cff9065e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8cefcbc-934c-4dd1-afbd-9524a7edb540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a619fbec-f85e-439a-b363-83cff9065e72" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8cefcbc-934c-4dd1-afbd-9524a7edb540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_772da4b0-d153-4495-a06b-0f106d564851" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d8cefcbc-934c-4dd1-afbd-9524a7edb540" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_772da4b0-d153-4495-a06b-0f106d564851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f1cffdef-3650-4e7b-9dbe-d03ba4f937d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_01421d10-012d-4cd1-8980-8bc704b64577" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f1cffdef-3650-4e7b-9dbe-d03ba4f937d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_012cddc2-9bd4-4a66-a33c-e6b448f063e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f1cffdef-3650-4e7b-9dbe-d03ba4f937d6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_012cddc2-9bd4-4a66-a33c-e6b448f063e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6ff7fb92-7e7a-4737-a1cf-05d05b91fdd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ad5fe60-545a-4948-a7e8-308981ff2049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6ff7fb92-7e7a-4737-a1cf-05d05b91fdd0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ad5fe60-545a-4948-a7e8-308981ff2049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_912eb377-27dc-488a-a4dc-2109af632fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ad5fe60-545a-4948-a7e8-308981ff2049" xlink:to="loc_us-gaap_TypeOfArrangementAxis_912eb377-27dc-488a-a4dc-2109af632fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eea3280a-ad31-4f31-9244-3b5e1ad9c0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_912eb377-27dc-488a-a4dc-2109af632fd3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eea3280a-ad31-4f31-9244-3b5e1ad9c0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_7f9bd8df-299d-4ac4-829f-90674df37a4b" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eea3280a-ad31-4f31-9244-3b5e1ad9c0ca" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_7f9bd8df-299d-4ac4-829f-90674df37a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyalPharmaMember_3b36a2af-f1ac-4847-8777-5222817ceec8" xlink:href="exel-20220930.xsd#exel_RoyalPharmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eea3280a-ad31-4f31-9244-3b5e1ad9c0ca" xlink:to="loc_exel_RoyalPharmaMember_3b36a2af-f1ac-4847-8777-5222817ceec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c025946e-8570-49df-9eb4-ae83d82cdc77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4ad5fe60-545a-4948-a7e8-308981ff2049" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c025946e-8570-49df-9eb4-ae83d82cdc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_5b03e3f7-1ed0-468d-b764-8a23dae2474f" xlink:href="exel-20220930.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c025946e-8570-49df-9eb4-ae83d82cdc77" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_5b03e3f7-1ed0-468d-b764-8a23dae2474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_0635e082-91ce-4d5c-8491-d1be2bada2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c025946e-8570-49df-9eb4-ae83d82cdc77" xlink:to="loc_us-gaap_RoyaltyExpense_0635e082-91ce-4d5c-8491-d1be2bada2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9021b358-8950-4de3-87c3-68febca5bb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45e8d38c-e4db-4be3-ace5-d57af3791da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9021b358-8950-4de3-87c3-68febca5bb5d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45e8d38c-e4db-4be3-ace5-d57af3791da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5c679491-d856-43e9-80e2-3c7f3e3edddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45e8d38c-e4db-4be3-ace5-d57af3791da0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5c679491-d856-43e9-80e2-3c7f3e3edddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d46bdd3-e16a-4456-b66c-979d89eed20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5c679491-d856-43e9-80e2-3c7f3e3edddb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d46bdd3-e16a-4456-b66c-979d89eed20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_84de864e-bdc5-4c35-bd15-ee03273850b4" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5d46bdd3-e16a-4456-b66c-979d89eed20e" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_84de864e-bdc5-4c35-bd15-ee03273850b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisAxis_15bfdddd-ed5f-44cf-92ee-da5f6b7806db" xlink:href="exel-20220930.xsd#exel_ProductOrServiceAxisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45e8d38c-e4db-4be3-ace5-d57af3791da0" xlink:to="loc_exel_ProductOrServiceAxisAxis_15bfdddd-ed5f-44cf-92ee-da5f6b7806db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductOrServiceAxisDomain_9d4e4270-86d0-416c-b189-3c6ac6a60805" xlink:href="exel-20220930.xsd#exel_ProductOrServiceAxisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProductOrServiceAxisAxis_15bfdddd-ed5f-44cf-92ee-da5f6b7806db" xlink:to="loc_exel_ProductOrServiceAxisDomain_9d4e4270-86d0-416c-b189-3c6ac6a60805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_f0efff7c-f732-4b03-b74d-1ba01e2e7987" xlink:href="exel-20220930.xsd#exel_CotellicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProductOrServiceAxisDomain_9d4e4270-86d0-416c-b189-3c6ac6a60805" xlink:to="loc_exel_CotellicMember_f0efff7c-f732-4b03-b74d-1ba01e2e7987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d96c968-3167-4e5e-b1a6-0b8ec7385b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_45e8d38c-e4db-4be3-ace5-d57af3791da0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d96c968-3167-4e5e-b1a6-0b8ec7385b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_dd56f889-beda-479a-92d2-faa030ae29d9" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d96c968-3167-4e5e-b1a6-0b8ec7385b8d" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_dd56f889-beda-479a-92d2-faa030ae29d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1555f9b0-66c8-4f6d-8212-6346380fe5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d96c968-3167-4e5e-b1a6-0b8ec7385b8d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1555f9b0-66c8-4f6d-8212-6346380fe5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_397be7d8-a35f-49f8-9f54-4b67b1afdabd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_2876b40f-c4e7-47c8-8c61-f35a1c3bb61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_397be7d8-a35f-49f8-9f54-4b67b1afdabd" xlink:to="loc_us-gaap_AssetAcquisitionTable_2876b40f-c4e7-47c8-8c61-f35a1c3bb61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_76625837-dbd9-435d-bcc3-4a0d13408f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2876b40f-c4e7-47c8-8c61-f35a1c3bb61f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_76625837-dbd9-435d-bcc3-4a0d13408f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d1d770a-527c-4bf7-94ca-a41cf69e58a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_76625837-dbd9-435d-bcc3-4a0d13408f40" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d1d770a-527c-4bf7-94ca-a41cf69e58a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember_ab3b0948-5ed6-4dcd-9d10-b30755690f73" xlink:href="exel-20220930.xsd#exel_CollaborationAgreementWithBioInventInternationalABBioInventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d1d770a-527c-4bf7-94ca-a41cf69e58a1" xlink:to="loc_exel_CollaborationAgreementWithBioInventInternationalABBioInventMember_ab3b0948-5ed6-4dcd-9d10-b30755690f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember_373380b7-647c-4c25-9b77-98cfc9b8e178" xlink:href="exel-20220930.xsd#exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d1d770a-527c-4bf7-94ca-a41cf69e58a1" xlink:to="loc_exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember_373380b7-647c-4c25-9b77-98cfc9b8e178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_b8102a33-0759-4c5e-9b81-f695a953ca08" xlink:href="exel-20220930.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9d1d770a-527c-4bf7-94ca-a41cf69e58a1" xlink:to="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_b8102a33-0759-4c5e-9b81-f695a953ca08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_c0e111df-9f42-4bc7-9166-0ff94d275f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2876b40f-c4e7-47c8-8c61-f35a1c3bb61f" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_c0e111df-9f42-4bc7-9166-0ff94d275f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_ca27ceab-45b1-4c5c-8068-880e1ee7fa5d" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_c0e111df-9f42-4bc7-9166-0ff94d275f88" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_ca27ceab-45b1-4c5c-8068-880e1ee7fa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_0c012fb6-e089-4d33-a850-f2b4f50aadf9" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_c0e111df-9f42-4bc7-9166-0ff94d275f88" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_0c012fb6-e089-4d33-a850-f2b4f50aadf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_bbeff56e-6a91-47e8-8f50-68fdff1d69a0" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_c0e111df-9f42-4bc7-9166-0ff94d275f88" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_bbeff56e-6a91-47e8-8f50-68fdff1d69a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_a912394a-d88d-4841-abba-95500406a985" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_c0e111df-9f42-4bc7-9166-0ff94d275f88" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_a912394a-d88d-4841-abba-95500406a985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0bef9086-5e82-49c8-9d1b-8dff760e8aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_2171d12a-5f59-4a25-b07a-3ef1f591835e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0bef9086-5e82-49c8-9d1b-8dff760e8aff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_2171d12a-5f59-4a25-b07a-3ef1f591835e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a732951c-eea5-41c7-a4f1-e066d5933a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2171d12a-5f59-4a25-b07a-3ef1f591835e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a732951c-eea5-41c7-a4f1-e066d5933a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2839fcb5-02bd-4e6b-86eb-cd2f82404b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2171d12a-5f59-4a25-b07a-3ef1f591835e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2839fcb5-02bd-4e6b-86eb-cd2f82404b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0b541c1b-d459-40de-9aa8-5fbc885551c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2171d12a-5f59-4a25-b07a-3ef1f591835e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0b541c1b-d459-40de-9aa8-5fbc885551c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_848357ff-5bfa-4d75-949a-651f30aa6c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f79e11dd-a5f9-48b0-839a-65f923fe6599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_848357ff-5bfa-4d75-949a-651f30aa6c37" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f79e11dd-a5f9-48b0-839a-65f923fe6599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e3aa3306-9870-4389-8006-576dc2063f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f79e11dd-a5f9-48b0-839a-65f923fe6599" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e3aa3306-9870-4389-8006-576dc2063f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_88492f49-602f-49b4-960d-b41e526eacac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e3aa3306-9870-4389-8006-576dc2063f62" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_88492f49-602f-49b4-960d-b41e526eacac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_937bc3d7-cea1-4aa8-a881-ad21468ebed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_88492f49-602f-49b4-960d-b41e526eacac" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_937bc3d7-cea1-4aa8-a881-ad21468ebed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_ae8ed183-9746-4dd2-a872-deb2d3e8ecd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_88492f49-602f-49b4-960d-b41e526eacac" xlink:to="loc_us-gaap_MunicipalBondsMember_ae8ed183-9746-4dd2-a872-deb2d3e8ecd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f79e11dd-a5f9-48b0-839a-65f923fe6599" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_c72bd28d-ae06-4a6c-bd36-ffb391a5d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_us-gaap_InterestReceivable_c72bd28d-ae06-4a6c-bd36-ffb391a5d79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_953efdf8-7375-492f-94b8-e26a3f285959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_953efdf8-7375-492f-94b8-e26a3f285959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfBondSecurities_f302608f-fba2-4d1c-ad2d-527fd3ccdf5f" xlink:href="exel-20220930.xsd#exel_NumberOfBondSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_exel_NumberOfBondSecurities_f302608f-fba2-4d1c-ad2d-527fd3ccdf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_50aaf167-dfb3-44cc-82ab-d3bcae0130ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_50aaf167-dfb3-44cc-82ab-d3bcae0130ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3d51ec01-c0ba-4e8e-a154-e71bcf1dfc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3d51ec01-c0ba-4e8e-a154-e71bcf1dfc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_93e72b01-dfae-4d5a-8d7d-1882f1bdc699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_210e597f-f955-42cb-a871-7bbfa34fe551" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_93e72b01-dfae-4d5a-8d7d-1882f1bdc699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cc7fc03e-1580-4dc2-9648-908fb261e1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e76e21e-2fc8-4537-b269-82c1f25143bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cc7fc03e-1580-4dc2-9648-908fb261e1f0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e76e21e-2fc8-4537-b269-82c1f25143bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_075543e8-99ea-407f-b14d-fd20ccd4bf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e76e21e-2fc8-4537-b269-82c1f25143bd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_075543e8-99ea-407f-b14d-fd20ccd4bf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_075543e8-99ea-407f-b14d-fd20ccd4bf5b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cbf58cfb-fdf7-49af-80a5-d5ba3517ccee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_CommercialPaperMember_cbf58cfb-fdf7-49af-80a5-d5ba3517ccee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ed5cb036-340a-41e6-a5f0-f5feff6115ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ed5cb036-340a-41e6-a5f0-f5feff6115ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_b4e8275b-ca42-4482-abac-1b123cd8b14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_b4e8275b-ca42-4482-abac-1b123cd8b14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_f04ab85b-f6c5-4b8e-bf77-76ddd3c4f15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_MunicipalBondsMember_f04ab85b-f6c5-4b8e-bf77-76ddd3c4f15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_82f13c7c-c70c-4b0f-b7cc-959cc045f9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_CashMember_82f13c7c-c70c-4b0f-b7cc-959cc045f9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e9f10d0b-bc05-4f93-adb4-0ca48d143591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e9f10d0b-bc05-4f93-adb4-0ca48d143591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0b5e6a89-9d95-4647-b71b-77f0b456e17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_590ba78a-9c3e-4986-b50c-8c1ba380140f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0b5e6a89-9d95-4647-b71b-77f0b456e17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e76e21e-2fc8-4537-b269-82c1f25143bd" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_18c63046-fa96-4f29-a8fd-64920b7735e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_18c63046-fa96-4f29-a8fd-64920b7735e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_007971a4-a4ff-4866-98b0-68957d992327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_18c63046-fa96-4f29-a8fd-64920b7735e1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_007971a4-a4ff-4866-98b0-68957d992327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23b45144-6657-4cba-bede-f9093ea817bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_18c63046-fa96-4f29-a8fd-64920b7735e1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_23b45144-6657-4cba-bede-f9093ea817bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_07fa4a9c-f458-43ab-a1e3-0faf5f598b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_18c63046-fa96-4f29-a8fd-64920b7735e1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_07fa4a9c-f458-43ab-a1e3-0faf5f598b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d6ecada1-4775-4a5e-a721-f2d7a7567b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_18c63046-fa96-4f29-a8fd-64920b7735e1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d6ecada1-4775-4a5e-a721-f2d7a7567b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3f1c5255-9e33-4924-9a2a-ca2b7fbdcdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3f1c5255-9e33-4924-9a2a-ca2b7fbdcdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_1683f802-f13d-49b1-9eac-d6a482e8e508" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3f1c5255-9e33-4924-9a2a-ca2b7fbdcdaa" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_1683f802-f13d-49b1-9eac-d6a482e8e508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_e2154ee4-2ecc-47a4-a923-ba9deea239a5" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3f1c5255-9e33-4924-9a2a-ca2b7fbdcdaa" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_e2154ee4-2ecc-47a4-a923-ba9deea239a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_bca4428f-edaa-401b-bdb6-622f6612d6b0" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3f1c5255-9e33-4924-9a2a-ca2b7fbdcdaa" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_bca4428f-edaa-401b-bdb6-622f6612d6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_0c485617-8735-418e-a87b-e4c8790696b8" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3f1c5255-9e33-4924-9a2a-ca2b7fbdcdaa" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_0c485617-8735-418e-a87b-e4c8790696b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_62091103-15f1-473b-b1c3-ed857cf2b369" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_62091103-15f1-473b-b1c3-ed857cf2b369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8844b072-ec8f-4008-9663-45a558dfb79a" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8844b072-ec8f-4008-9663-45a558dfb79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_82637847-785c-480b-aa08-a2271e1b97bf" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_82637847-785c-480b-aa08-a2271e1b97bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_3eba8069-6dcc-4c65-8da1-83eeae6fea1b" xlink:href="exel-20220930.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fc4fceea-b777-4d18-ac7c-e22717a9ba5b" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_3eba8069-6dcc-4c65-8da1-83eeae6fea1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4ff9f6b0-a5ec-43bc-a7f5-4b83be10cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f6d7e858-d9a5-4936-945a-7751441578fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4ff9f6b0-a5ec-43bc-a7f5-4b83be10cb1d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f6d7e858-d9a5-4936-945a-7751441578fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3d8fb619-7d3c-47cc-b787-55fd0ce17c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f6d7e858-d9a5-4936-945a-7751441578fc" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3d8fb619-7d3c-47cc-b787-55fd0ce17c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7505c944-5da6-4d9d-a56c-f24e1da392b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3d8fb619-7d3c-47cc-b787-55fd0ce17c40" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7505c944-5da6-4d9d-a56c-f24e1da392b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_b8fe72fb-eb2f-4995-ac06-f7c0fc6a22bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7505c944-5da6-4d9d-a56c-f24e1da392b8" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_b8fe72fb-eb2f-4995-ac06-f7c0fc6a22bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_13896989-bc8d-475a-a4bc-acd9033f3814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7505c944-5da6-4d9d-a56c-f24e1da392b8" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_13896989-bc8d-475a-a4bc-acd9033f3814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_85389a33-9f20-4ced-8dfc-f9e118588bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7505c944-5da6-4d9d-a56c-f24e1da392b8" xlink:to="loc_us-gaap_CommercialPaperMember_85389a33-9f20-4ced-8dfc-f9e118588bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_5a484f2b-8a1b-4499-a6fb-c054f0104172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7505c944-5da6-4d9d-a56c-f24e1da392b8" xlink:to="loc_us-gaap_MunicipalBondsMember_5a484f2b-8a1b-4499-a6fb-c054f0104172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2df9110c-620e-48dc-9e54-9a944cdc82d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f6d7e858-d9a5-4936-945a-7751441578fc" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2df9110c-620e-48dc-9e54-9a944cdc82d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_21f2e244-4d37-4895-9305-34912b7639ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2df9110c-620e-48dc-9e54-9a944cdc82d6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_21f2e244-4d37-4895-9305-34912b7639ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_002e7db4-18ce-4bfc-8d8d-46afef5072c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_21f2e244-4d37-4895-9305-34912b7639ed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_002e7db4-18ce-4bfc-8d8d-46afef5072c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_bc7ccb60-85eb-47fe-a360-db5e6be3674c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_21f2e244-4d37-4895-9305-34912b7639ed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_bc7ccb60-85eb-47fe-a360-db5e6be3674c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bdc81a7d-2e37-4f16-bed4-203824517dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_b1cfd0b2-8b57-4f1d-9aa3-c946c7206bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bdc81a7d-2e37-4f16-bed4-203824517dd4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_b1cfd0b2-8b57-4f1d-9aa3-c946c7206bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_af942acd-aaa0-4eaf-841f-00af44f7d7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bdc81a7d-2e37-4f16-bed4-203824517dd4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_af942acd-aaa0-4eaf-841f-00af44f7d7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b25685d8-07fa-4232-8599-c91f31f6cc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bdc81a7d-2e37-4f16-bed4-203824517dd4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b25685d8-07fa-4232-8599-c91f31f6cc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_25d0b356-27cd-4ca5-aa83-88dce40d7fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce632fd1-4e18-430c-bb16-40262aab3cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_25d0b356-27cd-4ca5-aa83-88dce40d7fb3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce632fd1-4e18-430c-bb16-40262aab3cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1a4f0161-883d-4f8d-8bf9-34efe5d56a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce632fd1-4e18-430c-bb16-40262aab3cb9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1a4f0161-883d-4f8d-8bf9-34efe5d56a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1a4f0161-883d-4f8d-8bf9-34efe5d56a83" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1a888dca-1de8-44ae-b0fc-d3d945cce4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:to="loc_us-gaap_CommercialPaperMember_1a888dca-1de8-44ae-b0fc-d3d945cce4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_1706979f-5e75-4265-911e-727aa2bcbce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_1706979f-5e75-4265-911e-727aa2bcbce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_a4a8d750-3da9-45fb-b221-839d032351b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_a4a8d750-3da9-45fb-b221-839d032351b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_6a643d47-7245-4867-aac8-939a9c7cf59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:to="loc_us-gaap_MunicipalBondsMember_6a643d47-7245-4867-aac8-939a9c7cf59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e09af174-d349-437e-a34d-e59cc4a4061e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e09af174-d349-437e-a34d-e59cc4a4061e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7f8e36cd-9010-4e6c-8552-2951f199a161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_171e54e2-3c83-41ad-a1d6-6d7bbc11d024" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7f8e36cd-9010-4e6c-8552-2951f199a161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea60d900-980a-41c8-a388-128e544ba626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce632fd1-4e18-430c-bb16-40262aab3cb9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea60d900-980a-41c8-a388-128e544ba626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e8d1640a-56ae-4f9b-8280-d7c4c262585e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea60d900-980a-41c8-a388-128e544ba626" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e8d1640a-56ae-4f9b-8280-d7c4c262585e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d8ed6d3b-7f63-4762-820e-f227d1426c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e8d1640a-56ae-4f9b-8280-d7c4c262585e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d8ed6d3b-7f63-4762-820e-f227d1426c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a807484a-ec86-4f00-b236-ef6cd617c347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e8d1640a-56ae-4f9b-8280-d7c4c262585e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a807484a-ec86-4f00-b236-ef6cd617c347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfab1d71-10c7-4217-9d8c-769d44af95fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce632fd1-4e18-430c-bb16-40262aab3cb9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfab1d71-10c7-4217-9d8c-769d44af95fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b8ed6c15-9061-41df-83e7-d6a30d9db043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bfab1d71-10c7-4217-9d8c-769d44af95fe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b8ed6c15-9061-41df-83e7-d6a30d9db043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4ba296a5-7411-44ae-8023-6282b37303df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b8ed6c15-9061-41df-83e7-d6a30d9db043" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4ba296a5-7411-44ae-8023-6282b37303df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a8afc2e-957d-4d69-94c8-3ee73225f660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce632fd1-4e18-430c-bb16-40262aab3cb9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a8afc2e-957d-4d69-94c8-3ee73225f660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b1b1be1-1f9a-44f0-bde4-3c08f0582d85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a8afc2e-957d-4d69-94c8-3ee73225f660" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b1b1be1-1f9a-44f0-bde4-3c08f0582d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_626029a3-9782-4f25-afee-6f8026244c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a8afc2e-957d-4d69-94c8-3ee73225f660" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_626029a3-9782-4f25-afee-6f8026244c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_06558a71-41a0-4bd6-982a-ce56cc0a6250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1a8afc2e-957d-4d69-94c8-3ee73225f660" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_06558a71-41a0-4bd6-982a-ce56cc0a6250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bf1c4317-182b-4aba-97c4-1cc3ff62ab98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_904fce0f-a277-450d-a871-4acbda32ad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bf1c4317-182b-4aba-97c4-1cc3ff62ab98" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_904fce0f-a277-450d-a871-4acbda32ad1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_42f126de-c145-4528-a807-e987ec2db7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_904fce0f-a277-450d-a871-4acbda32ad1c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_42f126de-c145-4528-a807-e987ec2db7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_86fb7a41-f3ac-4df4-8a02-41eae9b3ff52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_42f126de-c145-4528-a807-e987ec2db7ee" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_86fb7a41-f3ac-4df4-8a02-41eae9b3ff52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_2297a625-3f7d-4625-952a-f61904db1502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_86fb7a41-f3ac-4df4-8a02-41eae9b3ff52" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_2297a625-3f7d-4625-952a-f61904db1502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6367702e-f0fa-4f7b-9c63-b2d4941e69d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_904fce0f-a277-450d-a871-4acbda32ad1c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6367702e-f0fa-4f7b-9c63-b2d4941e69d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_8c964974-ce61-42bc-aeda-3d3d8502c19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6367702e-f0fa-4f7b-9c63-b2d4941e69d8" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_8c964974-ce61-42bc-aeda-3d3d8502c19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_b60b8c1b-95e8-4050-b1b8-c59c64036fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6367702e-f0fa-4f7b-9c63-b2d4941e69d8" xlink:to="loc_us-gaap_DerivativeNotionalAmount_b60b8c1b-95e8-4050-b1b8-c59c64036fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_60465114-42f0-4287-ab46-135424307a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6367702e-f0fa-4f7b-9c63-b2d4941e69d8" xlink:to="loc_us-gaap_DerivativeTermOfContract_60465114-42f0-4287-ab46-135424307a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_7b35f61b-0b57-41c3-b96d-805ec5921ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6367702e-f0fa-4f7b-9c63-b2d4941e69d8" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_7b35f61b-0b57-41c3-b96d-805ec5921ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_951c90a2-7e09-4d0c-96c8-b44dc5fe3ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_bae19922-bd2e-4272-9cc7-d2bec39200ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_951c90a2-7e09-4d0c-96c8-b44dc5fe3ad9" xlink:to="loc_us-gaap_InventoryCurrentTable_bae19922-bd2e-4272-9cc7-d2bec39200ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3c17fcc5-9892-4b64-8c58-5a877346c8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_bae19922-bd2e-4272-9cc7-d2bec39200ab" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3c17fcc5-9892-4b64-8c58-5a877346c8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a2adc545-903a-4dee-84e6-60f462c83e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3c17fcc5-9892-4b64-8c58-5a877346c8dc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a2adc545-903a-4dee-84e6-60f462c83e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_5b677445-b966-41e6-981e-b5ed45e52139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a2adc545-903a-4dee-84e6-60f462c83e32" xlink:to="loc_us-gaap_InventoriesMember_5b677445-b966-41e6-981e-b5ed45e52139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_cae67acd-82ab-4e0f-a374-fce2e7baeddc" xlink:href="exel-20220930.xsd#exel_OtherLongtermAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a2adc545-903a-4dee-84e6-60f462c83e32" xlink:to="loc_exel_OtherLongtermAssetsMember_cae67acd-82ab-4e0f-a374-fce2e7baeddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_457fc7fe-c6f1-47b9-bbf3-95716a3e8cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_bae19922-bd2e-4272-9cc7-d2bec39200ab" xlink:to="loc_us-gaap_InventoryLineItems_457fc7fe-c6f1-47b9-bbf3-95716a3e8cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_009a91ab-7326-4643-abc8-a1cca5546d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_457fc7fe-c6f1-47b9-bbf3-95716a3e8cea" xlink:to="loc_us-gaap_InventoryRawMaterials_009a91ab-7326-4643-abc8-a1cca5546d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_37417b98-8c42-4832-80f7-44c7754f1874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_457fc7fe-c6f1-47b9-bbf3-95716a3e8cea" xlink:to="loc_us-gaap_InventoryWorkInProcess_37417b98-8c42-4832-80f7-44c7754f1874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_82a47d58-f6bf-48ec-af45-1cc7934efb71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_457fc7fe-c6f1-47b9-bbf3-95716a3e8cea" xlink:to="loc_us-gaap_InventoryFinishedGoods_82a47d58-f6bf-48ec-af45-1cc7934efb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d8e3da51-e763-4c3b-a54b-19e5afbaea36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_457fc7fe-c6f1-47b9-bbf3-95716a3e8cea" xlink:to="loc_us-gaap_InventoryGross_d8e3da51-e763-4c3b-a54b-19e5afbaea36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_966788fe-c0e1-4e3e-9a6e-f890dbf1ce26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790e382e-e696-4eb7-9bf2-14072539338e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_966788fe-c0e1-4e3e-9a6e-f890dbf1ce26" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790e382e-e696-4eb7-9bf2-14072539338e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_01517ba5-34e3-49e8-a284-576288e361ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790e382e-e696-4eb7-9bf2-14072539338e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_01517ba5-34e3-49e8-a284-576288e361ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a1943964-d668-46e4-9b25-b3fd6ada74f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_01517ba5-34e3-49e8-a284-576288e361ae" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a1943964-d668-46e4-9b25-b3fd6ada74f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_52e95c83-4163-40f9-a69b-a98ecdbcf7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a1943964-d668-46e4-9b25-b3fd6ada74f9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_52e95c83-4163-40f9-a69b-a98ecdbcf7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f4c4b64f-8f54-4f37-a9e3-5e798c84bdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a1943964-d668-46e4-9b25-b3fd6ada74f9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f4c4b64f-8f54-4f37-a9e3-5e798c84bdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28fe5af2-9888-4e72-8c7d-2c5772905fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790e382e-e696-4eb7-9bf2-14072539338e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28fe5af2-9888-4e72-8c7d-2c5772905fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_72303d91-42df-4700-a26a-fa20e6a62062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_28fe5af2-9888-4e72-8c7d-2c5772905fd2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_72303d91-42df-4700-a26a-fa20e6a62062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e472c48-2841-4c51-a9ec-f6cc8d4df232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd9bc7d-a6f8-4b55-a430-31a5fe32de50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e472c48-2841-4c51-a9ec-f6cc8d4df232" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd9bc7d-a6f8-4b55-a430-31a5fe32de50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_796eca67-aafa-4904-88a5-ddc853285360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd9bc7d-a6f8-4b55-a430-31a5fe32de50" xlink:to="loc_us-gaap_AwardTypeAxis_796eca67-aafa-4904-88a5-ddc853285360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fde12f16-abfc-4c1e-ac5a-ddef80bf8f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_796eca67-aafa-4904-88a5-ddc853285360" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fde12f16-abfc-4c1e-ac5a-ddef80bf8f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_010e62d0-1653-4ddc-b1bc-5697ef122d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fde12f16-abfc-4c1e-ac5a-ddef80bf8f51" xlink:to="loc_us-gaap_EmployeeStockOptionMember_010e62d0-1653-4ddc-b1bc-5697ef122d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_da61ce98-51e7-4c7c-bda5-dd0a39bd8032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fde12f16-abfc-4c1e-ac5a-ddef80bf8f51" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_da61ce98-51e7-4c7c-bda5-dd0a39bd8032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a04298d0-3ea2-42bd-b6f0-43d3472c0b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fde12f16-abfc-4c1e-ac5a-ddef80bf8f51" xlink:to="loc_us-gaap_PerformanceSharesMember_a04298d0-3ea2-42bd-b6f0-43d3472c0b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c6732f41-7edc-4818-bd37-c6034030ba6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fde12f16-abfc-4c1e-ac5a-ddef80bf8f51" xlink:to="loc_us-gaap_EmployeeStockMember_c6732f41-7edc-4818-bd37-c6034030ba6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ec8441e-1d4f-43c9-8c26-c0be98286d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fcd9bc7d-a6f8-4b55-a430-31a5fe32de50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ec8441e-1d4f-43c9-8c26-c0be98286d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_303319e5-83d9-4f5e-a262-146b3529f7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ec8441e-1d4f-43c9-8c26-c0be98286d5d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_303319e5-83d9-4f5e-a262-146b3529f7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc1b8148-2cd1-46f5-add0-e2388fd442dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf9fcc1-e1cc-4d5e-a7ad-92b411da408c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc1b8148-2cd1-46f5-add0-e2388fd442dc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf9fcc1-e1cc-4d5e-a7ad-92b411da408c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_95b47178-519e-4c91-be70-56c03397eb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf9fcc1-e1cc-4d5e-a7ad-92b411da408c" xlink:to="loc_us-gaap_AwardTypeAxis_95b47178-519e-4c91-be70-56c03397eb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b341b4e-2dae-4556-8820-5cf1b713c940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_95b47178-519e-4c91-be70-56c03397eb3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b341b4e-2dae-4556-8820-5cf1b713c940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e9ece991-a30b-4740-b0e1-49aa4fff4d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b341b4e-2dae-4556-8820-5cf1b713c940" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e9ece991-a30b-4740-b0e1-49aa4fff4d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_627fac5c-b20a-4b04-aa2c-6d53a5130e30" xlink:href="exel-20220930.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_e9ece991-a30b-4740-b0e1-49aa4fff4d6e" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_627fac5c-b20a-4b04-aa2c-6d53a5130e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1560fb6d-1b83-4cb6-b43c-d98e21e85700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b341b4e-2dae-4556-8820-5cf1b713c940" xlink:to="loc_us-gaap_PerformanceSharesMember_1560fb6d-1b83-4cb6-b43c-d98e21e85700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_438d5809-0ef9-4b66-91d6-4945854d2783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf9fcc1-e1cc-4d5e-a7ad-92b411da408c" xlink:to="loc_us-gaap_VestingAxis_438d5809-0ef9-4b66-91d6-4945854d2783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7016848c-3012-4971-9104-ec772314078e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_438d5809-0ef9-4b66-91d6-4945854d2783" xlink:to="loc_us-gaap_VestingDomain_7016848c-3012-4971-9104-ec772314078e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e5f02116-f6a3-4e86-af13-6e5142379aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7016848c-3012-4971-9104-ec772314078e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e5f02116-f6a3-4e86-af13-6e5142379aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_cad6ac7e-e997-4df1-83e7-c680b505fc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf9fcc1-e1cc-4d5e-a7ad-92b411da408c" xlink:to="loc_us-gaap_AwardDateAxis_cad6ac7e-e997-4df1-83e7-c680b505fc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_32e73187-85bd-40cc-87e9-29909a2c10ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_cad6ac7e-e997-4df1-83e7-c680b505fc6e" xlink:to="loc_us-gaap_AwardDateDomain_32e73187-85bd-40cc-87e9-29909a2c10ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_Granted2020Member_d1df339e-436a-4dba-ac57-670b66210dce" xlink:href="exel-20220930.xsd#exel_Granted2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_32e73187-85bd-40cc-87e9-29909a2c10ed" xlink:to="loc_exel_Granted2020Member_d1df339e-436a-4dba-ac57-670b66210dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dcf9fcc1-e1cc-4d5e-a7ad-92b411da408c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_deffc386-50ce-4889-a103-e734038e8b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_deffc386-50ce-4889-a103-e734038e8b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dc90b132-49b1-483b-85be-ad1e64060218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_dc90b132-49b1-483b-85be-ad1e64060218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_164ec416-b71e-423d-9d25-ffd26b303f00" xlink:href="exel-20220930.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_164ec416-b71e-423d-9d25-ffd26b303f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_c81193dc-65db-49c4-9d40-a9cd2900eafc" xlink:href="exel-20220930.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_c81193dc-65db-49c4-9d40-a9cd2900eafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_62cbc0d8-8336-4aae-b8bb-26ec48476318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_62cbc0d8-8336-4aae-b8bb-26ec48476318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_58e7a8b9-aea8-4421-b387-f4ed5b407977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_58e7a8b9-aea8-4421-b387-f4ed5b407977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66eb8d01-194c-4680-843e-ec89838180fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66eb8d01-194c-4680-843e-ec89838180fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f096d9c6-5cc7-4bd9-b6f0-1e65b6ddbc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f096d9c6-5cc7-4bd9-b6f0-1e65b6ddbc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2e948603-560c-4323-97ca-6d1026cc9252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2e948603-560c-4323-97ca-6d1026cc9252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_34dec5d4-c007-4324-8357-a5b80b1fc3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_34dec5d4-c007-4324-8357-a5b80b1fc3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_4abbef97-4a4e-46b0-bca3-259af7528675" xlink:href="exel-20220930.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_4abbef97-4a4e-46b0-bca3-259af7528675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_de416b26-dfe9-4f9e-9270-c430161e701d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_de416b26-dfe9-4f9e-9270-c430161e701d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3c2c4238-05fe-4190-aad1-132294fad31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3c2c4238-05fe-4190-aad1-132294fad31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a7c7c6b0-3672-436f-894a-656cc9029a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a7c7c6b0-3672-436f-894a-656cc9029a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a45347d9-ecf0-499b-bea1-4c6c74e08771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a45347d9-ecf0-499b-bea1-4c6c74e08771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e7f32616-1d1c-4c0a-b47d-b2bab4c71085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b18a36d2-d30c-4299-a20c-9d15f9cb729d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e7f32616-1d1c-4c0a-b47d-b2bab4c71085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe883c3c-0047-44ec-b91c-26566cf73601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fbef674-a8fe-4d83-bd31-25d4cb90c76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe883c3c-0047-44ec-b91c-26566cf73601" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fbef674-a8fe-4d83-bd31-25d4cb90c76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_814d0d67-96ce-4266-ba7b-6d2af279dc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fbef674-a8fe-4d83-bd31-25d4cb90c76c" xlink:to="loc_us-gaap_AwardTypeAxis_814d0d67-96ce-4266-ba7b-6d2af279dc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_197cd947-37c2-4796-8147-a61481b38f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_814d0d67-96ce-4266-ba7b-6d2af279dc71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_197cd947-37c2-4796-8147-a61481b38f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TSRBasedRestrictedStockUnitsMember_5d6eeac1-a5b5-49e5-a1d0-8b168592b7f7" xlink:href="exel-20220930.xsd#exel_TSRBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_197cd947-37c2-4796-8147-a61481b38f8a" xlink:to="loc_exel_TSRBasedRestrictedStockUnitsMember_5d6eeac1-a5b5-49e5-a1d0-8b168592b7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aa6871-14ef-40d1-b6cc-2d6a35f1a592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fbef674-a8fe-4d83-bd31-25d4cb90c76c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aa6871-14ef-40d1-b6cc-2d6a35f1a592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_1be1f374-9e55-4219-b626-7455779ac218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aa6871-14ef-40d1-b6cc-2d6a35f1a592" xlink:to="loc_us-gaap_SharePrice_1be1f374-9e55-4219-b626-7455779ac218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_59b2bf12-7e50-4378-af6f-4563d5ba8616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aa6871-14ef-40d1-b6cc-2d6a35f1a592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_59b2bf12-7e50-4378-af6f-4563d5ba8616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_056aca66-0ab7-47f3-abc6-46549bec2423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aa6871-14ef-40d1-b6cc-2d6a35f1a592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_056aca66-0ab7-47f3-abc6-46549bec2423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0614d17a-f09f-4fd6-a694-aa23bad8f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aa6871-14ef-40d1-b6cc-2d6a35f1a592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0614d17a-f09f-4fd6-a694-aa23bad8f6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#ProvisionForIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5b9b4669-4712-47bd-8c3d-75cba1fa260e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5a0992b7-c80d-46ac-bb39-10a061bb6829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5b9b4669-4712-47bd-8c3d-75cba1fa260e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5a0992b7-c80d-46ac-bb39-10a061bb6829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_38d78310-4228-4171-a1f6-f2b19eb046aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_1c6a51f5-a64f-4e3c-852f-0e713ed322ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38d78310-4228-4171-a1f6-f2b19eb046aa" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_1c6a51f5-a64f-4e3c-852f-0e713ed322ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d3de253c-248d-4e8a-94eb-ce1c43a12aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_1c6a51f5-a64f-4e3c-852f-0e713ed322ad" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d3de253c-248d-4e8a-94eb-ce1c43a12aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7ac354c6-0074-4694-be93-802ffd7f0e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_1c6a51f5-a64f-4e3c-852f-0e713ed322ad" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7ac354c6-0074-4694-be93-802ffd7f0e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_36a66bb9-0366-4aa7-adbd-50db5b8cd210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38d78310-4228-4171-a1f6-f2b19eb046aa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_36a66bb9-0366-4aa7-adbd-50db5b8cd210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2cabc2a9-2561-4c62-a44e-7f013cc339e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_36a66bb9-0366-4aa7-adbd-50db5b8cd210" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2cabc2a9-2561-4c62-a44e-7f013cc339e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c2d59795-279e-43fd-a5cf-e7f8c60722a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_36a66bb9-0366-4aa7-adbd-50db5b8cd210" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c2d59795-279e-43fd-a5cf-e7f8c60722a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_10cee80b-053a-48b1-b2eb-a6ad0afdf039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_36a66bb9-0366-4aa7-adbd-50db5b8cd210" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_10cee80b-053a-48b1-b2eb-a6ad0afdf039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_78f4484c-356a-40e0-8d13-2cfe243b7386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38d78310-4228-4171-a1f6-f2b19eb046aa" xlink:to="loc_us-gaap_EarningsPerShareBasic_78f4484c-356a-40e0-8d13-2cfe243b7386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b733f59f-32ac-4b58-91ae-f4f2f8370142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38d78310-4228-4171-a1f6-f2b19eb046aa" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b733f59f-32ac-4b58-91ae-f4f2f8370142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_31d12697-e17c-4e41-b32a-ac1b92532a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb539ad5-3fd2-4994-9d79-db1e89c7606a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_31d12697-e17c-4e41-b32a-ac1b92532a07" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb539ad5-3fd2-4994-9d79-db1e89c7606a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e69b2e83-99ed-404b-ae8e-1da97b2d0db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb539ad5-3fd2-4994-9d79-db1e89c7606a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e69b2e83-99ed-404b-ae8e-1da97b2d0db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e75bbf6c-6879-49df-90e7-29688b1150a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e69b2e83-99ed-404b-ae8e-1da97b2d0db7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e75bbf6c-6879-49df-90e7-29688b1150a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_2d31a9d9-1b10-4d38-9452-dc7782360c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e75bbf6c-6879-49df-90e7-29688b1150a0" xlink:to="loc_us-gaap_StockCompensationPlanMember_2d31a9d9-1b10-4d38-9452-dc7782360c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38b3dd46-aee5-4de3-8900-209d6cb002a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_cb539ad5-3fd2-4994-9d79-db1e89c7606a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38b3dd46-aee5-4de3-8900-209d6cb002a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4ac49038-fbfc-40dc-8f04-a0a3409a18f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38b3dd46-aee5-4de3-8900-209d6cb002a7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4ac49038-fbfc-40dc-8f04-a0a3409a18f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_67a6debd-bb61-458a-90d8-bc8b991a02ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_fa24f61a-1279-4a57-b691-ddd9798795f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_67a6debd-bb61-458a-90d8-bc8b991a02ed" xlink:to="loc_us-gaap_OtherCommitmentsTable_fa24f61a-1279-4a57-b691-ddd9798795f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis_84e40146-1c63-4f70-9631-ee49f06301f2" xlink:href="exel-20220930.xsd#exel_LeaseArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_fa24f61a-1279-4a57-b691-ddd9798795f6" xlink:to="loc_exel_LeaseArrangementsAxis_84e40146-1c63-4f70-9631-ee49f06301f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_1b8a14ca-f884-409d-bcf0-63e846b5faa2" xlink:href="exel-20220930.xsd#exel_LeaseArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsAxis_84e40146-1c63-4f70-9631-ee49f06301f2" xlink:to="loc_exel_LeaseArrangementsDomain_1b8a14ca-f884-409d-bcf0-63e846b5faa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_657dd450-9287-4741-91a1-1d4fd37c7324" xlink:href="exel-20220930.xsd#exel_BuiltToSuitLeaseAndHeadquartersLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_1b8a14ca-f884-409d-bcf0-63e846b5faa2" xlink:to="loc_exel_BuiltToSuitLeaseAndHeadquartersLeaseMember_657dd450-9287-4741-91a1-1d4fd37c7324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseExpansionMember_c5106e87-6802-4c30-8895-cf9586dbb033" xlink:href="exel-20220930.xsd#exel_LeaseExpansionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_1b8a14ca-f884-409d-bcf0-63e846b5faa2" xlink:to="loc_exel_LeaseExpansionMember_c5106e87-6802-4c30-8895-cf9586dbb033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3590a693-d7f0-4f08-81ff-86fe6710486e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_fa24f61a-1279-4a57-b691-ddd9798795f6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3590a693-d7f0-4f08-81ff-86fe6710486e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_058b7e59-9b5f-4bc7-966d-6bcb07bf587b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3590a693-d7f0-4f08-81ff-86fe6710486e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_058b7e59-9b5f-4bc7-966d-6bcb07bf587b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9ba41cd5-5e9c-4cd4-89ed-2829f7f39285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_058b7e59-9b5f-4bc7-966d-6bcb07bf587b" xlink:to="loc_us-gaap_SubsequentEventMember_9ba41cd5-5e9c-4cd4-89ed-2829f7f39285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_fa24f61a-1279-4a57-b691-ddd9798795f6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_80ac20a1-ab89-42b3-9ff6-b0a0667c6d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_80ac20a1-ab89-42b3-9ff6-b0a0667c6d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4b257d93-3071-4dfa-b770-511531ff290b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4b257d93-3071-4dfa-b770-511531ff290b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_9af59be7-b0d6-4439-91e0-887077ef403e" xlink:href="exel-20220930.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_9af59be7-b0d6-4439-91e0-887077ef403e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9df61264-9fc6-4d69-850c-436dd3826cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9df61264-9fc6-4d69-850c-436dd3826cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_78072aed-674d-4ef4-bc4f-8b028d3bcc40" xlink:href="exel-20220930.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_78072aed-674d-4ef4-bc4f-8b028d3bcc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_46f5422d-b93a-47da-9376-00869ce437d1" xlink:href="exel-20220930.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_46f5422d-b93a-47da-9376-00869ce437d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_17b02606-f5f3-4faf-a4a7-85082b54e5d8" xlink:href="exel-20220930.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_17b02606-f5f3-4faf-a4a7-85082b54e5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5a276d8f-4bfa-4636-a276-052701dbe8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5a276d8f-4bfa-4636-a276-052701dbe8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2c0b1519-8148-4ff6-876e-3552e1803f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_OperatingLeaseLiability_2c0b1519-8148-4ff6-876e-3552e1803f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_31b60c0f-ef5d-47dc-9bb2-e039948d8e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_TenantImprovements_31b60c0f-ef5d-47dc-9bb2-e039948d8e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_d3f1e3af-b19a-46dd-a3a3-65a42016acac" xlink:href="exel-20220930.xsd#exel_TenantLeaseImprovementsAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_d3f1e3af-b19a-46dd-a3a3-65a42016acac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseLiabilityDiscountedPeriod_57a33da5-f054-4f8e-ba33-ee3aef7552c3" xlink:href="exel-20220930.xsd#exel_OperatingLeaseLiabilityDiscountedPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_OperatingLeaseLiabilityDiscountedPeriod_57a33da5-f054-4f8e-ba33-ee3aef7552c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a1d6018a-65f1-4811-81ef-39e31f491db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a1d6018a-65f1-4811-81ef-39e31f491db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_1313552e-06e0-401a-8b18-102c779767f8" xlink:href="exel-20220930.xsd#exel_LossContingencyNumberOfLawsuitsConsolidated"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d8e498fe-3e4e-4ab0-839e-427e66a09519" xlink:to="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_1313552e-06e0-401a-8b18-102c779767f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="exel-20220930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ad493f1f-f4b3-4a4b-b603-5a7cf3e97e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d88889fe-5190-4939-b4d5-e0807cc7c5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ad493f1f-f4b3-4a4b-b603-5a7cf3e97e20" xlink:to="loc_us-gaap_SubsequentEventTable_d88889fe-5190-4939-b4d5-e0807cc7c5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_093dc4a1-397b-4d92-b8e9-1d753f540321" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d88889fe-5190-4939-b4d5-e0807cc7c5dd" xlink:to="loc_srt_StatementScenarioAxis_093dc4a1-397b-4d92-b8e9-1d753f540321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_21b3494e-01cf-4d20-be27-fbf24c3802b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_093dc4a1-397b-4d92-b8e9-1d753f540321" xlink:to="loc_srt_ScenarioUnspecifiedDomain_21b3494e-01cf-4d20-be27-fbf24c3802b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f0c67131-89ab-4cc7-b3e8-4ef84c305d8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_21b3494e-01cf-4d20-be27-fbf24c3802b7" xlink:to="loc_srt_ScenarioForecastMember_f0c67131-89ab-4cc7-b3e8-4ef84c305d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a788cc78-97a3-46f0-94a4-c301dc6f15b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d88889fe-5190-4939-b4d5-e0807cc7c5dd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a788cc78-97a3-46f0-94a4-c301dc6f15b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee0181b2-e46d-4009-b4d7-275989c1c06b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a788cc78-97a3-46f0-94a4-c301dc6f15b7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee0181b2-e46d-4009-b4d7-275989c1c06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CybrexaTherapeuticsLLCCybrexaMember_7f7696bd-b7ee-4874-9e41-d47ee86e0165" xlink:href="exel-20220930.xsd#exel_CybrexaTherapeuticsLLCCybrexaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee0181b2-e46d-4009-b4d7-275989c1c06b" xlink:to="loc_exel_CybrexaTherapeuticsLLCCybrexaMember_7f7696bd-b7ee-4874-9e41-d47ee86e0165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SairopaBVSairopaMember_24e3ee61-3604-4fd9-968e-5a3d3bc7a84d" xlink:href="exel-20220930.xsd#exel_SairopaBVSairopaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee0181b2-e46d-4009-b4d7-275989c1c06b" xlink:to="loc_exel_SairopaBVSairopaMember_24e3ee61-3604-4fd9-968e-5a3d3bc7a84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d88889fe-5190-4939-b4d5-e0807cc7c5dd" xlink:to="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_c6789f6e-6d9a-4826-bc0b-337073625e63" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_c6789f6e-6d9a-4826-bc0b-337073625e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_c8fd8f8b-207c-4458-8665-a3c7abaa6c5b" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_c8fd8f8b-207c-4458-8665-a3c7abaa6c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_9c31f832-c0a7-4564-8e96-1862004af9c0" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementMaximumAmountOfWarrantExercise"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise_9c31f832-c0a7-4564-8e96-1862004af9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_0ba9d328-94b7-44f9-8ab2-f28ff71a96c8" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments_0ba9d328-94b7-44f9-8ab2-f28ff71a96c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_e66e5a97-282f-49b6-a85a-33e4b8fcd02c" xlink:href="exel-20220930.xsd#exel_CollaborativeArrangementRightsAndObligationsExerciseAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_73f7ec06-19fe-49fd-bc2a-acebe115aadd" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount_e66e5a97-282f-49b6-a85a-33e4b8fcd02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>exel-20220930_g1.jpg
<TEXT>
begin 644 exel-20220930_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
M186,?B.^A;_7./\ ES4_W5(_>$=2 F0 X;V+_@I_^WJO[.GA!O!_A>[7_A.-
M<@S)-&<G1K9N/,/I*XR$'4<L<?+N_)^21IY&=V9F8Y9B<DGU-?@?BQQ][*,L
MCR^7O/2I)=%_(O-_:[+3J[?UAX ^%'MYPXHS>'N1=Z,7U:_Y>-=E]CN_>V2N
MVBBBOYO/[("BBNO^ _P9U7]H+XN:'X1T=?\ 3-9N1$9"I9;:,<R2MC^%$#,?
MIZD5MA\/4KU8T:*O*3226[;=DCGQF+HX6A/$XB2C""<I-[))7;?HC[2_X(M?
MLI_VAJM[\5]8M_W-D7T_0%<?>D(*SW _W5)C!Y!+R="HK]&ZP?AC\.=+^$7P
M_P!'\,Z)#]GTO0[5+2W3N548W,>[,<LQ[DD]ZWJ_N#@_AVGDF5T\##XEK)]Y
M/=_HO)(_S%\0^,:W$V>5LTJ74&^6"?V8+X5ZOXG_ 'FPHHHKZ8^)"BBB@ HH
MHH *\I_:F_;0^'_['OAA=0\9:PL-U<(6LM+M0)K^_P <?NX\CY<\;V*H#P6R
M0#QW_!1?]O#3/V(/A&+J%8-0\9:X'AT/3WY4L,;KB4 @^5'D< Y9BJC&69?Q
M ^*/Q4\1?&KQS?>)/%.K7>M:UJ3[Y[JX;+'T50.%4#@*H"J!@ "KC&^K)E*Q
M]E?M!_\ !>+XE>.[RXM? 6FZ7X'TO)$5Q)$M_J##U+2#RER.PC)!_B/6OG'Q
M!^WM\;/$U^;FX^*WC^.1NHM-;N+2/_OB)E7]*\D^;VH^;VK912,N9GIO_#:W
MQD_Z*U\3/_"IOO\ X[1_PVM\9/\ HK7Q,_\ "IOO_CM>9?-[4?-[4[(+L]-_
MX;6^,G_16OB9_P"%3??_ !VN@^$7[9'Q>U+XK^%[>X^*GQ(N+>XU:TCEBE\2
MWK)(IF0%6!DP01D$'C!KQ+YO:NG^"O\ R6/PE_V&;/\ ]'I19!=G]'U%%%<I
MN%%%% !1110 4444 %%%% !1110 445\A_MG?\%A/A]^S+)=Z)X=:/QUXPAW
M1O:V<X%C8.,C]_.,@L#UC3+<$$IP:+7"Y]<75U'8VTDTTD<,,*%Y)'8*J*!D
MDD\  <Y-?+'[1/\ P6*^#/P'>>SLM7F\<:Q#E?LNA 30JW^U<$B+&>NPN1_=
MK\JOVGOV^OBA^UM?2#Q5XAFCT@MNBT;3\VVGQ>G[L',A'9I"[#/7M7C7S>U;
M1I]S-S['W#\;?^"\?Q4\=O-;^#]-T+P/9,Q\N58O[0OE7L"\H\K\H@<]Z^5/
MBI^TI\0/C?,[>+?&?B3Q CMN\F\OY'MT/7Y8L[%'LJ@5Q/S>U'S>U:**6Q',
MP^;VH^;VH^;VH^;VIB#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]
MJ/F]J/F]J #YO:NR^&O[17C[X.2JWA7QGXG\/JN/W=CJ4L,3X[,@;:P]B"*X
MWYO:CYO:D!]A_"/_ (+@_&[X>/''K5UH?C2S4@,NIV*PS!?19(/+Y]W#?0U]
M7_!3_@OG\.?&+PV_C;P[KO@NX?AKF C4[-/<E LH]<")OKZ_D;\WM1\WM4^S
M3*4F?T;_  D^/?@OX\Z-_:'@WQ1HOB.V50TGV*Z622#/02)G?&?9P#775_-3
MX8\5ZIX(URWU31=2U#2=3M6W0W=E</;SQ'U5T(93]#7V3^S3_P %QOB=\)G@
ML?&L-K\0=&4A3).1:ZE$O'295VOCDXD0L3_&*SE3[%*IW/V-HKQ']EK_ (*$
M_"_]KFVBB\,Z_':ZXR[I-$U+%MJ"<9.U"2)0.YB9P.Y'2O;JS- HHHH ****
M "BBB@ 9@BY/ '4^E?F+_P %&/\ @L[=#4K[P3\'+Y8(8"UO?^)XQF21P2&2
MTSP%'_/;DG/R8P'/>?\ !;O]N*Y^%'@NW^%?AF[:WUOQ3:FXUFXB;YK6P8E1
M"#V:8AL]"$4_WP:\-_X)&_\ !,JV^/4EO\3/'UKYWA&SN"-)TN1?EUJ6,X:2
M3U@1@1M_Y:,"#\JD/I&*2YF3)N]D>._LN?\ !-;XM?MN73>(EC;2]#U"8RS>
M(->DD_TXDY9XP09)V)S\P^4G@N#FOM7X=_\ !OQ\.](L(SXH\9>+M<O5'S_8
M!!I]NQQ_=9)7X_WQT_"N[_X*3_\ !274OV"M:\,^'_#_ (1TK5I-9L)+B.:Z
MN6BAM%C81J@B11D?1QZ8[U\<ZO\ \%\OC/?W.ZVT?X?V,0)VHFG7+G&>,EK@
M\CVP/:J]Y[$^ZMSZE\1?\$"O@]J5@RZ?KGCS3;H#Y)/MUO,F?]I6@R1]&7KU
MKY8_:=_X(;_$CX/V-QJG@N]M_B%I4 +O;V\)MM3C4<\0%F$N!_SS<NQZ)4F@
M_P#!?+XR:=?K)?:+X#U&WZ/$;"XB;'^RRS\'Z@CVK[6_81_X*P^$/VR-97PW
M?:?)X/\ &C(6AL)K@3V^HA02WD2[5RP +%&4$#H7P2%[R#W6? /[#O\ P53\
M=?L>Z]#X<\4G4O$W@JWD^S3:9=L?MND;20?L[/RNT]8G.WC V$EJ_8SX5?%7
MP_\ &WP!IOB?PQJ5OJVB:M$);>XB/!'0JPZJZG(92 5(((!%?*?_  5(_P""
M9&F_M->$+[QIX-T^&S^(^FPF9XX5"+XAC4<Q2#_GN%'R/U. C<%63XS_ ."0
M'[;]Y^S7\<H? OB&[DB\%^,+H6LD<Y(72[]L)',,_=#-B.3H,%6/W.4[25T/
M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
M X K#^%_PST3X-_#_2?"_ARQBTW1-$MUMK2WCZ(HY))ZLS$EF8\LS$G))-;U
M<\I7-HQL%%%%24%%%% !7E?[;'[0@_9<_9@\7>-$\MK[3;3RM.23E9+N5A%#
MD?Q .X8C^ZK=.M>J5^?_ /P<%^-I-,_9^\$^'XV*KK&NO>2 9^<6\#+@^V9P
M<>H'I51U=A2=D?E#JVJW.NZI<WU[<375Y>2M//-*Q9YI&)9F8GDDDDD]R:@^
M;VH^;VH^;VKI, ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:
MCYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;
MVH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;
MVH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#NOV7O^3E?AW_V,VF_^
ME45?T5U_/!^Q[H<WB3]K+X96,.?,N/%6F+D#.P?:HRS8]  3]!7]#]8U#2F%
M%%%9&@4444 %%%% !7X6_P#!5O\ :7N/VC_VP?$/DW#R:!X1E?0M+CW9C A8
MK-*.W[R8.V[J4$8YVBOVR^+'BQO 7PL\3:['_K-%TJZOUP,\Q0NXX/\ NU_-
MW/.]S-))([222,69F.68GDDGUK2FNIG4$^;VH^;VH^;VH^;VK<S#YO:CYO:C
MYO:CYO:@ ^;VH^;VH^;VH^;VH ]-_8I_Y/(^$O\ V.6C_P#I=#7]#%?SS_L4
M_P#)Y'PE_P"QRT?_ -+H:_H8K"IN:T]@HHHK,L**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ JOJFIV^B:9<7EW-';VMI$TTTKG"Q(H)9B?0 $_A
M5BO!?^"GGCR;X<_L$_$S4;=F62;2UTW*]0+N:.U;])C1N!^,O[9G[2FH?M9?
MM%^(O&5X\PM;R<P:9;N?^/.RC)$,8'0';\S8ZN[GO7EWS>U'S>U'S>U=2.</
MF]J/F]J/F]J/F]J8!\WM1\WM1\WM1\WM0 ?-[5T_P5_Y+'X2_P"PS9_^CTKF
M/F]JZ?X*_P#)8_"7_89L_P#T>E(#^CZBBBN4Z HHHH **** / ?^"B?[),?[
M5OP'N+>QAC;Q5X?WWVBR$#=(X'[RWSZ2J .H =8R> :_&6YMI+.XDAFCDBEB
M8I)&Z[60C@@@]"*_H8K\N?\ @L'^R%_PK'XC+\1]#M=N@^*YRFI)&ORVE^06
M+_28 M_OJ^?O 5^"^,G!_M:2SS"Q]Z-E42ZQZ2^6S\K=$?U9]''Q"^KUWPOC
MI>Y-N5)OI+>4/27Q+^\FMY'Q31117\VG]F!1110 4444 %%%% 'ZB?\ !'K]
MK[_A9GP[?X;:[=;M=\+0[]+DD;+7EAD#8,]6A)"_[C( /E8U]L5^ _PA^*FL
M?!'XEZ/XJT&?[/JFBW"W$)/W9!T:-AW1U+*P[AB*_<;X"?&G2/VAOA)HOB[1
M6_T+6(!(T3-E[64?+)"_^TC J>QQD<$&OZN\)>+_ .TL#_9N)?[VBE;O*&R?
MK'9^5GNV?P;](#P]_L;-?[:P4;8?$MWMM&INUY*>LEY\RT21V5%%%?KQ_/(4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7BW[;_ .V'I/['_P )
MI-4F\F\\1:D'@T73F/\ Q\3 <NX'/E)D%B,9R%!!8&NY^.GQMT']GGX8ZGXJ
M\1W(M]/TY,J@/[RZE/W(8U_B=CP!TZDX )'XJ?M,?M&Z]^U'\6+[Q5KTFUIO
MW5G:(Q,5A;@G9$GTSDG^)B3WK\Q\2..HY'A?J^&?^T5%I_=7\S_**ZO79,_;
M?!GPMGQ1C_KF-BU@Z+][ISRW4$_QDULM-&TURGCCQOJWQ)\7ZCKVN7TVI:MJ
MT[7-U<RGYI7;D^P Z #       K)HHK^1*E24Y.<W=O5M[M]V?Z#TJ4*4%3I
MI*,4DDM$DM$DNB04445!H%?IY_P1H_96_P"$"^'-U\2M8M]NK>*4-OI0<?-!
M8JW+CT,KK_WS&A'#'/PW^Q5^S7<_M4_M Z/X959%TM&^VZO.G_+"SC(W\]F<
ME8U/9I >QK]NM(TBUT#2;6PLH([6SLHE@@AC&U(HT 55 [   #Z5^Z>#/"OM
M\3+.L0O=IZ0\Y=7_ -NIV7F^Z/Y<^DAQY]4P<.&L)+WZUI5+=()^['_M]J[_
M +JL])%JBBBOZ8/XJ"BBB@ HHHH *BO+R+3[66XGD2&&!#)([G:J*!DDGL *
MEKQ/_@HUXYN/AU^PW\3=3M6*3G19+)&'5/M!6WR/<>;D>XHW _&']N']IR^_
M:V_:2\0>+IIIFTUYC::/"_'V:QC8B%<=B02[#^_(U>2?-[4?-[4?-[5U+0YP
M^;VH^;VH^;VH^;VI@'S>U'S>U'S>U'S>U !\WM73_!7_ )+'X2_[#-G_ .CT
MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
M@IIK7[1]\OPV\;6UYJ/B;3[-KBTUV*,NM[!'@$76!A)!D8D/$F0#A\&3[TKY
MN_X)I_L*6?[%GP71;Z.&;QOXB1+C6[I<-Y)QE+5&_N1Y.2/O,6/3:!](US2M
M?0VC>VH5P?[4OAJX\:?LR?$;1[4,UUJWAC4[*$*NXEY+25%P._)'%=Y0RAUP
M>0>H]:DH_%'_ ((D>,X?"G[>NCVLS(G_  D&EWNG1EA_'Y?G@9[$^01SUSCJ
M17[75^"/QY\'ZM_P3^_;SOETZ)HV\'Z]'JVCALJEQ:%Q-"N>ZF,A&QD9#CL:
M_<KX0_%31_C?\,=#\7:#<?:-)\06:7ENW\2AARC#LZME6'9E([5I4[D0['YD
M_P#!PO\ \EE^'?\ V!;C_P!'BN?_ &0/^",5O^UG^S-X8\?+\1)O#UQKQNO,
MLSH8O$B$-U-;C#>?&3GRMW3^+';-=!_P<+_\EE^'?_8%N/\ T>*^P/\ @CK_
M ,HX_AS_ -Q+_P!.=W3YFHJPK7EJ?D?^VO\ LAZS^Q5\;[GPAJET-4MF@2\T
M[4T@\E-1MWR-X3<VPJZNC+N."O4@@G]>O^"6NC_#%OV4-#UOX:Z+::0NK1*N
MM#S#->?;HQB6.:5OG;:Q)0'"['!55#5F_P#!5_\ 8V_X:Q_9ON+C2;7SO&/@
M[?J6D;5_>728'GVH/7]XJ@@=WCCZ FO@7_@C5^V8?V=?C[_PANMW7D^$_'DR
M6SF5L1V%^/EAEY^Z'SY;=.J$\)1\40V9^SE?GW_P<(^-X;'X"^ _#;,OVC5-
M?DU)%_B*6UN\;'\[I:_02OQ%_P""M/[2@_:I_;#N-/T%VU#1?"BC0-,$'[S[
M9.'/G2(!G=OE.Q2,AEC0CK4T]RI;'W)_P08\-3:'^Q-?7<H^76?%%Y=PDKC*
M+#;0]>_S0O\ K]:^UJ\Q_8U^!W_#-_[+W@KP7(JK=Z-IJ?;=IRINI"99\'N/
M-D?!],5Z=4R=W<I;!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /Y^?^"@?_ ">Y\5?^QFOO_1K5Y!\WM7K_ /P4#_Y/<^*O
M_8S7W_HUJ\@^;VKJCL<X?-[4?-[4?-[4?-[4P#YO:CYO:CYO:CYO:@ ^;VH^
M;VH^;VH^;VH /F]J/F]J_;3]B;]B;X0^-OV1/AOJVK_#?P?J6J:EX?L[BZNK
MC3(I);B1H@6=F(R6)ZFO4?\ AW]\$?\ HE?@7_P41?X5E[1%\C/Y^OF]J/F]
MJ_H%_P"'?WP1_P"B5^!?_!1%_A1_P[^^"/\ T2OP+_X*(O\ "CVJ'[-G\_7S
M>U'S>U?T"_\ #O[X(_\ 1*_ O_@HB_PH_P"'?WP1_P"B5^!?_!1%_A1[5![-
MG\_7S>U'S>U?T"_\._O@C_T2OP+_ ."B+_"C_AW]\$?^B5^!?_!1%_A1[5![
M-G\_7S>U'S>U?T"_\._O@C_T2OP+_P""B+_"C_AW]\$?^B5^!?\ P41?X4>U
M0>S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\ "C_AW]\$?^B5^!?_  41
M?X4>U0>S9_/U\WM1\WM7] O_  [^^"/_ $2OP+_X*(O\*/\ AW]\$?\ HE?@
M7_P41?X4>U0>S9_/U\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=_?!'_HE?
M@7_P41?X4>U0>S9^ .F:7=:UJ$-I9V\]W=7#!(H88S))*QZ!5')/L*^R?V.?
M^"+GQ!^.FI6FJ^.H;GP#X3.)'6Y3&J7B]=L<!YBSTW2X(R"$?I7ZV_#[X)>#
M?A+%L\+>$_#?AQ2-I_LS38;4L/<HH)_'K745+J/H"I]SD_@G\$/#'[/'PYL?
M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OF7_@L5_P HX_B-_P!PW_TYVE?35?,O_!8K_E''\1O^X;_Z<[2JCN@/PT^;
MVH^;VH^;VH^;VKI.</F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VKI_@K
M_P EC\)?]AFS_P#1Z5S'S>U=/\%?^2Q^$O\ L,V?_H]*0']'U%%%<IT!1110
M 4444 %%%% !1110 4444 %%%% 'GW[4'Q]T_P#9G^"&N>+]0\N1M/AVV=LS
M;?MERW$40[\MC)'10Q[5^&WC'Q=J'C[Q7J6N:M<O>:GJUS)=W4[]9978LQ]!
MR3P.!TKZR_X+ _M5'XN?&6/P+I5PSZ!X)D9+G8WR7.H$;9"1W\H9C'<,9>QK
MX[K^2?%CBK^T\T^IT'^ZH72[.7VG\OA7HVMS_0#P"X#_ +#R-9CB8VKXJTG?
M>-/[$?*]^9^J3^$****_*3]X"BBB@ HHHH *]P_83_8WU']L'XM)8'S[/POI
M)2?6K]!S'&3\L*$\>;)@@9Z ,V#MP>#^ 7P+U[]H[XIZ9X3\.P>9?:@^9)6!
M\JTA'WYI".B*/S. ,D@']K/V;_V>]!_9C^$^G>$] C_<6@\RYN60"6_N"!OF
M?'\38''90JC@"OU#PUX%EG>*^M8I?[/3>O\ ?>_*O+K)]%IN[K\/\:/%*'#&
M ^HX&5\967N_].X[.;\^D$]WKJDT^H\'^$--\ >%M/T71[.#3]+TN!+:UMX5
MPD4:C  _Q/)/)YK4HHK^NJ=.,(J$%9+1)=#_ #ZJ5)U)NI4;;;NV]6V]VWW9
MQ_QV^#&C_M!?"C6O".N1[K'6(#&) ,O;2#F.5/\ :1@&'KC!X)K\.?C#\*=7
M^!_Q-UGPIKD'DZIHMP;>4#[L@ZI(OJKJ58'N&%?OM7Q/_P %A?V0C\3OAY'\
M2-#M?,USPI 4U..-?FN[ $L7]VA)+?[C/D_*HK\C\6N$/[2P']I8:/[VBM;;
MRANUZQW7ES+=H_H+Z/\ XA?V-FO]C8R5L/B6K7VA4VB_)2TB_/E>B3/R[HHH
MK^43^\PHHHH **** "BBB@#[6_X(]_M>_P#"L?B))\-]<NMFA>*IP^F22-\M
MI?D !/99@ O^^J8^\QK]1J_GGMKF2SN(YH9'BFB8/'(C%61AR"".A%?LY_P3
MO_:TC_:N^ ]O=7DR?\)5X?VV.LQ\ R.%^2X _NR*">PW!P. *_I+P;XO]K2>
M1XJ7O1NZ;?6.[C\MUY7Z(_C/Z1WA[]7KKBC Q]R;4:J726T9^DOA?]Y)ZN3/
M?****_>C^4PHHHH **** "BBB@ HHHH **** "OF7_@L5_RCC^(W_<-_].=I
M7TU7S+_P6*_Y1Q_$;_N&_P#ISM*J.Z _#3YO:CYO:CYO:CYO:NDYP^;VH^;V
MH^;VH^;VH /F]J/F]J/F]J/F]J #YO:NG^"O_)8_"7_89L__ $>E<Q\WM73_
M  5_Y+'X2_[#-G_Z/2D!_1]1117*= 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7+_ !(^"7@[XPV7V?Q7X5\/^(XMNU1J.GQ7)3_=+J2I]P01
M7444 ?(_Q3_X(G? GXB"233])UKPA<O\QDT?4GVEO^N<XE0#V4+QZ=:^<?BA
M_P &]&L6HDE\%_$33;[J4MM:L7MBOH#+$9,_7RQ7ZC457,R>5'X2?%?_ ()1
M_'CX2>9)<>!;[7+./.+C0Y$U /\ 2.,F4?B@KP'7_#FH>%-4DL=4L;S3;V'B
M2WNH&AE3ZJP!'Y5_2S6'XY^&GAWXG:9]A\2:!HOB"SY_<:E91W4?/^S(I%4J
MCZD^S['\VWS>U'S>U?MG\8?^"+OP,^*4<LEAHNI>#;Z3)\_1+UE3=VS%+YD8
M'LJKD=QP1\E_&_\ X(!>./"ZSW7@/Q3H_BJW7++9WZ'3[P^BJ<O$Q]V9!]*T
M51$\C/@#YO:CYO:NU^,O[./CO]GK5OL?C3PKK7AV5G*1R75N1!.1U\N49CDZ
M'E&(KBOF]JI$A\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #YO:CYO:CYO:C
MYO:@ ^;VH^;VH^;VH^;VH ZOX%_%O4/@-\8_#?C'2V87OAW4(KQ5#;?.56^>
M,G^ZZ;D/LQK^BKPIXGL_&WA;3=:TV87&G:O:Q7MK*.DL4B!T;\58'\:_FJ^;
MVK]P_P#@CM\6&^*G[!OA5)I/.O/"\L^A3MGH(7W1#VQ!)"/PSWK*HNII3['U
M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
ML-+G.6:T<^F,F,GED!')1B?D[YO:NB+N8/0/F]J/F]J/F]J/F]J8!\WM1\WM
M1\WM1\WM0 ?-[4?-[4?-[4?-[4 =K^SQ\??$/[,GQ=T?QEX9N/(U+29<M&V?
M)O(CQ)!(.Z.N0>XX(PP!'[W?LO\ [2?A[]K#X-Z7XR\.2_Z/?+LN;5V!FT^X
M4#S()/\ :4GKT8%6'!%?SN?-[5]#_P#!.#]NK4/V)_C/'<7+3W7@O7F2WUVQ
M3DA <+<QC_GI'DG'\2EEXR&7.<;JY496/W>HJAX8\3Z?XT\.6.KZ3>0:AI>I
MP)=6MS VZ.>)P&5E/H00:OU@;!1110 4444 %%%% !7YO_\ !Q#_ ,B9\+?^
MOS4?_0+>OT@K\W_^#B'_ )$SX6_]?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U
M=)B'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5]?_P#!*/\ X* ^#?V%
MO^$]_P"$MTWQ-J/_  E/]G_9/[(MX)O+^S_:M^_S9H\9\],8SG#9Q@9^0/F]
MJ/F]J35]!IV/U_\ ^(@#X-_]"S\3/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?
M_DNOR ^;VH^;VJ/9HKG9^O\ _P 1 'P;_P"A9^)G_@NL?_DNC_B( ^#?_0L_
M$S_P76/_ ,EU^0'S>U'S>U'LT'.S]?\ _B( ^#?_ $+/Q,_\%UC_ /)='_$0
M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
M4444 %%%% !1110 5^7'_!9#]JG_ (61\5+?X=:3<%M%\(R>9J)1OEN;\C&T
M]CY2$KGLSR#L*^ZOVW/VF+?]E;]G[5O$?F1MK$R_8M&@?!\Z[<'8<=U0 NP[
MA".I%?B1J>I7&M:E<7EY-+<W5W*TT\TC%GE=B2S,3R2222?4U^$^,_%7L,/'
M),._>J>]/RC?1?\ ;SU?DNS/ZF^C;P)]9Q<^)L7'W*5XT[]9M>]+_MU.R\V^
ML2O1117\TG]I!1110 5]0?\ !-;]A2;]J7Q[_;VO6[1^!/#\Z_:MV5_M2888
M6RG^[T+D=%('5@1YK^Q_^RGK7[7/Q=MO#VF[K738,3ZMJ)7*:?;YY/N[?=1>
M['G"AF'[3?"[X9:+\&_ 6F>&?#ME'I^CZ1"(;>%>3CJ68]69B2S,>222>M?K
MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _GY_X*!_\GN?%7_L9K[_ -&M7D'S>U>O_P#!0/\ Y/<^*O\ V,U]_P"C
M6KR#YO:NJ.QSA\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #YO:CYO:CYO:C
MYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;V
MH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;V
MH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VK]4?^#>OX93:7\,O
MB%XNFC98]9U&VTNW9AC(MHWD<K[$W"C/3*>QK\P?!7@S5/B+XPTS0=%LYM0U
M;6+E+.SMHA\TTKL%4#L.3U/ ')Q7]!7[)7[/MG^RW^SQX8\$69CD;1[4?;)U
M'_'U=.2\TGK@R,V,]%"CL*RJ2TL7#<](HHHK$U"BBB@ JEXC\16/A#0+W5=4
MN[?3]-TV![FZN9W"16\2 LSL3P  "2?:KM?E'_P6>_X*'?\ "QM=NOA'X-OM
MV@Z3/CQ#>0O\NH7*-_Q[ CK'$P!;^](/1 6J,;NPF['@O_!2?]NZ^_;6^,;/
M927%MX(\/N\&B6;97S1G#74B_P#/23 X/W5PO7<3\X?-[4?-[4?-[5T15C /
MF]J/F]J/F]J/F]J8!\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U?57_!
M+3_@G]/^V/\ %7^UM=MYH_A[X9F5]2?E?[3F&&6S1ASR,%R.53C(+*:\@_9*
M_9;\0?M??&G3?!^@+Y7GGSK^^9-T6FVJD>9,XXSC.%7(W,57(SD?O9\"_@EX
M>_9U^%FD>#_"]F+/2-'A$:9P9)W/+RR-_%([99CZGC P!G4E;1%QC<ZBPL(-
M*L8;6UAAM[6WC6*&&) D<2*,*JJ. H   ' %3445@:A1110 4444 %%%% !1
M110 4444 %%%% 'PK_P6*_X)X?\ "^O"$GQ*\(6._P 9^'[?&HVL"9?6K1!U
M 'WIHAG;W9,KR50#\A/F]J_IEK\C?^"R'_!.\?!;Q7-\4?!MCY?A'7KC_B;V
M<*?)I%VY_P!8H'W896/3HKDC@,BC6G+HS.<>I\&?-[4?-[4?-[4?-[5L9A\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U;/P]^(.L?"GQQI?B3P_?3:;K
M6C7"W5I<Q'YHG7]"#R"#D$$@Y!(K&^;VH^;VI ?OO^P7^VAH_P"VO\$K?7K7
MR;/Q!I^VUUW35;FRN,?>4'GRI,%D//&5R65L>W5_/G^QC^UKKG[&WQNL/%>C
M[KBS;%MJNGE]J:C:D@O&?1AC<C?PL!U&0?WG^$'Q;T'X[?#;1_%GAF^34-%U
MJW%Q;RCAE[,CC^%U8%64\AE([5SRC8VC*YTM%%%24%%%% !7YO\ _!Q#_P B
M9\+?^OS4?_0+>OT@K\W_ /@XA_Y$SX6_]?FH_P#H%O51W)EL?EU\WM1\WM1\
MWM1\WM728A\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U
M !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\W
MM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\W
MM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U 'N__!,GX;3?%#]NSX;V<,32
M)INK)K$S#.(TM,W&2?\ >C4#U+ =Z_>ZOSQ_X(/?LCW'@GP7JWQ8UJU:&\\3
M1?V=HBR+AA9*X:6;'I)(J!>AQ$3R'%?H=7/4=V;1V"BBBH*"BBB@ HHHH X7
M]J#_ )-I^(G_ &+.I?\ I++7\ZGS>U?T5_M0?\FT_$3_ +%G4O\ TEEK^=3Y
MO:MJ1G4#YO:CYO:CYO:CYO:M3,/F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@
M ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;V
MH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;V
MH /F]J/F]J/F]JZ_X!_!/6OVB_C!H/@S0(3)J6NW0@5MI9;=.LDSX_@1 S'V
M4T@/UD_X(3?#27P9^Q;-K-Q'MD\6Z[<WT+$8+01JENO_ (_#*?QK[2KGOA1\
M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
MKYE_X+%?\HX_B-_W#?\ TYVE?35?,O\ P6*_Y1Q_$;_N&_\ ISM*J.Z _#3Y
MO:CYO:CYO:CYO:NDYP^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:O:_^
M"<?PTF^*_P"W!\-=,CC:2.VUJ'5)_ERHBM3]I?=VP1%M]]P'4BO%/F]J_4O_
M ((-_LCS>%_#>K?%S6K5HY]<B;2]!61>?LP<&><#_;D144\'$;]0PJ92LBHZ
ML_1JBBBN8V"BBB@ HHHH ***^<?^"FO[57_#-'[/5S#IMRT/BCQ9OT[2RC;7
MMUP/.N!W&Q& !'1W0]C7FYOFE#+<%4QV)=H4TV_T2\V[)>;/8X?R/%9SF5'*
M\&KU*LE%>7=ORBKM^29\&_\ !4[]JK_AHC]H*;2=,N/,\+^#"]A9[&RES/D>
M?/[Y90B\D;8P1C<:^8Z**_AG.LVKYGCJF/Q+]Z;OZ=DO)*R7DC_43AO(,+DF
M64<JP:M"E%)>;ZR?G)W;\VPHHHKRSW KHOA3\+=;^-/Q!TOPSX=LVOM6U:80
MPQCA5[EV/\**,LS'@ $UAV%A/JE]#;6T,UQ=7$BQ111(7DE=CA551R220 !R
M37Z]?\$W?V%(/V4_A]_;.N012^//$$*F];AO[,A.&%JC>O0N1P6  )"J3]KP
M/P=7X@QZHJZI1LYR[+LO[SZ?-]#\U\3_ !$PW"65/$RM*O.ZIP[OJWUY8[OO
MHKIL]*_9&_99T3]DOX1VOAW2U2XOI,3ZIJ&S$FH7&,%CW"#HJ] /<L3ZE117
M]FX' T,'0AA<-%1A!))+HE_7SW/\W\SS+%9ABJF.QDW.I4;E*3W;?]:+9+1:
M!11174<(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YC_\ !8W]
MD+_A!O&D?Q0T*UVZ3XBE$.LI&O%M>8^68^BR@<G^^I)Y<5\-U^_GQ3^&FD_&
M+X=ZOX7UVW^U:3K5LUM<)T8 \AE/9E8!E/8J#7X>_M&? 36OV:?B]JWA+7(W
M\ZPD+6UP4*QW]N2?+G3_ &6 ]3@AE/*D5_*WBYP?_9^._M3#1_=5GK;:,^OR
MENO._D?W=]'WQ#6;Y9_8>-E^_P .ERWWG3V7SA\+\N7=W.%HHHK\</Z*"BBB
M@ HHHH *Z#X7?$O5O@Y\0M'\4:'<?9=5T6Y6YMWZJ2."K#NK*2K#N&([US]%
M:4:TZ4U5INTHM--;IK5-&.(P].O2E1K14HR333U33T::[-'[R?L[?'/2?VD/
M@]HWB[1SMM]4A!F@+;GLYUXDA8\<JP(S@9&"."*[BOR9_P""3G[7W_"A_C!_
MPB.M77E^%?&4RQAI'Q'8WW"QR\\!7XC8_P"X20$K]9J_M7@3BJ&>Y7'$O^)'
MW9KM)=?26Z^:Z'^:OBEP)4X5SR>#BG[&?O4GW@WLWWB_=??1]4%%%%?9GYN%
M%%% !7S+_P %BO\ E''\1O\ N&_^G.TKZ:KYE_X+%?\ *./XC?\ <-_].=I5
M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#D?CE\8-+^ ?PEUSQ=K#?Z#HEL9RF[:UP_P!V
M.)3_ 'G<J@]V%?AC\5/B5JGQC^(VL^*-:F^T:IKET]U.P^ZI/15'957"@=@H
M':OL;_@LY^U3_P )GX]L_ACH]P6TWPVRW6KLC?+/>,OR1GU$:-G_ 'I"",I7
MPS7\H^+W%7]H9E_9U!_NJ%T^SG]I_P#;OPKL[]S^]/H]\"?V1DW]L8J-J^*2
M:OO&GO%?]O?$^ZY>J"BBBOR$_H0N:!H%]XJURSTW3;6XOM0OYE@MK>!"\D\C
M'"JH')))%?L;_P $^OV);']D/X8!KZ."X\::Y&LFKW:G=Y ZK;1G^XG<C[[<
MG@*!Y+_P2F_8%_X53HEO\2/&%B5\3:I#G2;.=/FTNW<?ZQ@>DTBGZHAQP68#
M[=K^G_"G@'ZC26<8^/[V2]R+^Q%]7_>DON6F[:7\0>/'BO\ VI6EP[E,_P#9
MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055225514448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,561,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227642848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 675,286<span></span>
</td>
<td class="nump">$ 647,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">871,706<span></span>
</td>
<td class="nump">819,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">215,015<span></span>
</td>
<td class="nump">282,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">26,711<span></span>
</td>
<td class="nump">27,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">52,903<span></span>
</td>
<td class="nump">57,530<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,841,621<span></span>
</td>
<td class="nump">1,834,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">551,735<span></span>
</td>
<td class="nump">371,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">107,909<span></span>
</td>
<td class="nump">104,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">116,415<span></span>
</td>
<td class="nump">111,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">280,008<span></span>
</td>
<td class="nump">131,002<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,961,372<span></span>
</td>
<td class="nump">2,616,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">30,572<span></span>
</td>
<td class="nump">24,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">66,927<span></span>
</td>
<td class="nump">61,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">62,057<span></span>
</td>
<td class="nump">77,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">43,791<span></span>
</td>
<td class="nump">33,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">18,277<span></span>
</td>
<td class="nump">86,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">80,109<span></span>
</td>
<td class="nump">53,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">301,733<span></span>
</td>
<td class="nump">337,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenues</a></td>
<td class="nump">6,491<span></span>
</td>
<td class="nump">8,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">159,838<span></span>
</td>
<td class="nump">51,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,908<span></span>
</td>
<td class="nump">8,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">469,970<span></span>
</td>
<td class="nump">405,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 322,541 and 318,842 at September&#160;30, 2022, and December&#160;31, 2021, respectively</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,512,669<span></span>
</td>
<td class="nump">2,427,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(17,538)<span></span>
</td>
<td class="num">(758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(4,052)<span></span>
</td>
<td class="num">(216,507)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">2,491,402<span></span>
</td>
<td class="nump">2,210,615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 2,961,372<span></span>
</td>
<td class="nump">$ 2,616,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227892720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">322,541,000<span></span>
</td>
<td class="nump">318,842,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">322,541,000<span></span>
</td>
<td class="nump">318,842,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227693296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 411,738<span></span>
</td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 1,187,145<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">15,305<span></span>
</td>
<td class="nump">11,874<span></span>
</td>
<td class="nump">41,989<span></span>
</td>
<td class="nump">39,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">198,837<span></span>
</td>
<td class="nump">163,370<span></span>
</td>
<td class="nump">554,989<span></span>
</td>
<td class="nump">471,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">114,983<span></span>
</td>
<td class="nump">101,558<span></span>
</td>
<td class="nump">340,605<span></span>
</td>
<td class="nump">302,404<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">329,125<span></span>
</td>
<td class="nump">276,802<span></span>
</td>
<td class="nump">937,583<span></span>
</td>
<td class="nump">813,808<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">82,613<span></span>
</td>
<td class="nump">51,621<span></span>
</td>
<td class="nump">249,562<span></span>
</td>
<td class="nump">170,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">9,498<span></span>
</td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">16,077<span></span>
</td>
<td class="nump">6,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Income before income taxes</a></td>
<td class="nump">92,042<span></span>
</td>
<td class="nump">53,260<span></span>
</td>
<td class="nump">265,779<span></span>
</td>
<td class="nump">176,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">18,832<span></span>
</td>
<td class="nump">15,056<span></span>
</td>
<td class="nump">53,324<span></span>
</td>
<td class="nump">40,236<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 73,210<span></span>
</td>
<td class="nump">$ 38,204<span></span>
</td>
<td class="nump">$ 212,455<span></span>
</td>
<td class="nump">$ 135,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">322,148<span></span>
</td>
<td class="nump">315,380<span></span>
</td>
<td class="nump">320,949<span></span>
</td>
<td class="nump">313,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">325,066<span></span>
</td>
<td class="nump">322,022<span></span>
</td>
<td class="nump">324,420<span></span>
</td>
<td class="nump">322,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 366,482<span></span>
</td>
<td class="nump">$ 263,117<span></span>
</td>
<td class="nump">$ 1,023,824<span></span>
</td>
<td class="nump">$ 774,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">34,384<span></span>
</td>
<td class="nump">49,694<span></span>
</td>
<td class="nump">123,977<span></span>
</td>
<td class="nump">116,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 10,872<span></span>
</td>
<td class="nump">$ 15,612<span></span>
</td>
<td class="nump">$ 39,344<span></span>
</td>
<td class="nump">$ 92,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227884512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 73,210<span></span>
</td>
<td class="nump">$ 38,204<span></span>
</td>
<td class="nump">$ 212,455<span></span>
</td>
<td class="nump">$ 135,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized losses on available-for-sale debt securities, net of tax impact of $2,457, $193, $4,752 and $949, respectively</a></td>
<td class="num">(8,621)<span></span>
</td>
<td class="num">(504)<span></span>
</td>
<td class="num">(16,780)<span></span>
</td>
<td class="num">(2,995)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 64,589<span></span>
</td>
<td class="nump">$ 37,700<span></span>
</td>
<td class="nump">$ 195,675<span></span>
</td>
<td class="nump">$ 132,902<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055225402944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact</a></td>
<td class="nump">$ 2,457<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">$ 4,752<span></span>
</td>
<td class="nump">$ 949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055222582800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 01, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 01, 2021</a></td>
<td class="nump">$ 1,879,113<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">$ 2,321,895<span></span>
</td>
<td class="nump">$ 4,476<span></span>
</td>
<td class="num">$ (447,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">135,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(2,995)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,995)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan</a></td>
<td class="nump">18,792<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">18,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(15,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">97,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Oct. 01, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Oct. 01, 2021</a></td>
<td class="nump">2,112,447<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">2,422,323<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="num">(311,673)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jul. 02, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jul. 02, 2021</a></td>
<td class="nump">2,043,077<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">2,390,654<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
<td class="num">(349,877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">38,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan</a></td>
<td class="nump">3,305<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(5,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">34,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Oct. 01, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Oct. 01, 2021</a></td>
<td class="nump">$ 2,112,447<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">2,422,323<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="num">(311,673)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">318,842<span></span>
</td>
<td class="nump">318,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 2,210,615<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">2,427,561<span></span>
</td>
<td class="num">(758)<span></span>
</td>
<td class="num">(216,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">212,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(16,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan</a></td>
<td class="nump">18,680<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">18,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(16,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 82,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">322,541<span></span>
</td>
<td class="nump">322,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 2,491,402<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">2,512,669<span></span>
</td>
<td class="num">(17,538)<span></span>
</td>
<td class="num">(4,052)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jul. 01, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jul. 01, 2022</a></td>
<td class="nump">2,391,260<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="nump">2,477,117<span></span>
</td>
<td class="num">(8,917)<span></span>
</td>
<td class="num">(77,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">73,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(8,621)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,621)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan</a></td>
<td class="nump">2,848<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(4,906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 37,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">322,541<span></span>
</td>
<td class="nump">322,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 2,491,402<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 2,512,669<span></span>
</td>
<td class="num">$ (17,538)<span></span>
</td>
<td class="num">$ (4,052)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227727632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 212,455<span></span>
</td>
<td class="nump">$ 135,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">14,929<span></span>
</td>
<td class="nump">11,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">81,718<span></span>
</td>
<td class="nump">96,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">11,931<span></span>
</td>
<td class="nump">3,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">7,390<span></span>
</td>
<td class="nump">35,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="nump">66,890<span></span>
</td>
<td class="num">(20,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(9,836)<span></span>
</td>
<td class="num">(26,956)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(35,166)<span></span>
</td>
<td class="num">(24,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(3,130)<span></span>
</td>
<td class="nump">11,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_IncreaseDecreaseInAccruedCollaborationLiabilities', window );">Accrued collaboration liabilities</a></td>
<td class="num">(64,976)<span></span>
</td>
<td class="nump">13,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">6,715<span></span>
</td>
<td class="nump">33,865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">288,920<span></span>
</td>
<td class="nump">304,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(25,989)<span></span>
</td>
<td class="num">(48,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(1,079,411)<span></span>
</td>
<td class="num">(1,077,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities and sales of investments</a></td>
<td class="nump">826,768<span></span>
</td>
<td class="nump">1,095,813<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(278,632)<span></span>
</td>
<td class="num">(29,829)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive plans</a></td>
<td class="nump">18,680<span></span>
</td>
<td class="nump">18,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(16,091)<span></span>
</td>
<td class="num">(15,049)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,589<span></span>
</td>
<td class="nump">3,193<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash equivalents</a></td>
<td class="nump">12,877<span></span>
</td>
<td class="nump">277,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at beginning of period</a></td>
<td class="nump">663,891<span></span>
</td>
<td class="nump">320,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at end of period</a></td>
<td class="nump">676,768<span></span>
</td>
<td class="nump">598,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract', window );"><strong>Non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">121,958<span></span>
</td>
<td class="nump">4,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred for purchases of property and equipment</a></td>
<td class="nump">1,643<span></span>
</td>
<td class="nump">5,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Unpaid liabilities incurred in asset acquisition</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInAccruedCollaborationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Collaboration Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInAccruedCollaborationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055252136560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for patients with difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 62 other countries as: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. a member of the Roche Group (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;18, 2022 (Fiscal 2021 Form 10-K).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2022, which is a 52-week fiscal year, will end on December&#160;30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the fiscal period ended October 1, 2021, and as of and for the fiscal year ending December&#160;30, 2022 are indicated as being as of and for the period ended September&#160;30, 2021, and the year ending December&#160;31, 2022, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies during the nine months ended September 30, 2022, compared to the significant accounting policies disclosed in &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055229640688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,482&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023,824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187,145&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:37.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.655%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,738&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:37.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.655%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,482&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:41.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,398&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,003&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule, and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contract assets and liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, we recognized $6.6&#160;million and $6.8&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2022, we recognized $33.9&#160;million and $125.0&#160;million, respectively, in revenues for performance obligations satisfied in previous periods, as compared to $48.4&#160;million and $116.2&#160;million for the corresponding prior year periods. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech and the recognition of license revenue for the achievement of milestones during the second quarter of 2022, allocated to the license performance obligations for our collaboration with Ipsen.</span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022, $83.1&#160;million of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he co</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mbined transaction prices for our Ipsen a</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Takeda collaborations were allocated to our research and development services performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K for additional information about the expected timing to satisfy these performance obligations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055229591344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</a></td>
<td class="text">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaborations, in-licensing arrangements and other strategic transactions to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading pharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K, as further described below, for additional information on certain of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, we recognized $25.8&#160;million in revenues in connection with two regulatory milestones totaling $27.0&#160;million upon approval by the European Commission and Health Canada, of cabozantinib as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to RAI who have progressed during or after prior systemic therapy.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022, $49.3&#160;million of the transaction price for this collaboration was allocated to our research and development services performance obligations that have not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $33.8&#160;million of the transaction price for this collaboration was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib sold by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and in connection with sales by our collaboration partners are included as a reduction of collaboration services revenues. Such royalties were $14.9&#160;million and $42.6&#160;million during the three and nine months ended September&#160;30, 2022, respectively, as compared to $11.5&#160;million and $33.7&#160;million for the corresponding prior year periods.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, which are generally paid upon the closing of the transaction, and also milestone payments (in connection with development, regulatory or commercial achievements) and royalty payments, which are contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations and in-licensing arrangements provide us exclusive options that give us the right to license programs developed under the research collaborations for further discovery and development. When we decide to exercise an option, we are required to pay an exercise fee and then, in most instances, we will assume the responsibilities for all subsequent clinical development, manufacturing and commercialization of the licensed asset.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we entered into an exclusive option and license agreement with BioInvent International AB (BioInvent), upon which we paid an upfront payment of $25.0&#160;million. Upon option exercise, we will pay BioInvent an option exercise fee, and BioInvent will be eligible for additional payments from us for future development and commercial milestones, as well as royalties on our future net product sales. In July 2022, we entered into an exclusive license agreement with Ryvu Therapeutics S.A. (Ryvu) and paid an upfront payment of $3.0&#160;million. Ryvu is eligible for potential future development and commercial milestones as well as royalties on future net product sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of September&#160;30, 2022, in conjunction with each of our research collaborations and in-licensing arrangements, and an asset purchase agreement entered into in 2021, we are subject to contingent payments for potential future development milestones of up to $364.7&#160;million, regulatory milestones of up to $453.4&#160;million and commercial milestones of up to $2,443.4&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055229520480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text">CASH AND INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. The standby letter of credit entered in January 2021, as a guarantee of our obligation to fund our portion of the tenant improvements related to our Alameda build-to-suit lease was terminated and the related collateral was returned in the third quarter of 2022, following the substantial completion of the building and the commencement of the lease.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831,896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,328)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809,568&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,328)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100,209&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $4.8 million and $2.9 million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2021, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three and nine months ended September&#160;30, 2022 and 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:64.520%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,495)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,328)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:64.520%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 276 and 133 investments in an unrealized loss position as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2021, respectively. All securities presented above have been in an unrealized loss position for less than twelve months except for 25 corporate bond securities and 1 municipal bond security with an aggregate fair value of $64.0&#160;million and an aggregate $2.4&#160;million unrealized loss as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the nine months ended September 30, 2022 and 2021, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809,568&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055228574752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,968&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986,717&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652,724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had one forward contract outstanding to sell &#8364;10.0&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The unrealized loss on the forward contract is not material as of September&#160;30, 2022. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the nine months period ended September&#160;30, 2022, and 2021, we recognized $1.5 million and $0.5&#160;million, respectively, of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055225769040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:64.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055229682448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,337&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,718&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,337&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,718&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 25, 2022, at the 2022 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The amendment and restatement increased the share reserve under the 2017 Plan by 28,500,000 shares. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022, 31,485,656 sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the 2017 Plan. The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 2 shares for full value awards, including restricted stock units (RSUs).&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, we granted 588,862 stock options with a weighted average exercise price of $19.99 per share and a weighted average grant&#160;date fair&#160;value of $8.36</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were 11,416,151 stock options outstanding and $19.6&#160;million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we awarded to certain employees an aggregate of 1,003,482 (the target amount) RSUs that are subject to a total shareholder return (TSR) market condition (the TSR-based RSUs). The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 1, 2022 through January 3, 2025. Depending on the results relative to the TSR market condition, the holders of the TSR-based RSUs may earn up to 175% of the target amount of shares. 50% of the shares earned pursuant to the TSR-based RSU awards will vest at the end of the performance period, and the remainder will vest approximately one year later, subject to employee&#8217;s continuous service. These TSR-based RSUs will be forfeited if the market condition at or above a threshold level is not achieved at the end of the performance period on January 3, 2025.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the TSR-based RSUs:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:90.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#8217;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, we granted 5,292,088 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $20.56 per share. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were 11,864,173 RSUs outstanding, including the TSR-based RSUs, and $193.8&#160;million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and service-based RSUs granted to employees during the nine months ended September 30, 2022 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were&#160;5,367,906 performance-based restricted stock units (PSUs) outstanding and $101.0&#160;million of related unrecognized stock-based compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. During the three months ended September 30, 2022, we achieved a performance condition for threshold achievement for 495,886 PSUs granted during 2020 (the 2020 PSUs) and have recognized $9.7&#160;million of stock-based compensation expense related to the 2020 PSUs during the three </span></div>months ended September&#160;30, 2022. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055228651312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">PROVISION FOR INCOME TAXES</a></td>
<td class="text">PROVISION FOR INCOME TAXES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and nine months ended September&#160;30, 2022, were 20.5% and 20.1% respectively, as compared to 28.3% and 22.8% for the corresponding periods in 2021. The effective tax rates for the three and nine months ended September&#160;30, 2022 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, which were partially offset by state taxes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three and nine months ended September&#160;30, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to non-deductible executive compensation, which was partially offset by excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055229679968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text">NET INCOME PER SHARE<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:50.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,066&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,084&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, unvested RSUs, including TSR-based RSUs, PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:50.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055228670992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Build-to-Suit Lease and Headquarters Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the office building (New Premises) associated with our October 2019 build-to-suit lease agreement (Build-to-Suit Lease) was substantially completed. The New Premises is 220,517 square feet and is in Alameda, California, adjacent to our existing corporate headquarters. The Build-to-Suit Lease term is 242 months, includes two five-year options to extend the term of the lease and a one-time option to terminate the lease after 180 months. In addition to the monthly lease payments, currently estimated at $0.7&#160;million, subject to an annual increase of 3% during the Term, we are also </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsible for paying operating expenses related to the New Premises. On April 15, 2022, the lease commenced for the New Premises. We determined the classification of the lease was an operating lease. Upon commencement of the lease, we recognized a right-of-use asset of $160.9&#160;million inclusive of $44.9&#160;million for the cost of the tenant improvements in excess of the allowance provided by the lessor and an operating lease liability of $116.0&#160;million discounted over 180 months using our estimated incremental borrowing rate of 4.9%.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we entered into the seventh amendment to the lease for our corporate headquarters located on Harbor Bay Parkway, Alameda, California (the Alameda Lease). The May 2022 amendment to the Alameda Lease (the Seventh Lease Amendment) provides, among other things, for the expansion of the premises under the Alameda Lease by 34,745 square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Expansion Space). The term for the 1751 Expansion Space will run coterminous with the term of the Alameda Lease for the existing space. In connection with the Seventh Lease Amendment, we remeasured our lease components under the Alameda Lease relating to the existing premises using an incremental borrowing rate of 5.0%. As of June 1, 2022, we have taken possession of the 1751 Expansion Space, and accordingly we have adjusted our right-of-use asset and liability by $4.3&#160;million.<br/><br/>For more information about our Leases, see &#8220;Note 11. Commitments and Contingencies&#8212;Leases&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSN I ANDA Litigation </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (individually and collectively with certain of its affiliates, including MSN Laboratories Private Limited, referred to as MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. The two lawsuits comprising this litigation (collectively referred to as MSN I), numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our MSN I complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties have narrowed </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN has, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claim 1 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial for MSN I occurred in May 2022, and a judgment is expected during the fourth quarter of 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSN II ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are invalid and not infringed. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#8217;s further amendment of its ANDA Filing with the FDA. On August 9, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 11,298,349 are invalid and not infringed. The two lawsuits comprising this litigation (collectively referred to as MSN II), numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated in October 2022 and involve Exelixis patents that are different from those asserted in the MSN I litigation described above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would also infringe certain claims of each patent, if those claims are not found to be invalid. In our MSN II complaints, we are seeking, among other remedies, equitable relief enjoining MSN from infringing this patent, as well as an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032. A bench trial for MSN II has been scheduled for October 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teva ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). On September 2, 2022, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#8217;s amended ANDA filing with the FDA. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873, 10,039,757 and 11,298,349, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On September 30, 2022, the parties filed a stipulation to consolidate the two lawsuits, numbered Civil Action Nos. 21-00871 and 22-01168, and to stay all proceedings, </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was granted by the Delaware District Court on October 3, 2022. Following a similar order granted by the Delaware District Court on February 9, 2022 to stay all proceedings with respect to Civil Action No. 21-00871, this case remained administratively closed, and Civil Action No. 22-01168 was administratively closed on October 3, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055229645408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<br/><br/>&#160;&#160;&#160;&#160;Cybrexa Therapeutics, LLC (Cybrexa)<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we entered into an agreement with Cybrexa Therapeutics, LLC (Cybrexa), which provides us the right to acquire CBX-12 (alphalex&#8482; exatecan), a clinical-stage peptide-drug conjugate (PDC) that utilizes Cybrexa&#8217;s proprietary alphalex technology to enhance delivery of exatecan to tumor cells. Under the terms of the agreement, we will pay an upfront fee of $60.0&#160;million for a warrant entitling us to the right to acquire the Cybrexa affiliate that controls CBX-12 and related assets, and to fund certain development and manufacturing expenses incurred by Cybrexa to advance CBX-12 during the warrant period. Cybrexa will continue the development of CBX-12 according to an agreed development plan, including phase 1 studies, and may be eligible to receive up to $65.0&#160;million in additional development milestone payments, during the warrant period. We may exercise the warrant for up to $300.0&#160;million based upon our evaluation of a pre-specified clinical data package to be delivered by Cybrexa. Following exercise of the warrant, Cybrexa would be eligible to receive up to $277.5&#160;million in additional payments upon achievement of further development, regulatory and commercial milestones. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sairopa, B.V. (Sairopa)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we entered into an exclusive option and license agreement with Sairopa, B.V. (Sairopa). Under the terms of the agreement, we will make an upfront payment of $40.0&#160;million for an option to obtain an exclusive, worldwide license to develop and commercialize ADU-1805 and other anti-SIRP&#945; antibodies, and for certain expenses to be incurred by Sairopa in conducting phase 1 clinical studies of ADU-1805. Sairopa is eligible to receive additional development milestone payments during the option period totaling up to $97.5&#160;million. Following the completion of the clinical studies, we may exercise the option for $225.0&#160;million based upon our evaluation of a pre-specified clinical data package to be delivered by Sairopa. Following the exercise of the option, Sairopa would be eligible to receive up to $465.0&#160;million in additional development, commercial, and net sales milestone payments, as well as tiered royalties on future net sales of products.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227798064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;18, 2022 (Fiscal 2021 Form 10-K).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span>. Fiscal year 2022, which is a 52-week fiscal year, will end on December&#160;30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the fiscal period ended October 1, 2021, and as of and for the fiscal year ending December&#160;30, 2022 are indicated as being as of and for the period ended September&#160;30, 2021, and the year ending December&#160;31, 2022, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule, and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227869936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,482&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023,824&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,738&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187,145&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:37.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.655%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,482&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration Risks</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:37.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.655%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues Disaggregated by Geographic Region</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,738&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983,830&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:41.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,398&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,003&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Other Assets and Other Liabilities</a></td>
<td class="text">Contract assets and liabilities were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055229482336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055225560336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Investments by Security Type</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831,896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,328)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809,568&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,328)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100,209&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):<div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:64.520%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,495)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,328)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:64.520%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809,568&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055229593776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,968&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986,717&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652,724&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055225769040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:64.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055225452352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,337&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,718&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,337&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,718&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</a></td>
<td class="text">We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the TSR-based RSUs:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:90.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055229577600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:50.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,066&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,084&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share</a></td>
<td class="text">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:50.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055222534384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>country </div>
<div>product </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS', window );">Number of countries with drug approval, excluding the u.s. | country</a></td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting from discovery efforts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products derived from other compounds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Countries With Drug Approval, Excluding The U.S.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberOfCountriesWithDrugApprovalExcludingTheUS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055225685088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 411,738<span></span>
</td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 1,187,145<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">496,141<span></span>
</td>
<td class="nump">357,462<span></span>
</td>
<td class="nump">1,427,451<span></span>
</td>
<td class="nump">1,051,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">(129,659)<span></span>
</td>
<td class="num">(94,345)<span></span>
</td>
<td class="num">(403,627)<span></span>
</td>
<td class="num">(277,294)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">366,482<span></span>
</td>
<td class="nump">263,117<span></span>
</td>
<td class="nump">1,023,824<span></span>
</td>
<td class="nump">774,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">34,384<span></span>
</td>
<td class="nump">49,694<span></span>
</td>
<td class="nump">123,977<span></span>
</td>
<td class="nump">116,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10,872<span></span>
</td>
<td class="nump">15,612<span></span>
</td>
<td class="nump">39,344<span></span>
</td>
<td class="nump">92,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 45,256<span></span>
</td>
<td class="nump">$ 65,306<span></span>
</td>
<td class="nump">$ 163,321<span></span>
</td>
<td class="nump">$ 209,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055222261248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Concentration Risks (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227662896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 411,738<span></span>
</td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 1,187,145<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">369,480<span></span>
</td>
<td class="nump">266,436<span></span>
</td>
<td class="nump">1,033,160<span></span>
</td>
<td class="nump">783,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">34,818<span></span>
</td>
<td class="nump">38,095<span></span>
</td>
<td class="nump">131,585<span></span>
</td>
<td class="nump">162,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 7,440<span></span>
</td>
<td class="nump">$ 23,892<span></span>
</td>
<td class="nump">$ 22,400<span></span>
</td>
<td class="nump">$ 37,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227753472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 411,738<span></span>
</td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 1,187,145<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">366,482<span></span>
</td>
<td class="nump">263,117<span></span>
</td>
<td class="nump">1,023,824<span></span>
</td>
<td class="nump">774,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">361,385<span></span>
</td>
<td class="nump">259,791<span></span>
</td>
<td class="nump">1,003,356<span></span>
</td>
<td class="nump">759,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 5,097<span></span>
</td>
<td class="nump">$ 3,326<span></span>
</td>
<td class="nump">$ 20,468<span></span>
</td>
<td class="nump">$ 15,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227706240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2021</a></td>
<td class="nump">$ 48,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">403,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(386,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September&#160;30, 2022</a></td>
<td class="nump">65,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks, Discounts for Prompt Payment and Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2021</a></td>
<td class="nump">14,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">261,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(255,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September&#160;30, 2022</a></td>
<td class="nump">21,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2021</a></td>
<td class="nump">8,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">36,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(169)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(32,765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September&#160;30, 2022</a></td>
<td class="nump">12,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2021</a></td>
<td class="nump">24,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">105,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(98,996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September&#160;30, 2022</a></td>
<td class="nump">$ 31,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227757728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract', window );"><strong>Contract assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">6,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">6,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total contract liabilities</a></td>
<td class="nump">13,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Contract revenue recognized, including revenue from deferred revenue beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">33,900<span></span>
</td>
<td class="nump">$ 48,400<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">$ 116,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exel_TakedaAndIspenMember', window );">Takeda and Ispen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 83,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract Revenue, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exel_TakedaAndIspenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exel_TakedaAndIspenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227701568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 411,738<span></span>
</td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 1,187,145<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">34,818<span></span>
</td>
<td class="nump">38,095<span></span>
</td>
<td class="nump">131,585<span></span>
</td>
<td class="nump">162,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">34,384<span></span>
</td>
<td class="nump">49,694<span></span>
</td>
<td class="nump">123,977<span></span>
</td>
<td class="nump">116,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">27,607<span></span>
</td>
<td class="nump">25,139<span></span>
</td>
<td class="nump">103,389<span></span>
</td>
<td class="nump">81,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10,872<span></span>
</td>
<td class="nump">15,612<span></span>
</td>
<td class="nump">39,344<span></span>
</td>
<td class="nump">92,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 7,211<span></span>
</td>
<td class="nump">$ 12,956<span></span>
</td>
<td class="nump">$ 28,196<span></span>
</td>
<td class="nump">$ 81,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055228108752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details) - Collaborative Arrangement with Ipsen<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>milestone</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amount of revenues recognized included in the beginning contract liability balance</a></td>
<td class="nump">$ 25.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberOfRegulatoryMilestone', window );">Number of regulatory milestone | milestone</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ContractWithCustomerMilestoneRevenueRecognized', window );">Milestone revenue recognized</a></td>
<td class="nump">$ 27.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 49.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Milestone Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberOfRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Regulatory Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberOfRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055222346352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 411,738<span></span>
</td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 1,187,145<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,351<span></span>
</td>
<td class="nump">22,734<span></span>
</td>
<td class="nump">18,903<span></span>
</td>
<td class="nump">34,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">34,384<span></span>
</td>
<td class="nump">49,694<span></span>
</td>
<td class="nump">123,977<span></span>
</td>
<td class="nump">116,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,690<span></span>
</td>
<td class="nump">20,078<span></span>
</td>
<td class="nump">7,755<span></span>
</td>
<td class="nump">23,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10,872<span></span>
</td>
<td class="nump">15,612<span></span>
</td>
<td class="nump">39,344<span></span>
</td>
<td class="nump">92,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,661<span></span>
</td>
<td class="nump">$ 2,656<span></span>
</td>
<td class="nump">$ 11,148<span></span>
</td>
<td class="nump">$ 10,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055228677728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 33.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055225596432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - GSK Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaboration Agreement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_RoyalPharmaMember', window );">Royal Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 14.9<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 42.6<span></span>
</td>
<td class="nump">$ 33.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_RoyalPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_RoyalPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055151457712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 411,738<span></span>
</td>
<td class="nump">$ 328,423<span></span>
</td>
<td class="nump">$ 1,187,145<span></span>
</td>
<td class="nump">$ 983,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech | Cotellic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossFromAgreement', window );">Profits on U.S. commercialization</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="nump">1,743<span></span>
</td>
<td class="nump">5,325<span></span>
</td>
<td class="nump">5,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="nump">$ 1,576<span></span>
</td>
<td class="nump">$ 4,011<span></span>
</td>
<td class="nump">$ 3,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProductOrServiceAxisAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProductOrServiceAxisAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055222550496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithBioInventInternationalABBioInventMember', window );">Collaboration Agreement With BioInvent International AB (BioInvent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Collaborative arrangement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember', window );">Collaboration Agreement With Ryvu Therapeutics S.A. (Ryvu)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Collaborative arrangement, upfront payment</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember', window );">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments', window );">Collaborative arrangement, maximum aggregate development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 364.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments', window );">Collaborative arrangement, maximum aggregate regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments', window );">Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,443.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithBioInventInternationalABBioInventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithBioInventInternationalABBioInventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227850528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 675,286<span></span>
</td>
<td class="nump">$ 647,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">16,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 676,768<span></span>
</td>
<td class="nump">$ 663,891<span></span>
</td>
<td class="nump">$ 598,488<span></span>
</td>
<td class="nump">$ 320,772<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055151529760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>bond </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer</a></td>
<td class="nump">$ 64,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Accumulated loss</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberOfBondSecurities', window );">Number of bond securities | bond</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberOfBondSecurities', window );">Number of bond securities | bond</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberOfBondSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Bond Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberOfBondSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055222733200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,831,896<span></span>
</td>
<td class="nump">$ 1,534,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(22,328)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,809,568<span></span>
</td>
<td class="nump">1,533,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,122,537<span></span>
</td>
<td class="nump">1,855,704<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(22,328)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,100,209<span></span>
</td>
<td class="nump">1,854,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">874,220<span></span>
</td>
<td class="nump">945,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(364)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">873,856<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">633,617<span></span>
</td>
<td class="nump">541,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(15,495)<span></span>
</td>
<td class="num">(1,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">618,122<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">307,494<span></span>
</td>
<td class="nump">33,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6,157)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">301,337<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">16,565<span></span>
</td>
<td class="nump">12,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(312)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">16,253<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">113,492<span></span>
</td>
<td class="nump">135,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">113,492<span></span>
</td>
<td class="nump">135,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">62,968<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">62,968<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">114,181<span></span>
</td>
<td class="nump">119,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 114,181<span></span>
</td>
<td class="nump">$ 119,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055150807760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 967,168<span></span>
</td>
<td class="nump">$ 454,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(22,328)<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">613,122<span></span>
</td>
<td class="nump">385,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(15,495)<span></span>
</td>
<td class="num">(1,672)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">301,337<span></span>
</td>
<td class="nump">18,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(6,157)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">36,636<span></span>
</td>
<td class="nump">43,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(364)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">16,073<span></span>
</td>
<td class="nump">7,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (312)<span></span>
</td>
<td class="num">$ (35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227791760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 1,260,834<span></span>
</td>
<td class="nump">$ 1,168,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">548,734<span></span>
</td>
<td class="nump">365,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,809,568<span></span>
</td>
<td class="nump">$ 1,533,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055151406128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,809,568<span></span>
</td>
<td class="nump">$ 1,533,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,809,568<span></span>
</td>
<td class="nump">1,533,668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,986,717<span></span>
</td>
<td class="nump">1,719,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">62,968<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,809,568<span></span>
</td>
<td class="nump">1,533,668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,923,749<span></span>
</td>
<td class="nump">1,652,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">873,856<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">873,856<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">873,856<span></span>
</td>
<td class="nump">945,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">618,122<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">618,122<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">618,122<span></span>
</td>
<td class="nump">540,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">301,337<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">301,337<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">301,337<span></span>
</td>
<td class="nump">33,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">16,253<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">16,253<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">16,253<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">62,968<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">62,968<span></span>
</td>
<td class="nump">66,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">114,181<span></span>
</td>
<td class="nump">119,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 114,181<span></span>
</td>
<td class="nump">$ 119,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055151546720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narratives (Details) - Foreign Exchange Forward<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;) </div>
<div>forward_contract</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of contract | forward_contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative term of contract</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOnDerivativeInstrumentsPretax', window );">Gain on derivative instruments, pretax | $</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnDerivativeInstrumentsPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnDerivativeInstrumentsPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227904832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 9,447<span></span>
</td>
<td class="nump">$ 8,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">39,380<span></span>
</td>
<td class="nump">27,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">11,325<span></span>
</td>
<td class="nump">12,927<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">60,152<span></span>
</td>
<td class="nump">49,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">26,711<span></span>
</td>
<td class="nump">27,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 33,441<span></span>
</td>
<td class="nump">$ 22,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055225683856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 37,337<span></span>
</td>
<td class="nump">$ 33,966<span></span>
</td>
<td class="nump">$ 81,718<span></span>
</td>
<td class="nump">$ 96,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">16,438<span></span>
</td>
<td class="nump">11,487<span></span>
</td>
<td class="nump">34,886<span></span>
</td>
<td class="nump">37,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 20,899<span></span>
</td>
<td class="nump">$ 22,479<span></span>
</td>
<td class="nump">$ 46,832<span></span>
</td>
<td class="nump">$ 59,104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055151564496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 37,337<span></span>
</td>
<td class="nump">$ 33,966<span></span>
</td>
<td class="nump">$ 81,718<span></span>
</td>
<td class="nump">$ 96,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,299<span></span>
</td>
<td class="nump">4,607<span></span>
</td>
<td class="nump">10,470<span></span>
</td>
<td class="nump">15,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">22,233<span></span>
</td>
<td class="nump">13,721<span></span>
</td>
<td class="nump">54,234<span></span>
</td>
<td class="nump">40,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">11,331<span></span>
</td>
<td class="nump">14,971<span></span>
</td>
<td class="nump">14,621<span></span>
</td>
<td class="nump">37,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 667<span></span>
</td>
<td class="nump">$ 2,393<span></span>
</td>
<td class="nump">$ 3,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055150612944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 25, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve under 2017 plan (in shares)</a></td>
<td class="nump">28,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,485,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,485,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward', window );">Reduction in share reserve after stock option or stock appreciation award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards', window );">Reduction in share reserve after all other awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted in the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,416,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,416,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,337<span></span>
</td>
<td class="nump">$ 33,966<span></span>
</td>
<td class="nump">81,718<span></span>
</td>
<td class="nump">$ 96,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,292,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,864,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,864,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,233<span></span>
</td>
<td class="nump">13,721<span></span>
</td>
<td class="nump">$ 54,234<span></span>
</td>
<td class="nump">40,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember', window );">TSR-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,003,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember', window );">TSR-Based Restricted Stock Units | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting award percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,367,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,367,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,331<span></span>
</td>
<td class="nump">$ 14,971<span></span>
</td>
<td class="nump">$ 14,621<span></span>
</td>
<td class="nump">$ 37,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Granted 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=exel_Granted2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=exel_Granted2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055226407936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Estimate Grant-Date Fair Value (Details) - TSR-Based Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of the Company's common stock on grant date (in dollars per share)</a></td>
<td class="nump">$ 20.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">46.85%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_TSRBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227882016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">20.50%<span></span>
</td>
<td class="nump">28.30%<span></span>
</td>
<td class="nump">20.10%<span></span>
</td>
<td class="nump">22.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055150601168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income, Basic</a></td>
<td class="nump">$ 73,210<span></span>
</td>
<td class="nump">$ 38,204<span></span>
</td>
<td class="nump">$ 212,455<span></span>
</td>
<td class="nump">$ 135,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income, Diluted</a></td>
<td class="nump">$ 73,210<span></span>
</td>
<td class="nump">$ 38,204<span></span>
</td>
<td class="nump">$ 212,455<span></span>
</td>
<td class="nump">$ 135,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">322,148<span></span>
</td>
<td class="nump">315,380<span></span>
</td>
<td class="nump">320,949<span></span>
</td>
<td class="nump">313,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">6,642<span></span>
</td>
<td class="nump">3,471<span></span>
</td>
<td class="nump">8,094<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">325,066<span></span>
</td>
<td class="nump">322,022<span></span>
</td>
<td class="nump">324,420<span></span>
</td>
<td class="nump">322,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227872816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share-based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities and contingently issuable shares excluded (in shares)</a></td>
<td class="nump">15,059<span></span>
</td>
<td class="nump">20,346<span></span>
</td>
<td class="nump">15,311<span></span>
</td>
<td class="nump">14,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055222127360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 15, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>segment</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Jun. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Estimate incremental borrowing rate (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LossContingencyNumberOfLawsuitsConsolidated', window );">Number of lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LossContingencyNumberOfLawsuitsConsolidated', window );">Number of lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseAndHeadquartersLeaseMember', window );">Built-To-Suit Lease And Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lease property (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">242 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend the lease | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease option to extend period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod', window );">Option to terminate lease (after period)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment', window );">Estimated monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage', window );">Monthly base rent, lease not yet commenced, annual percentage increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">$ 160.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Inclusive of operating lease liability</a></td>
<td class="nump">44.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 116.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OperatingLeaseLiabilityDiscountedPeriod', window );">Operating lease liability discounted period</a></td>
<td class="text">180 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Estimate incremental borrowing rate (in percent)</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_LeaseExpansionMember', window );">1751 Expansion Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lease property (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Terminate After Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LossContingencyNumberOfLawsuitsConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Lawsuits Consolidated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LossContingencyNumberOfLawsuitsConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseLiabilityDiscountedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Discounted Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseLiabilityDiscountedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TenantLeaseImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant Lease Improvements, Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TenantLeaseImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseAndHeadquartersLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseAndHeadquartersLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_LeaseExpansionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_LeaseExpansionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140055227669040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Forecast<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Cybrexa Therapeutics, LLC (Cybrexa)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Collaborative arrangement, upfront payment</a></td>
<td class="nump">$ 60.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments', window );">Collaborative arrangement, maximum aggregate development milestone payments</a></td>
<td class="nump">65.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise', window );">Maximum amount of warrant to be exercised</a></td>
<td class="nump">300.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments', window );">Additional development regulatory and commercial milestones payments</a></td>
<td class="nump">277.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Sairopa, B.V. (Sairopa)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Collaborative arrangement, upfront payment</a></td>
<td class="nump">40.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments', window );">Collaborative arrangement, maximum aggregate development milestone payments</a></td>
<td class="nump">97.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments', window );">Additional development regulatory and commercial milestones payments</a></td>
<td class="nump">465.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount', window );">Option to exercise, amount</a></td>
<td class="nump">$ 225.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountOfWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Amount Of Warrant Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountOfWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsExerciseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Exercise Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsExerciseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development, Regulatory And Commercial Milestones Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CybrexaTherapeuticsLLCCybrexaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CybrexaTherapeuticsLLCCybrexaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_SairopaBVSairopaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_SairopaBVSairopaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>exel-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exel="http://www.exelixis.com/20220930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20220930.xsd" xlink:type="simple"/>
    <context id="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0c2e3793b63a4e5fb7d9a4731fc85bfa_I20221024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-10-24</instant>
        </period>
    </context>
    <context id="i37a45756c9954dffb1597b6666f619f3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9c08664821924215a9a380432cc549fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i278c1109560d43989bb93fcb650c9afa_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7e0a6faac267459387d713c98a6da04c_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iaac13ba8b31b461a9ee349f6df7ec401_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8d1060e036714dc8b00e67d518425d7e_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i3969d7ffe515467786d9f03efe7dd44a_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4ffeb5a9e14d43f5bf61509594c23244_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i48e199975584423f9f9b5fc5676b433e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i86031b3c8cd74803ab4a6280a4faaea9_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ibd67de25ab5242d6acec13d5bb1dcd8c_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3212d047299943f1aefbd2a60b170c8c_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i9f0edff0af2d424980d236133e9e6a27_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if06c48663d594ceeabfd8945d8b2d8be_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if9baae3c0c274839b462d39623feea2d_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i825124e3b6104871b081a44c670a7a86_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ib3b23ba8f2c94ddcb48f6a85901903b5_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="ibdff014306a24f67bd885f70ff909a7d_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i6604d7fea14d4e8fb16b161c841a6999_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i64041df1701a4a07b8ef7d5c0f37f576_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i149d987491b846698276e3ab735170f7_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i54dcb905f0384fd8bce6b7e44c2faa57_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i44690402ba504bd1987f6bea7e60ccfc_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i68253ae6a74648f0b87bb4a6390ffc5f_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i00d8665815014c9aae47cbac0416c062_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i283a9472e4fa421799257a1a2bd9fa1c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id4697a4d7dcd4136b84bf95f0e95aac8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib8188cffbcf746278fdee32a78f4a8cb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0570e9a9f97c4dfc9839b7ab1860e680_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i80f67f4b8f82417db30834591fb44d60_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ifd4b7ab3407c44cb8b1ed0210197c8e9_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ic87ae071c1834ea6abd407e1ee1c295a_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i6899e05fb3f5440cb7983ea4ae13b93b_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i1f3dc37f9c84491ba474d260d6688295_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i2afa3de03a1043199b82592539c4213f_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i81def5dda1a6445d84955509b0fe837a_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i029f475a4cb743c883c1e02d0bd1e0ca_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i5d2bb7e98f0347679cc8ee55fd39e05e_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="if09ffd775b454fd28bc4ccc68d578a46_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="id6024509ae78487f8fce552a0976856d_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i25b72e0f00af411b8652e825b767f230_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="iacaf43cbe24a472ba26b4376244aeceb_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i22983ccf5d88438696ca9ed782f2b97a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1fa68b5c6fea4b5eb3e3e88045cc2288_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77a026db7c644033a1c8a0268a3cc765_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7950e15bb4194a85a2dfe92d26c1c011_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a29957ee8b14a00a22d941a4f3bb1cf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idb6a382becc140a4b1da483762a0959f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib6ac406b2dc941da8bb9bf4a2a0c6bc4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i058269d798474c4f81f2c52f1a695d17_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i98f25495c49942328fe52185ebb36868_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="icbe63aa422cd4993aa00fe1bec11e108_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i34b4239fc7694a5f9a055a4f8d0ea9d0_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i897ee6ad5f0f4e8a932659340f671c9b_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i48eab2e753614354a3732f75587e636f_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ic0c9d8627fe44d7983aa3b965e06e09b_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ibbb5c647740f4d2d99a83b98b0fc1e73_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7b44b1b4753f4fc19f53534dfb54799f_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i4f53e591b0874be8be6c8805109d1335_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i956b96970860433cac967eaa240e5cb1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0adfaf62ed654496b8aef139a0b4a6a0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i29e8fc05be13408780345631766d0815_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7b04ee7fa7f744f3bd93b05af54ac638_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ic228c7eb5cf24643909be765ba674a07_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i245c45138f3a4c37bf6f61ddc6a3d179_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i3c6da63ce1144dfe9238e2548fc27b35_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1ac64684837b4a6da52ae5943bd15379_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i11f269764820403288f53e33a88cf89f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i066aeee8d576453da3c5e154f00d7eac_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i27a38704423047618c2b8b7c1b51be0e_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i42beb11067e7404f9bc3d9896994366b_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i2c5cd1f508804375996b6d9886dc1ea9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i21a57c281a93454aaf7038dc3b541516_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ie65c3b49253c4aa7b9ec4c0202bebd90_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5bf8a00473bf46afaa5c09de8f46aba6_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i77ddea34c561403e81f6dd80be859a85_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id2eeedb844d94073adfe7b633274b258_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i50245b1220fd4277b1ff3bbe18a1c24a_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifb3f74547a9b413bac6630c8bb4155c6_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7149117a9e054f7f8e808e1fd2ff2e9e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib51bcc2f1cfb4c36aa8d080a8efad244_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i3c2a7f145b054c929254fd11464ef3b3_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia4e2dbdf48c448b29b598f9f2a0e5e19_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i97213e89d9b746b5bf8fbd85fd21333c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaa364ec98f294e0daf245b10590174ba_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i05ec8cf0e5c849b2922e3b9477ee666d_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia362249dbd9f44f1b5332ae17e959ded_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ib6dc5a498cf9414a802f893ec5b46c0f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5dddd16fbc8540e2a41581289baa917d_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iaa0b05764a414ac78f6fd87d606b97fd_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5c8fcad9f81446bcb60cc26cbc5f329f_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i93f8e2a75c804d01bd28137196447c82_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8da6b9fe3c7a45dfb9419e4c773ac239_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i218f04d9b7f145c4a3ab264f17ca1972_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i971168baf86d4f9c9aee82b5e9765ccd_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1fb1caa40c0048d0a80ef36f16745e1e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idde9ae17b3d542958541cede2a2481c6_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35a9f0667ea2442eb885a468202845d4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic52fe2f2070840529d3087ede78597e4_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04cd2aba94c64626b2bf9bb35be0b8ce_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0247826a7d194832a81af45a2cfe61dd_D20210102-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i445b3583a8f7464f94fbda78d87c16ea_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id4011737647c446caa0d25b062561b85_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ieb8931e56e6c45ec95b31d5e8b47dc6e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i10a8e5b6128d47dcbe8f521a6afdd884_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i20d1b5c68b7248bd894117cbe81a2b72_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id2aec28765054e47a8b50efa632378be_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iab572d16389b4a3d99847cab2ea41fcc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic93479bb75b140d3802fac8c321d4809_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7080625bcf434804949496009873718c_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic2efe1c927824b6abc801dccb6e57899_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7b606e33b09d4e47ac8222e71af4b57d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic30704e87cef4c1f82e032e0b9646586_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i92fb0f6b07fd46b6ba4261c7461fff4b_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib0c29019e5ac47c4817bdab99ce15b5a_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i6d39089578604b9b9931f9e265946ecf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3056fc81cda24a63be80c8307b00b2da_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i4c3de4e4a9084bf98f767229d2d7f1f9_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5b17a7fa5ce04b0bb62269c78f9e34bc_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ia90bd12e1079420ab8c09c67bb824c80_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i47e65bdb96ff4594b3069a428583550b_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if9de5a5db4474de1862cf88701e361a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a7784b834fd4f77b0d696e7db0b1345_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifedb850ea024432c901960f936fab351_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieda8f95f074144778888a0e634d3e42b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i001a107c11d44b3f8675588a5f182420_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i291663fb25df40058a0517d4e9d7425e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icc4ec47df1b34e468e64eed9bb89500e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6f0371d74e96407b87bcc99e5690f80d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7e205712f95140a09c2d11e6c6f425b7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4e9f925ab5174bc3b4fed38f74de06a4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exel:TakedaAndIspenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i545cd28e851247caac6d1d375512f1c7_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i90ee6fa4bd8843d2b764a321fa9de3f3_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if1c2d7715df546c183c0e89d6bd9ed3b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i38484c00f8ed449e838f354569fb8a60_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i9fcd1390271d4d2abc556f67a01c14b4_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5138e445f8ee4ac79c11a13ebfd1db6a_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i4e7d911a57c6474c92d558bab6c033a4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia0a570d5f6c8420c9d45e3db1337a2a8_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i932765cb697a4b078cea923c81edd920_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i80091c0e7cfb45668e3eb0d45b2c94f3_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i1364c1c302444d838efffd43064715f9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i41523be6e587448d8ab2f6b2f0c6f04b_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i4913e232a2ad4455a008eed936155e00_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3a62749d1d48443f886e9796c6337793_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id030fbf9dc0b477e938decac98663411_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ia0a001be0ff84fe794c78832456ead43_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9ee1ed1bb84547448046eae5336921cb_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i26a61b54755e49e39e3e69a7ee48adb1_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4ac924d3ae554ad193f222a56997ca8d_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i8201aa36633a4adc95d3929b8b7b08c7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7699082fc113461698ab25c1cdd41c5f_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ic70ffc1d027b441296ba4347fbd23534_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i43e9d3f2b70a49bf940167c1f27ee63c_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i3c59059ae1a643cf9613f787f7e2b135_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie402c1037bde46c5af87b543056ba92d_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ibaa37e09ed2a4cc1877653a23011c082_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia63686e881124ae08b1ebf7e9f49fd77_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia5970864bfa44baca1140501cee1fbfb_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ided9d969f2e1442982aa0a851fba5f6e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib50a0249433a4d278481e65be8ffe69f_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ia12b136a6e174c9bbad11748d01a0e9c_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i9da7e9b183de4698ac4c703b2c8f846c_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9527062f675b4046a1cebadb13e14991_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ibe693b49d3c949bd864806bd146b6a29_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8849b4c4c01946888c77e7fb6ccccb84_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProductOrServiceAxisAxis">exel:CotellicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i9c9d5031bdf542ceab4b6f6d4789fa7f_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithBioInventInternationalABBioInventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if0491f03c0124ea5a708fd9ea63f6bc3_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithRyvuTherapeuticsSARyvuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="ie2f04ac5f92f4dfdb4acf9ff8f6d9471_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i58839179e60147438d111534793e3584_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4cfa17414554476d91dacbdd5d9a0abd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ied291acb3b8349dcaa4d28395592f7e8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic96174b513db4b08a8d8022ebefad89f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7eb3542aa68a458ba55ced4e19e05fd3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ica491f30edaa49d7ad148efd0cbfa735_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibe0063762fe744f0a9698d6a8a86e957_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icc686d12fa4e4260b80a6d50f6424dc3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i701da0dfff384128b67d66f7cfc99222_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idef82cf2fbcf4ade8270cbe16f10de34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i172e305050d443b3a741d87593f63789_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i715f766ed6a447508a29b9beaf5cb949_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48ec553d89834f00b45ec9c811bb351c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if496ec13812c4ae893488d94baef090c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1a8f66e27ef54639adf8c0c31673352c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i843bbd1a33f649a78d35d947eff4b9a7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i51cbf38a72b74e8d987a9138cc078b1a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i47c2e10640954a49859ec7c33dbb8e33_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i81558c9856554de7833c4a2806a8b626_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id57f0a67c6b243ed9e67d6b085657e54_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1efce754a3e042719aca4d5d14d2cdc9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibd3d6d7024114c76b5161677a09f1ff1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8ee240d204304b82b2e177132d0e6bf1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icb3f78b5c5b94afd80179a24fb7390ab_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iec9a9b3bc1ed41a9bb7528566061b93f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i88202d8592004d2c8c4852504e52b931_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibea0c087b202475e99958164943828bf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i71fc629d67b1439596f3c19023047959_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8b2ebe36f5674bb58674bb6f4330233f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iebf3c208a48c4e599b699f4ab792b2db_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8475c0170e0e415f97fbec0694e96b99_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i04b2a87a345c443dae1c0c9599142457_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0b3c03a185f44b7cba57ea4cd0921028_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i674f190343a44c93a3f972959dd570b6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie5c375c63bd346fe978fb2534b5e3800_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a6d14de067741dca25498e9f73fd442_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i341945d209bf44d296c37ef93e0345ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id3c5b394503146d3a0d022b6c8b89b92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0a20eb1a92443bda7fa6b72c5a0d273_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie591104d91534932927cac2401b55411_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i830bd31e008547e886cd8a5ec319f87e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia04e0b0194d7409f8c9d6770aade56c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58211da7dc6f4d538de9873270446232_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i334c5f91f7f14f9fad4d7234cc49ea1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78e946b1e834488a8312b0d935e9f2a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f657f4786c94e5cabeabf0a738d4385_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i562efe5dbad445f48582bd754933cf24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3300c71f3304f4fabbe2333fa0e6f6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idede8e3136eb484884a82aa3c0a1d084_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie70ea002268c4a5caf09a2bd32761c1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fa1a26a550e4cdebc79e98ec28d3692_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica244ac307be4148a52ded97af82e32d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8f2c7e017a444199ea80ad69ff9dc0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9e3be485f1040e99231bf20c8737b87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f55ae80ed464185acbc13298bd9b539_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d00e7f272ad46b9a14aaa1be9bc4934_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ica8f66740885481388f5091f3a93fae0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i047d415cbf9345cca4b2a12bea7fee45_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i0e8f6cf25ef845f4a4e6a6141299a680_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib058f0cc5ab4445c89f49affa1efcd07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide600b04f8ca45209f922b07e1285c93_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6daa97f735eb4c3cad12840eb32ed958_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie101975b1642454ca5efd600cefeebb7_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3b4cfbc3bd5b41628d78e47135e8b32d_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i86f9773b234244db921193fc80b4b36e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i00ac7f01c92b4900a09d849019f8bbde_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if9969aa4426549599b32a31f08e5252b_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i00a5e6ea88544cb1abee1be0125a342f_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i017ac814620d4a70b0883a3c64a8d2a4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i718d736b87a94552b1617644f5ddccec_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i1a2435c09f4c4f918cabd7085d3ea04d_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i12f85bf38d0841c2b116c6c5df335710_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i01b89020b108466aac157e717fc794ba_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibc062842cb3848dd809f2e5dabf4b106_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ia10e996f6a0045d68c311365d48c8ee0_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ica6583f307a24123ab02aebe68d83ad5_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="id7f8b24349b54b9286007abc00e73aca_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id60e4edfc8694abe95bc6c4ad0cf0e80_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ifa1c4a397e174d8ba0fa3e03acd37402_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8a96d01dde304dfb8bbc5a56f6a329e5_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i7532b18472654211b7e84b715466a350_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7c8d8dce3a7e43c8b39da1d6b4cad521_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i81205acd3f214b2ebe487d5e61a93b20_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic592c97df7804add951c95d5fb5bae90_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i9361d6f5134f4f68b7477fcf36e854a1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib5282ce470894117a8f902fb69fc8b98_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if19df687aaf9496496468698046b7ca9_D20220525-20220525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2022-05-25</startDate>
            <endDate>2022-05-25</endDate>
        </period>
    </context>
    <context id="i3fc516136b174c0d801418fc499e2574_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia453aac57d974fd59f265a307e4added_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibd464ef4ba6e4d6092da7bde626f4870_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia156218652c64c5d967262937d5d66a6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:TSRBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i538b59a91622490788eb54a07ebcd4bb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie4cd574ea19b44f6a937ed92eb65fbdd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie7e73b13cdc64519849d7dc7c3a4bab1_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">exel:Granted2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaa050e767b3f498a8437c364816242c7_D20220702-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-02</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3bebe181ca4a4b9cb14ab2651a68a39b_D20210703-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-03</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="id5af708b788b494aaa583b5ab133bc7f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7a9356922a004cbe84b4a80ddb5be44e_D20210102-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ia6b335f201824eb588620f7043a28af2_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i937aea8377a0438cbd48a2aebc5ce5f0_D20220402-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="ie7222e9059aa47e8a777492f23afd218_I20220415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-15</instant>
        </period>
    </context>
    <context id="if12649f24e1842e8bf8c979b733e75c6_D20220415-20220415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseAndHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-15</startDate>
            <endDate>2022-04-15</endDate>
        </period>
    </context>
    <context id="ie0dc3aa0d4b14df392ed5c64240f0335_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:LeaseExpansionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="i0f6fd2e746f24312a8f2a7091b4e91e5_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="id8f643a473a8490da5ebb398751eb409_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="i09a2105efdab4080a91d211b2377ed70_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i02f61410057849a2be1a95901d4749f3_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="ic2fe2d2458b143ac93cfc5d3dd846556_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CybrexaTherapeuticsLLCCybrexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="ib2acd12af1dc4ed6b0cbbf446ab05dc7_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CybrexaTherapeuticsLLCCybrexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="i2df8f1634dda4f61b08a6be87c82e98b_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:SairopaBVSairopaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="ia221d1d4870d45218498c32c441b4569_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:SairopaBVSairopaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="country">
        <measure>exel:country</measure>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="milestone">
        <measure>exel:milestone</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="bond">
        <measure>exel:bond</measure>
    </unit>
    <unit id="forward_contract">
        <measure>exel:forward_contract</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="lawsuit">
        <measure>exel:lawsuit</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80L2ZyYWc6YzkzYmNjNjg2Y2E0NGFlOGI4ZTJmNjMzYWFmODUwYjgvdGFibGU6MjJlMDkwYjNiNTMyNDM4ZmFlMTI1MjRkYWM0YmIyNWUvdGFibGVyYW5nZToyMmUwOTBiM2I1MzI0MzhmYWUxMjUyNGRhYzRiYjI1ZV8yLTEtMS0xLTgyMTMy_9da8cdfb-285f-4b9c-8aba-728c3ac8c905">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80L2ZyYWc6YzkzYmNjNjg2Y2E0NGFlOGI4ZTJmNjMzYWFmODUwYjgvdGFibGU6MjJlMDkwYjNiNTMyNDM4ZmFlMTI1MjRkYWM0YmIyNWUvdGFibGVyYW5nZToyMmUwOTBiM2I1MzI0MzhmYWUxMjUyNGRhYzRiYjI1ZV80LTEtMS0xLTgyMTMy_5b9c9ede-34d7-470a-8ef3-0a416c29825d">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80L2ZyYWc6YzkzYmNjNjg2Y2E0NGFlOGI4ZTJmNjMzYWFmODUwYjgvdGFibGU6MjJlMDkwYjNiNTMyNDM4ZmFlMTI1MjRkYWM0YmIyNWUvdGFibGVyYW5nZToyMmUwOTBiM2I1MzI0MzhmYWUxMjUyNGRhYzRiYjI1ZV81LTEtMS0xLTgyMTMy_9c2caa4e-51d0-4cbc-a9d2-1cfd072a22e4">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80L2ZyYWc6YzkzYmNjNjg2Y2E0NGFlOGI4ZTJmNjMzYWFmODUwYjgvdGFibGU6MjJlMDkwYjNiNTMyNDM4ZmFlMTI1MjRkYWM0YmIyNWUvdGFibGVyYW5nZToyMmUwOTBiM2I1MzI0MzhmYWUxMjUyNGRhYzRiYjI1ZV82LTEtMS0xLTgyMTMy_f5bb4f1a-c098-424f-b28c-14ddf6a14613">0000939767</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80L2ZyYWc6YzkzYmNjNjg2Y2E0NGFlOGI4ZTJmNjMzYWFmODUwYjgvdGFibGU6MjJlMDkwYjNiNTMyNDM4ZmFlMTI1MjRkYWM0YmIyNWUvdGFibGVyYW5nZToyMmUwOTBiM2I1MzI0MzhmYWUxMjUyNGRhYzRiYjI1ZV83LTEtMS0xLTgyMTMy_b8c61408-8f0a-4fc1-8865-5b413526ad5c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6ODkyZjQ2YjdiYzAyNGNjZjhjYjg5NjViZjQ4MjljM2YvdGFibGVyYW5nZTo4OTJmNDZiN2JjMDI0Y2NmOGNiODk2NWJmNDgyOWMzZl8wLTEtMS0xLTgyMTMy_657c51ce-8fde-4166-8298-f57130da1433">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6ZGRjMzI1YmRhZTA2NGU0MGFlOTRkMGYzNTI5ZDY3MmIvdGFibGVyYW5nZTpkZGMzMjViZGFlMDY0ZTQwYWU5NGQwZjM1MjlkNjcyYl8wLTAtMS0xLTgyMTMy_99707f3c-0310-49f7-8e8c-93b700ea1b03">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl81NDk3NTU4MTU4MTU_43df44b1-e73d-47ae-9e5c-af6fd4c02814">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6YTk0N2UxNzkyZDM1NGMxNWJhYWVhNDAwMjE3NjkzMWUvdGFibGVyYW5nZTphOTQ3ZTE3OTJkMzU0YzE1YmFhZWE0MDAyMTc2OTMxZV8wLTAtMS0xLTgyMTMy_18420af4-fdbf-41a0-9965-e243b878cd73">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODkx_2d1a84e0-27a7-45f0-b5cf-02fc5cea3df3">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6YzU3ZWZkZDcyZmU2NGRhNThkM2Q2MjgyZThlNjM2OTMvdGFibGVyYW5nZTpjNTdlZmRkNzJmZTY0ZGE1OGQzZDYyODJlOGU2MzY5M18xLTAtMS0xLTgyMTMy_84c40751-cb26-4c97-85a8-cf1731ce84b7">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NzRjMzNkZTQ3ZGNlNDJmZWFmNjExNzg0ZTJjM2M1ZTcvdGFibGVyYW5nZTo3NGMzM2RlNDdkY2U0MmZlYWY2MTE3ODRlMmMzYzVlN18wLTAtMS0xLTgyMTMy_bb0ec148-5c36-4269-af4d-f5b097a724e3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NzRjMzNkZTQ3ZGNlNDJmZWFmNjExNzg0ZTJjM2M1ZTcvdGFibGVyYW5nZTo3NGMzM2RlNDdkY2U0MmZlYWY2MTE3ODRlMmMzYzVlN18wLTItMS0xLTgyMTMy_af196c3f-66b2-4f6f-905a-e8b0e80ce09f">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODg0_5fddd510-bf32-436b-b59e-dd42c377c024">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODg1_6798fb05-7838-44b6-8ea8-e1e0125dd859">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODky_4168bfe2-d121-46fe-8794-bb01ff8cab54">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODg2_c9d60c3d-8a95-48a4-81f4-782b2e641d57">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODkz_f022c3c0-d168-446f-8aae-d58186c3a0f5">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODk0_400d8a3d-f3d3-4ae6-bb34-ea40f638df7e">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NWYxYzk1ODgxZTA0NDQzZGE1MDczYzBiMDJkYjMxNzEvdGFibGVyYW5nZTo1ZjFjOTU4ODFlMDQ0NDNkYTUwNzNjMGIwMmRiMzE3MV8xLTAtMS0xLTgyMTMy_9de4a32c-5848-4875-a36a-26ee5144d6ad">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NWYxYzk1ODgxZTA0NDQzZGE1MDczYzBiMDJkYjMxNzEvdGFibGVyYW5nZTo1ZjFjOTU4ODFlMDQ0NDNkYTUwNzNjMGIwMmRiMzE3MV8xLTEtMS0xLTgyMTMy_7fdeb4b6-430a-4247-833b-248fcacf9e21">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NWYxYzk1ODgxZTA0NDQzZGE1MDczYzBiMDJkYjMxNzEvdGFibGVyYW5nZTo1ZjFjOTU4ODFlMDQ0NDNkYTUwNzNjMGIwMmRiMzE3MV8xLTItMS0xLTgyMTMy_7ccf9f7c-74a1-4551-aef9-dde358d12edb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODg3_b0d7cac2-ec94-4656-b6e2-1349a98d5fbb">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODg4_6667a983-e7ec-4cc9-a173-08ecc49e45a7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NmFkOGM3OTA3MmUzNGYyZjllNmNjYzY3ZjQ5MDhjNTIvdGFibGVyYW5nZTo2YWQ4Yzc5MDcyZTM0ZjJmOWU2Y2NjNjdmNDkwOGM1Ml8wLTAtMS0xLTgyMTMy_db45ac30-016b-4f57-979e-c98cc1f034f3">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NmFkOGM3OTA3MmUzNGYyZjllNmNjYzY3ZjQ5MDhjNTIvdGFibGVyYW5nZTo2YWQ4Yzc5MDcyZTM0ZjJmOWU2Y2NjNjdmNDkwOGM1Ml8xLTQtMS0xLTgyMTMy_2f33800e-7ff6-4cf0-b597-9416ead3d9cb">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGFibGU6NmFkOGM3OTA3MmUzNGYyZjllNmNjYzY3ZjQ5MDhjNTIvdGFibGVyYW5nZTo2YWQ4Yzc5MDcyZTM0ZjJmOWU2Y2NjNjdmNDkwOGM1Ml8yLTQtMS0xLTgyMTMy_2bba6a2b-f7bf-4e15-8e64-06691229ecda">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODkw_01a28733-4fcf-4f0a-88fe-d7e62e779fc7">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0c2e3793b63a4e5fb7d9a4731fc85bfa_I20221024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xL2ZyYWc6MDEyNzFjOTgyZDliNDEwYTlmMjhkOTRjMWEwMjA1MDIvdGV4dHJlZ2lvbjowMTI3MWM5ODJkOWI0MTBhOWYyOGQ5NGMxYTAyMDUwMl8xODI5_dd1653d3-8439-4b93-b098-f7734642b4cc"
      unitRef="shares">322561418</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNy0xLTEtMS04MjEzMg_d758c5c2-f089-48fc-b071-cd6fb148fe80"
      unitRef="usd">675286000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNy0zLTEtMS04MjEzMg_651fbf20-e254-43b5-a785-80449ad53db4"
      unitRef="usd">647169000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfOC0xLTEtMS04MjEzMg_2b607926-6ef2-4f52-92e9-4e8cc6553066"
      unitRef="usd">871706000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfOC0zLTEtMS04MjEzMg_57ca6e5b-324e-407f-b728-de8577258570"
      unitRef="usd">819905000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfOS0xLTEtMS04MjEzMg_ff67e678-a799-45aa-871b-30887f4d54c6"
      unitRef="usd">215015000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfOS0zLTEtMS04MjEzMg_10ca5535-3a56-4d3c-8bd9-35b55cfe23ad"
      unitRef="usd">282650000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTAtMS0xLTEtODIxMzI_e02cbac1-197d-4803-ab38-6e9563b4c110"
      unitRef="usd">26711000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTAtMy0xLTEtODIxMzI_fe94a74c-2037-4cfd-b4ba-ce46f55f3192"
      unitRef="usd">27493000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTItMS0xLTEtODIxMzI_6bf6a16e-fec5-48ae-be41-58044d06d3bd"
      unitRef="usd">52903000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTItMy0xLTEtODIxMzI_66c477db-5c49-4483-9929-bb81f624d1a5"
      unitRef="usd">57530000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTMtMS0xLTEtODIxMzI_e555a663-7c6b-449d-90c3-78964ec569de"
      unitRef="usd">1841621000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTMtMy0xLTEtODIxMzI_2cf20b04-b743-4897-ae3b-dbfe0eb8394e"
      unitRef="usd">1834747000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTQtMS0xLTEtODIxMzI_0731fa04-7634-423d-9062-0be1f54712be"
      unitRef="usd">551735000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTQtMy0xLTEtODIxMzI_fd80d528-1d8f-4248-9936-1b954ba37532"
      unitRef="usd">371112000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTUtMS0xLTEtODIxMzI_57b57cb6-3023-4089-ab22-7f5ce60695b4"
      unitRef="usd">107909000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTUtMy0xLTEtODIxMzI_779533a7-ad5a-4f2a-ba62-24a57a09ace2"
      unitRef="usd">104031000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTYtMS0xLTEtODIxMzI_f9a1bca7-e00c-47c9-b237-874b5b4add91"
      unitRef="usd">116415000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTYtMy0xLTEtODIxMzI_c9913c21-5089-4f2a-bef1-24d26b013555"
      unitRef="usd">111663000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTctMS0xLTEtODIxMzI_29a85e54-6e88-490d-945f-cbfcef6cf21f"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTctMy0xLTEtODIxMzI_1cd40ba4-6d47-4746-8ca8-f471c6819200"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTgtMS0xLTEtODIxMzI_ae88755e-c8c2-47b6-90af-0490d1b2c0e2"
      unitRef="usd">280008000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTgtMy0xLTEtODIxMzI_5d795ac2-1835-4336-8969-77b06d61de19"
      unitRef="usd">131002000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTktMS0xLTEtODIxMzI_cbed35f0-4864-4976-9bc2-40f05ebd78c8"
      unitRef="usd">2961372000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMTktMy0xLTEtODIxMzI_cba7b08f-9126-4f82-89b6-d0fd7cd16d39"
      unitRef="usd">2616239000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjItMS0xLTEtODIxMzI_92003ddf-f5f3-4b46-9a09-bfb90124c9b2"
      unitRef="usd">30572000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjItMy0xLTEtODIxMzI_a1b57458-0879-4ce6-8acd-f2dccdd0d756"
      unitRef="usd">24258000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjMtMS0xLTEtODIxMzI_c7400a53-10c2-4153-a5e2-0da2934cc083"
      unitRef="usd">66927000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjMtMy0xLTEtODIxMzI_d1f0a0dc-45ab-49a9-a1d9-69b7392b89a6"
      unitRef="usd">61969000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjQtMS0xLTEtODIxMzI_cbc38270-302b-4d71-98ec-4ce77468c44f"
      unitRef="usd">62057000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjQtMy0xLTEtODIxMzI_2dee84b8-871b-4f2c-8a6a-0a188807fe27"
      unitRef="usd">77544000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjUtMS0xLTEtODIxMzI_ff925608-1a8a-4dc0-925b-38a5463a5de6"
      unitRef="usd">43791000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjUtMy0xLTEtODIxMzI_55310cf5-83a6-4b84-8c22-401c18f99e4a"
      unitRef="usd">33700000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjYtMS0xLTEtODIxMzI_773a84a7-75e2-4f8e-b6f5-3bc8b94dd48c"
      unitRef="usd">18277000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjYtMy0xLTEtODIxMzI_fb73b32f-bca1-41c2-a471-88ca60804d3b"
      unitRef="usd">86753000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjgtMS0xLTEtODIxMzI_451ed19d-a14e-47d8-ba02-230cfc3aaab5"
      unitRef="usd">80109000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjgtMy0xLTEtODIxMzI_3103d7a6-3ebf-4b14-a3af-9dfece1f75d9"
      unitRef="usd">53366000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjktMS0xLTEtODIxMzI_1b7cab71-6a98-4240-8a7a-9f9b065b18a9"
      unitRef="usd">301733000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMjktMy0xLTEtODIxMzI_ef6937e9-c545-40f3-9db8-14ed7bbdac00"
      unitRef="usd">337590000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzAtMS0xLTEtODIxMzI_8f2e4ad0-eae6-45b9-8e92-37ce02bfa5da"
      unitRef="usd">6491000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzAtMy0xLTEtODIxMzI_95de69ca-6186-419d-bb40-b25950dca04d"
      unitRef="usd">8739000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzEtMS0xLTEtODIxMzI_694575f9-e1fd-402e-81ad-f13b85c62b92"
      unitRef="usd">159838000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzEtMy0xLTEtODIxMzI_c442118d-79bb-48b7-97ff-b511ed85a64a"
      unitRef="usd">51272000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzItMS0xLTEtODIxMzI_dbb7c5b0-807a-4a21-b391-2db9fd73aa7e"
      unitRef="usd">1908000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzItMy0xLTEtODIxMzI_9fa9e140-35e5-4cf6-b568-b729ec32173b"
      unitRef="usd">8023000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzMtMS0xLTEtODIxMzI_48313467-6f19-454c-8762-b029df378282"
      unitRef="usd">469970000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzMtMy0xLTEtODIxMzI_946550cc-f89d-4b2a-b958-e1c99d18b501"
      unitRef="usd">405624000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzQtMS0xLTEtODIxMzI_d54b1b0e-b84c-43c4-b7d3-a90858b292d8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzQtMy0xLTEtODIxMzI_11bcd1a9-32cb-4083-a514-74508680d20a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjpkMTFiZTM5MWY0ZDA0ZmFlODQyYjJlODA0MzRmMTNjZl8yMQ_7a466327-04e5-4d16-bf24-76e3bff7dc02"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjpkMTFiZTM5MWY0ZDA0ZmFlODQyYjJlODA0MzRmMTNjZl8yMQ_a37c71e0-6f53-4264-a9f4-9071aae192a3"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjpkMTFiZTM5MWY0ZDA0ZmFlODQyYjJlODA0MzRmMTNjZl8zNQ_4936bc2b-4d7e-4126-8ca0-858508dbcc29"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjpkMTFiZTM5MWY0ZDA0ZmFlODQyYjJlODA0MzRmMTNjZl8zNQ_5a43d80d-2a4f-4d67-becc-d277187dfb81"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjpkMTFiZTM5MWY0ZDA0ZmFlODQyYjJlODA0MzRmMTNjZl82MA_04b4daeb-6bfb-4c5f-adfe-22d23fbb3f29"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjpkMTFiZTM5MWY0ZDA0ZmFlODQyYjJlODA0MzRmMTNjZl82MA_6292b3d0-baad-4bd7-a2f8-8eb6b587db4c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMS0xLTEtODIxMzI_2ae9ffbd-c9aa-45be-871f-23037ce31289"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzYtMy0xLTEtODIxMzI_d5ab79ab-cfe8-4803-bc0e-4a248501d07c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl8xOA_0c5770c2-c570-4cbf-96b7-523ad0e4e175"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl8xOA_27a75278-0f9d-4d50-9c94-e62654ea7a7d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl8zMg_3cc78733-c5f9-4905-b884-f0a07a382e38"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl8zMg_6d79e4df-06ff-445f-be61-9a554c74daea"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl83OA_c911be28-8eae-4f9c-949c-e34620454448"
      unitRef="shares">322541000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl83OA_ecc47c08-2c6d-45d1-94d0-c0d795818779"
      unitRef="shares">322541000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl84NQ_7e60924d-8d68-438e-924f-18701baf885e"
      unitRef="shares">318842000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMC0xLTEtODIxMzIvdGV4dHJlZ2lvbjplYjk1YmMxMjJlYjY0NzFkYWRlNGE4NTRmYWRmNzI3Nl84NQ_c885091b-09fe-4b05-af7e-bf1631150476"
      unitRef="shares">318842000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMS0xLTEtODIxMzI_01972061-5bf7-4e6a-8a07-2c1cb6210e7b"
      unitRef="usd">323000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzctMy0xLTEtODIxMzI_08f3809c-0152-4be4-9310-90ae4e9c58c3"
      unitRef="usd">319000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzgtMS0xLTEtODIxMzI_8dd8b364-e07f-40bc-8955-6bdefa2e2cf5"
      unitRef="usd">2512669000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzgtMy0xLTEtODIxMzI_d104e345-31aa-41bc-9885-40d370dfc06e"
      unitRef="usd">2427561000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzktMS0xLTEtODIxMzI_f184518d-d983-4531-9747-744ed1e611a9"
      unitRef="usd">-17538000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfMzktMy0xLTEtODIxMzI_dc959ab4-9d44-4900-9f26-43042109b548"
      unitRef="usd">-758000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNDAtMS0xLTEtODIxMzI_e406675e-7e00-4f52-bd0f-c3ba6728708f"
      unitRef="usd">-4052000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNDAtMy0xLTEtODIxMzI_fbc50c7c-0d82-4d16-91cc-647a132df4cd"
      unitRef="usd">-216507000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNDEtMS0xLTEtODIxMzI_62ed4920-391f-4842-b3a5-d0927398f127"
      unitRef="usd">2491402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNDEtMy0xLTEtODIxMzI_b493f46f-80e4-48b1-84ec-d15f4f6d006b"
      unitRef="usd">2210615000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNDItMS0xLTEtODIxMzI_35c78909-818e-4421-83ea-610252b0c56b"
      unitRef="usd">2961372000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xNi9mcmFnOjU1NzNmZTBjNjA4NTQ3N2ViMjkwYjRjZGJlMjUwNWE0L3RhYmxlOmM0YTI1ZDA0YTEzNjRkMWViMzliMmRkMDc2MzM4MjBmL3RhYmxlcmFuZ2U6YzRhMjVkMDRhMTM2NGQxZWIzOWIyZGQwNzYzMzgyMGZfNDItMy0xLTEtODIxMzI_651c464c-088f-4a7a-b8a8-de6d4ef1484d"
      unitRef="usd">2616239000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i278c1109560d43989bb93fcb650c9afa_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMy0xLTEtMS04MjEzMg_38e3b007-f059-4afa-bd38-8dcff3636b6c"
      unitRef="usd">366482000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e0a6faac267459387d713c98a6da04c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMy0zLTEtMS04MjEzMg_50af4c92-e8fb-4586-93e1-04914920724e"
      unitRef="usd">263117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaac13ba8b31b461a9ee349f6df7ec401_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMy01LTEtMS04MjEzMg_7a776844-fbb8-45e3-89ca-61593d5d7896"
      unitRef="usd">1023824000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d1060e036714dc8b00e67d518425d7e_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMy03LTEtMS04MjEzMg_a27be67f-7809-4369-b6d3-8953f5c9462e"
      unitRef="usd">774577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3969d7ffe515467786d9f03efe7dd44a_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNC0xLTEtMS04MjEzMg_9a901ccd-9a8e-48c4-9246-d87873432d13"
      unitRef="usd">34384000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ffeb5a9e14d43f5bf61509594c23244_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNC0zLTEtMS04MjEzMg_731c357c-bcc9-4384-87f6-135cb3c45fad"
      unitRef="usd">49694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48e199975584423f9f9b5fc5676b433e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNC01LTEtMS04MjEzMg_bc934172-bcf8-447d-af74-e61800e545c2"
      unitRef="usd">123977000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86031b3c8cd74803ab4a6280a4faaea9_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNC03LTEtMS04MjEzMg_c6f22005-e83d-4c92-b079-63e262ecf15c"
      unitRef="usd">116862000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd67de25ab5242d6acec13d5bb1dcd8c_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNS0xLTEtMS04MjEzMg_b18adcd8-ba5d-4ba8-a368-cf76e5bcb845"
      unitRef="usd">10872000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3212d047299943f1aefbd2a60b170c8c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNS0zLTEtMS04MjEzMg_5a5f80e6-9bd3-4dca-b3d4-3e6e65ce8426"
      unitRef="usd">15612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f0edff0af2d424980d236133e9e6a27_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNS01LTEtMS04MjEzMg_51d9488b-1be2-46c2-92fc-80fac391ef98"
      unitRef="usd">39344000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if06c48663d594ceeabfd8945d8b2d8be_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNS03LTEtMS04MjEzMg_9aeb5cf4-8ad1-4d0a-b1e1-d1531ebba305"
      unitRef="usd">92391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNi0xLTEtMS04MjEzMg_c3c24c35-78a2-4ad4-9118-3f3ab6603e59"
      unitRef="usd">411738000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNi0zLTEtMS04MjEzMg_74bdfb0e-7a9d-4b74-a136-1246b0efcb04"
      unitRef="usd">328423000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNi01LTEtMS04MjEzMg_c54b7894-a480-4bc0-81c2-97b2de9eb46c"
      unitRef="usd">1187145000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfNi03LTEtMS04MjEzMg_1b357370-1af1-40cc-852f-4eb3d98fe925"
      unitRef="usd">983830000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOC0xLTEtMS04MjEzMg_2fb26b87-5c51-4f7d-870c-f3130ea520ca"
      unitRef="usd">15305000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOC0zLTEtMS04MjEzMg_9cd572b0-1961-473e-b8c2-84b9eeb586f8"
      unitRef="usd">11874000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOC01LTEtMS04MjEzMg_1aa61d98-1d1c-4c5b-b9db-672270139c1d"
      unitRef="usd">41989000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOC03LTEtMS04MjEzMg_281ba82c-7770-4acc-a670-c107343e643d"
      unitRef="usd">39956000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOS0xLTEtMS04MjEzMg_23aab516-3899-41d9-b7e4-1d006e6953bd"
      unitRef="usd">198837000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOS0zLTEtMS04MjEzMg_ed23d226-6c91-4e9e-85ec-a2c78e5db921"
      unitRef="usd">163370000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOS01LTEtMS04MjEzMg_d00c4325-b5d5-4951-ad13-0d494386c89b"
      unitRef="usd">554989000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfOS03LTEtMS04MjEzMg_81f79629-ac63-417c-8c5c-745159493d17"
      unitRef="usd">471448000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTAtMS0xLTEtODIxMzI_c6b4c26d-732d-4522-8b10-2b4558630c7c"
      unitRef="usd">114983000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTAtMy0xLTEtODIxMzI_ab1f1688-df4e-4d83-af73-72811fc63132"
      unitRef="usd">101558000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTAtNS0xLTEtODIxMzI_79818db4-e796-435a-ae16-b150686f802d"
      unitRef="usd">340605000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTAtNy0xLTEtODIxMzI_b6f09a15-e177-45fc-9944-b98ee9f7dfbe"
      unitRef="usd">302404000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTEtMS0xLTEtODIxMzI_0969ccf7-9046-468d-916e-c056cd90a747"
      unitRef="usd">329125000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTEtMy0xLTEtODIxMzI_9189c89b-3d54-4d06-bf7d-ba2b341ed5cc"
      unitRef="usd">276802000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTEtNS0xLTEtODIxMzI_242c7805-9914-4719-9732-2e58c08bb1ab"
      unitRef="usd">937583000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTEtNy0xLTEtODIxMzI_79724783-fcb5-4561-85f0-5ef7719b2288"
      unitRef="usd">813808000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTItMS0xLTEtODIxMzI_c9f2e860-1728-44a0-a25b-646f85c3b888"
      unitRef="usd">82613000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTItMy0xLTEtODIxMzI_8ce1c068-638f-478f-aee2-4865caab1af9"
      unitRef="usd">51621000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTItNS0xLTEtODIxMzI_cd983915-d570-4115-ad06-c96afe8c5a5a"
      unitRef="usd">249562000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTItNy0xLTEtODIxMzI_765457f4-b89b-4432-a8a3-7873ac30467b"
      unitRef="usd">170022000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTMtMS0xLTEtODIxMzI_9c45ef61-6845-450c-8898-58cbaea7903e"
      unitRef="usd">9498000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTMtMy0xLTEtODIxMzI_ea57eb8e-5526-4aa6-bce7-0915f3337222"
      unitRef="usd">1658000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTMtNS0xLTEtODIxMzI_ecb43fe6-b728-4edf-bd88-6ebc6891bba4"
      unitRef="usd">16077000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTMtNy0xLTEtODIxMzI_322d118f-deed-49a1-8ceb-1ff794b547d8"
      unitRef="usd">6231000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTQtMS0xLTEtODIxMzI_ded368ae-02c8-424e-a001-3028dae32abe"
      unitRef="usd">-69000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTQtMy0xLTEtODIxMzI_c0f39b8a-41c0-476b-a7e9-84d5db6ac4dc"
      unitRef="usd">-19000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTQtNS0xLTEtODIxMzI_c63cf43a-7452-47b0-9572-5aa7d28c022d"
      unitRef="usd">140000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTQtNy0xLTEtODIxMzI_cd83b80d-2c76-4186-bdd5-1c1eea22dff6"
      unitRef="usd">-120000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTUtMS0xLTEtODIxMzI_5d1c198a-499f-4fed-9dfd-85aa59a26ec9"
      unitRef="usd">92042000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTUtMy0xLTEtODIxMzI_47057d1d-d5e3-4b2d-acfa-81a8ba1bd45f"
      unitRef="usd">53260000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTUtNS0xLTEtODIxMzI_99db1bbf-685d-4982-8fc2-f9f819fc204b"
      unitRef="usd">265779000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTUtNy0xLTEtODIxMzI_e053ec0f-98fd-4e02-ac63-01ac08bab1f1"
      unitRef="usd">176133000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTYtMS0xLTEtODIxMzI_53e94e76-e1e8-4524-892e-1d98c382d5a5"
      unitRef="usd">18832000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTYtMy0xLTEtODIxMzI_df4ef6ee-6abc-4f01-9995-7eee0c5e2b04"
      unitRef="usd">15056000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTYtNS0xLTEtODIxMzI_ba834219-556e-477f-be04-7d70234abe4b"
      unitRef="usd">53324000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTYtNy0xLTEtODIxMzI_cd57bfaa-bb91-462f-90b9-20244ccc81f8"
      unitRef="usd">40236000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTctMS0xLTEtODIxMzI_889dbc69-cf05-4582-8067-599f9c261a92"
      unitRef="usd">73210000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTctMy0xLTEtODIxMzI_1f6f8b86-278b-4f63-a418-c6e38dc6dd9f"
      unitRef="usd">38204000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTctNS0xLTEtODIxMzI_b96f8e34-4f97-4c48-b413-5fc22d7afe47"
      unitRef="usd">212455000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTctNy0xLTEtODIxMzI_fc8fca3f-c8bd-40e1-a0db-2d0e882cb922"
      unitRef="usd">135897000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTktMS0xLTEtODIxMzI_af8c9812-f86c-4cd8-8cc2-c3876efed11b"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTktMy0xLTEtODIxMzI_e2b08333-422f-4063-8bc4-ecf08b9a8345"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTktNS0xLTEtODIxMzI_19cfb9ee-d3ab-4dfd-b643-e4dcd544c67a"
      unitRef="usdPerShare">0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMTktNy0xLTEtODIxMzI_1b7e678b-22cb-4a35-8c88-83c4a84bbffe"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjAtMS0xLTEtODIxMzI_c166bc86-c867-4741-a570-6e678ee0095b"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjAtMy0xLTEtODIxMzI_28dacb57-e729-44f5-96a7-df7dd34c5b64"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjAtNS0xLTEtODIxMzI_2b68a748-bb3d-4890-9f8e-0ddecb184328"
      unitRef="usdPerShare">0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjAtNy0xLTEtODIxMzI_2592c4fd-12f1-41cc-b6bf-8bec35b6d458"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjItMS0xLTEtODIxMzI_febdea61-4101-4a5b-ab9d-a7a48040e83a"
      unitRef="shares">322148000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjItMy0xLTEtODIxMzI_b47dcaaa-caad-4421-bf5a-82f44ca8542f"
      unitRef="shares">315380000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjItNS0xLTEtODIxMzI_18116302-0c27-4db1-9bf6-4fff70cf994d"
      unitRef="shares">320949000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjItNy0xLTEtODIxMzI_093674d5-4de6-4a90-a35f-1892dae4da1e"
      unitRef="shares">313990000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjMtMS0xLTEtODIxMzI_b198bd09-986d-4f36-90c9-7c6e90be1772"
      unitRef="shares">325066000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjMtMy0xLTEtODIxMzI_f73b231d-c4fc-4cb4-9b7d-6f69d0f935d7"
      unitRef="shares">322022000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjMtNS0xLTEtODIxMzI_c39fd5eb-d0f1-4c1d-ba8e-5a294fe5b0a8"
      unitRef="shares">324420000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8xOS9mcmFnOjU5YzM5MDcyZWEwNjRhYjRiYTBmOWJkYmY5ODg3MmNkL3RhYmxlOjAzOTAwYWE1NWI3ODRhMWE4MTJmYTVmNzYzYjk5YWZmL3RhYmxlcmFuZ2U6MDM5MDBhYTU1Yjc4NGExYTgxMmZhNWY3NjNiOTlhZmZfMjMtNy0xLTEtODIxMzI_d07b041c-8e17-4835-9875-296ab2c754b0"
      unitRef="shares">322084000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfMi0xLTEtMS04MjEzMg_889dbc69-cf05-4582-8067-599f9c261a92"
      unitRef="usd">73210000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfMi0zLTEtMS04MjEzMg_1f6f8b86-278b-4f63-a418-c6e38dc6dd9f"
      unitRef="usd">38204000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfMi01LTEtMS04MjEzMg_88dff030-d061-47ee-ba11-84c8c8ecae5f"
      unitRef="usd">212455000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfMi03LTEtMS04MjEzMg_6a1e99be-fb1a-4cff-b998-444a07560966"
      unitRef="usd">135897000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC0wLTEtMS04MjEzMi90ZXh0cmVnaW9uOmIxOTUzMjgxZGRhYTRlZmM4MjNlNzQ5ZWQzYzZlOTJhXzg2_1e4c54ba-a30e-4d4d-87a0-9cd8d3495dbd"
      unitRef="usd">2457000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC0wLTEtMS04MjEzMi90ZXh0cmVnaW9uOmIxOTUzMjgxZGRhYTRlZmM4MjNlNzQ5ZWQzYzZlOTJhXzkw_163d3cf8-c634-41c0-bc2c-0eefb8cea42a"
      unitRef="usd">193000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC0wLTEtMS04MjEzMi90ZXh0cmVnaW9uOmIxOTUzMjgxZGRhYTRlZmM4MjNlNzQ5ZWQzYzZlOTJhXzk0_2ad40c17-57f9-4f68-b46f-e4a1afba0cd8"
      unitRef="usd">4752000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC0wLTEtMS04MjEzMi90ZXh0cmVnaW9uOmIxOTUzMjgxZGRhYTRlZmM4MjNlNzQ5ZWQzYzZlOTJhXzEwMQ_adfe2fbd-8ac3-46b9-9fd6-0f7e7d2505e5"
      unitRef="usd">949000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC0xLTEtMS04MjEzMg_64e4256b-6a84-44ac-afa3-7b1e90a5f36e"
      unitRef="usd">-8621000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC0zLTEtMS04MjEzMg_395a0654-0940-4d7c-bb26-a9520f03175f"
      unitRef="usd">-504000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC01LTEtMS04MjEzMg_df3c120c-578f-4741-878b-303cdd2565b6"
      unitRef="usd">-16780000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNC03LTEtMS04MjEzMg_627b5036-0117-400d-96ca-7380e4bf3e4b"
      unitRef="usd">-2995000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNi0xLTEtMS04MjEzMg_b68677e4-c4a5-4975-b84a-14ad6371157f"
      unitRef="usd">64589000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNi0zLTEtMS04MjEzMg_fc1d60a8-6475-4184-baa6-820292d126c5"
      unitRef="usd">37700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNi01LTEtMS04MjEzMg_2fc63b8c-234a-4b77-ab4f-37fb1233ad25"
      unitRef="usd">195675000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yMi9mcmFnOjhmZTU1ZTY4NTQ5NjQyYWRhNmMxOWFjYzcyODZkNjY1L3RhYmxlOjQ3ZDdiNjA1MGVmZTQ0MDRhODk2MGUyM2JjMmQ1NWI1L3RhYmxlcmFuZ2U6NDdkN2I2MDUwZWZlNDQwNGE4OTYwZTIzYmMyZDU1YjVfNi03LTEtMS04MjEzMg_bda69211-9a81-436d-9c56-566c861cc89f"
      unitRef="usd">132902000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i825124e3b6104871b081a44c670a7a86_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMy0xLTEtMS04MjEzMg_88f9a0fa-3479-4ec7-b11d-1ede53d55c61"
      unitRef="shares">321800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i825124e3b6104871b081a44c670a7a86_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMy0zLTEtMS04MjEzMg_c5dea7d2-fc07-4517-96e2-ed9af9716315"
      unitRef="usd">322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3b23ba8f2c94ddcb48f6a85901903b5_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMy01LTEtMS04MjEzMg_0991e768-a5dc-4d16-8ae8-66989b700767"
      unitRef="usd">2477117000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibdff014306a24f67bd885f70ff909a7d_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMy03LTEtMS04MjEzMg_703def8c-fbf3-441d-a802-acaf1009cd74"
      unitRef="usd">-8917000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6604d7fea14d4e8fb16b161c841a6999_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMy05LTEtMS04MjEzMg_4453e24f-4b70-4d89-ace0-0aa40893b7de"
      unitRef="usd">-77262000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i64041df1701a4a07b8ef7d5c0f37f576_I20220701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMy0xMS0xLTEtODIxMzI_157eac20-425f-45ab-9b0a-e93ab3dfd6ca"
      unitRef="usd">2391260000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i149d987491b846698276e3ab735170f7_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNC05LTEtMS04MjEzMg_7f9433ea-eab2-41db-bbe4-f1485aa71c7d"
      unitRef="usd">73210000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNC0xMS0xLTEtODIxMzI_6c043b1f-57d8-4ac8-8816-a1b18ef7f077"
      unitRef="usd">73210000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i54dcb905f0384fd8bce6b7e44c2faa57_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNS03LTEtMS04MjEzMg_e532fa6e-90c8-49fb-b8b4-f5672fec9817"
      unitRef="usd">-8621000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNS0xMS0xLTEtODIxMzI_2700dfcd-3e26-410e-a03f-b0eadbb6cdc6"
      unitRef="usd">-8621000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i44690402ba504bd1987f6bea7e60ccfc_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNi0xLTEtMS04MjEzMg_419ed4dc-3082-4766-9460-e7829a682d0a"
      unitRef="shares">741000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i44690402ba504bd1987f6bea7e60ccfc_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNi0zLTEtMS04MjEzMg_07f7c624-b6aa-4851-9a9c-d9d38ed4c644"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i68253ae6a74648f0b87bb4a6390ffc5f_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNi01LTEtMS04MjEzMg_2f996cd1-797c-4186-8b38-1b680a392bf0"
      unitRef="usd">2847000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNi0xMS0xLTEtODIxMzI_ecfef656-12da-4cc1-9e4b-5726ca80beec"
      unitRef="usd">2848000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i68253ae6a74648f0b87bb4a6390ffc5f_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNy01LTEtMS04MjEzMg_278a7f65-ae69-45d7-a036-be0d22d63d61"
      unitRef="usd">4906000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfNy0xMS0xLTEtODIxMzI_32931e5d-9265-4640-a6d0-db9903e22b7f"
      unitRef="usd">4906000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i68253ae6a74648f0b87bb4a6390ffc5f_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOC01LTEtMS04MjEzMg_c61fefde-9196-4807-9c6b-2940fbfe979f"
      unitRef="usd">37611000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOC0xMS0xLTEtODIxMzI_5f8059ee-aa4e-480a-b392-a7d916540f91"
      unitRef="usd">37611000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i00d8665815014c9aae47cbac0416c062_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOS0xLTEtMS04MjEzMg_72b95f3d-e8ce-4adf-8715-f90d571b8106"
      unitRef="shares">322541000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i00d8665815014c9aae47cbac0416c062_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOS0zLTEtMS04MjEzMg_448eb1da-a79e-4386-b820-b671bb54d1fb"
      unitRef="usd">323000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i283a9472e4fa421799257a1a2bd9fa1c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOS01LTEtMS04MjEzMg_f68e1dec-610e-4fc4-b21d-468c6652c160"
      unitRef="usd">2512669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4697a4d7dcd4136b84bf95f0e95aac8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOS03LTEtMS04MjEzMg_8acfa912-4205-4100-9fa3-3725d095ebd4"
      unitRef="usd">-17538000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8188cffbcf746278fdee32a78f4a8cb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOS05LTEtMS04MjEzMg_44115f66-1f75-4311-9d90-c4b8227a123f"
      unitRef="usd">-4052000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfOS0xMS0xLTEtODIxMzI_2903f0c0-02e7-4204-bfa9-7ce62f39c7f2"
      unitRef="usd">2491402000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0570e9a9f97c4dfc9839b7ab1860e680_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTQtMS0xLTEtODIxMzI_2586ec11-7852-44fa-87d9-50a77a9f01e4"
      unitRef="shares">314822000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0570e9a9f97c4dfc9839b7ab1860e680_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTQtMy0xLTEtODIxMzI_bf9d30d8-7b3f-4fba-bce0-9cda51de4ecc"
      unitRef="usd">315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i80f67f4b8f82417db30834591fb44d60_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTQtNS0xLTEtODIxMzI_8e774cbe-bf40-4c42-b723-d2d7fd895cfa"
      unitRef="usd">2390654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifd4b7ab3407c44cb8b1ed0210197c8e9_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTQtNy0xLTEtODIxMzI_f5526f80-1518-4c20-98f1-624b06c52b7a"
      unitRef="usd">1985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic87ae071c1834ea6abd407e1ee1c295a_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTQtOS0xLTEtODIxMzI_e95beb8d-5de5-4f33-b843-47aa23920287"
      unitRef="usd">-349877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6899e05fb3f5440cb7983ea4ae13b93b_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTQtMTEtMS0xLTgyMTMy_ec510cb7-36c5-41d4-82dd-c7d2a6e2dd82"
      unitRef="usd">2043077000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i1f3dc37f9c84491ba474d260d6688295_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTUtOS0xLTEtODIxMzI_6e495d0a-6de3-4e44-92dc-f8cf4b986463"
      unitRef="usd">38204000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTUtMTEtMS0xLTgyMTMy_ddfb530c-499b-4fbf-b55d-ab16ec274acc"
      unitRef="usd">38204000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2afa3de03a1043199b82592539c4213f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTYtNy0xLTEtODIxMzI_ae4feb4a-bf01-4290-b0a8-c5832643b5e9"
      unitRef="usd">-504000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTYtMTEtMS0xLTgyMTMy_43966c99-8339-4bd2-9f65-17246063e3c3"
      unitRef="usd">-504000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i81def5dda1a6445d84955509b0fe837a_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTctMS0xLTEtODIxMzI_c46ca3bb-6c05-499f-adec-5bfb997fb364"
      unitRef="shares">1483000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i81def5dda1a6445d84955509b0fe837a_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTctMy0xLTEtODIxMzI_bae53e67-11ab-434a-8474-9df7fa6742bc"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i029f475a4cb743c883c1e02d0bd1e0ca_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTctNS0xLTEtODIxMzI_889e2c47-19a7-4bb4-a1bb-c6a967786512"
      unitRef="usd">3304000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTctMTEtMS0xLTgyMTMy_a4da3d7b-89b6-4b87-9fd1-0bada84d04ce"
      unitRef="usd">3305000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i029f475a4cb743c883c1e02d0bd1e0ca_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTgtNS0xLTEtODIxMzI_f6916f24-4fed-40a4-8812-495da7414b64"
      unitRef="usd">5958000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTgtMTEtMS0xLTgyMTMy_871daf8c-e7d5-4a18-a5d6-957831e4ba9b"
      unitRef="usd">5958000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i029f475a4cb743c883c1e02d0bd1e0ca_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTktNS0xLTEtODIxMzI_2305893c-d63a-47c7-8a4b-5f3717c9cb7c"
      unitRef="usd">34323000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMTktMTEtMS0xLTgyMTMy_e0519cd1-3efe-461e-b561-b1e7e017c247"
      unitRef="usd">34323000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5d2bb7e98f0347679cc8ee55fd39e05e_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMjAtMS0xLTEtODIxMzI_791dd566-c808-411f-a249-64459ee5becb"
      unitRef="shares">316305000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5d2bb7e98f0347679cc8ee55fd39e05e_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMjAtMy0xLTEtODIxMzI_b0630a73-b085-4ffa-8a98-cee45249e6c5"
      unitRef="usd">316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if09ffd775b454fd28bc4ccc68d578a46_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMjAtNS0xLTEtODIxMzI_477c6c4d-0c4e-4218-8315-69bacf4df36c"
      unitRef="usd">2422323000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6024509ae78487f8fce552a0976856d_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMjAtNy0xLTEtODIxMzI_db23d639-d043-4640-840c-22a5e4b5fd91"
      unitRef="usd">1481000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25b72e0f00af411b8652e825b767f230_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMjAtOS0xLTEtODIxMzI_19a19aa5-d65f-4ceb-a16f-ba825c278378"
      unitRef="usd">-311673000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iacaf43cbe24a472ba26b4376244aeceb_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmE2MTIwZjQxN2I4MDQ2ZjFhYzVjNGM3NTM4MmVmODA3L3RhYmxlcmFuZ2U6YTYxMjBmNDE3YjgwNDZmMWFjNWM0Yzc1MzgyZWY4MDdfMjAtMTEtMS0xLTgyMTMy_a942ab13-398e-4802-b5d3-bb558d295545"
      unitRef="usd">2112447000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i22983ccf5d88438696ca9ed782f2b97a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMy0xLTEtMS04MjEzMg_4f8dc0af-be1a-4081-bf3b-9d3c7d04d4a7"
      unitRef="shares">318842000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i22983ccf5d88438696ca9ed782f2b97a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMy0zLTEtMS04MjEzMg_dabd5b60-0073-4e2f-a64b-92b27bb93c73"
      unitRef="usd">319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1fa68b5c6fea4b5eb3e3e88045cc2288_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMy01LTEtMS04MjEzMg_15319750-b18b-47a6-8db3-4cb0d20b309e"
      unitRef="usd">2427561000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77a026db7c644033a1c8a0268a3cc765_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMy03LTEtMS04MjEzMg_c842194a-c6be-4fee-b2d8-8e1342751fdc"
      unitRef="usd">-758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7950e15bb4194a85a2dfe92d26c1c011_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMy05LTEtMS04MjEzMg_d1cc422b-3b6d-4c8e-a639-25ac52279ff5"
      unitRef="usd">-216507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMy0xMS0xLTEtODIxMzI_5c968e48-718f-4045-b5b5-a78f51fe055e"
      unitRef="usd">2210615000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i3a29957ee8b14a00a22d941a4f3bb1cf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNC05LTEtMS04MjEzMg_5e35253e-61d3-4e23-9492-ade69cde7399"
      unitRef="usd">212455000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNC0xMS0xLTEtODIxMzI_8437a22b-1414-43c2-9618-a9e2ae542ba3"
      unitRef="usd">212455000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="idb6a382becc140a4b1da483762a0959f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNS03LTEtMS04MjEzMg_917a1f03-1aa2-47ab-8c25-535f5e0ab35b"
      unitRef="usd">-16780000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNS0xMS0xLTEtODIxMzI_e751bbe1-6d8b-43c9-a08f-23dac1a1a350"
      unitRef="usd">-16780000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib6ac406b2dc941da8bb9bf4a2a0c6bc4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNi0xLTEtMS04MjEzMg_99fb2a5c-e591-43ce-bfc3-bd689746683c"
      unitRef="shares">3699000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib6ac406b2dc941da8bb9bf4a2a0c6bc4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNi0zLTEtMS04MjEzMg_9867d2a9-b90a-41eb-bfc0-6ab345a56bcf"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i058269d798474c4f81f2c52f1a695d17_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNi01LTEtMS04MjEzMg_96a979ca-0567-47b1-9cbf-fd1ad07e00bd"
      unitRef="usd">18676000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNi0xMS0xLTEtODIxMzI_3b540f36-ecf5-4b03-a5fd-a155c8bc1caf"
      unitRef="usd">18680000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i058269d798474c4f81f2c52f1a695d17_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNy01LTEtMS04MjEzMg_b52744ac-fcb5-496a-bd59-3f96eee3b3a7"
      unitRef="usd">16091000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfNy0xMS0xLTEtODIxMzI_77c7cb90-d8a9-49a5-9e66-c296af4f8cc0"
      unitRef="usd">16091000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i058269d798474c4f81f2c52f1a695d17_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOC01LTEtMS04MjEzMg_92df1d2f-d31b-4066-9d88-ec5792bb83d9"
      unitRef="usd">82523000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOC0xMS0xLTEtODIxMzI_b49b3f15-7361-42eb-90d9-8d054508e26e"
      unitRef="usd">82523000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i00d8665815014c9aae47cbac0416c062_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOS0xLTEtMS04MjEzMg_d6a9b6fa-26ac-4944-b74d-f452765eb105"
      unitRef="shares">322541000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i00d8665815014c9aae47cbac0416c062_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOS0zLTEtMS04MjEzMg_cce28ac9-89a4-4ee3-aba8-ced7ff5f3352"
      unitRef="usd">323000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i283a9472e4fa421799257a1a2bd9fa1c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOS01LTEtMS04MjEzMg_318fff7e-a004-4642-ba66-8be0d004dd7e"
      unitRef="usd">2512669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4697a4d7dcd4136b84bf95f0e95aac8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOS03LTEtMS04MjEzMg_adaf7b31-977c-41b9-973c-46a737fa2b29"
      unitRef="usd">-17538000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8188cffbcf746278fdee32a78f4a8cb_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOS05LTEtMS04MjEzMg_2a737fac-5697-4f52-b592-10c780b1c058"
      unitRef="usd">-4052000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfOS0xMS0xLTEtODIxMzI_5a1755ad-6ab5-435e-9dde-f322d80f570c"
      unitRef="usd">2491402000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i98f25495c49942328fe52185ebb36868_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTQtMS0xLTEtODIxMzI_904163da-42b7-48c2-b128-508d85e03533"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i98f25495c49942328fe52185ebb36868_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTQtMy0xLTEtODIxMzI_1298f688-ff9f-4c8d-bdc4-04219a53ef30"
      unitRef="usd">312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icbe63aa422cd4993aa00fe1bec11e108_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTQtNS0xLTEtODIxMzI_4dbfdc34-11f0-4c4b-ac4f-0c312e913805"
      unitRef="usd">2321895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34b4239fc7694a5f9a055a4f8d0ea9d0_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTQtNy0xLTEtODIxMzI_c9e38edc-4f66-4a91-bc54-40df5491b6ae"
      unitRef="usd">4476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i897ee6ad5f0f4e8a932659340f671c9b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTQtOS0xLTEtODIxMzI_a31fdc05-f35a-4015-a1b4-dbf4b79ce76f"
      unitRef="usd">-447570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i48eab2e753614354a3732f75587e636f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTQtMTEtMS0xLTgyMTMy_bc62cfa4-c274-4dec-a5a3-0ef3f7415b9b"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic0c9d8627fe44d7983aa3b965e06e09b_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTUtOS0xLTEtODIxMzI_dbd67927-4ce0-400e-9e48-17e96a651fc2"
      unitRef="usd">135897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTUtMTEtMS0xLTgyMTMy_007b9b71-f921-4b72-9c6f-a5372a20a389"
      unitRef="usd">135897000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibbb5c647740f4d2d99a83b98b0fc1e73_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTYtNy0xLTEtODIxMzI_ea0f1cd6-ea96-4cbe-8b27-80bb4fcaba7c"
      unitRef="usd">-2995000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTYtMTEtMS0xLTgyMTMy_6ab68952-65c7-4d41-a02c-e4b5acf1aeac"
      unitRef="usd">-2995000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7b44b1b4753f4fc19f53534dfb54799f_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTctMS0xLTEtODIxMzI_b181d70c-613b-4702-9114-294d587e528f"
      unitRef="shares">4678000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7b44b1b4753f4fc19f53534dfb54799f_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTctMy0xLTEtODIxMzI_156213b7-7009-460a-b287-f06ce2115c01"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4f53e591b0874be8be6c8805109d1335_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTctNS0xLTEtODIxMzI_e211570f-4035-41e3-97c3-1a389ed9fa1d"
      unitRef="usd">18788000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTctMTEtMS0xLTgyMTMy_09e34f1f-bc69-41de-8f69-6ba889d4da2d"
      unitRef="usd">18792000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4f53e591b0874be8be6c8805109d1335_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTgtNS0xLTEtODIxMzI_a7ee1081-9e2d-4807-8722-e737f6f1824d"
      unitRef="usd">15371000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTgtMTEtMS0xLTgyMTMy_e93d7321-b5db-4865-a986-4e19fc2ce505"
      unitRef="usd">15371000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4f53e591b0874be8be6c8805109d1335_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTktNS0xLTEtODIxMzI_d5c63650-82e4-4cb9-9def-4898f2717970"
      unitRef="usd">97011000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMTktMTEtMS0xLTgyMTMy_2b2f53ba-e13f-4310-9d38-b1b101818bc7"
      unitRef="usd">97011000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5d2bb7e98f0347679cc8ee55fd39e05e_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMjAtMS0xLTEtODIxMzI_52f2d6fa-c285-4466-b2e4-55e09153eaa4"
      unitRef="shares">316305000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5d2bb7e98f0347679cc8ee55fd39e05e_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMjAtMy0xLTEtODIxMzI_4023119f-7485-4c34-862a-e2463bc34d1c"
      unitRef="usd">316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if09ffd775b454fd28bc4ccc68d578a46_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMjAtNS0xLTEtODIxMzI_47705539-727b-49c7-be8a-5781adab143d"
      unitRef="usd">2422323000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6024509ae78487f8fce552a0976856d_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMjAtNy0xLTEtODIxMzI_482a7061-5990-435a-b4a4-03201eacc38d"
      unitRef="usd">1481000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25b72e0f00af411b8652e825b767f230_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMjAtOS0xLTEtODIxMzI_41cf401b-7286-4f82-86f7-bc176da25cb0"
      unitRef="usd">-311673000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iacaf43cbe24a472ba26b4376244aeceb_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yNS9mcmFnOjI5NWFjN2M1NGI5ZjQ3MzU5MDNlOGExYmU1NmEzNzBiL3RhYmxlOmQwODE3MWI4ZmIwOTQ4YTE4ZDJkZDcyYzU4NDdiNmM5L3RhYmxlcmFuZ2U6ZDA4MTcxYjhmYjA5NDhhMThkMmRkNzJjNTg0N2I2YzlfMjAtMTEtMS0xLTgyMTMy_67775bd0-bb08-4452-8124-5daacca80839"
      unitRef="usd">2112447000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMi0xLTEtMS04MjEzMg_4e6a99a4-49bc-44a1-b242-935ce057113c"
      unitRef="usd">212455000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMi0zLTEtMS04MjEzMg_fc8fca3f-c8bd-40e1-a0db-2d0e882cb922"
      unitRef="usd">135897000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNC0xLTEtMS04MjEzMg_30db53ac-abd9-4e9e-977c-a74e40a1531d"
      unitRef="usd">14929000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNC0zLTEtMS04MjEzMg_e9f7c583-e6c1-4cfa-9fe6-3f904c735ac6"
      unitRef="usd">11699000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNS0xLTEtMS04MjEzMg_3a5dcdfd-0300-4093-977d-0aab17c200c8"
      unitRef="usd">81718000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNS0zLTEtMS04MjEzMg_cda5d5d0-c224-4b17-a463-f49fe8a259a0"
      unitRef="usd">96654000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNi0xLTEtMS04MjEzMg_f32077fe-6865-4432-9755-a41cfa903b5a"
      unitRef="usd">11931000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNi0zLTEtMS04MjEzMg_7a08d9ad-1079-4363-b13b-0f7889b3644a"
      unitRef="usd">3952000</exel:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNy0xLTEtMS04MjEzMg_f0fe44ea-6131-423b-9324-43f3d62d7f2b"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNy0zLTEtMS04MjEzMg_a47b29f7-1e43-43d4-a6cb-ed003ef9e885"
      unitRef="usd">-32365000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfOC0xLTEtMS04MjEzMg_e9b5c4a4-88df-4569-aa4a-7b057c7f0521"
      unitRef="usd">-7390000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfOC0zLTEtMS04MjEzMg_94975213-b5df-4f4d-b2b7-3f26f1d17f07"
      unitRef="usd">-35871000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTAtMS0xLTEtODIxMzI_da6cbf9e-f7ad-4314-8c42-a59736c354bd"
      unitRef="usd">-66890000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTAtMy0xLTEtODIxMzI_795d132a-2f28-42c4-a560-bdeb615386a3"
      unitRef="usd">20124000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTEtMS0xLTEtODIxMzI_995acbd0-d211-4adf-af0e-9020fbde1d33"
      unitRef="usd">9836000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTEtMy0xLTEtODIxMzI_25b59340-271e-4651-94b0-fb3a20c502df"
      unitRef="usd">26956000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTMtMS0xLTEtODIxMzI_31c769f7-5f37-4d80-b23f-75f875beb528"
      unitRef="usd">35166000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTMtMy0xLTEtODIxMzI_70fbf17e-6aec-4564-806d-fdbe3a5aead0"
      unitRef="usd">24252000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTUtMS0xLTEtODIxMzI_b3d3dc20-f238-4295-b650-0931720085fb"
      unitRef="usd">-3130000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTUtMy0xLTEtODIxMzI_e1e3ddb9-aa2a-4d6b-b7a9-6104cf9b9461"
      unitRef="usd">11434000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <exel:IncreaseDecreaseInAccruedCollaborationLiabilities
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTYtMS0xLTEtODIxMzI_82a8bfb2-cdd8-450e-8501-00d7bc06075b"
      unitRef="usd">-64976000</exel:IncreaseDecreaseInAccruedCollaborationLiabilities>
    <exel:IncreaseDecreaseInAccruedCollaborationLiabilities
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTYtMy0xLTEtODIxMzI_f85ed745-ad43-47d9-8f20-04a259f2dc71"
      unitRef="usd">13947000</exel:IncreaseDecreaseInAccruedCollaborationLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTctMS0xLTEtODIxMzI_ff3cab39-a6f2-4e8d-9d6a-6db90e15aa1e"
      unitRef="usd">6715000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTctMy0xLTEtODIxMzI_350501ac-c6ac-46d5-8b9a-11ebde6c8622"
      unitRef="usd">33865000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTktMS0xLTEtODIxMzI_ea0ee515-5e02-4bb5-986c-93bde19aa9d7"
      unitRef="usd">288920000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMTktMy0xLTEtODIxMzI_515e7f52-1cb1-46d5-b278-e97c87e2699c"
      unitRef="usd">304352000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjEtMS0xLTEtODIxMzI_53ee6850-1abf-435d-a73e-cb0bbaa1aa9a"
      unitRef="usd">25989000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjEtMy0xLTEtODIxMzI_0b2c2470-bbcc-4b28-8723-355000e7304e"
      unitRef="usd">48265000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjMtMS0xLTEtODIxMzI_eb7d2578-4e61-4541-816f-e0bf95aa18d7"
      unitRef="usd">1079411000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjMtMy0xLTEtODIxMzI_21604cfb-5475-46b8-826f-353bbcd04589"
      unitRef="usd">1077377000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjQtMS0xLTEtODIxMzI_440a2e0c-c65c-422e-8ca8-fb5e2fae44f9"
      unitRef="usd">826768000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjQtMy0xLTEtODIxMzI_60a9d008-38b6-482e-bdd2-964efcf41a59"
      unitRef="usd">1095813000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjUtMS0xLTEtODIxMzI_91c8de0e-b6ec-40a5-a940-9834d45cfa33"
      unitRef="usd">-278632000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjUtMy0xLTEtODIxMzI_6ee5a83b-accf-45e6-b86f-5ba3858e47ee"
      unitRef="usd">-29829000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjctMS0xLTEtODIxMzI_fa415496-78a7-4483-b135-16f6a1fb7c8f"
      unitRef="usd">18680000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjctMy0xLTEtODIxMzI_a217dfd3-1a60-4a9b-baf9-e290feec5798"
      unitRef="usd">18242000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjgtMS0xLTEtODIxMzI_4db85822-7124-4e40-8fb5-8bfd36640885"
      unitRef="usd">16091000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMjgtMy0xLTEtODIxMzI_b78ae3fa-33c5-413b-967e-ca2ee25aff41"
      unitRef="usd">15049000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzEtMS0xLTEtODIxMzI_0172da2a-95af-4530-9f40-8931afb65d24"
      unitRef="usd">2589000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzEtMy0xLTEtODIxMzI_8385c921-ab7f-4f16-af4b-b87416478b2f"
      unitRef="usd">3193000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzItMS0xLTEtODIxMzI_6beff7b2-6b52-40cf-8255-86325366a552"
      unitRef="usd">12877000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzItMy0xLTEtODIxMzI_15e39bfc-dde9-4c84-94fd-2cdf71e1d71d"
      unitRef="usd">277716000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzMtMS0xLTEtODIxMzI_69fa3cf8-3ed9-460f-a835-39d8d3968d25"
      unitRef="usd">663891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i48eab2e753614354a3732f75587e636f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzMtMy0xLTEtODIxMzI_2b559ec0-4ab5-4e57-9b57-b4f59bc2a96b"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzQtMS0xLTEtODIxMzI_1267ea22-82b8-441f-b759-03faf11d47e8"
      unitRef="usd">676768000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iacaf43cbe24a472ba26b4376244aeceb_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzQtMy0xLTEtODIxMzI_93c6dda8-31d9-4e0f-84d4-d0bf878edb3b"
      unitRef="usd">598488000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzktMS0xLTEtODIxMzI_8901720b-fa85-4cf7-bdae-a42d5f391ce9"
      unitRef="usd">121958000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfMzktMy0xLTEtODIxMzI_d33a0c6d-4db2-4d82-a010-cb0248ee864d"
      unitRef="usd">4893000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNDEtMS0xLTEtODIxMzI_b1868bf7-9733-49fa-bdcc-b829550706ee"
      unitRef="usd">1643000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNDEtMy0xLTEtODIxMzI_303d7ae0-0717-4367-91b4-33653cd9a6e4"
      unitRef="usd">5143000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNDItMS0xLTEtODIxMzI_edf92cf0-4ca4-4659-95ce-dbe2240cef70"
      unitRef="usd">500000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8yOC9mcmFnOjhlODk5ZWIwMzZkNzQ3YjJiNmQ4MTNjYTcxNGI1ZDg1L3RhYmxlOjE2ODY3ZjlkN2RmOTRhMDg5ZDNkNGQ3NjRjMWQyMWVmL3RhYmxlcmFuZ2U6MTY4NjdmOWQ3ZGY5NGEwODlkM2Q0ZDc2NGMxZDIxZWZfNDItMy0xLTEtODIxMzI_c110055d-24d6-431a-aa6a-3b98755375ae"
      unitRef="usd">9000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk3Mg_a7d3e284-f4f1-4712-8f34-407358fd6fc2">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for patients with difficult-to-treat cancers. Using our considerable drug discovery, development and commercialization resources and capabilities, we have invented and brought to market innovative therapies that appropriately balance patient benefits and risks; we will continue to build on this foundation as we strive to provide cancer patients with new treatment options that improve upon current standards of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Today, four products that originated in Exelixis laboratories are available to be prescribed to patients. Sales related to our flagship molecule, cabozantinib, account for the large majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 62 other countries as: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#x2019;s (BMS) OPDIVO&#xae; (nivolumab), for previously treated hepatocellular carcinoma (HCC) and, currently by the FDA and European Commission (EC), for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and COMETRIQ&#xae; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other two products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. a member of the Roche Group (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;18, 2022 (Fiscal 2021 Form 10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Fiscal year 2022, which is a 52-week fiscal year, will end on December&#160;30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the fiscal period ended October 1, 2021, and as of and for the fiscal year ending December&#160;30, 2022 are indicated as being as of and for the period ended September&#160;30, 2021, and the year ending December&#160;31, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies during the nine months ended September 30, 2022, compared to the significant accounting policies disclosed in &#x201c;Note 1. Organization and Summary of Significant Accounting Policies&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements adopted by us since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i956b96970860433cac967eaa240e5cb1_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjkx_58c68580-6b81-47ce-87ca-32149a68f2b7"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberOfCountriesWithDrugApprovalExcludingTheUS
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfMTA2Nw_ccaf5794-c9d5-47fb-88a0-40cfee914b6c"
      unitRef="country">62</exel:NumberOfCountriesWithDrugApprovalExcludingTheUS>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i0adfaf62ed654496b8aef139a0b4a6a0_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfMTc0Mg_39572ac5-bdba-4723-b6ac-9bc92a596b63"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk2NA_98a5cf46-e9eb-4e03-8e8e-9e47ed67b3a6">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk2Nw_ea8707f9-521e-4ea5-bf6e-e2bd295d4d12">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed with the SEC on February&#160;18, 2022 (Fiscal 2021 Form 10-K).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk1OA_d57bb99c-a6c3-412c-8339-9ffaff325920">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;. Fiscal year 2022, which is a 52-week fiscal year, will end on December&#160;30, 2022 and fiscal year 2021, which was a 52-week fiscal year, ended on December&#160;31, 2021. For convenience, references in this report as of and for the fiscal period ended October 1, 2021, and as of and for the fiscal year ending December&#160;30, 2022 are indicated as being as of and for the period ended September&#160;30, 2021, and the year ending December&#160;31, 2022, respectively.</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk0OA_7fd39603-1ce7-4ee3-bafd-278f7ce8997a">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNDIwOA_e5d2dd2b-e751-4689-8582-5fd8994441b9"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk0OQ_17bca455-3d2b-4000-84f1-22ad8f0a913b">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk1OQ_00c61344-58dc-4a87-a89b-d3c28ce50fa4">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#x2019; equity.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNC9mcmFnOjYxNmFiZmVlMmEzMjRkYTQ4NDhhYTU5MmMzOTNkYzVmL3RleHRyZWdpb246NjE2YWJmZWUyYTMyNGRhNDg0OGFhNTkyYzM5M2RjNWZfNjk4Mg_747476c8-ea85-4268-b711-86a6bcddb6db">&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements adopted by us since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since the filing of our Fiscal 2021 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDg0OA_0c799b84-1d9c-459d-8900-a92ca1989b43">REVENUES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,627)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(255,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(386,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule, and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Contract assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2022 and 2021, we recognized $6.6&#160;million and $6.8&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2022, we recognized $33.9&#160;million and $125.0&#160;million, respectively, in revenues for performance obligations satisfied in previous periods, as compared to $48.4&#160;million and $116.2&#160;million for the corresponding prior year periods. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech and the recognition of license revenue for the achievement of milestones during the second quarter of 2022, allocated to the license performance obligations for our collaboration with Ipsen.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022, $83.1&#160;million of t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he co&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mbined transaction prices for our Ipsen a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd Takeda collaborations were allocated to our research and development services performance obligations that had not yet been satisfied. See &#x201c;Note 3. Collaboration Agreements and Business Development Activities&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2021 Form 10-K for additional information about the expected timing to satisfy these performance obligations.&lt;/span&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDg0NA_9c147fad-d26b-4b94-ba00-1a3957292ae9">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,627)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,023,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29e8fc05be13408780345631766d0815_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMy0xLTEtMS04MjEzMg_f132589e-fb1a-4d51-bfb5-99e690fa259c"
      unitRef="usd">496141000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b04ee7fa7f744f3bd93b05af54ac638_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMy0zLTEtMS04MjEzMg_8ea4023f-1885-43f8-b7c3-b32c5b440461"
      unitRef="usd">357462000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic228c7eb5cf24643909be765ba674a07_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMy01LTEtMS04MjEzMg_362d68e9-96f9-4452-b759-ce23eb92cce3"
      unitRef="usd">1427451000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i245c45138f3a4c37bf6f61ddc6a3d179_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMy03LTEtMS04MjEzMg_bc46c6e2-16da-44b2-a5e2-a02439456a53"
      unitRef="usd">1051871000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c6da63ce1144dfe9238e2548fc27b35_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNC0xLTEtMS04MjEzMg_8ffbaece-da2c-4a24-8e5d-74f358e8720f"
      unitRef="usd">-129659000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ac64684837b4a6da52ae5943bd15379_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNC0zLTEtMS04MjEzMg_73361daa-e959-4a57-a07c-36438623dcf7"
      unitRef="usd">-94345000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11f269764820403288f53e33a88cf89f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNC01LTEtMS04MjEzMg_ca859939-79e4-4ead-82da-f0f4ff4ba3a0"
      unitRef="usd">-403627000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i066aeee8d576453da3c5e154f00d7eac_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNC03LTEtMS04MjEzMg_1823220b-0602-456c-8a33-e5ad17fc05ae"
      unitRef="usd">-277294000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i278c1109560d43989bb93fcb650c9afa_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNS0xLTEtMS04MjEzMg_38e3b007-f059-4afa-bd38-8dcff3636b6c"
      unitRef="usd">366482000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e0a6faac267459387d713c98a6da04c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNS0zLTEtMS04MjEzMg_50af4c92-e8fb-4586-93e1-04914920724e"
      unitRef="usd">263117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaac13ba8b31b461a9ee349f6df7ec401_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNS01LTEtMS04MjEzMg_727ed75b-f74c-4db8-94f5-84372fd1c217"
      unitRef="usd">1023824000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d1060e036714dc8b00e67d518425d7e_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNS03LTEtMS04MjEzMg_a27be67f-7809-4369-b6d3-8953f5c9462e"
      unitRef="usd">774577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3969d7ffe515467786d9f03efe7dd44a_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNy0xLTEtMS04MjEzMg_9a901ccd-9a8e-48c4-9246-d87873432d13"
      unitRef="usd">34384000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ffeb5a9e14d43f5bf61509594c23244_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNy0zLTEtMS04MjEzMg_731c357c-bcc9-4384-87f6-135cb3c45fad"
      unitRef="usd">49694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48e199975584423f9f9b5fc5676b433e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNy01LTEtMS04MjEzMg_bc934172-bcf8-447d-af74-e61800e545c2"
      unitRef="usd">123977000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86031b3c8cd74803ab4a6280a4faaea9_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfNy03LTEtMS04MjEzMg_c6f22005-e83d-4c92-b079-63e262ecf15c"
      unitRef="usd">116862000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd67de25ab5242d6acec13d5bb1dcd8c_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOC0xLTEtMS04MjEzMg_b18adcd8-ba5d-4ba8-a368-cf76e5bcb845"
      unitRef="usd">10872000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3212d047299943f1aefbd2a60b170c8c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOC0zLTEtMS04MjEzMg_5a5f80e6-9bd3-4dca-b3d4-3e6e65ce8426"
      unitRef="usd">15612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f0edff0af2d424980d236133e9e6a27_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOC01LTEtMS04MjEzMg_51d9488b-1be2-46c2-92fc-80fac391ef98"
      unitRef="usd">39344000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if06c48663d594ceeabfd8945d8b2d8be_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOC03LTEtMS04MjEzMg_9aeb5cf4-8ad1-4d0a-b1e1-d1531ebba305"
      unitRef="usd">92391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27a38704423047618c2b8b7c1b51be0e_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOS0xLTEtMS04MjEzMg_6976af98-1ce0-4520-82cb-82f4ad6d7f15"
      unitRef="usd">45256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42beb11067e7404f9bc3d9896994366b_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOS0zLTEtMS04MjEzMg_c0c6de27-9d43-4574-85f5-1f8bded0c356"
      unitRef="usd">65306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c5cd1f508804375996b6d9886dc1ea9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOS01LTEtMS04MjEzMg_a861bd63-d776-4328-a378-5501a75975f9"
      unitRef="usd">163321000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21a57c281a93454aaf7038dc3b541516_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfOS03LTEtMS04MjEzMg_54ed94e0-13e9-4e85-bde9-2fa5628a5639"
      unitRef="usd">209253000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMTAtMS0xLTEtODIxMzI_31429fd4-f62d-47ee-b212-7da6274d5216"
      unitRef="usd">411738000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMTAtMy0xLTEtODIxMzI_43ae1f82-2e35-4f5f-a46c-de353e1305e6"
      unitRef="usd">328423000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMTAtNS0xLTEtODIxMzI_6f3101de-abc4-443b-b325-9185553ebd4d"
      unitRef="usd">1187145000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjFmMjM2MTIwYTIxYTRiZWFiNzEzYWEyZWEwYzRhYmZlL3RhYmxlcmFuZ2U6MWYyMzYxMjBhMjFhNGJlYWI3MTNhYTJlYTBjNGFiZmVfMTAtNy0xLTEtODIxMzI_0eb2fbf6-1913-4f47-ab7d-883fdc27d037"
      unitRef="usd">983830000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDg3MA_68455a9d-82a4-4cb8-9368-d2a32a3acfea">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie65c3b49253c4aa7b9ec4c0202bebd90_D20220702-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMi0xLTEtMS04MjEzMg_d8d92ba0-575d-4f9b-a711-75ae16edbda6"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5bf8a00473bf46afaa5c09de8f46aba6_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMi0zLTEtMS04MjEzMg_b8f87609-f4fa-4ad7-bc4e-08ecd11a72a6"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i77ddea34c561403e81f6dd80be859a85_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMi01LTEtMS04MjEzMg_7577109a-f077-4e20-af61-9262f9ad08e0"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id2eeedb844d94073adfe7b633274b258_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMi03LTEtMS04MjEzMg_960b225c-6ac5-4265-8e79-642fab5aafae"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i50245b1220fd4277b1ff3bbe18a1c24a_D20220702-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMy0xLTEtMS04MjEzMg_49566a87-4534-4157-bd2f-fdecbfaa705a"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifb3f74547a9b413bac6630c8bb4155c6_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMy0zLTEtMS04MjEzMg_4a58bea2-b81d-4047-909d-9a4435d1c963"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7149117a9e054f7f8e808e1fd2ff2e9e_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMy01LTEtMS04MjEzMg_170b0cc9-5078-4b4b-98a2-e5a5bc39eb4c"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib51bcc2f1cfb4c36aa8d080a8efad244_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfMy03LTEtMS04MjEzMg_c37d93bd-b263-4a4d-92de-187ce7abd0b7"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3c2a7f145b054c929254fd11464ef3b3_D20220702-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNC0xLTEtMS04MjEzMg_814b178b-8002-49a5-8e2a-33d5c0d0cb7a"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia4e2dbdf48c448b29b598f9f2a0e5e19_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNC0zLTEtMS04MjEzMg_0e45b70b-8c11-44f6-95c7-8723b5cb8e31"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i97213e89d9b746b5bf8fbd85fd21333c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNC01LTEtMS04MjEzMg_23766742-81b4-479f-b040-df941d35eca8"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaa364ec98f294e0daf245b10590174ba_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNC03LTEtMS04MjEzMg_4d87a664-3c69-4518-9108-926610005018"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i05ec8cf0e5c849b2922e3b9477ee666d_D20220702-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNS0xLTEtMS04MjEzMg_81c0fc4a-0415-4942-8f83-236c9f8e2f6a"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia362249dbd9f44f1b5332ae17e959ded_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNS0zLTEtMS04MjEzMg_58a58c7d-f579-46d4-b39d-8ec8151b96eb"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib6dc5a498cf9414a802f893ec5b46c0f_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNS01LTEtMS04MjEzMg_aea37bb7-7d18-4d47-bf0c-90194b94ea7b"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5dddd16fbc8540e2a41581289baa917d_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNS03LTEtMS04MjEzMg_c7b9cfa4-57da-49c7-94de-81f53d076419"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaa0b05764a414ac78f6fd87d606b97fd_D20220702-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNy0xLTEtMS04MjEzMg_aaffd8bd-0b27-4d08-963a-6e7d9902a36d"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5c8fcad9f81446bcb60cc26cbc5f329f_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNy0zLTEtMS04MjEzMg_dcb279a3-a8c0-4365-9d69-800a0adadcbb"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i93f8e2a75c804d01bd28137196447c82_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNy01LTEtMS04MjEzMg_67572b8a-c37f-4caf-9bc8-f41c1093839f"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8da6b9fe3c7a45dfb9419e4c773ac239_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmNlM2ZjY2Y4ZGZmYTQ3YjFhMjJjYzFjZDNjZDQ4ZjIzL3RhYmxlcmFuZ2U6Y2UzZmNjZjhkZmZhNDdiMWEyMmNjMWNkM2NkNDhmMjNfNy03LTEtMS04MjEzMg_a30ae449-8f24-4ce4-8155-2794d88245c3"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i218f04d9b7f145c4a3ab264f17ca1972_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfMS0xLTEtMS04ODgyOQ_3bccc27e-3113-4a66-9126-fb53828fc14d"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i971168baf86d4f9c9aee82b5e9765ccd_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfMS0zLTEtMS04ODgyOQ_77753b40-c7c5-4ec3-9035-5f070331aeb7"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1fb1caa40c0048d0a80ef36f16745e1e_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfMS0xLTEtMS04MjEzMg_fafc39eb-7d97-49e9-9b24-cc92a633a941"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idde9ae17b3d542958541cede2a2481c6_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfMS0zLTEtMS04MjEzMg_b5c28117-03ea-49b0-8239-f38745894f2c"
      unitRef="number">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i35a9f0667ea2442eb885a468202845d4_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfMy0xLTEtMS04MjEzMg_174be163-c322-4102-bd61-a0351c92bb3c"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic52fe2f2070840529d3087ede78597e4_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfMy0zLTEtMS04MjEzMg_d2f82033-4d6f-4705-abc5-c25bbee2f3fc"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i04cd2aba94c64626b2bf9bb35be0b8ce_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfNC0xLTEtMS04MjEzMg_cdae35cc-2ffa-4ea5-9b60-af1e0fa43ec6"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0247826a7d194832a81af45a2cfe61dd_D20210102-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOmY4OGJhYzgyZDQyNjRjZjY5OTg4OGI1MTk1MTAwMmRhL3RhYmxlcmFuZ2U6Zjg4YmFjODJkNDI2NGNmNjk5ODg4YjUxOTUxMDAyZGFfNC0zLTEtMS04MjEzMg_807eeb3b-5982-4432-8e6e-87e79e024f76"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDgzOQ_29a2b733-1080-4f07-b394-4a2d29725b6e">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i445b3583a8f7464f94fbda78d87c16ea_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMi0xLTEtMS04MjEzMg_4804c691-4961-40d7-8292-246210783628"
      unitRef="usd">369480000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4011737647c446caa0d25b062561b85_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMi0zLTEtMS04MjEzMg_6823d723-60b0-4e56-933b-1e2e3c620a4d"
      unitRef="usd">266436000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb8931e56e6c45ec95b31d5e8b47dc6e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMi01LTEtMS04MjEzMg_cd18d884-5d0d-4d29-a1d4-6975960be66d"
      unitRef="usd">1033160000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10a8e5b6128d47dcbe8f521a6afdd884_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMi03LTEtMS04MjEzMg_7a02aa93-1774-4306-88da-0e3d06cb6991"
      unitRef="usd">783583000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20d1b5c68b7248bd894117cbe81a2b72_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMy0xLTEtMS04MjEzMg_7b53e2dd-02b3-4cdf-a4ff-17e597e72297"
      unitRef="usd">34818000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2aec28765054e47a8b50efa632378be_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMy0zLTEtMS04MjEzMg_5ecc78f0-fd3e-490b-8fdc-d0edebaf804b"
      unitRef="usd">38095000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab572d16389b4a3d99847cab2ea41fcc_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMy01LTEtMS04MjEzMg_5edfd92e-acbb-4b75-a4ac-498ac257a4ea"
      unitRef="usd">131585000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic93479bb75b140d3802fac8c321d4809_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfMy03LTEtMS04MjEzMg_ae07ab6f-af9c-4bf7-9e55-5b47081910ae"
      unitRef="usd">162822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7080625bcf434804949496009873718c_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNC0xLTEtMS04MjEzMg_ac25f32f-b0ac-466b-b560-c23f48054ba0"
      unitRef="usd">7440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2efe1c927824b6abc801dccb6e57899_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNC0zLTEtMS04MjEzMg_a538e1bc-8992-4b08-9c99-6c1ccc194086"
      unitRef="usd">23892000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b606e33b09d4e47ac8222e71af4b57d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNC01LTEtMS04MjEzMg_3f2f9382-0403-4ec5-ac68-29755b872b45"
      unitRef="usd">22400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic30704e87cef4c1f82e032e0b9646586_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNC03LTEtMS04MjEzMg_c3cdcabd-4edc-475c-9644-c30b35f88c91"
      unitRef="usd">37425000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNS0xLTEtMS04MjEzMg_867e537a-ea6d-420e-9a89-6cf821e9f6d2"
      unitRef="usd">411738000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNS0zLTEtMS04MjEzMg_559d3a38-d40e-4517-a3a2-09ec3dd9dc21"
      unitRef="usd">328423000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNS01LTEtMS04MjEzMg_1ecd80c9-3e44-43a0-af52-36fbaf11e80c"
      unitRef="usd">1187145000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjEyNTg1MWQwMDAxMjQ3NTlhY2FmNmZiZDVkZTJhMDJhL3RhYmxlcmFuZ2U6MTI1ODUxZDAwMDEyNDc1OWFjYWY2ZmJkNWRlMmEwMmFfNS03LTEtMS04MjEzMg_b5fe5a75-e62a-4946-b419-80463f17d004"
      unitRef="usd">983830000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDg0Nw_560c66ff-1efd-4df7-a62e-0ffad0a71cfd">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule, and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92fb0f6b07fd46b6ba4261c7461fff4b_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMi0xLTEtMS04MjEzMg_cfd87573-80dc-495e-ace6-b7e648a8a428"
      unitRef="usd">361385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0c29019e5ac47c4817bdab99ce15b5a_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMi0zLTEtMS04MjEzMg_876eb391-3551-4a16-9593-26aa08ca162d"
      unitRef="usd">259791000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d39089578604b9b9931f9e265946ecf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMi01LTEtMS04MjEzMg_3e747fbc-2242-404a-a85c-84f349ed235d"
      unitRef="usd">1003356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3056fc81cda24a63be80c8307b00b2da_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMi03LTEtMS04MjEzMg_5109c5b8-6516-4b78-a78f-36b7721942b7"
      unitRef="usd">759000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c3de4e4a9084bf98f767229d2d7f1f9_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMy0xLTEtMS04MjEzMg_64fa667e-1df6-4da4-bd4c-83e7056a5422"
      unitRef="usd">5097000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b17a7fa5ce04b0bb62269c78f9e34bc_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMy0zLTEtMS04MjEzMg_82c82d00-79bb-4271-a3cc-1cbe11215345"
      unitRef="usd">3326000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia90bd12e1079420ab8c09c67bb824c80_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMy01LTEtMS04MjEzMg_3ea61437-80ac-48e9-8347-ab5d7b9622ac"
      unitRef="usd">20468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47e65bdb96ff4594b3069a428583550b_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfMy03LTEtMS04MjEzMg_9b862b6f-0afa-4772-9850-f44b38461605"
      unitRef="usd">15577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i278c1109560d43989bb93fcb650c9afa_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfNC0xLTEtMS04MjEzMg_2f05c431-2334-4c30-8391-c03a01d16d07"
      unitRef="usd">366482000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e0a6faac267459387d713c98a6da04c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfNC0zLTEtMS04MjEzMg_9f2a5a70-d555-4ebc-bddc-40214bd663e9"
      unitRef="usd">263117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaac13ba8b31b461a9ee349f6df7ec401_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfNC01LTEtMS04MjEzMg_0f5572e0-6829-41d2-80c1-6d9cecd43dc1"
      unitRef="usd">1023824000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d1060e036714dc8b00e67d518425d7e_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjI0OWQ5ZWRlYjViMDRjMWQ5OGY1NWYyMDI0OGI4ODMzL3RhYmxlcmFuZ2U6MjQ5ZDllZGViNWIwNGMxZDk4ZjU1ZjIwMjQ4Yjg4MzNfNC03LTEtMS04MjEzMg_dcd12b9f-de2e-4a27-b2ab-88b527075421"
      unitRef="usd">774577000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDg1Mg_b6fcbca3-8971-44f2-be93-3caaef6daa89">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(255,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(386,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if9de5a5db4474de1862cf88701e361a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMS0xLTEtMS04MjEzMg_7995cd7e-f744-4c37-ab7a-653f46fa143e"
      unitRef="usd">14625000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1a7784b834fd4f77b0d696e7db0b1345_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMS0zLTEtMS04MjEzMg_fab8088d-5cee-431f-b5b4-b1e573b2da14"
      unitRef="usd">8875000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifedb850ea024432c901960f936fab351_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMS01LTEtMS04MjEzMg_1187c586-b147-4dfc-b26d-e8560c09bace"
      unitRef="usd">24825000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMS05LTEtMS04MjEzMg_01d1557c-ca95-43a2-901b-bddfcdcf03b8"
      unitRef="usd">48325000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="ieda8f95f074144778888a0e634d3e42b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMy0xLTEtMS04MjEzMg_af756419-55e9-42bd-8dad-399205a14d58"
      unitRef="usd">261143000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i001a107c11d44b3f8675588a5f182420_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMy0zLTEtMS04MjEzMg_4a345502-dc22-468a-bc43-5c7177513ceb"
      unitRef="usd">36847000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i291663fb25df40058a0517d4e9d7425e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMy01LTEtMS04MjEzMg_fa034fdc-305a-46cb-b078-9c1386f475e9"
      unitRef="usd">105280000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfMy05LTEtMS04MjEzMg_28fab06c-1f84-4043-8efe-d5682c6ff0a2"
      unitRef="usd">403270000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="ieda8f95f074144778888a0e634d3e42b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNC0xLTEtMS04MjEzMg_5558d036-bd43-4538-b5c0-5134db634164"
      unitRef="usd">632000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i001a107c11d44b3f8675588a5f182420_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNC0zLTEtMS04MjEzMg_6c70c60c-634b-467e-84b2-cb363250c47e"
      unitRef="usd">-169000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i291663fb25df40058a0517d4e9d7425e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNC01LTEtMS04MjEzMg_8b3927f6-281d-4ea5-9ba1-fdca795e89a1"
      unitRef="usd">-106000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNC05LTEtMS04MjEzMg_d5f70118-e41c-4c01-abbe-20dc7bcf188f"
      unitRef="usd">357000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ieda8f95f074144778888a0e634d3e42b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNS0xLTEtMS04MjEzMg_614f7ef4-e492-47fe-8c66-e0bbbab936d4"
      unitRef="usd">255002000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i001a107c11d44b3f8675588a5f182420_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNS0zLTEtMS04MjEzMg_be855f49-95ef-4416-bffc-897002c05b98"
      unitRef="usd">32765000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i291663fb25df40058a0517d4e9d7425e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNS01LTEtMS04MjEzMg_9310e1eb-9aad-495a-b967-457b5a9e75e9"
      unitRef="usd">98996000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNS05LTEtMS04MjEzMg_d53a29c8-72c0-4c66-9ed6-fc263ae6bc06"
      unitRef="usd">386763000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="icc4ec47df1b34e468e64eed9bb89500e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNi0xLTEtMS04MjEzMg_789a255e-ea23-4a39-bebe-3940ae3e7772"
      unitRef="usd">21398000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6f0371d74e96407b87bcc99e5690f80d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNi0zLTEtMS04MjEzMg_49b336d0-1b26-46b6-b3e9-382b8f6569f6"
      unitRef="usd">12788000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7e205712f95140a09c2d11e6c6f425b7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNi01LTEtMS04MjEzMg_9332c76a-2d8e-49b8-b4d5-a8347c57101c"
      unitRef="usd">31003000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjBhMDUwYTE4ZTY2MTQ1ZTViM2VhNzFlZmVmYzRmOGM3L3RhYmxlcmFuZ2U6MGEwNTBhMThlNjYxNDVlNWIzZWE3MWVmZWZjNGY4YzdfNi05LTEtMS04MjEzMg_d92abb2f-031b-498d-9238-cad236348ce1"
      unitRef="usd">65189000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNDg1NQ_2733307d-8aea-4025-9670-63134a552119">Contract assets and liabilities were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfNC0xLTEtMS04MjEzMg_742d572b-04e1-4ebb-9824-e2be3a1d901f"
      unitRef="usd">364000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfNC0zLTEtMS04MjEzMg_747567b1-ed63-4f34-bb23-ad39e63f6125"
      unitRef="usd">1665000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfNy0xLTEtMS04MjEzMg_6c3104ea-f7a3-4c58-85d1-c817bd135cea"
      unitRef="usd">6932000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfNy0zLTEtMS04MjEzMg_ba21ab27-94ce-409e-b853-bee953f4477f"
      unitRef="usd">7814000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfOC0xLTEtMS04MjEzMg_1e46b377-6fa2-4cda-81bb-eba00097b1a6"
      unitRef="usd">6491000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfOC0zLTEtMS04MjEzMg_b3df5665-9daf-486e-bd41-2374ca43b08c"
      unitRef="usd">8739000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfOS0xLTEtMS04MjEzMg_31597365-9713-4530-9a1d-becd6d9f95c6"
      unitRef="usd">13423000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RhYmxlOjc5Mjg1MTkwOGE4ZDQ5ZjI4MTQyMTE0YmEzNjc1MjRmL3RhYmxlcmFuZ2U6NzkyODUxOTA4YThkNDlmMjgxNDIxMTRiYTM2NzUyNGZfOS0zLTEtMS04MjEzMg_7ea3b021-e65c-4aba-b25b-b0123b0648c5"
      unitRef="usd">16553000</us-gaap:ContractWithCustomerLiability>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE5Mjgy_247340c0-e724-4ee3-91be-67c9b11d3be0"
      unitRef="usd">6600000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE4Nzg2_9902e657-aaab-4a1e-98cd-0ea42a78fbb5"
      unitRef="usd">6800000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE5MzEy_7d9ce258-7669-4851-8b3b-122bbfc51312"
      unitRef="usd">33900000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE5MzQ2_ce68406f-4460-493a-a480-a2b63e157eb7"
      unitRef="usd">125000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE5MDU1_1e11791d-cae6-4a35-b7f3-c5402cc7db60"
      unitRef="usd">48400000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE5MDcw_57435d2d-a90a-4a72-9bee-2d921e86db85"
      unitRef="usd">116200000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i4e9f925ab5174bc3b4fed38f74de06a4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml8zNy9mcmFnOjhmOTQ1MmY0NjI2ODRlMmM5NjdhOWI5ODUxNzEyZDlhL3RleHRyZWdpb246OGY5NDUyZjQ2MjY4NGUyYzk2N2E5Yjk4NTE3MTJkOWFfNTQ5NzU1ODE5NDU1_a38cf8a1-4322-4a1e-9ae1-4fbec36127a9"
      unitRef="usd">83100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNzE4OQ_57c4d1a6-86ed-4e98-9e2c-38e3c40adbfd">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaborations, in-licensing arrangements and other strategic transactions to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading pharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;Note 3. Collaboration Agreements and Business Development Activities&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2021 Form 10-K, as further described below, for additional information on certain of our collaboration agreements and in-licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Commercial Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2022, we recognized $25.8&#160;million in revenues in connection with two regulatory milestones totaling $27.0&#160;million upon approval by the European Commission and Health Canada, of cabozantinib as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to RAI who have progressed during or after prior systemic therapy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022, $49.3&#160;million of the transaction price for this collaboration was allocated to our research and development services performance obligations that have not yet been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $33.8&#160;million of the transaction price for this collaboration was allocated to our research and development services performance obligations that have not yet been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Pharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib sold by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and in connection with sales by our collaboration partners are included as a reduction of collaboration services revenues. Such royalties were $14.9&#160;million and $42.6&#160;million during the three and nine months ended September&#160;30, 2022, respectively, as compared to $11.5&#160;million and $33.7&#160;million for the corresponding prior year periods.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Commercial Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#x2019;s ZELBORAF&#xae; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#xae; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research Collaborations, In-Licensing Arrangements and Other Business Development Activities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our research collaborations, in-licensing arrangements and other strategic transactions include upfront payments, which are generally paid upon the closing of the transaction, and also milestone payments (in connection with development, regulatory or commercial achievements) and royalty payments, which are contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations and in-licensing arrangements provide us exclusive options that give us the right to license programs developed under the research collaborations for further discovery and development. When we decide to exercise an option, we are required to pay an exercise fee and then, in most instances, we will assume the responsibilities for all subsequent clinical development, manufacturing and commercialization of the licensed asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, we entered into an exclusive option and license agreement with BioInvent International AB (BioInvent), upon which we paid an upfront payment of $25.0&#160;million. Upon option exercise, we will pay BioInvent an option exercise fee, and BioInvent will be eligible for additional payments from us for future development and commercial milestones, as well as royalties on our future net product sales. In July 2022, we entered into an exclusive license agreement with Ryvu Therapeutics S.A. (Ryvu) and paid an upfront payment of $3.0&#160;million. Ryvu is eligible for potential future development and commercial milestones as well as royalties on future net product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of September&#160;30, 2022, in conjunction with each of our research collaborations and in-licensing arrangements, and an asset purchase agreement entered into in 2021, we are subject to contingent payments for potential future development milestones of up to $364.7&#160;million, regulatory milestones of up to $453.4&#160;million and commercial milestones of up to $2,443.4&#160;million, each in the aggregate per product or target, as well as royalties on future net product sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNzIxNg_1f6ca181-bb5f-447f-be42-b368cdec5fa9">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i545cd28e851247caac6d1d375512f1c7_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMi0xLTEtMS04MjEzMg_b34da901-d1d4-4047-8e12-64f52045bfb8"
      unitRef="usd">27607000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90ee6fa4bd8843d2b764a321fa9de3f3_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMi0zLTEtMS04MjEzMg_d25af809-31a3-4f53-9430-7535adc205be"
      unitRef="usd">25139000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1c2d7715df546c183c0e89d6bd9ed3b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMi01LTEtMS04MjEzMg_c04ce9e1-1dcf-487a-9d16-2847b5f768d9"
      unitRef="usd">103389000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38484c00f8ed449e838f354569fb8a60_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMi03LTEtMS04MjEzMg_3f3582df-b8ef-470d-8623-1e88d8102808"
      unitRef="usd">81246000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fcd1390271d4d2abc556f67a01c14b4_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMy0xLTEtMS04MjEzMg_456a8085-bc98-4575-8489-d3d93ed15854"
      unitRef="usd">7211000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5138e445f8ee4ac79c11a13ebfd1db6a_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMy0zLTEtMS04MjEzMg_28ebfc3f-0261-430f-aaf5-d7b88098f1c6"
      unitRef="usd">12956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e7d911a57c6474c92d558bab6c033a4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMy01LTEtMS04MjEzMg_4d5f2b78-1ffe-45b0-998b-3e446e6853ca"
      unitRef="usd">28196000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0a570d5f6c8420c9d45e3db1337a2a8_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfMy03LTEtMS04MjEzMg_95aa36c8-7c38-43dc-a4c4-ca21fbfe8922"
      unitRef="usd">81576000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i932765cb697a4b078cea923c81edd920_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfNC0xLTEtMS04MjEzMg_6977b243-6513-4380-8f56-de1f49425ef7"
      unitRef="usd">34818000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80091c0e7cfb45668e3eb0d45b2c94f3_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfNC0zLTEtMS04MjEzMg_b74751b7-52dd-465c-a30d-a0fb2b201d50"
      unitRef="usd">38095000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1364c1c302444d838efffd43064715f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfNC01LTEtMS04MjEzMg_7e0a156b-fc03-4644-a854-d8a52a6e8516"
      unitRef="usd">131585000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41523be6e587448d8ab2f6b2f0c6f04b_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjRlNWFkMDIyMjkwYjRkNWE4M2U1NzliNzk4OGI5YjQ5L3RhYmxlcmFuZ2U6NGU1YWQwMjIyOTBiNGQ1YTgzZTU3OWI3OTg4YjliNDlfNC03LTEtMS04MjEzMg_1d330055-5dc7-470c-ba4d-3e70eb3e7a6e"
      unitRef="usd">162822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i1364c1c302444d838efffd43064715f9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxOTQ0_ceb5fede-c52c-4196-954a-80637bc290ed"
      unitRef="usd">25800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <exel:NumberOfRegulatoryMilestone
      contextRef="i1364c1c302444d838efffd43064715f9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfMjc0ODc3OTA3NzI5Ng_61ae0318-1d91-438a-bdbf-bc58a585aa94"
      unitRef="milestone">2</exel:NumberOfRegulatoryMilestone>
    <exel:ContractWithCustomerMilestoneRevenueRecognized
      contextRef="i1364c1c302444d838efffd43064715f9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxNjM3_3aba26e6-ec1a-45f8-8586-ce3d39a0bc39"
      unitRef="usd">27000000</exel:ContractWithCustomerMilestoneRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i4913e232a2ad4455a008eed936155e00_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxOTc4_17b8a163-77b4-4519-97e7-806e8179a120"
      unitRef="usd">49300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a62749d1d48443f886e9796c6337793_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMi0xLTEtMS04MjEzMg_df03fa53-ce11-4761-b4b5-8bbd15f36001"
      unitRef="usd">2690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id030fbf9dc0b477e938decac98663411_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMi0zLTEtMS04MjEzMg_a31491a0-4d13-4a9f-b4c0-24fd6982abee"
      unitRef="usd">20078000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0a001be0ff84fe794c78832456ead43_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMi01LTEtMS04MjEzMg_1f46eabf-80c6-4ad8-897a-32ac97e6ace3"
      unitRef="usd">7755000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ee1ed1bb84547448046eae5336921cb_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMi03LTEtMS04MjEzMg_7eaa4757-c788-478a-afd4-8a5f7647acb4"
      unitRef="usd">23476000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26a61b54755e49e39e3e69a7ee48adb1_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMy0xLTEtMS04MjEzMg_dc0b00f8-b6fa-4b29-a836-e74b7db8e5e5"
      unitRef="usd">3661000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ac924d3ae554ad193f222a56997ca8d_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMy0zLTEtMS04MjEzMg_b6fe7ebe-c908-4138-a261-eec072deea8c"
      unitRef="usd">2656000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8201aa36633a4adc95d3929b8b7b08c7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMy01LTEtMS04MjEzMg_8ab7e913-bcf6-4341-95e9-e3aa262d3bb1"
      unitRef="usd">11148000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7699082fc113461698ab25c1cdd41c5f_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfMy03LTEtMS04MjEzMg_ef39f962-762e-41ad-87e4-8726c4508576"
      unitRef="usd">10815000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic70ffc1d027b441296ba4347fbd23534_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfNC0xLTEtMS04MjEzMg_327c83e8-d7ca-45ea-863d-00ee75fe2d54"
      unitRef="usd">6351000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43e9d3f2b70a49bf940167c1f27ee63c_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfNC0zLTEtMS04MjEzMg_f4a3a93f-4f63-4830-a7cb-7d822dd81c8e"
      unitRef="usd">22734000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c59059ae1a643cf9613f787f7e2b135_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfNC01LTEtMS04MjEzMg_de884c33-dd47-450d-beb2-86d51b854b1b"
      unitRef="usd">18903000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie402c1037bde46c5af87b543056ba92d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjVlNzU5NjVhYmY5YTQyZWY4MTJkOGIyNDI2MWEwODMyL3RhYmxlcmFuZ2U6NWU3NTk2NWFiZjlhNDJlZjgxMmQ4YjI0MjYxYTA4MzJfNC03LTEtMS04MjEzMg_5e90f046-e486-4156-97a3-34142d56e5bc"
      unitRef="usd">34291000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ibaa37e09ed2a4cc1877653a23011c082_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxODQz_a0f6ec63-8363-464d-9424-825d6109d966"
      unitRef="usd">33800000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="ia63686e881124ae08b1ebf7e9f49fd77_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfMzYwNA_2d03e6fd-6177-45c7-a8af-4e525c206903"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="ia5970864bfa44baca1140501cee1fbfb_D20220702-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxODc0_95b00254-206f-4d4e-87b7-29eb9cda2e72"
      unitRef="usd">14900000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="ided9d969f2e1442982aa0a851fba5f6e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxOTA0_ccb35097-1e0a-4440-a689-cfb70dd10335"
      unitRef="usd">42600000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="ib50a0249433a4d278481e65be8ffe69f_D20210703-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxMjY4_6266890f-bbe9-4abb-aa01-5e69d511a6bf"
      unitRef="usd">11500000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="ia12b136a6e174c9bbad11748d01a0e9c_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIxMjgz_a75c12ba-5e0a-4108-af71-b76229bb31ae"
      unitRef="usd">33700000</us-gaap:RoyaltyExpense>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i9da7e9b183de4698ac4c703b2c8f846c_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMi0xLTEtMS04MjEzMg_c111f67c-9824-499b-9cee-ca2e619ff89c"
      unitRef="usd">1504000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i9527062f675b4046a1cebadb13e14991_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMi0zLTEtMS04MjEzMg_c12941c4-179a-4b1e-8a35-f3321ec0d900"
      unitRef="usd">1743000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="ibe693b49d3c949bd864806bd146b6a29_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMi01LTEtMS04MjEzMg_156956be-229c-469e-b98a-0894f60cdae9"
      unitRef="usd">5325000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i8849b4c4c01946888c77e7fb6ccccb84_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMi03LTEtMS04MjEzMg_593e97a9-6311-4ada-8b4d-8ec6d67dde6a"
      unitRef="usd">5697000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9da7e9b183de4698ac4c703b2c8f846c_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMy0xLTEtMS04MjEzMg_d96b04df-c5d4-424f-b92a-a046a1a2ce45"
      unitRef="usd">1494000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9527062f675b4046a1cebadb13e14991_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMy0zLTEtMS04MjEzMg_21a60e30-eead-420c-876e-3b5bfbb502d8"
      unitRef="usd">1576000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe693b49d3c949bd864806bd146b6a29_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMy01LTEtMS04MjEzMg_63fc545b-7926-4648-a2ed-56b870851dc8"
      unitRef="usd">4011000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8849b4c4c01946888c77e7fb6ccccb84_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RhYmxlOjFmMjM4NTY1YTJmYzRkZDM4YjJkNDk5MTY5MDYxMGU4L3RhYmxlcmFuZ2U6MWYyMzg1NjVhMmZjNGRkMzhiMmQ0OTkxNjkwNjEwZThfMy03LTEtMS04MjEzMg_f7adc9e7-5748-489f-a462-31d4c421edc6"
      unitRef="usd">3309000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i9c9d5031bdf542ceab4b6f6d4789fa7f_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODI2MTU2_a22841b8-5fc0-4737-b031-06147ad405b9"
      unitRef="usd">25000000</exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="if0491f03c0124ea5a708fd9ea63f6bc3_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIzMDE0_1d3cbc36-6906-436a-b656-7a3b24688f4e"
      unitRef="usd">3000000</exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
      contextRef="ie2f04ac5f92f4dfdb4acf9ff8f6d9471_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIyMDIx_105873e1-aa93-4dfe-87c3-5c61334a02e3"
      unitRef="usd">364700000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
      contextRef="ie2f04ac5f92f4dfdb4acf9ff8f6d9471_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIzMDQ2_618cdf10-15bc-4705-8fe4-a815234e13a2"
      unitRef="usd">453400000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments
      contextRef="ie2f04ac5f92f4dfdb4acf9ff8f6d9471_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80MC9mcmFnOjNiMWZjZmVhYmE4MDRjOTliNTY4Y2E1MjQ3ZmUwOTM0L3RleHRyZWdpb246M2IxZmNmZWFiYTgwNGM5OWI1NjhjYTUyNDdmZTA5MzRfNTQ5NzU1ODIzMDc5_b03cf2f6-2cf4-4d5b-864f-a9668b3c621e"
      unitRef="usd">2443400000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMzAxNA_912ba8c5-c2f8-4104-82bd-79e5e75cdf30">CASH AND INVESTMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. The standby letter of credit entered in January 2021, as a guarantee of our obligation to fund our portion of the tenant improvements related to our Alameda build-to-suit lease was terminated and the related collateral was returned in the third quarter of 2022, following the substantial completion of the building and the commencement of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,122,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable was $4.8 million and $2.9 million as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31, 2021, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were insignificant during the three and nine months ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were 276 and 133 investments in an unrealized loss position as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31, 2021, respectively. All securities presented above have been in an unrealized loss position for less than twelve months except for 25 corporate bond securities and 1 municipal bond security with an aggregate fair value of $64.0&#160;million and an aggregate $2.4&#160;million unrealized loss as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During the nine months ended September 30, 2022 and 2021, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjk3MQ_a10b2a2e-9772-49fb-a0d5-be205a7127e3">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjk5NQ_4367e9b5-7337-4298-9ac3-dee0a7b8ad5e">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjZiYTc4ZmQ1MDAwZTRmZTc4ZDE0ZmNlY2NhYzJkN2FmL3RhYmxlcmFuZ2U6NmJhNzhmZDUwMDBlNGZlNzhkMTRmY2VjY2FjMmQ3YWZfMS0xLTEtMS04MjEzMg_d758c5c2-f089-48fc-b071-cd6fb148fe80"
      unitRef="usd">675286000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjZiYTc4ZmQ1MDAwZTRmZTc4ZDE0ZmNlY2NhYzJkN2FmL3RhYmxlcmFuZ2U6NmJhNzhmZDUwMDBlNGZlNzhkMTRmY2VjY2FjMmQ3YWZfMS0zLTEtMS04MjEzMg_651fbf20-e254-43b5-a785-80449ad53db4"
      unitRef="usd">647169000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjZiYTc4ZmQ1MDAwZTRmZTc4ZDE0ZmNlY2NhYzJkN2FmL3RhYmxlcmFuZ2U6NmJhNzhmZDUwMDBlNGZlNzhkMTRmY2VjY2FjMmQ3YWZfMy0xLTEtMS04MjEzMg_159ba7a8-1cd1-4150-8d5b-d2b1699c3057"
      unitRef="usd">1482000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjZiYTc4ZmQ1MDAwZTRmZTc4ZDE0ZmNlY2NhYzJkN2FmL3RhYmxlcmFuZ2U6NmJhNzhmZDUwMDBlNGZlNzhkMTRmY2VjY2FjMmQ3YWZfMy0zLTEtMS04MjEzMg_97d9eb47-10f6-4a14-9918-20333f6c6bca"
      unitRef="usd">16722000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjZiYTc4ZmQ1MDAwZTRmZTc4ZDE0ZmNlY2NhYzJkN2FmL3RhYmxlcmFuZ2U6NmJhNzhmZDUwMDBlNGZlNzhkMTRmY2VjY2FjMmQ3YWZfNC0xLTEtMS04MjEzMg_e3433ad6-c302-47a3-9111-40ff42222fda"
      unitRef="usd">676768000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjZiYTc4ZmQ1MDAwZTRmZTc4ZDE0ZmNlY2NhYzJkN2FmL3RhYmxlcmFuZ2U6NmJhNzhmZDUwMDBlNGZlNzhkMTRmY2VjY2FjMmQ3YWZfNC0zLTEtMS04MjEzMg_69fa3cf8-3ed9-460f-a835-39d8d3968d25"
      unitRef="usd">663891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjk5Mg_be828481-e247-42f2-b0e2-8627fc570cb3">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,122,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,855,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i58839179e60147438d111534793e3584_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMy0xLTEtMS04MjEzMg_664f00aa-a747-4954-8db1-8ee19f810862"
      unitRef="usd">874220000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i58839179e60147438d111534793e3584_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMy0zLTEtMS04MjEzMg_37277cb7-591f-4550-8179-b06a55299fb7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i58839179e60147438d111534793e3584_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMy01LTEtMS04MjEzMg_52415716-338b-43a2-8903-0ff74bf26b27"
      unitRef="usd">364000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i58839179e60147438d111534793e3584_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMy03LTEtMS04MjEzMg_793f306f-a571-4972-a1d4-238e0fe9795a"
      unitRef="usd">873856000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNC0xLTEtMS04MjEzMg_4f5b157f-4b69-4ffa-87c5-12fa14b2edbb"
      unitRef="usd">633617000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNC0zLTEtMS04MjEzMg_167ea2f2-5fd0-4cdd-be80-d88fd76d83bd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNC01LTEtMS04MjEzMg_4e2d1e74-32fa-48b2-8847-1ce7fb1a2b43"
      unitRef="usd">15495000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNC03LTEtMS04MjEzMg_19e38a0a-4690-4f0b-8197-b2365c1700a5"
      unitRef="usd">618122000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ied291acb3b8349dcaa4d28395592f7e8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNS0xLTEtMS04MjEzMg_4feb25bd-8f65-4d62-8558-a5cd29516502"
      unitRef="usd">307494000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ied291acb3b8349dcaa4d28395592f7e8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNS0zLTEtMS04MjEzMg_826f6da0-ef1a-4290-afb4-7e3b74e74aea"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ied291acb3b8349dcaa4d28395592f7e8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNS01LTEtMS04MjEzMg_5d46eace-ae76-4cd3-b3e1-82940295e28b"
      unitRef="usd">6157000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied291acb3b8349dcaa4d28395592f7e8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNS03LTEtMS04MjEzMg_11406855-5cc8-45fe-b515-2870fb4f9c7c"
      unitRef="usd">301337000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNi0xLTEtMS04MjEzMg_712cab7d-a9dc-4033-b2bd-f05b4a8fd705"
      unitRef="usd">16565000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNi0zLTEtMS04MjEzMg_c617e6a4-8f04-4203-89b1-30889d47fd4c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNi01LTEtMS04MjEzMg_bdfb596b-8641-4978-97e6-fc03cbeff21b"
      unitRef="usd">312000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNi03LTEtMS04MjEzMg_bb562aad-7fa1-4daf-9acb-069cfa9296af"
      unitRef="usd">16253000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNy0xLTEtMS04MjEzMg_019dd0c2-323b-4022-87de-5eb92eec1bed"
      unitRef="usd">1831896000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNy0zLTEtMS04MjEzMg_b50c7c50-a673-4374-89ce-4144a0831edd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNy01LTEtMS04MjEzMg_f79be4a9-0a5f-4e38-bc51-b2ff34a04e23"
      unitRef="usd">22328000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfNy03LTEtMS04MjEzMg_52f7d2ea-d524-4124-9cd8-6b91bb2754fb"
      unitRef="usd">1809568000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i7eb3542aa68a458ba55ced4e19e05fd3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOC0xLTEtMS04MjEzMg_16b0c2bb-8851-4789-b0c3-a104b2876fa7"
      unitRef="usd">113492000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i7eb3542aa68a458ba55ced4e19e05fd3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOC0zLTEtMS04MjEzMg_b6a102e6-912e-4deb-8b52-d9b987742092"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i7eb3542aa68a458ba55ced4e19e05fd3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOC01LTEtMS04MjEzMg_5b698df6-6ad7-4b61-beff-1368ea956a33"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i7eb3542aa68a458ba55ced4e19e05fd3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOC03LTEtMS04MjEzMg_3e2ae531-c797-473d-a274-d7bebd65f0b5"
      unitRef="usd">113492000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ica491f30edaa49d7ad148efd0cbfa735_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOS0xLTEtMS04MjEzMg_660e5c11-5a89-4f03-8d75-c4fa1fdbce90"
      unitRef="usd">62968000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ica491f30edaa49d7ad148efd0cbfa735_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOS0zLTEtMS04MjEzMg_4f3fe7d8-c408-4ae9-a3a3-94c2f7dfaf86"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ica491f30edaa49d7ad148efd0cbfa735_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOS01LTEtMS04MjEzMg_39b35d4c-788b-4060-b2e7-d8de9216a02c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ica491f30edaa49d7ad148efd0cbfa735_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfOS03LTEtMS04MjEzMg_ede79158-7e67-4517-b643-f091e99f5dc5"
      unitRef="usd">62968000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ibe0063762fe744f0a9698d6a8a86e957_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTAtMS0xLTEtODIxMzI_9be13a92-0180-4344-b677-ba44f7494ba6"
      unitRef="usd">114181000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ibe0063762fe744f0a9698d6a8a86e957_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTAtMy0xLTEtODIxMzI_4a0f0ec4-4c40-4650-a6d2-407889955ffe"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ibe0063762fe744f0a9698d6a8a86e957_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTAtNS0xLTEtODIxMzI_6732e5ec-4731-47ae-8e96-431a0073ec25"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ibe0063762fe744f0a9698d6a8a86e957_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTAtNy0xLTEtODIxMzI_9f089710-367c-4ec3-a4a8-57b8a4aed11b"
      unitRef="usd">114181000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTEtMS0xLTEtODIxMzI_0786e5c2-3ee3-4b9a-9de8-49b4d2036360"
      unitRef="usd">2122537000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTEtMy0xLTEtODIxMzI_7263f7f0-a584-4788-bfe1-300cdd292b35"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTEtNS0xLTEtODIxMzI_86478670-6843-4e10-a539-1347687763ca"
      unitRef="usd">22328000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjc2ZDM0NzJkMjZjZDQ3OWQ4YmI2ZDNjNGVhOTA5ZmZjL3RhYmxlcmFuZ2U6NzZkMzQ3MmQyNmNkNDc5ZDhiYjZkM2M0ZWE5MDlmZmNfMTEtNy0xLTEtODIxMzI_9d5e7d3f-5992-4a7d-a3c8-28b08d3f92d1"
      unitRef="usd">2100209000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icc686d12fa4e4260b80a6d50f6424dc3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMy0xLTEtMS04MjEzMg_2d2199f7-eed8-4fa2-9ba6-d91245288c16"
      unitRef="usd">945801000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icc686d12fa4e4260b80a6d50f6424dc3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMy0zLTEtMS04MjEzMg_c264142c-f413-4e7d-b16e-2d7a230c590d"
      unitRef="usd">42000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icc686d12fa4e4260b80a6d50f6424dc3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMy01LTEtMS04MjEzMg_edb1e95c-7f51-4c6f-859b-52f6a797c6e3"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc686d12fa4e4260b80a6d50f6424dc3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMy03LTEtMS04MjEzMg_f23ec107-35dc-4f47-816c-03d66edbbff2"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNC0xLTEtMS04MjEzMg_ffa7a991-c631-4210-8350-55f9c1398852"
      unitRef="usd">541774000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNC0zLTEtMS04MjEzMg_44e7290d-046a-48a0-aa44-72bfde58d07d"
      unitRef="usd">876000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNC01LTEtMS04MjEzMg_75e6994d-6f99-4640-a218-41abaac29147"
      unitRef="usd">1672000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNC03LTEtMS04MjEzMg_6d7e0a52-f321-46f9-abb1-895ecc063d01"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i701da0dfff384128b67d66f7cfc99222_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNS0xLTEtMS04MjEzMg_f2d30699-4938-4624-8a14-b57097cac77e"
      unitRef="usd">33965000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i701da0dfff384128b67d66f7cfc99222_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNS0zLTEtMS04MjEzMg_48cde852-a508-42db-a1be-9e9e7fb63180"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i701da0dfff384128b67d66f7cfc99222_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNS01LTEtMS04MjEzMg_de1f04d2-ba47-407d-a09d-8d92969e7185"
      unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i701da0dfff384128b67d66f7cfc99222_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNS03LTEtMS04MjEzMg_e0eebd7f-119b-4f0e-b98c-2b254481f1df"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idef82cf2fbcf4ade8270cbe16f10de34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNi0xLTEtMS04MjEzMg_657ce787-b38b-41c0-bea2-2344c1231c31"
      unitRef="usd">12924000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idef82cf2fbcf4ade8270cbe16f10de34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNi0zLTEtMS04MjEzMg_1665ff73-065e-4e37-b942-f5196cbea599"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idef82cf2fbcf4ade8270cbe16f10de34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNi01LTEtMS04MjEzMg_ac4d8d1d-3d99-409c-a1ea-35933f0831b7"
      unitRef="usd">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idef82cf2fbcf4ade8270cbe16f10de34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNi03LTEtMS04MjEzMg_370dfa5a-f603-403f-bdc8-37fc55f2f858"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNy0xLTEtMS04MjEzMg_1ff01e5d-a95a-4578-8467-8bfbdf036611"
      unitRef="usd">1534464000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNy0zLTEtMS04MjEzMg_7b8d3564-78bc-48d8-9570-c0c732fc7c9b"
      unitRef="usd">934000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNy01LTEtMS04MjEzMg_5de6c428-42ba-4b57-aa3f-551b0b43f3f9"
      unitRef="usd">1730000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfNy03LTEtMS04MjEzMg_889e2559-fc14-4e79-b2e1-12492824454b"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i172e305050d443b3a741d87593f63789_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOC0xLTEtMS04MjEzMg_103d3075-d5d0-4f80-bc90-8d2cf1a9c771"
      unitRef="usd">135653000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i172e305050d443b3a741d87593f63789_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOC0zLTEtMS04MjEzMg_039a10bf-b0e5-4640-8f24-8e61acc298a6"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i172e305050d443b3a741d87593f63789_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOC01LTEtMS04MjEzMg_b9a94146-9f7a-4022-a4f6-9b96e8de69fb"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i172e305050d443b3a741d87593f63789_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOC03LTEtMS04MjEzMg_49372d60-de96-42f1-9710-579f414cf16c"
      unitRef="usd">135653000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i715f766ed6a447508a29b9beaf5cb949_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOS0xLTEtMS04MjEzMg_15f32e69-9d01-4ee9-9b00-8bd9e87ece3f"
      unitRef="usd">66531000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i715f766ed6a447508a29b9beaf5cb949_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOS0zLTEtMS04MjEzMg_bac8b01a-8236-42a9-bc11-76a2ae498a2f"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i715f766ed6a447508a29b9beaf5cb949_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOS01LTEtMS04MjEzMg_429db479-465a-436e-9177-daf70671e8ca"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i715f766ed6a447508a29b9beaf5cb949_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfOS03LTEtMS04MjEzMg_2dac35f8-55f5-404a-ab9c-733d6f3d59e3"
      unitRef="usd">66531000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i48ec553d89834f00b45ec9c811bb351c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTAtMS0xLTEtODIxMzI_a443df73-3ed8-43a8-978b-8e06cf9915f3"
      unitRef="usd">119056000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i48ec553d89834f00b45ec9c811bb351c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTAtMy0xLTEtODIxMzI_0ce18fbb-ac79-4258-a5df-e6a792afd58c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i48ec553d89834f00b45ec9c811bb351c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTAtNS0xLTEtODIxMzI_1d481180-a618-4da7-88b0-3530e55cbbe8"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i48ec553d89834f00b45ec9c811bb351c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTAtNy0xLTEtODIxMzI_ad65bcb6-676c-4894-bd52-b48f759da0c5"
      unitRef="usd">119056000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTEtMS0xLTEtODIxMzI_34d80c81-7aaf-4307-a6f9-d2a2531d39ae"
      unitRef="usd">1855704000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTEtMy0xLTEtODIxMzI_f01caddb-df3e-4f1a-8158-678ccbda4d37"
      unitRef="usd">934000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTEtNS0xLTEtODIxMzI_7011d323-572a-42e1-a40c-a5b28ee72b92"
      unitRef="usd">1730000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjIwMWI3NWM2YzBmMDRmMDVhZWE2NTMyNjFiNGRlMDNiL3RhYmxlcmFuZ2U6MjAxYjc1YzZjMGYwNGYwNWFlYTY1MzI2MWI0ZGUwM2JfMTEtNy0xLTEtODIxMzI_954c25ec-d076-4652-b88c-9008c7ce9b49"
      unitRef="usd">1854908000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMTM0OA_bc7cf352-8cd2-4c4a-aaff-cece99db81d5"
      unitRef="usd">4800000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMTM1NQ_5d7f025c-7eed-46f8-8f2f-6ec1d2a1489f"
      unitRef="usd">2900000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjk2NA_1b4c500e-a873-4769-ae0c-c8cc5699f171">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfMy05LTEtMS04MjEzMg_14290957-c96a-4a7f-b8b8-78fa30ffa24f"
      unitRef="usd">613122000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfMy0xMS0xLTEtODIxMzI_0d1bd52e-d8f6-452c-b478-a821c1b19162"
      unitRef="usd">15495000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ied291acb3b8349dcaa4d28395592f7e8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfNC05LTEtMS04MjEzMg_a1a48e8a-ebd4-4afd-a03e-c3464df83184"
      unitRef="usd">301337000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ied291acb3b8349dcaa4d28395592f7e8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfNC0xMS0xLTEtODIxMzI_48fff48b-cfe2-4068-ac35-57878c437aac"
      unitRef="usd">6157000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i58839179e60147438d111534793e3584_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfNS05LTEtMS04MjEzMg_7f72281f-2e4e-4a8e-b5a2-1618225f50e7"
      unitRef="usd">36636000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i58839179e60147438d111534793e3584_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfNS0xMS0xLTEtODIxMzI_66916dfb-3359-4b1b-b835-cde49b178322"
      unitRef="usd">364000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfNi05LTEtMS04MjEzMg_37065f48-7b78-4572-a27a-ad762c740e9f"
      unitRef="usd">16073000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfNi0xMS0xLTEtODIxMzI_34a9a842-4afd-4b00-ae79-5d28231e845b"
      unitRef="usd">312000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfOC05LTEtMS04MjEzMg_6ec9b638-83d2-4cc4-acda-ff082a011abc"
      unitRef="usd">967168000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjA0NDc1ZDRlOTY3NTQzZDJiZjY0MDNmOGFlYTFiNDhkL3RhYmxlcmFuZ2U6MDQ0NzVkNGU5Njc1NDNkMmJmNjQwM2Y4YWVhMWI0OGRfOC0xMS0xLTEtODIxMzI_1e35497b-85f5-4cc8-99bf-b383ad7e83a8"
      unitRef="usd">22328000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfMi05LTEtMS04MjEzMg_954d2e79-af48-4ae9-9845-8cb28631c019"
      unitRef="usd">385053000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i7b8fa4e7e5a8414ab1e8138e46e68a0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfMi0xMS0xLTEtODIxMzI_5d506384-3208-4ad8-be12-3820773738f8"
      unitRef="usd">1672000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="icc686d12fa4e4260b80a6d50f6424dc3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfMy05LTEtMS04MjEzMg_5dbaaac8-4169-47c0-bbb1-e2abb67d317a"
      unitRef="usd">43290000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="icc686d12fa4e4260b80a6d50f6424dc3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfMy0xMS0xLTEtODIxMzI_95bac544-e1e5-450b-adb8-521149e07db0"
      unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i701da0dfff384128b67d66f7cfc99222_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfNC05LTEtMS04MjEzMg_b4af110e-462f-416b-bc30-a242df6eba20"
      unitRef="usd">18962000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i701da0dfff384128b67d66f7cfc99222_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfNC0xMS0xLTEtODIxMzI_e9ad3fac-3ffd-419d-bbee-a0d903b973b1"
      unitRef="usd">21000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="idef82cf2fbcf4ade8270cbe16f10de34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfNS05LTEtMS04MjEzMg_7fb607b6-9496-493b-a4bd-5b8469f91b5e"
      unitRef="usd">7475000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="idef82cf2fbcf4ade8270cbe16f10de34_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfNS0xMS0xLTEtODIxMzI_83de70ac-dbab-4a8f-b135-3382b01e201e"
      unitRef="usd">35000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfNi05LTEtMS04MjEzMg_db577575-542d-432d-8f23-b690120b979f"
      unitRef="usd">454780000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOjBjMTk1OTM0OWRjYjQ1NTViYmVjNTFjYWJkODAxMzUxL3RhYmxlcmFuZ2U6MGMxOTU5MzQ5ZGNiNDU1NWJiZWM1MWNhYmQ4MDEzNTFfNi0xMS0xLTEtODIxMzI_22cbc9ca-5f82-4f2d-a728-765f85e55965"
      unitRef="usd">1730000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjAwMg_72b30679-96d3-45aa-839f-937bb60fc229"
      unitRef="investment">276</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjAwOQ_755fd77d-9197-4816-be5a-c337cf693c74"
      unitRef="investment">133</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <exel:NumberOfBondSecurities
      contextRef="i4cfa17414554476d91dacbdd5d9a0abd_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfNTQ5NzU1ODE3NzE3_1b9563d5-6808-40bc-b5ec-92fbd225b488"
      unitRef="bond">25</exel:NumberOfBondSecurities>
    <exel:NumberOfBondSecurities
      contextRef="ic96174b513db4b08a8d8022ebefad89f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjc0ODc3OTA3MzMwNg_f48a8556-76b1-4587-9a5a-6c9e26b4335c"
      unitRef="bond">1</exel:NumberOfBondSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfNTQ5NzU1ODE3NjU0_c83d6f92-e7fb-4dcd-ade6-a37dc395d5b4"
      unitRef="usd">64000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfNTQ5NzU1ODE3Njk1_4101529e-1e79-47c7-b598-1c64c03a6598"
      unitRef="usd">2400000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="iacaf43cbe24a472ba26b4376244aeceb_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjM0Ng_0cba800f-1af4-43d0-8f9f-43cb3c280a87"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjM0Ng_86fba902-04da-492b-89ff-7b0c56bc0967"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RleHRyZWdpb246ZmYwMmFjY2JlZmIwNGY4ZGEwMTUwNTBlN2UxY2VjZDlfMjk3MA_20887b01-c11d-45fe-add5-f19bd1310065">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOmVmNjRhNWY4MmM0MDQ1ZmRhZWI3ZGQ5MDk2NmVlOGFmL3RhYmxlcmFuZ2U6ZWY2NGE1ZjgyYzQwNDVmZGFlYjdkZDkwOTY2ZWU4YWZfMS0xLTEtMS04MjEzMg_8670bfe1-0bf9-4176-84d6-505f8809ea0f"
      unitRef="usd">1260834000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOmVmNjRhNWY4MmM0MDQ1ZmRhZWI3ZGQ5MDk2NmVlOGFmL3RhYmxlcmFuZ2U6ZWY2NGE1ZjgyYzQwNDVmZGFlYjdkZDkwOTY2ZWU4YWZfMS0zLTEtMS04MjEzMg_fe6cc996-1452-4bcc-8ee1-56b6df73fba5"
      unitRef="usd">1168256000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOmVmNjRhNWY4MmM0MDQ1ZmRhZWI3ZGQ5MDk2NmVlOGFmL3RhYmxlcmFuZ2U6ZWY2NGE1ZjgyYzQwNDVmZGFlYjdkZDkwOTY2ZWU4YWZfMi0xLTEtMS04MjEzMg_8d6120f2-2099-43f5-8c2e-63d6911945fa"
      unitRef="usd">548734000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOmVmNjRhNWY4MmM0MDQ1ZmRhZWI3ZGQ5MDk2NmVlOGFmL3RhYmxlcmFuZ2U6ZWY2NGE1ZjgyYzQwNDVmZGFlYjdkZDkwOTY2ZWU4YWZfMi0zLTEtMS04MjEzMg_e41590c7-d40c-4bd9-9c16-a157a57061b7"
      unitRef="usd">365412000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOmVmNjRhNWY4MmM0MDQ1ZmRhZWI3ZGQ5MDk2NmVlOGFmL3RhYmxlcmFuZ2U6ZWY2NGE1ZjgyYzQwNDVmZGFlYjdkZDkwOTY2ZWU4YWZfMy0xLTEtMS04MjEzMg_1bd56e1f-053d-44d6-b95e-4807d8baaa46"
      unitRef="usd">1809568000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80My9mcmFnOmZmMDJhY2NiZWZiMDRmOGRhMDE1MDUwZTdlMWNlY2Q5L3RhYmxlOmVmNjRhNWY4MmM0MDQ1ZmRhZWI3ZGQ5MDk2NmVlOGFmL3RhYmxlcmFuZ2U6ZWY2NGE1ZjgyYzQwNDVmZGFlYjdkZDkwOTY2ZWU4YWZfMy0zLTEtMS04MjEzMg_1143ac89-34a5-413e-ad17-352f0d0e9084"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfMjM1Ng_7f49712e-0e1c-4878-85b6-1a925c470528">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,986,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Forward Foreign Currency Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we had one forward contract outstanding to sell &#x20ac;10.0&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The unrealized loss on the forward contract is not material as of September&#160;30, 2022. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the nine months period ended September&#160;30, 2022, and 2021, we recognized $1.5 million and $0.5&#160;million, respectively, of net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfMjM2Mg_2b56b19e-af1c-44e6-894c-471dc69e5310">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,986,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,652,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if496ec13812c4ae893488d94baef090c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfMi0xLTEtMS04MjEzMg_6cbb714c-387e-429b-b19f-159c428749b7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1a8f66e27ef54639adf8c0c31673352c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfMi0zLTEtMS04MjEzMg_234bf425-f088-4245-8fbc-73c972c97bfb"
      unitRef="usd">873856000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i843bbd1a33f649a78d35d947eff4b9a7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfMi01LTEtMS04MjEzMg_a252c4b0-4ee6-4285-925e-9774ad2a0d38"
      unitRef="usd">873856000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51cbf38a72b74e8d987a9138cc078b1a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfMy0xLTEtMS04MjEzMg_23d8f508-7c27-4c49-85e9-9c2df109fbc4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i47c2e10640954a49859ec7c33dbb8e33_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfMy0zLTEtMS04MjEzMg_9930a240-bda5-4161-81f0-5461a8646463"
      unitRef="usd">618122000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81558c9856554de7833c4a2806a8b626_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfMy01LTEtMS04MjEzMg_dbff3f95-95ea-4f1b-b1b0-55c65eb70598"
      unitRef="usd">618122000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id57f0a67c6b243ed9e67d6b085657e54_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNC0xLTEtMS04MjEzMg_d63e4dee-0375-4f98-a604-f6b1c279aecb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1efce754a3e042719aca4d5d14d2cdc9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNC0zLTEtMS04MjEzMg_76ae33bb-97d8-4e0c-9d96-54468285b164"
      unitRef="usd">301337000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd3d6d7024114c76b5161677a09f1ff1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNC01LTEtMS04MjEzMg_eca85d65-9472-42ce-9965-88263f7d1b38"
      unitRef="usd">301337000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8ee240d204304b82b2e177132d0e6bf1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNS0xLTEtMS04MjEzMg_ead0979d-3be4-4ba1-b47a-0838720ef4d4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb3f78b5c5b94afd80179a24fb7390ab_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNS0zLTEtMS04MjEzMg_1c777fe8-b209-4ece-a3de-a7e8fbcde0f7"
      unitRef="usd">16253000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec9a9b3bc1ed41a9bb7528566061b93f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNS01LTEtMS04MjEzMg_ecdc702e-afac-478f-bb69-aab200cc2729"
      unitRef="usd">16253000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i88202d8592004d2c8c4852504e52b931_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNi0xLTEtMS04MjEzMg_1f2faa02-f4ac-4492-9fe1-1f79f2fdee10"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibea0c087b202475e99958164943828bf_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNi0zLTEtMS04MjEzMg_a909dee1-ff1c-4269-bb04-f244f64032e2"
      unitRef="usd">1809568000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i71fc629d67b1439596f3c19023047959_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNi01LTEtMS04MjEzMg_37072a4a-d55f-4109-94af-730a75e30d35"
      unitRef="usd">1809568000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8b2ebe36f5674bb58674bb6f4330233f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNy0xLTEtMS04MjEzMg_56335ebb-903f-4e4c-89d6-f7730e177292"
      unitRef="usd">62968000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iebf3c208a48c4e599b699f4ab792b2db_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNy0zLTEtMS04MjEzMg_a8ca3796-49f6-4451-b879-f39285d09420"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8475c0170e0e415f97fbec0694e96b99_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfNy01LTEtMS04MjEzMg_6b9a2cce-a1ec-42b9-a11b-855983199ed0"
      unitRef="usd">62968000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i04b2a87a345c443dae1c0c9599142457_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfOC0xLTEtMS04MjEzMg_4a7049b2-a9d6-4c1a-809f-081a025d7cc5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0b3c03a185f44b7cba57ea4cd0921028_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfOC0zLTEtMS04MjEzMg_fe81a064-6ff1-4c45-b3c7-1ad8546a9cc2"
      unitRef="usd">114181000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i674f190343a44c93a3f972959dd570b6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfOC01LTEtMS04MjEzMg_0e2bdcf2-cf0f-453d-b2e7-f8e18edebdc3"
      unitRef="usd">114181000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i88202d8592004d2c8c4852504e52b931_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfOS0xLTEtMS04MjEzMg_95f57dd0-ba33-472f-9047-d98cbccb656f"
      unitRef="usd">62968000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibea0c087b202475e99958164943828bf_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfOS0zLTEtMS04MjEzMg_08d88bd5-ea39-4285-9de1-53ddfb881604"
      unitRef="usd">1923749000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i71fc629d67b1439596f3c19023047959_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOmFmODRiNjEzNzRmNDRjZDU5ZWM2Y2Y3M2Q0ZTM5ODEyL3RhYmxlcmFuZ2U6YWY4NGI2MTM3NGY0NGNkNTllYzZjZjczZDRlMzk4MTJfOS01LTEtMS04MjEzMg_ea22ca1e-f1f5-467b-bef9-c4685cd940c8"
      unitRef="usd">1986717000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie5c375c63bd346fe978fb2534b5e3800_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfMi0xLTEtMS04MjEzMg_47a15ce4-b854-4d72-9cb9-3ecf4823015a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9a6d14de067741dca25498e9f73fd442_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfMi0zLTEtMS04MjEzMg_e66a792c-71db-4cc4-ac3e-9fc122a26287"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i341945d209bf44d296c37ef93e0345ef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfMi01LTEtMS04MjEzMg_1cda12da-c02a-429e-8814-2c3174e15c31"
      unitRef="usd">945841000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id3c5b394503146d3a0d022b6c8b89b92_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfMy0xLTEtMS04MjEzMg_eb8ba3ee-511d-46a3-aa70-fda2ac355457"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib0a20eb1a92443bda7fa6b72c5a0d273_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfMy0zLTEtMS04MjEzMg_412e7167-69b2-48fb-84ea-24b47deda186"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie591104d91534932927cac2401b55411_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfMy01LTEtMS04MjEzMg_c4eb7ac3-e210-47ef-83c3-f949a83393cc"
      unitRef="usd">540978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i830bd31e008547e886cd8a5ec319f87e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNC0xLTEtMS04MjEzMg_312bf827-26b1-474b-bece-df8c74e97a4c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia04e0b0194d7409f8c9d6770aade56c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNC0zLTEtMS04MjEzMg_30f80f9e-76b3-44e3-9704-ea19d8714634"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i58211da7dc6f4d538de9873270446232_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNC01LTEtMS04MjEzMg_2c42afe8-1691-4b59-97ad-960a5c0cb9e3"
      unitRef="usd">33945000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i334c5f91f7f14f9fad4d7234cc49ea1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNS0xLTEtMS04MjEzMg_7c607202-8bfd-4b48-896a-9b97ba411858"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78e946b1e834488a8312b0d935e9f2a0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNS0zLTEtMS04MjEzMg_308eeb62-6511-4bd3-8dbe-e0150bb17430"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f657f4786c94e5cabeabf0a738d4385_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNS01LTEtMS04MjEzMg_e666efbb-e05f-444c-9a31-cf503b0c66da"
      unitRef="usd">12904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i562efe5dbad445f48582bd754933cf24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNi0xLTEtMS04MjEzMg_821eaa55-d5f7-4759-ad10-524d7d8fde4c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic3300c71f3304f4fabbe2333fa0e6f6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNi0zLTEtMS04MjEzMg_264a2ebb-ed1a-45c5-8c99-d401a3232e45"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idede8e3136eb484884a82aa3c0a1d084_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNi01LTEtMS04MjEzMg_7eb6c7f6-1385-4962-832a-4d6acffe6ae4"
      unitRef="usd">1533668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie70ea002268c4a5caf09a2bd32761c1d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNy0xLTEtMS04MjEzMg_2ebea58e-f05c-4e63-b3d1-6806d7e295e9"
      unitRef="usd">66531000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0fa1a26a550e4cdebc79e98ec28d3692_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNy0zLTEtMS04MjEzMg_8b54f2b2-4075-4c3d-bbd4-a05cda3961ea"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ica244ac307be4148a52ded97af82e32d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfNy01LTEtMS04MjEzMg_a1fdd889-d38f-4dca-9267-cfa67192a27f"
      unitRef="usd">66531000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id8f2c7e017a444199ea80ad69ff9dc0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfOC0xLTEtMS04MjEzMg_3f94b807-0eac-4057-ad07-1a93add4db5c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if9e3be485f1040e99231bf20c8737b87_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfOC0zLTEtMS04MjEzMg_86dd6249-0886-409d-856d-f55bde6c7872"
      unitRef="usd">119056000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2f55ae80ed464185acbc13298bd9b539_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfOC01LTEtMS04MjEzMg_20150137-d573-42f1-b682-9dd46a62222a"
      unitRef="usd">119056000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i562efe5dbad445f48582bd754933cf24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfOS0xLTEtMS04MjEzMg_74770736-16d0-48c4-ba17-9e0c0f2d1b63"
      unitRef="usd">66531000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic3300c71f3304f4fabbe2333fa0e6f6a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfOS0zLTEtMS04MjEzMg_9baafffc-9098-4a2a-a0d6-c8de81242ebf"
      unitRef="usd">1652724000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idede8e3136eb484884a82aa3c0a1d084_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RhYmxlOjY3ZjM3ZmRhNzk3YzQ4ODNiZmU5YzE0NjQwNjYzNDFkL3RhYmxlcmFuZ2U6NjdmMzdmZGE3OTdjNDg4M2JmZTljMTQ2NDA2NjM0MWRfOS01LTEtMS04MjEzMg_609587c1-e86c-462e-b698-86b419e764da"
      unitRef="usd">1719255000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i5d00e7f272ad46b9a14aaa1be9bc4934_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfMTgxNw_a3ba4df0-0199-4a22-b0f8-e5b8537806f9"
      unitRef="forward_contract">1</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5d00e7f272ad46b9a14aaa1be9bc4934_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfNTQ5NzU1ODE2NDg4_b58108dd-cd26-49d2-bde4-eabdbf00fd39"
      unitRef="eur">10000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="ica8f66740885481388f5091f3a93fae0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfMTkwMQ_7ff6a84a-f87e-4167-b57b-71ff7856c67c">P3M</us-gaap:DerivativeTermOfContract>
    <us-gaap:GainOnDerivativeInstrumentsPretax
      contextRef="ica8f66740885481388f5091f3a93fae0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfNTQ5NzU1ODE2NDYy_e1e93473-9d61-439d-bf70-796efc1f4ed9"
      unitRef="usd">1500000</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:GainOnDerivativeInstrumentsPretax
      contextRef="i047d415cbf9345cca4b2a12bea7fee45_D20210102-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80Ni9mcmFnOjg0MmFiOTA2MmI3ODQ3NDJiYWZkYzU1NWM2MjU0MTc0L3RleHRyZWdpb246ODQyYWI5MDYyYjc4NDc0MmJhZmRjNTU1YzYyNTQxNzRfNTQ5NzU1ODE2MzEw_c91c304b-ecab-482c-adec-8c2b40ddb0ef"
      unitRef="usd">500000</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RleHRyZWdpb246ZTI4YjRjZTExOGY4NGVmNDlmNzcwMDU0MzQyMDdkMmVfODQ_7dcdec90-123e-4d85-a70f-7c4b3d3e4ccc">INVENTORY&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RleHRyZWdpb246ZTI4YjRjZTExOGY4NGVmNDlmNzcwMDU0MzQyMDdkMmVfODA_c115b0db-e29f-42e5-bb9a-8ccd09f71fa2">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfMS0xLTEtMS04MjEzMg_4634fde5-a570-4d3d-b5e0-745e990ac4cf"
      unitRef="usd">9447000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfMS0zLTEtMS04MjEzMg_164262f6-0c46-4734-9b9e-8a3876165ed9"
      unitRef="usd">8867000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfMi0xLTEtMS04MjEzMg_aadfaf07-12ce-441e-b965-39a086e0e8d1"
      unitRef="usd">39380000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfMi0zLTEtMS04MjEzMg_65bf5017-0148-4624-ac10-125574ca9ba9"
      unitRef="usd">27717000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfMy0xLTEtMS04MjEzMg_51a611cd-b3d6-48ba-8e82-667556cda9a5"
      unitRef="usd">11325000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfMy0zLTEtMS04MjEzMg_3166ced0-0130-4b24-b07c-275d3018cc4e"
      unitRef="usd">12927000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfNC0xLTEtMS04MjEzMg_fc90998a-92e9-493f-a50f-ec133169e29c"
      unitRef="usd">60152000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfNC0zLTEtMS04MjEzMg_825f0919-ceb7-4854-81b7-ee521264c857"
      unitRef="usd">49511000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i0e8f6cf25ef845f4a4e6a6141299a680_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfNy0xLTEtMS04MjEzMg_a2eb5cb5-fa1f-49c7-a3f3-a5c2ed15510f"
      unitRef="usd">26711000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ib058f0cc5ab4445c89f49affa1efcd07_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfNy0zLTEtMS04MjEzMg_8b52668c-56ac-4f0e-a264-32641e6a699c"
      unitRef="usd">27493000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ide600b04f8ca45209f922b07e1285c93_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfOC0xLTEtMS04MjEzMg_136c46b0-5bd2-499b-bd50-536c97d16549"
      unitRef="usd">33441000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i6daa97f735eb4c3cad12840eb32ed958_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfOC0zLTEtMS04MjEzMg_4e87cb3a-1f30-4a47-8820-6356768ac429"
      unitRef="usd">22018000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i6daa97f735eb4c3cad12840eb32ed958_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfOC0zLTEtMS04MjEzMg_b695a512-7b30-4817-9f26-31d40573334a"
      unitRef="usd">22018000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfOS0xLTEtMS04MjEzMg_d3bd2ffa-8149-475f-b2cd-facd970222bc"
      unitRef="usd">60152000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i9c08664821924215a9a380432cc549fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml80OS9mcmFnOmUyOGI0Y2UxMThmODRlZjQ5Zjc3MDA1NDM0MjA3ZDJlL3RhYmxlOjIzZDVhNzhlZjBiOTQ1OTNhNTE4NDIyNWNlMWJlYjc2L3RhYmxlcmFuZ2U6MjNkNWE3OGVmMGI5NDU5M2E1MTg0MjI1Y2UxYmViNzZfOS0zLTEtMS04MjEzMg_f2971c4f-db61-4238-accd-e9bf4798063c"
      unitRef="usd">49511000</us-gaap:InventoryGross>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMzYxOQ_e0448d80-d806-462e-a793-1bf116b6ff15">STOCK-BASED COMPENSATION&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 25, 2022, at the 2022 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The amendment and restatement increased the share reserve under the 2017 Plan by 28,500,000 shares. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022, 31,485,656 sh&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ares were available for grant under the 2017 Plan. The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 2 shares for full value awards, including restricted stock units (RSUs).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2022, we granted 588,862 stock options with a weighted average exercise price of $19.99 per share and a weighted average grant&#160;date fair&#160;value of $8.36&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hare. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were 11,416,151 stock options outstanding and $19.6&#160;million of related unrecognized compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, we awarded to certain employees an aggregate of 1,003,482 (the target amount) RSUs that are subject to a total shareholder return (TSR) market condition (the TSR-based RSUs). The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 1, 2022 through January 3, 2025. Depending on the results relative to the TSR market condition, the holders of the TSR-based RSUs may earn up to 175% of the target amount of shares. 50% of the shares earned pursuant to the TSR-based RSU awards will vest at the end of the performance period, and the remainder will vest approximately one year later, subject to employee&#x2019;s continuous service. These TSR-based RSUs will be forfeited if the market condition at or above a threshold level is not achieved at the end of the performance period on January 3, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the TSR-based RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#x2019;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2022, we granted 5,292,088 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $20.56 per share. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were 11,864,173 RSUs outstanding, including the TSR-based RSUs, and $193.8&#160;million of related unrecognized compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options and service-based RSUs granted to employees during the nine months ended September 30, 2022 have vesting conditions and contractual lives of a similar nature to those described in &#x201c;Note 8. Employee Benefit Plans&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were&#160;5,367,906 performance-based restricted stock units (PSUs) outstanding and $101.0&#160;million of related unrecognized stock-based compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. During the three months ended September 30, 2022, we achieved a performance condition for threshold achievement for 495,886 PSUs granted during 2020 (the 2020 PSUs) and have recognized $9.7&#160;million of stock-based compensation expense related to the 2020 PSUs during the three &lt;/span&gt;&lt;/div&gt;months ended September&#160;30, 2022. For more information about our PSUs, see &#x201c;Note 8. Employee Benefit Plans&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMzYzOQ_0a78209b-16e0-4667-9c6e-21ce16b380f1">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie101975b1642454ca5efd600cefeebb7_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfMy0xLTEtMS04MjEzMg_6ae7038b-3bfd-469a-9a38-14ee70bef8e0"
      unitRef="usd">16438000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b4cfbc3bd5b41628d78e47135e8b32d_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfMy0zLTEtMS04MjEzMg_aa1f3123-1255-4380-8ab7-8f8102aa9c3a"
      unitRef="usd">11487000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i86f9773b234244db921193fc80b4b36e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfMy01LTEtMS04MjEzMg_c525c833-5401-4188-89ed-c845c91c6bc8"
      unitRef="usd">34886000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i00ac7f01c92b4900a09d849019f8bbde_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfMy03LTEtMS04MjEzMg_c6049196-81a5-4435-a499-b98393faea99"
      unitRef="usd">37550000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if9969aa4426549599b32a31f08e5252b_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNC0xLTEtMS04MjEzMg_202fdc8e-9e1d-471d-97e9-7661a15a9cac"
      unitRef="usd">20899000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i00a5e6ea88544cb1abee1be0125a342f_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNC0zLTEtMS04MjEzMg_c3e8d60c-6467-4f99-bcaa-a52f8331b736"
      unitRef="usd">22479000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i017ac814620d4a70b0883a3c64a8d2a4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNC01LTEtMS04MjEzMg_a2a0f5d7-ec53-4500-838f-4e89b0ae04ee"
      unitRef="usd">46832000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i718d736b87a94552b1617644f5ddccec_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNC03LTEtMS04MjEzMg_d4a50e1e-44fd-4987-a608-b8baa65299a9"
      unitRef="usd">59104000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNS0xLTEtMS04MjEzMg_b8e02b64-1fee-49bb-996d-194d06b92939"
      unitRef="usd">37337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNS0zLTEtMS04MjEzMg_5cb21673-edc8-4c5b-987e-f75b41f2d17d"
      unitRef="usd">33966000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNS01LTEtMS04MjEzMg_44eb7adb-3fe2-42d9-bccc-c0f46b3bf5c5"
      unitRef="usd">81718000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOjMxMTY3ZmEyYmMwZDQ1MWI5OTkwYjcxOTMyNTgxZmI1L3RhYmxlcmFuZ2U6MzExNjdmYTJiYzBkNDUxYjk5OTBiNzE5MzI1ODFmYjVfNS03LTEtMS04MjEzMg_b0fddfdb-8953-4da6-a30c-d7af255251f9"
      unitRef="usd">96654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1a2435c09f4c4f918cabd7085d3ea04d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMi0xLTEtMS04MjEzMg_39afa3a0-9438-4957-b188-168d23d5aaa7"
      unitRef="usd">3299000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12f85bf38d0841c2b116c6c5df335710_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMi0zLTEtMS04MjEzMg_2fe3fd99-8e94-4301-a292-e60a5d2c9cc2"
      unitRef="usd">4607000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i01b89020b108466aac157e717fc794ba_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMi01LTEtMS04MjEzMg_be61d16e-08a8-4807-9849-a7d3afccd003"
      unitRef="usd">10470000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc062842cb3848dd809f2e5dabf4b106_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMi03LTEtMS04MjEzMg_a353723d-c581-45a3-b563-d6b8d16d0cf8"
      unitRef="usd">15203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia10e996f6a0045d68c311365d48c8ee0_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMy0xLTEtMS04MjEzMg_7a837628-2584-4c8e-bab7-05cc566a4004"
      unitRef="usd">22233000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ica6583f307a24123ab02aebe68d83ad5_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMy0zLTEtMS04MjEzMg_234f34a0-ca6b-49df-b658-12475845e0fc"
      unitRef="usd">13721000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id7f8b24349b54b9286007abc00e73aca_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMy01LTEtMS04MjEzMg_ebf9be84-ccec-4e33-8613-d466d6303569"
      unitRef="usd">54234000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id60e4edfc8694abe95bc6c4ad0cf0e80_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfMy03LTEtMS04MjEzMg_a861cbf3-caea-4c4b-b7c7-70596ac5cc4b"
      unitRef="usd">40802000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifa1c4a397e174d8ba0fa3e03acd37402_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNC0xLTEtMS04MjEzMg_3f06b92d-762b-43b0-a7a7-06277e60a8cb"
      unitRef="usd">11331000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8a96d01dde304dfb8bbc5a56f6a329e5_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNC0zLTEtMS04MjEzMg_061ed7e8-ec37-427c-a3bf-b13fa8d10752"
      unitRef="usd">14971000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7532b18472654211b7e84b715466a350_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNC01LTEtMS04MjEzMg_90cceb85-3864-4290-bc4c-9199b8f0e3ea"
      unitRef="usd">14621000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7c8d8dce3a7e43c8b39da1d6b4cad521_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNC03LTEtMS04MjEzMg_37096564-e813-44a2-ba4e-65f2ed8700ef"
      unitRef="usd">37616000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i81205acd3f214b2ebe487d5e61a93b20_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNS0xLTEtMS04MjEzMg_c22a5e08-7942-4939-b8e8-36963e5d3869"
      unitRef="usd">474000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic592c97df7804add951c95d5fb5bae90_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNS0zLTEtMS04MjEzMg_c6a5c404-889b-4f17-b314-5b253fe953b4"
      unitRef="usd">667000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9361d6f5134f4f68b7477fcf36e854a1_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNS01LTEtMS04MjEzMg_c0baabde-fe89-4b9a-b50c-a725eb5f3086"
      unitRef="usd">2393000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib5282ce470894117a8f902fb69fc8b98_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNS03LTEtMS04MjEzMg_c928ab5c-595e-4818-a89d-f739a144f5ec"
      unitRef="usd">3033000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNi0xLTEtMS04MjEzMg_14c0d988-dde5-456d-96e1-2ed35cf872cf"
      unitRef="usd">37337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNi0zLTEtMS04MjEzMg_5e9378b7-2475-4e0e-889a-bfaea64df3c9"
      unitRef="usd">33966000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNi01LTEtMS04MjEzMg_e808b7b7-de95-45f7-90f1-ab3f07965c34"
      unitRef="usd">81718000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmJjYzNjZjQ5ZDUzNDRkMThhZmYwMGMyMjMxZDJiYzdlL3RhYmxlcmFuZ2U6YmNjM2NmNDlkNTM0NGQxOGFmZjAwYzIyMzFkMmJjN2VfNi03LTEtMS04MjEzMg_e039f76b-89fa-44de-8f60-90e0278f67af"
      unitRef="usd">96654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="if19df687aaf9496496468698046b7ca9_D20220525-20220525"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNjAy_e79a2346-2d6b-4ab1-aa0d-2416be79810e"
      unitRef="shares">28500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNDM5ODA0NjUxNTkzMA_58383855-4f43-43ae-873d-9a98811c1796"
      unitRef="shares">31485656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNzQz_d0b987ce-d542-4e9d-b5ce-a6eaafa64178"
      unitRef="shares">1</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfODA1_2eeb367c-15f3-4ea9-b0bc-8a9418baa700"
      unitRef="shares">2</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4MzUx_7568ae58-e158-467d-974a-6bbdda268bf9"
      unitRef="shares">588862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfOTY1_3cccc010-4b07-46db-9c5f-677191be7709"
      unitRef="usdPerShare">19.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMTAyNg_3560f72c-3c9a-4d20-bd29-9b0f0a3f313a"
      unitRef="usdPerShare">8.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4Mzgw_2fbf8883-96e7-4cc5-b946-ac1b71b14163"
      unitRef="shares">11416151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4NDA5_c6105cc6-85db-482b-8e2f-c33bcc37d63a"
      unitRef="usd">19600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3fc516136b174c0d801418fc499e2574_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMTIwNg_7cad7fd2-febf-45c5-800c-d8d4611deebf"
      unitRef="shares">1003482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i3fc516136b174c0d801418fc499e2574_D20220301-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMTY0NQ_758052e3-9bb3-447e-9980-fc6cd4ab4c5e"
      unitRef="number">1.75</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia453aac57d974fd59f265a307e4added_D20220301-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMTY4MA_ad3d7d43-99a6-4a1b-8de2-261a15927185"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia453aac57d974fd59f265a307e4added_D20220301-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMTgzMQ_a5d78e44-0dc1-4773-ac77-877410a89e3b">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMzY2Mw_9e3e5e5e-3e7a-4963-a800-712bfaf20f85">We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $33.17 per share for the TSR-based RSUs:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibd464ef4ba6e4d6092da7bde626f4870_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfMjE2MQ_8c97f439-a761-4be3-b0c6-ef9bea68a53f"
      unitRef="usdPerShare">33.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharePrice
      contextRef="ia156218652c64c5d967262937d5d66a6_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmFjYzllMTUxODYyZjQzZGRiYTA5MTAwZTM1N2JmNTBlL3RhYmxlcmFuZ2U6YWNjOWUxNTE4NjJmNDNkZGJhMDkxMDBlMzU3YmY1MGVfMC0xLTEtMS04MjEzMg_beab1213-263e-4edf-9c61-55d1a1c63cb8"
      unitRef="usdPerShare">20.70</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ibd464ef4ba6e4d6092da7bde626f4870_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmFjYzllMTUxODYyZjQzZGRiYTA5MTAwZTM1N2JmNTBlL3RhYmxlcmFuZ2U6YWNjOWUxNTE4NjJmNDNkZGJhMDkxMDBlMzU3YmY1MGVfMS0xLTEtMS04MjEzMg_b3c06552-d76b-4b8f-81e5-514d5acf059c"
      unitRef="number">0.4685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibd464ef4ba6e4d6092da7bde626f4870_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmFjYzllMTUxODYyZjQzZGRiYTA5MTAwZTM1N2JmNTBlL3RhYmxlcmFuZ2U6YWNjOWUxNTE4NjJmNDNkZGJhMDkxMDBlMzU3YmY1MGVfMi0xLTEtMS04MjEzMg_c76df5a7-27a1-43d8-bae7-3209a4684275"
      unitRef="number">0.0159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibd464ef4ba6e4d6092da7bde626f4870_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RhYmxlOmFjYzllMTUxODYyZjQzZGRiYTA5MTAwZTM1N2JmNTBlL3RhYmxlcmFuZ2U6YWNjOWUxNTE4NjJmNDNkZGJhMDkxMDBlMzU3YmY1MGVfMy0xLTEtMS04MjEzMg_25583fe7-9178-4092-aa8a-3d1d03bf2e0e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id7f8b24349b54b9286007abc00e73aca_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4NDM3_45988936-8c7e-4aba-bc55-3b157948938d"
      unitRef="shares">5292088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id7f8b24349b54b9286007abc00e73aca_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4NDU4_c61bde3f-b012-43f1-992d-500f97cc7509"
      unitRef="usdPerShare">20.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i538b59a91622490788eb54a07ebcd4bb_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4NDgw_c7f7b70f-5812-4e6d-9785-7c9a8585fec4"
      unitRef="shares">11864173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i538b59a91622490788eb54a07ebcd4bb_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4OTk2_e049bc8f-b444-43b0-b8af-d290f863febe"
      unitRef="usd">193800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie4cd574ea19b44f6a937ed92eb65fbdd_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE4NTIz_fb62df27-bf73-4442-b4db-b1e168eeca1e"
      unitRef="shares">5367906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ie4cd574ea19b44f6a937ed92eb65fbdd_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNTQ5NzU1ODE5MDM1_adcd6e7e-9928-43ea-a01f-84d66d043c4a"
      unitRef="usd">101000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie7e73b13cdc64519849d7dc7c3a4bab1_D20220702-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNDM5ODA0NjUxNTk3OA_63282d1b-e04c-42b9-8240-a754377071e7"
      unitRef="shares">495886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7e73b13cdc64519849d7dc7c3a4bab1_D20220702-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81Mi9mcmFnOjI4YzE5YjA1NTdiYTQ2ZTI5ZmZkYmNhNTkwYjNkM2ZhL3RleHRyZWdpb246MjhjMTliMDU1N2JhNDZlMjlmZmRiY2E1OTBiM2QzZmFfNDM5ODA0NjUxNTk1Ng_34de550d-9307-4a21-b68b-39ff76513361"
      unitRef="usd">9700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81NS9mcmFnOjAzYjk0YzE4YWFmMjQ0OTE4N2ZmMTc5ZDc2MjllY2Y4L3RleHRyZWdpb246MDNiOTRjMThhYWYyNDQ5MTg3ZmYxNzlkNzYyOWVjZjhfNTIy_6e7565d3-a96b-4fbc-b156-3a82690fc872">PROVISION FOR INCOME TAXES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rates for the three and nine months ended September&#160;30, 2022, were 20.5% and 20.1% respectively, as compared to 28.3% and 22.8% for the corresponding periods in 2021. The effective tax rates for the three and nine months ended September&#160;30, 2022 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, which were partially offset by state taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rates for the three and nine months ended September&#160;30, 2021 differed from the U.S. federal statutory tax rate of 21% primarily due to non-deductible executive compensation, which was partially offset by excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81NS9mcmFnOjAzYjk0YzE4YWFmMjQ0OTE4N2ZmMTc5ZDc2MjllY2Y4L3RleHRyZWdpb246MDNiOTRjMThhYWYyNDQ5MTg3ZmYxNzlkNzYyOWVjZjhfNDM5ODA0NjUxMzQzMQ_40af2db2-136f-4077-814c-a596e14baa94"
      unitRef="number">0.205</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81NS9mcmFnOjAzYjk0YzE4YWFmMjQ0OTE4N2ZmMTc5ZDc2MjllY2Y4L3RleHRyZWdpb246MDNiOTRjMThhYWYyNDQ5MTg3ZmYxNzlkNzYyOWVjZjhfNDM5ODA0NjUxMzQ2OQ_43fedaae-e3ae-4048-8ed1-480f86555602"
      unitRef="number">0.201</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81NS9mcmFnOjAzYjk0YzE4YWFmMjQ0OTE4N2ZmMTc5ZDc2MjllY2Y4L3RleHRyZWdpb246MDNiOTRjMThhYWYyNDQ5MTg3ZmYxNzlkNzYyOWVjZjhfNTQ5NzU1ODE0NDI4_16182108-9c2a-4da0-8003-96f45e1cce34"
      unitRef="number">0.283</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81NS9mcmFnOjAzYjk0YzE4YWFmMjQ0OTE4N2ZmMTc5ZDc2MjllY2Y4L3RleHRyZWdpb246MDNiOTRjMThhYWYyNDQ5MTg3ZmYxNzlkNzYyOWVjZjhfNTQ5NzU1ODE0NDM1_1bd58953-28ee-4161-8cdf-572092e863c4"
      unitRef="number">0.228</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RleHRyZWdpb246MDI4YzBhZWIyZDczNDQ0ODg3ODdmODk5MGRhMTQ0ZGNfNzQ3_b97b3bfe-e550-4b85-8940-6007c7dec559">NET INCOME PER SHARE&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities included outstanding stock options, unvested RSUs, including TSR-based RSUs, PSUs and ESPP contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RleHRyZWdpb246MDI4YzBhZWIyZDczNDQ0ODg3ODdmODk5MGRhMTQ0ZGNfNzU3_384bf119-098b-4c4c-b87e-05312b094380">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy0xLTEtMS04MjEzMg_2a9c3c86-a970-48b3-b90d-27c72602770d"
      unitRef="usd">73210000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy0xLTEtMS04MjEzMg_44c62d4f-e19b-4517-b1c2-6544e824323f"
      unitRef="usd">73210000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy0zLTEtMS04MjEzMg_20a6a81f-7686-48c8-88fb-a619a91414e4"
      unitRef="usd">38204000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy0zLTEtMS04MjEzMg_88e58389-3777-429d-af18-9ce3341b3d92"
      unitRef="usd">38204000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy01LTEtMS04MjEzMg_338bdceb-78be-467c-9e1f-2deacafebca5"
      unitRef="usd">212455000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy01LTEtMS04MjEzMg_c0a5fa9f-2265-433d-a267-c0311a320ee9"
      unitRef="usd">212455000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy03LTEtMS04MjEzMg_c96f2e37-50f5-46e9-9e5d-11a48b15f9fe"
      unitRef="usd">135897000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMy03LTEtMS04MjEzMg_e5815647-8297-4b41-8575-479cbf04b57c"
      unitRef="usd">135897000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNS0xLTEtMS04MjEzMg_febdea61-4101-4a5b-ab9d-a7a48040e83a"
      unitRef="shares">322148000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNS0zLTEtMS04MjEzMg_b47dcaaa-caad-4421-bf5a-82f44ca8542f"
      unitRef="shares">315380000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNS01LTEtMS04MjEzMg_18116302-0c27-4db1-9bf6-4fff70cf994d"
      unitRef="shares">320949000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNS03LTEtMS04MjEzMg_093674d5-4de6-4a90-a35f-1892dae4da1e"
      unitRef="shares">313990000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNi0xLTEtMS04MjEzMg_b0442bf3-137e-417b-8c56-7e01c49500a1"
      unitRef="shares">2918000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNi0zLTEtMS04MjEzMg_6ffba483-110f-4d3f-bbf1-6ccd7df026e5"
      unitRef="shares">6642000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNi01LTEtMS04MjEzMg_2de4d9c7-bfab-4b81-b72c-2378e36b5abc"
      unitRef="shares">3471000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNi03LTEtMS04MjEzMg_9b532cf4-a0e9-4a86-9272-5f72f7a863b9"
      unitRef="shares">8094000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNy0xLTEtMS04MjEzMg_11ab27e6-d02b-4b9a-97eb-20ef3217982b"
      unitRef="shares">325066000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNy0zLTEtMS04MjEzMg_f73b231d-c4fc-4cb4-9b7d-6f69d0f935d7"
      unitRef="shares">322022000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNy01LTEtMS04MjEzMg_04927659-821a-4f5c-8113-a745a6b566e0"
      unitRef="shares">324420000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfNy03LTEtMS04MjEzMg_d07b041c-8e17-4835-9875-296ab2c754b0"
      unitRef="shares">322084000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfOS0xLTEtMS04MjEzMg_bd1ba8dd-5906-4063-a69f-091707145122"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfOS0zLTEtMS04MjEzMg_0ca9ca3c-bd33-4050-a864-e9c0a12ef429"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfOS01LTEtMS04MjEzMg_f92e325c-a284-434c-8965-ee971ceccec3"
      unitRef="usdPerShare">0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfOS03LTEtMS04MjEzMg_058b2932-3a92-4f53-ae9f-01a1c15dcb6e"
      unitRef="usdPerShare">0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if9baae3c0c274839b462d39623feea2d_D20220702-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMTAtMS0xLTEtODIxMzI_53bd56f6-f789-41ab-8142-012d7347b2d4"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaa760b88a73b49e1a3c52459273419db_D20210703-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMTAtMy0xLTEtODIxMzI_cee634d2-c31f-443f-9b3f-05b5a2688e2d"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMTAtNS0xLTEtODIxMzI_00b15a35-a947-4107-973b-652af1e1528f"
      unitRef="usdPerShare">0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0c6cc1263d194d89bfde3114f81f2e1d_D20210102-20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjdlMTU2ZjYzMDllMTQ5MjA4NTRjYzQ4NGZkYTRmNTgzL3RhYmxlcmFuZ2U6N2UxNTZmNjMwOWUxNDkyMDg1NGNjNDg0ZmRhNGY1ODNfMTAtNy0xLTEtODIxMzI_c030024a-8cb9-48de-93c5-caef1d683151"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RleHRyZWdpb246MDI4YzBhZWIyZDczNDQ0ODg3ODdmODk5MGRhMTQ0ZGNfNzUy_efaf7690-1731-491b-941a-327caf97ef25">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaa050e767b3f498a8437c364816242c7_D20220702-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjVhYTRiNjQwODU3MDQ0ODVhNjdjZmY3MmUxZDU1ODkxL3RhYmxlcmFuZ2U6NWFhNGI2NDA4NTcwNDQ4NWE2N2NmZjcyZTFkNTU4OTFfMi0xLTEtMS04MjEzMg_21dc9ec0-99ed-44e1-a63a-de78be29e145"
      unitRef="shares">15059000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3bebe181ca4a4b9cb14ab2651a68a39b_D20210703-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjVhYTRiNjQwODU3MDQ0ODVhNjdjZmY3MmUxZDU1ODkxL3RhYmxlcmFuZ2U6NWFhNGI2NDA4NTcwNDQ4NWE2N2NmZjcyZTFkNTU4OTFfMi0zLTEtMS04MjEzMg_646df0e6-df65-4d78-89a4-b6138a20ae65"
      unitRef="shares">20346000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id5af708b788b494aaa583b5ab133bc7f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjVhYTRiNjQwODU3MDQ0ODVhNjdjZmY3MmUxZDU1ODkxL3RhYmxlcmFuZ2U6NWFhNGI2NDA4NTcwNDQ4NWE2N2NmZjcyZTFkNTU4OTFfMi01LTEtMS04MjEzMg_573f7012-11c3-4e95-9dbe-59eb9f25ed5d"
      unitRef="shares">15311000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7a9356922a004cbe84b4a80ddb5be44e_D20210102-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml81OC9mcmFnOjAyOGMwYWViMmQ3MzQ0NDg4Nzg3Zjg5OTBkYTE0NGRjL3RhYmxlOjVhYTRiNjQwODU3MDQ0ODVhNjdjZmY3MmUxZDU1ODkxL3RhYmxlcmFuZ2U6NWFhNGI2NDA4NTcwNDQ4NWE2N2NmZjcyZTFkNTU4OTFfMi03LTEtMS04MjEzMg_813e4077-26a3-4507-a00b-2b9bca2b421a"
      unitRef="shares">14213000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMjc0ODc3OTA5Mzc5OQ_d6d2eb8c-fa9b-47fc-a339-daa02653247a">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Build-to-Suit Lease and Headquarters Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, the office building (New Premises) associated with our October 2019 build-to-suit lease agreement (Build-to-Suit Lease) was substantially completed. The New Premises is 220,517 square feet and is in Alameda, California, adjacent to our existing corporate headquarters. The Build-to-Suit Lease term is 242 months, includes two five-year options to extend the term of the lease and a one-time option to terminate the lease after 180 months. In addition to the monthly lease payments, currently estimated at $0.7&#160;million, subject to an annual increase of 3% during the Term, we are also &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;responsible for paying operating expenses related to the New Premises. On April 15, 2022, the lease commenced for the New Premises. We determined the classification of the lease was an operating lease. Upon commencement of the lease, we recognized a right-of-use asset of $160.9&#160;million inclusive of $44.9&#160;million for the cost of the tenant improvements in excess of the allowance provided by the lessor and an operating lease liability of $116.0&#160;million discounted over 180 months using our estimated incremental borrowing rate of 4.9%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, we entered into the seventh amendment to the lease for our corporate headquarters located on Harbor Bay Parkway, Alameda, California (the Alameda Lease). The May 2022 amendment to the Alameda Lease (the Seventh Lease Amendment) provides, among other things, for the expansion of the premises under the Alameda Lease by 34,745 square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Expansion Space). The term for the 1751 Expansion Space will run coterminous with the term of the Alameda Lease for the existing space. In connection with the Seventh Lease Amendment, we remeasured our lease components under the Alameda Lease relating to the existing premises using an incremental borrowing rate of 5.0%. As of June 1, 2022, we have taken possession of the 1751 Expansion Space, and accordingly we have adjusted our right-of-use asset and liability by $4.3&#160;million.&lt;br/&gt;&lt;br/&gt;For more information about our Leases, see &#x201c;Note 11. Commitments and Contingencies&#x2014;Leases&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSN I ANDA Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (individually and collectively with certain of its affiliates, including MSN Laboratories Private Limited, referred to as MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#x2019;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#x2019;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#x2019;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#x2019;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#x2019;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. The two lawsuits comprising this litigation (collectively referred to as MSN I), numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#x2019;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#x2019;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#x2019;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#x2019;s counterclaims with respect to U.S. Patent No. 9,809,549. In our MSN I complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties have narrowed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN has, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claim 1 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial for MSN I occurred in May 2022, and a judgment is expected during the fourth quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSN II ANDA Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; arising from MSN&#x2019;s further amendment of its ANDA filing with the FDA. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patents No. 11,091,439, 11,091,440 and 11,098,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are invalid and not infringed. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 7, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#x2019;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,298,349 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(pharmaceutical composition). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#x2019;s further amendment of its ANDA Filing with the FDA. On August 9, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 11,298,349 are invalid and not infringed. The two lawsuits comprising this litigation (collectively referred to as MSN II), numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated in October 2022 and involve Exelixis patents that are different from those asserted in the MSN I litigation described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#x2019;s submission of its ANDA constitutes infringement of certain claims relating to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if those claims are not found to be invalid, and (ii) upon approval, MSN&#x2019;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#x2019;s ANDA product prior to the expiration of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; would also infringe certain claims of each patent, if those claims are not found to be invalid. In our MSN II complaints, we are seeking, among other remedies, equitable relief enjoining MSN from infringing this patent, as well as an order that the effective date of any FDA approval of MSN&#x2019;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032. A bench trial for MSN II has been scheduled for October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Teva ANDA Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received notice letters from Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#x2019;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book. Teva&#x2019;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#x2019;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed. On September 17, 2021, we filed an answer to Teva&#x2019;s counterclaims. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#x2019;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,298,349 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(pharmaceutical composition). On September 2, 2022, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#x2019;s amended ANDA filing with the FDA. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873, 10,039,757 and 11,298,349, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from infringing these patents. On September 30, 2022, the parties filed a stipulation to consolidate the two lawsuits, numbered Civil Action Nos. 21-00871 and 22-01168, and to stay all proceedings, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which was granted by the Delaware District Court on October 3, 2022. Following a similar order granted by the Delaware District Court on February 9, 2022 to stay all proceedings with respect to Civil Action No. 21-00871, this case remained administratively closed, and Civil Action No. 22-01168 was administratively closed on October 3, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ia6b335f201824eb588620f7043a28af2_I20220430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMjY5_ec6f8455-5bef-4a88-ba6d-ae105c01a763"
      unitRef="sqft">220517</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia6b335f201824eb588620f7043a28af2_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMzk2_6c2aeae4-2756-4b56-aee0-a25794b39106">P242M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <exel:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i937aea8377a0438cbd48a2aebc5ce5f0_D20220402-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfNDA5_0004e1e4-e0f0-4594-b2b0-65242d2245d5"
      unitRef="segment">2</exel:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia6b335f201824eb588620f7043a28af2_I20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMTM5OTU_9024a157-84f6-4460-9ed2-2744f5cdbfc6">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod
      contextRef="i937aea8377a0438cbd48a2aebc5ce5f0_D20220402-20220430"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfNTEz_ab12c7ae-97eb-43aa-9e28-9e2e4324293c">P180M</exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment
      contextRef="i937aea8377a0438cbd48a2aebc5ce5f0_D20220402-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfNTgz_3a743fc7-e74d-4bab-8589-09db03c55161"
      unitRef="usd">700000</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage
      contextRef="i937aea8377a0438cbd48a2aebc5ce5f0_D20220402-20220430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfNjIw_85745324-0e26-4efe-9029-accffbe32b29"
      unitRef="number">0.03</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie7222e9059aa47e8a777492f23afd218_I20220415"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfOTI0_21551c67-ba0a-4bcc-b7ac-62b38aaaefcd"
      unitRef="usd">160900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:TenantImprovements
      contextRef="ie7222e9059aa47e8a777492f23afd218_I20220415"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfOTQw_04e28aef-2d3e-480e-89f4-0cda9e2a9fbc"
      unitRef="usd">44900000</us-gaap:TenantImprovements>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="ie7222e9059aa47e8a777492f23afd218_I20220415"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMTA2OQ_38ff7bdc-2654-428a-b7a0-2f5f3a9bd679"
      unitRef="usd">116000000</exel:TenantLeaseImprovementsAllowance>
    <exel:OperatingLeaseLiabilityDiscountedPeriod
      contextRef="if12649f24e1842e8bf8c979b733e75c6_D20220415-20220415"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMTA4OA_cdc22f89-c60d-4c44-81a0-263fa0157c8f">P180M</exel:OperatingLeaseLiabilityDiscountedPeriod>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie7222e9059aa47e8a777492f23afd218_I20220415"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMTE0MQ_f6d73bd6-c4f7-40cc-81ed-b5a21d941de2"
      unitRef="number">0.049</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ie0dc3aa0d4b14df392ed5c64240f0335_I20220531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMTQ3Mw_56c7793b-52ed-4220-952a-7036876ffd72"
      unitRef="sqft">34745</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i0f6fd2e746f24312a8f2a7091b4e91e5_I20220531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMTg5MQ_2f8d227a-5620-42b1-92e4-d87e0114f836"
      unitRef="number">0.050</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseLiability
      contextRef="id8f643a473a8490da5ebb398751eb409_I20220601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMjA0MA_22d873af-bf35-45f2-91d2-612b9ece51ba"
      unitRef="usd">4300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id8f643a473a8490da5ebb398751eb409_I20220601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMjA0MA_622510ba-d7a5-4703-bcc8-c424f71035a7"
      unitRef="usd">4300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <exel:LossContingencyNumberOfLawsuitsConsolidated
      contextRef="i09a2105efdab4080a91d211b2377ed70_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfNDk1OQ_cf94eaf7-edc3-4945-84ec-ee660c7e3108"
      unitRef="lawsuit">2</exel:LossContingencyNumberOfLawsuitsConsolidated>
    <exel:LossContingencyNumberOfLawsuitsConsolidated
      contextRef="i02f61410057849a2be1a95901d4749f3_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMjc0ODc3OTA5Mzc5Nw_7a1dca06-e20b-4cc4-b4e3-5fc7e6f2b043"
      unitRef="lawsuit">2</exel:LossContingencyNumberOfLawsuitsConsolidated>
    <exel:LossContingencyNumberOfLawsuitsConsolidated
      contextRef="i37a45756c9954dffb1597b6666f619f3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82MS9mcmFnOmY3NTQ4NGRlNTA3NzRhNTdhMjM4ZTAyMjQzZTZlY2M5L3RleHRyZWdpb246Zjc1NDg0ZGU1MDc3NGE1N2EyMzhlMDIyNDNlNmVjYzlfMjc0ODc3OTA5Mzc5OA_2b36055c-8994-4e28-b53c-bf6a9cb47414"
      unitRef="lawsuit">2</exel:LossContingencyNumberOfLawsuitsConsolidated>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfMjc0ODc3OTA4MjkxNQ_f101c713-e313-4eac-9bc0-6937632b3f32">SUBSEQUENT EVENTS&lt;br/&gt;&lt;br/&gt;&#160;&#160;&#160;&#160;Cybrexa Therapeutics, LLC (Cybrexa)&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, we entered into an agreement with Cybrexa Therapeutics, LLC (Cybrexa), which provides us the right to acquire CBX-12 (alphalex&#x2122; exatecan), a clinical-stage peptide-drug conjugate (PDC) that utilizes Cybrexa&#x2019;s proprietary alphalex technology to enhance delivery of exatecan to tumor cells. Under the terms of the agreement, we will pay an upfront fee of $60.0&#160;million for a warrant entitling us to the right to acquire the Cybrexa affiliate that controls CBX-12 and related assets, and to fund certain development and manufacturing expenses incurred by Cybrexa to advance CBX-12 during the warrant period. Cybrexa will continue the development of CBX-12 according to an agreed development plan, including phase 1 studies, and may be eligible to receive up to $65.0&#160;million in additional development milestone payments, during the warrant period. We may exercise the warrant for up to $300.0&#160;million based upon our evaluation of a pre-specified clinical data package to be delivered by Cybrexa. Following exercise of the warrant, Cybrexa would be eligible to receive up to $277.5&#160;million in additional payments upon achievement of further development, regulatory and commercial milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sairopa, B.V. (Sairopa)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, we entered into an exclusive option and license agreement with Sairopa, B.V. (Sairopa). Under the terms of the agreement, we will make an upfront payment of $40.0&#160;million for an option to obtain an exclusive, worldwide license to develop and commercialize ADU-1805 and other anti-SIRP&#x3b1; antibodies, and for certain expenses to be incurred by Sairopa in conducting phase 1 clinical studies of ADU-1805. Sairopa is eligible to receive additional development milestone payments during the option period totaling up to $97.5&#160;million. Following the completion of the clinical studies, we may exercise the option for $225.0&#160;million based upon our evaluation of a pre-specified clinical data package to be delivered by Sairopa. Following the exercise of the option, Sairopa would be eligible to receive up to $465.0&#160;million in additional development, commercial, and net sales milestone payments, as well as tiered royalties on future net sales of products.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="ic2fe2d2458b143ac93cfc5d3dd846556_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MTUw_ececcf4a-5e6d-477b-b11a-208aaa90cc0e"
      unitRef="usd">60000000</exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
      contextRef="ib2acd12af1dc4ed6b0cbbf446ab05dc7_I20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MTY1_eb3c6a48-4448-44ee-ac93-225d467d22a3"
      unitRef="usd">65000000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments>
    <exel:CollaborativeArrangementMaximumAmountOfWarrantExercise
      contextRef="ic2fe2d2458b143ac93cfc5d3dd846556_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MTgw_e86b3436-6331-4176-8e63-7ad3bbe39462"
      unitRef="usd">300000000</exel:CollaborativeArrangementMaximumAmountOfWarrantExercise>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments
      contextRef="ic2fe2d2458b143ac93cfc5d3dd846556_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MTk2_4129d04a-9615-4b6c-a41f-0645ce4d1efc"
      unitRef="usd">277500000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments>
    <exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i2df8f1634dda4f61b08a6be87c82e98b_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MjQz_be38382c-f3a0-4ee7-a834-91320dcf6e1a"
      unitRef="usd">40000000</exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
      contextRef="ia221d1d4870d45218498c32c441b4569_I20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MjI4_abcb6eb5-b824-4c71-918f-d69dbeb05559"
      unitRef="usd">97500000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsExerciseAmount
      contextRef="i2df8f1634dda4f61b08a6be87c82e98b_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MjEy_c19b4821-41e1-4850-9789-f7de20c02363"
      unitRef="usd">225000000</exel:CollaborativeArrangementRightsAndObligationsExerciseAmount>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments
      contextRef="i2df8f1634dda4f61b08a6be87c82e98b_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0OWRhNTg2MTc2NzRkMjA4OWNhMjgxMWI5M2FhMTQyL3NlYzo1NDlkYTU4NjE3Njc0ZDIwODljYTI4MTFiOTNhYTE0Ml82NC9mcmFnOjRlY2JhMWRiODg0MjRlNzhhODk1NjhlYTM3ZThkYmVlL3RleHRyZWdpb246NGVjYmExZGI4ODQyNGU3OGE4OTU2OGVhMzdlOGRiZWVfNTQ5NzU1ODI3MjU4_62bf1b7b-387e-4d49-9916-46c41852462c"
      unitRef="usd">465000000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M=E L"MD8EN/#V04JW4JT8EUY\LGFK23):3K%[# CN4]\D9'?2)C@#ICA055
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M=">V6C0KH8:%>>J/SGN[6U$</]LW/^? "-U6]%WPVIEFS%8 C$[9S&5$/)S
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MG;(EKMC&"S(X<OP39\C8Z2&R4[;8*5OBBFV\"D-K@'_V)!D;SHA]GX9J/V#
M89\@%*B5P'"8+)U^J+4$!F 04"^8L,EXZ FPO2?X,U\U+:]=M=/39*=LL5.V
MQ!7;>#&&G@7;>Q9[&7#:ISAEBYVR):[8QJLP]"G8WJ>\H SHI\V$DI"J5<!P
M*!WYD=HJ&V (DT@[ C/AD!_Z$R8=#_T)MO<GRZ8GN>?=$2=H)E06A=H^ U;&
M5R>C2[;8*5OBBFV\-D,#A>T-E+TD.&V/G++%3MD25VSC_^$?VB-B;X]^7!)Z
M@O&3/ Q48V"">;[6LQM@)")4=04&6"0KAWHJ/C]Y"V;+JG7[^E$M6_%]*;KW
M'(Z_'E]Q^M"^V*/\?HTNELCP>XPNDNX%IH&^>Y_J4UJM\[(&!7N0MX+G@:Q>
M5?>*4G<A^*Y]!^>>"\&W[=<-2S-6-0#Y]P?.Q?-%<X/CBV*+_P!02P,$%
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MY3S&F!Q1=XOU1/&-:8>67&%S988Y-M@@- "_KSA7AXG>H&W9DW\!4$L#!!0
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M&<YVD$8 W^="Z.W!**C_+<1_ %!+ P04    "  ,@F%541I&KT\)  "03
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MH&O06_R6\^?F[+77W<K'JOK47;S;W,[\KD>\X.NV@\C$OR>^Y$71(8E^_#F
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MR@^T@0$J)H"BI:!H['I$9")&.0';Y007A0?K]?M<K'6QK]("67.O0-'2B??
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MA26(";8S>-6_$N/1Z11Z_/X;6.^'YZ_%?M<M!Z(BAQ/,FL/)/S);$4H /&7
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M31B 6(T>M>T2(5K!*^DN X(N$(T UVIMMX0!"RFO<,+<V8)3LF5L$H03F2R
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MA5_@PY?*EORK=V(K]"[\<0EN5XX6X#U=ES1?Z(#VOT&<_ =02P,$%     @
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M2C(VQ^D%IYUSJB],&,NG;5WC,*IN0N*@5=+H]8TXM[+-B1SF6@GHE1D@P92
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M?)N3K^XO4O<4)-#T:_^7QG8^._OE_9N/?_^;[FX.,#<U$C>(K6G<#0S _EY
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M*%\7K%%AXD57<+K 5G<XUIW;B61!T9$!HL!7Z8!(NLY.7:T \M0M"? E(V!
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M=K\;^!>K%NY;_5A9J^;N<29X*3018'^BE.U>Z(+UCS?7_P502P,$%     @
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M5CUO-+[K'&7KJM*&Y*VV\+MS1$7#E&XIY'40Z79;Y$;)-6(& A%#'[.G1Z_
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M;C^.@&[#8;% TUX)G&&VC21U)($;OJ'7Z- (+BT<P3#L=/HT#L)!KP_W5)!
MM*71&5H+Z3!,!S&P?MA/^G NE*"'F\-*Z]Q"DH0IZT+"PB'KPZUV7!)1+PZ3
M+J-)9QAVDP1F7'*5(<SKCI5);JU8BHS[$A_!:64,.852F[KFA<ID18_3BQ#M
M(1P!ZY&"Q$_Z86>8PC>M5I_(1;$7J>F@#,@VA_9$1VY2,IL 8V&<#-X4O.]A
M1*_JM4"SJKN2I<NIE&M*MXVVC>^DJ?>7]*9K7G*S$LJ"Q"5!X^-^-P#3=*)F
MX7195_]".^HE]71-S1N-3Z#O2ZW=;N$W:/\.IG\!4$L#!!0    (  R"855
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M=ACPAD_@_9$''Z3-E;$M(?PX7UA'_'G\W">Y0SS:C^BOS)EM1([CB.^$17K
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MZ!+WT3-])M4+%*O*ZE@ 12L+GY^]?O_NXN-__PWV1YY$FT:T_O*GV7@T_9$
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M<B2V)T,13:+H&;SMSL?M@+?]4A_%GR<+YRTRXJ_'W*W1IH^C<96\<Z6,Z7B
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M;(;XX;C >Q3]1F@2A,/9T<#S3$ HRQU[/JX4DTTE'V2U15T]X;!UE8:8H&]
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M"Y!,"1@^2$,P;LC^R#>\86@,8I\1"1?0%7HQ.#["9)C\^L/N2 9D?09D;\Z
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M30OP^T(INWLA!?T7Q>M_ U!+ P04    "  ,@F%5_-!I_)D#  #\"   &0
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M^@2B\PF8C_%:M6P+,Z<UL>0C./.OO_(3[[L+]**17G0)?;[&C[OH:C"IG[3
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M#G+<D55(9*Z#K9$LE,B@BS$:_XHIT2$K0 X>F85YM"N;DW)3;X<S4/]4V6S
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MCAYHL:<"O <?U+*\Y2S9KR1HNJ-4D,V&TPV1- $/WQK$VXA*DF;BG6)^OH_
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MWR[D"DIT!F6$HW :XFXXLP;.[+_.K5[[JCVXM0IT@9F=@0DG,)IU0X&!%>#
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MY+2IH3U:XT%NXQDF:.=?)&@<];W-(>L@R.T@0Q7M-3P!6T_ %SY=+BH:/C<
M&$Q0U/,-BZT%8*=87Y:T.OZEI 5A3UTKXM@MXD,E#9]+^V@6S69]@%I[3&YM
M'R9I==+V+@R&0?#M2[;?VEC4?>[*[5,)RD_4:H^QN=ILT=Y6&Y/V\6I_]Z/^
MRF6Y!"G=ZM#@>JJI$-66:76B^*'<IGSD2I-:'NZIGGUA'M#WMYRKYQ-3H-FX
M7OX+4$L#!!0    (  R"857U1IC>700  (X7   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;*U8:X^;.!3]*Q9;K5JI'=[DL4FDF0#:2JUV--/N?G;
M2:P!F[6=I+N_?FU@R ,/2K;^$H*Y]QQS#G[=V8&R%[Y%2( ?94'XW-H*44UM
MFV=;5$)^1RM$Y),U9244\I9M;%XQ!/,ZJ2QLSW$BNX286(M9W?;(%C.Z$P4F
MZ)$!OBM+R/YY0 4]S"W7>FUXPINM4 WV8E;!#7I&XGOUR.2=W:'DN$2$8TH
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M(PWV5C?,\#$#90-P?2NE>9S8#9KG,?H+4$L#!!0    (  R"857$K;3:O 0
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M%HU)TU [M@_3/ICDMK%P[&"[+?S[73NAM"44D*I*C1V?<W)]3F*[NY3J3F<
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MZBM_^(OM Z*UOP5/R^8O>-ACO1%8;,J*9WMCR2!+\MW_^-<^$4<&D%@,T-X
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M)$Y!$1=,&&D.JI%#>6L'K%02XI?8)D"G^/;.P4#>VCE00@S=2GRZ!4%=8,.
M(-2M;P,N(C3TH.6^5&(,>ZJQM0E!768UECJ$( M#I</0+<1]NI NMV-\M)W:
MLS2@;"R5($.GEIUJ0(%AF7%(NSM" ZY>9F);9J6%T"V&,RX*+N**@3FW'4*<
M'GI7WD#>VO$J:871BW0?IV+WSL% WMK'-"7?R"W?I[L/TM78E[M3V-T &7"4
MP""P[#"0DFWDENWG=Q^D*W.W^Q@@8>!;*!Z==MW"W:/][#VU-S=R]T"[1$TX
M/[#T(*0D%[E/INX>M#=N+38,(4)==CJ.$B\*+%L@I-00N=7P[N+V GR3>2PW
MXK$YFMSS+1-Y/4H9EP7/2RYD?N45$X5(;$EV?DGO0<) WMHI4>J+Z(O,4IR:
MWCL' WEKYT#I.W+K^S/:E"[8V M(U!5V$PY'/K7<N$K;D5O;>W0I7;^U+J5#
M+.J.E+HCM[KWZ5'Z87;L0ZIU? ,,V7@J54;N$^^)!J4?8K$'L78<-^&PW":9
MV6&EE]BMEY\W>;)("GE"L^Z1W![Z%MY0WMKQ*O'%\"6:#W9*>N\<#.2MG0.E
M[MBM[L\8YNIB#7WJ=S7=!$,1LNR0\-&PV:WIS^\]6-?M;N\Q0*"M;)2LXY[C
M9GOSP?HI=HQA=P-B1-EH*JG%[H.NN_=@_>0*?41QEYH!AB+;(! K#<1N#:P'
MLT9:3K/>M3:0MW:02D;Q_S:TQH-.K8?RULZ34G-\[N :&R;2$)-(JR0##LO>
MA2WWJQ)R/-3H&I^>73LA[5_ E):3P4;71#_<:K^"N2!MADI]R3D3:V(81)M6
MV(1SK#!1PDC<POB9Y^P19+'XP2JPVECV0VXG?>MN*&_MD)74$O?$^@7[$QET
MJCV4MW:>CGY>/G>J370%]U&D_3AJ@LE;UW+,($KJR5 S;7)ZINV$M DJN2>#
MC;2)?J;5&+H@;89*J\DYXVRBGV&-ZVN .=97"20Y,<QF\OY;)8NXDJ<6O@)+
M5O R,=^)@PZUA_+6CENI+G$/M5^R00TZ^![*6_OY$B7^]-S!-]4%'4("0]BY
M@XVXR*.6J3)5ZD^'&GS3TX-O)Z1-4.D_'6SL3?6CK\;0!6DS5')-SYEV4\/#
M5<85-N$,*SPY>HZP?HCS<RSNY8J!E*VDH7<1R-C$[KG(W47%B^;1PCFO*IXU
M+]<L7C)1 ^3G*\ZKIXOZ:<7#TZG3_P!02P,$%     @ #()A59)_W[(?!
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MY<=[P6]%6AC(OR^3)'_\4KSD[_!2Q_G_4$L#!!0    (  R"856%YLIL4P,
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MJ_4I7&B-)#,3&7SB;,9S;C@I7>^!#.A(WF%:*L7%PGG=2*$:PY1IKN&_3[0
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M,^.?J]V,A\SID&+1D&+Q0&)'.;6MIT./]8,:3BM\N,=PK' \/NDX?3#'&YW
MHAZ8%X2N<])S>F#^V+9.-S;FP3&P!+[6YV^!KFTJV6SBN]GNC'^C3[8G\W/[
M>F'WS$?JFX ^=C[)-Q\4WE.^SBM!"ECA4M;5"!LD;\[HS4"R6A]"[YG$(ZV^
MS8"FP!4 _U\Q)O<#M4#WI63V+U!+ P04    "  ,@F%5AC0) U\$  "A&0
M&0   'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6S%66%OHS88_BL6.TUWTK5@
M3"#IDDAM8=I).UW4W&T?IGUPP4E0 6>VT[3_?K:A)!"775>?^J6 \[R/_;Z/
M\Z2OF>XIN^,;0@1X*(N*SYR-$-L+U^7IAI28G],MJ>0G*\I*+.0C6[M\RPC.
M=%!9N+[GA6Z)\\J93_78@LVG=">*O"(+!OBN+#%[O"(%W<\<Z#P-W.3KC5 #
M[GRZQ6NR).+;=L'DD]NR9'E)*I[3"C"RFCF7\"*!H0K0B#]RLN=']T"E<DOI
MG7KXE,T<3ZV(%"05B@++RSVY)D6AF.0Z_FE(G79.%7A\_\3^JTY>)G.+.;FF
MQ9]Y)C8S9^R C*SPKA W=/\;:1(:*;Z4%ES_!?L&ZSD@W7%!RR98KJ#,J_J*
M'YI"' 5('G. WP3X_8#@F0#4!*#OG2%H H+OG6'4!.C4W3IW7;@8"SR?,KH'
M3*$EF[K1U=?1LEYYI3;*4C#Y:2[CQ'PI:'IW=B5+G8%K6LK]Q[%6\ PLY:;,
M=@4!= 62<EO01T+ DK#[/)77#69$@@R1R8.Z)^!]3 3."_Y!PKXM8_#^W0?P
M#N05^+JA.XZKC$]=(5-0"W'39KE7]7+]9Y:+P&=:B0T'2961S! ?#\=/!N)=
M6;JV?OY3_:[\0<(EV9X#Y'T$ON?[AO5<#X=_2<4Y\* .AZ9T7C=[\K]G[Q0#
MM9L):3[TW'+4ICB[/=T2EXSA:DVDP0AP^PB.<0O\J(<O]YAEX*_?)27X)$C)
M_S;MCGK^P#R_,M4+OL4IF3G2-;G<JL29__P3#+U?3-+8)(MMDB66R#HB!JV(
MP1#[_"L5N !<^T(M47HL):F_W29Q:MY0\ZH?J/LYBA"*IN[]<=4-*#0)PRXJ
M/D6-803'751RBI),HZ!%=0HP:@LP&BR MD1 MRI=HT4-AK]T$]HDBVV2)9;(
M.AJ$K0;A&SM):%-$FV2Q3;+$$EE'Q*@5,?I!3E+SCHX]PI],>D9R"@I"K^<V
M\2D(>D'D]7S$@!KY'C+[R+A-?SR8_@WA@N6ID'GK&H!=E0NCH0SRO'0OVB2+
M;9(EEL@Z8DQ:,29O;"@3FR+:)(MMDB66R#HB0N_0K7@_R%(:XN/ON._["/5,
MQ0"#*%+_'7=LQ0 ;!3X*>KYB@ 7>V//-Q@*/FC8X6(8%8?J,H)*=V']XRS#3
M2_>E5;;8*EMBBZVKB7_0Q']CAVD68$M*FVRQ5;;$%EM7RD,;"P<;K->X##JU
M#X@0[+N, 19,HA.7,<'"OADE!AB*0A@^XS*'1A .=X+)<K$P)CD8]N)]:),M
MMLJ6V&+K"G!H1.'HK2W%:B]KE2VVRI;88NM*>>AGX6"G]1I+"4\..8(HZ!O*
M*2@,^[V0 >2C">J[R2D*>:C?"[E'1\XE86M]UL]E4KM*U >&[6C[/N%2GZ+W
MQJ_@Q34TC,?J_8,^XC[0UR\O/F.VSBL."K*24WGGD526U>\#Z@=!M_K ^Y8*
M04M]NR$X(TP!Y.<K2L73@YJ@?2LS_Q=02P,$%     @ #()A53.GID?0"
MJ5(  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULQ9Q9;]M(%H7_2D'=
M:"1 (I$L<9';-I"8RP28= P[Z7X8]$-9*DM$*%)#4G8\Z!\_Q<6BBJ1+8GP,
M^R&A:-[OEGB/:SE<3N^3]'NVXCPG/]91G)V-5GF^.9E,LOF*KUDV3C8\%K^Y
M3=(UR\7'=#G)-BEGBS)H'4T,3;,F:Q;&H_/3<M]E>GZ:;/,HC/EE2K+M>LW2
MAX\\2N[/1OKH<<=5N%SEQ8[)^>F&+?DUS[]M+E/Q:;*C+,(UC[,PB4G*;\]&
M'_23@#I%0'G$GR&_S_:V2?%5;I+D>_'AT^)LI!4MXA&?YP6"B?_N^ 6/HH(D
MVO'?&CK:Y2P"][<?Z7[YY<67N6$9OTBBO\)%OCH;.2.RX+=L&^57R?V_>/V%
MS((W3Z*L_)?<U\=J(S+?9GFRKH-%"]9A7/W/?M0G8B] IT\$&'6 T0XPGPB@
M=0 ]-F!:!TS; =,G LPZP#PV@U4'6,=FL.L NRQ6=7;+TK@L9^>G:7)/TN)H
M02LVROJ6T:(B85Q(\3I/Q6]#$9>?7^?)_/O[CZ*8"W*1K(7",U9JY#WY@Z4I
M*X1"WK@\9V&4O15[OUV[Y,VO;\FO9$*R%4MY1L*8?(O#/'LG=HKMKZMDF[%X
MD9U.<M'"(L]D7K?FHFJ-\41K=/(YB?-51KQXP1<]\:XZGAZ*]]7Q,T7\1)S9
MW>DU'D_O1T,)_,P>B&&^(X9F&'VGXU!T.B94?S+<58=?\XT(UYX,]]3A7^;Y
MF&A5=KWO7#XO>_#3V:5*T)W0:<FC3S6GT.K[FZ[0/PB5QTLNNM><W#R0_>,N
MV4.Y^\,]2Q?D/_\62/(IY^OL[Y[O\['*/^W/7PPI)]F&S?G92(P9&4_O^.C\
MMU]T2_N]3QA(F(N$>4B8CX0%()@DK^E.7E,5_?Q3/!<S@8P7'6#9+9(Z!]F*
MKB05*M9MLHE83-X\'I&][5-1E<8LTQ3SB+MSPS&UXN=T<K>O$&5[ABH$"?.0
M,!\)"T P22'F3B&F4B%_;-<W0@C)[>.PR>[$F,IN(D[$C)(L12^4'Q*',L/0
M+@8)<\V.;*D^=4S+M&39>LBL_K%9 U!6J?#6KO"6LO!7?+&MYMV=OH'=YD(2
M63$'(\FF/"9Y_,PVHBWSL!JD6#D"'5"'LAE#U8&$N4B8AX3Y5D=!>DLZH'22
M=.R==.SG28=%$4GR5;%5*"0[)!%ENJ$20<)<),Q#PGR[.R*W) )*)TG$V4G$
M44KD2]EM9-7X(>:LHOY"#V3#TS YV&,HT4/E@(2Y2)B'A/E.1PZFXSA66Q.@
MG)(F9CM-S)ZIB44212S-BEV5/GKEH<PR5!Y(F(N$>4B87\&<_0%E-I[-6NH
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M]5[$ZD.>;,K7\MTD>9ZLR\T59PN>%@>(W]\F2?[XH4BP>SOE^?\!4$L#!!0
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MN?H%AP9K&2 NN:!9$RQGD)&\_D<_&B,Z 9)''V W 78_P#T3X#0!SK4CN$V
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M&LMT9G4=63<$+52A]$*%++O4XT[6WIA5 /E^0ZDX-JH!VFI^_A-02P,$%
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M]XIW&!/8,;]OLC;I.B_>K-".N:8/]34]WJ,&3/3Z>^XT7Y0AB=Y.RKV"VSO
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M/"U^KAB=,Y&?H(\O.%>/&WF"W3<RQO\!4$L#!!0    (  R"857 (!OI8@,
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MK(SDC"]LN V!<<$+Z2E=_SI=")'JP<*A[<&M4>OD3!32Y+89[.]1/7P+6/;
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MN'PG2N[^,'NAPYF-L27WX=!N)VYO!2_<3@A?JDD\G<XG)9<Z^OBAZVMI)_#
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MB(F9)R,V#X)YX[R$F)AY,F+S'-]^:,81Q,3,DQ&;9[!J=-($MO*]$D*&/@)
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M1I%5H\BJ4635*++J_Y3UR=KU7__;T-_SUM3=>SX;?B"Y>@502P$"% ,4
M"  ,@F%5!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    (  R"854;=NY7[0   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  R"85697)PC
M$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ #()A56AST8_8!0  UAX  !@              ("!# @
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  R"855^,@7Y
MS08  $,<   8              " @1H.  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    "  ,@F%5\H%:.-0"   2"@  &
M@($=%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ #()A
M5?7,@M;F!@  -"8  !@              ("!)Q@  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    (  R"854LP*N3? ,  +X+   8
M      " @4,?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M"  ,@F%5@.2'%N "   Y"   &               @('U(@  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ #()A55$:1J]/"0  D$P  !@
M             ("!"R8  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    (  R"855]RWI:'0<  $ >   8              " @9 O  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  ,@F%5MD=MBQ$-   2
M(0  &               @('C-@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ #()A520G^-+5"P  '2$  !D              ("!*D0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  ,@F%5L C]
MAR(-  "Y)0  &0              @($V4   >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    (  R"855K7!ZZ,@D  ,@9   9
M  " @8]=  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M#()A56B5!VEM!P  3A(  !D              ("!^&8  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    "  ,@F%5-/K.T]D"   :!@  &0
M            @(&<;@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    (  R"855 1/F0!PD  $L7   9              " @:QQ  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ #()A56 N>RLT P
M'@@  !D              ("!ZGH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    "  ,@F%5<(P-_C$$   Q"@  &0              @(%5
M?@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  R"8548
ML&S[/Q   .(Y   9              " @;V"  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ #()A55[4/Y]A!0  1 T  !D
M     ("!,Y,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  R"857]ZNRYSP,  %()   9              "
M@:VV  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ #()A
M58[.<VC= @  )08  !D              ("!L[H  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    "  ,@F%51_\O;VL$  !T"@  &0
M        @(''O0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   (  R"8540Y&F/L@,  %X)   9              " @6G"  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ #()A59'Y)Z,: P  \0D
M !D              ("!4L8  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    "  ,@F%5H[4UV@ %  #$(   &0              @(&CR0
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (  R"855).+#K
MR@4  (\U   9              " @=K.  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ #()A57) ,*G7 P  $A0  !D
M ("!V]0  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  ,
M@F%5N9ZB8=@#  !$%   &0              @('IV   >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (  R"854<?]P+X@0  ,06   9
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M970S-RYX;6Q02P$"% ,4    "  ,@F%5YS)CHU0"  !7!0  &0
M    @('!\P  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M  R"854LD[K68@,  ( .   9              " @4SV  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ #()A5:+:? >7 P  T@T  !D
M             ("!Y?D  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    "  ,@F%5,F+5"P,$  !\$P  &0              @(&S_0  >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (  R"856I:]VZ'0,
M "\*   9              " @>T! 0!X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ #()A5?HOL<#% P  01(  !D              ("!
M004! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  ,@F%5
M086*$[\&  "I*@  &0              @($]"0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    (  R"8562?]^R'P0  !H4   9
M      " @3,0 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ #()A5;A_MR/# @  X08  !D              ("!B10! 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  ,@F%5?6%&07D(  #@40
M&0              @(&#%P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    (  R"856%YLIL4P,  .$*   9              " @3,@ 0!X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ #()A55WK:0L@
M P  XPL  !D              ("!O2,! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    "  ,@F%55"A">LD#   U$0  &0
M@($4)P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (  R"
M856&- D#7P0  *$9   9              " @10K 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ #()A53.GID?0"   J5(  !D
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M=#4V+GAM;%!+ 0(4 Q0    (  R"854=L&F[00<  "]#   9
M  " @15& 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
M#()A5< @&^EB P  . L  !D              ("!C4T! 'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    "  ,@F%5&4//'5H#   D%0  #0
M            @ $F40$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  R"8567
MBKL<P    !,"   +              "  :M4 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    (  R"857<&0/JAP0  + F   /              "  915 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    "  ,@F%5$R?LNN\!  "E(@  &@
M        @ %(6@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    "  ,@F%58B/G&-@!  !((@  $P              @ %O7 $ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     0@!"  42  !X7@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>285</ContextCount>
  <ElementCount>249</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome</Role>
      <ShortName>Condensed Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Collaboration Agreements And Business Development Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities</Role>
      <ShortName>Collaboration Agreements And Business Development Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Provision For Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxes</Role>
      <ShortName>Provision For Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables</Role>
      <ShortName>Collaboration Agreements And Business Development Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Revenues - Revenues Disaggregated by Concentration Risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Concentration Risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenues - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Collaboration Agreements And Business Development Activities - GSK Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - GSK Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Fair Value Measurements - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails</Role>
      <ShortName>Fair Value Measurements - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails</Role>
      <ShortName>Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Provision For Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails</Role>
      <ShortName>Provision For Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForIncomeTaxes</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsandContingencies</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="exel-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/SubsequentEvents</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exel-20220930.htm">exel-20220930.htm</File>
    <File>exel-20220930.xsd</File>
    <File>exel-20220930_cal.xml</File>
    <File>exel-20220930_def.xml</File>
    <File>exel-20220930_lab.xml</File>
    <File>exel-20220930_pre.xml</File>
    <File>exel20220930exhibit31110q.htm</File>
    <File>exel20220930exhibit31210q.htm</File>
    <File>exel20220930exhibit32110q.htm</File>
    <File>exel2022930exhibit10110q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20220930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="732">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel-20220930.htm": {
   "axisCustom": 2,
   "axisStandard": 21,
   "contextCount": 285,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "exel-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 436,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 41,
   "keyStandard": 208,
   "memberCustom": 32,
   "memberStandard": 35,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Collaboration Agreements And Business Development Activities",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities",
     "shortName": "Collaboration Agreements And Business Development Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashandInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stock-Based Compensation",
     "role": "http://www.exelixis.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Provision For Income Taxes",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxes",
     "shortName": "Provision For Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Net Income Per Share",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Commitments and Contingencies",
     "role": "http://www.exelixis.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Subsequent Events",
     "role": "http://www.exelixis.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables",
     "shortName": "Collaboration Agreements And Business Development Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:NumberOfCountriesWithDrugApprovalExcludingTheUS",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:NumberOfCountriesWithDrugApprovalExcludingTheUS",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i29e8fc05be13408780345631766d0815_D20220702-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "ie65c3b49253c4aa7b9ec4c0202bebd90_D20220702-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Revenues - Revenues Disaggregated by Concentration Risks (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails",
     "shortName": "Revenues - Revenues Disaggregated by Concentration Risks (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "ie65c3b49253c4aa7b9ec4c0202bebd90_D20220702-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i445b3583a8f7464f94fbda78d87c16ea_D20220702-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i92fb0f6b07fd46b6ba4261c7461fff4b_D20220702-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i9c08664821924215a9a380432cc549fd_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i9c08664821924215a9a380432cc549fd_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Revenues - Contract Assets and Liabilities (Details)",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
     "shortName": "Revenues - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i9c08664821924215a9a380432cc549fd_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i932765cb697a4b078cea923c81edd920_D20220702-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i1364c1c302444d838efffd43064715f9_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i1364c1c302444d838efffd43064715f9_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "ic70ffc1d027b441296ba4347fbd23534_D20220702-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "ibaa37e09ed2a4cc1877653a23011c082_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "ibaa37e09ed2a4cc1877653a23011c082_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "ia63686e881124ae08b1ebf7e9f49fd77_D20220101-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborationAgreementPercentOfRoyaltyOnNetSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Collaboration Agreements And Business Development Activities - GSK Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - GSK Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "ia63686e881124ae08b1ebf7e9f49fd77_D20220101-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborationAgreementPercentOfRoyaltyOnNetSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
     "shortName": "Condensed Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
     "shortName": "Collaboration Agreements And Business Development Activities- Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i9da7e9b183de4698ac4c703b2c8f846c_D20220702-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementIncomeLossFromAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i9c9d5031bdf542ceab4b6f6d4789fa7f_D20220601-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i9c9d5031bdf542ceab4b6f6d4789fa7f_D20220601-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Cash and Investments - Narrative (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i71fc629d67b1439596f3c19023047959_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i5d00e7f272ad46b9a14aaa1be9bc4934_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "forward_contract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Fair Value Measurements - Narratives (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails",
     "shortName": "Fair Value Measurements - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i5d00e7f272ad46b9a14aaa1be9bc4934_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "forward_contract",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i37a45756c9954dffb1597b6666f619f3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "ie101975b1642454ca5efd600cefeebb7_D20220702-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Employee Service Share - Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i1a2435c09f4c4f918cabd7085d3ea04d_D20220702-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if19df687aaf9496496468698046b7ca9_D20220525-20220525",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if19df687aaf9496496468698046b7ca9_D20220525-20220525",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "ia156218652c64c5d967262937d5d66a6_I20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
     "shortName": "Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "ia156218652c64c5d967262937d5d66a6_I20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Provision For Income Taxes (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails",
     "shortName": "Provision For Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "iaa050e767b3f498a8437c364816242c7_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "iaa050e767b3f498a8437c364816242c7_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseLiability",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "id8f643a473a8490da5ebb398751eb409_I20220601",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseLiability",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "id8f643a473a8490da5ebb398751eb409_I20220601",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "ic2fe2d2458b143ac93cfc5d3dd846556_D20221101-20221130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.exelixis.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "ic2fe2d2458b143ac93cfc5d3dd846556_D20221101-20221130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "if9baae3c0c274839b462d39623feea2d_D20220702-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i98f25495c49942328fe52185ebb36868_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i98f25495c49942328fe52185ebb36868_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20220930.htm",
      "contextRef": "i0eddf30a4c4d47a7997863ab7b313fdf_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 67,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_AccredoHealthIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accredo Health, Incorporated",
        "label": "Accredo Health, Incorporated [Member]",
        "terseLabel": "Accredo Health, Incorporated"
       }
      }
     },
     "localname": "AccredoHealthIncorporatedMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_BuiltToSuitLeaseAndHeadquartersLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Built-To-Suit Lease And Headquarters Lease [Member]",
        "terseLabel": "Built-To-Suit Lease And Headquarters Lease"
       }
      }
     },
     "localname": "BuiltToSuitLeaseAndHeadquartersLeaseMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks, Discounts for Prompt Payment and Other"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationAgreementWithBioInventInternationalABBioInventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement With BioInvent International AB (BioInvent)",
        "label": "Collaboration Agreement With BioInvent International AB (BioInvent) [Member]",
        "terseLabel": "Collaboration Agreement With BioInvent International AB (BioInvent)"
       }
      }
     },
     "localname": "CollaborationAgreementWithBioInventInternationalABBioInventMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementWithRyvuTherapeuticsSARyvuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement With Ryvu Therapeutics S.A. (Ryvu)",
        "label": "Collaboration Agreement With Ryvu Therapeutics S.A. (Ryvu) [Member]",
        "terseLabel": "Collaboration Agreement With Ryvu Therapeutics S.A. (Ryvu)"
       }
      }
     },
     "localname": "CollaborationAgreementWithRyvuTherapeuticsSARyvuMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementIncomeLossFromAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Income (Loss) from Agreement",
        "label": "Collaborative Arrangement, Income (Loss) From Agreement",
        "terseLabel": "Profits on U.S. commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementIncomeLossFromAgreement",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementMaximumAmountOfWarrantExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Amount Of Warrant Exercise",
        "label": "Collaborative Arrangement, Maximum Amount Of Warrant Exercise",
        "terseLabel": "Maximum amount of warrant to be exercised"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumAmountOfWarrantExercise",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsExerciseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Exercise Amount",
        "label": "Collaborative Arrangement, Rights And Obligations, Exercise Amount",
        "terseLabel": "Option to exercise, amount"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsExerciseAmount",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments",
        "terseLabel": "Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate development milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development, Regulatory And Commercial Milestones Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development, Regulatory And Commercial Milestones Payments",
        "terseLabel": "Additional development regulatory and commercial milestones payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentRegulatoryAndCommercialMilestonesPayments",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "terseLabel": "Collaborative arrangement, upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaboration Agreement with GlaxoSmithKline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative Arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "label": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "terseLabel": "Contract revenue recognized, including revenue from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ContractWithCustomerMilestoneRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Milestone Revenue Recognized",
        "label": "Contract with Customer, Milestone Revenue Recognized",
        "terseLabel": "Milestone revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerMilestoneRevenueRecognized",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CotellicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cotellic [Member]",
        "label": "Cotellic [Member]",
        "terseLabel": "Cotellic"
       }
      }
     },
     "localname": "CotellicMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CybrexaTherapeuticsLLCCybrexaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cybrexa Therapeutics, LLC (Cybrexa)",
        "label": "Cybrexa Therapeutics, LLC (Cybrexa) [Member]",
        "terseLabel": "Cybrexa Therapeutics, LLC (Cybrexa)"
       }
      }
     },
     "localname": "CybrexaTherapeuticsLLCCybrexaMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_Granted2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Granted 2020",
        "label": "Granted 2020 [Member]",
        "terseLabel": "Granted 2020"
       }
      }
     },
     "localname": "Granted2020Member",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_IncreaseDecreaseInAccruedCollaborationLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Collaboration Liabilities",
        "label": "Increase (Decrease) In Accrued Collaboration Liabilities",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedCollaborationLiabilities",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen Pharma SAS"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Domain]",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LeaseExpansionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Expansion",
        "label": "Lease Expansion [Member]",
        "terseLabel": "1751 Expansion Space"
       }
      }
     },
     "localname": "LeaseExpansionMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "verboseLabel": "Estimated monthly base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage",
        "terseLabel": "Monthly base rent, lease not yet commenced, annual percentage increase"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of options to extend the lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option To Terminate After Period",
        "label": "Lessee, Operating Lease, Option To Terminate After Period",
        "terseLabel": "Option to terminate lease (after period)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminateAfterPeriod",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_LossContingencyNumberOfLawsuitsConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Lawsuits Consolidated",
        "label": "Loss Contingency, Number Of Lawsuits Consolidated",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfLawsuitsConsolidated",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NumberOfBondSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Bond Securities",
        "label": "Number Of Bond Securities",
        "terseLabel": "Number of bond securities"
       }
      }
     },
     "localname": "NumberOfBondSecurities",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NumberOfCountriesWithDrugApprovalExcludingTheUS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Countries With Drug Approval, Excluding The U.S.",
        "label": "Number Of Countries With Drug Approval, Excluding The U.S.",
        "terseLabel": "Number of countries with drug approval, excluding the u.s."
       }
      }
     },
     "localname": "NumberOfCountriesWithDrugApprovalExcludingTheUS",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NumberOfRegulatoryMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Regulatory Milestone",
        "label": "Number Of Regulatory Milestone",
        "terseLabel": "Number of regulatory milestone"
       }
      }
     },
     "localname": "NumberOfRegulatoryMilestone",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OperatingLeaseLiabilityDiscountedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Liability, Discounted Period",
        "label": "Operating Lease, Liability, Discounted Period",
        "terseLabel": "Operating lease liability discounted period"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityDiscountedPeriod",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductOrServiceAxisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Or Service Axis",
        "label": "Product Or Service Axis [Axis]",
        "terseLabel": "Product Or Service Axis [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxisAxis",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_ProductOrServiceAxisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Or Service Axis [Domain]",
        "label": "Product Or Service Axis [Domain]",
        "terseLabel": "Product Or Service Axis [Domain]"
       }
      }
     },
     "localname": "ProductOrServiceAxisDomain",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products derived from other compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities",
        "label": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member]",
        "terseLabel": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities"
       }
      }
     },
     "localname": "ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting from discovery efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RoyalPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royal Pharma",
        "label": "Royal Pharma [Member]",
        "terseLabel": "Royal Pharma"
       }
      }
     },
     "localname": "RoyalPharmaMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_SairopaBVSairopaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sairopa, B.V. (Sairopa)",
        "label": "Sairopa, B.V. (Sairopa) [Member]",
        "terseLabel": "Sairopa, B.V. (Sairopa)"
       }
      }
     },
     "localname": "SairopaBVSairopaMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions",
        "label": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "terseLabel": "Reduction in share reserve after all other awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "terseLabel": "Reduction in share reserve after stock option or stock appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "terseLabel": "Maximum potential to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_TSRBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TSR-Based Restricted Stock Units",
        "label": "TSR-Based Restricted Stock Units [Member]",
        "terseLabel": "TSR-Based Restricted Stock Units"
       }
      }
     },
     "localname": "TSRBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TakedaAndIspenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda And Ispen",
        "label": "Takeda And Ispen [Member]",
        "terseLabel": "Takeda and Ispen"
       }
      }
     },
     "localname": "TakedaAndIspenMember",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TenantLeaseImprovementsAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Lease Improvements, Allowance",
        "label": "Tenant Lease Improvements, Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantLeaseImprovementsAllowance",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20220930",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r39",
      "r41",
      "r87",
      "r88",
      "r235",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r168",
      "r267",
      "r273",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r168",
      "r267",
      "r273",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r164",
      "r220",
      "r221",
      "r267",
      "r271",
      "r443",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r164",
      "r220",
      "r221",
      "r267",
      "r271",
      "r443",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r40",
      "r41",
      "r87",
      "r88",
      "r235",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r103",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r103",
      "r108",
      "r219",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r267",
      "r272",
      "r476",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r267",
      "r272",
      "r476",
      "r487",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r103",
      "r108",
      "r219",
      "r287",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Abstract]",
        "terseLabel": "Contract liabilities:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r45",
      "r47",
      "r48",
      "r463",
      "r482",
      "r483"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r48",
      "r55",
      "r56",
      "r57",
      "r95",
      "r96",
      "r97",
      "r362",
      "r403",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Operating Activities [Abstract]",
        "terseLabel": "Non-cash operating activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r326",
      "r327",
      "r328",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r289",
      "r330",
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "netLabel": "Total stock-based compensation expense",
        "terseLabel": "Recognized stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of lease property (in square feet)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r13",
      "r84",
      "r147",
      "r156",
      "r162",
      "r190",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r358",
      "r363",
      "r388",
      "r404",
      "r406",
      "r446",
      "r461"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r31",
      "r84",
      "r190",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r358",
      "r363",
      "r388",
      "r404",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r171",
      "r197"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Debt securities available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r176",
      "r178",
      "r457"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r176",
      "r177",
      "r456"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r170",
      "r172",
      "r197",
      "r450"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total debt securities available-for-sale",
        "verboseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r368",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid liabilities incurred for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r9",
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r72",
      "r77",
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r72",
      "r389"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r351",
      "r352",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r451",
      "r468"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r222",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 322,541 and 318,842 at September\u00a030, 2022, and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r51",
      "r53",
      "r54",
      "r59",
      "r453",
      "r471"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r385",
      "r386",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r385",
      "r386",
      "r485",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r385",
      "r386",
      "r485",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r133",
      "r135",
      "r136",
      "r137",
      "r385",
      "r387",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r168",
      "r385",
      "r386",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Other Assets and Other Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r245",
      "r247",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]",
        "terseLabel": "Contract assets:"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r245",
      "r246",
      "r268"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r245",
      "r246",
      "r268"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r245",
      "r246",
      "r268"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenues",
        "verboseLabel": "Long-term portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amount of revenues recognized included in the beginning contract liability balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r62",
      "r443"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r134",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r173",
      "r197",
      "r204",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r185",
      "r202",
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r185",
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "terseLabel": "Accumulated loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r182",
      "r198",
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r183",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r181",
      "r201",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r184",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r75",
      "r145"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r41",
      "r369",
      "r370",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of contract"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r267",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r291",
      "r292",
      "r320",
      "r321",
      "r323",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r60",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r109",
      "r112",
      "r119",
      "r120",
      "r121",
      "r125",
      "r126",
      "r376",
      "r377",
      "r454",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r60",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r112",
      "r119",
      "r120",
      "r121",
      "r125",
      "r126",
      "r376",
      "r377",
      "r454",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r55",
      "r56",
      "r57",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r128",
      "r191",
      "r243",
      "r244",
      "r326",
      "r327",
      "r328",
      "r341",
      "r342",
      "r375",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r403",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r378",
      "r379",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets Measured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r236",
      "r238",
      "r239",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r379",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r381",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r236",
      "r279",
      "r280",
      "r285",
      "r286",
      "r379",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r236",
      "r238",
      "r239",
      "r279",
      "r280",
      "r285",
      "r286",
      "r379",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r236",
      "r238",
      "r239",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r382",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r187",
      "r188",
      "r189",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r201",
      "r203",
      "r206",
      "r207",
      "r237",
      "r242",
      "r374",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainOnDerivativeInstrumentsPretax": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain on Derivative Instruments, Pretax",
        "terseLabel": "Gain on derivative instruments, pretax"
       }
      }
     },
     "localname": "GainOnDerivativeInstrumentsPretax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r11",
      "r209",
      "r210",
      "r211",
      "r212",
      "r406",
      "r445"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r57",
      "r63"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r338",
      "r339",
      "r340",
      "r343",
      "r345",
      "r347",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "PROVISION FOR INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r106",
      "r107",
      "r146",
      "r336",
      "r344",
      "r346",
      "r473"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r74",
      "r441"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r16"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r29",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "CASH AND INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease option to extend period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r84",
      "r157",
      "r190",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r359",
      "r363",
      "r364",
      "r388",
      "r404",
      "r405"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r84",
      "r190",
      "r388",
      "r406",
      "r447",
      "r465"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Unpaid liabilities incurred in asset acquisition"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r35",
      "r84",
      "r190",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r359",
      "r363",
      "r364",
      "r388",
      "r404",
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "netLabel": "License revenues",
        "terseLabel": "License revenues",
        "verboseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds",
        "verboseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r72",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r49",
      "r52",
      "r57",
      "r58",
      "r76",
      "r84",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r117",
      "r147",
      "r155",
      "r158",
      "r161",
      "r163",
      "r190",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r377",
      "r388",
      "r452",
      "r470"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r109",
      "r110",
      "r118",
      "r121",
      "r147",
      "r155",
      "r158",
      "r161",
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income, Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r111",
      "r113",
      "r114",
      "r115",
      "r116",
      "r118",
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net income, Diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r147",
      "r155",
      "r158",
      "r161",
      "r163"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Estimate incremental borrowing rate (in percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r94",
      "r141",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r50",
      "r53",
      "r356",
      "r357",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r42",
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized losses on available-for-sale debt securities, net of tax impact of $2,457, $193, $4,752 and $949, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r43",
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r70",
      "r325"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "netLabel": "Net product revenues",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r213",
      "r406",
      "r458",
      "r467"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r406",
      "r466",
      "r486"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r333",
      "r442",
      "r500"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r12",
      "r81",
      "r488"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash equivalents included in other long-term assets"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r244",
      "r406",
      "r464",
      "r481",
      "r483"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r191",
      "r326",
      "r327",
      "r328",
      "r341",
      "r342",
      "r375",
      "r478",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r143",
      "r144",
      "r154",
      "r159",
      "r160",
      "r164",
      "r165",
      "r168",
      "r266",
      "r267",
      "r443"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Total revenues",
        "verboseLabel": "Royalty revenues on ex-U.S. sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r135",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r256",
      "r257",
      "r270",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues Disaggregated by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r400",
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "verboseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r318",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r26",
      "r27",
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r81",
      "r444",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r288",
      "r290",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r133",
      "r135",
      "r136",
      "r137",
      "r385",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration Risks"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "netLabel": "Collaboration services revenues",
        "terseLabel": "Collaboration services revenues",
        "verboseLabel": "Collaboration services revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in share reserve under 2017 plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted in the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted in the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of the Company's common stock on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting award percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r30",
      "r448",
      "r449",
      "r460"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r55",
      "r56",
      "r57",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r128",
      "r191",
      "r243",
      "r244",
      "r326",
      "r327",
      "r328",
      "r341",
      "r342",
      "r375",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r403",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r128",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Share-based Payment Arrangement"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive plans and stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r244",
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive plans and stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r20",
      "r21",
      "r84",
      "r169",
      "r190",
      "r388",
      "r406"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r396",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r396",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r396",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r396",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r407",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Inclusive of operating lease liability"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r187",
      "r188",
      "r189",
      "r237",
      "r242",
      "r374",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesGSKNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r279",
      "r455",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government-sponsored enterprises",
        "verboseLabel": "U.S. Treasury and government-sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r138",
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r89",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at September\u00a030, 2022",
        "periodStartLabel": "Balance at December\u00a031, 2021"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r111",
      "r121"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r109",
      "r121"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL108322424-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5291-111683"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r501": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r502": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r503": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r504": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r505": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r506": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r507": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r508": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r509": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r510": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r511": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r512": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r513": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0000939767-22-000110-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-22-000110-xbrl.zip
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M%:\;8:/TT4;'U,J+[-M]_.W9-1P?$M9+]_2JU8^^O8N^]XI^Z2\!_A[ [ N
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MN )M*)A)+C-)(9%)"6 Q_-\;^J73QT7T?T#0!6*K2-H',E,HI;DB.N,@"BD
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MX;.7"9GTG('DS@4K%(6:TD6*.F5>/%1G/S [$Z M3YA52IY[#26;#)Q2BKG
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M5:B'4C"]VN_L-7;W>_[DH!5]>P3M>.^FYV^W%RM;(@'CW$BCP40 ';UG2:C
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M0# ?;&0N:A,"1>T4L2^ YYN:[DW?\8%!K4*B\(YB!.(J03+M*'*PRDJE6%@
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M;D!H!$JFZ)\$((/T!GBR1CF9B2A8MP"X/#ASGJ 9XRH;K9$H&8!1%& *%UQ
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MV9?:[XE5(""9'U0F.76D&0L,LB4+J$@ILA,B,(-<6!5=!;;+^3HJ0SZQ.3C
MWIMN9W^ O>/5?A\'55$8G;QW)ANI,$"4T2?"A$+Y( 4FIVR5%68FT$QP\HZ(
M@3,J<%W*!D'TY&H2*5)$X@XAF#$O-"/R,-?JL]&)W6/<'I"O+6?>;M>VL(]E
MV&65G'(95NF>E+;K9R=T-7QX=FCN2"$FQPXE:5P.48:D G M;#(6P7#211O*
M3,&('1HFYYX=SCW ? BPG"Y'M#H[8V00DC084G $(L5TT;( 06JL4&0W]P#/
M)KYC/IK,>'0B@*-OS"5+'\HBMQ 25BB^FWN 9Q+E9>>T\QY : 6EA!_992]Y
M9A:54"(LF@_>QG:[U=E_C1WL^3;!O)J.6YT6!?S#T'^,] ,PJ-E[8])>A1I]
M&86#&+@/B#P@XT)YLM]YT;SQ?$ ]$[]<IMNCY: %2^ -A:;62B^C!F^3\+!H
M?GD^H)Z)AS:<6+74H>PP#8HL-M?<:("L4HH1XZ)YZ/F >B:^FGL!4D7F,D3(
MCMOH0S+,JB31,T@5\M6K9=1\Y_P$KX.[?GS2[IXCR4 W'FV>%/07T1-SD:TJ
M&\27M'(>26>YCCJJE*54AK,*>>*Y 7)&?C98QP0+G(#4VOO(E4'#38[&0? 5
M\K-S ^1,O&B(3 L+(@9IP:9DR<@*5,F'# 2NKI 7G1L@9^(C/2]9>F6]%V.@
MDK91<BZU2F"CQ:M<@PK[R"TDKM.* TQ#*-]V6H/^UO;;1?23T6ME99;,$//A
M0OK A,> VB8*9Y*JOI^<#9@S\97)9!N(P((+"H(35C/"E0PO0R-]7 !?.3/-
MG+Z_3)HA8,K1:@<^H%.!""SXQ&)F:%GU_>7,-',&8\">$W34L<@-)!L\R[Y4
M*O8Q20-,5-]G_HF]W.T=CZ;1?6\QQW>M=SHQGA)*!BD'&T)47A4N)(7#!?"6
MTX9Q)G[2*"D"MV#*C S!% Q:"(:K$F!*5:5LV3F!<3;CLI%(:HHHO4&0T0;I
MDN=)!XC$7 6OOH><@39.WS=:+I@JCC +#L.-2<&:I%!S[V00"Q!/7AL86$2_
M&)43T9F4C67$4)-3/#J55 XJ>'2+-MJZB#[124VF,RLN2V4?;8,!8W+,4J-5
MX'GU?>*4M7 &(ZQ*6!$1#+,..#?>9L=$#MI1$!F<K;X_G+(6SB!.Y"Z1\AGO
MLP.GR[^:XG^RJCJ8Z-U8"Y50]<L/#PWA3X@^/9RZH^A_WO0^:; Y*JZYU('B
MZ\B291RXS1&<0Z',93:&O+1><GYST6^(_C !?6=[ZW??QW3;B,G#6S)Y=TLF
M/TM;O\\4 RCI?50F.0,Y*9<I4O.2$<\G=H&I0G#^39"U.OLW,BP*F1\B^K)[
M7+(I1ED80^1[Q/8/<+/SO5S(I4#]B&LLJ_,Q0_ :(6GF1/(F)-1"9XHV*ASQ
MSP&<TV<ZGBLMN-5*1 U1):>-T,))"AN3UKX"&[3.'L4'60JFI W*><>U$."8
ML18#10]DN$-,$$+E@)GZ7,7#;$\+,1$+0L]= (KN/*D*)B<P:(K14ZHL+%,8
M('L80 P:&;B,B0R8XLZ"2R9%$Z4G'Q5XU<:\BB'_S)*])A)#JD*/SAZ(Q3RJ
M:2?OF6)(N 69P5EO09*D:+!D9D'$*JWB7*4KI%;[M"02?]J1;/TLMD^)U[_J
M=8\+(SX=# GQ9E[WO0ZQYS[!/.+,Y[=?X :]+B;Z<V;]9]LO9):K#!B06QX]
MD-UP,7#P@4(E[K7UTH4JC;LNJF#,)A-(^6R8#43  KA27TI9&11Y%BE#-+E*
M\<ZB"L9LYDR)^BGMA"C)FS&4>6_PEJ445$" *JTV75C!F$U6KPY2JDPVP0J@
MH,U:+1C9$)!>6)_%.$2 ^3,40\;Y!BER7NWU2L6H<E[_,S;Z^VFK/=CI;I^V
M!J-FG?0O].D_I]2OV.L/?WOHN 'N7Y:N_Y_\92FZTT'O>3EP>?*=*\91!.C1
M6VF,)U!M# FL+ZF_4454^7)$#"XYY1+XGS7R<'=:"),Q\FB$$.B8*LO.#5IO
MC $GLI ^)\'MI2[S!Y\\6A!(;^HR5S^GRS?F^H0&E\G:<@L";2@;Q!H7C)1H
M5-27&LC'<WU+N'Y> _E=YR,_;WH?#60I2@K;$U!(EK)T A-!"@)89N1GQQJH
MYF_>ZKN0#H^MGYWXX0D/K6MJ4EN!:+)\:$"3ODDNO,W"&^9X '0<IXC'K'H@
MV:R)RX&1OE2725YA"-)9HS@&8&[< _KA^?X/]X#^C.'>1P:<I\BF%$#S],*6
M><=32?X5Q($PF?$.G],@.C_6 WPB[+'M/_;)"M]>RWA\\(=))!.YE"ME3!D2
M*B\"<N^48SP!$8X\+LK(V?R9N:OX[C3TAZ7&!^NE(N:7 \PW&CRPO:-H;C(;
MR(B,(@E0EOR/]-')F*-*,B4+6JDQM^"7XS^<SQ^[OP2@0+*9/W-&G_FBE^>A
MAV=^YP![_@0ID(_]-V]>CG^][\Q#OS=X?E4I8SMBQU/WCVX^/#3^I90KCK[_
M ))Q@\;PNX\64=/)9!0*'Q-YR\Q3!$PZL!A"!M ^,)6B&>OW4GKF4'JNVQ4^
MF7E+D;+-7$M(R0/9_L"LUP&MB98"3ALJ8%<F"\Q$!'';MWK=$__[W^,/BVA*
M/$E#(EY@#05%2E#(ZVR4(@(0!U?:S:\I>90"<W_K\:QU]KR'_>YI+V)_]/6
M0O_A\Z36AQ>_T?_&24/@*!RQI:B6@228==$+2\S<40C-0;PO[/'3.?W!>9O
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M]NZ[77I'BM37MMJ-8W(5%W^WF_R6J#P$AI&#K:LHR5D([>H4HZ=Z5H$Y@E$
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MZ++ND-=LZ75+J>QC34;91 "WI4!4 -\2@.?4ATR\E'M&033%>1KU(2::U8?
MI".4"R$*@&E?RBX%2&VR$^*7T2B\'9R<5(_#JM2%CS-<N:4];O$+R@$S5HLH
M$&34&M"0  9% N^2CTGZQ&C:VI:\+S5VR#*ISH6.Z085K2M!ZYPF0'U XFQ&
M:T"557F4H+W5D%!1+W668>GCVCFT;K(?8=9[\.13!$/-UEBM6G AIOM@-/0U
MHJIMUGFUH"/8K!HH(2)X[5EF'2?!$)N %'6!.N9)<5\R3?J$Z [9']6!T#$E
MH6)W]=B=TQA$4$;8#%NJN0#D/&L,1AI0RA$9) V1FJUMRFG&[@8&,#3?S55'
M=8=90L;E&L-J@['7L%[QC9][[6FWW623RK/M\>R?"SJ2=S%PD0B@E@AH5-:1
M7-&62"(BNJ"TUUE'ZAM)^UPMS;1KEF52R>S>DUF[F325S%HEL_D#)V>S>J@3
M&,HD8-(L*XW9Z@LD!>4#E8&;0F:2RC[C;06=U12:)3IH_;KWZ*>]7_>.]G:?
M]1X=[/2>'1T^_M]_'OZZL_OTV?_YKXPZ]6-O]\GO>T<O6NJRQ;,0PNBL=.;L
M<)NMZXYRDX\J/_;9.AE8-S@93 >Q-MM:^[I!C[QOFO_VWMCWI3QH[;&UH1UM
M6C,"SQ?,;[/U4E.1V]:C7B\6-BK'<3R$!$DD#N@P&X66&'#)&4(9>N-*]A#I
MB^4MPN[YS2L%;0@%M6:Z50I:/07-F7*6.J%0:"!:&4 ?)6CK R06O ^!A+RU
M9%,.^TQTZ>CNOE2SSI 8G\7RC*>E:)EMH%CR&ET<QC2H#;56JA"5J=\]?7,R
M>A_C3^<37EFI=59:K,GD55X&5G"@I/C(:7YE161 @F6&H\\;#M_:EK)O6%L%
M6CKD#:\8;E&CJ!B^+0S/:1:!)F))\*6]C0,TUH"EP8 T3G'#G#8V:Q:2]LWR
M_3F[%XNX/II%OE3&TIN.!_GG!2=@C5%L6[6([^+)1TYZ?#[OOWZ>\$I+K=/2
M8JTE[SS73)%2+B'34E 4C(Z^F#Y*H=0>L20TL#X12ZL6W?.Y5 POJUI4#-\!
MAN=+.(88-3H]:YJ'B7G05EH@EFJMB4J1J:UMI?H"ETYSJ$Z+&Z/Q:71V>MZJ
M(L7\(IS%WG34\V>3/!MQ7)T6*W-:/#Z?XGS7/'4?>>E]9:7666FQ$%-*A@E)
M-%"K;=8L/('\!P=<6X&26Q%B-GB0]Y7I4A&7ZK3HB&91,7P'&)Y/AQ"<$I\$
M:&XE9!4#07M6PG2IISH9$]%N;?.,8;)TAXKJM%CB..3DQ+K1>'8>4GT6M^6S
MN#CME9A61TR+19J4XE:C5:#*.0@F'<')S%/<>>T,AH#:;VU3W6>JNBTV$,:M
MNBTJC&\-QO/UHIWBCK,$SEL*2#T#BXJ"UMYFTX%@X&YK6\N^$FM4J6D#VH,N
M[VJY$P8Y_*(3Z+**T$:;9^T6F)@Q:77\KI(^%RM-H* Q4!/ 4HR *FAPEC!@
M/!MMGEMKG<CT2?JTEKK>1 RW6VBB8OA6,#RG G%*>%!6 H\N 3J*8+E-8$**
M/M*D1#!;VX+WN90=PG";+I;U:0+:DFOE'G8&;*T95Z6G%=+38J$&ZI2W+IMD
MTAI=.OH0T%99,,DX(H6CVIJ2DU-Z<;5EHG6F3$.+;IA["/G6NGA5R*\6\G,:
M24S2<!4-9#&)4I&%9V7$:<@V1E#.!>M+U4S.55^8MOJ2=Z^8P1IEK'_N!_IF
M-&Y0.4H94><-.\;QKS@\JRZ0%4:9Y)N6KWL^F!Y_/*W^Y$>NE?M6P%H?'BTH
M*CJQB#80B#9*0.$,Z&@8<.4C82Y9$>S6MNQCC3;91"RW%FU2L7P'6)[30$R)
M#3/>@J0Z8[EX.)W+EH=CP@@2O"48MK9U-CFZY-;<C'I)-U Q2G\\.\U#[YU$
M.XDU\.16SEL^3OJO9<XK-:V4FG87U QIBA23@4A3R,81BZ"I#9 H=UIXR9PI
MO0F%Z6O>I0H!-?*D8XI&Q?'MXGB^9B-FX5$=0!GG +538%1*X 2E,6AA98EL
M%;3/.E5K:)/=&/.M06KXQFV%;USPL%;^607_+-8Z"\XI+QP!390%M(R"XX8"
M"RYO(HI;JS+^:-\LWR*DNBNZ!]]6(S<J?%</WWD/1;(F4B3 112 /LFL.4@-
M3C$3/6=4-8&K?<*6/A3MGH=B38(V:K#&72L7%XBITE%[=+18( PUIQRE IFH
M 13H02O)P!%F0N)*,\VVME&:OE%K<V1;HS3621.I6%\5UN=5#Y1"$.\A:1,
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M]C[3(6C')4(D*@$2YT$;(4"Z$)-ED?DDMK997U#6E[)+=8)KI$_'%(2*W]O
M[WS(#R48.0K@M,3IT8Q?DTWFC.3 %0G)$QD+?I&IOI!=JME_C[K+GYV>G908
MB-YHUEAU=/IF'(_C<#+X*_9.1I/[4N?[;[>B54SR\^57"_3T60Y-N;_'%Z6P
M-\Q"B;]F41S$Z6$ZLN\J;;5'6XO]T!+5*$K=X& T!Q2<@E&H0"'&0*.DM/1#
MHYFS+BG__??JCUAG9'^_OM$6LBMX;P;>>9W#&V&L0S !L43M$#")24!.LCR)
M<:(<6RO1$>3>&Y_%!44C&V\#/YC>$V?%G>H53^/4YA&%73L>YOF:7!##SDP*
M595HBXT.=A8[ED4D4BH10<5,1)@$ Q=( L^=E8II173:VL8^$8OG@]?GH^JX
MZ""66]<D*I9O&<MSFD5R7A"O/)"@V:Q2CZ'>@T1E*6<AH0];VXS*OB"J&VB^
M+VZ,63'PR4TJK=5*P:L\+KE8]&ZW$43EIO:XZ9*692P&-(P -S0!:LQZ!K<"
M C%,<:,39:KQM!K:1])6MZ-:'GPC0-_6&4L%_8I!/Z>0.#0\H4R@2<32WXR"
MQN@A4)$PR4"(= 7TC)*^I&)=0-^F2X23:RDM=X+0A0XF38SG=928:]9AGCW5
M0Y[G(HS.W$G\)*;E2*XS,_C?=S@Q:\_Z*V@ \V@8ZAZPRCU@L<<<%UYI0PQH
MJB.4AI>@>2Q=M0D3S!$O9GN D;3/EV]SV3J.[MA/59FT,FEG].?*I+?*I'/:
MM!34HT0/1.ML0EMEP6FK\_S*@#'1;%07]U[6I&6?\;:"#>^>21MU^X>IS5_Z
M,6OH0@FB4SM^-1@V7V^^Y"X?,P3&MX=*UNC,Q[%G?8E1LL/W^<E[P]&T*,[C
M_.=A;Y!']&K<A$6/I[U1ZDV/XR3V'H^&(0XG,917S00VQY _#X9VZ ?Y[4T1
MF*8MR(/>E_E3%V;B?!P"\T#?C"9--.'#<3RQ)>_JQ[>#,#W^2!T7/G4N6/+Y
M(];E(9Q-K_Y(*<@)>9[+PGHX.3O-(GC_8\?DP.?2S"[\+$_2$%#FOF"%EE1)
MA8$1;;QEFE)GN+44V1^TU$:=?>AX_+GFU:L(;ASMGV!3?K"']N2M?3_9^N'+
M99GGXJ) KIK+"]-&OUH\*Z6;S)*^QB3-9)39>51ZP&?!9_#'<7E7'H6]ZR'T
MCL=E[_JO;TM)9=05<BAX*BUS"DS^\8/=OFP%7)CYVUNAZM(5NON?W5_W_K/W
MK-_;.WC\X$I4W_4P'Q\>[.P>/-O=Z>57SPY_W=MY=)1_>7:4_]G?/3AZUCO\
MN3S!X?YN9Y_A;X-A9MK16;Y'F/1[\9V/>2]Z$\>SZB0]>YHWONGD[]U]@+.A
M/0N#O"E</<9K$'"SAWXF_F;?SD,_L6\F\>''%S^&P>3-B7W_<#!L!M)\Z".]
MG^\6Q6,UMV<WWS>[_)GL'I 9X9T[R\Z_^?SR@^;2G!XRN\;Q@9+\RLOD ;WR
MVM=N2_$!8^J[;OOU:]R(=1DL?8!<KLM@5S>S_.K+<[>]Q(K_B)"L7<>;O_,;
M[N.OE.6< 7FUUJ>Y%B%=;DM\>AJS7D]SE'6-V-O/[SN>]':S"A(^ESGH<=*_
M1C>T;Y[LK=F4'.2_7'=&[L&"ON#!^\(>7K1X;V(.=W,JBE?]^A-QO5Z:]WU"
M:1L4<L_FK"[".UB$*U5MVBI%?B<A?$_C7W%X%B</E^F-VMIZ767CU#K(K@WR
MEE&YIBD\!W':>S,>A3,_[8W/T;I,4/.&G8ANUIDF4]I32HR0)" WVCAG>/).
M"N*-3?:/G28Z1!$&UPL3.>?WG\>CT^)%+D-X/I@>/SZ;Y'F(X]UW_N2LS-^C
MR23F_\+:9#D?/OMTWBE>?-@7^SO^_<OGNV\/7C\]?O'ZZ>#%T4^GA\__]>>+
MTQ?B<.<5WS\]^//3>>?K1Q\.CQZ]??%\EQX\W^.'Y>SR^6[^CG^=OCCZ]VDY
MLWSQ^D_QXOG+A?/._9WR73_E<?Q.7[SV>/#+[KL71_EY3E\>'SQ_D<=]D,=Y
M<OSR]&7Z>-:Y_XS@_NO=IKJYCMP1HB 180"S2,$%KD$'GQ*77#KIM[:YE'W4
M;86-K%'@1R6J-2$J%8F5R5K/I$)AN%9!4>Z-MC)8@KXA*IJ)BD,3A4'(-Z(P
M*E'=+5%]F",J06Q";QA$77IL"BW!\$B!H*$EY4$Q+$5D).]3NIAV58FJ$E4W
MB"I3%.7.:L>I0TFMB9&C23(D%3T2>JY144*K1K461$7GB$I9I:1&A.2<SD05
M.91@"I T;TM!!*6-W-JF?<)X7S.L5%6IJJ-4I0,EDD3"I:(8O,YV0I0J"*J1
MY74<SW4J.C/^JD[5>:KB<U1EF7)9H@F4)MGXX]* DZ'PE>!)>(.299U**>P+
MU7V=JA-.]<Z[[WX=^!($>Z7K[B9)LIN9!\N--$&E% 45*)72,IA$>$Q1A8!8
M?5YK17L'CQ=\7L8:0KT/8&Q)EM(>2Q,8"4&71G_(6:"EJ#GVN5Y:/:O5_;H'
M<,S8=B);7EFKP;S1N91U<V*$0<\X0ZR^HC4#^+RO2''JN5 >G/=%K]$(6B4)
ME OON$>1;-C:1M.7I@)\$P&N(S7&*"&R'<YX,LDXD;R02CKD/%8?RYH!?-['
MXKSA2!7+ $\:$%4H';=*;VBJLY$J4'BVM4T9[YOE#9>*\.XA7$O"::9R[8-"
M3;AU:"73Q&*R-EI371-KAO!YUX27*1,S$1 U#] <_#BB#$@>F631)RI\1CB5
M?2W;JF.U,:Z)-8TL>EQRH]QYDF(OW^2O@8^3Y3P5ZU=<] 8LZ()4(3)AG6#(
M@K0^>LJ#<(X&'[2OGHJU8L%G"YX*1[4MD@1G169!9S58+C7XI&04SCN-(K,@
MZ>O6:KITZ""I IPSR@)!Q;(U@SQ1&Y,+S$KBJ")>UZB6=0/X0E2+%4F3*,&X
MP &#M^!X0.!11BE\U,C*8;'H2UH!OH$ -XG$D!*QB05D:#0)C$O*>3116J:J
MIV+- #[OJ1 T&-3: 761 4K/P+#D09-D/3<T)J.WMKGI<]S 4) *\$2D1RUE
MULH-9C/3NA2T01&T8_G_-89BW0 ^[Z@P-CKA$T+6U&G>P4G>P6FDI?HNI]$Y
MRTE6T0WK9[!W'N#=":%@XH'JJI]B5K&WC0"*>UAE/!EG;>2>>*90<^-0LL"-
M9#QE=F2A^BS6BA '"SX+SSU#SP4H;;/&8[,U8RC5P!.W3DK"HS!;VTAI7UW2
M-[&CQ<AK!X+;B8U7DCBMK>(.3:26>\%0E-X52$UPU=VQ9MRP$)B!+B1'(BAK
MBC]3(5C*)5"&,O\Y>4<P6T-,]Y'QR@V5&SYS XDA)$XL>@RHK#)&:9EW%.4X
MY2FDZBE9,VZ8]Y1XD?D@F\9@49/,#9Z IL5=HK*E'$W,BF(Y\>U3K?H4UZ:-
M266'6V$'+[VG3/) #09M7 J14XI)T\0B#=7-LF;L,.]FH8X+Q14!:A,%)-Z#
M%BP!1L>#T2D:5MPLFO<U)^O-#9T(%NFDX^7P32S!(<-7O?CN3<EB^<XR45\6
MW5]!<:/KNL7K(-=PD-UQDG8[F&O2]%YX-1J%29GL4#/-5NX++9-^F'XI4UY:
MQYQ'T#W+DU^5D[:4D\/%A#*6')-.*Q!>9.4DJ0!:$0\IFZ8D6L&(MTT4!R=M
MV2UK:IIL)HY;]UM6'-\*CN?=D\8'H9C+1H:1&<>*1W#:,]#H3(Q.:)ET"3KO
M:U7SQC80QZW[&"N.;P7'\ZY$:JVDP6B@@7I +QRX3,,@%6.*4&X\+?F?M&_T
MT@W<*HX[B..VO8$5Q[>"XWFG']/46<T\**4(H/4>K,RO?-:E./(HD8<F>-((
MV7D<=\*MUWFWP=,XB7;LCYLFZ"'^%4]&;TI+QIK\=0N!5+.ISPRW\WGB=V>>
MULISK?'<8IH7X]8Z025P;0Q@5EW J8A9?2%$1FD$=YGGJ-%]S;M?AZM&B=^]
M Z%B^;:P/.]#B('QP)@$Z0T%C":"%C$K+LPK'45PAM&,9<G[7"U]4%FQW#TL
MKR!0J6+Y=K \[T?(VZ]'S@0X$02@$11LH!Q(0(-<2Y]-RZUM(; -1T+%<@>Q
MW'Y84<7R[6!YWI>0)::R<63 >LFSCJT\:"\\*!14&#19Q&IK&Q7M(RZ=EG"/
M$K6Z[$QX%D_R'U_U>Z_B,([M2>-4L.%T,!Q,IB62Z*]8@Q)6[E<XE\(O,QED
MYGOTA00J^;5=Z/OH42&^QLEPN+/W;O_#WA]>.O1,!E"<!4#!&&A'"3"'0F3U
ME'C5E-,JFDQ;B1?U2*1#J&[=PU!1?0>H?O\EJJVCB4JM(22,D!547LI@<E!,
M4YJRGD-Y*8-):#^#O*)Z\U#=NJ^AHOKV47TPMU<KHZD.#B%F@P60"PLV4@F.
M"B)+"!)AY=0325_6<,*-1'7;7H>*ZCM ]=Q>[60BQE(!D2J5-?#DP1A$<$;'
M:)(*R67SF!/61]+]X,+N!#-TOU#,:"%K:9E@AGN8W+F2-(D2R'5.?)/*?.TQ
MW^Z"[X$8:;Q/"@S!K,]('<!0&<$3(7TPQ"I4I>B#Z5.VM#YS4Y2LT1'+/43^
M2A(K*O)7AOPYG<=0;<H9*? @L-3&RT9,28YREKDLP!B$]UO;3,E^MFDJ\BOR
M5YR*49&_*N3/^S 8EG G(K*-0S/R%35@%,_Z613:$^T<M6YKVW#5%\N?-U3D
M;Q3R5Y&\49&_,N2_G_=>*H9*<TC>"4 A*6B1"(B85*8!QYC66]N:\KSGMQ5G
M<3\*M5SNU.FDXV-OZ$>GL9?&H]./[H_1L%;*O6.WQZ?R.3/Q_#J:5"YLD0OW
M%J,N3-ZQM"1 %2MM"BT!RX0#B3)IX7FV; L7LKZDM=IEQ?XJ'1\5^ZO&_IP>
MI'VDGD@-DNN4+:#\P\;2 D1+X:W-!E R6]N"]B5;NB] Q?XF8;]UUT?%_HJQ
M/^_]\,%D?8T*"*+DK=/\RA;GIS?2IJB]L,)N;3,T?=%:\](*_LT ?]O>CPK^
M58-_W@$B!0J5$%PY^4#D#*RV')16W'I.4"JWM4T5Z6?R7F_P=R(*I*,.D&D<
MQ\FT-VA05ZM7K-RY\7'&9S1W.#V.X\IS[?'<_H)SPW@4,4D*4F-Q]!(/6AL-
M0GMG8U9;"<^H,WTTW4^GJZFQ=^^AJ !>-8#G%)5HA8I.1Q""24!K)3@?%9!L
MN23.N6*L9(_TY?*Y(Q7 W0-PZVZ&"N 5 WC>S1"]PZPN9=@VQPLQ)'!!:Y#1
M>:D-=<YB*373)ZI6C=I$!+?M*Z@(7C6"Y[9@SEB@5*<\H3$ &DM!^^B IJ0,
M.H$JZ*UMV6>\]@Y>WVB(!DCGGH#>W\Z30/[>[PWC]Y6U7+_DM[_=KF=@DA\T
MOUIPA18Y'(R&HR]=HI_2WRJ9W8#,GBPX!$(,7&H;@3"?U1&&$6S><H 3ID.6
M*+,EPTTN%LKZ>W?RVFJVZLT!VX(GH +V5@ [IWUXDC*]:@M(/0%4TH%5T8#&
M((*3-AN&I2A,!>P: /9.XPLJ3-N$Z4(T@>0^(;>E5!W+,'4$C% ,1";>P+3/
M,BK5H;&MMI<5K%W:75LP\NON>BNPG=]=@^9.DP#,*YFW6"W!A2" >EKL&!92
MDAFV;!&V'=I>ZPG_-U(<7$RC<?QHW$_MNUK=X>XC 3X&.CV:3L<#=S:U[B0>
MC7ZSXSB<5H=F>Z3W^X(/0(1,;Z:8%,8DP!0#F) "Z*RL"&.9C-YL;1O6)U@3
MOBL-K#:>H-+ K=' G.Z#B@@5:( @(@=T+(#UR8*F5CM+74"1MK8%[S/95@^,
M2@,;00,KB$JH-'!;-##ON3"9MZES":06Y7A3,]#),T@F6Z\FOR+HMK:9%'VE
MVNJ?47E@,WB@_=B&R@.WQ@/SD89$\.A) J.S+8 Q"ZWIPD&H+<5@FC+6)25"
M]BE?\VHP-0KB*O#_-A[]-9@4V&>H+>\P63^O[]W[1([LNW/O[D]Q&-.@TEZ+
MM/=BT1G"H\&H)$0:=6FZ@: -BU!:DWNN61!69-HK73W;2@2K9S<=0O&*7!H5
MQ:M%\9SR4GIK)!DC2.L\8,J6IS%&@(HQ$B\B<Z1$68L^68,FY!7%7?%(5!2O
M%,7SK@AG-4=&#0@A(Z!2"5PD""ID)8JC=;&X(@3O<];]ZOL5Q5WQ)U04KQ;%
M"S$50KED+3A7FFM+EL 09XK($+WW69AZ:QM)G_'N[\4UMN(J7!_$JPHGK-93
M>MD$W FQ_??JGGOMF;QUWTA>;;4VSBKXVR]X1+3.9J^7!GPBI69$.1 B4H$P
M)AG/)+6&;6TKWL];\7K[@6]\'E29[=XS6^O^HLILJV.V.<V4)IFTTQ*8T@XP
M20X6J08O(]?!RQ!,VMKFNL^6[^Y6F:TR6P<>^"Y]:)795L9L"YXSDYDM<LRD
M9A1D"6IP2#F(Y!D+RJ98VK<QROHH[EO[MDIME=K:=BQ6:EL=M<TI;<GKY"U/
MX+4+@"12L"0X8(%$K9EWIJF QD5?F[8J*-6XI(Z1VV=G8^]-'/<FQW8<'UX9
MDG2-A[X@89YE&$9G[B0NB/C*(YHVCGGJ*-=SE)TX$IBI(KRC9P,_V<G +U/U
M:L-4K377IGZ+XV>%<=MU\K-YI6K7CH=YEB8?OZY919_T)U+UIVOH3W\NN/-M
MTMYHRB!IZ;-I&#1H[QEXKI6,*09*W=8V><#:"NI>(].O4LZ:4<Z2WO=*.:NA
MG/E4$N:(YIP#,I:RR28Y:.<1HD]$.U.BO$2A'-I6>GFEG$HYJZ*<)=WBE7)6
M0CGS#G!J?'(F1@A9-("EG(63R"%B\$$@>JELH1RY=,A9I9Q*.:NFG.7<U95R
M5D,Y\]$$3D59 @D8\YER+!?9L-+9NN(>K4;G4HJ%<K#[AE4G',\S9F(/F.BH
M5VMG<'(VC6&9X.1-H=_+'FUCZ'?5?JWS=50)^"8$_/K18N=V*J7S6D+^OP)4
M2,&67JZRT'*,A!C1DF>K>\E"E70VC'16[=FJI/.=I#.G]94V"=X)!5$Q XA)
M@)%604@J!(Y>9+.S'=]6)9U*.FONVZJD\WVD,^_=8D[FC:$$=3H> +4A8)*.
M0$(6AJ,:.=.-=VOIV,Y*.I5TUMR[54GG.TEG7M/)RJ?'%("R1$O[&0].N@3:
M1<^SFA-0-*2S?)'HFL5]9SZMY\TO,8#-H[&O8G[ T].,XR;"<M(;G4TG4SML
M'N.[PBV_<711[[$V]Z@^XN^.?/STP/>DLLN,/%9=$N C=3V:,=?!V:F+X\/4
MZ "3P\_$=7[:57,TVE(5]A8\L2FZ$*TL6D(V%=$*!]:9O*DHBYH@B9K;K6W.
M6)_BTGWJNV>B5'RO(C&^XOON\#UG"CA4P5MK(?\(@,@HN"0L:)80O=4"64F<
MIZ+/=>UPMYGX;CT]O.+[SO"]$#VG*94\:UY%.0,,CH)Q20)F&T$1GXS!4/9O
MTC>X= ^(BN]NXKOM'.F*[[O#]]S^G<E8*@PB0SMF5%M#P'*1@&K#@HT8+(UE
M_^9]8[J_?W?"F]=Y3\05T6K7XKKK!@ZO*]?=EB_B7 8+E%?9KCVVVU_P1CAJ
MM O$@-$R6RN)2S#$&U!>1D-<I$JQHLV(/MG$=("*\%OT1E2$WPK"YVO"9*DR
M3O-JQE1RFAUF>T4%D$F:0)+A(JB9OS&S=T7X1B+\MOP1%>&W@?!YCX3G)@41
M'60XTXSPC'5G=01AF<$4A2-6%X1C'UE;58@KPCN&\%OR2%2$WPK"YULV$>4(
M4@\Z*^20K3"1]74E@!EI'?-*H"/G>[ANJQKOFOHDEKMY?><*A/5#TYDV_QL&
M?VW_(__X^(E3.WXU&#9EQLR7-.QCYK;Q[3$N*XQ[=!Q[UOO1:?[.]WGI]X:C
M:9ST,M/U\B &>42OQO:D]\:.I[U1ZDV/XR3V'H^&H;3+">554_S09G[L_3P8
MVJ$?Y+<_F^8_G.;GF3SX!,%/$]&PH4 3K-"2JN)X9$0;;YFFU!EN+47V1RG:
M^-VSM_T/-_YA>_&KS^]R>Y.N+IWTW?_L_KKWG[UG_=[>P>-+9J@CPWQ\>+"S
M>_!L=Z>77ST[_'5OY]%1_N794?YG?_?@Z%GO\.=\:?^WI[O_S._;^_=N>9[#
M_=W./M'?!L.\A$=G^1YA\O?N#O-L:,_"(&/JZC%> PD-!7W:\V;E#?/03^R;
M27SX\<6/'REL,&P&TGSHQ_.[SW:VA\6%/;?G-=\WN_SCVT&8'C\T^H&4C1)W
MOE&=?_'L*GW07)K;B&?7D#S@2E]YF3R@5U[[VFTI>V"8^J[;?OT:$KXN@\U?
M2>2Z#':%,VNN>]O;5MV^:>"9A;=>8L'-(+]:$\Y<B[J.CL<Q]O;S^XXGO=VL
M)H3>L_@F*P/9DNIQTK]&D/BF3<E!_LMU9V39U7+!I7"#$M7=G#?6^&:_G5-P
MG0>]+Q-&V\#7ALU)740K6$2=R/;X5EQ%%L,M.S"_H^GE8OGQ^]%EY,;/O68N
MZ]KT\A)O]/O]P4=O]/'IRZ/?Z<NC%WAP]$0<O'[R_D7YWM/]=X?/?W[]XH-_
M?[CS\L^#UR_H9V_T$_YR)PP.7C^B^[_\.W_^"=G?>7I\N/,GV__E]_?[[%^O
M]T^?%$\UG?=&'^R$/P_8'MO?^?WMR^<O3PYVGKP]^&47#X]>O'UYM/?AQ>G^
M^Y<[Q5/][[0_F'FB]Y\1W'^]^V'_U:WVO+PI,#J>?U^);>.)K?:\7!MB^S!'
M;+?9\K(26R6V#CQP;7FYB<1&%S2VD!+A! (I><<J1G"64M#HM=?1VRA2:QTO
M*[-59NO  ]>.EYO(;'R.V:2ET1@7(3EJ 7U*X(S1@(B6*"&)D;*UAI=WRVR=
MR.3J)+<=3H_CN!1C>C..QW$X&?P5>R<9>;4*T_V^QUKXY3\AYD(\R_DMH+S_
M(67-<]ZVY_YL.([Y7A]B:+!4ZIL->_8O.S@I03&0]S28Y)TK[X,N<V#T9^/!
M=! G_=XPSJ+C[+O>X/1-9MKRVW_?I6NXX8?'%^EAMCO__ND1_SDZ*1/^BQT,
MRY9].'SVZ8$>C0>3?&DG_SI\]5N>SU$XLN_JIM[6IG[PF+S]8E,?&/+R/\?$
MG_Y[:)^;L\/3O7>'1[]_*//Q\I?\/4=/3UZ>[N?W'IP<?'@B7CY_\N'%AY<G
MAT?_.O[/AU?L#QK1"W06+"<1LJT:0"M+P/B@ T<C@@O9V,FFSJ)"T+_10FW=
MU;>2A5K7XAVMQ3_?_D&S3<%]*BY$CJ4L* 'GF0>2=PJG?;3(;%9/S6+3A9NM
MQ-9],Y4R[\\R)7\P&Y!XJD"H9(KC6T/>=!-$M-0F9TFFSJUM["NQF"#:L\-P
ML[7:MK5=67.3EN/NV_TG?]B0(DLN[]S6<T#I#)@4))"DH@I,$!'%UO9E]97Z
MO7&<O(GYE[_BR?LO(\8WO(31WVY7QY[D!\VO5HW&;(L<IKI]M(O7^9 .B1&9
MD ZDU5E/0>O!)LM!.1H-L2)QF>UBW9<E'FX.<7_O3K&C6LSLYDS0@A%SZTQ0
MP7X3L,^'.7 C+)$"@1@DV4!6'IQC$JP1C"3"J2JG@>*2&(<*];6&>@M68MWT
MUY<'YJ,"\EK(=ACQV>K3:=824I? )TZX#UG)EL*5LS/95Y?4*:Y4L-Y4L+P1
M7JE@?:E@X1B=*2<(SP8V+?5%" E@I+>@N"817>+Y1_&9&[,8'M0A)JB%1>[-
M.V\IGN'VLZ:^H,Z;YD^=/^1YA,IYQ0*>,19&9Z7^01GVU?$K&QG.UN:4='/?
MO\NC]4LV^KIAM[YA+^9@.:FE4A'!HQ6 1@EP&BU0M$%R1:E0V8:7V!=ZZ1X$
M+2+HCBL%5MZLO-F-I*[*F[?#F_.^S^1ID,1JD)@I$ZE&R#NB!)W%9EC(%K$7
M6]M<]15IJU)JY<W*F_>5-UN/2ZJ\>3N\.>\K9LE+[K0'QK.6B4XIL X3<)4<
M99S;P$0)9!-]J9;.(*O$68GSOA-GVT%RE3AOASCG/>LN6&FR@,!830&Y#&"\
MD""D]%I2[W6I*4 YZQO25O>-[A%G+2*]RB+2YT]V/@R!>9QO1I-!64$/Q_'$
MEEC(\\*TYT1TX5/GJX1\_HAU>01GTZL_TK$9Q[DHSPL_;U!B6VQ]_-#Q^',>
MUJL(;ASMGV!3?K"']N2M?3_9^N'+Z<AS<7'NKS%M5'PMIRNEF\R2OL8DS624
M*7TTMHV,,VG$<7E7'H6]ZR'TCL=ET_NO;TM)97PUA9PS<AZ7_3(#XA\_V.W+
M5D"':EAO4HWS9T>'C__WGX>_[NP^??9__DLSJG[L[3[Y?>_H16>?:X,JG;=8
MY/]V*Z)G.GQ R/>51.</./F^"MM?NZUZ(-7WUN;^VC7&VR_?7L>ZFK'J!\BO
M70Z]SNM-QJJOOGKQKDL7^5Y\;Z=+"G^K)GQOH4CS^0S-:?G,-/.Q=-7X:UN#
MW9S.QZ/3T]$PFT<C_^<RI:VO559B/'J[$#>ZWM/W*(^Q*./VI-$??K.# (-A
M\_JQ?3.8YK_72;WQI'I_=GIVTECPL](T7\9TE:#7.JU+3>M.3 ,_F-99O/G^
M,YHV[J3,E\>CD_PDD__I[?Z_L\'T_34V'8K+;#HW$4JGYW#6_'+EBV\S)NO1
MZ>AL>!VDWF!*;O&MM]J=H3';;_-$ZB=[8H<^]NRT]Z^S89P=-RQHH=^=/+_$
M >8:G-I=VH=7,T$91NXD):@5=413B^BE(E99+?_8.X^P_?9Y759L&YY>SUZ[
M[P\^]=K=$P?/?WY]P/;IP2][XN7K)WS_P^]B?^?@Y+#TP3W]G1Z<[GXX^/#3
MX-.!W>EN'M/>V_S>=P<LWWOG"7OY^N?C%Q_^_?K@EWU^<+2/^Z?_/CW<><3G
M#^Q>'+UXM__ZI].#G5W^XO6KMP<[+T_WR_<_WR<O/GBZ_^'5^Y?/7^1[AK3_
M_I+N!LE8DBQP5 8P>@6.T@ TABAX$,)+6EKMTKY>/D3L1CA9UT*Y&QFM<+.'
M7C-F6XQ':(O6+BJ>,[6S\M7-^&H^HM6+$*T*#)(G"E!0!49&!C$8FXRBDE/1
MM :O7%6YZEYPE>..<6=U8MY@"-ZA3M)J80@UA#NQ#%=5Q:LU(IL/,27&T*BD
M!BN"!PQ4@K91@Y1&&Y>-2R554[=3J3ZE*R_F7>FLTEDW:C6XTKR#(B?2,DQ2
MN:"U2(JD9(C)6__5?'9%B89*;"LEMOD04$5XB$E[2"YQ0,S&I-6$@?4VY=5@
M?%!8BJN92TCMQL45*I]5/NLXGTE),*@4+<6 42='9?Z/>HW42F-,Y;-N\9F8
MXS-$P6/>B4H:4*D?ITVFLDB 6(M$&^Y4B%O;64MC<M'HK(16"6T=".TF?(8D
M[^F)9L*RI>N0TS&I(#Q)7"6AEO*-51IKS]&?*:QQ]A_N[+W;_[#W!Q4J6L\R
MA3&1R4Q8!\81"]%PZWA(07I;#$YN:*:R]?#U;W*;IZO[R5_K3/*2)^WXR6,3
M7L]^_+XDL YEP5;Q5/%4\53Q5/&LCWANH/]2-,%HA88ZC<5;SY2,I<@'%UDG
M3NK&1>76L'WJ.NC !X\73'F5#'(>L\YK'8-LQ3AP+B(DBEI8JZA7(9ORO,]H
M6^60*G0[!-W6ZT%6Z*X*N@OFJ_0$N:,)A H:T'H-6E,)ECI:/!")*-5![-YV
M6]7;1-Y5C8B_RUY=OP+TWZ?2U?X 53Q5/%4\'1?/34XX!0;O#!&)<(TI:.>C
M="HB>I:L%=>QB&[87:.H6Q_K>?TV&I<!/II.QP-WUE1L.!K]9L=Q.*T:66L:
MV;.%.(\H>!:OC&!(UL70I&Q,:9>-*2$52]$;355MHK<V@*]\W&GQ=+O;:>7C
MV^?C!0N9*4)"\@%X9!*0D@B6\ 2.1!N<DSYXV2E"WN33V[W)Y*S)-1VE8B&7
MJAV3$O#0:^K ]6(3\%#.=S,LBMW\YB1_V3TYZ+U9BBFB- 0)<U80=($:K9)T
MT:HHB??)W]AIUP2>%/G$<+'SVBSOM/GYDYW$4&@N<UQ3O:]RTTVX:;%_"U(3
M0[82@!/- )648% 2B$HS8Z5F@=BM;86+Q%2][FN&X45UY+8 _&][<A8K?MO
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M]Z?%V3<93..S./YKX./,A?XT^M&K87.7QIM>E8#VE( _%^QDQHG0AGL(DEM
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MU^+[\L27@[A&88C#6G$7M8O2:XT%P280QL23B&^MGN<GV]/;&$OY53@ACIE
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MO,M -129+;BV5+CR BCDDN5EG:6,MS'&P@X*%P];G4[V .9,F"5<O)+T0_<
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M,(<)H;4+A!%!L0S))3>MR)Z4Y'P:K0':T*VPNA 490@0#"Z,)U=DX:SD)A7
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M>:H<NXO[*X>[PJ<:"A<("IL;,WXPG7(LI(\H6)HWP5&.=!0!*9Z8T%$KBA-
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M4L*GN&.5D9?6"9L 9E4?D+(/'K]PR!*OR3T+?7ZF8B0OUZBF1"?,\][!G(+
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MJF1T6?8I/$YCR2IG<ED:BU<%YX_3V#O?=N%V:YCEVJBP?]2+L=B!\X[ZQ1:
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M%AB$#<X"\ GDO-$H,]DCV @-"BP8%@,16O!<T8N2>Y>?6;T"@T6^!6$Z<BY
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M3E#HPD]>,+5)'HHGNM"%KQ-=^(.-;*$+?R2VV4(77NC""]/S2C,]+V-,UF9
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MG>\..X->-D=RAX;].+F_GT?LHC9,GHS:G\-6+JQ#\<SPYP9,WSUM^,S#KN]
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MO?6'O?.*=.NX"^WJ9-(MU#_M=OJPUX5:%1MXVFO.QD"6<@<3P,(D6!R@@PP
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M0_][U ]82_ R'FLIN:8$;$5*A#66:<P9]5YPDT+Q#ZP\B"U249"4,(DB(&L
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M\VK!=\1XT!AT":2L38@SK$#/3 8%:JE@)#!C8T[MTT+4U?T)C)8NE"M>J+W
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M/%MIXLY.NMH/=T,;/5 YWSX$AE8?P\\+0UL\4_P...Z-)(H[05APW&%M==
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ML*) \%C*+01H1)(%:0@Q7"2[M"*X;JC[T[NZN,/\J?M3$YA:W9]2W:>Y3.2
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M[JH>]S2R)P,9RS8KL>LAFXC!'8O0/\HM W^C^]/+^\YRWO]5MD.LVR_^=I/
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MA# A:4Q1! <6!1>) _^D+BC!#6,^45X;%O.(7K/9,6 P1&N%0$$DA;@2!ME
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M+PS&5&(TX1]P<:81L'0A7QGRJ]+W55*0/VT'J' LONQ%N+@2O*,>6/L=V->
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M-R(WB/8 V02#?&,[Q_9DN/2ORX\&SW5Q'F\Q!>.FF=<\<4IW>6)]BP>NYAO
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M1;1+*WJ9S1I@<^5?J.3_.0S"+(R+Y')YCCDJ?:8 3:7=O&@>GS&P;!R-AB/
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MF_D1.M%<:Y(=&WR0L<PYI!K83;3(8I*0YD'*@#GS/.?O8[)\77#;3>SFII:
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M+/#<+ E,'G@IF!0(+..'D6E%:6RYB>_;(VI\6[1'10@,G*\Q_#1 ?^43MIH
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M?40\$<.517LI->.1DF73>]6L5C8"#<H#;P16EVL[+,P<%EB1'7L\LOD*-ER
M">PUZ\U9\-0'S0KF5NHX 3/]$7"?Y\2V"1+0,],PX!;A-;JC%R_])=;U/X;&
M%GEF_S>? AL,:M5%J%PS]IDC:%H%)-.4W\OX92 <MP1T%Y::C2_U4UCZ:4Y
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M&:B@.:@3Y2SJ7\,J=L![N\"+)!]6_]3^YJ9,.>-9H";%ZA21NE6'A5R(!K8
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M4D.1M8Y:4H26:C-/U_HO-3Z 7'.>#3IL09=&XTNP,C*5Z30VO:0PC#;PEQ%
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MY[;RM'\5]I>S66]9?]M?]>WFTD%%3D%9B?6A\24T=I%0PR\9[W49GF@?U\&
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M%V(J^=)&YZ3:USE-0QGJ+Q'3* E/GVRN %T5N7Z%&&TT9%7:^O#YF$V;^)+
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M%BOY*3QK*JJ=24_+U(:<LDI1&<7)$Q"7Q!["JT<-BHD2JM%@!$HFDP&*=]^
MFIRB-2(B:]AN,!%E(S+;<50D\.\;T,OGQH;^M*3P_;V#@]U71YJA><6^(FN
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M)T]YXV![S]P^V7VW6==WUYM1IX <00.J-O:.3S;5%8D)I-3+I.0346!>IJ;
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MY])(MZQG/L.:R^E\PFD,7=+>G&B.U\WG"C@ (7)6]H(O:4*CE'T](ZZ6#EA
M7W$Q2ES,LFH">G3>H\=Z5?-,S=5-6'5F9$B#N)6Y["9; FE VY$ST^@,Q#!J
M8WY>Z#)7V5?7',\F8 HHV+;UZG!_]^3/_X"X*S I,R[TZ,K%]**H2FJ,VZ.!
MS?6\9W4 U+I&8R#.^2PGHPT+T!*YZ+I0-J?**3462+6I K?%8S%63T&;+?MR
MNTR@4F.%X9LQQQ22GIE+N:=&\^N8 8.;NANP,Y)S8.09:!V$%YK5PV@IB:3N
M*FU.3A7?&AJ_%1>(6$A7G6!,#7LK-*2@KMSJ#@"]$,>]"'"#E#7%:=%8T(1E
M;O.$TFGRGAO]'"G_+\TJEF/KJ0E1C?H5)8EM<(CF<0*!(?*H&/J[,-U/531.
MV*>B;)(02(#/-)80&T9J*FK>YM#8Q=F'>29[DB78^-(9@M1YB4]L7RI)X.7K
MQD-AR5G.B6ZN/T1D='DEQ)=B6I7<#C9\UGO0M76R5+)&]1A?>YZ=,I[ZH71K
MQ51"6R@Q%3?')L+?&@ B<&[GLIN"K T3MR(6=(K(/E.!/L$N<7?M;G$Y][4@
M_$PN"Q[R23PO*XK>#HVMBN9<(SD2H#R>\WC<A!#LM$PT>+Z(D: 5V ]VFJN?
M5[^1WM"B$AKC*5+.--,2A[Y?UJ@K4AQ)N.<6^$A.UCLH@*FBPLZAB[&7.% <
MN!X,D<L)^XR'U'H0#29OO!F$,Y9A24QJX-JIP$]J/"PIJIG, B=%*29@$ZC*
MF)_FE4BM20F&;VU!)I%]4(]\)NP8*D]5,U,'..U<))_K=0EAVEX!J($2-"V<
M8%&"J ;QU+FJ"9O.0?VAVBG;&-JB,YEN3J''#N1=B7))]4H@O(2WE M*4/'+
M(AMTWGBSRJLU,!2VA+Q0-<@KU'IC\+K4IM($:"AM1?6$"5HK.94V5:16G>49
M'2J"[58).U>%2AI"4\T:;3JX6IWJ^08*>DUBV73D6%H,C<,I%</*4@ST7&0S
M"<U4UQTO,T;ZD6,U\\*Z)%R-FM$GZY[E"'8AZ;H#=YL01$*6J;,@ETI@)N%>
M,-_=MB@D*&FS?5[W($YIZ2D[%]92,P"XY,#:*@/4-EQS52L$/2U1)09JD#_D
M@Z),20(T9@=?(J14GETJ>+&NRF[4G_%ZUKVDJ/IL!$(=%F+5F$FZ5QJQ7U%R
M*1U)[Q$&C, !$#-0%VV3!I03UJ8TZFRZ99,+YAM.BMS>HQ&7Q]L2*W.R??1N
M&^_J1O5E]1.VC[8'\D05W9,)(3RYABV+<$>D,:2TUH._T+R0QA75K>LS.AT7
M,87W:T-A#ILM)?26L!DQ82DL*S!!Q-B ,W"^0(].)0<G9P4>D,1/(7PE?"9(
MV:E0F*P>4:8!'+!B78)C26(6&'8UO(.FHOIL1*6=XIN6-?!,)*.<$ /&_RD2
M*:=Y11(X"R=(B;X1<JHTCV,4#:W@&@VCI7GP",E>!BF';=-T3I)'!"7PM,'Y
M;8@R+),A#.]E3ZCM"*JK4OUZ:GQRHTH:6QX(R6R2S^2("45N0'G8M(8W"O_Y
MI)TVHDJMV;?!<Z+H9L->42[IYNC@@ A;0C6#=(ZN?7)"9#?ZP-'XXF*Z.%V1
M3JZE\) O#8]'V$\XX;MS&;I_'.4GPPYV.@(\J9:J'30P3M"MR76905G'@9JH
M?7V14[?(*>R+G'[*(J<UT!3'',?3S:CQ6<B)%9G:AD&-:B0F $2>UA&51E .
M.SE CBIM7)2G;)I_DWC88&US/I.1UPD:K*(B\EP,PZ#:X+0IJN?3YMQKB?:(
MUHRVI="FE?XK/C:?GHG&/1$8Q%]K\T+@?U95D>1U!Z%XIYK$UQ!6@R:&I0S!
M27.&BG[)4P6A-^5);51)J,KNT,<.=I16R'"2\VDS4##52\%-$4HHKJ]AYF(N
M30RQO-3F%[AS&%MH?$JDW!K8O1@5P))7(2:?BY=W+#,\(DRS-/1+#9=Z'FW1
M44]DA:JPVV0B:) R25,D!NG;Q7G1<;QST<)[*6FDP0L=_+ FO8C$03.:E*!_
M0U9OR050-C:Y%A.<6,5$: KO<#RNUW23AL:E!X$=KPRQ]1MMC?>+=KB>:8_7
M.<H;XT\072B*T<2%8WHF!*X&5+&T."=7TO =$YG5=^&+_#/85[2[2]R=C$61
MA2QK*L8$'U0I^?2Z!/[')CTPN"ORU_08.==^/I->JR<:CO&Z<=BRI%:D-BIQ
M,=T;&0CO5,:5U%&+,B278#$D4$G6?K"M@T!LY9/EK+^%Q]H#V6S^FH(R2.]R
MI@;Y(_B?4J[!JDO!Q:P2CD1:I[7$JQ!'N4CENV2+DWB/?(T4:JN^3QOB(@ZY
M:ONE3AB)SEJ1T%E\9&LMNGVW]32[1J>^XLUBZ0X>""H&X:TM$5YY^K\O;F#I
M62_63>(MS;&OC\"[97GUD?1.UV<#5TH)M5PT?;5ZI_HTAF873HFIC(T4,U<J
M3U',*S1U-V^'XMEQ2D7?F?9[$2K!I/S8><5_4?_Q*]@)YV C_Y)/:>7TI5_E
MTZ6SO$3RTOO$GZ73&(7#R _1;YR5\/]3]6+I4@[)I?SG+%W\FQ,,+6?UGZVA
MO?)O5SW6=H9^Z-WIL5?_S;/N]LT?9K'^,!H%SV2MS^I@G]5B@0H"YT9/_2=)
M!!V:4L+1(TD\HQ@I2KG_?>&^J,-75#;XBW/^U;#;\@TK"1<,09)$(F9U3\(]
MNDZQ6J*&#0V(3@Q'GH?>5G23;0FQO7)CC[,GB;Z.?<G[!4X+,G;;QI4!=I7>
M;7>?B]=GX2Y?+/]H"6J/_MNYCUM7CWBPZ.S-Z.$=./GH\V^?(4C)-71QB_-Z
M9B1T@!G7GH(>A((>7II.\C0=\W65IO6VI$U+68GSF4224(M[%GS2G/3PO1N]
MBE-^I .S[TEZW/ZC/\3Q]?3V6/0F!?7*PUEH!DH2SK/LJH.Y4EH_4DR#)/6R
M5NON.5VWSQM3AV6L\U'\_>'VW=POX="LQ8;=T6C@A4Y'6=_WYO&OMSR$JR31
M=<S6E68]\?Z8Q.N,W(%M!S\V\>IG.-<_X_L(>7TNUHV>XD[7AI'_<1.SKA>"
MO1#$#=L#RW$'H>/]V&+PSOOX*6GW.1!N$'@#/[AO[;U.-/M3JNXG\276AH7;
MJOO640,)(7+7R/=C[O2M1!)<%3&X$?$OV>^ZT[<W<,/;ZMKEU_J@HJGSRCN)
MIN=W.UXT&$7][:SI[9BN_4!7LZ;ROR>'*ST7\%NB6QN /;<^UO78HT$XNJTY
MUU_/(UW/Z.<2I8^4@'L24WJ[!72#\Y,(G^.[+.LEV[\Y03_)*=C6( SNZ#W>
M3=SH;3Z5T_^<;L<?C.S^=M;T=DS7>J"K61LA^2!)D1^4'-QHX'IW3 CTS/K0
MMQ,Y S>ZK2?<W\YCB5+_CBF)YRI*[RE(+6[5&3K^FF;7VJ,F;NLWR?R$[*)S
M8;]I,<>>/+7@GRY_?O\'LYZ.MF?;@\ -[^9NW]_I/'$4I>>/GC]697S#@>>X
M/SE__*!11L?_N<*,O;3LI>4#E^O983"PO3ORU0\C+WL.Z3ED17@D= ?AK>.9
M/QI__*CVQ$]6 4+!E7\2$,_+-< VHB?=')P).P/?R<[ 9P;4]*8LJFJAK7$@
M #;G>M 3 C8A$K[$;YPNFSK;PSOIO_7P3L]LL3V\4[_8'MZIAW?Z/LR,GQ.<
MYX[G]<Q(J(=WZN&=>GBGZ_FDA]NY_8'U\$X]O3T+>ON1X9V61T*>'N#I24J?
MGA(>XDDV[$6C@>W=L=KP 8+E#U**V!/OCTF\KA\,O%NWH#TSXKU-'>T#H$0\
M48'ZNJ!$K$$!;B\$>R%X9<6(YX 8]'L=?I\ 3\^<=I\'X5J^/0B#^R;<=:+:
M)U;>3X09NR[*>UT*/!X>XNE)=KJSHE;B\:&>GD1^;=A.-!CYT>;C@%_<33X]
M>1G9TUQ-Y U<S^]O9NUNQGTH/)^U,>*>*<33T_"I9[F#D1/TC+I^5^,$P<")
MO/YJUL[ ]GILI[MDW]:^ _T>!ZT\9E_,LPJ5/$I?S--85O<PJN51^V*>,DS8
M\\=/QQ_W,0WF^?/';0*2S\A:O6O"\$=W*WMIV4O+)QP;\_SE9<\A/8<\W'R:
MY\\?#V]//*LQ-<\ZQ+(^?>A7MFXO"Y,8\:7^7=^/K?_6]V,_L\7V_=C]8OM^
M[+X?N^^F[?NQ^W[LQZ:@OA^[8],^[W;/OC^V[\?NZ6V-#ZSOQUXV[6OKU>'^
M[LF?_^E;L'^.!BYW9 _<\+: OS]+^U9/O&M-O(X?#8*[3BMZ+L1[FR1'WX+=
MMV#W0O#G$H+VP++<@>L_2>/C,]#A/R7M/@?"#4![PY/[!NP?2W4_"2+.VK#P
MS]. O8V!@J.]]S])P[4_L**':A_]D9K2GD;H#%SGH?K2^LOY7LZYX_B]YRKT
M>VJX,F9C#;S1'0>6]KSZX,ZD?X>RXOYV'DO-/>: JC60I'WO==\+TO>"7)_"
MZWNO>_[H^:/OO>Y[K_O>ZUY:]M*R[[U>9P[IV>/99BR?INMZG=CB1S4C'K/E
M>@W,B.?4<GURQHU\FI2<59SZJ)<.PLZ*TIC!)V?4Y4;SLK%9:2*:E?ABLY*!
M1?,#[-5.BLDY*^'OLX(>D11ER:OS8HI7"V_*X=&7G)7&.6R@2*N!Z/*&/\!!
MP3YA$6,V$]^O%UID\)9_T$J<X!\# Q_)DUG^A8\O!Z(=G!O3.2T'/CN?YK,*
MF3X5T[[A6<P8\PH.S8#SQ]:A0#S-^T?[./ Y#$B,G7(ZFHJ/QW+A"<='ZZ+N
MVQV2X(CZI-H;N,.Y#5=VO<O[]CT@B/.BRF=Y =(!3Q7>)AO1!1DWOR5%J55_
MA<5P@//9ZJ_<H+W^,4G;B3I-48U_SW0KV#G<K!G#A7\V60:+_(6-+]AE]>*?
M[:W!OIKG>(,CL/VKF#G+;K/C\ 8;%N>=<B 41O<% I67^"E8!7OJ)1C %-G_
MOOA;[GM1ROQP9 >CP$L=*XP2YH2V'4<N8[;G? Q *!$( S(7O!!(I_K7/]G+
M99>YMF+U#Y1@Q2?@:&!>-C.*>;E<LD[8I18X6H*4?,)P[22[[BI)!_2X*H==
MP>_P!<6T,J8%RE(6%U_X:HFQ=F=9 DF=3N$[BP>(IPJGE*Z86"".'X[-2'F5
ME'D,NP>Q_C]_"QW'^O4 3D-(8GLH_O>P/&7P(B)?>M3Q? +'<8GO. 91EF=@
M:X"ZV$KH=7CR[\"63')>T3/M7_%ZX+K%XQKOJ? /0-!D>I)&>YU/88TY&QO'
M,_C%!"E=/D1\&PAC/$_%BM^Q<F;L[0V,/?BD$>)ZD*A>P[[A =AR9;PNRHEA
M6^:_A\8]7>W*I-=CFB6X^Y77VU:Z#V"0@#W"JH8Y(OBSFH^)[."HFLO$/PI,
M&H--<+WXF>0,SISC459-8P8_>PIL6$[QXO'>[>#7RG ]ZY6Q4\Z!KL#$(/HJ
MB].238P-_ ;]6?YF$]9VEB=G($2F2%&5D>+WX*=YQI+9O.0E6DH9G( Z/_&)
M<_ED/+P$S&<0-@8'19VCV$UP3;!$6!3H?<5!$PY\UGPY;.6_\[P45#LT;GUA
MBD(?4Y+<Q&A=MJXG8X/[(-BL+";&&3P4-CF?Y6,EW"2Y-N_TN6B$5>-I\+08
M'@/:FVBQ _>=TA!<K2[.P)C7A)H:2.O&+)\0K%3;9SB'8T+:AO] !S/'G^&\
MX=AJKD5UA =7H<^!LAH_T69L4S)GVCIINM@+\"74>VM^.06K7*B>$H0&<O4Y
MR^GRF^]EE\#< ]@.['A<U:Y1.C1:MD<.CR^!UHV+'%Z6%*BRYL([T8;)2EZ]
M_CA;YDLZ+]7^[\6"62-RI"?]DL_@XTF+0)=W0+\%YW *)W+4K3=X\HU<R5=J
MV?IZ3_D47-_Q^%*2-__%V&";\H;))"-1 G>,OSHO2O4C+(I7LP+$+5 JJ0BB
MJZ2I_&8E+#43))*#G3\> \G.P9@!Z@4"F%T:8[$>H32$JLMG0/.I$</;)T3G
M,?D*4I@I]2KH1U X_KY>SD4Q'^/7#9:<Y;#-5- \V,FU;8?;+RM8""Q,'X7X
M(IC/1I$D\_+_L??ES6TC69Y?!=%3LV%'0"J2NLLS':&27=WJ*9?=MGNJ]Z\-
M$$R*:(, &X=DUJ??=^4%@H=D':2$C=CILD@"F2]?OOO]WIO@U?!U4.3S**WF
MYEMOZ&FO8B81K&X,Z\UY;?_8_[R/-V *]PEL/BV&T<OY\.7=K[]>7K"H_@O0
M'*@13[:(_5=RS7M#7$T&;9>@V6V/?:BJ&P6B+6UR&=(L1JMI*'YC "NY3E "
M.4_$J- /_7T)$,/Z4VVB_S XW3_R_WS7@-7*,,P/_;/6UQ\<[/?;7[\V:!,L
M$H\ #YE_C?V/SV+00XR';L(7!QCLX?CI'H9)B3$\3MGKGSXZJY!W<_SF\6T_
MGQ;]@_W> #?_BYS39LSQP^!H_]0_:) [5D)$I754R6<#=9LA-\$7;Y)J$E0W
M.7SCJ@8AE8-+::02NH:H6H!'?D!@1_\=]4PD2#0#B7(-<FG(;LB[&@4ED/ "
MI$I2EIHA_ZI *$V"BRB+1E%(+@A<K3\BU/W)D+4Z;#:'9Q31;&XO"ZCQBLP+
M]&Q&Z.(8(XC6CS<9E4$TND8# <RG AR#*BK!?4WBX.V7"[Q!XP*<#]P??(KR
MTG@6<(4^G5^";,C9#"/C"8.P(VTZP"\H""=7I9R7< CP9%GI1A*QX_S;</[M
M@]5]N C]T^^["!'P>:_)YXZ2=M2S$7O!E^BK&D7&41XG15DY"C4 C4V&P-\B
M)*X7FJ<E3(=)%MDU?/CX]O)_/[0SO\_V=09<"LOGJ*3'\I\N+CJF? IQ3%S8
MWS_[3BY$\%#_$6WR&1ERI$ N36%A(_&OQ?)$4<F\BLS#@1#GARAL-2N+D0I.
M63$*_EV#6VG\HSY+^<M9J3+#X64]U&(=WQ)<@T,O@<G9#*PH_F^QIM^]/R=>
MMDQ/<MZR-7[H\_4,:)7D=8E1+?R:&H4HH/<<$0XB?5?,T$\-6]SQ\FTPA&AB
MPW=>JL\G/B7[0**4"_HSKZLR&2GM]9!=CP*4Y,X^/T8\ PR?L>$*:OTX\*S&
M$S F@X>U5\%>Z;?8JR>]_<.[VJN;$HD4O XW</2BR&_ S0*[H?&0I@AO2FXV
M?NL".-:[-/WCT#G944T&AG-]M;DD:>V; 'Y9)/!1HKQX3<M/]&O?_<,AC=4?
MVG#R5HJD%9T"8D<E<N/?1P5X0GC%]X,%%KW;L9N(#SL'/PP<1N(#WC_5?VBR
MB!. ;NA3[RS-MEJ8JJFWZ95'=V<I7L>"+[V:A38R!IJ<Q)8!_ =0L;<?G--6
MEZ;DG9^6PAD2+DA<ID6I<ATEJ8Y#' \"BJ8AFQE9H07%CLC2#S48WQ-TW]$8
MHC!&>8LX1LV1/WB([]9'8.Z3FF3]8R(=I";!MS]J9:R#1W'M6SW[HQ81O9ZA
M?U=\0^&/:"Y850!/4=_VB(#>;>M*-QK\=]#K2C=>:NG&([.:$5K#N2.08 -+
MY-%A4_T]E#QJF(L'R^3@W0O#MDOGO&4#KLXD(TT2LZP+RKOJO%*53/$_*69O
MO2X.U%LK#CX=P4=I/J-/;9PMQ/P!:.]1,AXG,3H!\$9P@T9)# Y2C2ESQWGS
M M1.L"X&HEQC38B3--")5IUYR'4.Z[Y*,1X_B77AZ>[/.B2_8SFMB]6)!6U&
MM^6T1FH,'@-J\*:][F2ZZAF<.S"9QR,VZT4I*+)DAYC[\))@&%4B[Z#)L&:5
MP$/PRBD&6X-\"/J8=@%L['X[SDO,627385V47(^A38^UAEC)];"ZJJJL9[-T
M'K3E<:3.JO%-?'<IV63E.;U( C1XV,@!X<I^,7Y5#'[[M)+,?+CS>+==-W)G
M9->:XY#DU4*>B#7*2=/V?""5<M*JT,Y.O\-UP\H%Y53]K*'#HU=K117X8<.:
M0[?P"+U8B@D L?@QXME<?/C\_O)B#Z-Q2!GYYT%_ &Q4CQ)['^@=6!5"WE\^
M'I=P.8;S9C78XO-_^W)^\05>0 ^<WYU^#U5]WZ">Q%3\< VL-RDE\)C/*EPV
M)W#WQK5+M?[";DQ!?0ER-O-"H%M5=>7BUS^F%-'LM57$(/WX%-1 KHZ"N)[6
M[.Z"8JB ./6,;D$C4JYC%5=I/HS25LZ+:]+E'#Y"+APJT""D<B22JR_E0G-(
MR"5:^J)24'^[!<N.Z,UUQAGI33BU&I/-0 ?P@LY:5-AB(NAA-.A!:Y"HWUM6
M?;*^UTE_\^ _3?P3DY^T:RJO95>"32F2_"9NM,2DBC([+Q-X)B]F1-ZF887!
M3_U&KO*B[[0'\]M>U2BDC$JGP)[:"T*R._4[C$%,OVN4+.X(MSJ%E8LF]2+S
M8FVDD1GWW-JQ-*.E7SA::TLXF0!?F()2W_.5NLA(1[4;BU\>TA33>R"F-[!G
M_/PLIW5MK5^6F_85I"EY[G( O&ZJQ)-?#K:(BV[M:)=T=G_)028$G_-TM#U;
M6=NE$<OBKVCQV&))S($7A&N%><G=[%[[63>[=\<6V\WN[1;;S>[M9O=VDU>[
MV;W=[-['YJ!N=F_#IMWMT:#=+-5N=F_';UM,L&YV;]M GH4PQ],/\7T20BR@
M%MX&M&YC&IQL#,3W)$3H'X4'O:/G,4BRXZ(GXZ)^>'IR^!!<]"#4W'*4R4$W
MUK:31ITTNC,1#OOAV>G95G'1BV>A7>*?@[/P[.BXTV;W-->O4V:;3JK2"=TL
MIWZ9%9S7?7,WO[F& 78A?O 7IQ9B U6Q0Y+J;/5LV%T5.G<,GN[F$:[6-B_L
M".]C-.:SYYCNTN_\$7:7_I:IC1T9Z;&8JL#"6:?<%VLS%W#4N=PW*Q/LEK#E
MQ00\Y%2GSZ(Y=WAGP2*.P6:UYPO8M[J$-,FPRA<[>'E2!Y P*;#:FLJLN9$C
M#&Z*I%)[H_PF\S:EOLT2Q) +X;]B5?*&<L0]4)6RC^9^1X*^8R"F/>RWF =I
M?@4[3^*27^,#6I>,'K5 UJ<<BR*]68W.D*UJ'2J>HFW(M* N@7H:,=]:<!?B
M7M. 0T1NZ<!)\QMENN2$11K] 'ZY,\(M(_IA3&4MC5;Q54C)NUO'_LGM9W9;
M8M]]FQ&.[_;L;%V?QRBGPZL*N#O!N$9>&-8%+(BZP9>T;2O9)@K'2+/&WG"^
MI[ED&(%X);[!^SCC!IFU3TLRDA$H8K!U_(H K'X*7O5?N]]_$[P:O&9X?\+S
M!LT\%SCB@]<L\/8#Q/5QW\'+2%4T$A1RYS,".IK.4FK5,!@_U/@")$.E+R#E
M!G>A!'+!^A+1)B3$D@H(CX +I8BHD>#6D4SE2\?---,9BJB2FI^&2M! L8=F
MR)UYB8#XZ9=7!=S14O;D;5NVQ6#WN!A"SE,5:3.$]\AR%/<^"ABPGP 3CQK?
M0>62<9\?WM=HEHSLNT)LETFF[L00ZADLL16FP_5IXOKT&[5N':Y/A^OS,*R&
M4U>B&+C' 2A#0>=*&KBLPT1@D%5-UA](& JAXZTO%2+2^TUL\)N$9ZTPHC/U
M$8-A.,N1*H@\AT;A&-$*L7WX.DIK*QD$-YF>1%+="#/G'5ND_U?C;:Y57& V
MB<*:+[9_=6U?+[&'9J<6V[5]=8N]3=O7K1-:#7-PT#6(;6=1=-<@UC6(=0UB
M.\9!F\O=KI5L1SM5NM:>KI6LX[<M)M@]\]L=:L/NJ^GL23+;:T,L/WU/N>V]
M<>J=ZWF[17:+O&TE_-:N\):+O!=9UBA'<VMU^H/]P=&6RC4G-WPW"7;[,KSN
M&=TS=N$9#VCBL%@XVU*9<.'E];G$YK;=+W=J%WN2W2ZTB]UJ:]M94'K2#P?]
MWMWZEM96FZ[>YF-V*W9,]J1]<4?AP<GJXO-=8+*6TO&[,]SVG,Y=>_"_\V2V
MK=J\DSG/2N;TSWKAV9J.EUT0.AV7;367'1^%QP=W[/O>(BY[IJJM_S0GLVVJ
M[<'#5MOJGWY418GSXU,3?+\3XD?+UK><\0\.PL'QX);,O^*$'THL;1IK>5ZG
M,S@.S_JGW>ELZ>D</LG);)O2Z-A!;(C>87AZV.]NZW8>S^EA>'9RTIW.=I[.
MX*"3I2\Z091GV,N=R/COO*[*9*3,W+7OP=_;H5MP&IX=W=:HZ&($CW0XQ^')
MR6T]I>YP'LN/?9J3V3;]T;&#=LW"@][N9ZN?Z>GT3\.3WFU-\>YT'DN4/LV]
MV391>@=3?/NP5;MO/M4W[REM<I>./GG$'G[_I_[I8V)'T.WZ0.@8S>G0QH>[
MEZ4<[Q]ML)86^!TL[=X[V&]!@QA&I6+TEE?]UVM:[9Y7\.55/SSN]UYW4;%M
M.Q@PE([/;JN.N]-YI-/9Z_=N6Q'W/*.6'4/H4K+PL$NF;^OI'!R$1[TNF;ZE
MI[-W^#079]MDZ4-G@ :G6YH!^I)7/E3>HXSMVO);T<<I@OT[%B=_W[B@[8RC
M/9N#[9V$)T?=P>YB@/1I,K3;IJBZ:[Z1S7D6'IT]R>S2[;SFS^9@>X/P='#'
M'-9S/-@=.KM^5ROP*,T>VXQ1XHT4^"Z8DH=#WMDT$/!<%KDMS]@)8NW$(K<#
M&F47<ZB_\K029YY5C%CW0QGTL',9U<'W9%1WS\08'(:#X]O&FKL*I\<ZG7YX
M<-K5GVWIZ?1OVPKR/,WSCAVD[/XD[-VZ;ZN[K(]T.B<'X>#LMCV/W>D\5E+U
M:4R0;1.E77UF6WVF/U5QUQR*@]?!BZK1!(_BM'?;?&%7O?)H-FO8.^Z:R[?T
M=)ZHA';;U&#'#N)1'(:#PTZ4;NGI'!R#O]>5:6[IZ3S1R6R;*'WI59J>[_ @
MA9J[="D.ST!DW;$J;#,"[%!XY%F<Z,%A>'A7))9G=Z([=&ZW;B)XG@&O[H*O
M=]C[X<&M0<>>ZPU_'D?:.PL/CN^[UG97CW2'#F[0 8Z\]'K,SU4>?]W#\#[N
M<XH0W%3G]#THW,]#J!V'AP=W]+FW0Z;=8YSD>9QH/SR\=?'1<SW1'3JWPPZA
MMKO@&\8.3D_OF%YX=A?\>9SH27AT=,<<XK,[T1TZM[VGR<AOF\C>ZM:*P1.5
M/Q6J5%$13ZC#H@5U8@=*H Y?6$]%/SRZ->!65VKZ6#4VX?')TQ3N=X>SWN<<
M='F1CA^\A'7_M*O:W]+3 45WTNLF36SIZ?3OBOKQS&3IBYT5RB50R_R'I0-$
M-PP4\)9^.@ JC/)ZF"H.%GQ''&5K"+?Y7.?[),EVWK#^V6EX>O!]:8#OHLL3
M1YRZV]#=!C?+>1 >G'Q?A'67;\,SC;_>VNM\GO'7#3EW"7MVDK.3G,MI<71T
M&)Z=WG$,P3.0G-UMZ&Z#$]<ZZ8>'A]]7+K7+M^&9VA']KNGLCA&7[9N+UGWS
MJ;[9L4KWS=NPRH]5!-I/%Q<L*^ X.-9:(\E&*JM^VKM/1)NS=<)S@,+S_[7\
M/[\TXFE6?[1_NK;^8["J_J._;DPAZ\7%_WNO52R;'<+'(IE&!3PN2+(XK4>J
M],+B\")55L!C)D >T&[5**CR(*\+^-E>2JBG<#H-M-/HJE *'U,&41G<J#3%
M_V5<U&E2QO"'*%-Y72Y.G=P/7@(G#+:<$^K9N(#?!:G VHZ5*D.;0QF#[<:G
M/ITFE1RT0;Z=17-]]F4>)\0S-TDU6<<ULR*_*J)I"=^!_U8QK!2IY_%(6457
M:O\EL,C!EK/(3!5EGF4J-0(BA//,RCJM\&B)'>JJ3$8J@'=>PYDSC\B!Y\4\
M*.O9+$U4^2+.\W";SO-2GR)<V"!*TSSF*YB/@RN5J0)N79P7,SPHQ7(9I?[2
M'*H^X'#A$_PM_"Z9#NNB%)60(!PV<$Y,KS22H:%"BB+*KN@7_)5/>3Q!9:3B
M&@4*/.2MBM5T" )GT.N?W0</_?F_AL6/?U[Z(+@!5R"^\+C/&D_!QSZ>!TI'
M^*6-;9:ZU@^]&C@:D R%BM!0@+,QK'*OS+WA8I:E^(-Q7A#'5Q.P3XA7,_AQ
M,(4G3LI P5F.@L]J5C%;'?1"8*W!($3C!;L<HX*M'WP$7 _8XRQG13@K$GCT
M'+:,<C')1W 5;E2A\ ,1G([UY%&J58YJU5<5"5U%N(!\M]9(6'CK) &J\[LC
MD$5PN>=PK<>EJH+A/(B ,/QR?'?>/OE[/[AH70 _6S2 E>JP R#L%/8&+Z@F
M23':PU<C1F56%5%<66[(BZLH2_Z@*^Z:#-= ^[P 4W&2DU;(BXIE@K<.6((F
MW<BA[*A62-4)< #A[I<MI@<>V35\'6W.?_[:.QO0R__Y<Z\W *ZL1PD)+VNK
MXO<O/OSVY?SBRQY\)0;!]$>4 =V3(7U_OI;2FLXB[Y8MZN+#Y_>7%WL'_8-0
M_W=OT.?#-I^U+ #59O!Q@7=6$0@NH/X4US11T2@&45'A9R[1X5D1L[6%&VU>
M*?<@@5W6Z/V5JP-J1\@A\ #4/WRY<*<U? V$V4TU(5Z%E?GKL>H(-,DU*&4D
MR1?X.5S3FI7+<AX/DG*10A7]&%Y0 LO!6J(E+A$\EL4(\'KP[QI.'UX!WV=I
M(8P1H<<48QAZM.H'?5XSRA>4V\$$?I?E%5O#JD1:14S!&!D'-XX[4G#E%' ?
M*$H%WP_2'+1E$6 ( '<"]O,H@9MW,U'\:KOXFP18/(_CNM@/-AI;X9R:+T ?
M0&Z&:]FV_42TS^%2?[W\:W-S OC3-!C6X*  ]3W>VHQ:^@5P8>H"-XG;OE<]
MLY14:0[B:)-=N41T=[BLKU_?X"=F!?Q5 @^)25),\U$RGI,?"59WE*!]L63Y
MT4U4C$KW0#9<]FIN8GHO?:LF6IO<7VIEBB5S= BFSJ*O<9.,JHGD(-Q?21:L
M9W\2#<L\!5-YZ4_:S%GV6H!M0#X]LCU[,&AT1SG_=U)88_Y*[0V!!;_N16-8
MY$]1>A/-RS_]Z&\-]N72<0,2H/>V?,?C\6UV?+J)'TGT'J&"(&;Y"62_*MA7
M_*_HJ9<0P.T8__>?_B,Y.CP;14>GQ_V3XY/#T:!W>A9'@]-^?WAV$$7]P\'_
M.P%/A)0.7$@P RH4PO_U8_3GML-<RGR/S&I1/$E  +(A,PX^?O[')J+/RG4M
M^A[*>5@JV>\D:=IVNR,^[B5(;G#>:8L4?[A.U(TOP6/8[%5>@/;"S:VM\H8_
MEG&1#-&2&H(IB6X:4CN+DQD)=W2PP'8MT$I+DXJD;C &C8/N":B8:?25+&,5
M)R4Y,86Z MV"?T,+=>D"='"3K+W2?21[4RHKP):@KZ*_X/L]Q'%D ".09XS6
M^0CV72*CJ#0!<1>!30Q_BNB]8_AW*B:U:/X%1PHI.,OQNJ*#!T><< A(^YGZ
M^^QT3J>JB/&+]B=+ER2_F*DJ(>*-YAGP1 P[_QUC366.-%2KJ67)*Y8S>@3
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M:;Y2&9T[< G8UI.@G**\F>:IBNN47<!ADCNWK+3Y*U*]AK? 34%-DDC^8ZJ
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M(=NC?_S";(]= FY; !3+VMJ]%X'#;@_B=5?<+(8K*.N4X"&\M29^8;0&H)C
M_BAE*9_"7A1C2IA/#!+!,$H1Y*?<76B!CT5^G92(LH&GQ- "P9?H6W/&P%:S
MX,S;A!QGA9M@=NBP!CJL@1U<;(<UT"VVPP7H< $Z7( .%^"A< $Z#EK&05V;
M?\.FW>TNXJ[MNFOS[_AMBPEV9WY[SLW['Y=&-KH^_A?2"'BZ=NKRRVT$['AW
MNWGW*.P='3]OWKU-VNVYM.\-OF]6W//JWNMD8"<#5VSXZ" \&'S?-+FMEX%W
MWL>+9-Q=X-K#7C@XN&_-O4TL^Q+5]D&'O[-Q+]-#E'1UW]RF;ZYA@)WJ67LW
M'JN8!K=4T3>J6'HAX J#WOYM?9&N8_PY\\/I?H<@\%W\L"W/:,\U;SO[]?97
M%[5W7+;+ISO87PU;U9WN]SUCUTK?U8+9U38E>[-B]U$"#\-*]W&13^D)_]C_
MO!^,U8AF])555-557LSI-31WK_^?B],3U;>8)K["<H8J4^.D*INS'M4WG*A7
MTC/TT'-_3N*H+K"Z'K\L9?5VRAZ-#)2IO69Q^+H8UI[@L&D9KDAE^"W3%7$C
MDL+<HJKYAS]J%AQRWOU[.FYLMX"WX)A>K$&'HXUK&5COSKMO.X<GYY3]ECG!
MR>B__[3!7-:#/ZWEF0=CD?;ZA5^3?]?)2$]*OHAFV( 1?%)E7A= YUV90WY>
MXF&U\^P >VN"230*?ACL]X-ADJ9XN, 3<51.0OJ_@0(R7$<I3LH-L>^F*I(8
M.:KY(9')-M*4"\T^/_3WS\P[(EK66Q6[J^KS3=H/?L>[!QHUF9%DF4053X:]
MNBK4E=P>FBM:%S3CGM:"[U]<<3G)BVJO4L7475P074=)2ET>>.6EOPGXGV ,
M]:!LV.ZURFKI%:*^CZ%,'[8?W<".0#+0L^H2-XJ35.EFT4!M\VAZ4Z1'I>(\
M<9Z]6P7]@98PW-.B+^ XP:FNP4AV7$T2O- XRGM7Y.P'H "+N#F?38&'4R@^
M!(?TL,V()Y,GRM$X9LHM4?E^IM8R_>%XD-?@!P4][Z= 36=I/E?*R$R"M@0)
M4,.OW\!32E^>XNF.@ O2?#;5<])'21GG8 W.<>%7132%']H2'Y#:<]KY&R:&
M_J=4 @%#H7YX$Q3Y/$I!\)C/<^8EES5+8'!X#KX4/TIY]O(XBF58=)LLWDH6
M057\!6AS48L,^5L^+(/SN(*["\:TPJ/"(=+1#9)!2XP SWK0ZY^$<'5 \R:*
M=112N0(FJ?3X:#@[%14QBP?WN-S3!7T)%,FXP5$F7E]F>IIRN.%#D),R''>=
M72ED#:/$9>2TEE;"@<,:^Q3+2H'\G=8@!H8@X:9PN8%X(S020*2 >@=N D$
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MY/PZL_6M=V##9;6I;>LC7KQFM#1")-4 3H+2QR^Y'1AH>P'6W8J8[L:C6R'
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M045TX;FN1<63#'9S-7<,3)$#H&; 8*^I65.7F&"S=CY%U:-'"%%4HV8W )[
M15_\XA(YBGPWYY6AE#ZQWO+?R14L[FARC!CK1A^OBJ(+&6]1%BP:J7_7'"$
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M1YPJ#,3T9UWMP5'+>$P.%RW<9'-WN:X1QS5\("<#'W694<<4W-Z_".B0B]2
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MM>>'+\WS$G2+V&.J@1:=3C4(\/;(IFNA5%1K7@>8P# +\#_'HC,UQ91/-'"
MF!,R> B4KD5.4.OO3VCG\0<%.8CLLG8W@%2B0') \12KGJX5B:*9*_!4L3]E
MR93<4^E Z:7=BBD53^O$J&$(!C=ABD9DD^AJNUOB 0C5(UCPFPE'D,T[Y]/(
MI!F1?":G[DV=DPX EB7L^N4J#BS&EAL+59H(*SK4KW@+!FL$9L; S+,1F/E9
M C/OGMDH./SV<@C0I=B^P_=410X8=[SQS)00.]<FW+FF)%L'FOZK2W"0N<2Q
M]Q%)N0;G.?CN1Y4AQ6)HO9JC%H$3$IR;Q<K)/FPC_&'O4](9$J(K)T68]ETX
MWNODHJ]L<TP.R%V[>=.]/9C?TIJY!N%H'77&[<(AJ;V?+U*>T_+KGNHJZ#KP
MVIG^O%1G)'?NRD6"VYN@-86NECIR^9#63 $%4&?XF@UT3DK;7<)-;#U[5URL
M%<6C^]80R;X@DVD37L-$<TW($3_5]C<RT3B><[,L29>[OT:D8VF(\W%0B5[-
MDE(E["V[&5LU)WVN>?'3P2 8.AO2%Q3@28P@$Y@T4O%X!);*.^&T1#SHQ6%F
MS+Q8S(ZSIT1)J3Z@J<R09-=1_8-81LO,YTFZ,T813N;$RLX\/)#&G&*;^/;W
M0-8#-Y(29N U2^1_ 5"&)*E$LP/E*.);\RZ&2G1 $JX2&T+0Q+()H"G$A4V'
M<4@][AJYQG3&U!.?0^LR"N#"<E8A6[!MD?T."V.<HO5*;2I/-^#3V^E2],"N
M1!.I<'J>J:G]X@0/:?N0FE< ']-P"!Q:M#1:1&&(A%Y>#3BN"1U:TXW=3D.]
M$"X"'B+\:B>AU^Z5FPIRY&10C6HN]=;O?D--%'=%_TDW!>YLDF#4]:U12%M)
MI J-&BI_))UP4>BWA197&3H@4&)^_ALN3R=UO>$PG'RDD(M?V5$,)PD<@!KA
MZE.0GP1A8X(V][9[!#D9Y,;<P:M)P?&?,U*<:%4NH5OP.,[XBNS'DBLS0S=E
MPLD%MWUS.=*@E[)&^E#%EC&'62?STWMW,#F;%?'+7"[J"V!HO-+<"6&Y+![,
MBXUW'C$)LR8J.'IT&'X'VE2D(Q& _ 9'J*<E^9,CS_8G("%US::NKN4.XWI0
MNE.VY:RP0\P'?%EM,]<#?:6A,*1+)FU4ZA_;8G'>9^LV!<"*<!/$CN;1$X$7
M,(SKU]C!((=,%0'198-GG8H/!44/2!U,YI'R22]YY8?9+ZVRH1$V ! T:(!(
M4,C-OW:)92;X2CTA9\\(Y_F1]&(FD%(*E(P,>42@W6^6TXCE#PLU#@-93?ZZ
MQ]&"'B8E -'3E^1BTW?&).W82G%JFMIR8#7T\1"#_IY#?/J:YN(96H77DGI\
M:I_NR^>OG[U^^M4--JY*849O$#2&V\F(-;'TR^G'Q$>@<\E+IDH2',Z0#H4&
M 6_2U':193::+@%J%.U*W@OV20UWV*Q,Q73X=4/98%*SA: 0<?&&0$W:FAR0
M+_.>93">/@69L!N@;.-D/_Q;12BLV=9VWL"F<QN):I>O:1%QJ%#@A[0.OF3*
M>1S..A_0B.^*9Z_KYBV-3W)T(?@LR$?1=%BZ"A.0K?;W6DV4?1(N+NJ)RUBA
MG>$2"CS( H<;[DG3MG;^?  S2+1U:#IJ^Y48WH[UX7190:0G466C%Q !%@'#
M?=CW=G_7&R-JAB)#Z'#N'+.U(K(E$5EP0L+;D;XN\[81(:E+H:VUGZI"M!OL
M $;K+)BX!I\?PJU:\#V@_FQGG0A1X:NS18G<HH3%,5AG(H N/22N$3[I"H>U
M<S\586Q#KCU"?+WQ6I"X)'Q#<D$XUHU!SC16AP !0L=1WTX:N[A0;:VQ:T2T
M9DFL5_Q-T-8L-DIQ#",)*A/*<D$3#F8Q"!"Q?AGR4=DMN*:,#/I3'53&")>Z
M8&5,"D:W;@7Z("T3GKO4 RW1&2! ZIJ?#[.^_)9H?_:9Z "FX46;F>*1<M&M
M889'U66/'G'B^G!O>WY<&8D7K\&DH8J1-:G6W''WIC<9,FS.\?%:DIS]V\=B
M4]N/'07?]0,Y\*EBL,<0L5]H55M+/#^UE\2<NQ0D&VDG,76Q48O.SBRZ8XC_
M!A(W^18IV(;=+'CZ;AR%)K(#+H3.V!? B?9OZH.HQ%.Q 0V"4%ZDB)C)$#'3
M#L:.PCRL$_V><)@CHU(P.XY-0:DJP ;%.>5'TQRL>Z[#D/25:QBXEH4OOVRL
M6<'*=;Y#E%P.Y1BOWR&Q/8FC.3 ,1BS7B!ZT;\#)5ZI1X"L%=/VR %3TOMCH
M?C^_G=C!!B.*F:EM9_IG6^4]'ZN\GVN5]R#YO%\J8/Z;4/'VI<;WOV)\_^%X
MZ3>,BYY#M$KI#[#@D\V%:8ZL:2PF;T-Z?<R"."]:-RZH_@%57J%LTJPI[*F^
MGG!B0A#;!!/:TN/N #TM8("1X5?=,K=!]E(J(M$](9$7V.5A&MO&K-;=_>J3
MIS.H;JP?"Y4F.Z*-)RWP29MK+X(1^/S]O(KX%SMQ<]"V:V=)R1&C_PXJ%^ N
M^GG"_ >GD2KK_-NSDU.8F[:S;J$.L(87  -Q7:<,14(SP@5H33F]$K_TWA*_
M!#X,7@MUC]$_=Y__2OP/?UE]M=AKH%IG:X]:'+D(O+:R7_*"1(/D%4A#3CDX
M"%>@T0,3X6&YP"P$W#;;MMVB_86>31!S@GJCRISS=$=HP()'UR.GG=O/,AK)
M\2$Q2<3J<8W.5![$688S _# ACL^MF]%1M/-RX517OR\0&\6\V"-2P4R:S?_
MFIX6#)@#$'J%IJ4=3QOM0;+,I?^86H K01'.QF\F+!W0VN68M>YW??43?NPA
M7JT7$$2S/UL$%K:OM 4O-S?%5;G8*):#6ES/"DM(3#AZHX7A0:;!V-O'A;DV
MRA*X&(0L./\#1G!=:>"37R4^&R*[C6QWH%4>K)RGDPG:L$L #*/VI+5GX">C
M@JDNN]":;N,WPCD+SBH^7-#ZK[EY#J3'PZ(Q1-&.E4VUU:&(5JY:@E,Y=HJ
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MWDR\=?&H$M6_"#\I"<5]!L3N5DP2D;DC9).;%JSG>WU[=.0<CB;W6@H,J84
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M"W(+';\6-)L2BUSI5([+-NSN6M85)!/]:[?=>HHI2<SX]V#)V&G=#JP&Z2?
MV_.>">NXUL9#%E4Q[L%2<"/"+'M!RMPA0'T[F75ZFTO#O  P.G"QPL5>1&%6
M0V8'EA63\=8 !\!;VM>]*J$\*Q3FX:)-BPUHDG?JDN7>"=[2V@Q1T:(".,L*
MHT!D#>Q;L=RYV&*^F'28FU))<A!ZPMM2[JN8U/K2%I2G=P1H0PI4L5 7+Q"Z
M.66A:#'G4D T88>07UHK>A_,M7/$1)05PN0OM:R>FM7SL"-?N.@2.'AMQM./
MKNOX-NR8S61/>G6*UH:]G8MR>-:)$L/%<#S0*DH-!%%H17.>2??.$)&:"F!]
M.<SWXP?;;HO.5WCRR)HAEMZ@OA5U(B\*ENY223 I\[$,58>H*$ N63>X 3X(
M)S\5983B-MD)O!?BIWP;J">:75)*G3GQ@[.Q5:!#"1]3#.-5:BB"/DIJF5J1
M>WAM./^ -4X<2[*SJ.X:7862%?@^6$:"]D_KN&[ 3Q4L'B:A$8NU;GPI#[<E
M@Q8&+/:U<!!AD5+1W'G[#5/C3@GUM&"YXF=U?7:N _O*]'.(K2^J<4D!' \<
M ,^.K,V7,,%&B049%2PZTRZS%W&C7+1M/2F+3N'PG8Y>NI9!&20D <=#D@5:
M[$9S8PJ+84E=G^F>Q 1^[@#=^+2[]#WPCD3NBC#]P=L&>G\$"G1D/;&7X[4E
MJ'RPIK"K72]18P?P%I2QI^TLFYD0%3=S/)YD<ZD.IU2?EL4[>^K\VT3'L(O:
MT%LHEJU6F<)$=>FKUHX]M9@979_E'A5JP\#'Q94T_*SL]X?G9E1XP$RA=<\*
M^_P7*!70B*G3XQJ48>C0;CS: #R*# D5G/ZN/TX4LF4J7> L7\1<UZCX$N!.
MD90F_4[^P$!.$' ^RK9H.TQLPR:B;<L<[^!U\R@PNDEH-L,&:Q_)TXF 3J1_
MA^@<0C.U;1WF RE$^P=!D:@ ,@$7:X:^#60K9>"%#4AYZZ_]K*>F.1WVB:Z.
MV&;W5,JP!*N7$Z4IAFUF+4A[?)31A,0S0P@(!&RNP(E$O)BK88B]>Y^H,1D=
MWA8K#RS^2\3A'K'IF^'_GMPI@KY$FB1(WB=HBPVTN&*,MJGL$TRV['SMVLC:
ML'&G:T%S4 51=R%0&/MLT)E!U5,2T0Z]QGDYDS9N.[SDRI'M0*2+75GH,-GE
M959S9,6'J]HX I/YB+HK.!+#LS)4M/<4'';58^EB7F!IA\\%K>T01QK]5D/<
M9P"W \L*UA^YCW69C K84@]!WUJOSP*V$[MRD*>?+!CB1-Z["B*'7B-W?"L,
MFJ21'FJ#N2_G]QO&E3HJ.$A94I5^Y[G4 Y0.HCVV=L_D6;)U!J_&['+.9.1<
MU"VLHW\A#C@''IA01(=+FFY)+=BT-LRY,*J'F,Y!&_A@+>S1$_X#4I+9#U38
MY2H9_P%EK@.CN+P%.A*EB$;CS(!3GMB+#]<6Y34+_6$@!"<W8'H^K*TDG)0Z
M>::9SD)]$A4X\2+G [=:+R\ 9S%+J!R(?M+$#J5\8CC32$3F"?D]N$8@U#H#
MK-\<:NL("8JUZ64GTHR)Q@8D/Q(M5&]@8\F^!8+Q-DB)$?^2XZN+"N1*TDI6
MB"@CHNO"'EN4>'"!G#OI@C*/8CG2PC'B>;RI(R*1WJX ?PODOO50<F> ZQ9C
MG).D6& ,<Z4TF0?:7D5 S><X73EW;A>.HW=B5;P0 DK3F$,)OA2BC^"A,:B5
M.@GT:KB6R,91$U2U0GF.%>NX8OUHK%B/%>L[66J"C4,@]59+Y$!-[O!0I'2(
M-S?<?2H=15Z^UO\<X_[ E$E6+#+(WLI"E,$JH$.$>#G;;R3ODSQ=8X0+$%7O
M9B5+?U^5TS4$Y-#D+=T0Z8B^/P9JA 3E0U]1>"9,JKDG\?=.O=R=.3T'Y,?<
MT'G$SDDFC00(FU\8W"YCA\%G-6G2,SRAR-UVE8 <T''(D*XT4?S50D7 *%?*
MTL[L48EW<)##N\M-1()J^Z. G]HEY&WL74$=;6'#6' %59 IJS?P!I1XIJH1
M0X[1B\5@C8A;IW@BK[%TX,5XL$O'>]\J\DX [WRN"/2QVKJO$^D;X4,[8MZ9
MB4B>>P9MJ.4 .%/,17KQ)/=TZO7S0"@'O*JP24A%F?[AA I/<ZR+OZARJ(K[
M3Y<APJ9VER!FY?4A=]LM8TG[]5H O56#QA8</%>^"1,IPG( @[GO?8/.@AVB
M;L?V1/7D&4@GWB'HB3IT?=!S6S/B&M5Z^7DV,8A%QR5!J58]EYQY)K4MI';6
M#QD6)ZF54W"<:KR'X5:Z>]/AI7.X4B)R:P2S; >'>RGAR+?K3=HGR9V']3Y#
MS#43/W,2E[Y,01*A@2$!>W@&;T^DUXOJJFQJ[,ME2_6*%_Y/0IY\.*]VPZ/R
M#X3\6Q/X[Z*9 O9B,H=<F=0/+TH$N\.*]V6),G0KB *=H=ZZ4Q9#SA4VO5?3
M!<:<;6>]Y4O#'08VVM)5*G\'Y]M@7P1V%BY]?;;M%IO#6TS#+5:#ALH),3@:
M5#2!Y ,OF*+4#H^?'3=$ 3'"SBGSV0F=O"Y$\4#/_S44M92I^,/U6AHH9562
MQ(3T)<)')Q,$MY!/V7FJ16XBF0.Y?BZL;>1H4C+\7VMKS11B/7K:0+PV(BE7
M\M1([R"2SGQ1#B3\LW#'!SFY),BW9FX=.G:8"W:8X=XWOD1\L;W%R_4#_\CP
M%N8=<#-RCZLD,;#&!;M!)J>KT<#8%2&9XS+=!:2+>["VEQ5@B[8\O>O, /)A
MW4S W?7TK,1K6Q)#PMHY3X'DM'<L:L4'P.N(M<01BE**FD[OL5IWW"TU'0#W
MA&.8Q^(L2I'<!$8XR5+/@T/H".OKT1!*/DX5"H)+Q5=0[KQLW+RGNNU)G)RW
M<3@&Z>9' &XRCQL0O\ZO8:>^,"L0T@/KN76.OC!X])?V 8W*KB"'5\_<((:/
MVH$('2_#<6U$J'U@EXG[53>1]X4 J5:9)X!,$_F2[[RK (*/]V5LB-RW,YRQ
M]9@&_J=43 $]42Q,W"Z&C6)2YB?%4V)RS1-3''62"9G9U"043@,N$+4?@DB
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MI=UN'9R+I;PA$KL9J(- 'QX,T<P@P)E,LI"VJ@G+?%^RMO,7K!>.+$1M5W9
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M<]LV%G[OK\#J9;LS57Q-$WOJ[,ARDO74B3VVTW:?.A )21B3A * LM1?OP<
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M(CV%: 9C3H87'35:=N-1\D\/#]Z )G&1G("LZ:N?#X"$>#>+FL2TROHN.@(
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MH5C:#D%]3Z8D".NCEY2W 7)TN Q(3+I#K=MGGH<'C&LU>B-.S,#2"]S+4-"
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M%"*/7$;-+*\]P<!*!JK4U$T4#K,01?.M3(<M7G8LI=:==#+M4:"M'=&+(;_
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M3,LB6)#",XR08G99 F]=7G*4_5_W4>_N$NVA%]):M]+@4JKEU4X55:N$.8N
MU=*@5<5%%-B\]\)1]G_=1[V[2[1A;Z'E#O)\>D(_FLZ6KN)%%GHT7 D++-4.
M1SH&P2*2B\A-).=1Z(SK$WC#/GS#P^^S]IH(;&/'GEY/$;Z)@<<OSZ=D&]20
MX+)SP7C^QSZ)VSN_JX>3A=W&N9ZPS05H;S@86FYUM%';X +925P@%&&NG3%L
M_=9]:_G6GOLU!E@OA.%) K.^M@DWML8 !3 9H@$!W)J,C1?ES6CVKUE<>_)K
MG-4?P'L4HUQ$"D5E1CM?;:#A%?/1.&8L<&&YC,'T/M(K>(8_,VC$@NOEC(V$
MWDO/WC5LYZ',B"7FY K!6%Z*5:_X3K2#TEI<[Z#$J$+O5!CT*& HU7<7[S&$
M_W^#_SN=79QNG9=SRYPXJBCJ=4G$6UT/^FLF( 9KE:#=.6]W_'I',/#ZFP\5
M^F^ARFDSD38.^OX.I_BJ?(/IPIK; E3#D/]&(,.'_/?5T+0O\0ZF^\!!)6<Y
MK7<\,QVDIKW)119TC,ES&\"'^Z?S6P+^@ZB\BU1;A_N?E3(^&9,M/9^6W])_
MX7P^G3R?SCY^ZW21*>Y!D0=G/3EO.JM4"\@TBTEQF[(J:3T!=H.7NM7KAO5;
M&^EEVJM06Y\37$7X_!]O_Q/A9/'A.D2G?8$,DKF@'$&DP4?AD/%B5+!:Q@*F
ML]XWO^]!*;Z16/N;\*_*,QKR>#X](^?C1YR]QQM(JI3U4=0@B\1TGK$; ^=D
MZQ8NI'0TBNW._KJ]]P$QH;F86U?4O?PXQPL<Q05$Y.1R9HM,8W5M-(W<!ID+
M%&5(L5NI^\I#[[TN=Q50P^.!<TZE-,,\/5]5:B^3<Q9A7F&3*%P1SC,%4M8X
M:V$>8%F@P8T33IIX9X!QFQ?=>X6V%&0/%Q!<<RQ__/(C3M*'4YC]L31!<PE*
M1$Z&IQ6BWE5?6%"V,%GW%6% @6B=Z7P7I@?@A/<B_AY.@*_CNT!W<5OB%OAZ
M:D-Y%[;#=*1LJ]$[Z=) ';UT)[P#I[(HH41@SKIZL:U,M.K59JT0C88@5,+6
MEVX=ABYW=*T\+%NZ:*$'EMQ1R'!Q!W*JUFE.C-?PAR[:L6@(I))<1!#1(F_?
MI6P+8$=P0K27/KM5E>R@C#Y:89ZWRYJ_P83C3W7WO8QO.$+E:=,-]3[U[,@\
M"^3B<.>=E=Y:W?Q:KDU8'A@OFHA\D"WFRSOZT^6BB09<XN0SU;.S&C8E#[>0
M14;#C,ZF %JWO^YS(YR';:[N)/0>DMFNCY;^<,7_;: -9:1^A74T]NEN*KSS
ML'D_^0^Q9%R!"#9Z5^OLN$X$T=/J"& S$R"#+<FZ(%I? 3HX-;K;HKTSHXO8
M^V#$RKJY!G&UQ^G:8<R697"&X$7@S!<9&2YOL3)"R^V*#+NPXG9(1V!=[*J^
M=5HTE/U&4W/(Y,M?</I^!A\_C-,;?$^OZB_U<M.;^D^\W&J,:VF7R$$69^IA
M4]8V Z@@>!'2F**X]/JNM,M-[^RYQ4.6'(RH=V6AXV0GU:\\K8")<^MUO6'1
MMS8BC['% WAGG%.&R02AGAP7!LD$LAYMR6 D3Z7U;4,/H\5#%_ZT:/'015%#
MMWB(6D&IN8O&BWH-G38LR%+;>=KLI"*YQ('FTG&U>-B'(\T$?@PYGI>W]WQ=
M[.'D_.:>&$#19L&4$HIIE0H++I'Y*3@/7(> <JL6,W>D@6T$<)3-'CJI=]I:
MS(U3 %>M?J]"NC OMP#5,/US(Y#ATS\;*6K:EY2'HX#RUF5#:#+'>G%7O0F2
MULJH O=..,BXU=VEQZ7Z6[) !]5\!^$VU/@RH#S[,OK[VQ&X6&3QGJP45\C)
M\XG1(&OU'@97C+#IUDM.YYC^\G[ZZ8?5$\\UO/KFJX*_OF_8;))&@I_N);6&
MIEX=TT]GL^G'BR. G(#3;F.9I V)&"DL\Z@<4T6X>BPD<+M3W#LFY]5WWF<-
M[B6_'N;?_WH]"CD)59/_LE.::4L+B[?:,G0)O49I,-[FW76;?__K]7W6WHY2
MVYB4TTMHZG=<K&JC-P135K]M$)OJ^JJ&P:F]1KD6G2I<@0NH0O!<&R%\CEYF
MX8Q1Y#?[--KUI3V'IY*&X#@15R@@PQ^"91$<;0F1UA)ON.5AJ_*8>QZ>2M:C
MB"&QK")-Q10""SX!\T(H0PK-R@Z<'7)/PE-=^-,B/-5%44.'IQQF&>J95DJZ
M7AU>KYOG0=3K&:W*M!F4-% WW^,*3^W#D68"/X;PU(V]^))(I2CKF)0FD/6F
M) - 8!:L10^2._50KFIIK]2[.I!V$>Y@/2BW ?6(.I!VTM%6S2AW$?!@VA>2
MZ^BT8>2B1:8#+8318F)<>6*V=RFE?/^TWK4#:7NE=Y%K[ST,)29N/%<LE)K1
M4._U!L<E,U)X[VBD)?C&IL!1]C#LI)1;>QAVD6CKTN/G$,D@77SY?)%3XM&D
MB)9Y0_:G)D0U$=8R@H :HTE:K$63-W5 ^_;!P]OW>\AXVDA K:N%GU<DL_&_
M+L;$C03PF8'7P+1TEH&&Q%)PBL!I!7:[.WN_?>[]5=7NXADV!O4L+<:?Z&DX
MATG^:5(=P3<XI^4%?X239?/:,IU=N=]O=77+N!:R7S:[A:O-;AM$J_H#U3"N
M-9#DUB)@+N:D="3R9$E^./@"/(<$RLH4K!:C_N'M;J[] T[.+BZ/_/_.X&1<
MOM3 PZIHH;Z57,2SV16GMG;4*I*<DRR48IJ#9QYIB?.R")F42G*[B-$=9EQG
M8/O:,;]-/RT=WI>3KZ^^%#2!6*EJ_F9Z<O+S=/8GS/((.1CO:TO2DNLU>P48
MJ-I=S)&_E@(&2*VMG1U@#FL3]<NH=5NI;ZWU$$J['>AJ*1@)([@"L"R96K@(
MX;P'*XO"H*$]SI?F3?RV C;\_M^[BJ=]ZZ>UI7<[PF<Y+S4R?S<ET^G3N/JI
MS^)\&68>D7&*2HC",D8RGU0P+,0L&3<ZV> #A/5"OPU6X>X8'BZ#AE1.Z\XR
M6\(F\2QO57@Y>7XVFY%,7^-L/,TC$VS@]#_FP!B"3O_$FEQC17"0LT^J;-=U
M;#\<PW%K4%WOP*\6BCK0NO45^FN"/%L!3W4BZAR8(0N;Z:3J70XZ,@1M9 X!
M<MFNW=$^*)[XU4Y)/;1;N1W["ZQQA I^5*)*IFADWD;"R1VP:(5A)J(U6?L<
M=.O"M&VQ/=SML5<M]5 2O:4A:#%RC9ZIF&FB$2P&GB>&P4=7BN":M[Y^<P=#
MO9^HP/G!I08/IGC!I !)D]X0%Z1WS->U@#NKD]]* HTB H/D  SGZ?:KCT-G
M!VQ'Z<LZ:M#1DG]E:_0W,EWJ_7W@%(TTYV@]HE@/:O<\V0[5I*)G5G1:L7?2
M3@\GD7?L*ZO4U2TP]M3+8AM\AVEJT8=^NVWZNROG4$0JM52L6,4$5YQI4==R
M*S(3]&4204!46U76W L"W='ZXECXTT4GS8]?/\#L?;UY[H\*[/*\A@QF<LY.
M/RY>PY>Z45ZTE18!R5&*9#\GL@2LU>2&D]^40Q(F.P$!M^O_VNFUP_L6[=4V
M'43FS9NX7PS_YZ^M<9_/D)SI^<^X/!!\/B6TS^;S\7Q1/[?"#%:!<-Z0: +M
MVB'4(@OKR 7B3B3CDI-V*Y[L"."A,68(/31O W\%\V4)1:S]RB_ E2Q$DIPI
M4RL;"2B+FCQFH\#*8%S@27<FR4UO>LALV%NRPV:)7!0.U!J!95; KV.(XY-E
M>D&#?(]M'M\P<Z/S:-9R,*1*"3"!]\)I@R*J;(L-J%WBPG UZO*BGBN/%*T;
M43K/2DR%:5E/#JV3M)X(5:Q5/C1OR-IWY=%-52Q+"?^.B]7QP]? =$)T& V+
M:%P]@*!=N'#/0-D<%<U7GWOH%+<MO".L-.K"EQMZQ_6BF'XN,]P(=61"LKQF
M_:7@-=.> 'JC,RLY!UJ[O(^V=1>EV_ <I(M</XKL0)A.6NC!+;^(;)%]5B-:
M9 ?4RR'.\.H:?B&+2?Y].DEK@C'1(9I0&,1Z"87D@@4G- LJQ\RE2V3A-6;1
MOI@?V'HTJ K[:8%Z;7I<0/^R C[RRC@124#+K&+-R5Z,,I'#D%)2@NQ4:YIW
MO=P"U_!4&E;;6ZQD>ZEJ:#I]E<=(*T(FLV:)!X)9$!GH $SQQ,G"]1Q+ZS/&
M+:$]D6IOA?5S[<QFF"/NHU *: <W.3"-4K%@+6>F *W=9""0]S0DFYXXM*-R
M6E]:=BNREY-55X+?\<^+#ZYL@S>8IN\GX__&/-)2RNA+9$99@B\QL""58#8&
M6EV]1\_76AIMK#K:%\L#,9T.H9F!EJ37."O3V6D-P+V*)^-SL;VE?^=EC+EF
MEN&G\?1L?I&ZF(,SR4*-Z]'\R#;1U'"!(>847$D1PA!V53?4#X2%!U)C#UE=
MES.C"I,FS8WH1U)[I;(#QC'4LZ*<6:QQ9>?)"199:<+9F&M; 7M@=&JOC![N
M>+R]E:P43DL3&8^Y]C(+CCR(C"R[X'007"3;.J9P+WK?[,.*9@(_='9;S=)Z
M7BU-G'V$&7D(<+KJ A%$X-Q+EDLTY'=BILTX&9:E"=EHT-*WZ,I\T[N/LO=-
M)Z5.&PJW<?>3-_CQ;)8^P!R?T5"7)%J'>-&J90N0#7OA; UL^-XX^^MP.I0"
M#L:6X)-#+23C14"]/XB,]R@CDXI#"@5LA*TZK!TW2V[II7,@DG21>^NTCW?P
M!V9X-LDOYQ\O[S27*=J2;:3E46:FG?4L@#",)Y\%SR$:M5W]YDU/'[90O"<M
M3%N*<)B+D9Y/3TCYT_,KG"Z%41-=?CR;DT4UG[^@S?)D^K'^^&L7B6_^["+!
MX6Q",!<?\.9G_DENV\N/<]SG<J4#HFV0<7(LLEY+8/$YEP266^*UYB6''+FJ
M,9FBA7?.C@Z(>]_ S^5+/N&SV0PF[R^AU\CJAE^_HZ_F<%X(]M6KD-P#5Q)H
MQDHD.S%*!CX(%BR)2Y"=*&+KI.N6^ _1X;?D!(I;SD2N]Y4&DY@GCYGY%&/)
M)GHO6SNH]Z+#[\%XV:(;<!>E]I"K\S9]P'QV@J]* RF>>X#2*<<%#RQSGY@V
M4K(08F%0BLF)MA\.K8\XVX]BJ.C+T7#WP$0XAOC.C5T^K=#D.:)C3EI=,Y)I
M:BKEF(PEB5#+/7T+?^V8>AL?F@IW=43NHI+!>N)N ^H1=43NI*.MFN/N(N#!
MM(^V.$S)DR.;"_FU@?@=!6<6A"B$NH!T]T_K73LBMU=Z%[GVD-7U*T&9S"\J
MAV*)%FVLM6:U<LC7NW)$]HP<O<"M$ZBWN^2I@V'S#8!CZ8C<22G35A+MP_@]
M']=%Q]^H#1=DB8/PGNE<SR:5%(P,*IF2D<Z8UIGIWP!X".K=7:(]S-Y:K?RJ
M7+%+EHN4*4;59JXLY$B@,-6K/.@KC#D#DOV<8^M\@!N!/'+KKIV2>DAQNBX,
MN'G\*Z)O [>G5A0=H1ZF*T4#):^7'PR@H3X*7SK"YC9C$E 77_I')PZ,;*G"
MT*B,QA@7<^LHZ5$0ZHXN%8?G4Q?%M+\>X.:%^3+<O\)(IK?+43CF4\):Z4XK
M<MU^!>:23$0(?+M.GEN^\ #9WWUJ;=JSR(_Z1'(YJ&_^]O<JVCK\X0\<MP!S
MN//$KI):.R[,.L:B@C0B.EV0>^>#]<IR7Z078>?CPBU@'=%I(*W,EOQ 8#);
MQ;30D7G%D7%CHRM1@8+VA2S'<QIX:U' ]0( 5-HXCI9E$>I&1\Y9"#(SDU$1
M:WB"V/J6QFX([_D98!<V=JH)VD^5K3L9_7Y695KS-]^?G=0/?OEM?(($>8(C
M1##!"L&2L()<=]K-@'9)YGA4IK@01-CNSJ%;7O((6=)4[NWMRNO4O41VG;HN
M>D[0:IUM*0257/\8LJK1'9^1(Q=INS;>W=[[6%G3HW9ZB*!L5PX2K8H0E&)^
M*0Q;) N<['&GG$\"I?7;]1N^_[4Y!^=8?XKKH?*KAQ@F>.TM.8!,>*2-."4:
M6Q":U1W8R:B=:W[S]5/6RMYL/3 1#IVU<GL\+,8L19"!63(AF#:E)M478-9E
M)6S18+ UI1_Z24<G<FQUTM%%24<0D-X&[M-)QUY*WC,RO8N&CH!8HEZS)F5D
M6578RSX<J00F<@G!IMIJ13U$0NUTTC$DG[HHYE G'<[Z))T#IKG)]8YNS@ <
M.=&:\\Q3=F8]Y?BAGW1TTMHN)QU=1'[4)QT[UM6<%Z3=F^*K;^'>N^JK6Z2]
M=IZB@+L2BLQ0HDZR1*<]@O>Y@ T%X\#E5]\"/Z(3%P\A!O+3F?- DSBC8^"R
M8%ARR8(6C)Q;[[?'=.*R2ZE.DJ)$DSD302#32$L>K:F"C,(@5/;1(K9.QGA\
M]5==>-FB_JJ+4N]'_15RPX$GSM 8SK1.),' #<-H;<@BB6):GZ4^1;+VYNZ!
MB7#H2-;&F@)= &/!Q+*M25TV109:.B8E%&F*<EENM4\][OJK3E2XJ_ZJBTH&
MJ\#9!M0CJK_JI*.M2G%V$?!@VO?.<JY+8=P%P;0SFD'Q] \G9"%J!>H1U%^U
M5WH7N?9>?Z6338IKSI3TO!YI*^;!V7JCCY;!6I_]5DJ^[_57G91R:_U5%XGV
M7G\%09&UK22+0L1ZI:YD0>M,2M'!6Q!%9-/:;CW&^JM]U+N[1 >KOW*2<ZP=
MU"&'FH,=#?,!/%,>;-&U24%N[9X\]%/)7:R[=DHZ@OJK;> ^G4KNI>0]3Y%V
MT= 1G$J6"!FC,TP+1RLH)$,>O4;F5;):E!R3:[U8'06A=CJ5'))/710SY*GD
M>;Q_!=('77*2B24IR1X'R1D8Y5CDSF=$D3"NM;G?X5CRZAN/_URRD]ZV/9?<
M6>A'?3!Y/JICJ<':!LWACA4[RVKMU!"E#(K8I[0'C60;EP*Q."^$5JE@V/74
M<!M<1W0H6$0JA53'E*V&)-(4#;F:M5Q%T"4HEUM?:'J$AX)WY#YS(5.F%8:%
M98=SL):!4HG51B;:%VX5MCXY?0Q)ZUVXMUO2>A?%W8^C/BZT%%EP1D/+9'%E
M01:7Y\S3-LIUM-JXUA&QIZ.^O=EZ8"(<^JCO=B<"K @E8F+%&V1:D3L1E575
M0"PE<&O0M;Y4^J&'ASJ18ZOP4!<E'8$7OPW<I_#07DK>TYW?14-'0*SL$Y84
M$PM*I]K@3# H,;-@I :'.1K=NB/@41!JI_#0D'SJHIB#A8><DQETY"P+HVJC
M/<. VUCOQN V&ZN]$7=Y\P\L/-1);SN%A[H(_:C#0[^\_:\#AH-N>OOAPC]W
MRF(]23Q;5]"Y&*!H4,$C)*65T,F#@ "[AGMNPG%$X9W$I0G:(O/&D=,2<F$!
MHV: 7F5/SG%J[BX>0WAG?8&XHM'79)C3_[TJ;Z9?X&3QY=7D=UR\!3*:3>0*
M57&U=1?)ROK,HK.:>9 J TKM=.FZ.&_SXGL>Q>E"L4T+>'/]]!#,6>'YZ?/'
MFDXSXE89K/>7!5'[ON5ZBX<.@C:9B#)"!EE:>ZW?(GB$M&F@BAY<B![\=PW9
M%*PWQVL#)!SM&=E"GBE.;KPHI:;S/$7YCHV6!R;"<4?Y@I 8E7-,NDQVOO?
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MXP6**88FF6E]X5T3X$^<W%N=?90$;Y31M\,998L)<G6O74VP H,,G!2LR.S
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MXWG-[#J;X8@G[8T5]<9/11:UJ$FLWD6&.GD7N TV#K#7WX#LB:=#JK:AL]3
M?)GDSN%72W04@BLF3*GNH:))*9*B.>J-2T5&9;=LI3DP\H?H51T_!8[*?KA[
ML%O&>[W7.G(G&2;:GC3GG@5K:14R8(S/);H QS )CC6H_S!F1@]D.2HS9@\)
M?!N*]M(J5V\[=][4>\]Y9  D!J@*1!&#B]L5K![%<)ZFR]&0Y7Y94R.%$3S9
M@\SFZG@G:YBO07:O2%UH"X+8[E*I?G$^$;Q_]1ZH=DR@LR@%,EGJS<M&.18E
M(?8RB2*-T"JVOLW^WM:.[7/,T5H7QUX[5IOG:85DV02LH1I7R"70F94L>4I9
MQ](\ ?$>UHYUTOB6M6-=)'_LE3C;C.6I=FP# 9L0I,^2G%VT>^R,-8%'<!Y8
M2 J9#MZR:'AB/HD(RG.A>>L6]\?/U!UKQXZ&J%V4VDOMV,4]#Z^!-J!5?4FB
MX?M4(HFCD#42H##/H5ZR2IB,<(E,E>8U8S< N>=U/YUT>ZU6;%_%])#D?GL!
M&V:3(E>6*<UI3@FTM6Z=LV(*EF*%,*D]:QYNI>%^[&FEJ![6G+^_?3=#F)_-
MOI"8?IE^PMED>177JHVL1B^=B2Q!O;Y$>\D@0F(B"JE2]G69;LRB6P$]8A:U
M4U0/>>@W%D86KB%ZPE1LO=X]>F2QD$/M;,Y9D8]-U'ZJ5^V3,WNKI8?T\!I<
M6R&IC954#:PDQVO;;$YV'^V:+)B0$M>FA.;]%[Z^_1'38D<5])#N_=MT@E]^
M@]D?N/CY["M%,13!,X\L)DX4+4$QR%$S3JN;ST(K$UJ7=-Z,Y!&3I(%J>@AU
M/\?98ES&]+$Z]!?XL7827$'CT: %'UC(@:!9[8C+(C+G"H_:6"23O/5RLAG.
M(Z9.*R5=YX\=I%O"9:H7_?B&$TN<3\N53U]&?,MYQ+?*].9VETV;+?0-LI=>
M#8-*=JW5@P4P/J<BI2K:2DW?.1VS%L&#BE[=T.JA;[B#7NJ02\W=2LQ*3A.:
M),$"FIHZ&;1..7F96U?;'4FGB+NZT*YUG;W,,Y6B2)1:UWNG'4F,UBN:CH8<
M]2!D=%8%;.W\-A_$L9_H=V'E]C6-0VC\2&ZD&'$NT54+3/B$]>XAVJ-SO0K8
M0L%BN).IM:V\"\YCJJ@=A!X-[J3HI-L>8H.[8%YOX1W)N4S1<N8-1J9=00:*
MOLW5#HRHK-.MC?(&L)_8.JSF![]=8]72UV:'WGB6 ]0K7I1E01L@9Z3V]!#&
M^3(L.8\X*6J?G;JU+HX]*4IE7Z(5@;FL:IUE2N3D>L>,*9FGZN(VO]G\'B9%
M==+XEDE1721_["DFVXSE*2EJ P&;$*3/7)-=M'OLC'6&FT3; 3,9:BO44)OE
MV\2*U"@RJ"#72UT? 5-W3(HZ&J)V4>K@#;6C+^ADB0SCLILO&;F0N&7%)5Z2
M!2F;I[4_Y#273KKNE.;215$]A%9NSYX0R@<;?& Q5>_:F7IU<TR$, >N5%%>
MM+YQ["&GN>S#HG:*&BQ!TQM"5>_:#D5RIA-FYG.AX=;[8LB^]3&UOC[G(29H
M[K?V[*N8H9*B#&BOBXS,@XA,TT+(P-*RF+C1A0NNA6M-E@>8%+4/5_96R\:D
MJ*;'TI=GC[\MET,\'_[N)\BW/J_!8>_V>-?.98NUJ%P(9 YX#;6ZCM9XU!%<
M"1H\C&Y]\IX!G(M'/YO/<5GI^>L8XOAD9;DL7Y=?3=Y4:V9&?*4/_#Z=S"Z^
M77;%^!HB$X2V)(FL]J,F5MK @DZ>*42GI#0TTN9AGY8#&*SSJX^"_H."B1*
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M7Y_ Y'<XO2@<VV9,/87S^AC/8:* >]!D?>D[%AW?%_Z6C$(681G$DIA.M.-
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M)^9+K<7@H#0/(/SZ%G)H 9X#/T"NQ"$X>\T;'%SI?1P^7CK6>P[GW+M.T:@
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M$<YX(J/C!+UU1U@T2F0EJ>"]FB_@" ]4 _^Z5XN]@Y^M^MK)=#8UQ5K1E.X
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M-=;-UH2Y0(WM_69[/V*-H\@LJV66U0IN9YG-L^%?P.Z"HLS+8NNG"+"XV3J
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MN1F;&*A %9<C!G)+Q%,O$7%GS(]#EH KZ48+-A7+PEC6#BR><@6@8C0FZ_Y
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MA=X>!U>3[(%J(]9L8;E23<[;-%_+WBBT4E"LX??4L)RYRB!D#8Y$[2AF4RW
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M2R4P2T?J-9]D1:P],'SS>4K\64VPQ%>1?R;W_Z?]?ZM)?:3DX6\SQ&DR)/&
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M8X'BRZ"\&A#+6HY0&5>XH/W7"Z^_L_5;3=#?WML)I<Z+B>.RD"'(IC&B@5P
MME S=XCB?LL'6J<CN)4OHRVM_!7XKG"7,S=MYHW("]_J)[N1K+317KLK.#F$
M?*;Y_%&WD39_^IL0Q8KZ\H!S=]W.[<\LEKRX?"X]1J'A<R==U@!V  Q6DEA\
M^@&JKA;?<X2W"YPC/.L>&$I\R$JRV*.G9"+#,LZ_B-K#$OIZ3Y?4\K7JC(=.
MQ:"N?OZ/TP;E&>0&>J8K1_\$/C9QO.UA5GU56V5<:N"06*KKQ5.'U @>TFU^
M!1=5Q('G'C,T'FL&VV&^Q3!B$\6]UMV@J [*=>&[?7Z D^#PE/E2X&;IJVK\
M-YFF2QR33("F5-2@ORT%XX(2TRN9P$1!*\*&4HVA>5'>9E"*ZG!9/EF.1F]3
MHX_<6DSSHQC<VFTL /"T@AO2>>1SJ*W8?^A@,TY:)KS_BX%"B(-C_-#9+,1U
M,"I_H3*!<-Q;Q&@/>)GM'IC#_N73SK^,X!G7MJ35MJ3Y^N\-;]Z!=8P(UY#H
M6UP?41X/K-==NGSSK4Q6%IXD0VU6"Z\VYKGR5EH'V-'S;A6$=JPQ%!\*(=X@
MX)UXN\<WPZ2AXV[IE[&USXQ2E926H1-++YA ;-2I+?5#,U$3CUJ:[[B4::31
M7S)V4O+P6M7LM]7<QU<X/6H;S N'*FXXF9HF,%1YA:<* UN?L:4=Y(];*=37
M2_3Y$BSUH?_W?- $=.@R@UT1#QNH-2@G,H&7^(C&!,D":^[Q?;2*\S477YOH
M/->P3I^/]%4Y41H9O JA2$-IW UKM8.QR<3 *KZ&43=]\;K2K#(&2?G@HZ1[
M'7@&*5!85:4VF%8'>M]MH\K,'X:S$5^0TJ!=6B'5$":5,7'U2X3WRO>;[1,M
M1),T$VKTWUE3FAQ;F< _=&*K6UKRZLK_LM.GY;+G_0<B:LB)LO\9_+_]X&-,
MP XZQ#H^6D*]Y'&P97,\KL[QNVK[87NB_BZ&2'G4J0G'^-[(-TV73^WRW5N]
M!^N9L=5#C\-.3B$%F$!_&TCBYVX9TWGZ% ^<\N<V,(O]-R5B!:$BD(/G]1=U
MB9?@A^YH'2!7I)_)[U28\<$Z%C?H*IU;3=XE?YC1,LG+[;RG<<F":D]A):L0
MDQPT3O<JC5I*'1.0[-D'7VEB3'H>L:KO_[KS@K@(RU8R]0)H\FZ,4X@KV.(B
MHGKV>[RZ2%3.^;JX03\,U?#:ES-HS5">]E&5/967*04D]SJ4@)I/F@>ZWCRK
M+R?+ 5[I&/3^TV+P>2$)@O$%MCT SP_$:&^Y?4I)2+1=AB.D"-Z0]60C6XR2
M0V([=RRM"+?LU)T.?:)LO#)'\S?YAQ0C8^K2?W3C9YG  !^YE)(S#AO$$@+>
MIR/T*8%I]MN!(:X9CAD6Z,.CN@=:]3TYRYW#3IJ8&%XTW'OBM>.F.38!U9_*
MT!<FR-'#S:&,N,NPCGIKHZ?:C\!-?W#[7RF--8UD]*(+QVK!XYNI=?2>.&#A
MM%'#E]OE!+QC4"'#$2=VMQ\;_CH3.A,\@<(GHXK([ZD<B--!61-^1J3L<HQ@
M6&K)%M=QQ=;^F99+6OR[^_V/['B+.JPABM#%59[V&+M)$@\JT*VP-N\5/3L\
M<D=CYFG_P99/=W<#DL\! )#2KMG.M96"V"!0(/M:IMT@T8?[&*S=Z]B=<V]M
M=:X[HI 37W2;*LU)/WC5?)$D/.['.R:PM$#*JXM;<GE*LF@D-8UH9A>YV!]A
M L^OM&!3/)5_"1063Y)E'WC!_QSZ\E&UC@@;)I!40)('1>?[%8:JE>WOO *T
MWK]\;,E:(S<D/$Y.(<%JR)L0'@V1.Q;##GV1W[DK12ML(J\WL7T[>]?W[%ZU
MN[@@T'2Z:3Q,(*J1($?=/\ $9M=_DLW9[6");*/'/]-DF# 4/LN*G?*"T+YK
M@':%*!>J9ILT-#LOXY8%O=XGZT0XG8=<GM0ZYK_;K+"D\>1K(O<[JB3((P70
M0>L6;<HWBP)6&QA\A<6^QL/15^>-8P(?7Q0F8?A>Y;J]L]TX?>>'K*Z.6'=H
M;+N^.L[8U4=NKPMWKMI@N&W3UZL<HR$ZZ9ISHEF]2WFSB]N0 !01A^*%SJ8A
MKH!1-WP-C+H&8&!U)UDS@@/K]&D2*U#*E!-R")V[-+.()DT8$K?,/G<ZH[H5
MO%,A"TNW/WY*6 Z4&%U(")5J<J1DG*Z;+I:^3HQ_EQ>*'W1\9X%)&$$;IS-B
MIE34 L]6&S;B9XUBSD<:ADR&MT\E6RAVSK:#MPTHH^2 WG-Y7)S![8ZF/8F@
M.&)#(.NW-(10!"U/D%5(_9C-ABZ%HFA, ,W8+;>FSK&!DF("GQQ0E%VHIG7]
M/_^]Q%_'+%\.AA:"E'F-@:)P8UNAO30,XT4Z$\ ?9@+"79G81Q$AYCY54="@
M48T' BFX[!08=>I#1%>%+@%%XVF<4*Y=B*\GY]P;SU 0/NU0^/ V!J'#V]A>
MQMN8. <[TVD9KR'>1LR;J1UWT 39W] TQFY-"QW_6)]C(IVJ9L7V)NZ#L-ML
M5^F6 K*(\7V,:((.!-T^.RL??4C* U*GO$O$9?2Z2$Z)==4^#<#01\1X'I!V
MG*\:BA-^[;@UB<G'XC]"B$:6EPD',:D4\49<%\SC$B%VM-W@XZ9N$M?SQ'CZ
M NJFY\4FO!-FR$.\89])QG%>;R=78\Y<[&9?"Q-HS8PS=LS;BJMK3ZX[O2[^
MEE@Q&#:<5N3N7-E688F--84G5R0Q <.T-,);YY-FPK:N;OM#4R6KUD_TQ-!W
MH43\_U<V%"+,&!HC7EOA8'2:\B%%B:&QE?RD-\^;SW(/67_%&MJRR1\/9'A)
MG&.(BBQ#WF+Y&8!'+1E!DK+7.-T!S_?.1)^:TNNX\X)F<.ULE%QI=#A%S73%
MV)925%VJ%9%_RK7BJ6[WQD>E";I3UE)I.SO=^ 7/ECZ?AT'<@^Y8J;WT,+L,
M>ZNS2)>NMDVK+"4DB< $(LP:.;K#62&03,)$DMZ@BV6RC'.<=K-&D$KRUF82
MUHPA T:%8Y7<B OO'#\>*,"PCF@_X6V8:"]H1S1*6$?8NK% _3U@P2C\2X90
MP5ML#O+$PZ+.F8@B^]7!0G6R IJ.<J 9G2;&O2)VY9^2#"FWP9YZ@JUBQ+6H
MH?##C[A JF1+RWN)54G7(FGL3ZKL\F/L=2&=RQZP(4%?\ [;.6;5#ZEZV2*>
MLTZ[K%C&^8'W*<K]?HSB-RZ0>284'GBC:_#2:/6H9B/R&23%LT=-?MP\=RJ<
M!V/*L]4L6"G5D,V6*&AO/0["$7\SX[#=S(C7RF(O]3#B$CV]0 )%$.C\[*=E
M-Z24Y[5?Z?0+'$=H4RTU)T M%/\4EH+=@\*_80*LR$-W:MUD0US&*RX=YT'?
MB;]S KI1?ZGN*JH\5"O+A]_.]N![.YZ*<@.+H9I$H7 %ML@T/, *<%R$)8'\
MU%?Q0\R=Z:\&#&V'L<QWN5OB\Q&-E+(YY<!0@8/'/TW);6T972GOX7+:>JJR
M]<4C8M&=NLL#2K[06;[ S1@D:;8\*NO+MMYIJ/I9MRD8>E<'6M?((CBGR4-E
M6,02GM#4'A>K2%Q2%:4[C)EL^.A/#L^<;WS07S*1=S0[Q0PNOB4;)!MD)IIT
M49/;U&7J-Q/<C70!C]0<"D<OA;QO]]<X ,*YIG\H4KC2'XM380)QBM 10ZB'
MEN%.&X!0$<)@0U&],(MSA#U$E/\RCL$5]F1_LX*=^-5"9[7:.:G0EP):TBZK
MRS1TU-6$J^X/'EC'WG^BLZ%(@80<]UE,EHZ0BRM?3Q?M1 FMH1QSNS.*-@*?
M:W![>]8&RWMX1[HG\_5BMCQPMF15K+=-]J!$$O9]^^+SI. %!@N-OQ?U4"[D
M'>2EJQL3N-[G?.7JI938P3.M4850_T/RD-1TGD((AV'%[<XDS"F%*(O"D:AS
MI/A2%7.NNG&1Y+WBIY1S=2R+9B- UP^!Y:+) 1G>)-CM(GI;I _T@BG$ZQ);
M^V-PI=:LKW6;.](PG:75%&OBC"Y%$SPV+>*/((Z!]8J#O3(RW27&1X8;R\Y\
M/[.LH[[@A2U6@0;:3[ZU5-NO(9J)]E0?FRV/@K;"#E$:BKCL8O*NQ=V$Q^ZC
MQ\OY>V&#F(#GMZ1@J;F(H-^S@:OHP??D#@J**DBYY\;![\A^H+>&-[=KZ<([
M!A,XCEQ6BXA3@]]/X]B=>T'-G<8-(Q.[H?<Y7MZ?Y_&[28HM%A3@T$?>^M:P
M$'3AQ);!Y..#9L%I#69Q));QB'K]PP@'4MMFD)I1AN6">=]GZDQI\:.<=6,6
M_YLJ;)\D7SP',D+A&6*&.633)58FL'N<$C-1]CT$ML.^%/9BO3R2IRY2AO&I
MMB??K^5.>,W9BPSAODH7$NO2$D@2<-/3$^-%$1.1I2%ZSN-=4.JXF#%=JEGC
M%ZTZH"G\'^,(1G^??6?[$?B6(DG>AA0,P=L[(AC-*2NSK.BH/14,XQS-U?YB
ML_LV_^F+_+L$3SO6@2IYCL'&!)JMB7'T@$=,8-WK)_-8]P&-_53QW^=HB$"J
M':KZG@8$V9IK.9L@\)#F-K'7_2JY\.D+Z[L3PIMKH;Y5&V%GAP]=>_RPH&8&
MQV=JT#^DH]"EM?]THJ<(J$H_V43I SM^Z"%RJ&#4K;Y?N9_&ZKFX6.!9[I)Y
M.88J^W)71P:JX+%V"/_"MQ+("*8%,^A-WJ8D4BU@VFK&X_S)7>S.(5>[UYQ2
MZ^>HWYZ>%'AW:5$>5^"! WG65?1398W&8>@Q%+X<Q:/V;,V" M7K*.>P:464
MF,@ML4]9594GM]"26-47IO2#T?FI=1QA:ZH>10U($=).5>=5N-RDMZLZ\G9>
MCE9N&D\=[6=6H#<IV.)P:^TO5/K7Z\N)7XGRKQ?PSSH9N11'JJ8'%3_Y=92'
MA ZB:61$C/3/&]9R3>2=<,I4?R54//:+.'H-N4<3!K$.3W.F>) :LRP?(A7R
M#%ED4^]_:^7KM/'[/C-2ZW/ !T8T8K#/$&<:Y Y@P\I5LRFR!(IC_-Z>Q>[A
M-^P2&U5!E9782*QR 42Y0#_O>HH8ZBH3V*>A3I&;^!%&3\2/<3^L%"XT/B#>
MGQVK<Z+]HI =PFZ@2A%GNF9$B."93]B+D]G0XS/L4?AXH[?HLKOM8_):G8]Q
M1X#1NB)9?[$;M/<&RD?B6WP.*5,)>\C5]N3UZ$C']"OEKF]-'2>B@P[E0!ND
MSADM&J8/T\.2RK7(YN"*7M+DZ-E.22&UYVG/2B=DYQ3T='D'?5VB"_8)W52-
M?UNUK'6-/-_:\<?\$[^OK#[@IA&S%0+>$>32OC]&#ERC5D-9Y6+WWI6!H\8]
M&FPBJT]&=:OMAJP-13U=M=[1#C*NW67TXFPDMX?L& $6X#PX9D'22R_N<Q:"
MO^NK#C+8J_[N_C'UO9K0L3WERHQ]QYC KI9"RH8HMJX=8KXU>CBO6%BG:Q(6
M9QXK'Q"E?_OPBV.HJ>2='"V?-2*#==]&BZW8>*PLEH#_U4<IH#I;*K^*5>I:
M5[]D+3UZ O<YFJX2'>M1O4>G_P.M=DK<%S]=V4MQ9P)[: C5+FEA#0E27$C!
M]UX(M'_749^RXRBW*-,).JF;F+W"8-,'9R[:@[V;Y5BK ?F9CW'-,M=[4*/[
M:KJTY&%B_NW^JVE"FOP0+<'X%=CQ>29 A,F%;FZJ9N6C LEG=CY+LL?)NB2<
M-<>OJG]3_UHQDZ,Q/[P=5P<C7L#X#<;XR:*S/=;T2EDFHY?ZUL10@R9^(C[\
M7AN86*C]&.4DMB["CZQ\--5WQ8EQTO[FSA4X?%]ASX1!^R'>>[*LM+4GBUZB
M.I] -T54GK7'+8B20_#J5\>2ZQ[)"CU"Y7Z'LL[O)6,*L/<@%"F.E]!'8;8(
M99_49CP3.'J6-Z#&\85Z91(WY^B5,E-I0-K@S:'S?-4GO9O4^Q LU(/@H+=H
M;E3!A0[*TWIQ0Y*R;]8D56'0=@A2.'=,AW5QD9;=W2>NZE'5K^- #Z48DTQ!
M57@,L>,+!5U[-*8R*\FA<Y_3LI#:X8Z,@U_GG_!K[]8^\5P3D0KNIC9H,C;V
MV'S<2[ER>_R(QC'HJ^U'8G;A/'LK3X9IG=&&SA0;K$*-GH=5F^B'@NS[-:20
M/K.(([5 =E("EK7+^2;8$QU%GD;QZ6(?B3S=3^]H>S4Y>]HX8GA*5<>2X]9B
M^\!7B:0\Z?](%18-!\Z)CNR6MR^%!R"YYXH.')W?1R_)DH1@CY;H/@Q7Y=.Y
MD[X<>916 X+&;#M%2CDTE82A<;.,[X_F/3RW>=J^(Y&Q*V!41&7[VP,F\.+9
M'.S<SZ3H@5#;XE^3E[]<O3:!ORC.7Z\+K/\=.K!$%!&N18N%O4*3=Q<Q@<YI
MK#H8\.@0)N#GH::Q1FD<#\C*H959J&MT0(G1PC\FO=$C'*GCDI*/;KE##=*2
M@F>4?@G[%-!9VD '7-<?+"/@:*()?'FLXWP!3NUO(B/>FQ7P6SO[V-S)N^JC
M QO?C:Q+>O?,_4#[M//M=_O,!,P$CF1([><13A/NBYXF8SJQ%!EQ&E<MXW#6
MM;4)/C]IU#C,1XP)< U<0)-6Y"$4^DVH?_/.ZZ[691];M6;$VY8LS\3TMA[]
M]H>M[JF#_(*SOU[ WW0LB;@@-XX]E(!&DRZ,K )=5^^CK)/SW2>Y%X4.M;1H
M7=J[!_L4A7_/!(J<T=1'B*-FR^]&<0V#;%F5)?>+;[9%Q$XK,H$$P[LDFC2_
MYPXS[#XDW&$=,N!-CB9Q+":2XG1)<8&B3$ GQRE.*;/N<II%CJ -)RJWRJWA
MEO^])AZNL$Z#F(C9J.!QE%U$Q*@@_0OC\$/&66);^\<O\YVVR0C/OJ<'17PO
MTF3#7GL+[A75%B_,?GKW'U720!HKU;HTCGC(&Y$.5J#VO$U^2%YR<W<[4U-_
M-#1Z7O_N'AT18-\)4P)D:8/JX#!6V-@PL-'<YP@].)>2Y2ISKIWF-32S4KPK
M0NGZGB?[&MGVL4D-0_'?H$0#".4A_*@><:UZ<XC&0:"&6HU<8@)E?<L="1>/
M*QP&3_>T7%._5NV8<H'3#:6>'X:S?]QCAP?_>/M__\T;LJA*%7"$%:(;AF '
MYJ9UU<5P?.=_I.1)W7/ZP*G*#UE.VE1;WW^IG\,1=$\P5E:K#9$_49Y7*I*,
M$U8 R@/\?7[3J;YLW/Z3U?BZ#_RJQU_.2&LM?A6J"_Z::'P58'DNQ4% U:IS
MX<=JZ>(UC.,Y(7J="KINA?E%$4D2DU%>>6=$WT9(M^HTB_1M/&TQ50K]F0K3
MN?CS2;V5*?41LL./?(<>KV8Y<65UD*J7OYH_&1T3M6QR^'(D[8)J@##UZ\AY
MW%?3&29 .\XW8:_0/D"MUH"$!6?G9%=,/K>;X26>Q5,?/':99TVYY?:,^V/D
MUN4,AZ+SR^E/?;Q=%'NG)K/4UJ[5)]@?B7UPWU,D2D>].>U7M@E><Z<Y?F$>
MOU[/_YMU5#$#WHP;IH0Q>N@@G!&C">NT1*E!<I8#E8.@CG(!)J=G6HM))O$E
M+*JL@\G2_>L USH/G>.W3._1WRNGD+S@H9HP 7OOB$$HN9K$$?UX]:'@X9AU
M&5GU@="]MS.[PL?*XU6=YV]>/3<H1?X^WAARK K&KJ:7W<C(T^S*QN!8U.K9
MB\&(5@9K&UZK:.W2$<Z/TJY_&S\5GZ CWI?_I?1M#]<?R&'6WU#%3RQ_['#H
MT8-1DZL:G$R@?RJ9"<RY*M+WFZZU4[E!#CZ) #TZY[L6$^B:==P^DBGI[*@/
M^J34V9I_[R73C/EW'RN#OMRQLFP3J,CZK*?055)3%[SO@7@'H$\PD:I&X5,3
MU-X3VA>Y2/(&10_,Q+IP>BT;.Y<?+EFLQW<60T*QA79+I]*0?;!\V*MR6X\U
M=HOFUJ.V96C*6FYHY/Z[KJSPUO[YY9D*3_??<-U2>^:/QQ7_9\RWA%;#MJ21
MX$*_M:$9$=>F-?XJ-0Q9MC7 ];V9_4W7J;$RV,2I(HU4$QIK<5%.@!+)-'!S
M[&'N(65M/')U3",JC25M1]]9CSU8?F>GSWG%4?S)4:?NWX^ZNE#P.GSOB74A
M;&(P#61HOM6,)A@Q$RDL5^=S$.?L-U[2XJ!SE%88-\DKMQZ_<VPE8V9E!\R7
MTES-Z(MJ/YVSF6QK()LS)Q?;WC)RF&ZV[D)BG]\88Y](6=8K,81_+GJC+DJ2
M6Q$KBB3I<1O VE+)=_]8G+P-*M1=7G0,EO  H8H*&%SJ6W*OZ5CIFHS,Q<7R
ML]QM-WGY&KM\%M P4237(UEH)RGIF8C#E+AD2L9%].+VEY#'18>B-VT$CBH)
M=/;D?EL^$DQOH.PCI6K3$RLY'U;*=EK0V6\_U^Z4MUVRA4B_QE*UJ](772*K
M]V SRD7'F<"2- ?9691!#C99D7B$SGR&-/$N1.VAGU!39S2TH0J_&11".$>6
M\AV<<5$)N5:([U<B!PPT>;9)M-5_KV"+9WRL$!P_\#.C$501GWO%5N%JFNFL
M?IK=\4R@L:[JR3*KAJ$-KS!_T\V+=QU+*'.DHHOT!.21>:0D2:"IJ'M]LN43
MM+ST#;W)&C;^3&U'=[H*$$E)IUY'=I9N+FF1[E/KS=??F\-'S :%N7C\B\5M
M=-9_Z##$1#8QK0CMB;1)#U@& 4W5U$S=-%V#MDAEX&S:AQ#\Q$*$0<3VM)+,
MW5FL=ZI:T4U]4K2%C(*38HO'1,-V41V:;_X\N<1'*27#H;N@K;<U=3IF*'H1
MF 6J?GY#,EMS4C#C2KJA4?2'D:'>HC*? 89?5PK;S5MSGW_6(UZ)ZA0I%0%7
M?_&3Z=P,[7 R&02/E^R$-EQ=UOTQYZSQ-TK;-UW6+M[/^AYQ60I#7SMZN/8X
M39G*@VQSAQ;H+[$D4VQ--+LZ*X<R?J!7:WZ<55X;^! 3IO_@M6 #UCD_3 AW
MH<OID?2G\+X?+:*^>ZV/&4IT[#9F^08 &C'45#\UJ272V1\Y[".IG]6F>IG
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M$4*3^,L(WK<$V]#MN%^D(ZQ#CJ9*Q4?0.;$[0:68)$=,9@C0B5J,(-@+%-&
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MHR[4(W'(:FS>?F@N9G$S93:J'D)F)(9=-H_QE'N"MY6G]^,<]C]^%ELE[4@
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M]#^ ],6$<Y]%.>$!AB N<^'O:9:YN0G(+$"X6Y?@1@!EC:<P0)HE/@#&6&*
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M&KR@$M_C&CX5S48!G]Y[_' NW5O/;-/3H4/%)%XE2;"SP$?26DNV3LDP77C
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M=R8-=6YH7(GN"PJ;6=[-M0G0N4/[R>WT%]CG2((\DI!*/\%-C*5Q8+;S2@&
M&C=]('/U[I]2]0<_3&O-]_V)G]028OM_[A<),U0.#)T%,P$>@4Y.C;'W*8NF
MVI9VV<G,0VQ+*B*U)/@:DUV^WMI$I?NVZ.0X7?<"8/[E]SX:O]2O]OQ SZ)_
M/3YMW!LR_SUZF\?]-A413/BUB#-Z!O5K/4),#;_V)]5I<!I;^_^:*_G]]2LQ
M9_&Y[%_V"#'2<F<>S_C>IQ0]]YNNV?]QC[_M*]/)T:JV-)(W-<SVWO5(S7E>
M"^VZ78)[A4*.Q@<=K0WAL!L%!R,)USJ'I)V'U"<[^A+?2#% >_-K*BD:KZ:R
M-:&=3M"-%*NPM,53T#$T,WH$/1),,B^AY=8RS1]E&[0:.+/Z*/5F.5-KQ367
M-)+.'OV:':Q/#4TF$"6I%F0WLZJ>Y<7IHMKW<8M+QZ(]6P\$-IGQ>!Y_LNMA
M$%V)*/,,6>"FH+A_@\OY% F:B[!0CE^%=$%WPR_>U(L\[9T%X[C8A?*1*H)0
M?,0ARZ*%MCF .S0]@W_REY89EF@*#[W'"UL8T.(KU?AEL\C."=&:8P[8N_ <
M+2%O)DK;!0\&R XTJ^>CP37PI,6X;N)X4$-[C(M=QC0F[]$;WG=FSS^Y>/S
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MN<@@Z@ZRVG9R +F+H))JP3S!'7BT7WEW<:_(4?_WL*7 &39.9)7?,LR(RL,
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M_*.T&V+*[4J1Y3=&;*;/:_6Z7)AM:RCQ640>ND,H<2G)"$ +FC45]\SVAS!
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M4#MJU1Y A-FVG3X+P!DL @AAJN,"Z3+F#+!T8UA_F5&J&G$C3#@D+^\YZDC
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M#4Y]LU=_1 W^S(6$0 C7()LJG4$8D@P,.=N//@:LS !@[=\B5QZAN)#X>[6
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MZ/L D=\%2/=S&@/TK(4N+D6^M)WI1.&FUB.P)'2Q;RH]0:/(.8+>[T5J@<@
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M.$DK*+:&K])Q/>RG4EXA<N><P/ARWT+^J0\M7Q/TL[=+>;=TQY%C.O-3G7
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M*VG8 =0(8=ET0.$7;3*-]KFAWVX=5S[-M/-QY;*BU@W*'C7MBW^$FO9?2_0
M_"Y..K5%N1TRH4\.9P/M"-@-B#3OG<'YRV*08/P>JC[TQVO53:B 1G 8%[#6
M*:0"&>:GX<^;E#)7NNSB+D^XVWG?W?+1]9PHC3/'B^EF84CVY? 4:"/\0 %)
M(\M;WZ>ZPZ'85*J4^TXYWU.7EDBE=>3#+]OOKI&XB7"\I#'Q*WZ_'EXM=#6]
MIZ3:=:+ <85_8<D+<#PL!Z![MRX+\  @T@ER9!H^94(NKI$Q\TK467=XDN@W
M;%UA8U\ MSVNK!@1N954B02ZWV?BI0'2%.;/EUX7_-SS&OX=? 3Z(W"<&IPH
M%$*28HK $B.QC$#)6B7>,BI N20)Y)EO=G:%:2Q8LLW#DLZ;KE%(1"2@9X>/
MPM!/,P@X*B!(?B)42=BKJ=XJK*0-1HP9TH8KQ5ICWQD *Z5RH#DA/.P60+].
M53<93[>/(C]1I%;5$RK)<5),P_LQ&>D8LKL>6^+6CC].N<L&>>OXU]CUL\$W
MIRTY.=M]_&F:,TER(HI/,@TN3L858J@ %L-$17/5MXW"43JZ"FFAL!>GU2T4
M:X&WIO=",.2>4X75@AZ2/U%H&,O!F@V':! _6M>>6;HO28<NSD[-R2_NNM=Q
M=8P\,_&=K\651&_IZH;+PR/&E6JB.F?U(Y_5ZC"="6 XL\90$-HZ<SDR].>K
M[K/*WTIE('K@Q'-;))8;1#BXB"B/U5Q:8+O[!M>^L>;F=C*"'/F"PL^Y1K[O
M@+4-W'98][V_<Q/A/D$VZJ,TS?C*#W/&3(Y-'C[J6GON1.M"_9L'RF>BKJ6?
M'S6P&:#$9R'>TK3Y[3BR';&<BHM>&BK^I((=/];TRHYM81]CXQS2!;$%(3Z=
M@/ !6-'=;]H*R_ZWV?;^BO?Z[KT)87EXQOW?/(3QOQG_87[[GV)^0X2!,)]!
M)?HDD>A@MO'C3\(C*YK#4]?=3X;,(#\=B,SL;G?6!XU&*?N$[6Q-"D4_006-
M'>JM4LTW\4_4['1X7%4>F\WP- :PTOQA?XSZZ44<FA!,',Z!=D(X2M <MHUQ
M6/TR<1;Y+;$TONDH <(-@.]+L([=&H2-F+LK([H31&];LE+5H]2]31+I';X/
MI0(VH!CP\OO577U6[N]UQ9M#NDIU5  2*C23DAPQ:9T21M$"U5S_R9F*&'])
M/M1;(^C5K/7]B;QLR3%CO22'90<L4"H*IDS/'_L%$*-\H+<[4SCF3D"EXU>Q
M85]^*Z/B"]=Z<WK,68:=;L3TENX(]"8Y+=7ORMBA2F0:*YF.S-E-;S>W5U?1
M G6X(\.XB _V#-VK\E >*SY"$2:^UI^> "7:9'C=JX_;(YP9( 2,+U[D65MK
M@;T86 -C) #[@_=V)!\?$R$H$35X7S'%>D\>TW1H*LG*67>7H&=(6Y]6BV%Q
MZ4T$%"(L$8OCQXALLKRG%CG>^*FJKL+<8<*DJ9UJ:0U)TA8^L?$"_B9HX>T%
MZ< 4<B]2H=3-#A?F*_;$U9KFJL@2I%]EVK=]*4=>[9ZE NK5_4XZV*F5KBL8
M8HA3%<4,*,7E&DEI5/F7D=38<F>E;43++4J(R)H:Y0AR]PSM?A#)D@IXGKI7
M GX!>\'LR7T3-7/OK?20[R)NYXY?%?WP4&1[M<F,J<*0P.JA>W(W59Q<0@4,
MUUAM]G?6-XC(U)7->[YAHVRKK+^'+:_R^Z72D,%Z.=GOYZX26DJS!A= =JM$
M:Z9 $"Y\4<;,*ER!\^0U/GF_K3Z8QX7J09?I\JDIOE/QB-Q%G"_!GKB9"VV'
M<$I!V.=%VP63+EYTV'KH)#;\XJ&3I0EF/?C(J#)B!!2,8GX"#X?2=?EI?AS)
M'XO--\[O+0[DK*6P<4Z\GE9?^A+52W::T*<9(#N+\7L-MS:STN#>:M9MO?:D
MI;%9&N+!-H>@!CB;"5''K]0_,K8=ON[;JJ1!NKM6 3E<O==^F8F9^+=NN12!
M$Q/Q^O6P0U5\+@BO7./N)\=X^\D6O4MU4F@+SNFW!-T#L=^YUFGB4B.TX=!+
M]W#)8&8[U'Q"4#>'5)+@A>O@[&^77A[NZ#$)6 U@8:ZUU'5J  ^%$(KPB&5W
M_"$MWR:NQ!$'4=&\<P*B&P-HG"JOL[Q%E.&GRUKWS5TM1( ?(<7T)/;=>BA/
M95DAT6E"'G%2X7'.0D)Q<$=OM*6Z\N4*."%";:C&%@\BL;-C.U"^,T,+O)S?
ML5^5M.*BH@+Q;UO&\_V>_31)>JT,Z'=P0VL8SEA\:+]&V8L5!=64A7!>&8&.
M<,=<H?[6^Z!7I^W&H PT&=3V7U_CAH6.'41:<TQJKC+=;NG<H +BO=^NK%(!
M8FK:[_';V3\FOR7P';Q3?(F\J^/%1$BAF:?,9R15\WPU#J U4L>\HDBH^-.G
MXTE?^!]@,*_:?0["KJ".4P2\ B>$PAW<T4?MN*("\PS?-WI:7 I6I<]J6<C\
M>.^EV@$N,@LY!H:IUF+QJ  UG19(4Q B\<O=YA,B9R\'TY=;HQAV^UPS=M@Y
MMT!:607@":9F,#W)']>ZR'L,S_MF4DRQL'Q9\"@NEG3Y;'W3^%(9_5!%Z[=/
MOTZJVE4T1'RKU;VI(?3T/!TR_N5\7\R(B2;/%=S'& W^!]E<SV(T% #TLM)$
M3IH",9,SV D%Y#P%C4E?0RZMDZ/]MSMIDE=Z.:T;0G[R: VSL>XR5$/3I8!B
M6.W]/))%NBV0$<JY<'T6#'='A4I7>I)'N_")=I[T,RHMKW8DMF_>+P0E_M2/
MIWA[]N*SG^FS7L;#OQE$+4:3N'<Q-SMAEDYL=FN"_?T*R@[=?*N-3@>\0%LC
MGYF^4$"O: ^&;N]5S]:<DJF-'@B9F(F6@NJ.[#SH6;D?_5;C2;NSBF_62W'2
MH:+L0N>1+>'S*9^D_[$-XY]QQ,/AOU%ZL4@%_$:_:8X\S\\CQ7N_WV:X?Y.)
M8$:;U@&2"%%H5XXH4B>'"*&<,;$UX^Y<WMC-=A"U'Z*/D3K2R&@JPMJ"%6;Z
M5+!..0?8HUJ_CFY D]@-J( U4^@/RL->WG;6#C0-0A-#]V/&R8R@4R"<J3D-
MCSR!-2@##]'\NR&1!JT"%H$4343+CT@HODAEUHKV%:0;=#@G2A#\!9QXD1;;
M3%6 )L\P!<(V1$E[I,[N-,PBT#_U)ZQ3=.V/_I=HR\ D.((*P)^@KT7ML$$%
M89@*6C@5,T<%A#Y5.D8%?"_"2]+TL ]$BH>\_&'<>-OIY4&T4.Y7[]%)!3 #
M_&@F]*/5I!6%,0^V?1%UY@><5DPX[@%%40&_>I'4WYVT'E\IGB4R[#=>1.U7
M<T+Z4R<IP5IV<(<*^/5[1/]R3MRW_Z3@2]_=BC:I@%^_AJ_0D@/M'Y[%@99K
M)QVL;N&2WTQ6*V%52C3+A_5*D4&G.4N?9LBF\<_V'!?9H_Q&?$<195(IFN(-
MX-U]P[2/7+]WGC^$4QZ>2T/#CZU_[CFO&.HQ#&EPWCW!9FG^](,[?S\61&*M
MI!QA&R\1:I#$C!\9NT2$320&* P,3_>M] M;*14*G;LT+DI:N8-2@=5:PS I
M0%R0C0R$9J?](\WOA#N]<'H(M?_P\)5U&JQ-@R5@EG@G:*I\>-MT#R5C>]]U
MF/Z]W8M_N2A(Q2!KVWVQM&CX&+!.B;/(;M3<Z+W*$:9*CH4N60J+ZL&WA"/6
M^[NH@ ? @4P]<BGTRK64QME!HIWFL'O!PGD0MN\HGNM4<^+9@_?=.A,/7$",
MHNF([!I$"TR[>/W.L0@YQ^C4X?3\]&(5QJ.V$O39BE]E^6.T-03+0 -;A'O?
M0>:H !_/YT^D#3,@&Y':I(Q!:9$,@$+^W-4CN;$ENFH*L0NZ[;\^[6>OTZ+6
MAA9")7,'S38Y'1QPVR+I6NR#3:UED=*;:882?1/1+1Q,:#VMTVKG&_JH#%EV
M,\H@3?FK,'- 'M.!$\[7,(&ZG(8C6B84ZQ^JN]-,.4(+.@[L)M+PWP=I---P
M*Q7 Y >6YSX$^-0U*VM9[#8?\?;K]$OFKS>%IE83ARK.K3S8^#NW,TXCEO#X
MK090D5#C*+#)C+-L35I,T*38 2ZXQM?P4ET^M>#:RE6^HW3 ZO'/5,"RT,3J
M4#UF+!XK?ER3$NU7>='!]%DBN.R.0@L_%6"CL=CY3(^'&=(QV[X,H06 M5=!
MCODJ!"$B^G1C&]@=4^T=,VY:J*VN[(R\%+T]SZO1C+]@@3T;+]NT,'U3#^29
ME</+@5>"8\''#19VM*:X@N.SO\3K(26NS,V^^&)AH?3\A"WYP5\E&5BW:6N:
M_@05T/(.AZ2@I('D?6,H]=_@J;GO*6@,C(?\?,_N[=],8$-H!J;V_!X]@-(Q
M<A!J0I&&9I%:^"NI5,!A, $V"/HLADELVP4-(5?7+:,YU[LY.IP'FPY!E7]4
MVDG['TJ*_F.F,'4PI?Q_S'@ ?VE0%]?^M+(&/_S'K/\C9GWW @9$O!A?!PZ%
M7NWT UE,C(=VFMG%XVP(JXI!"0V?-<\UI;=4\)\7E7RJ+<_[AA )DX-_WB*]
M1]2C=CF+Q\G"8:B4B@X7S4=8$5I4?^?/YV3_TV@O^TATQ" [7#P6%>"G[WMT
MZPJ4HS_/W68BD->^L-:%)R\WYM#DB6<QA\"V9!!M,@*5:'#O>SP6L3M#$W54
M_Q3\)]GK3"9/7Y NW!FDR>"0'VVF/HHW0[;:::(]39OBHWMD_-<A4:C51 A%
M'A+SHZE0W)(&C_/A^!-6]:"=DR1W*L!OB*8*0S0-0P?#-@2(BY1M6K"'+=D6
M^HL62VX6_?)Q-'%PXM"4YZC3L/$K*)('BI_R9YE;0DMA#=?@1VDBU\3WD]?M
MJ(!FZ]__")H"?T/WH8FADA-P\F&H'!50XP C+@-_]8:DV+_(^]T?^F2:[DJ"
MC'_Y@<6_>DF[-?"?5^&,U6K(DLJNKY<38;Z+I.H^,0HT[NRN=ZUEP=YEMKQW
MWO7*MN.H0M%[;!;"_:?-,QE?R@UT&&1S.Q,VQ\ZZ<\W@J^% G_S>F>L2_W[-
MP29JR\SXRMOD).BQQ3&)7N?O-FS3DX$>?97O:@P^WEM8N6_U?A]8V>ZHGF R
M;T1NGU]AF .R4\QX-^H][_%2<>:C%[DNWDN\&V9<.AICED=,I#""=W6G!DA"
MG04U*^UJD$M(TA%&MYU;7W8:_%6AWGWH!G%>6SB+@DNN5[A1F8Q108F[P&A/
MV1<KM]AG@VK*<@# LD$O2;&Q2E5?OEW8?,%^-*52U1ZE/S-(2?:"U;%XV?&E
MOM$I>JT[TS^42(2G;T!&-9[L\:O;[^YUL=)U-G6W9(5]^^:<<TA#*0!EL+=%
M"OKTB-*A=!S"[I70RQ0E/7=H(,GUB9WE;"MO#/(@^NZ6[R4G'IHUTJ1\&1_J
M9X.Q5ID_SK<[O*X@:RYGU>%"!8A'91+U*8:!/222PW78S=P=E3I'.L+=*.^W
M:F.P^O Y^##4:8E@M*E'D<;O-CKE:?N)OP:/A)?8B!?WDRK!GV% SY6EI-;S
M*2@_T.OKOY46*@,-@3%78G=OD;CZJL[F"N?YO#8L+1N.*RHS>_3.O[?PI5RV
MQ9R6YVM])1%&S5,W#7SP,Q&Q6DK9<YV]SYKU:R?/AM=K-*5QO38:E5J!?X6C
M:786'N*#K ,#;<>X^\42NO4Z'8WZ9I1<RGTN)R_4'\VL>.G;=QH:3U.\Q[#'
M0.)M/Q'V1K%#_1[9'QO$-ENPVHYB]"/OL;DWM _/3CUL8>Z?"8*=Q,<?[6U9
ME\5DYGD&KK(CV^U)W7.PC&0>?/[Q\U\O6-Y?RL3UA.U*&B/4TE*G^G_*'PO[
M?__+9O,H''>3"AC>3Z&! -:O.*19Q7"&G2OGABR_H]@*6IQ>D>W.Y=1=3,0I
M 3\A/:EJG5F5GN55^]F$OK4.W>3#*8\01\-41"[P!# <X&W0KZZ7)?LE7LJ,
M_D@PR]U.V0+W.@P.;BCI1WJ!&1O>*=IGLA;W5UXL3" ^KN8E]_9]HP2=1["0
M V&VE; A-$8ZJHBO(?E<MXMYOG(9]T46IC&Z07Z.AP.GVSJZS?HA([*.#U5.
M!P5+'ET]G-:]!LL9+(B@ B36(S)9WV!SI@<&UGHRA3C%I8<K?#-[#6G?:9J9
M\&^7E2Q4XB.I=%).$D_IX85"Q5.ZBTW9!E<*5OCGN<XOR<4I %)CU/?S/S-V
MW]ZC@$\CU\ FG(D3%%:BWI9G$$G&I=*@+(ABJKU]F-=,S6!"EC=24/MX@_3=
MR(%T$;Z9Z&$[ K(/9(^.&@H)VP1>Z=<";Y@"P9:M\X0PC1O8@.68#M\BWEKE
MM?^JSF<+IOL[XVG(%RK@A/1X,/1LB!YNI2C'VB@=M5-9R9B)?*<8>):>OKO:
M/QI'3V$LPFM.?%:QPIX&:> )<%ZZN+L$;A*LWZ#G(Q7P[(;&)B(4^I,;,LE>
MD1H"65-H]K;6D7+$[U;4>??<:O-:&72]8+9EUW <%6!IX!GA6Z:=E#L?'0+B
M(;'C?48?XQ#A"K*3 @\KN3Q26>O/;^D^NK][@@$Q>VJ&D![@69H@R^<1I3YP
M^?/[RZ]:SNST0=O9ESG)E^]"T,  E#TB''2\[F(XGJ^I3Z)YZP%7PS)@#M9;
MQ+(\3[;K(LG39MR'_+%*CE5_\D#_*_'[E5UY&:--LI8A,-38XF*'U6#A[@WH
M7"<DS .",QZ/CBMMC;'CY2U_"!_32+W!006,7P6FTT1/8EO%3D]QF_?Y@6P'
M.XC%UIK^2@[U&ZF#A>NIA-(//24B_KQUQKEMH0X.#W36VB5#L9%JKLU/E4J(
M=R?11.&MY8/8JT/RT:$[;_(<WHL%)>6_4G;[8IVBAU74$!JK<FH>Y_ SQAO-
M=N#5PA14)B_0M3B [R;,91/6.;"XU,'/_A]WM7:5:;-J0CE"8D F<)#4:R[U
M8B?L_4#AG\"[]Z:N?^!%R3XD=T,28:5.)-;$2?%E*R?WE*$RG%5@ 9U:U\;V
MN_0JL.8+')?RM5I=AN?N]R+ZVWY ?QLNFY-3 S^'4(__9A3P5PD<3A)#/.$U
M.=./&S/]8JJD5_J W1JJU@:X*F1/( ]=Y9TZODEF5#U9R]7,E7,.D),CP7+\
MZ1'2+,T'T%/:Q#X0]<V(A;E&;^!&':\^QINI5EQQ%.!%GTO9W^,M/IB[85N^
MH&COP/J!%DT>_/?L$?K?NNC=8=_K?8-]M=C+P#TPAI%Y[=:[]S8\]E!1<I<:
ML03/Y9SY-5J])#*Q,\'R#%3>>"TKN_#N"%GOKZI;169@Q OQR\M6NZRDLVL;
M@V?*\300/]&9SSVS>WG#MYQ^ZQ3H/,@?)TO7NM._++VKYN5)N$^4R?5"-\0Z
M%'7W/V:;^Z*597+%K^P<?6XA_>!]21[A&- !D/7J$&,#J(2^D6S<9"98MBY]
M[!8XAE_H:]%S%YY+@9TL+@O:&E_Y$Y\[95]^$Z5BTK>JH)5ONB 7U-,?O[6N
MV-C8T&&F,>5JF/1B*D:#?R<A_R\[_-?^9G7>S\"^0-+[H: 1/0)>0Z&[+.HJ
M5@?-=^KIA^,:_,^>]:%L:6CE]5[%;!;L,2@8A'OI%=9WA1@TZ<6*8 0T:R"O
M6A3?(Z]$GN5A [B>.+4^2V(VIQS&7+0H(K9C-7F:.<<G[#B[5R5:9+YE=J>9
M;4-;>G?<#.['J_PX=NW=+X]=HVOU<R!>^@#]#F,LB6;P2FAWDO*WW7\TMXF8
MF',KA/CX)MUKPAGW>4@ O&1V"8&@-(]S2XLSV(5UJ0%W;B;YL=O[O,D]>=*"
M%/J0))HGVP3>$#-CHEFV@^073Q##=ICW0S>2M3+#I)*VY(ZG8"F*,V<<(Z,A
MPLK[/BU=+SVL+)PJ<NK\".GD#X +;J(<Z87R>*%TOKNW<4?*Z'==Y.U;&;(8
MPK5D'@#B>9@#+C-(O_O53/\-EF4R'6T]2\)J;\ F](C!XQ,RD>*E1">#MY&'
M")[;3]HR0?B5AHTPO=WJ.)6Y*<2B $SRUK"VV@%7AF5((1"G+DX\'TV2\@R(
MG: "PE<#O1;K2VDH.OZ43'O^X(?]'N"QA$M/L;D7@?#W$;9J.5(1%4#'SI\?
M;??_ %W;[UQX0GX5+5/<01:KV[*0$!A!T@:UH\L*4W4/4KGU4)5%S_+/=6?T
MC+]-F+8C0LX"30U!S\$&BK)A\Z(EI 7:%)3PR?V!E,._Y()^09S$7;TGT$;Q
M'5(W:H,QC";0#@A1)JQ.G<+KIUTA[U=>PLT1G^SZZC:8$@PR(G,5V,*9BSUH
M\4G:AW]AZ-=+8BB*O4N<P Q[Z7]+P)H61DFW<+\=.;-?:.PEL+/WUTSYT\TD
M-A5"-A40] JO,S[1%^MLK(J+2+9,N5MCG+AVJ9B@I'.R? E]9DED!3'L1GB+
M)+]!62T;-T ?.^3=1CWJ_. 'E%NN'7 9O;-O2?XY7S8K\57V@CY77[J+M[<4
M4D;?M;B[G8_-V_2%Z#<P?XR&4$__A)(D7O]3?3-_/<HGLQIT?EQUKR05$K.$
M7G!*==KG;\6N)-C8/)+NU8TR+%G5I(QJM[77%(K0EABI"V;S@W%MK_2PCQPD
M2,[V\R57(XR+H0=PI$5"_B!D62.8P_@"9?7ZU!,=>KT#WH@EV.Z%14@)NG'8
MB<FF,O_)P"6E_*PWK3:$[:G=2O\>LR7ONN"'NUJXRHFX<)S3%R.K8#]Y"UYX
MZOR)4(<),VVY.//>=[27]^:/\>E?'&/'G6K/I0*LL:D4-'T*S%&3%A^:K8ZN
M.LVB>/ST# \Q3VT_I@*&%O*-J(!X9W^_3/&B7G%?L,>NGH?S?)SS\' ]:W5U
MA:B+*M=!]9='#]ZY"J![2L^1G96"RHW1, 361I:N[+'\_1YGYT&'>[=+^S;:
MPD5:SE845;WXD,QY7\J-[UA>WH_C"OHGD<O87>$1Z%<XKWBQ5YP^CI"9N,SF
ML8T<+@*.QJW@WV>O1N8W34!*=2?&D:M+'^F7+7!<6YK(*!!1H]B_?X>_^<@-
MC-MA\TX!R.LIS.D(MV+]62@_+JQCK6D.,=Y5]7%T*QJ=F6!FM<3+2 P@6LG?
M;6@C)U2GWBN&Q<$(BSY4@'M-*8CU?#9BR;)K-:.D/%C3-]S3.CU,51A?\9[U
MS!K#F8C[TB3G;NUO5,#-4UJF?SDB>X]UWYG\%&6[304\'H_6\TEOB $>7>2V
M=V_1Y_<^@)>XVSOI]/;!XX)-CA$[0ES3SFF=5NY<F]0R9)EJW 6^!U^%)5H>
MJ!TX<>T0*CF'+$/S ++0_G'<>Z(P.&AGNF_9N+Z3L]CJ57EY$?W,<Y_B&SBY
MI0?T#'9;L$/$^@$];]X+NT6>&>,:[M'DZ@K*YDX+Q7#GII?O9M[E2;^C_CLV
M-W-,'W9!/PW2/C"S&%R^5Y#R!A1^_=^2>9$N$*]2AQR3([H56%>8E;A/C*K=
M+TSH&[Y7JKQNH#ZG:W''-UMV@>DC_0$8"%2,6D)/K@[>FXR<#2*9/B!LW2FT
M\TT[F%_"4:G%^&K] JEG2N(H [!3P!N^K+LK2 01OA!MA())QN8S#%L:#_V9
MVMPS;M]4:$E<:WV?"[A\_)#PY<++D>C9Q)\^#V%-+J+9)Q@7M)%7S@'4P#:S
MJU+U*C@^?_CCKMC.)H *0,LJ[W;&OKQ6:U$/9*<9O8\<_PA;P+_P J%-CD99
MGC8G5!(W4X@RMPSY@N=)Y%OX>Z[S!&NUQ$O++QETZ>F27GFU.RN=Q"5G8M&G
M#.8JQ"+[,G-MW<2J\_.K+#6L7D7MRSJM@1A!$06WEH3,=T^2>-BV(%95^(RJ
MDUB3Z@@+W:?;#JF*?F5KWA1!T9%]+#>F']\W=QNIHL-HB4^$!$C!C\_%95ND
M67N\&C121JUU2-W)1;LU\Z]I\*_9/?J?:!?[Y[:,_:\)KQ=(E$%,O!Z"U(N'
MFEU,N&*PF71S6!-IR=%2&CGE6M,P<AY].[,0\0UXT$OR/C$<>TSR6J?]3(^T
MPZ-IT:7E%*!45^7!._+'P?>^\+S7WV#=%8"B2V&?QY?P$]$'#-]..?#V^']V
M!^(WGTQ5=?E@6MHC-NZD?LK+T=1D/X96W^/I^JF)-<>,#\\:_5R*<53_?B6R
M>V/T"GUY17E2G:K3R7W?EL  P&&AH8+^:2")S9=RY#05P,AM6D%4PPPO#QV/
M55)0\68D502URI!\]\DUGP(8[W8QW3B8<ZGR4V(A!H73@0U7[!+ZB$UH"X%&
M9(""TNJA%Y:#$"FK8^[G:,M-0^(JR-VYVO/4^E]$9<JL)_%WYB+WLFZZL%HQ
M$ ;>31F@ EAA)27#WJE$WXEW;S:%IF'%,QP613=YUB1,HG2OMHAF5 42;I'C
M2-=V(7XVW7[ #^)O9N%RE.W8)T8..:]F;F,CL%=U6T8:]?ED@=7P?93#7KX$
M=Z)AFA>HCO (K=XYP9SA_#@)+2X:2=*1MWB[DRPA<<A=P('9);(CI:[NF' 3
MM['!0V0),O)1,,=+?I=S$<(Y/TYU.ZBEROHLZ_>JSW&(O9VZO4/Q&!?K3OK=
MP@5%40&<1.@X5V3>X?B^_!/N /_Y%,[AT5B1K_?WKYVBZ<U\'(H/AOD,Q&GC
M<<:-;GYW<0[1\1.G?; 400(MKDTS+:<"##[X#UB8=Z>4\SUM235RG?LVRYM9
M^_/=/ON_T1"U]V>2(C$PS^\"OBE^$LPTKI6Q:"1=-VIDT@"U3H)=9SH3^/+:
MF:F3(MP_:7,:_2IJB7W7VIH**$75BOC[]'\MPA^"E_:;=NN6?RYK'KOCO996
M^U@!_^:KA;VO.TP)5AB];%< ;1KGSE/03UTI*[(WMJWP]L_.&HIA;/+G,'>5
MP7TZ??,:>99X#>]TC;B,&U;#6P4[Q=[I=,]U<7$Z/Q%?Q!<]X?Y ]_4:I_JR
MR5ID9*I(DAC+79T[_V\'/;XHTBFAB>)Q%I C.IC@W- EF)@K6"AY=%*JN+U)
M@PKPD=[?\^GTXE8%2@&&"1S_K-@<X,>>ZV?0EV_$C3ZE2DY*$0T/9KLUD9[(
M&Z.>Q?ZQX<8:C_Z<NUN/IV7GGI4.^#/Q]#^3</I?<5& P@!K%>T(X<3:#T1)
MY>=?L^V0UP\ZI,>-RGV5Q!*9]U\BW%-GZ@,3S\K4:_AQ[K*UYXVHE8+9%I$R
MWPLYQ [8QBU2 ='U%TAVR\*S-2Q^4EV48WY2WZLNI#0]["*!+%@C/YG'"8>Q
MN_$N#8B"734*@LL3*\N_%]/ LLX_BWNW&D$YW(SK<J*A."1]O>GEJT/JRR59
M[AH4DZRP'G+ZED<ML\/6"+V.2.->NX$F#00>H[2L>T'J?9"-[;:]J7"3%\75
M!Q^;0;_Q<,[N)Y<SWP73,Z/NU&7H?!:6*]JP#3M?8/[@O^K^MILI1^QV=6'U
M4E"TOL0\4HPI3,$0I=W5>J4?:<(DA_'D9GYZX(FGRD!_8N+,Z\LCK+<]!(98
MNITV--LK!6;0YB%K"GIN[^ZVXFPWA;^J>GLZM0HO;PONY>4/:N^1;J2 K"\4
M)UW&?L.A AD'#)?LT[]M\_I1MBT8JEZ52MR4X=J."A,A6LFUY\YX+;PE:6YE
MK,X/BO/GQ<> >K2Y6R3*!0W5A&MSK[_6,7/*@[]/&EZWIVGP&MI9)(5X#X<T
M)G;CZ35QZ!#[H5V]WHP3]1P3^N4>H+JPR]^:G]))ASQ\J)3M?ZRD6-+$U$2]
M4)5%W4S#-(I55XT_1AG@J@6MAM7*P!ZJ@RQ (>/#<E/,FECTB>L9FV5.2RW:
M'$:I/AL7U0X^!;S, 0_A0/3ZDT=]4@JR;W:X+E6*KRK!9;Z3^ANH &:)$8$W
M"K?SA=<K,H^OYOI[FU>NIE38;R &N0F&G:#'J.<>-:>[>B^*IS7L9'PL.FG+
MSE%K/G)F+O<[DVO#SAL6?8(C_7X5^NL<)E+W'QZ(T4R!]*/=2./?UD7U'H9E
M1S5I=:3?G+Z@. SK"W]<;$2+7DS5&/Z[9J?M:-K\1Y)?HB8.X=-@+%(BIA7@
MT/03BQ>X\ [>T7'F<Y^??:7LQ'B[0([UK\XV@H(3P$WB(3ZHH,UA6(F-7&^1
ML8G03< :)]A2C^XU0?@8E)?2":>31@QF3A+R)\1<9=;S^,4<G._D>1*FX!>?
M4 $63S>OGGV]EJ:_A@Q_#R3#HR@]]6I;NLFE0Y*+:W&+'12U+<_.K0;IQ&GX
M@-<@E HX'B^VE:08WP%D7)L>'9F@13<D9TK87RHHYY38_31[:X[[7>\DW?TX
MXA^OV^FH-S.ZD\T7D">?>T&XONR1?#](U>9F\;R6;L;R^>)NXXP2+8Y)B8W%
MKC=<G3H1L5J*]\ W$Y8Z=[_NRONYT>)XIL AF?!BM]+Q^\\Y/XB5+\V:\0=%
M\^3NDWSV*N#JN<HPTEZ5B/9>!/>1(@&KX\LW]8:RXE^W<=@ F0?&G0O;T'20
M4!H *=.@$]E,0)5XG0K[F#SMTH":5!M-6!;H[S)&),S!$FHN. MHLZ*% L.@
M3=!-H;%C2^->*/>MSDV:T= ?A"<&_5,;-!;'/PG5R]9<A ZBCFT8F*^_*AGV
M'0YJNA8P6M-Y!;;\'KR]-6^FLM<?LTHZ846X6=[E(.T4/C2*>%WQ')Q&]%)'
M23:7^:=@?-GN<KU"MXD_DCSIH:JF!WW]JT[NAR1UHLT'$@1GNA7B!TX;7#02
M3 ?&N]D\27S5?$?-_8&SRH6C:?L8SG"1X.0J&"9\C)\H)##[HH93S7\2?;C
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M_YOK-V+KE<Z\C_,'7[<HB;'<C+F<<>&PHD'&.GG"J"G335:ED*C[(^,\AV@
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M'*%=G_Y)Q9NV0SOV2*=^UD4( PPSUC)1'07C]5.6-,[=1_!AS>ASH0),9SI
MJYWI'33@\)X*.*;$X16(%8H4]9.?\#^W9=)7PKZ&*2F)=D-F"Z5D+1B&ZN[U
M^O<O TFG-"F'OV;20BS&Q/N]0_WWB<\*KI^DK%UZNW1NHJ;ML.)]B8-P0/G^
MS_D^5,#2ZNYYK_T$?1S6IH8>MYP14P2XZ!AE45G%5Q5[Q;1\ZN@R)^;(AFWK
MO9K@5Y$T>)!U_O?8["-AM<K0_7;PXO&E\,G5_42'//.^$E0A.0DA<$E9(7=
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MZ>^B/_$D;")"@)^ 3='A8DP$\7H(ZU?6)H7RE:7VR,K $4VEAN::)9WJIVO
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MW?GFGOKJ-;+H_)^<[ON?\3\W]K\B3N,#-8GTN'@3O,>G\3DY@<+W&<OYSE2
MQ]775(#W2 Z3!RO1'']O4B\;'SUYI6@RTM:IV#9ANGM4NWXE6Y%5S4*W[MG
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M.8DBI5BFOV I2CG$<1Q!AA&%H< B21$*E$PG\_4,F,@"_G*W4K;6R*<Z?W%
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M9([MZVM4!AN=]8Q=:0W5K(057>_Y.<;YV>!OMQ3QC&K?^QCM@-[9 .J\\'"
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M*O#=5-LBJ^_!K !TO\JH,+&-U59L8Z$?,E-@3K^!_%$+<FPKU\>K8,=T;SS
M/1/ES;OKBP.!J'M53B_ QEZP-!@8B\%WQN;O+P"3^EH)+L7_631'[!= F^J/
M<'L<!T]\W8>&@])]CQ"__EKT*:I#1,?GA?E<W2CS[=K(F0@22Y*8K7Q%8].G
MF)B/!8&(IBCDB"2,6!6":9$Q.K*OM314;1S*+0IWB"TX@F8[WWK"J&>^7,)S
MHVK'<HLTSX?'(=;B?)@&"JYPA\LME*(=B-;8B2.W#A<LT:[[3G3$B4N]]OW:
M2IW\Z65SS:J^OVG4TW3KT5(O"_%%C_=G_08T;>(G@1)*,V, 419I]YJ%'&9I
M$D"2,<D2)%B<6G5V[U/)L5%NK2DPJH+?&@T="V7U,I)VWO%;CT_/=.\R-+X:
MC'G!KM].9.>I.(:695Y MNQMYD=6'XU3-MZV<;&_S*J\5IAKWV QI?/FQQ/M
M\:((DQC&/!00AT3 C#(*0RI4*N-(2I%-"GEO;OCJJ[^*E6I63$$:IMA3L#_6
M^+G4NFTOF#_6>R4^6Z[8C9P=AP\U$*-IV7+Q>FS RBQ]]<:P^E=#M75Q@GF0
MMB]V&HVH+8P3A&YM8]P>W;40]K/^',S*EP]YD5</4OP\FXEJ$HLD#J6((5*F
M&"T5%+(@EI!)(1BC2@KF%-ES6,S8?.*5<N#>:.=:[/H@D'9D>#X\/?/;6L$+
ML :IUO$"U-\=GR6NVZ#P5MWZH)"!"UNW&;I?T[KUZJY^6ID_4U/R]-VLJ&.6
MC3>X7(JQ!!-" ZHI &<0DRR%-$L4Y%C_#]$DY)G3F56;L+$1P497L%*VXRJY
M%6);3\D/<+V[0!TPZ^#/G ;#FZ/2(FI@#^2TT?NNA<4];K0A9#ZY*N;Y_.56
MWN<FR:&8FS7C!%/$-5U@*#CG$,>40DHQA4%$XY"A.*$BL:&*8P+&1@^-CF"C
M)#!:VA'#41#;R< '-#T3@",JUE/_E.D'IGLE^0_WL^<?]:W-3-=_V4SPHP\<
M9%*?,F<UD4]>-[IZ@9,X49D*"($X,\GG*D@AP2B!*<9I&@>8*Q2,I#J@$Z4,
M4%'G \U+\"N=+ERZEO<\G!9'I^,9I)[)K=^J;'O1,.-Y"493O&^$!\UC>2G&
M5)7/ZAB\9Q7^7ZFX=_!8?B"1'8_W%ZR2_UAH45=FOZ+:I+4%+,XP#21DM8,@
M*8,$J0#B@!+.2,885TYG],<DC6VQ</?+3W=7__7+U>>OX.I7_>>=XS'[443M
M=@^\X-3SQW6C(VB4["E/\"06O@ZPC\H9]A3ZE+E[1\DG;^@2Y:B5U23T4=)*
M+K.4)Q0))3*,89C%F@(RP2&)"(.F0I74M)"JP"I@YYB L7& 5A'6]3*G1LE5
MK0*7Z+T#(%JXYV="T_.T7VH':O56%0?.!,4EGO$\<(8*9G0"R3&0\3@"[5&,
M!^X;,(3QN-:[\8LMU_44O'@LTL:L[NO%_655+1Z?ZLX11B7CH;W/35E0[;/1
MN9P$,L4XC 1DTG2%DZ&$A' " T8082+!$;4JWS>8QF-CVI5NX"674^$YHO'L
MX;5TV<8T:'V[?L806%L"MJW=;LQCZA]O7[<T&=0V7X#-UAG8LOL"K"P'ZW?"
MV#Y@)*6O81HJK/)L?<<58^D+?N> 2V^"1[?#OQ5[5(=];"*43,;43W4RGDER
MY $))&,I9 )1B%&:0AI&%*J0\2RDL:(!&\E!@*5)8SLOV(OV--J.9]O8]D5Y
M\R.&'H;_SW@2 30XX$A_F*W8U(-OW05H8&K-O!WK"SB:XXT>7L0_\RE([R_D
MF,Y,',?^+=L;66KZ_\H)C./(#-D(R5&SKJ%>ET)HLJC>Z;_>E%]G?Q23E"0L
M)5C"2 4(8LP19!&)3-'9-!$1850Y1GOMR1C;KL(RM&FIIR8[\R]-4$97U["O
M?4#;G2!/,/7LE71"J$,(V%$,SH@"VW_FP(%@1XW:CP4[?FFW+<VOLJ#%_/K1
M-/)JL@4G.%.AP@F#8<JPJ0V7P(S@#"K&.68<18I@ESW(?1%CF][7!9\N3#D0
M4X%B]B1-^?_B?GE8,\TIRZ?.!>H/ &NW^W<>7#U/\T8YL*V=OPVUXY9[V@$[
M(&#0+:OC!K[>8VJYLF-5L]5;O3P)J=;M$L),R10% M(T0\UT)TAQF* LXFF$
M%$-NM<F.21K;K%\KNJX=_U?'\F!',;6;Z5Z0ZGG";T!:*=E+HXF34/BJEG54
MSK UKTZ9NU>YZN0-W6CAW:RH9M-<U%L$7_3?^,LFP$C&/)-)%D/.&('85':F
M)(IA2D44LB"FC#@5B6T3-C9RJ%O+&G=@1VDW?F@%UXXB?$'6]Y[DMIH7H%$4
M_+;\;R^Q7#;(>"*-5E&#\H:-T:^IP^J>KKVMZ+SV3F[4LILIG:[3U%??PH1S
MP6.D8)K0#.( $YA%(M6K"X&Y4 EFTJJ<G8O0L;')6F?#*&NMUP4@;#ZIW0?
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MC]?OKJ\<:Y(/_J98G@B,>/S[/CK8,OUBMU=SO1;8-G^W4^@&@>V.#^:>+1#
M!@6P@J&GLNQO-8B^SB*&5G_80XLW&IR]TXVWTL-3R.XRH)O>2S2A64(C)B*8
MH2" .),,4IXH&,4XB=.8!#RP6E;8"!O;%VNI6ET#?S;7;-2YQLMQ?"T//CRA
MUO>QQUY@[CH[0&O:8TSN 3CZBL?=%O6VL;@'C#X9AWOHGHX9_@M6R7\L3,4
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MB<RX2&(L$[,W%VLZL[/K'9G#:8MN9NKOPZPM=&4UZ45%[L+V!ML%I9U1[D*
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MJ>GT=T^YXB_C+"Y03&"6%AI_H3*(">-:<F<DSC"+6.%4V:M/_ <H_65?$1I
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M M'_(_I+%,7@N2G"_5> HN@JBJ(FA8R^K'\LEL:'^5<P7:U>I"A]-:W,LO\
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MJ"21*DYQ 8N,,(CR.($LXAED.18*<8HY<BK'9#/IV 1@F^8R@8FVB'6-?;7
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M$3C)(E/./(VS*"58^:D.E@2,;>O?\Q]2O,RDL7H:7NJ2M^9?TSF=EYTB*]9
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M :E8 &T>SH/OK(EX QA(/7&??U"=Q1N>?47&?R#/#!2M)9D.NV66:H(B3)"
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M8)Y$ 40LSR -D(YYQQ'&J5!+5Z/KZ^<$C&V96>M8+C VI8IL[K^<!;*=&GS
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M%('>S.)8R#C@"$.><@Z1S#&D(B*0!5F&0\2H-*MW92YR;#18ND>*K9J ;"R
M<KF"A;+AORU3,%U&W6SMY!?+G@FSA'&GX617RZ;$4>O?RW+*'"1?*8LN"QPV
MZ9 Q $=I@\S?=..?Z?I9W_E[>5V)9[$H9M]$50)GYZ#YYW+.9XNOVCFC?3/3
M14.'U:Q0?[I1OVZRAGX6ZZE\)-^?TCC0@>4YC$6D]GAYSF >H!!F&>-!AB,<
M!JD-:_6EZ-BX3M>$>-NY=>>E.PPL%R=(#_!]7IR A7IY*<&:? >SEU?MJ%"_
M_36:H"2;@+^&>:Q^HDF61.69Y5]SE$^ 4OY5L+4"='[>?3'L=\>,>\?PC>B9
ML:?7=Q-@0-M[D0"UU6400%VU; *H4,^J!> V#=D$$*F^ST 9[(_I^^X23_-#
M;VH..JOT#?;A7-2[/$<7/RF>#Z(+O@@U-\[86O Z^F#_@\:3NT4V"0A* P$S
M',<0A6D&29I*B B7F"4LCB*K^YI>M!K;W*35G)P(0]H9L@M6.ORL\8)E?(&7
M_C6;4@;OM9[G#\,.FUSJL5ZV!5[!]A4)X46G82,F?,)X%%GAM?&.R<AVA\R[
MZ%*6I5SP@.EB AE$,2>01A&'.:6)H(214"9..<E."!L;'>NXW\^/TR__ZYB)
M[!2>9CSI"Z6>Z6]7*&JG9X_!L)<0\9VE[)2HCTE6UF+TV9QE;>\XN(RN=:%$
MNM1YB[XU#VE_(=]G+V\O55:$J?P7T7]:WWX7*S8KQ%,F2:!6?D0M^40(D0RQ
M8A*10I2C..-<!DEF5$*J@PYCHY5:6T!*=?4)PA^5PKKB-15 U'H;EH_JTCL&
M7JK^,>][C=8T8#\A_:8G*B-T-8_:#+"QH_\NL/"%]=\5 SG+^ND2.X=:-S!;
M/6Z.30_GDNMF^Y[/KF-3CD4.WV@A_O.FQ-Q^VZ9ZS7C"14A3F"$==!C('!**
M.$1)%&&$ QT2956L\(20L4TE.QU!J:1EP<%3,)HM4+N"TS/G'^+B/UUN&P"^
M*O&=$C%L1;T6(X\JX[4]ZVUCNCUO$I*F1 01S'(BU+Z4Y9!BP6 J:*ZVI K+
MO.N^=*RGA*=W78[QC6T8.^]51WA2YPJ:CXUJ3V=I;9(^>IMZZ=S+Y!77O!J/
MY/L=5ZW/Y(R5"]FJHMQ3)#(B21[  $L,$9,2$HP$#*4($"$D(M+(8WY1TM@(
MH\X:H;0%^^J"2E_;_!KG &[G"Z^P]<P6SH@YY-FX@$:'7!OG6AXXW\8% X]S
M;EQZP74UH9VIVF]ZM5ZO9O1MK9<HC\M[4M:#2>(\YS+C,&:!6E"@,(8XI!BF
M+%>KBY"G:6!U5[E=G!5%#'!9N=)V$\4PJWY;D^^VEY4O@&RZHO %7>^+BA*G
M*@8$-)751WF5NMO0$*^!(&80>5MHM H;>*UA8OCQ<L/H+<<0XZ(0ZRM651%4
M;/7S;"'NUN*E>,*!%%*F*0PD4YP2A"'$E(<PR;* \%CM7+C1X?=%26-;<92*
M@H:FX'>M*RB5M=RAG(?7C$V\@-8SD3CB91\I? D+7P'"9^4,&Q=\R=RC<."+
M+SA2!&/Z'+2X)^^:>*X67'VR>A/\N+*8^MMG95W]RV8KGJO=2DI#"C'721$H
MSB$- Z8X!=-8T$2&H=7A9E>%QD8XUR?2K-C>6>C:1X9T-"#R?;-6;0JH;2FC
MG&IK0,.<?BX]>,+1%^-U56=88O0$WA%_^FK7C6;O5[/E:EN_>4Z*8KN%W 5F
MWXB"K6:OI;N5QI3)3.8P$TD(U9Z/Z 4:AX)AC$2"HP0;Y9IQ56!L-'JHM.7N
MSQI_,\KL$]6>*?)0WPG0 =YD5>=.:MP7 +_?+^<S]@YZ"9]RA= 3.UJ+'Y0-
M7<$Y9#_G=MS8[F96D*]?5Z*J;C*5=0&"TO/6".#,,\S",-<'600BF6*84Y%"
M3/((QT1FA%A5ES>2.C9>>V#/@K^I%<I2@GT#]"=.Y4K,T#<C..^8]LQJ9R&L
M_>S]<)@52IZ(RTSFH&QE!<,A1=F]W$NAI.U^B2#,91Q&,)!Y"E$J(DBQ%/H'
MCO(XBDEBY<(WE#LV;C*I_>/JW3?M"C.:Z@'@WI=?7K#U74^IISVHJ=0QU52Z
MM*.T?=W]CN,V=V% 2:862%&.,HAP@"".XAPF7*A/),<RL+ZH.,[LA5HS^ZN"
M=N6SG8SOF13*RW<]E,0^LM7CG;D/*71]9-"IVVM>LAF>'-KZ+/ZS6%\?'+.F
M<1 'B&8P2S*D!FA&(95(P"Q%) LS&4?<:D-C(7MT(W@SHQ&MK^V!MPWHAL.]
M'RC[YH,S2<=+S3=I'*[F\^4?92U8N5R!ZY7@NO+94A?AJ2WKYPZO/:(]YBP_
M)_G#,YA?@,0DG_FE)ARNS.FS;\&7_Q1DOG[6(0BK5WU10O#-4B./)4(T@237
M3!8*H@LT<BB"))2YQ!E.C)QZ)L+&1EVUNJ#2=P*:&EM<NKH$<3MO^0:N?W_;
M6<Q<"BU> L_B:II'$ >Z@^;T!;2[8F8(2NM=LDMM#'=IS-":O=MAIN^XD*N4
ML_E,M54LY?5O#Y6(ZUJ ^N;4W^$HYB2*A0[KQ)D.G, 0\S"&*(@ERX)(A)G1
M(9.%S-%1[59K?5*K]*Z_\Z"AN0UKF %OPKS>X>R;@ V0=")B,TAM^-@[M$/1
MLA>(+7G:"JQVNC9K:D#6MK)MG[SM7OV [&*5KU7-*RN=.?A&5/^JW^=O.D_:
M[7?VK.\C?U$VW$HIU#Z6Y92D21!#C!,]'00!I"*5D,DXE&4VFU1:520;5'VK
MF66 6P,ZE^:L5E^7661EKBO]$XAF.BP=%[;:9;\Z?&# ?&7VWQCS@\YQ?@\&
M.$SUD0%M BH4P 8&\,,&B!_+Q7F%!=B  30:H()C)"G3G+MQ#+G5[)7_\R1A
M<^X8K]G:W+5PFUG_)69?GY4:5]_$BGP5U1VZF]G\37WV\$P4"4S?UL5:C4LE
M?1>?],0"-3?&*(8Y0[IXE\PASG,$2:XFR !1E"*KTM&.>HQM%U5JK-/5-/+D
M_Z#FO*(TX4>[.<RU;\PFHP$0[WE6V5@ :A/J:[=Z2U 9 !H63$!MVZ013NEO
M3NB(IB=R=]5B4);N"-4AW79MSM47^?*BLQ21^3UY%:MZ[YVD0K(XR" .2001
MRCBD0:33[0=I)GE($FEUE>^DE+%QWDY)\*JUM/4OG@)2I%&01;&"3R0I1)F:
M8RA**)0A1Y@SS'"8/ZD.I\O!H&Q*^W.!:>J6[0A0[P[8+3*E@GT$9[1!X,UC
M>DK&P+[1%C./O:!M#[MF7[D6VK<ZOUMP\?U_Q/L3#RG#B6)*%#&BEI,X@H12
M"<,PH2P)<YDQ:I=UY4#"V$BSSAU2:PE*-8'2TS;+RB&0[6/="SP]CW-K9!RR
MJ9RQOD,6E<,6!\Z><L:@XZPIYQYTO+&LVN3UEF=79>*SZMV;Y0N9+9X2$F"*
M(PYEE&=J040CB&6FMHF,H%3&@A.*K&XD7Q XMF'>U'>O>HQ6&?Q>*6V;ZN 2
MZ&;SO4\H^_:H=4/1_M:P(32^;@5?$C?LK5]#XX]N]9J^U[&4]:?W7P31J>#T
M+NZG59E-DKV7%4-)E*!(R P&DC"(6(8ACN,,BC#,4$@D$78U&@UDCHUP&GJ"
MK:)6%5EM #=C&L\P]DPV3@BZ%[>^C(GO&M<M$C^FU/5E",Y6O#9XU7%ELSTH
M*KZ(N0Y&>EP^DN\Z%O2YJJ^E:T'JXZ5/I!!<W]<6BZ**N>""1%+F$119J&B(
MIA',HUC 7,@T"%":4$2?%OIVG6K58NWCKI+1\,JKX76D6']#[6&]9/\&:CVJ
MU&1E)@$=H[YDLS)6L0RT+K/+E?]]%G.N*S!JE[#:'Y _R(I;.H6[=*KAHJKG
M/AHH,;96$)8:ZJPM)17NY=_?^*7*,'>=_[)A()C2^>QK>[R8_8JL.ZZ^%FL=
M-!EV'=<=LJ,EGH<F'7/YUU?SI_)T\\UZX)_>=\_4W]XK3195YOJ$Q0P)FL,L
M# A$":*0A#* *!=JY8AIEL9V!0!\:3:VE60S&T)%"+0DA*9Q^Z7LZ?O>@UOF
MT"9>S*W?<[>;T?>'=&;?9'[4CY],^_&30S_:UTCPC;FOP@K>]!JV&H-O.(]*
M.'@7X.J!/5U3YE0]O3C/&<D3?0<TP1"%D>*H+ TABE.&\SQBJ5E\OX/LL='Z
M]?3GGZ\^3;]</=Y-/X.K?WRYO?WE]O/C [CZ? ,^_?IP]_GVX0'<W/YV^_/T
M7O\%7%T_WOUV]WAW^V#KC#3O(%,792^P]^ZX/%/'JO]ZB Z >7-SFDL>V/EI
M#<FQ2]2^"8^U%+_H>)?B:L%W&ZUB4TBKSMHC=E[;7V9S4:R7"U'S;_$4Q&$J
M&4V@0!&'* I22(,\A+$D418*(5AFE,ZP3R5'QYI[8Y@T]\*KTM(R<GFYLW4"
M7C8%'#?F K:+8'C9& Q>:XL]U!#L^L5H)^&Q=/='L?4$5$8"967CC*-H5"/<
M]G0C5F5KZV8=/8:>]E!.<L >__AZDWWWO)^BE)ZZQ*EJ95?9'U_6TA-Z1G4O
M?<ERVSE-U\]B=3;E\E-&.&59GL!8[9$@8BR%>8H(I$DN>9(*0M/,9K/4+FYL
M,WVI+:@S3C<3Q=MM?BY@;+;?\8=<SY-F!=J)I.[;O#?^]C1FH'C:QEP0-NC.
MQ<SPP\V*X5OV@9S7L_7[U4J0ZR473Z&,TR1/U29">SM1GN<P#P,*8QX$/&$Y
M#D*CZT"'#8^-':[+=-Q*.:"U,P_6W .K??!W@:#OM;&9]58!F:=,=8K#W&MH
ML/#+4^HWHRY/_KU#!:EBFVP-A3C$@<R@%+G:QC.201RE".)0J/''LB"3Q+IL
M5#'6)'97#P^WCY8'D > F<VY[C#T//@JQ?JIDG+29I]5GHH/JF!RTK"3]9R.
MGW+T5*MM:KG&G\HRO$4[QM7XN"VC5K;?11DD,J0XA%F<ZOL.80B)B"D,LECD
M*(J3-+!*3VDD=6QC>JMTZ9ILJ/U?H%+<.:.U62>8$8)W:'OF"2^HVGMQ;5#R
MY:$UDCFL]]4&AB//JM7+;O2D<U>2XOE^M?PVXX)_>O^U$/QN\=-L019,7Y!E
MZ]FW<H>P'2910 *BE_6<<JS7]BDDC$L8"4X8U7?]N56N:WL5QD9<95H2.5_^
M450YX^5&=4"VNENFV77H%S/ZZA?MGKE,IPXJP=ZHKV-3?M 6@-GB1[ U NRL
MZ(7=W$'T1'4."@S*>^X '9)@AY8<%VRGXWU3E+$<\QBR-(TAPAA#PF4 0XDS
M%DK&122M5FB=@WZ'69*I>:>.WV,-/2V77UU"J/_\T=&Z8F&9N.J[5M_#.8D9
M-+Y652.(7;8+2^XGXOA2<-NYV+9I6;6M^(=Z<%W<+:J$3@=)2LH_WJC5WO8B
MRU. XA"'+(5Q$B"](XS4,(P0#$F(<IHEBH72[GS3F_YC([)M;B!2YP;ZJE6&
M7/MHI5(:?--:E[F9N';2K0J@<TJ4>9HLTS0-_4WI0J.CZ/\!^?E<D'-KC/,$
MU!A,0(6"SEI9X3 !1TFGRD> !@-H-$ )1]^<WWL_]CJ9]*?]"&:IWKO&;/KK
M7XT.P0<-1^2NO/.3Y$SB.,]A3!(!49H%D B.H* QDX*A ">1=>#!25%CFZTJ
M__E\N?@*E;B7CF$'I]&U"#GHC-D@X09[808[/3U'&K1BX3/*X+2@X2,,6@T^
M&5W0_D:WR&=%9%]7HJ0Q?<WPR_NWMT<EDKR*M_6,%0]7^I,ZSQG-$Q%DH81Q
MK-,_$!+!G/,("I*$@8QP&E(CITH''<9&+'M6@*T9Y7U=H-4&34O P]^N_@9^
MT)\;KH&[=%<[(0W4"3TSE3O^+A4B'#O"+1JXIPX9/MC7U\!P#N)U0-(T1M>F
MZ0\)P76P_5R$K4M37B>G3[/EW>*;^N5NH;A]43Y YE>?MI_7XRW.<)BE4D*$
M]-$RSS&DDF<0!S'C"0X0,3OJ\:/.GVK*VNH.]HP"5Y_ #]N_^9F[3'NSTS36
M0Q]]Y(QFUCU^IS;3?O(RR_707V.8\#H.*U\SGR6ZCI.@J90QS(>6B!A.C;:M
M.LR2CP]?RO.F7:&+TK7XZV*V+C8#,F*$,TQA'.JY,(PI)$0PG>T[BI( 4YX8
M9>LSE#>V>4YI7!\^-PK>5!FQ2JTMR-$ ;(-9RB^$/4]#E]!SF6-,OK/FDXA?
M. >:)9R_E'93@#DVK1QOT,QP)&YNTQY+6[SF=N"^N33XN+QB_WF;K<3]:ODJ
M5NOW>]7SZZL%U_&%K_J1ISB/0YQ&.>0L#G3=.P9SG"-(HXQ1%&0!BODF<:'9
M$;RY<*/!L)^BL&>"OE<-/:NN*6M,OM9Z3\K\@Z7&U95_?0!J=T9OT2%F9_:>
M01Z&P#=*@_42U&J#^RW(I>95.;BM\OX.]NT!\W30;R%XT(-_>T .'0$.+;C1
MF>))H5[21=1NQ#<Q7Y:-UJ%6]2PM"8IQ(A(8)IE0/)9%.L<?TOW!TE#&@9!6
MCD0#F6-;76Y4+H<0WREM1U4F8)MQE&<(>R:G/?0:^FY"^GJH/6,!D"<R,I$X
M* M90'!(/S:ONO'.C5C-OI5Y'![%ZF4JKY>+*@P_X5D:Q"2 (5<4@Y)(0II1
M @/"PCA&),JH5:#P.4%C8YB=GJ",65"+)%:K:D<R9Y$U8Q8?>/5,)SL5)^"Q
MQNKZ$E;6#'()"$^T<5;,H%QQR=A#@KCXO",KS(I-?B^U+Y_*+XI\%F_BY]E"
MW*W%2_'$<Q$3F::0!WD.49B&D%#,819F7,H\%()999Z\)'!T++&GK_[BUQJ#
MW[7.H%3:\G;G1= -B<,CE'T32#<4[:G$$!I?E'))W+#48FC\$<68OM<U!?HM
M62UFBZ^Z5O0FL'/&],JG*GI:)M?=I59%$<-8I B&*8]TG@C%0+'Z(7"2B(Q2
M@A.KFJ2.>HR-F)IIL77<[-MZ.[9*.ZJE?V4)T/<0[Q9L^2)T''@5.>Z:R=RN
M]\RH;( ^Z9GAFMVQL6&']>1$GU2)R$$O>7,[XND] [F=%A^4;]P)JO/9Q=V:
M<SQ4TC'O4_EK(<I<(%.Z)HJU^=WB]CM[UF'T/RU7TU>A7:F+KS_KRB>;F-?W
M)ZE6<#%' 4QSKIV7-(,DB6/($<I"&HE$!E9%QSKH,C:.+4V!2PG?"J$K^^C\
M-<O:'GVG1M06E65DYF5!F48*7<NCJ@Y=:'B$-4S']'VTM>D390<H#0'31I?<
M-KMD:PTHS=E&W'NHQ>H15%_'81TT&?:8K#MD1\=G'IJT8]YBM7[2M2&G\A?R
M?\O5]5NQ5JNK55W!E,B Q3*E,,*Y4)P:"9AG*(<A"B.,6,"%63GH5BEC8\N-
M=I9E8=N1;*<V;_CT3%KFT!@3D)'I;=2B&FC0BOIM1RGM;0]"%D;F;6C [.%S
M [S9%VJS^^^__V7SB?JA4TG\_2__#U!+ P04    "  ,@F%5.,KM9=Q^   J
MT04 %0   &5X96PM,C R,C Y,S!?<')E+GAM;.R]69>;.7(F?.]?45_/[1==
MV!<?VW-4DJI'X^J21E+;,W/#@R60HILB99*I*OG73X"Y[USP\D6JNT^UE$JE
MB$#$@T!$()9_^N^_?Y[]\!67J^EB_L]_X']D?_@!YVF1I_.3?_[#7S[^#.X/
M__U?_N$?_NG_ _C?/[W_Y8=7BW3Z&>?K'UXN,:PQ__#;=/WIAW_/N/KK#V6Y
M^/S#OR^6?YU^#0#_LOE'+Q=?OBVG)Y_6/P@FQ.V_7?YC<59IZR*$&!RHR#EX
M1 DL!"DM#RJH\O^?_"-WW+$< YB<#*A4-'@;/,CDO1"JQ(BX^=#9=/[7?ZR_
MQ+#"'VAS\]7FC__\AT_K]9=__/''WW[[[8^_Q^7LCXOER8^",?GCQ4__X?S'
M?[_S\[_)S4]S[_V/F[^]_-'5]+X?I(_E/_[O/__R(7W"SP&F\]4ZS%-=8#7]
MQ]7FF[\L4EAO>/XD73\\^!/U3W#Q8U"_!5R Y'_\?97_\"__\,,/9^Q8+F;X
M'LL/]?>_O']S8TG\'6?3WZ>K/Z;%YQ_K#_SX<D%P>!=.*KF;?[[^]@7_^0^K
MZ><OL\OO?5IB^><_U'\,5:[,2U87_6]7__C'J_6_+'%%D-GL]Q?ZQOEGU-7V
MHP5_7^,\X]D>+U:9+=*-'YI5#B^6%_]R%B+.-M^=9)Q.-I_\(J[6RY#6$RT%
M%BD3Y!204.@5>*\ET+<)72FF[,+-K5>R5T3W1B K3'\\67S]D3[XQ\J.^L6&
M+QN>W%GNC#?[T7UQ_C[2STY$4 I#")!8XJ"<8Q"D<A!$$<YJ;[)0!Y%]?;6;
M5%^7Z8ME^F&QS+@D!7*Q7%BF._*]"=[SG_CQ2UC2!T'Z-)WEBW]=-4D+6:T7
M#3AW)A8B]P\_T*X++I>8?SF3RH.;V^QL36H5-S_90N+_ZS0LZ1-GW][CE\5R
M/9&>(R;TH+6.I!*#!%=8 %&4+U55F0,Q^\#"6^% ](^#0_C9"23>X7*ZR*_G
M^15=Q1-D+#&=,H3*!L4D7:J.:9 !G<$4(HNQ"2!N++L5'&3_<-B?EYV X>,R
MS%?3ROAS0 >M3?%&@N61]B"S!L<+@BW6*22^,/1M;H=;*V\%"=4_) [BZ,BH
M>#U?3]???I[.\-?3SQ&7]<8+)?H,D<E B'86?(6U5E)(RVR15A^$AMLK;H4"
MW2\*#N)@%])_CR?3RH3Y^M?P&2<V).:CX2"9)Q^J: ?.>P=)\,0E%]&9P_3!
M?:MNA0+3.PH.X&072'A#+OV25-B&\1^(__AR<3I?+[^]7&2<D*U;LLX1,!-;
ME":S.%H49 -)IY7BC'YK (Q'B=@*)[9WG+3C<Q>P^1A^?Y.)?=,R/8M6G&M"
M:]#G6"(0U,E[LO4>E%E "#Y+77*QRC4 S /+;P45USM46O"V"Y"\R)E$L#K_
M[9?I'/DD*<T\6H*VX87<:T:&=$@)0HXB>:.-U[D!0.Y9>BMP^-[!<2A/>P+&
M2_KR[?+CXK?YA LE-?<(Q09-]Z8@%YNK^L?('.$]E9+:P>)JX>U"5^R9H&)/
MAO:$B<W5^';Y;KGX.ITGG)C"E ]D09E2R+2F>Q*"H'V@=RB3358V,4WO7WT[
M='0<V6S&VIX@\FZQ6H?9_YU^V9A.3GCG&"/:C?"@5%1D.M%^;(Q)28O2"M,.
M(#?6W@X>'0<\&[%U9'!4K?=BB6%#M]0LF6(]I)")%9J8XK4-D(R1]&W-D1]F
M7UQ?;3L =!SBW)MU(XN\OI'.WGU:S"\B,#$[:YBT8%PBN#*+];J+X'01*(DS
M3MF#Q'Y[Q>U$WW$H\R 6CBS^#YA.EP1=LF,^3M<SG*B09"C.5..7KK(0&4&W
M/M]YSH1-0?-4#A+_[16W$W_',<R#6#BR^#\N0\U"^?#M<US,)JI('FKNAT\R
M$O4Y@W=20\+(9>9,$:X/DOV-Y;83?,=AR_V9U\FA?_U[^A3F)[B)MR9A@F1!
M@96%W)R@+41R>$$C0Q635DX=%J"\;]7M,-!Q2/)@5G;A#KP\759VG;W 54B3
M#$Y7$YF+UI:88G1.9,9X!DYRA!B"*MDE$P\T!1Y;?3MH=!^";,#:+B#R9DZ?
M1NR8?L5781W.MS41I1BAA8% _PB4%0PB1@=212N$1F]%BR#D_:MO!Y'N Y$-
M6-L%1.HS[O)E6./)8OEMXKE09.AXL)XQ4H**?""&F6Y&F0JFDAD[+'7JGD6W
M2YOJ/@:Y/R.[P,&'SV$V^^ET-9WC:C6)ELP?B1&RJ^^XE2D^$ZJ9ESEED7@Q
M+:)*-Q;=#@?=1QOW9V07.'C]&9<G=.7]:;GX;?WIY>+SES#_-@E<&BL=@ZS1
M5I\H ;&%+*3"R%,*4I<@&N#AWL6WPT7W8<;#&=L%/CY\PMGL@GI"MW*&23#%
M>5 Y, B<[CVM C(MHDNQQ75Q?<WMT-!QS/% -G8! B+\<TWC6*2_?OA$?%N]
M/5W72H[J64]T-NA$R" =K_$3SR$*3BHON. Y3S*S%M;E8S1L!Y*.HY.-V3PR
M:%Y\QGFN>:,_S\+)1#&9G6,<3"ZIYHAQ\%8%(*LH,2^4S_JP)\T;RVT'A8XC
ME?LSKY/TZY^GJQ1F_P?#\F?ZSFI2C#2F" L^U5QASPHXC0Y\B39)&Y/6A\6L
M'EAX.R1T'+ILP="N,'%667"V";216Y0%1)'54":3*"IE0)84HR7W.>@V%5MW
MEMX.%QV',]LPM0_#@K:Q#+,W\XR__RM^FU@NDI%"U+P=NN08\Q"\#Z"+#:Z0
M!Q7:!#-O+KL=(OJ/8A[ S+%S&L[":5>:[J+\R >7!;<5S%& TIC)G[8>F$2+
M(25=#BSE>FCE[3#1<=BR"4N;P>*??KS#QU_H&_N79A/(YRO,],5J,9OF6H'_
M4YC5XG)RM7"]NKF#;6NVG_S41L7<NU%_8)7WZ0I.0O@RV23$U8OC;?EY.J?%
MIG1[+,[JNB[A%EWV0L@(4J7Z+(:1S Q2&H[YPI+GI83',E-+6,4-%,X7/3MU
M.%NO+KYS=?QVH6M?Y7*QQHO5BMAZN4N&BCL3'$2VJ6K,"F+<A&%L3I;G@.FQ
M0,8^N[Q)P3@UY(,AX4+Q-&#WB#?13>K/%>CE)I0/*J7  #U3I#R%!A\3@F9*
MDD)%R^5C,?+],7.+D'&A<XAD[P7)(6SN "LOP^K3BWFNO[W^S]/IUS"CS:Q>
MK%^&Y?+;='[R;V%VBA-F3,*2) 2F"M0L$XB<C++@.%WCSF*RK#%VMB*L!RP=
M!(#%T-+H &(?/BV6ZX^X_/QF_A57ZZJW5Y-D!1+A'I+UGK0S<2G:G$$F\OVR
MMD6(QRK/]KJG[Z%CG!X8PP'H8%YW@)?WF)"@'V>X^A77%YD*B0S]$JH+L>GJ
M(0-=YR6YVN1#$>Y%P4<+!_8!S+V$C-,F8SC$',[M#B!3T3ZG'_E&6YA$Y1TC
M+Q"TK#%G[SSX^M(@DBTRY(0J/!:PWP<IU]<?IVG&< #9F[<=X.+=$K^$:7[]
M^Y?JK]+-^G;]"9<W>#0A,"OIE0(6D9$)F!)X%PPI2^:],58[\5C,;A^X;$'6
M.$TWAD-1:TET *Z;Q(>LF71* -^D9A?BBW-"@M6!UPZ'3*I!W:MQ^G,,!YC]
MN;L_-!;K,&L"C5\6\Y/;5IADQJ%$"T[K#*H^<WA#JC/P((TN&I5X+"=I'X#<
M0T8/!F\3[_M0%G>@0-XM%U]PN?[V;A;HT,QS=?F^U)W4F]8%D3'(##QK.CN9
M,4(\ST",*2X'*8E3S:^EA^GIP>QM@IMF3.\ 0*_.EZW=:C[CQ_#[&9\VAEHF
M11N]!IW#ID5-(68Q#E8EH[(1*CS:)6P?^#Q,30\F<1/P-&)X!]#YTV*1?YO.
M9I,23"R"("]2O:-U).UI,0 G5F0C6?#86L]<K-V#C=L$%GLQLP,07+/!?UW,
MTX49[GVP6080)I*/5QL*>.\5<)&UI8N5>]G:(;J7D!XLVB;P.)S->V/E*R[C
MHJF_,ZG]!9 S4G2EIF4@R^")'V 8*S(SIT66C>%QMO(XG>4&>SC:B9$]^#33
M$*>SZ7J**S*;-EF^GQ8S8OJJFE#K;Y>LR3DQ*1/M*YA"K"D>'!,*/%JF?1'1
M<6P,D&UI&]?[&?S9>A 1=7!/7=O7[1!#PN"8X@ELD+9&JVM:N4A0@C!6T%]9
MT]RK?I":<9\CAY'^PQ [1!0=@.I%2K6EY^I=^%9?/RXB385)H[1)I-@% R51
M0H@J@]3,.$D>(.;6#Y/W4](-F Z2\^VK[W"F]P&=Y2GFUY^_S!;?$'_".9;I
M5;!2IE@P& -D_P=0/$NZV,E H&\)%4,,)C</!3]*T;C7WG!0:B6$$2%5LRLO
MMO*2_G*:R%R[P[!)1LQ:H8<@4B25'0L=$"Y &QNT1!=EN97P=S<]=+NEQ@WT
M-<;* -SM0/V\/%VM%Y]Q^1[+Z3Q?[.>B"\A$&\FE5 5<5N17\)HHI#P')UU(
M)=@D1.OW[\<I&C?\-Y#Z:2B$7M3/8D9_<][S_,Z&"G><#D,!+3T9C9$<5<=K
M)RJ&7INH? IN)PWTV&KC1@:'5$+->-R!'CJ+:YUM[!ZMZFIRF0H"7-'DR6)-
M4V01 1VWW$B58_,4O\<I&C>@.) >:BB$#B!USPZ$%MIYEZ#ZK*!$07)4'6W(
MN>2LS[8\VN.GC8<_;NQQ(.@<R.P.8I(O%_,-&_Y]NOYT<2%?:M5KL?8H5? J
M*9!)N1KQ,. \>02A9'(QBY+BT;Z#>YE$VY'6C6LV7,AH""%UH*K>?L%ZC<]/
M?L% 'WG/AHSE6AB4$'.Q==I# &]- )N06Z&*)SNP]07X%%'=N'?#X:VM8+IX
M>MM<\M>8=VTOTI-UJ#('ZX(GC>WIU(1DP21R7$T.,I7'>BGO;67=2TTWGMZ
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MW+P ?7C<#M9GK5/<[B+$7OI9G7[Y,MNP,LPN6/EF7A;+SV?"O&"JI+N"%ZF
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M$/7NY#K4QDY#1U)NT33N T9#'WD0(70)JHO=G)\^:5"$$@-88VT=FY+HD.0
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M>OFNW#A/YX8IHSE7I#:%T;^<A1"5 2ZU$DHR<GM:%UZLH^4E'5RWP=P>LNH
M<[^$V@#RL?AO]GZ*\_#GN8U2DPL=@2VZ0?)$#/(F@V,:29$$Q]0:?,\2=?HE
M$VU0V%9ZS>#8.(U26_>-"<;[M$U^\(PFJ9&G*6O8JOCZ);>'TK=GTE[SY%D0
M8)%Y"J99 F^2@ZA43KJ@#+EUH[0GR-G7&-T^^C5I"OUT'5+%@-Q[(2!FTA(E
MK" %21:RB)BD)QB&UG[_HX0,WSJX!0I63<C^/.]@%WL5+L(XX<<OB/.W]=M5
M*(NIH8G;DI(&[[P %8T"E[0#34&YE8J8E%NGPM;1T@E\=A?SY  \[Q0[RZ/*
M( +ICZIUNY*VYHP(3J$!PXHR(CF)LO6A[GIJAL5/&VEO *$=6-\!B&[4ZZYE
MD8[DUBE: +E;IAYNU_H5CA U9J51"RX/M3-W,DVWE737;%B[L7I K%3W\?S=
M_ M.WT[&G^EYE]?QPW(5*:"QM2.Y$R&"6IPA2ZN@)!1HR5+GU:WJH9?[]"N&
M/2]J#(>&W.S(?GR_BPN5)KM:9^8D4S@H&SW$6&2MLN,F2'0)6W=K>DC%\%,%
MVCHM>_*Y)Z1\"/_Y+=!S1^%B=LZ8#YX3TJT49 *-DA!B[4G 4PI:*Y-]:T_E
M44(Z<7)WE.XZL.S,ZI[P\L_)]%^_CM]/)PEGY+99Q8D9CIPU16Z;J^,'6+&@
M5+)6J\*=/<10HX>4=&)A&B-F=V;W!)F?1^/1[ OF7R:3/#NGG5393*Y],;'0
M*C!!*+1I$^ZMK^V/HVW=8>MQ2H8?)'((R.S.[)X@\\NT3O[+#F4.F@/:VE8D
MR0A!JPC<HPZ%-O @6S=Z^9&"81,$AX+(]LSM]6;$Q_DD_>M5F&%^/;G\BN/9
MXHDW$XLGY>QB@3G,;RZ_7DR^(S[^'[SYL_Z(>^0%#D-(D^3"$7C4*$-Q=R1=
M$Z%WK_Z BV&@KR>S^>SC%U*=6(E['[XO,E1WQ]?&6.>J;C"LMX<E@@\&H3C/
M<JVZQ^8=\_:C>%]K>3>9^U9TBRZ-N'CE PDN!4T_O2L?,$T^C^ODU??DCTZN
M*;V.BZQG*!V%1&@\.:88+?A8!'#%K-#22^E:5],?9"$#UZX>#\NK=GYX6'3A
M29 !)%-&S*Z<_>&LF7%-?G2H$XR1=CZ/%'4)IT!;(USM)LI#:X0_0<ZP..T
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M(>M-EN;]$GX@8-A=;V<Q/@Z''7C: 2#6Z-%"44B72-_>C6\N@Z(N3'!NH)A
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MN'H%7O&:B^7 LRI9VF2E4!L!8_-W]H25780[.3RGAP;0@NXW?WX-XWJ_>+F
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M=^7>A:V%X@3K'%'NP-M FZ\I##QMP4#T\YQ,X;IYC[U'"1FX-TZK;:<=LSM
MS ^W@\?Y]PEIP>TGG^BG&;EOM5IOJ1"(C#M>C[Z5J?W3V()A%H35WOG$$S.M
MB]RV)'%8YZ8!*!Z4>Q].0D.?U+S^'J?X9_CT!:?A*U[-1VGV]NWKY:?+]=AB
MC3>U<85%!.6L E^;MV9%OSM#JS4KUYO6G-!L\+*!VQ<=4M*3 [)]:!A]#*/I
MY&MX]8_E#S?M\Q1*1$,.HV'U"#U[\,:1K0^R%NG9X%3>"#F//W_8[>QH8&G
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M:KU.ODAU)R;4MQMA8GXZEW-2\?<G%3?)22#9[/2$B0D1['U!T%8MJ.ZSH'5
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MX6L?S"Q7@J.LZG((#; <,K-]R+8C^ZU?W^17_R&0^R3I]#]02P,$%     @
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M?H!H08<B$69F\^BF:>UJ<E!S*/(+X5'7E1+,I8>'PJ L5QE0K%W>#T.IF%/
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M^NO:?U!+ 0(4 Q0    (  R"856>WO(LXYH" "^0&P 1              "
M 0    !E>&5L+3(P,C(P.3,P+FAT;5!+ 0(4 Q0    (  R"856TW!ERE!(
M #_/   1              "  1*; @!E>&5L+3(P,C(P.3,P+GAS9%!+ 0(4
M Q0    (  R"857P>/3@]!D  &\# 0 5              "  =6M @!E>&5L
M+3(P,C(P.3,P7V-A;"YX;6Q02P$"% ,4    "  ,@F%5X_FUG#54   0Q ,
M%0              @ '\QP( 97AE;"TR,#(R,#DS,%]D968N>&UL4$L! A0#
M%     @ #()A56'1*I%9$0$ PL8! !0              ( !9!P# &5X96PM
M,C R,C Y,S!?9S$N:G!G4$L! A0#%     @ #()A57M%[\;PT   >J<( !4
M             ( ![RT$ &5X96PM,C R,C Y,S!?;&%B+GAM;%!+ 0(4 Q0
M   (  R"854XRNUEW'X  "K1!0 5              "  1+_! !E>&5L+3(P
M,C(P.3,P7W!R92YX;6Q02P$"% ,4    "  ,@F%57[!J5DH(  #M)   '0
M            @ $A?@4 97AE;#(P,C(P.3,P97AH:6)I=#,Q,3$P<2YH=&U0
M2P$"% ,4    "  ,@F%5'F(* D8(  #1)   '0              @ &FA@4
M97AE;#(P,C(P.3,P97AH:6)I=#,Q,C$P<2YH=&U02P$"% ,4    "  ,@F%5
M#Q:"S*H%   2'   '0              @ $GCP4 97AE;#(P,C(P.3,P97AH
M:6)I=#,R,3$P<2YH=&U02P$"% ,4    "  ,@F%5U*HJE\0$  #:/0  '
M            @ $,E04 97AE;#(P,C(Y,S!E>&AI8FET,3 Q,3!Q+FAT;5!+
4!08     "P + /<"   *F@4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
